<SEC-DOCUMENT>0001062822-20-000015.txt : 20200312
<SEC-HEADER>0001062822-20-000015.hdr.sgml : 20200312
<ACCEPTANCE-DATETIME>20200312172631
ACCESSION NUMBER:		0001062822-20-000015
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200312
DATE AS OF CHANGE:		20200312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		20709885

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lxrx-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742,d:54910e5d8bdb46bf84d5ecc54d3bafab--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:lxrx="http://www.lexpharma.com/20191231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl81LTEtMS0xLTA_a69b9694-2b49-41d8-b5f7-dd9ecee8af16">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl82LTEtMS0xLTA_3e7fb043-f487-4d78-bd6a-3c61230b5594">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMC0xLTEtMS0w_10951cd0-5a1b-4fef-8310-8e0d7dc3a28b">2019</ix:nonNumeric><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMS0xLTEtMS0w_a6520e78-1cdb-4a77-b525-de6f9c622479">FY</ix:nonNumeric><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMi0xLTEtMS0w_9b0682fc-fad1-455b-af93-91d69484911c">false</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzItMS0xLTEtMA_8ea96369-abfa-40b6-b59d-a408df885010">4</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzItMi0xLTEtMA_200f12c2-0b78-42d7-9ebe-3d9751b4ecef">4</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzMtMS0xLTEtMA_12a86c68-6207-4329-888d-aee45318bd87">61,741</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzMtMi0xLTEtMA_c56f6097-8417-4296-b92c-7db16ad36b0d">60,006</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzQtMS0xLTEtMA_7c42ac67-987b-41d2-b1a1-33e322da1e7e">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzQtMi0xLTEtMA_b56f876f-08d0-4500-a03d-7fbec7ad107e">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzUtMS0xLTEtMA_9a4be0ec-7dfc-4e47-a7cf-8473a165e16c">5,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzUtMi0xLTEtMA_850a43b4-5236-4d6d-b900-8b6e5a2bd9db">5,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzYtMS0xLTEtMA_afff9bd4-b982-4e84-ae62-46d58b8bf47c">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzYtMi0xLTEtMA_79fd79d5-bb1e-461a-b91e-eb7d20eb9f17">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzctMS0xLTEtMA_1cb6c44e-d652-40e7-b5b6-adb0722247aa">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzctMi0xLTEtMA_4169bd2a-5338-47c2-9a45-6c84172dd99d">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzgtMS0xLTEtMA_028b51ef-c4d6-4cbf-8761-af3d8f15d7f5">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzgtMi0xLTEtMA_03fac5fe-820d-4b5a-ba62-6d0f43e38cda">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzktMS0xLTEtMA_8f6d5986-4fbd-4639-932f-9037c84f724d">225,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzktMi0xLTEtMA_dc7475d4-e8ea-4381-81ce-69b4c1b458ef">225,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i7501ea3be2a741529ff3306e73060964_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzEwLTEtMS0xLTA_bbb6662a-7a57-4f28-a8aa-728ed9fcd76e">106,679</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzEwLTItMS0xLTA_2854f468-3d8b-4ba4-a565-e43d1a5d042c">106,162</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzExLTEtMS0xLTA_525fe59c-bfa7-42e5-b934-3705e1bc472c">407</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzExLTItMS0xLTA_899dc8d9-fde5-4f1a-9a4b-5c59591275fd">236</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMS0xLTEtMA_87106309-86c8-4c5a-85e8-c3452708c067">7,096</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMi0xLTEtMA_c915c111-f99f-4398-a21a-0b89d1521652">6,010</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMy0xLTEtMA_448a2543-2a93-49eb-af4d-ebf853e94ad1">4,905</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMS0xLTEtMA_14a71d00-4882-4b68-9fda-b9d4b2be78b8">7,122</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMi0xLTEtMA_45c89cee-f28c-4b36-a76a-62ef79f70dad">5,686</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMy0xLTEtMA_6ae5b854-2c2a-41c8-8eef-ef87b641e3ef">4,567</ix:nonFraction><ix:nonNumeric contextRef="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b">P3Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzM1_da523249-8560-4c0a-a483-57694c053469">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzEzNg_3f425cae-a1fd-40af-af14-9aed1943090c">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzIxNw_bc439bbf-aab1-4f29-a66e-b683ef38a15d">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzI4MA_ad1b657f-caae-42a2-a65b-0f0b8df15150">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzMyMw_39f2de35-20b7-4817-92e6-259093748f72">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzM1OA_326a2626-8c5c-45ae-b33f-d83d3879d3a8">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="iead7811281254bcbb2692b1ba9a8a25b_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjMvZnJhZzphNTlhNzAyMDc2MTk0YTUxYjM5NzQ2NjM4NjBhNTFmMi90YWJsZToyYWMwZmU1OTEzMzk0MjUyOGYxMDU2ZTUyM2Y3NzExYi90YWJsZXJhbmdlOjJhYzBmZTU5MTMzOTQyNTI4ZjEwNTZlNTIzZjc3MTFiXzEtMi0xLTEtMA_389b0044-7dd2-45e0-b3c6-2369f7e1ee17">2.1</ix:nonFraction><ix:nonNumeric contextRef="i7aba92216bb9424f8d15c759003ae223_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzMtNC0xLTEtMA_a588fa87-a839-486c-b9af-52eca205a69f">3</ix:nonNumeric><ix:nonNumeric contextRef="i3c89489e14d14a80a43bc37c4139f132_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzMtNi0xLTEtMA_4b381142-89e6-4f83-a697-d19200a1cbd5">5</ix:nonNumeric><ix:nonNumeric contextRef="ib68552052df34ab5921379e6cebe42c0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzQtNC0xLTEtMA_2bbb5d57-b0fe-43cf-b738-3db19cfdd825">5</ix:nonNumeric><ix:nonNumeric contextRef="i826b9f0fff2b4a2999f965a6464b4373_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzQtNi0xLTEtMA_8b755bdb-2977-4ac4-9cb2-7e0af16c9588">7</ix:nonNumeric><ix:nonNumeric contextRef="i28f89df9133a45d3809aeee03abe338a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzUtNC0xLTEtMA_57309094-8b57-4af6-b58c-ad3d23836da2">3</ix:nonNumeric><ix:nonNumeric contextRef="i4fe56801915047618583b6f63ff8c91c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzUtNi0xLTEtMA_cfc109f1-d9e6-4648-b3f5-646189b6e4cc">7</ix:nonNumeric><ix:nonNumeric contextRef="i24f85df61eb445838e80f6b878175cb2_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzYtNC0xLTEtMA_dfa7fc87-69fc-480e-8c12-cc80955f49a3">3</ix:nonNumeric><ix:nonNumeric contextRef="i5eaa1ca4276f4306939acd691adbae4b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzYtNi0xLTEtMA_20363ce3-2307-4f50-9d33-c3f5c3f66af0">7</ix:nonNumeric><ix:nonNumeric contextRef="ia58710b444204c06a40a6e1eec7042b4_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzctNC0xLTEtMA_0cbfe455-04cd-4d1e-a667-156e38637ea1">15</ix:nonNumeric><ix:nonNumeric contextRef="ibc7d3efc2a38441eae57d3f6c2f543cc_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzctNi0xLTEtMA_f57c8757-e244-4a4c-acfa-979ea2113ac9">40</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODEvZnJhZzo2NGE1YWM5YjE4YzY0OTZkYWVmZTVhYzJkYjUyZTdmMC90ZXh0cmVnaW9uOjY0YTVhYzliMThjNjQ5NmRhZWZlNWFjMmRiNTJlN2YwXzcw_2af9e7ed-362a-49aa-9786-fe8350793bd6">no</ix:nonFraction><ix:nonNumeric contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI1ODY_709f0024-f6ab-4884-930f-af1897447d75">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0ODk_cd815874-61d3-4e93-b842-9068c8947236">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM5MTI_05762f89-6afe-4eba-b7d3-725a92223b9e">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="ie9d39defcce14b468b07992b453eadce_D20171201-20171231" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY1MzU_04b7db4d-7fa9-457a-afc5-ab80eee00947">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNjU_271664d5-aa24-4596-adff-6eaadc2549e8">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i93792b54ada2484d8b1bab2bf045cd99_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxODc_3e3d37a1-a8e6-4c56-8f56-a53ef432e351">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id86a6b1aaaba4df58235feed7b3ecf76_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxOTM_6c3cd917-a52f-4bb3-8628-3b363616b2f4">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="lxrx:DefinedContributionPlanRequisiteServicePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzYyOA_b159658f-ba94-40d2-bf42-41b82bcb07e0">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ0ODM_07c80404-0919-4d69-96df-eb1aa3ad8777">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lxrx-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib5c88259cb8e4b92bfdfaa68b9ab937e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i52f9f923aa5d4203ae1082950c943805_I20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7501ea3be2a741529ff3306e73060964_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967751fea12e4973a32d9fe35e3e91d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a26c1b854e6492a9cee1d79baa36f4f_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ebb2384f82444fdb95c578d086dd541_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2837d1af8744496a83b9465b01d9c7af_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129f3fad6d374d8db3b6389a173ed459_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57757fd132344fe38d2ce518c20bb378_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8cccc7e982e4621be9e20764d4dfc15_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffcd61f6da4749d4b7cc1ab6f3055a80_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5028bb7c1904d74ad203e9136d8d368_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i017c2651d77947d4bb01b4651850b16e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be9572e894e461092c842e6748a2b74_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2402ec5193524658955d7c90d3a16896_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2e221d098b491cbeaab0aa52d099ae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e0a311a22b411e9fd8665266ff4e44_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b4b3353a5c41bbaa44ce871c92bba3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac0714597ff49c483b52893312f674c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48208aca804f4529a47984a51825c00c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98be0b7d6a10477d8c718994e04dc1c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c089f26a424433a6a985286efbaae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae9845aba89468b8e79334b8836b87a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2669261eb809451d87dbe16b0e36331d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lxrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0e9da8ecf2c54fbe8f306aa71dd97256_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id200f3fdbfab4a1d8d40cdc784c65d06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead7811281254bcbb2692b1ba9a8a25b_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c449fb5ca67473f98ac63f3ac55af83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3eec56c8d824574affec4d66d71660d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0a69895e164f97977732e2bfd75452_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe9e860df2f49179681c5585ac22f36_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54c610d056a4769931c5fb35bdfbf57_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52761b423ed94c999cfcf4ff49cffcae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42edf1b0c174407b6dc7acf67878cbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa3a2a02ed444c58bd99b8c7d318975_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ec419047d94a2ba32418d003ec5498_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2edf8da90db84523a6fc9be2eb374ea8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0883ce436140d4aedbccded39fec5c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d5f1656d844951addb1fa04625751d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d65b504af44fc3a8e21bcd23052cfd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326024d73cea4d15aa9ac4c2c5c24f6a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3e10389e3543398ede188dc42287b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3b8f069656465fb49124367dada928_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490ae890935942b1b6b3556c3099574e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b49290934c41a6aad3724b4c80bbd6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b062ad588146aca58efd416bfc6a9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bcb52391538408c8580e9d00fbeb629_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1340081d4b804484b5d1dca5c73bf782_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9476eb367804eba9e26e39f94e0c1d3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i428262586cfe46008e720b64332fe571_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c95eef01a704b3a945e493cf9b53436_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aba92216bb9424f8d15c759003ae223_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c89489e14d14a80a43bc37c4139f132_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68552052df34ab5921379e6cebe42c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826b9f0fff2b4a2999f965a6464b4373_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f89df9133a45d3809aeee03abe338a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe56801915047618583b6f63ff8c91c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f85df61eb445838e80f6b878175cb2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eaa1ca4276f4306939acd691adbae4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58710b444204c06a40a6e1eec7042b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7d3efc2a38441eae57d3f6c2f543cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518a6981e36c42a6a7263b4a8fad852d_I20170227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6df2280ae0495591132f2f5d361b8e_I20010712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2001-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef4d236906043df99288d5dec2fccfc_I20100730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i337cde26133a4419842ffadf1b382833_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505f2df038f048d09e005588782957fa_I20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d9306784934680a1912cb049ecc58c_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d39defcce14b468b07992b453eadce_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc703c71a5994ba2b8a490586719cf93_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17260f0b7b8f41c4812252456551f9ea_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676db318ef444ad296e217ae53030a14_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e588be725e4af58a772fca835425ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93792b54ada2484d8b1bab2bf045cd99_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86a6b1aaaba4df58235feed7b3ecf76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf18c961781453a902022b81e8fb9be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1681c8bfaf4cb7885ec38236a3a489_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>lxrx:milestone</xbrli:measure></xbrli:unit><xbrli:context id="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd14d4f858f4035ae6b02237f016ab7_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b309ec36344fefbc30f63b0cbe55bb_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb28917800949f293202b0888b3e175_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b945f8014e44862a193e174495bd0fb_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e86892468984645956d23c25fe705dd_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_1"></div><div style="height:18pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.926%;"><tr><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV81NDk3NTU4MTQyMzg0_884129dd-5f50-4bb6-a146-6d5be2057a95">10-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.762%;"><tr><td style="width:1.0%;"></td><td style="width:8.471%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.808%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:52.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Mark One)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YmU1NWM1NDRiN2FkNDI4NGE0MDcwNzBkNDYwMTlmOWYvdGFibGVyYW5nZTpiZTU1YzU0NGI3YWQ0Mjg0YTQwNzA3MGQ0NjAxOWY5Zl8xLTAtMS0xLTQzNTE_1e111496-a6fa-4ee0-97e8-af3db3b5d161">&#9745;</ix:nonNumeric></span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Fiscal Year Ended </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YmU1NWM1NDRiN2FkNDI4NGE0MDcwNzBkNDYwMTlmOWYvdGFibGVyYW5nZTpiZTU1YzU0NGI3YWQ0Mjg0YTQwNzA3MGQ0NjAxOWY5Zl8zLTItMS0xLTQ1NTU_d976a395-9f97-4392-a9e8-091c4e01b297">December 31, 2019</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">or</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.305%;"><tr><td style="width:1.0%;"></td><td style="width:8.201%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.799%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YTA1YWY1ZmQ2MTM4NGM3Nzk5YmY5NDYzZTRiZDdlNDcvdGFibGVyYW5nZTphMDVhZjVmZDYxMzg0Yzc3OTliZjk0NjNlNGJkN2U0N18wLTAtMS0xLTQzNTM_aaef369c-4a3a-4e15-b617-99ff12fc0e31">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Transition Period from _____________ to _____________</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTgz_ca35fecb-e234-4904-8687-3c3b38186f5b">000-30111</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8xMDk5NTExNjMxNDcw_f36229e3-f119-4392-b238-21f7917f1ed9">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.446%;"><tr><td style="width:0.1%;"></td><td style="width:2.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:42.619%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.308%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.529%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NDJjZWZmZDgzYWM4NGRiMjg2NzExMTQ1Mjc2MjczMWUvdGFibGVyYW5nZTo0MmNlZmZkODNhYzg0ZGIyODY3MTExNDUyNzYyNzMxZV8wLTEtMS0xLTQzNTU_cc82fff8-0aba-4925-810c-a67176b9b99b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NDJjZWZmZDgzYWM4NGRiMjg2NzExMTQ1Mjc2MjczMWUvdGFibGVyYW5nZTo0MmNlZmZkODNhYzg0ZGIyODY3MTExNDUyNzYyNzMxZV8wLTMtMS0xLTQzNTc_63b1f41b-79c7-4af2-8326-fd3972bdbb0f">76-0474169</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer Identification Number)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:77.118%;"><tr><td style="width:1.0%;"></td><td style="width:1.479%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.655%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.340%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.340%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.776%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.963%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.447%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTEtMS0xLTQzNTk_570e65d1-3c75-4ab7-b8e6-ee2e765308a8">8800 Technology Forest Place</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTMtMS0xLTQzNjQ_b2fdf16d-a17b-4050-93f6-d778f0072938">(281)</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTYtMS0xLTQ1NjE_6ec01671-2f0a-4639-87d2-df3fe11a63b2">863-3000</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTEtMS0xLTQ1NjM_f6b7abbe-8940-45bc-8a79-c1cf95bdda98">The Woodlands</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTItMS0xLTQ1NjU_079f6dc7-036b-4901-822c-f7da4474e17e">Texas</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTMtMS0xLTQ1Njc_68e3dda8-5a82-44e8-9df6-296e3a6a7aeb">77381</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Registrant's Telephone Number, Including Area Code)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices and Zip Code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.491%;"><tr><td style="width:1.0%;"></td><td style="width:2.185%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.127%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.301%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of Each Class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of Each Exchange on which Registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTEtMS0xLTQzNjc_316d725b-8cd4-4b26-8f0b-5f228f9cc161">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTItMS0xLTc1Nzc_5ead25f9-a4e7-431a-aa04-6c7a6572ea49">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTMtMS0xLTQzNjk_f47b355c-945d-4550-af2a-c23a13d0b941">Nasdaq Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(g) of the Act:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;&#160;None</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act of 1933.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTM2_aba2aa1d-91e3-4f72-9862-81b0744c7070">No</ix:nonNumeric> &#9745;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQw_1b0779fe-0688-429c-8dfa-38e429caed23">No</ix:nonNumeric> &#9745;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQ0_d778554d-ce43-4bc5-9790-54b71d863cd7">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQ5_27d623f7-02ca-4f6b-a42e-0a7d949b70c6">Yes</ix:nonNumeric> &#9745; No &#9744;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;&#9745;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.&#160;&#160;(check one):&#160;&#160;Large accelerated filer &#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTU0_d67f7cdd-b805-4772-abd6-dc7a94413d80">Accelerated filer</ix:nonNumeric>&#160;&#160;&#9745;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Non-accelerated filer &#9744;&#160;&#160;&#160;Smaller reporting company <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTcz_89bd0c86-cc79-4da7-8e43-31d249298e00">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Emerging growth company <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTc2_723637c3-db43-4ce9-bd19-c354ee0f1cbe">&#9744;</ix:nonNumeric></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. &#9744;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;Yes <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTc5_03b231d5-26b6-4c05-9a29-0450eaf7d33d">&#9744;</ix:nonNumeric> No&#160;&#9745;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant&#8217;s most recently completed second quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="ib5c88259cb8e4b92bfdfaa68b9ab937e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8yNzUy_9fe5f8aa-7cfd-495c-9713-16b36030ea2f">259.5</ix:nonFraction> million, based on the closing price of the common stock on the Nasdaq Global Select Market on June&#160;30, 2019 of $6.29 per share.&#160;&#160;For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.&#160;&#160;As of March&#160;6, 2020, <ix:nonFraction unitRef="shares" contextRef="i52f9f923aa5d4203ae1082950c943805_I20200306" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8zMDEx_77a85645-773a-4084-9fa6-172e70074f8f">106,969,973</ix:nonFraction> shares of common stock were outstanding.</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Documents Incorporated by Reference</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTgx_9710d433-1371-4311-8de2-49663d63dc1e" escape="true">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2020 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2019, are incorporated by reference into Part III of this annual report on Form 10-K.</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.926%;"><tr><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_7"></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:4.002%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.458%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.540%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Item</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PART I</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_13">Business</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_49">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_49">17</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_52">34</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_55">Properties</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_55">35</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_58">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_58">35</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_61">35</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PART II</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_67">36</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_70">Selected Financial Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_70">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_73">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_76">47</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_79">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_82">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_82">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_85">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_88">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_88">50</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PART III</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_94">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_94">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_97">Executive Compensation</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_97">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_100">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_100">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_103">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_103">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_106">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_106">50</a></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PART IV</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_112">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_112">51</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_115">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_115">53</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_118">Signatures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_118">54</a></span></div></td></tr></table></div><div style="text-indent:36pt;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Lexicon name and logo and XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are registered trademarks of Lexicon Pharmaceuticals, Inc.  Zynquista&#8482; is a trademark of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________________________________________</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In this annual report on Form 10-K, &#8220;Lexicon Pharmaceuticals,&#8221; &#8220;Lexicon,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Lexicon Pharmaceuticals, Inc. and its subsidiaries.</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________________________________________</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This annual report on Form 10-K contains forward-looking statements.&#160;&#160;These statements relate to future events or our future financial performance.&#160;&#160;We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Item 1A.&#160;&#160;Risk Factors,&#8221; that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this annual report on Form 10-K to conform these statements to actual results, unless required by law.</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_10"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_13"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_16"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon Pharmaceuticals is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the commercialization or development of our three most advanced drugs and drug candidates:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are commercializing XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy.  We have granted Ipsen Pharma SAS, or Ipsen, an exclusive, royalty-bearing right to commercialize XERMELO outside of the United States and Japan.  Ipsen is commercializing XERMELO in the United Kingdom, Germany and multiple additional countries.  We are also developing telotristat ethyl as a treatment for biliary tract cancer and are conducting a Phase 2a clinical trial of telotristat ethyl in biliary tract cancer patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing Zynquista</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">TM </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 diabetes.  The U.S. Food and Drug Administration, or FDA, has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter.  Zynquista has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&gt;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 27 kg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2 </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, who could not achieve adequate glycemic control despite optimal insulin therapy.</span></div><div style="padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease.  We are conducting a comprehensive Phase 3 development program, which includes one long-term outcomes study designed to demonstrate benefits in chronic heart failure and chronic kidney disease in type 2 diabetes patients and another long-term outcomes study designed to demonstrate benefits in acute decompensated heart failure in patients with and without type 2 diabetes.  We have reported preliminary top-line results from the first four Phase 3 clinical trials of sotagliflozin in adults living with type 2 diabetes.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported top-line results from two Phase 1 clinical trials of LX9211 and are preparing to initiate a Phase 2 clinical trial of LX9211.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon Pharmaceuticals was incorporated in Delaware in July 1995, and commenced operations in September 1995.&#160;&#160;Our corporate headquarters are located at 8800 Technology Forest Place, The Woodlands, Texas 77381, and our telephone number is (281) 863-3000.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are made available </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">free of charge on our corporate website located at www.lexpharma.com as soon as reasonably practicable after the filing of those reports with the Securities and Exchange Commission.&#160;&#160;Information found on our website should not be considered part of this annual report on Form 10-K.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_19"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Drugs and Drug Candidates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are devoting most of our resources to the commercialization or development of our three most advanced drugs and drug candidates:  XERMELO (telotristat ethyl), which we are commercializing for carcinoid syndrome diarrhea and developing for biliary tract cancer; sotagliflozin, which we are developing for type 1 diabetes and type 2 diabetes, heart failure and chronic kidney disease; and LX9211, which we are developing for neuropathic pain.  We have also advanced a number of additional compounds into various stages of clinical and preclinical development.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">XERMELO (telotristat ethyl</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We commercially launched XERMELO, an orally-delivered small molecule compound, following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  XERMELO was discovered by our scientists and inhibits tryptophan hydroxylase, or TPH, the rate-limiting enzyme for serotonin production which ordinarily is found primarily in enterochromaffin cells of the gastrointestinal tract.  Carcinoid syndrome is characterized by frequent and debilitating diarrhea and can result when these cells become cancerous and metastasize to the liver or other organs, where they overproduce serotonin.  The recommended dose of XERMELO is 250mg three times daily, and the full prescribing information for XERMELO includes certain warnings and precautions relating to constipation.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into a license and collaboration agreement under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize XERMELO outside of the United States and Japan.  Ipsen has received approval from the European Commission to market XERMELO for the treatment of carcinoid syndrome diarrhea in all member states of the European Union, Norway and Iceland and from certain other regulatory authorities to market XERMELO in additional countries.  Ipsen has commercially launched XERMELO in the United Kingdom, Germany and multiple additional countries.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of our life cycle management of the program, we are conducting our TELE-ABC Phase 2a clinical trial evaluating the safety and tolerability of telotristat ethyl and its effects on biliary tract cancer.  The trial is expected to enroll approximately 53 patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer in an open-label, two-stage study of a 250mg three times daily dose of telotristat ethyl over an initial 7-day treatment period, followed by a 500mg three times daily dose of telotristat ethyl over subsequent 21-day treatment cycles until cessation of treatment for disease progression, toxicity or patient withdrawal.  Standard of care, first-line chemotherapy doses of cisplatin and gemcitabine are administered on days one and eight of each 21-day treatment cycle.  The trial is designed to be conducted in two stages, of which the first stage is expected to enroll approximately 20 patients and the second stage is expected to enroll approximately 33 patients.  The primary efficacy endpoint under evaluation is the progression-free survival rate at six months, with secondary endpoints including progression-free survival at 12 months, overall survival rate, survival rates at six and twelve months, disease control rates and weight change.  A safety analysis of the first six patients who completed at least the first 21-day treatment cycle supported the continuation of enrollment with no adjustment in the dosing regimen.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sotagliflozin</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of type&#160;1 diabetes and type 2 diabetes, heart failure and chronic kidney disease.  Sotagliflozin was discovered by our scientists and inhibits both sodium-glucose cotransporter type&#160;2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type&#160;1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract.  Our scientists discovered that mice lacking SGLT1, SGLT2 or both exhibit potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism, and found that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We had previously granted Sanofi-Aventis Deutschland GmbH, or Sanofi, an exclusive, worldwide (excluding Japan), royalty-bearing right to develop, manufacture and commercialize sotagliflozin.  In September 2019, we and Sanofi agreed to terminate our collaboration, pursuant to which we have regained all rights to sotagliflozin and have assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Type 1 Diabetes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA issued a complete response letter in March 2019 regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter in November 2019 and March 2020.  We are currently evaluating the feedback provided in the FDA&#8217;s most recent response.  In April 2019, Zynquista was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&gt;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 27 kg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2 </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, who could not achieve adequate glycemic control despite optimal insulin therapy.  We have not commercially launched Zynquista for the treatment of type 1 diabetes in the European Union or any other region.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have completed three Phase 3 clinical trials evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 1 diabetes.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our pivotal inTandem1 Phase 3 clinical trial enrolled 793 patients with type 1 diabetes in the United States and Canada in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  The primary efficacy endpoint under evaluation in the trial was the reduction of hemoglobin A1c, or A1C, versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing an event of severe hypoglycemia or diabetic ketoacidosis, or DKA, change in meal-time, or bolus, insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.43% for the 200mg dose (p&lt;0.001) and 0.48% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.07% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Benefits in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo, with statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm and in the percentage of patients achieving A1C levels of less than 7% without any severe hypoglycemia or DKA events and weight loss observed in the 200mg dose arm and statistically significant improvements in all secondary efficacy endpoints observed in the 400mg dose arm.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 80.6%, 81.7% and 79.8%, respectively; the incidences of serious adverse events were 7.5%, 10.3% and 11.1%, respectively; and the incidences of discontinuation due to adverse events were 4.1%, 4.9% and 6.5%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 26 (9.7%), 17 (6.5%) and 17 (6.5%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 1 (0.4%), 9 (3.4%) and 11 (4.2%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our pivotal inTandem2 Phase 3 clinical trial enrolled 782 patients with type 1 diabetes in Europe and Israel in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 24-week treatment period, followed by a 28-week extension.  Insulin therapy was optimized in patients over a 6-week period prior to dosing.  As with inTandem1, the primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemia or DKA event, change in bolus insulin use, body weight, fasting plasma glucose and patient-reported assessments.  Data from the study showed that patients treated with sotagliflozin experienced statistically significant reductions in A1C from baseline of 0.39% for the 200mg dose (p&lt;0.001) and 0.37% for the 400mg dose (p&lt;0.001), as compared to a reduction of 0.02% on placebo after 24 weeks of treatment, meeting the study&#8217;s primary efficacy endpoint at both dose levels.  The A1C benefit achieved with sotagliflozin was sustained with statistically significant results over the full 52-week duration of the study for both the 200mg and 400mg doses.  Statistically significant improvements in all secondary efficacy endpoints were observed in both the 200mg and 400mg dose arms compared to placebo.  Over the full 52-week treatment period, the incidences of treatment-emergent adverse events in the placebo, 200mg and 400mg dose arms were 61.2%, 68.2% and 68.8%, respectively; the incidences of serious adverse events were 6.6%, 10.0% and 8.0%, respectively; and the incidences of discontinuation due to adverse events were 3.5%, 3.8% and 6.8%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the full 52-week treatment period was 13 (5.0%), 13 (5.0%) and 6 (2.3%) in the placebo, 200mg and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the full 52-week treatment period was 0 (0.0%), 6 (2.3%) and 9 (3.4%) in the placebo, 200mg and 400mg dose arms, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have additionally reported pooled continuous glucose monitoring, or CGM, data from the inTandem1 and inTandem2 clinical trials.  The percentage of time during the initial 24-week treatment period spent inside the target range for CGM glucose (70-180 mg/dL) increased from 52.2% to 57.8% in patients treated with 200mg of sotagliflozin and from 50.7% to 64.1% in patients treated with 400mg of sotagliflozin, with no relevant change observed in patients receiving placebo.  The differences from placebo were clinically significant for both the 200mg and 400mg dose groups (p=0.026 and p&lt;0.001, respectively).  The increase in time spent in range by both sotagliflozin dose groups was a result of significantly reduced time spent above 180 mg/dL, while the time spent below 70 mg/dL was not increased.  These results translate into an additional 1.41 hours and 3.02 hours that a patient would spend within the 70-180 mg/dL target range in a 24-hour period, for the 200mg and 400mg dose groups respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our inTandem3 Phase 3 clinical trial enrolled 1,405 patients with type 1 diabetes in the United States and Europe in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a 24-week treatment period.  Insulin therapy was not optimized in patients and eligibility criteria included any background insulin therapy.  The primary efficacy endpoint under evaluation in the trial was the proportion of patients achieving A1C levels of less than 7% at 24 weeks without experiencing a severe hypoglycemic or DKA event, with secondary endpoints including the change from baseline in A1C, body weight, systolic blood pressure and bolus insulin use.  Data from the study showed statistically significant superiority of sotagliflozin (28.6%) compared to placebo (15.2%) in the proportion of patients achieving A1C levels of less than 7% without experiencing a severe hypoglycemic or DKA event (p&lt;0.001), meeting the study&#8217;s primary endpoint.  Patients treated with sotagliflozin also experienced statistically significant improvements in all secondary efficacy endpoints compared to placebo.  The incidences of treatment-emergent adverse events in the placebo and 400mg dose arms were 52.5% and 55.1%, respectively; the incidences of serious adverse events were 3.3% and 6.9%, respectively; and the incidences of discontinuation due to adverse events were 2.3% and 6.3%, respectively.  Potential cases of severe hypoglycemia and DKA were reviewed by a blinded adjudication panel, which determined whether such cases met pre-established diagnostic criteria.  The number of patients with positively adjudicated severe hypoglycemic events during the 24-week treatment period was 17 (2.4%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  The number of patients with positively adjudicated DKA events during the 24-week treatment period was 4 (0.6%) and 21 (3.0%) in the placebo and 400mg dose arms, respectively.  Results from the inTandem3 trial were published in the New England Journal of Medicine in September 2017.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are conducting a comprehensive Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease.  This Phase 3 program includes two long-term outcomes studies: SCORED, which is designed to demonstrate benefits in chronic heart failure and chronic kidney disease in type 2 diabetes patients, and SOLOIST, which is designed to demonstrate benefits in acute decompensated heart failure in patients with and without type 2 diabetes.  We have cooperated with Sanofi in the transition of responsibility for such Phase 3 development program, which was previously conducted by Sanofi, and other activities relating to sotagliflozin.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have reported preliminary top-line results from the first four Phase 3 clinical trials of sotagliflozin in adults living with type 2 diabetes.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We reported preliminary top-line results in July 2019 from our SOTA-MET Phase 3 clinical trial.  SOTA-MET enrolled 518 patients with type 2 diabetes and inadequate blood sugar control on background metformin therapy in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a 26-week core treatment period, followed by a 53-week extension treatment period.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo at 26 weeks.  Preliminary results from the study showed that patients treated with sotagliflozin experienced a statistically significant reduction in A1C at 26 weeks versus placebo, meeting the study's primary efficacy endpoint.  Sotagliflozin was generally well-tolerated in the trial, with similar overall incidences of serious adverse events in patients treated with sotagliflozin and placebo.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reported preliminary top-line results in July 2019 from our SOTA-CKD3 Phase 3 clinical trial.  SOTA-CKD3 enrolled 787 patients with type 2 diabetes and moderate, or stage 3, chronic kidney disease in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 26-week core treatment period, followed by a 26-week extension period.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo at 26 weeks in the overall population of patients with stage 3 chronic kidney disease and in each of the subpopulations of patients with stage 3a and 3b chronic kidney disease.  Preliminary results from the study showed that patients in the overall stage 3 population and patients with stage 3a chronic kidney disease who were treated with the 400mg dose of sotagliflozin experienced a statistically significant reduction in A1C at 26 weeks versus placebo.  Although sotagliflozin demonstrated numerical improvement on A1C at 26 weeks, a statistically significant reduction in A1C at 26 weeks versus placebo was not </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">achieved in patients with stage 3b chronic kidney disease.  Sotagliflozin was generally well-tolerated in the trial, with similar overall incidences of serious adverse events in patients treated with sotagliflozin and placebo.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reported preliminary top-line results in July 2019 from our SOTA-CKD4 Phase 3 clinical trial.  SOTA-CKD4 enrolled 277 patients with type 2 diabetes and severe, or stage 4, chronic kidney disease in a randomized, double-blind, placebo-controlled study of 200mg and 400mg once daily doses of sotagliflozin over a 26-week core treatment period, followed by a 26-week extension period.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo at 26 weeks.  Preliminary results from the study showed that patients treated with the 400mg dose of sotagliflozin experienced a clinically meaningful reduction in A1C at 26 weeks that narrowly missed statistical significance versus placebo and achievement of the primary efficacy endpoint.  Sotagliflozin was generally well-tolerated in the trial, with similar overall incidences of serious adverse events in patients treated with sotagliflozin and placebo.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reported top-line results in December 2019 from our SOTA-EMPA Phase 3 clinical trial.  SOTA-EMPA enrolled 770 type 2 diabetes patients on dipeptidyl peptidase-4 inhibitors, with or without metformin therapy, in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin and a 25mg once daily dose of empagliflozin over a 26-week treatment period.  The primary efficacy endpoint under evaluation in the trial was the reduction of A1C versus placebo at 26 weeks.  Data from the study showed that patients treated with sotagliflozin experienced a statistically significant reduction in A1C at 26 weeks versus placebo, meeting the study's primary efficacy endpoint.  The trial also achieved a key secondary endpoint of noninferiority of sotagliflozin versus empagliflozin on A1C reduction at 26 weeks.  Sotagliflozin was generally well-tolerated in the trial, with safety results comparable to previously reported safety results in type 2 diabetes.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to such trials, the Phase 3 development program also includes the following randomized, double-blind, placebo-controlled studies:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOTA-MONO study of 200mg and 400mg once daily doses of sotagliflozin as monotherapy in approximately 400 patients over a 26-week treatment period;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOTA-SU study of a 400mg once daily dose of sotagliflozin in approximately 500 patients added to sulfonylurea alone or in combination with metformin therapy over a 26-week core treatment period, followed by a 53-week extension treatment period;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SCORED long-term outcomes study of a 200mg once daily dose of sotagliflozin, titrated to 400mg if the 200mg dose is tolerated, in approximately 10,500 patients with cardiovascular risk factors and moderate or severe renal impairment over a study duration to be determined by cardiovascular outcome events;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOTA-INS study of 200mg and 400mg once daily doses of sotagliflozin in approximately 560 patients on background basal insulin alone or in addition to other oral antidiabetic drug therapies over a 52-week treatment period;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOTA-GLIM study of 200mg and 400mg once daily doses of sotagliflozin in approximately 930 patients on background metformin therapy compared to up to a maximum daily dose of 6mg of glimepiride over a 52-week treatment period;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOTA-BONE study of 200mg and 400mg once daily doses of sotagliflozin in approximately 360 patients aged 55 years or older, with or without any stable anti-diabetes therapy, evaluating efficacy and bone safety over a 26-week core treatment period, followed by a 78-week double-blind extension treatment period; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our SOLOIST long-term outcomes study of a 200mg once daily dose of sotagliflozin, titrated to 400mg if the 200mg is tolerated, in approximately 3,000 patients with acute decompensated heart failure and with or without type 2 diabetes over a study duration to be determined by cardiovascular outcome events.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">LX9211</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">LX9211 is an orally-delivered small molecule compound that we are developing for the treatment of neuropathic pain.  LX9211 was discovered by scientists working within our drug discovery alliance with Bristol-Myers Squibb and inhibits adaptor associated kinase 1, or AAK1.  Our scientists discovered that mice lacking AAK1 exhibit increased resistance to induced neuropathic pain in preclinical models.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reported top-line data in December 2018 and December 2019 from two Phase 1 clinical trials evaluating the safety, tolerability and pharmacokinetics of LX9211.  The first trial enrolled ten cohorts of healthy volunteers in a randomized, double-blind, placebo-controlled, ascending single dose study of daily doses of LX9211.  The second trial enrolled five cohorts of healthy volunteers in a randomized, double-blind, placebo-controlled, ascending multiple dose study of daily doses of LX9211, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">followed by a maintenance dose for 14 days.  In both trials, LX9211 demonstrated a safety, tolerability and pharmacokinetics profile identifying the maximum tolerated dose and supportive of once-daily dosing, while exhibiting dose proportional pharmacokinetics.  The most common adverse events were headache and dizziness, and there were no drug-related serious adverse events.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are preparing to initiate a Phase 2a clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic, or DPN, pain.  The trial is expected to enroll approximately 282 patients experiencing DPN pain in a randomized, double-blind, placebo-controlled study of initial 100mg or 200mg loading doses of LX9211, followed by 10mg or 20mg once daily doses of LX9211, respectively.  The effects of LX9211 will be assessed over an 11-week evaluation period.  The primary efficacy endpoint under evaluation is the reduction in an average daily pain score at 6 weeks, with secondary endpoints including the proportion of patients with 30% or greater and 50% or greater reduction in pain intensity at 6 weeks and the proportion of patients discontinuing treatment due to lack of efficacy.  Certain patient-reported outcome measures will also be assessed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have obtained exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1 from our alliance with Bristol-Myers Squibb.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Drug Target Discoveries</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our internal drug discovery efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, more than 100 targets with promising profiles for drug discovery.</span></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_22"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Collaborations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians, as we have with XERMELO in the United States.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.  We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Strategic Collaborations</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ipsen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We entered into a license and collaboration agreement with Ipsen in October 2014 under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize XERMELO outside of the United States, Canada and Japan.  The collaboration was expanded in March 2015 to include Canada.  We have received $24.5&#160;million in upfront payments and $22.7 million in regulatory and commercial launch milestones under the agreement.  In addition, we are eligible to receive up to an additional $9.6&#160;million upon the achievement of additional specified regulatory and commercial launch milestones and up to &#8364;72&#160;million upon the achievement of specified sales milestones.  We are also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the licensed territory, subject to a credit for Ipsen&#8217;s payments to us for the manufacture and supply of such units of XERMELO and customary royalty reduction provisions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Bristol-Myers Squibb</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;We established a drug discovery alliance with Bristol-Myers Squibb Company in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.&#160;&#160;Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006.&#160;&#160;We initiated the alliance with a number of neuroscience drug discovery programs at various stages of development and used our gene knockout technologies to identify additional drug targets with promise in the neuroscience field.&#160;&#160;For those targets that were selected for the alliance, we and Bristol-Myers Squibb worked together, on an exclusive basis, to identify, characterize and carry out the preclinical development of small molecule drugs.  Bristol-Myers Squibb has the first option to assume full responsibility for clinical development and commercialization of any drugs resulting from the alliance which enter clinical trials, other than LX9211 and additional compounds acting through AAK1.  We received $86&#160;million in upfront payments and research funding under the agreement during the target discovery </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">portion of the alliance, which expired in October 2009. &#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76&#160;million for each drug developed by Bristol-Myers Squibb under the alliance.&#160;&#160;We will also earn royalties on sales of drugs commercialized by Bristol-Myers Squibb under the alliance.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We jointly developed LX9211 with Bristol-Myers Squibb as part of the alliance, and obtained from the alliance exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.  We have agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication and up to $16 million in clinical and regulatory milestones for each of the second and third indications, if applicable.  We have also agreed to pay single digit royalties on worldwide net sales and up to $40 million in commercial milestones.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Genentech</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;We established a drug discovery alliance with Genentech, Inc. in December 2002 to discover novel therapeutic proteins and antibody targets.&#160;&#160;We and Genentech expanded the alliance in November 2005 for the advanced research, development and commercialization of new biotherapeutic drugs.&#160;&#160;Under the original alliance agreement, we used our target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech&#8217;s internal drug discovery research.&#160;&#160;In the expanded alliance, we conducted additional, advanced research on a broad subset of those proteins and targets.&#160;&#160;We have exclusive rights to develop and commercialize biotherapeutic drugs for two of these targets, while Genentech has exclusive rights to develop and commercialize biotherapeutic drugs for the other targets.&#160;&#160;We retain certain other rights to discoveries made in the alliance, including non-exclusive rights, along with Genentech, for the development and commercialization of small molecule drugs addressing the targets included in the alliance.  We received $58&#160;million in upfront payments, research funding and research milestone payments under the agreement during the research collaboration term, which expired in November 2008.&#160;&#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the extent of our efforts in the alliance, up to $25&#160;million for each drug target for which Genentech develops a biotherapeutic drug under the alliance.&#160;&#160;We will also earn royalties on sales of biotherapeutic drugs commercialized by Genentech under the alliance.&#160;&#160;Genentech is entitled to receive milestone payments and royalties on sales of biotherapeutic drugs which we develop or commercialize under the alliance.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Collaborations</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have established collaborations with a number of pharmaceutical and biotechnology companies, research institutes and academic institutions under which we have received fees in exchange for generating knockout mice for genes requested by the collaborator, providing phenotypic data with respect to such knockout mice or otherwise granting access to some of our technologies and discoveries.&#160;&#160;In some cases, we remain eligible to receive milestone or royalty payments on the sale of mice and phenotypic data or on products that our collaborators discover or develop using our technology.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_25"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Manufacturing and Product Supply</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not own or operate manufacturing or distribution facilities or resources for clinical or commercial production and distribution of XERMELO or any of our drug candidates.  Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations, or CMOs, who, on our behalf, manufacture&#160;commercial supplies of XERMELO and clinical supplies of our drug candidates, and will continue to do so for the foreseeable future.  We have selected well-established and reputable global CMOs for our active pharmaceutical ingredient, or API, and drug product manufacturing that have good regulatory standing, large manufacturing capacities, and multiple manufacturing sites within their business footprint.  We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our CMOs.  Our quality department audits these suppliers on a periodic basis.  Our commercial suppliers are subject to routine inspections by regulatory agencies.  We work closely with our third-party manufacturers to ensure compliance with current good manufacturing practices, or cGMP, and other stringent regulatory requirements enforced by the FDA and foreign regulatory agencies in other territories, as applicable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Raw materials that are used to manufacture our API are sourced from multiple third-party suppliers in Asia and Europe.  Third-party API contract manufacturers in Asia and Europe stock sufficient quantities of these materials to ensure they can manufacture adequate API quantities per our requirements, for both clinical and commercial purposes.  We store API at third-party facilities, and provide appropriate amounts to third-party drug product contract manufacturers in Asia and North America who then manufacture, package and label our specified quantities of finished goods for XERMELO and our drug candidates.  We rely on sole source third-party drug product contract manufacturers in the United States to manufacture, package and label finished drug product for commercial distribution of XERMELO.  We also rely on a single third-party logistics provider, with two distribution locations, to provide shipping and warehousing services for our commercial supply of XERMELO in the United States.  Our third-party contract manufacturers also need to obtain materials such as excipients, components and reagents to manufacture our API and finished drug products.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Within our supply chain, we have established safety stock amounts for both our API and drug products, and store those quantities for XERMELO in multiple locations.  The quantities that we store are based on our business needs and take into account scenarios for demand, production lead times, potential supply interruptions and shelf life for our API and drug products.  In parallel, for business continuity reasons, we have established a backup supplier for our API and are in the process of evaluating and expect to establish an additional or backup supplier for our drug product in the near future.  We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of XERMELO for both our and Ipsen&#8217;s commercialization efforts in support of the current approved indication of carcinoid syndrome diarrhea, as well as the potential indication of biliary tract cancer, if clinical development in that indication proves to be successful and gains regulatory approval in the future.</span></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_28"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Marketing, Sales and Distribution</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions.  Our specialized sales team promotes XERMELO in the United States, concentrating their efforts on oncologists, oncology nurses and pharmacists.  We have also built an internal medical affairs function with responsibility for responding to external inquiries regarding the appropriate use of XERMELO with regularly updated and well-substantiated scientific and medical information.&#160; We have a limited distribution network consisting of specialty pharmacies and specialty distributors who distribute XERMELO in fulfillment of prescriptions in the United States.  We rely on Ipsen for the commercialization and distribution of XERMELO in territories outside of the United States.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To help ensure that all eligible patients in the United States have appropriate access to XERMELO, we have established a comprehensive reimbursement and support program called LexCares.  Through LexCares, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria.  In addition, LexCares is designed to provide comprehensive reimbursement support services, such as benefits investigation and, if needed, appeals support.</span></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_31"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Competition</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.&#160;&#160;We face significant competition in each of the aspects of our business from other pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and governmental agencies that are pursuing research or development activities similar to ours.  Many of our competitors have substantially greater research, development and commercialization capabilities and financial, scientific, marketing and human resources than we do.&#160;&#160;As a result, our competitors may succeed in developing products earlier than we do, obtaining approvals from the FDA or other regulatory agencies for those products more rapidly than we do, developing products that are more effective than those we develop or commercializing products more effectively and profitably than we do.&#160;&#160;Similarly, our collaborators face similar competition from other competitors who may succeed in developing products more quickly, developing products that are more effective than those developed by our collaborators or commercialize products more effectively and profitably than our collaborators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The competition for our products and drug candidates includes both marketed products and drug candidates that are being developed by others, including pharmaceutical products that are currently in a more advanced stage of clinical development or commercialization than are our own drug candidates.&#160;&#160;These competitive marketed products and drug candidates include compounds that employ different mechanisms of action in addressing diseases and conditions for which we are developing our own drug candidates and, in some cases such as sotagliflozin, that employ the same or similar mechanisms of action.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our ability to successfully compete with these potentially competitive drug candidates and other competitive products currently on the market will depend on, among other things:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efficacy, safety and reliability of our products;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability, and the ability of our collaborators, to complete preclinical and clinical development and obtain regulatory approvals for our drug candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and scope of regulatory approvals of our products;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability, and the ability of our collaborators, to obtain product acceptance by physicians and other health care providers and secure coverage and adequate reimbursement for product use in approved indications;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability, and the ability of our collaborators, to manufacture and sell commercial quantities of our products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">protection of our intellectual property; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal competition for XERMELO includes the use, above their maximum labeled dose, of the established SSA therapies octreotide and lanreotide, injectable products currently marketed by Novartis and Ipsen, respectively, as well as lutetium Lu 177 dotatate, a radiopharmaceutical product currently marketed for the treatment of gastroenteropancreatic neuroendocrine tumors by Advanced Accelerator Applications (a subsidiary of Novartis).</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our principal competition for sotagliflozin in the treatment of type 1 diabetes would include established insulin therapies, as well as selective SGLT2 inhibitors currently being prescribed off-label, but which may gain regulatory approval, for the treatment of type 1 diabetes in the United States.  Such selective SGLT2 inhibitors include dapagliflozin, empagliflozin and canagliflozin, currently marketed for the treatment of type 2 diabetes by AstraZeneca, Boehringer Ingelheim and Eli Lilly, and Janssen (a subsidiary of Johnson &amp; Johnson), respectively.  In addition, AstraZeneca has received approval in the European Union for the use of dapagliflozin in type 1 diabetes as an adjunct to insulin in patients with a body mass index of 27 kg/m&#178; or greater, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our principal competition for sotagliflozin for the treatment of type 2 diabetes would include such selective SGLT2 inhibitors, as well as DPP-4 inhibitors such as sitagliptin, currently marketed for the treatment of type 2 diabetes by Merck.  We expect that our principal competition for sotagliflozin for the treatment of heart failure would include such selective SGLT2 inhibitors which may gain regulatory approval for the treatment of heart failure, as well as angiotensin-converting enzyme, or ACE, inhibitors and the combination drug sacubitril/valsartan, currently marketed for the treatment of heart failure by Novartis.  We expect that our principal competition for sotagliflozin for the treatment of chronic kidney disease would include canagliflozin and such other selective SGLT2 inhibitors which may gain regulatory approval for the treatment of chronic kidney disease.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_34"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Government Regulation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development, manufacture and sale of pharmaceutical products are subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.&#160;&#160;In the United States, new drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the FDC Act.&#160;&#160;The FDA and comparable governmental authorities regulate, among other things, research and development activities and the testing, manufacture, quality control, safety, efficacy, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, export and import of pharmaceutical products.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The standard process required by the FDA before a drug candidate may be marketed in the United States generally includes the following:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">preclinical laboratory and animal tests performed under current good laboratory practices, or cGLP;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">submission of an IND, which must become effective before human clinical trials may commence;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for its intended use;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">submission of a New Drug Application, or NDA, for approval of commercial marketing and sale, or of an NDA supplement, or sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and current good clinical practices, or cGCP;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA approval of the NDA or sNDA.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This process for the testing and approval of drug candidates requires substantial time, effort and financial resources.&#160;&#160;Preclinical development of a drug candidate can take from one to several years to complete, with no guarantee that an IND based on those studies will become effective to even permit clinical testing to begin.&#160;&#160;Before commencing the first clinical trial of a drug candidate in the United States, we must submit an IND to the FDA.&#160;&#160;The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial.&#160;&#160;In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial may begin.&#160;&#160;Submission of an IND may not result in FDA authorization to commence a clinical trial.  A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, and the FDA must grant permission for each clinical trial to start and continue.&#160;&#160;Further, an independent institutional review board for each medical center proposing to participate in the clinical trial must review and approve the plan for any clinical trial before it commences at that center.&#160;&#160;Regulatory authorities or an institutional review board or we may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase 1 clinical trials are conducted in a limited number of healthy human volunteers or, in some cases, patients, to evaluate the safety, dosage tolerance, absorption, metabolism, distribution and excretion of the drug candidate;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase 2 clinical trials are conducted in groups of patients afflicted with a specified disease or condition to obtain preliminary data regarding efficacy as well as to further evaluate safety and optimize dosing of the drug candidate.  Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Phase 3 clinical trials are conducted in larger patient populations at multiple clinical trial sites to obtain statistically significant evidence of the efficacy of the drug candidate for its intended use and to further test for safety in an expanded patient population.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the FDA may require, or companies may pursue, additional clinical trials after a product is approved.&#160;&#160;These so-called Phase&#160;4 studies may be made a condition to be satisfied after a drug receives approval.  Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up and to including withdrawal of NDA approval.  The results of Phase 4 studies can confirm the effectiveness of a drug candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After completion of clinical trials, FDA approval of an NDA must be obtained before a new drug may be marketed in the United States.&#160;&#160;The submission of an NDA requires payment of a substantial user fee to the FDA.  An NDA must contain, among other things, information on chemistry, manufacturing controls and potency and purity, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability and clinical data.&#160;&#160;There can be no assurance that the FDA will accept an NDA for filing and, even if accepted for filing, that approval will be granted.&#160;&#160;The FDA may convene an advisory committee to provide clinical insight on NDA review questions.  Although the FDA is not required to follow the recommendations of an advisory committee, the agency typically does so.  Among other things, the FDA reviews an NDA to determine whether a product is safe and effective for its intended use and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.&#160;&#160;The FDA may deny approval of an NDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial.&#160;&#160;Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.&#160;&#160;An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy or otherwise that could restrict the commercial applications of a product or impose costly procedures in connection with the commercialization or use of the product.  Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market.&#160;&#160;In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to obtaining FDA approval for each product, each drug manufacturing establishment must be inspected and approved by the FDA.&#160;&#160;All manufacturing establishments are subject to inspections by the FDA and by other federal, state and local agencies and must comply with current Good Manufacturing Practices requirements.&#160;&#160;Non-compliance with these </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">requirements can result in, among other things, total or partial suspension of production, failure of the government to grant approval for marketing and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes many years, with the actual time required varying substantially based on, among other things, the nature, novelty and complexity of the drug candidate and of the disease or condition.&#160;&#160;Government regulation may delay or prevent marketing of drug candidates or new diseases for a considerable period of time and impose costly procedures upon our activities.  The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all.  Success in earlier-stage clinical trials does not ensure success in later-stage clinical trials.&#160;&#160;Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results.  Furthermore, data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.  Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages.  Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Once the FDA approves a product, a manufacturer must provide certain updated safety and efficacy information.&#160;&#160;Product changes as well as certain changes in a manufacturing process or facility would necessitate additional FDA review and approval.&#160;&#160;Other post-approval changes may also necessitate further FDA review and approval.&#160;&#160;Additionally, a manufacturer must meet other requirements including those related to adverse event reporting and record keeping.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug.  Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency.&#160;&#160;Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which FDA has approved the drug and are otherwise consistent with the FDA-approved label for the drug.&#160;&#160;Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.  Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA.  Such off-label uses are common across medical specialties.  Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances.  The FDA does not regulate the behavior of physicians in their choice of treatments.  The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use.  Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various United States federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various United States federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDC Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The United States Orphan Drug Act is intended to incentivize the development of products for rare diseases or conditions that affect fewer than 200,000 people in the United States.  If a drug is being developed for a rare disease or condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug&#8221; for the same orphan indication.  If the FDA has previously approved another same drug for the same indication, the sponsor of the subsequent drug would be required to provide a plausible hypotheses of clinical superiority over the previously approved drug to obtain an orphan designation.  Upon FDA receipt of orphan drug designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses, the ability to apply for annual grant funding and waiver of PDUFA application fee.  In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity for the approved orphan-designated indication.  Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication.  Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">basis of a surrogate endpoint.  Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments.  For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs.  Priority review is designed to give drugs that treat serious conditions and offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months of NDA filing as compared to a standard review time of 10 months from NDA filing.  Certain other types of drug applications are also eligible for priority review.  Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track-designated drug and expedite review of the application for a drug designated for priority review.  Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint.  As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial.  In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.  Drugs designated as breakthrough therapies are also eligible for accelerated approval.  The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional programs intended to expedite the development of drug products were included in the 21st Century Cures Act, or the Cures Act.  The Cures Act includes various provisions to accelerate the development and delivery of new treatments, such as those intended to expand the types of evidence manufacturers may bring to the FDA to support drug approval, to encourage patient-centered drug development, to liberalize the communication of healthcare economic information to payers, and to create greater transparency with regard to manufacturer expanded access programs.  Central to the Cures Act are provisions that enhance and accelerate the FDA&#8217;s processes for reviewing and approving new drugs and supplements to approved NDAs, including provisions that:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require the FDA to establish a program to evaluate the potential use of real world evidence to help support the approval of a new indication for an approved drug and to help support or satisfy post-approval study requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">provide that the FDA may rely upon qualified data summaries to support the approval of a supplemental application with respect to a qualified indication for an already approved drug;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require the FDA to issue guidance for purposes of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require the FDA to establish a process for the qualification of drug development tools for use in supporting or obtaining FDA approval for or investigational use of a drug.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Cures Act amends Section 114 of the Food and Drug Administration Modernization Act of 1997 to help clarify and facilitate the dissemination of healthcare economic information, including by broadening the definition of healthcare economic information, expressly extending the dissemination of healthcare economic information to payors, and clarifying that healthcare economic information must only relate to an FDA-approved indication rather than directly relate to the indication.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regulation Outside of the United States</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to regulations in the United States, we are subject to the regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the United States.  Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas.  The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under European Union regulatory systems, a company may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the European Medicines Agency, or EMA, whose Committee for Medicinal Products for Human Use reviews the application and issues an </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">opinion on it.  The opinion is considered by the European Commission which is responsible for deciding applications.  If the application is approved, the European Commission grants a single marketing authorization that is valid for all European Union member states as well as Iceland, Liechtenstein and Norway, or the EEA.  The national authorization procedures, the decentralized and mutual recognition procedures, as well as national applications, are available for products for which the centralized procedure is not compulsory.  The mutual recognition procedure provides for the European Union member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State, or RMS.  The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state.  Under this procedure the applicant can select the member state that will act as the RMS.  In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States or CMS.  Within 90 days of receiving the application and assessment report, each CMS must decide whether to recognize the RMS assessment.  If a member state does not agree with the assessment, and the disputed points cannot be resolved the matter is eventually referred to the European Commission, whose decision is binding on all member states.  If the application is successful national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conditional marketing authorizations may be granted for a limited number of medicinal products for human use referenced in European Union law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if the risk-benefit balance of the product is positive, it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, unmet medical needs will be fulfilled and the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.  Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As in the United States, we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, orphan designation is available for products in development which are either intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union, or intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the community and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.  Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product.  The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare Regulation</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business.  If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.  The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent.  Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information.  Other countries also have, or are developing, laws governing the collection, use and transmission of personal information.  In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1996, as amended by the Health Information Technology and Clinical Health Act, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the PPACA, created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services, or CMS, annually certain payments and other transfers of value provided to physicians and teaching hospitals made in the previous calendar year.  In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.  These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.  In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For those marketed products which are covered in the United States by the Medicaid program, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers.  We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply.  These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear.  Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial penalties.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Regulations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the foregoing, our business is subject to regulation under various state and federal environmental laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act.&#160;&#160;These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by our operations.&#160;&#160;We believe that we are in material compliance with applicable environmental laws and that our continued compliance with these laws will not have a material adverse effect on our business.&#160;&#160;We cannot predict, however, whether new regulatory restrictions will be imposed by state or federal regulators and agencies or whether existing laws and regulations will adversely affect us in the future.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_37"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Patents and Proprietary Rights</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are able to protect our proprietary rights from unauthorized use by third parties only to the extent that those rights are covered by valid and enforceable patents or are effectively maintained as trade secrets.  Accordingly, patents and other proprietary rights are an essential element of our business.&#160;&#160;We own or exclusively license patents and/or patent applications throughout the world that claim our products and drug candidates, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim telotristat ethyl and associated crystalline forms, pharmaceutical compositions comprising telotristat ethyl, and methods of its manufacture and use;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Argentina, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and South Korea, that claim sotagliflozin and associated crystalline forms, pharmaceutical compositions comprising sotagliflozin, and methods of its manufacture and use; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issued patents and pending patent applications in Europe, the United States, and other countries throughout the world, including Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, New Zealand, South Africa, and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="padding-left:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">South Korea, that disclose and/or claim LX9211, pharmaceutical compositions comprising LX9211, and methods of its use.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we hold rights to a number of patents and patent applications under license agreements with third parties.&#160;&#160;Many of these licenses are nonexclusive, although some are exclusive in specified fields.&#160;&#160;Most of the licenses have terms that extend for the life of the licensed patents.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.&#160;&#160;We have filed patent applications and hold issued patents covering our approved drug, XERMELO, and each of our drug candidates.&#160;&#160;None of our United States patents that claim XERMELO or one of our drug candidates has a normal expiration date earlier than 2026.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All of our employees, consultants and advisors are required to execute a proprietary information agreement upon the commencement of employment or consultation. In general, the agreement provides that all inventions conceived by the employee or consultant, and all confidential information developed or made known to the individual during the term of the agreement, shall be our exclusive property and shall be kept confidential, with disclosure to third parties allowed only in specified circumstances. We cannot assure you, however, that these agreements will provide useful protection of our proprietary information in the event of unauthorized use or disclosure of such information.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our patent and intellectual property rights are subject to certain rights and uncertainties.  See &#8220;Risks Related to Our Intellectual Property&#8221; under &#8220;Item 1A.&#160;Risk Factors.&#8221;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_40"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Executive Officers</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our executive officers and their ages and positions are listed below.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.245%;"><tr><td style="width:1.0%;"></td><td style="width:26.125%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:62.881%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Age</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Position with the Company</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pablo Lapuerta, M.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and Chief Medical Officer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alan J. Main, Ph.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Commercial Supply Operations</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander A. Santini</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Praveen Tyle, Ph.D.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Research and Development</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Brian T. Crum</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President and General Counsel</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">James F. Tessmer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President, Finance and Accounting</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lonnel Coats</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> has been our president and chief executive officer and a director since July 2014.  Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining our company, most recently as chief executive officer from 2010 to 2014.  Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson &amp; Johnson, where he held a variety of management and sales positions.  Mr. Coats serves as a director of Blueprint Medicines Corporation and holds a B.S. from Oakland University.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pablo Lapuerta, M.D.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;has been our executive vice president and chief medical officer since February 2015 and previously served in a series of medical and clinical leadership positions since joining our company in 2011.  Dr. Lapuerta was formerly vice president at Bristol-Myers Squibb Company with responsibility for global development of an Alzheimer&#8217;s disease drug candidate, and prior to that served as senior vice president, clinical strategy and chief medical officer of Cogentus Pharmaceuticals, Inc. and in a variety of clinical development leadership roles at Bristol-Myers Squibb, where he worked for 11&#160;years before joining Cogentus. He holds a B.A. in biology from Harvard College and an M.D. from Harvard Medical School.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alan J. Main, Ph.D</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. has been our executive vice president, commercial supply operations since May 2017 and previously served in a series of manufacturing and scientific leadership positions since joining our company in 2001.&#160;&#160;Dr.&#160;Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until our acquisition of Coelacanth in 2001.&#160;&#160;Dr.&#160;Main was </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">formerly senior vice president, U.S.&#160;Research at Novartis Pharmaceuticals Corporation, where he worked for 20&#160;years before joining Coelacanth.&#160;&#160;Dr.&#160;Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alexander A. Santini</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> has been our executive vice president and chief commercial officer since November 2016 and previously served in a series of commercial leadership positions since joining our company in April 2015.  Mr. Santini was formerly vice president of market access and an executive member at Bayer Healthcare Pharmaceuticals, where he had executive responsibility for market access, pricing, trade and channel management and payer account management, and prior to that served in a variety of commercial leadership roles of increasing responsibility during eight years of service at Bayer and 22 years of service at Berlex Laboratories.  Mr. Santini served as a non-commissioned officer in the United States Air Force, where he completed the Radiologic Technology Program at the United States Air Force School of Health Care Science and an AAS in business marketing from Westchester Community College.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Praveen Tyle, Ph.D.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> has been our executive vice president of research and development since May 2016.  Dr. Tyle was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as president and chief executive officer from January 2013 through April 2016 and prior to that as executive vice president and chief scientific officer.  Prior to his service at Osmotica, Dr. Tyle held a series of scientific leadership positions within the pharmaceutical industry, including executive vice president and chief science officer for the United States Pharmacopeia, senior vice president and global head of research and development and business development and licensing at Novartis OTC, corporate senior vice president of global research and development and chief scientific officer at Bausch &amp; Lomb Incorporated and vice president and global head of pharmaceutical sciences at Pharmacia Corporation.  Dr. Tyle serves as director of Eyegate Pharmaceuticals, Inc. and Orient Europharma Ltd.  Dr. Tyle received his B.Pharm. from the Indian Institute of Technology, Banaras Hindu University and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Jeffrey L. Wade</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> has been our executive vice president, corporate and administrative affairs and chief financial officer since February 2015 and previously served in a series of finance and legal leadership positions since joining our company in 1999.&#160;&#160;Mr.&#160;Wade was previously a corporate securities and finance attorney for ten years with the law firm of Andrews&#160;&amp; Kurth&#160;L.L.P., where he represented companies in the biotechnology, information technology and energy industries.&#160;&#160;Mr.&#160;Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute.&#160;&#160;He received his B.A. and J.D. from the University of Texas.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Brian T. Crum</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> has been our vice president and general counsel since May 2010 and previously served in a series of legal leadership positions since joining our company in 2001.  Mr. Crum was previously a corporate securities attorney with the law firms of Brobeck, Phleger &amp; Harrison LLP and Andrews &amp; Kurth L.L.P., where he represented companies in the energy and information technology industries.  Mr. Crum received his B.B.A. and J.D. from the University of Texas.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">James F. Tessmer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> has been our vice president, finance and accounting since November 2007 and previously served in a series of finance and accounting leadership positions since joining our company in 2001.&#160;&#160;Mr. Tessmer was previously assistant controller for Mariner Health Network, Inc. and prior to that served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation.&#160;&#160;Mr. Tessmer is a certified public accountant and received his B.B.A. from the University of Wisconsin &#8211; Milwaukee and his M.B.A. from the University of Houston.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_43"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of February&#160;28, 2020, we employed 184 persons, of whom 29 hold M.D. or Ph.D. degrees and another 53 hold other advanced degrees.&#160;&#160;All of our employees are located in the United States.  None of our employees are represented by a labor union and we believe that our relationship with our employees is good.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_46"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019, 2018 and 2017, respectively, we incurred expenses of $91.9&#160;million, $100.2&#160;million and $152.2&#160;million in company-sponsored as well as collaborative research and development activities, including $7.1&#160;million, $6.0&#160;million and $4.9&#160;million of stock-based compensation expense in 2019, 2018 and 2017, respectively.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_49"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risk Factors </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.&#160;&#160;The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We depend heavily on the commercial success of XERMELO.  If we do not achieve commercial success with XERMELO, our business will suffer and our stock price will likely decline.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that a significant portion of our total revenues for the next several years will be attributable to sales of XERMELO in the United States, but we cannot be certain that XERMELO will be commercially successful.  Our future sales of XERMELO will depend on numerous factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number of patients with carcinoid syndrome diarrhea who are inadequately controlled by SSA therapy, as well as the number of newly diagnosed carcinoid syndrome diarrhea patients;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">competition from SSA therapies, radiopharmaceutical products and any additional products for the treatment of carcinoid syndrome diarrhea that may be approved by the FDA in the future;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the safety profile of XERMELO, including whether previously unknown side effects or increased incidence or severity of known side effects as compared to those seen during development are identified with the commercial use of XERMELO;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effectiveness of our commercial strategy for marketing XERMELO and our execution of that strategy, including our pricing strategy and the effectiveness of our efforts to obtain and maintain adequate third-party reimbursement;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the acceptance of XERMELO by patients, the medical community and third-party payers; and</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to meet the demand for commercial supplies of XERMELO and to maintain and successfully monitor commercial manufacturing arrangements for XERMELO with third-party manufacturers to ensure they meet our standards and those of the FDA, which extensively regulates and monitors pharmaceutical manufacturing facilities.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we believe that XERMELO has a competitive commercial profile, our current estimates of the revenues that XERMELO could generate in future periods may change based upon the above factors, and could prove to be incorrect.  If our revenues, market share or other indicators of market acceptance of XERMELO fail to meet the expectations of investors or public market analysts, the market price of our common stock could decline.  In addition, if one or more of the factors above negatively affects XERMELO sales, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in type 1 diabetes.  If we fail to obtain such regulatory approval or fail to successfully commercialize sotagliflozin for type 1 diabetes upon such regulatory approval, our business will suffer and our stock price will likely decline.&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA issued a complete response letter in March 2019 regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter in November 2019 and March 2020.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot offer any assurances that the FDA will grant marketing approval for sotagliflozin in type 1 diabetes, on acceptable timelines or at all.  Furthermore, regulatory approval in the United States for sotagliflozin in type 1 diabetes, even if obtained, may limit the type of patients in which sotagliflozin may be used, such as on the basis of body mass index as in the European Union, or otherwise require specific warning or labeling language or a formal risk evaluation and mitigation strategy, or REMS, any of which may reduce the commercial potential of sotagliflozin in type 1 diabetes.  Even if approved, our existing capital resources and commercial infrastructure are insufficient to commercially launch sotagliflozin for type 1 diabetes and we may not be successful in obtaining such resources, building such infrastructure or otherwise effectively commercializing sotagliflozin for type 1 diabetes.  Should we fail to obtain regulatory approval in the United States for sotagliflozin in type 1 diabetes, or fail to successfully commercialize sotagliflozin upon such regulatory approval, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We depend heavily on our ability to successfully complete Phase 3 clinical development of sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease, and obtain regulatory approvals for sotagliflozin in those indications.  If we fail to successfully complete such Phase 3 clinical development and obtain such regulatory approvals, or fail to successfully commercialize sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease upon such regulatory approvals, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are conducting a comprehensive Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease.  Our existing capital resources are insufficient to complete the two long-term outcomes studies included in such Phase 3 development program that are designed to demonstrate benefits in heart failure and chronic kidney disease.  Although we seek to collaborate with another pharmaceutical or biotechnology company with respect to the development and commercialization of sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease under terms which would provide additional funding for the completion of the Phase 3 development program, we may be unable to successfully enter into any such collaborative arrangement on reasonable terms, or at all.  If we are unable to enter into any such collaborative arrangement, or if we are otherwise unable to raise sufficient additional capital, we will likely elect to, and may be forced to, delay, reduce or wind down the long-term outcomes studies included in such Phase 3 development program.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if such additional funding is secured, we cannot offer any assurances or predict with any certainty that such Phase 3 development will be successfully completed, that positive clinical data will be obtained from such Phase 3 development efforts or that regulatory authorities will grant marketing approval for sotagliflozin in type 2 diabetes, heart failure or chronic kidney disease, in any such case on the expected timelines.  Furthermore, regulatory approvals for sotagliflozin, even if obtained, may limit the type of patients in which sotagliflozin may be used for type 2 diabetes, heart failure or chronic kidney disease or otherwise require specific warning or labeling language, each of which may reduce the commercial potential of sotagliflozin in those indications.  We cannot offer any assurances that the Phase 3 clinical development program will demonstrate a competitive commercial profile for sotagliflozin in type 2 diabetes, heart failure or chronic kidney disease.  Even if approved with a competitive commercial profile, our existing resources and commercial infrastructure are insufficient to commercially launch sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease and we or any potential collaborator may be unsuccessful in obtaining such resources, building such infrastructure or otherwise effectively commercializing sotagliflozin for type 2 diabetes, heart failure or chronic kidney disease.  Should we or any potential collaborator fail to obtain regulatory approvals for sotagliflozin in those indications or fail to successfully commercialize sotagliflozin upon such regulatory approvals, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other drug programs.</span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to obtain regulatory approvals for the commercial sale of any products that we or our collaborators may develop, we or our collaborators are required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of our drug candidates.&#160;&#160;We or our collaborators may not be able to obtain authority from the FDA, or other equivalent foreign regulatory agencies, to initiate or complete any clinical trials.&#160;&#160;In addition, we have limited internal resources for making regulatory filings and interacting with regulatory authorities.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trials are inherently risky and the results from nonclinical testing of a drug candidate that is under development may not be predictive of results that will be obtained in human clinical trials.&#160;&#160;In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger-scale, advanced stage clinical trials.&#160;&#160;A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving positive results in earlier trials.&#160;&#160;Although Phase&#160;2 proof-of-concept clinical trials of sotagliflozin in type 2 diabetes patients were positive, we cannot assure you that the Phase&#160;3 development program for sotagliflozin being conducted in type 2 diabetes, heart failure and chronic kidney disease will yield positive results.  Negative or inconclusive results from a nonclinical study or a clinical trial could cause us, our collaborators or the FDA or other equivalent foreign regulatory agencies to terminate a nonclinical study or clinical trial or require that we or our collaborators repeat or modify it.&#160;&#160;Furthermore, we, one of our collaborators or a regulatory agency with jurisdiction over the trials may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks or for other reasons.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any nonclinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.&#160;&#160;Nonclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval.  The FDA or institutional review boards at the medical institutions and healthcare facilities where we or our collaborators sponsor clinical trials may suspend any trial indefinitely if they find deficiencies in the conduct of these trials.&#160;&#160;Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practices.&#160;&#160;The FDA and these institutional review boards have authority to oversee our and our collaborators&#8217; clinical trials, and the FDA may require large </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">numbers of subjects or patients.&#160;&#160;In addition, we or our collaborators must manufacture, or contract for the manufacture of, the drug candidates that we use in our clinical trials under the FDA&#8217;s current Good Manufacturing Practices.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The rate of completion of clinical trials is dependent, in part, upon the rate of enrollment of patients.&#160;&#160;Patient accrual is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the nature of the study, the existence of competitive clinical trials and the availability of alternative treatments.&#160;&#160;Delays in planned patient enrollment may result in increased costs and prolonged clinical development, which in turn could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or potential products.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our collaborators may not be able to successfully complete any clinical trial of a drug candidate within any specified time period.&#160;&#160;In some cases, we or our collaborators may not be able to complete the trial at all. Moreover, clinical trials may not show our drug candidates to be both safe and effective.&#160;&#160;Thus, the FDA and other regulatory authorities may not approve any additional drug candidates that we develop for any indication or may limit the approved indications or impose other conditions.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our drug candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.&#160;&#160;Failure to obtain regulatory approval for any drug candidate would prevent us from commercializing that drug candidate.&#160;&#160;The process of obtaining regulatory approvals is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved.&#160;&#160;Before a new drug application can be filed with the FDA, the drug candidate must undergo extensive clinical trials, which can take many years and may require substantial expenditures.&#160;&#160;Any clinical trial may fail to produce results satisfactory to the FDA.&#160;&#160;For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results.&#160;&#160;Furthermore, prior to approving a new drug, the FDA typically requires that the efficacy of the drug be demonstrated in two double-blind, controlled studies.  The regulatory process also requires nonclinical testing, and data obtained from nonclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.&#160;&#160;In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review.&#160;&#160;Changes in regulatory approval policy, regulations or statutes or the process for regulatory review during the development or approval periods of our drug candidates may cause delays in the approval or rejection of an application.  Even if the FDA or a comparable authority in another country approves a drug candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials.&#160;&#160;These agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our or our collaborators&#8217; ability to commercialize any products that we or they may develop will be highly dependent upon the extent to which such products gain market acceptance among physicians, patients, health care payers, such as commercial health insurers, Medicare and Medicaid, and the medical community.&#160;&#160;If such products do not achieve an adequate level of acceptance, we may not generate adequate product revenues and we may not become profitable.&#160;&#160;The degree of market acceptance of such products will depend upon a number of factors, including:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effectiveness, or perceived effectiveness, of our products in comparison to competing products;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the existence of any significant side effects, as well as their severity in comparison to any competing products;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential advantages or disadvantages in relation to alternative treatments;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">current and future indications for which our products may be approved;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to offer our products for sale at competitive prices;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">relative convenience and ease of administration;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the strength of marketing and distribution support; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sufficient third-party coverage or reimbursement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we are unable to maintain an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to successfully commercialize any product that we or our collaborators may develop, we or they must build or maintain an effective commercialization infrastructure supporting such product, including sales force, marketing organization and distribution capabilities.  Factors that may hinder efforts to effectively establish, manage and maintain such infrastructure for products that we or our collaborators may develop include:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inability to recruit, retain and effectively manage adequate numbers of effective sales and marketing personnel;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inability to maintain relationships with third-party logistics providers, pharmacies, third-party manufacturers and other third parties instrumental in the commercial manufacture and distribution of such products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inability to establish or implement internal controls and procedures required in connection with sales of such products;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inability of sales personnel to obtain access to or convince adequate numbers of physicians to prescribe such products; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential lack of complementary products to be offered by sales personnel, which may put us or our collaborators at a competitive disadvantage relative to companies with more extensive product lines.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our collaborators are unable to sustain our or their sales force, marketing infrastructure and distribution capability for such products, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our collaborators will need to expend significant time and resources to train our sales forces to be credible, persuasive and compliant in discussing such products with the physicians treating the patients indicated under the label.  We or our collaborators will also need to continue to train our sales forces to ensure that a consistent and appropriate message about such products is being delivered to potential customers.  If we or our collaborators are unable to effectively train our sales forces and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of such products and their proper administration, our and their ability to successfully commercialize such products could be diminished, which could have a material adverse effect on our financial condition, stock price and operations.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to successfully commercialize any products that we or our collaborators may develop is highly dependent on the extent to which coverage and reimbursement for such products are available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers, including managed care organizations and group purchasing organizations.&#160;&#160;Many patients are not capable of paying themselves for the products that we or our collaborators may develop, and rely on third-party payers to pay for, or subsidize, their medical needs.&#160;&#160;If third-party payers do not provide coverage or reimbursement for such products, our revenues and prospects for profitability will suffer.&#160;&#160;In addition, even if third-party payers provide some coverage or reimbursement for such products, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans often varies based on the type of contract or plan purchased.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in some foreign countries, particularly the countries in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.&#160;&#160;In these countries, price negotiations with governmental authorities can take six to 12&#160;months or longer after the receipt of regulatory marketing approval for a product.&#160;&#160;To obtain reimbursement and/or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost effectiveness of our drug candidates or products to other available therapies.&#160;&#160;The conduct of such a clinical trial could be expensive and result in delays in the commercialization of our drug candidates.&#160;&#160;Third-party payers are challenging the prices charged for medical products and services, and many third-party payers limit reimbursement for newly approved health care </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">products.&#160;&#160;In particular, third-party payers may limit the indications for which they will reimburse patients who use any products that we or our collaborators may develop.&#160;&#160;Cost-control initiatives could decrease prices we or our collaborators might establish for products that may be developed, which would result in lower product revenues to us.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than XERMELO, our drug candidates have been manufactured in relatively small quantities for nonclinical and clinical trials.&#160;&#160;If any of these drug candidates are approved by the FDA or other regulatory agencies for commercial sale, we or our collaborators will need to manufacture them in larger quantities.  We may not be able to successfully increase the manufacturing capacity, whether in collaboration with third-party manufacturers or on our own, for any approved product in a timely or economic manner, or at all.&#160;&#160;Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.&#160;&#160;If we or our collaborators are unable to successfully increase the manufacturing capacity for any such product, the regulatory approval or commercial launch of that product may be delayed or there may be a shortage in supply.&#160;&#160;Pharmaceutical products typically require precise, high-quality manufacturing.&#160;&#160;The failure to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our collaborators are subject to extensive and rigorous ongoing domestic and foreign government regulation of, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of any products which receive regulatory approvals from the FDA or foreign regulatory authorities.&#160;&#160;The failure to comply with these requirements or the identification of safety problems during commercial marketing could lead to the need for product marketing restrictions, product withdrawal or recall or other voluntary or regulatory action, which could delay further marketing until the product is brought into compliance.&#160;&#160;The failure to comply with these requirements may also subject us or our collaborators to stringent penalties.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, without limitation:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the federal Anti-Kickback Law, which constrains our marketing practices, educational programs, pricing policies, relationships with healthcare providers or other entities, and other business activities, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">state and federal government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported price may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and potentially limit our ability to offer certain marketplace discounts); and</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">state and federal marketing expenditure tracking and reporting laws, which generally require certain types of expenditures in the United States to be tracked and reported.  Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, certain marketing practices, including off-label promotion, may also violate certain federal and state health regulatory fraud and abuse laws as well as false claims laws, including the civil False Claims Act.  Suits filed under the civil False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement.  The filing of&#160;qui tam&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to defend a civil False Claims Act action.  When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our operations, the exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to sell our products or operate our business and also adversely affect our financial results.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may be expected to prescribe our products and from whom we may obtain patient health information are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA.  Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.  The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification.  These laws could create liability for us or increase our cost of doing business.  International laws, such as the EU Data Privacy Directive and Swiss Federal Act on Data Protection, regulate the processing of personal data within Europe and between European countries and the United States.  Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A primary trend in the United States and some foreign countries is toward reform and cost containment in the health care industry.&#160;&#160;The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals that may have the effect of reducing the prices that we are able to charge for products we or our collaborators may develop.  Healthcare reform measures which may be adopted in the future in the United States and foreign jurisdictions may result in more rigorous coverage criteria and significant downward pressure on the prices drug manufacturers may charge.  As a result, our revenues and prospects for profitability could be significantly harmed.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the United States, third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. They may use tiered reimbursement and may adversely affect demand for products we or our collaborators may develop by placing them in an expensive tier.  They may also refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals.  As a result, significant uncertainty exists as to whether and how much third-party payers will reimburse for newly approved drugs, which in turn will put pressure on the pricing of drugs.  Further, we do not have experience in ensuring approval by applicable third-party payers outside of the United States for coverage and reimbursement of pharmaceutical products.  We also anticipate pricing pressures in connection with the sale of products we or our collaborators may develop due to the increasing influence of health maintenance organizations and additional legislative proposals.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs.  We may become subject to similar requests, which would require us to incur significant expense and result in distraction for our management team.  Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of our company, such findings could further harm our business, reputation and/or prospects.  It is possible that such inquiries could result in negative publicity or other negative actions that could harm our reputation, changes in our product pricing and distribution strategies, reduced demand for our approved products and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pharmaceutical and biotechnology industries are highly diversified and are characterized by rapid technological change.&#160;&#160;We and our collaborators face, and will continue to face, intense competition from biotechnology and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research and development activities similar to ours.&#160;&#160;In addition, significant delays in the development of our drug candidates could allow our competitors to bring products to market before us, which would impair our or our collaborators&#8217; ability to commercialize our drug candidates.&#160;&#160;Any products that we or our collaborators develop will compete in highly competitive markets.&#160;&#160;Further, our competitors may be more effective at using their technologies to develop commercial products.&#160;&#160;Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and marketing capabilities.&#160;&#160;As a result, our competitors may be able to more easily develop products that would render any products that we or our collaborators develop obsolete and noncompetitive.&#160;&#160;For example, dapagliflozin, empagliflozin and canagliflozin are currently being marketed by AstraZeneca, Boehringer Ingelheim and Eli Lilly, and Janssen (a subsidiary of Johnson &amp; Johnson), respectively, for the treatment of type 2 diabetes and certain other indications, such as heart failure, cardiovascular death, major adverse cardiovascular events and end-stage kidney disease.  Each of those products act through SGLT2, one of the targets of sotagliflozin. &#160;In addition, there may be drug candidates of which we are not aware at an earlier stage of development that may compete with our drug candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We face business disruption and related risks resulting from the recent outbreak of the novel coronavirus 2019 (COVID-19), which could have a material adverse effect on our business.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercialization efforts and development programs could be disrupted and materially adversely affected by the recent outbreak of COVID-19. As a result of measures imposed by the governments in affected regions, many commercial activities, businesses and schools have been suspended as part of quarantines and other measures intended to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the International Health Regulations Emergency Committee of the World Health Organization declaring the outbreak of COVID-19 as a &#8220;public health emergency of international concern,&#8221; and the World Health Organization characterizing COVID-19 as a pandemic.  While the COVID-19 outbreak may still be in early stages, international stock markets have begun to reflect the uncertainty associated with the potential economic impact of the outbreak and the significant declines in the Dow Industrial Average at the end of February and in March 2020 has been largely attributed to the effects of COVID-19.  We are still assessing the potential impact COVID-19 may have on our ability to effectively conduct our commercialization efforts and development programs and otherwise conduct our business operations as planned, but there can be no assurance that we will be able to avoid part or all of any impact from the spread of COVID-019 or its consequences, including downturns in business sentiment generally or in our industry and business in particular.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Our Capital Requirements and Financial Results</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our commercialization efforts or product development programs.&#160;&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had $271.7&#160;million in cash, cash equivalents and investments.&#160;&#160;We anticipate that our existing capital resources and the cash and revenues we expect to derive from product revenues, collaborations and other sources will enable us to fund our currently planned operations for at least the next 12 months.  However, we caution you that we may generate less cash and revenues or incur expenses more rapidly than we currently anticipate.  Our currently planned operations for the next twelve months include the continued commercialization of XERMELO in the United States and the continued nonclinical and clinical development of telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although difficult to accurately predict, the amount of our future capital requirements will be substantial and will depend on many factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our sales, marketing, distribution and other commercialization activities for XERMELO in the United States and the revenues we generate from such activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of Ipsen&#8217;s sales, marketing, distribution and other commercialization activities for XERMELO outside of the United States and Japan and our receipt of any milestone payments and royalties;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain regulatory approval for the marketing and sale of sotagliflozin for type 1 diabetes in the United States;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing, progress and results of our clinical trials of telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates and our ability to obtain necessary regulatory approvals based on such clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the amount and timing of our research, development and commercialization expenditures;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effect of competing programs and products, and of technological and market developments; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our capital resources are insufficient to meet future capital requirements, we will need to raise additional funds to continue our currently planned operations.&#160;&#160;Our ability to raise additional capital is dependent on a number of factors, including the market demand for our securities, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.  If we raise additional capital by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preferences over our common stock.&#160;&#160;The affirmative and restrictive covenants and the pledge of substantially all of our assets as collateral under our existing term loan with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP, or the BioPharma Term Loan, restrict our ability to raise additional capital by issuing debt securities.  We cannot be certain that additional financing, whether debt or equity, will be available in amounts or on terms acceptable to us, if at all.&#160;&#160;We may be unable to raise sufficient additional capital on reasonable terms, and if so, we will be forced to delay, reduce or eliminate our clinical development programs or commercialization efforts or obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception, including an aggregate net loss of $113.4 million for the three years </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ended December&#160;31, 2019.&#160;&#160;As o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">f December&#160;31, 2019, we had an accumulated deficit of $1.3&#160;billion.&#160;&#160;Because of the numerous risks and uncertainties associated with successfully developing and commercializing drug products, we are unable to predict the extent of any future losses or whether or when we will become profitable, if at all.&#160;&#160;The size of our net losses will depend, in part, on the rate of decline or growth in our revenues and on the amount of our expenses.  We expect to continue to incur significant expenses over the next several years as we expect to make significant investments in the commercialization of XERMELO in the United States and the continued nonclinical and clinical development of telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the commercial launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  Future revenues from our commercialization of XERMELO are uncertain because they depend on a number of factors, including market acceptance of XERMELO, the success of our sales, marketing, distribution and other commercialization activities and the cost and availability of reimbursement for XERMELO.  Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any products developed or commercialized under the collaborations.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to spend significant amounts to fund our commercialization activities with respect to XERMELO in the United States and our planned nonclinical and clinical development of telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates.  As a result, we will need to generate substantial additional revenues to achieve profitability in future periods.&#160;&#160;Even if we do achieve profitability in future periods, we may not be able to sustain or increase such profitability on a quarterly or annual basis.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operating results have fluctuated in the past and are likely to fluctuate in the future.  A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain regulatory approval of sotagliflozin for type 1 diabetes in the United States;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our ongoing nonclinical and clinical development efforts;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and amount of expenses incurred with respect to our nonclinical and clinical development and commercialization efforts;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our success in establishing new collaborations and technology licenses, including for the development and commercialization of sotagliflozin, and the timing and financial terms of such arrangements;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success rate of our development efforts leading to opportunities for new collaborations and licenses, as well as milestone payments and royalties;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing and willingness of our collaborators to commercialize pharmaceutical products that would result in milestone payments and royalties;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products and technologies;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">general and industry-specific economic conditions, which may affect our and our collaborators&#8217; research and development expenditures.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of these and other factors, including the risks and uncertainties described in this section, our operating results have fluctuated in the past and are likely to do so in the future.&#160;&#160;Due to the likelihood of fluctuations in our revenues and expenses, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred $245.2 million of indebtedness.  Although the affirmative and restrictive covenants and the pledge of substantially all of our assets as collateral under the BioPharma Term Loan restrict our ability to obtain additional debt </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">financing, we could in the future incur additional indebtedness beyond such amount.  Our substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product commercialization and development efforts and other general corporate purposes;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and marketable securities and funds from external sources.  However, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt.  Funds from external sources may not be available on acceptable terms, if at all.  In addition, a failure to comply with the covenants under our existing debt instruments could result in an event of default under those instruments.  In the event of an acceleration of amounts due under our debt instruments as a result of an event of default, including upon the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, properties, assets or condition or a failure to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce their security interests in the collateral securing such indebtedness.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we do not effectively manage our affirmative and restrictive covenants under the BioPharma Term Loan, our financial condition and results of operations could be adversely affected.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of our assets.  In addition, the BioPharma Term Loan requires that we comply with certain affirmative and restrictive covenants, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us.  Our failure to comply with any of these covenants could result in a default under the BioPharma Term Loan, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable.  If we are unable to repay those amounts, the lenders could enforce the security interest granted to them to secure that debt, which would seriously harm our business.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Our Relationships with Third Parties</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We are significantly dependent upon our collaborations with Ipsen and other pharmaceutical and biotechnology companies.&#160;&#160;If pharmaceutical products are not successfully and timely developed and commercialized under our collaborations, our opportunities to generate revenues from milestones and royalties will be greatly reduced.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into a collaboration agreement with Ipsen for the commercialization of XERMELO outside of the United States and Japan.  We have also established collaborative arrangements with other pharmaceutical and biotechnology companies with respect to the research, development and commercialization of drug candidates from other programs.  We have derived a substantial majority of our revenues to date from these strategic collaborations and other research and development collaborations and technology licenses.  Future revenues from our existing collaborations depend upon the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.&#160;&#160;If our relationship terminates with any of our collaborators, as occurred with our terminated collaboration agreement with Sanofi, our reputation in the business and scientific community may suffer and revenues will be negatively impacted to the extent such losses are not offset by additional collaboration agreements.&#160;&#160;If milestones are not achieved under our collaborations or our collaborators are unable to successfully develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by those collaborations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have limited or no control over the resources that any collaborator may devote to the development and commercialization of products under our alliances.&#160;&#160;Any of our present or future collaborators may not perform their obligations as expected.&#160;These collaborators may breach or terminate their agreements with us or otherwise fail to conduct research, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">development or commercialization activities successfully or in a timely manner.&#160;&#160;Further, our collaborators may elect not to develop pharmaceutical products arising out of our collaborative arrangements or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products.&#160;&#160;If any of these events occurs, we may not receive collaboration revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may pursue opportunities in specific disease and therapeutic modality fields that could result in conflicts with our collaborators, if any of our collaborators takes the position that our internal activities overlap with those activities that are exclusive to our collaboration.&#160;&#160;Moreover, disagreements could arise with our collaborators over rights to our intellectual property or our rights to share in any of the future revenues of compounds or therapeutic approaches developed by our collaborators.&#160;&#160;Any conflict with or among our collaborators could result in the termination of our collaborative agreements, delay collaborative research or development activities, impair our ability to renew or obtain future collaborative agreements or lead to costly and time consuming litigation.&#160;&#160;Conflicts with our collaborators could also have a negative impact on our relationship with existing collaborators, materially impairing our business and revenues.&#160;&#160;Some of our collaborators are also potential competitors or may become competitors in the future.&#160;&#160;Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors or terminate their agreements with us prematurely.&#160;&#160;Any of these events could harm our product development efforts.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We depend on third-party manufacturers, including sole source suppliers, to manufacture commercial quantities of XERMELO.  We may not be able to maintain these relationships and could experience supply disruptions outside of our control.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on a network of third-party manufacturers to manufacture and supply XERMELO for commercial sale.  As a result of our reliance on these third-party manufacturers and suppliers, including sole source suppliers for certain steps in the manufacture of XERMELO, we could be subject to significant supply disruptions.  Our supply chain for sourcing raw materials and manufacturing drug product ready for distribution is a multi-step endeavor.  Third-party contract manufacturers procure raw materials, convert these raw materials into API, and then convert the API into final dosage form. Establishing and managing this supply chain requires a significant financial commitment and the creation and maintenance of numerous third party contractual relationships.  Although we attempt to effectively manage the business relationships with companies in our supply chain, we do not have control over their operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We require our own commercial supply of XERMELO for sale in the United States, and are required under our collaboration agreement to supply Ipsen&#8217;s commercial requirements of XERMELO in the European Union and other territories outside of the United States and Japan.  We currently rely, and expect to continue to rely, on sole source third-party manufacturers to produce final drug product and package and label XERMELO.  While we have identified and expect to qualify and engage back-up third-party manufacturers as additional or alternative suppliers for the production of final drug product and packaging and labeling of XERMELO, we currently do not have such arrangements in place.  Moreover, some of these alternative manufacturers will need to be approved by the FDA before we can use them for manufacturing XERMELO.  It is also possible that supplies of materials that cannot be second-sourced can be managed with inventory planning.  There can be no assurance, however, that failure of any of our sole source third-party manufacturers to meet our and Ipsen&#8217;s commercial demands for XERMELO in a timely manner, or our failure to engage qualified additional or back-up suppliers for the production of final drug product and packaging and labeling of XERMELO, would not have a material adverse effect on commercialization of XERMELO and our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supply disruptions may result from a number of factors, including shortages in product raw materials, labor or technical difficulties, regulatory inspections or restrictions, shipping or customs delays or any other performance failure by any third-party manufacturer on which we rely.  Any supply disruptions could disrupt sales of XERMELO, which could have a material adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We rely on a single third-party logistics provider and a limited distribution network of specialty pharmacies and specialty distributors for distribution of XERMELO in fulfillment of prescriptions in the United States, and their failure to distribute XERMELO effectively would adversely affect sales of XERMELO.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on a single third-party logistics provider for shipping and warehousing of our commercial supply of XERMELO and a limited distribution network of specialty pharmacies and specialty distributors for dispensation of XERMELO to patients in fulfillment of prescriptions in the United States.  Although our third-party logistics provider stores our commercial supply of XERMELO at two separate warehouses, the use of a single third-party logistics provider increases </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the risk that a fire or damage from another type of disaster at either of the warehouses may result in a disruption of our commercialization efforts.  Our use of a limited distribution network of specialty pharmacies and specialty distributors for dispensation of XERMELO involves certain additional risks, including, but not limited to, risks that these specialty pharmacies and specialty distributors will:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">not provide us accurate or timely information regarding their inventories, the number of patients who are using XERMELO or complaints about XERMELO;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">reduce or discontinue their efforts to sell or support or otherwise not effectively sell or support XERMELO;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">not devote the resources necessary to sell XERMELO in the volumes and within the time frames that we expect;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">be unable to satisfy their financial obligations to us; or</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cease operations.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our third-party logistics provider or any of our specialty pharmacies or specialty distributors do not fulfill their contractual obligations to us, or refuse or fail to adequately distribute XERMELO and serve patients, or the agreements are terminated without adequate notice, shipments of XERMELO, and associated revenues, would be adversely affected.  In addition, we expect that it may take a significant amount of time if we were required to change our third-party logistics provider or any of our specialty pharmacies or specialty distributors.</span></div><div><span><br/></span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We rely on third parties to carry out drug development activities.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on clinical research organizations and other third-party contractors to carry out many of our drug development activities, including the performance of nonclinical laboratory and animal tests under the FDA&#8217;s current Good Laboratory Practices regulations and the conduct of clinical trials of our drug candidates in accordance with protocols we establish.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, our drug development activities may be delayed, suspended or terminated.&#160;&#160;Such a failure by these third parties could significantly impair our ability to develop and commercialize the affected drug candidates.</span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We lack the capability to manufacture materials for nonclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently do not have the manufacturing capabilities or experience necessary to produce materials for nonclinical studies, clinical trials or commercial sales and intend in the future to continue to rely on collaborators and third-party contractors to produce such materials.&#160;&#160;We will rely on selected manufacturers to deliver materials on a timely basis and to comply with applicable regulatory requirements, including the current Good Manufacturing Practices of the FDA, which relate to manufacturing and quality control activities.&#160;&#160;These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory requirements.&#160;&#160;In addition, there are a limited number of manufacturers that operate under the FDA&#8217;s current Good Manufacturing Practices and that are capable of producing such materials, and we may experience difficulty finding manufacturers with adequate capacity for our needs.&#160;&#160;If we are unable to contract for the production of sufficient quantity and quality of materials on acceptable terms, our product development and commercialization efforts may be delayed.&#160;&#160;Moreover, noncompliance with the FDA&#8217;s current Good Manufacturing Practices can result in, among other things, fines, injunctions, civil and criminal penalties, product recalls or seizures, suspension of production, failure to obtain marketing approval and withdrawal, suspension or revocation of marketing approvals.</span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our products and technologies.&#160;&#160;The patent positions of biotechnology and pharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions.&#160;&#160;We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our products and technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.&#160;&#160;We will continue to apply for patents covering our products and technologies as, where and when we deem appropriate.  However, pending patent </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">applications do not provide protection against competitors because they are not enforceable until they issue as patents.&#160;&#160;Further, the disclosures contained in our current and future patent applications may not be sufficient to meet statutory requirements for patentability and our applications may fail to result in issued patents.&#160;&#160;Once issued, patents still may not provide commercially meaningful protection.&#160;&#160;Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from developing competing products and technologies.&#160;&#160;Furthermore, others may independently develop similar or alternative products or technologies or design around our patents.&#160;&#160;If anyone infringes upon our or our collaborators&#8217; patent rights, enforcing these rights may be difficult, costly and time-consuming and, as a result, it may not be cost-effective or otherwise expedient to pursue litigation to enforce those patent rights.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our patents may be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties.  As a result, we may be involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United States and elsewhere.  The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation may be substantial and the outcome can be uncertain.  An adverse outcome may allow third parties to use our intellectual property without a license and negatively impact our business.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our products and drug candidates.&#160;&#160;&#160;If any such patents are issued to other entities, we will be unable to obtain patent protection for the same or similar discoveries that we make relating to our products and drug candidates.&#160;&#160;Moreover, we may be blocked from using our drug targets or drug candidates or developing or commercializing our products and other drug candidates, or may be required to obtain a license that may not be available on reasonable terms, if at all.&#160;&#160;Further, others may discover uses for our drug targets and drug candidates other than those covered in our issued or pending patents, and these other uses may be separately patentable.&#160;&#160;Even if we have a patent claim on a particular technology or product, the holder of a patent covering the use of that technology or product could exclude us from selling a product that is based on the same use of that product.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions.&#160;&#160;Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, if the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements).&#160;&#160;In addition, many countries limit the enforceability of patents against government agencies or government contractors.&#160;&#160;In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.&#160;&#160;Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives.&#160;&#160;Such compulsory licenses could be extended to include some of our products and drug candidates, which could limit our potential revenue opportunities.&#160;&#160;Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secret protection for some of our confidential and proprietary information.&#160;&#160;We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection.&#160;&#160;While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets.&#160;&#160;In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products and those of our collaborators, as well as our nonclinical and clinical development efforts, may give rise to claims that they infringe the patents of others.&#160;&#160;We are aware that other companies and institutions are developing products acting through the same drug targets through which some of our drug candidates currently in clinical development act, have conducted research on many of the same targets that we have identified and have filed patent applications potentially covering drug targets that we have identified and certain therapeutic products addressing such targets.&#160;&#160;In some cases, patents have issued from these applications.&#160;&#160;In addition, many companies and institutions have well-established patent portfolios directed to common techniques, methods and means of developing, producing and manufacturing pharmaceutical products.&#160;&#160;These or other companies or institutions could bring legal actions against us or our collaborators for damages or to stop us or our collaborators from engaging in certain nonclinical or clinical development activities or from manufacturing and marketing therapeutic products that allegedly infringe their patent rights.&#160;&#160;If any of these actions are successful, in addition to our potential liability for </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">damages, these entities would likely require us or our collaborators to obtain a license in order to continue engaging in the infringing activities or to manufacture or market the infringing therapeutic products or may force us to terminate such activities or manufacturing and marketing efforts.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may deem it advisable to pursue litigation against others to enforce our patents and intellectual property rights and may be the subject of litigation brought by third parties to enforce their patent and intellectual property rights.&#160;&#160;In addition, we may become involved in litigation based on intellectual property indemnification undertakings that we have given to certain of our collaborators.&#160;&#160;Patent litigation is expensive and requires substantial amounts of management attention.&#160;&#160;The eventual outcome of any such litigation is uncertain and involves substantial risks.</span></div><div style="text-indent:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that there will continue to be significant litigation in our industry regarding patent and other intellectual property rights.&#160;&#160;We have expended and many of our competitors have expended and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation.&#160;&#160;If we become involved in future intellectual property litigation, it could consume a substantial portion of our resources and could negatively affect our results of operations.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners.  We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information.  The secure maintenance of this information is critical to our business and reputation.  We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access.  These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage).  Cyber threats may be generic, or they may be custom-crafted against our information systems.  Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions.  It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents.  These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information.  A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others.  Cyber-attacks could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.  Our network security and data recovery measures and those of our vendors may not be adequate to protect against such security breaches and disruptions.  These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees and independent contractors were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.&#160;&#160;We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.&#160;&#160;Litigation may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention.&#160;&#160;If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel.&#160;&#160;A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain drug candidates, which could severely harm our business.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Employees and Facilities Operations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have experienced and may continue to experience growth in the number of our employees and in the scope of our operations.  This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth.  To effectively manage our potential growth, we must continue to improve existing, and implement new, operational and financial systems, procedures </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies.  We may need to increase our medical, clinical, commercial and other personnel, and recruiting and retaining qualified individuals is difficult.  If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified personnel when advisable, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are highly dependent upon the principal members of our management, as well as medical, clinical and commercial staff, the loss of whose services might adversely impact the achievement of our objectives.&#160;&#160;Retaining and, where advisable, recruiting qualified medical, clinical and commercial personnel are critical to support activities related to successfully executing on our commercial plan for XERMELO and advancing our nonclinical and clinical development programs for telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates.&#160;&#160;Competition is intense for experienced medical, clinical and commercial personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products.&#160;&#160;Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any break-in or trespass of our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our equipment and assets could subject us to liability and have a material adverse impact on our business, operating results and financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our facilities are located in The Woodlands, Texas and Basking Ridge, New Jersey, and therefore our facilities are vulnerable to damage from hurricanes.  We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events and any insurance we may maintain may not be adequate to cover our losses.  If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Environmental and Product Liability</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We have used hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development processes have historically involved the controlled use of hazardous materials, including chemicals and radioactive and biological materials.&#160;&#160;Our operations have produced hazardous waste products.&#160;&#160;We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials.&#160;&#160;Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials.&#160;&#160;We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets.&#160;&#160;Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, these hazardous materials used by these parties.&#160;&#160;Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be held liable if any product that we or our collaborators develop or commercialize, or any product that is made with the use or incorporation of any of our technologies, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale.&#160;&#160;Regardless of merit or eventual outcome, product liability claims could result in </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop.  These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products.  We have obtained limited product liability insurance coverage for our clinical trials and commercial activities.  However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer.  Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.  On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects.  In addition, the pharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation.  A successful product liability claim or series of claims brought against us could harm our reputation and business.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Invus, L.P. and Invus C.V., which we collectively refer to as Invus, and their affiliates currently own approximately 60.8% of the outstanding shares of our common stock and are thereby able to control the election and removal of our directors and determine our corporate and management policies, including potential mergers or acquisitions, asset sales, the amendment of our articles of incorporation or bylaws and other significant corporate transactions.  This concentration of ownership may delay or deter possible changes in control of our company, which may reduce the value of an investment in our common stock.  The interests of Invus and its affiliates may not be aligned with the interests of other holders of our common stock.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Invus has additional rights under our stockholders</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> agreement with Invus, L.P. relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our stockholders&#8217; agreement with Invus, L.P., Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates, rounded up to the nearest whole number of directors.  Invus has designated three of the nine current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors.  No Invus-designated directors currently serve on the audit committee of our board of directors.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The provisions of the stockholders&#8217; agreement relating to Invus&#8217; rights to designate members of our board of directors and its audit, compensation and corporate governance committees will terminate if the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%.  Invus also has the right to terminate these provisions at any time in its discretion.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our stock price may be extremely volatile.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the commercial success of XERMELO and the revenues we generate from sales of XERMELO;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">results or delays in our or our collaborators&#8217; clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the announcement of FDA approval or non-approval, or delays in the FDA review process, of our or our collaborators&#8217; drug candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actions taken by regulatory agencies with respect to XERMELO, sotagliflozin, LX9211 and our other drug candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the announcement of new products by our competitors;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments in our relationships with our collaborators, including conflicts, litigation or the termination or modification of our agreements;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the announcement of an in-licensed drug candidate or strategic acquisition;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to achieve operating results projected by securities analysts;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in earnings estimates or recommendations by securities analysts;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the satisfaction of outstanding debt obligations or entry into new financing arrangements;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments in the biotechnology or pharmaceutical industry;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">departures of key personnel or board members;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA or international regulatory actions;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">third-party coverage and reimbursement policies;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disposition of any of our drug programs or other technologies; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">other factors, including general market, economic and political conditions and other factors unrelated to our operating performance or the operatin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">g</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> performance of our competitors.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These factors may materially adversely affect the market price of our common stock.  In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies.  For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks.  Likewise, the broader financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks.  These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock.  Excessive volatility may continue for an extended period of time.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted.&#160;&#160;A securities class action suit against us, such as the securities litigation which is currently pending, could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We are subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation and we are currently a target of this type of litigation.  On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us, and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and we filed a motion to dismiss such first amended complaint on September 30, 2019. The plaintiff filed an opposition to our motion to dismiss on November 14, 2019 and we filed a reply in support of our motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through January&#160;17, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.  This case, and other litigation of this type, could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business.  Any adverse determination in litigation could also subject us to significant liabilities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Future sales of our common stock, or the perception that such sales may occur, may depress our stock price.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A substantial number of shares of our common stock is reserved for issuance upon conversion of notes evidencing our current indebtedness, upon the exercise of stock options and upon vesting of restricted stock units.  If our stockholders sell substantial amounts of our common stock (including shares issued upon the conversion of notes, exercise of stock options or vesting of restricted stock units) in the public market, or if the market perceives that such sales may occur, the market price of our common stock could fall and it may become more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.&#160;&#160;For example, following an acquisition, a significant number of shares of our common stock held by new stockholders may become freely tradable or holders of registration rights could cause us to register their shares for resale.&#160;&#160;Sales of these shares of common stock held by existing stockholders could cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Conversion of our 5.25% Convertible Senior Notes due 2021 may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The conversion of some or all of our 5.25% Convertible Senior Notes due 2021 will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the notes.  Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock.  In addition, the existence of the notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.&#160;&#160;If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline.&#160;&#160;If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may acquire additional businesses, technologies and products if we determine that these businesses, technologies and products complement our existing technology or otherwise serve our strategic goals.&#160;&#160;If we do undertake any transactions of this sort, the process of integrating an acquired business, technology or product may result in operating difficulties and expenditures and may not be achieved in a timely and non-disruptive manner, if at all, and may absorb significant management attention that would otherwise be available for ongoing development of our business.&#160;&#160;If we fail to integrate acquired businesses, technologies or products effectively or if key employees of an acquired business leave, the anticipated benefits of the acquisition would be jeopardized.&#160;&#160;Moreover, we may never realize the anticipated benefits of any acquisition, such as increased revenues and earnings or enhanced business synergies.&#160;&#160;Future acquisitions could result in potentially dilutive issuances of our equity securities, the incurrence of debt and contingent liabilities and amortization expenses related to intangible assets, which could materially impair our results of operations and financial condition.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_52"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1B. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unresolved Staff Comments</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_55"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Properties</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently own approximately 260,000 square feet of space for our corporate offices and laboratories in buildings located in The Woodlands, Texas, a suburb of Houston, Texas, and lease approximately 25,000 square feet of office space in Basking Ridge, New Jersey.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, our subsidiary Lex-Gen Woodlands, L.P. entered into a term loan and security agreement refinancing the previously existing mortgage on our facilities in The Woodlands, Texas.  The loan agreement provides for a $12.9 million mortgage on the property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.  The mortgage debt, net of issuance costs, was $11.0&#160;million as of December&#160;31, 2019. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $15.0 million.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until April 9, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.&#160;&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our facilities are well-maintained, in good operating condition and acceptable for our current operations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_58"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division. A first amended complaint was filed on July 30, 2019 and we filed a motion to dismiss such first amended complaint on September 30, 2019. The plaintiff filed an opposition to our motion to dismiss on November 14, 2019 and we filed a reply in support of our motion to dismiss on December 13, 2019. The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019. The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes. The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_61"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mine Safety Disclosures</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_64"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_67"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#8220;LXRX.&#8221;  As of March&#160;6, 2020, there were approximately 359 holders of record of our common stock.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Performance Graph</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following performance graph compares the performance of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period beginning December&#160;31, 2014 and ending December&#160;31, 2019. The graph assumes that the value of the investment in our common stock and each index was $100 at December&#160;31, 2014, and that all dividends were reinvested.</span></div><div><img src="lxrx-20191231_g1.jpg" alt="lxrx-20191231_g1.jpg" style="height:226px;width:682px;"/></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.573%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.802%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2014</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lexicon Pharmaceuticals, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Composite Index</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nasdaq Biotechnology Index</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing stock price performance comparisons shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this annual report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate such comparisons by reference.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_70"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selected Financial Data</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The statements of comprehensive income (loss) data for the years ended December&#160;31, 2019, 2018 and 2017 and the balance sheet data as of December&#160;31, 2019 and 2018 have been derived from our audited financial statements included elsewhere in this annual report on Form&#160;10-K.&#160;&#160;The statements of comprehensive income (loss) data for the years ended December&#160;31, 2016 and 2015, and the balance sheet data as of December&#160;31, 2017, 2016 and 2015 have been derived from our audited financial statements not included in this annual report on Form 10-K.&#160;&#160;Our historical results are not necessarily indicative of results to be expected for any future period.&#160;&#160;The data presented below has been derived from financial statements that have been prepared in accordance with accounting principles generally accepted in the United States and should be read with our financial statements, including the notes, and with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this annual report on Form 10-K.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:46.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.813%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statements of Comprehensive Income (Loss) Data:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,209&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,014&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:20.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development, including stock-based compensation of $7,096 in 2019, $6,010 in 2018, $4,905 in 2017, $3,938 in 2016 and $3,693 in 2015</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(703)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:20.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative, including stock-based compensation of $7,122 in 2019, $5,686 in 2018, $4,567 in 2017, $3,514 in 2016 and $3,150 in 2015</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,157&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">222,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128,424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103,279)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(130,624)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(127,171)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,326)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,269)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,030)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,274)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) before taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(135,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(131,445)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,560)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,014&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(131,445)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,560)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Net income (loss) per common share, basic</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares used in computing net income (loss) per common share, basic</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:46.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.813%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Data:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Cash, cash equivalents and short-term investments</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346,504&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">521,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">216,506&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">417,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">284,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">436,539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">475,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">651,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243,887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">231,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,341,444)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,471,577)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,365,241)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,240,257)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,108,812)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lexicon Pharmaceuticals, Inc. stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,101&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26,405)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_73"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 7.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis should be read with &#8220;Selected Financial Data&#8221; and our financial statements and notes included elsewhere in this annual report on Form 10-K.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.&#160;&#160;We are devoting most of our resources to the commercialization or development of our three most advanced drugs and drug candidates:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are commercializing XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy.  We have granted Ipsen Pharma SAS, or Ipsen, an exclusive, royalty-bearing right to commercialize XERMELO outside of the United States and Japan.  Ipsen is commercializing XERMELO in the United Kingdom, Germany and multiple additional countries.  We are also developing telotristat ethyl as a treatment for biliary tract cancer and are conducting a Phase 2a clinical trial of telotristat ethyl in biliary tract cancer patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing Zynquista</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 diabetes.  The FDA has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter.  Zynquista has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&gt;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 27 kg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2 </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, who could not achieve adequate glycemic control despite optimal insulin therapy.</span></div><div style="padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease.  We are conducting a comprehensive Phase 3 development program, which includes one long-term outcomes study designed to demonstrate benefits in chronic heart failure and chronic kidney disease in type 2 diabetes patients and another long-term outcomes study designed to demonstrate benefits in acute decompensated heart failure in patients with and without type 2 diabetes.  We have reported preliminary top-line results from the first four Phase 3 clinical trials of sotagliflozin in adults living with type 2 diabetes.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported top-line results from two Phase 1 clinical trials of LX9211 and are preparing to initiate a Phase 2 clinical trial of LX9211.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We commercially launched XERMELO following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen&#8217;s ability to successfully commercialize XERMELO outside of the United States and Japan and our receipt of any milestone payments and royalties; the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin; and general and industry-specific economic conditions which may affect research and development expenditures.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future revenues from our commercialization of XERMELO are uncertain because they depend on a number of factors, including market acceptance of XERMELO, the success of our sales, marketing, distribution and other commercialization activities and the cost and availability of reimbursement for XERMELO.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future revenues from our collaboration with Ipsen are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from Ipsen's commercialization of XERMELO.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, including XERMELO in the United States and Japan, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have incurred significant losses and, as of December&#160;31, 2019, we had an accumulated deficit of $1.3 billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants.&#160;&#160;Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.&#160;&#160;We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates.  As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of our product, which occurs upon delivery to the customer.  We recognize product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below. Our net product revenues reflect our best estimates of the amounts of consideration to which we are entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to our customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customer Credits:  Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  We expect that our customers will earn prompt payment discounts.  As a result, we deduct the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">rates and expected utilization.  Our estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to us the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  Our estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenues in the period of adjustment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  We perform the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation.  We apply this five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer to the customer.  At contract inception, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  We develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, we evaluate whether development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within our control or the control of our licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, we re-evaluate the probability of achievement of the development milestones and any related constraint, and if necessary, adjust our estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to our intellectual property is determined distinct from other performance obligations identified in the agreement, we recognize revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and we recognize revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may receive payments from our licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until we perform our obligations under these agreements.  Amounts are recorded as accounts receivable when our right to consideration is unconditional.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist of costs incurred for research and development activities solely sponsored by us as well as collaborative research and development activities.&#160;&#160;These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are presently devoting most of our resources to the commercialization or development of our three most advanced drugs and drug candidates:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">XERMELO (telotristat ethyl), an orally-delivered small molecule drug that we are commercializing for carcinoid syndrome diarrhea and developing for biliary tract cancer;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate that we are developing as a treatment for type&#160;1 diabetes and type&#160;2 diabetes, heart failure and chronic kidney disease; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">LX9211, an orally-delivered small molecule drug candidate, that we are developing as a treatment for neuropathic pain.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The drug development process takes many years to complete.&#160;&#160;The cost and length of time varies due to many factors including the type, complexity and intended use of the drug candidate.&#160;&#160;We estimate that drug development activities are typically completed over the following periods:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:59.932%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.953%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.115%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Completion Period</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preclinical development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1-2 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 1 clinical trials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1-2 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 2 clinical trials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1-2 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Phase 3 clinical trials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2-4 years</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect research and development costs to remain substantial in the future as we continue to fund our nonclinical and clinical development efforts and advance new drug candidates into clinical development.&#160;&#160;Due to the variability in the length of time necessary for drug development, the uncertainties related to the cost of these activities and ultimate ability to obtain governmental approval for commercialization, accurate and meaningful estimates of the ultimate costs to bring our potential drug candidates to market are not available. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record significant accrued liabilities related to unbilled expenses for products or services that we have received from service providers, specifically related to ongoing nonclinical studies and clinical trials.&#160;&#160;These costs primarily relate to clinical study management, monitoring, laboratory and analysis costs, drug supplies, toxicology studies and investigator grants.&#160;&#160;We have multiple drugs in concurrent nonclinical studies and clinical trials at clinical sites throughout the world.&#160;&#160;In order to ensure that we have adequately provided for ongoing nonclinical and clinical development costs during the period in which we incur such costs, we maintain accruals to cover these expenses.&#160;&#160;Substantial portions of our nonclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For nonclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the vendors and clinical site visits.  Our estimates depend on the timeliness and accuracy of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the data provided by our vendors regarding the status of each program and total program spending.  We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&#160;&#160;Although we use consistent milestones or subject or patient enrollment to drive expense recognition, the assessment of these costs is a subjective process that requires judgment.&#160;&#160;Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Our estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract. In accruing the relevant costs, we estimated the time period over which services will be performed and the level of effort required to complete each study.  Upon completion and settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record our research and development costs by type or category, rather than by project.&#160;&#160;Significant categories of costs include personnel, facilities and equipment costs and third-party and other services.&#160;&#160;In addition, a significant portion of our research and development expenses is not tracked by project as it benefits multiple projects. Consequently, fully-loaded research and development cost summaries by project are not available.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based Compensation Expense</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize compensation expense in our statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;We had stock-based compensation expense of $14.2 million for the year ended December&#160;31, 2019.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $24.0 million, which is expected to be recognized over a weighted-average vesting period of 1.1 years.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock options is estimated at the date of grant using the Black-Scholes option-pricing model.&#160;&#160;For purposes of determining the fair value of stock options, we segregate our options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in our stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended December&#160;31, 2019, 2018 and 2017, respectively:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017:</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-lived assets include property, plant and equipment, right-of-use assets for leases, finite-lived intangible assets and goodwill.  We regularly review long-lived assets for impairment.  The recoverability of long-lived assets, other than goodwill, is measured by comparing the assets carrying amount to the expected undiscounted future cash flows that the asset is expected to generate.  Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount, and the asset's residual value, if any.  We use internal cash flow estimates, quoted market prices </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">when available and independent appraisals as appropriate to determine fair value.  We derive the required cash flow estimates from our historical experience and our internal business plans and apply an appropriate discount rate.  There were no significant impairments of long-lived assets in 2019, 2018 or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indefinite-lived intangible assets, composed primarily of in-process research and development, or IPR&amp;D, projects acquired in business combinations which have not reached technological feasibility, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  Estimating future cash flows of an IPR&amp;D product candidate for purposes of an impairment analysis requires us to make significant estimates and assumptions regarding the amount and timing of costs to complete the project and the amount, timing and probability of achieving revenues from the completed product similar to how the acquisition date fair value of the project was determined.  In 2019, we terminated certain research and development activities related to a program for treatment of irritable bowel syndrome and as a result, recognized $28.6 million of impairment to indefinite-lived intangible assets.  There were no impairments to indefinite-lived intangible assets in 2018 or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;We have determined that the reporting unit is the single operating segment disclosed in our current financial statements.&#160;&#160;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;We determined that the market capitalization approach is the most appropriate method of measuring fair value of the reporting unit.&#160;&#160;Under this approach, fair value is calculated as the average closing price of our common stock for the 30 days preceding the date that the annual impairment test is performed, multiplied by the number of outstanding shares on that date.&#160;&#160;A control premium, which is representative of premiums paid in the marketplace to acquire a controlling interest in a company, is then added to the market capitalization to determine the fair value of the reporting unit.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if we encounter events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2019, 2018 and 2017.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date.  The purchase price allocation process requires management to make significant estimates and assumptions, especially at acquisition date with respect to intangible assets and in-process research and development.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These assumptions are based in part on historical experience and are inherently uncertain.  Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: the feasibility and timing of achievement of development, regulatory and commercial milestones; expected costs to develop the in-process research and development into commercially viable products; and future expected cash flows from product sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the purchase price allocations for acquisitions, we estimate the fair value of the contingent payments.  The estimated fair value of any contingent payments is determined utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 3, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of new accounting standards on our consolidated financial statements.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations &#8211; Comparison of Years Ended December&#160;31, 2019, 2018 and 2017 </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis should be read with &#8220;Results of Operations&#8221; and our financial statements and notes included in our annual report on Form 10-K for the year ended December 31, 2018.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenues and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:55.562%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.658%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar increase&#160;(decrease)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage increase (decrease)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Years Ended December&#160;31, 2019 and 2018 </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Net product revenues </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8211; Net product revenue increased 22% in 2019 to $32.3 million, primarily from revenues recognized from the sale of XERMELO in the United States.  Sales of bulk tablets of XERMELO to Ipsen were comparable in both years.  Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">    </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Collaborative agreements </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8211; Revenue from collaborative agreements increased in 2019 to $289.2 million, due to $260&#160;million in revenues recognized from amounts payable by Sanofi pursuant to the termination of our collaboration agreement and recognition of amounts allocated to the performance obligation for development activities of sotagliflozin in the Sanofi collaboration agreement.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Royalties and other revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Revenues from royalties and other revenue increased 44% in 2019 to $0.5 million.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019, no customers for XERMELO sales represented more than 10% of revenues.  In 2018, two specialty pharmacies, Biologics, Inc. and Diplomat Pharmacy, represented 25% and 14% of revenues, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019 and 2018, Sanofi represented 89% and 53% of revenues, respectively.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Sales</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total cost of sales and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:55.374%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.716%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.716%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.720%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cost of sales&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar increase&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage increase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Years Ended December&#160;31, 2019 and 2018</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of sales increased 30% in 2019 to $3.2 million.  We began capitalizing inventory in 2017 following FDA approval of XERMELO, as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to FDA approval were recorded as research and development expenses in the consolidated statements of comprehensive income (loss).  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The pre-commercialized inventory is expected to be sold over approximately the next twelve  months.  As a result, cost of sales will reflect a lower average per unit cost of materials.  Cost of sales in each of 2019 and 2018 included $1.8 million of amortization of intangible assets related to XERMELO. </span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:55.562%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.658%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar decrease</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage decrease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs and stock-based compensation.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Years Ended December&#160;31, 2019 and 2018 </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Third-party and other services &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Third-party and other services decreased 12% in 2019 to $55.9 million, primarily due to decreases in professional and consulting fees and lower external clinical development costs relating to sotagliflozin.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.&#160;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Personnel &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Personnel costs decreased 3% in 2019 to $20.7 million, primarily due to lower headcount.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock-based compensation &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Stock-based compensation expense increased 18% in 2019 to $7.1 million, primarily due to a shorter vesting period of the annual restricted stock unit awards granted in 2019 and 2018.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Facilities and equipment &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Facilities and equipment costs decreased 3% in 2019 to $2.7 million.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Other &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other costs decreased 13% in 2019 to $5.5 million.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:55.562%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.658%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total selling, general and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar decrease</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage decrease</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses consist primarily of personnel costs to support the commercialization of XERMELO and our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Years Ended December&#160;31, 2019 and 2018  </span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Personnel</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Personnel costs increased 1% in 2019 to $28.4 million, primarily due to higher incentive compensation costs.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Professional and consulting fees</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Professional and consulting fees decreased 39% in 2019 to $12.2 million, primarily due to lower marketing costs.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock-based compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Stock-based compensation expense increased 25% in 2019 to $7.1 million, primarily due to a shorter vesting period of the annual restricted unit awards granted in 2019 and 2018.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Facilities and equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Facilities and equipment decreased 8% in 2019 to $1.8 million. </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Other &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other costs decreased 8% in 2019 to $7.3 million, primarily due to decreases in sponsorships and contributions to charitable foundations.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment Loss</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Impairment loss of $28.6 million in the year ended December&#160;31, 2019 was recognized to an indefinite-lived intangible asset associated with the 2010 acquisition of Symphony Icon, due to the decision to terminate research and development activities related to a program for irritable bowel syndrome that was among the assets acquired.  </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense and Interest and Other Income, Net</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;Interest expense was $20.7 million and $20.8 million in the years ended December&#160;31, 2019 and 2018, respectively.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest and Other Income (Expense), Net.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Interest and other income, net was $3.4 million and $3.5 million in the years ended December&#160;31, 2019 and 2018, respectively.&#160;&#160;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Tax Benefit</span></div><div style="text-indent:54pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax benefit for the year ended December&#160;31, 2019 was $6.0 million, due to the release of the deferred tax liability related to the impairment of the indefinite-lived intangible asset (see Note 7, Income Taxes of the Notes to Consolidated Financial Statements, for more information).  There was no income tax expense or benefit in 2018.  </span></div><div style="text-indent:18pt;margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Income (Loss) and Net Income (Loss)&#160;per Common Share </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income was $130.1 million, or $1.16 per diluted share, in 2019 as compared to a net loss of $120.5 million, or loss of $1.14 per share in 2018.&#160;&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements.&#160;&#160;We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc.&#160;&#160;In December 2017, we entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP (the &#8220;BioPharma Term Loan&#8221;) under which $150 million was funded.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, we had $271.7 million in cash, cash equivalents and short-term investments. &#160;As of December&#160;31, 2018, we had $160.1 million in cash, cash equivalents and short-term investments.&#160;&#160;We generated cash of $113.8 million from operations in 2019. This consisted primarily of the net income for the year of $130.1&#160;million and non-cash charges of $28.6 million related to impairment of intangible assets, $14.2&#160;million related to stock-based compensation expense and $5.1 million related to depreciation and amortization expense, including amortization of debt issuance costs.&#160;&#160;Partially offsetting this was a net increase in operating assets, net of liabilities of $58.3 million.  Investing activities used cash of $155.9&#160;million in 2019, primarily due to net purchases of investments of $155.8&#160;million.&#160;&#160;Financing activities used cash of $2.2&#160;million, primarily to repay $1.3 million of debt borrowings and to repurchase $0.9 million of common stock.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Facilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In August 2018, our subsidiary Lex-Gen Woodlands, L.P. entered into a term loan and security agreement refinancing the previously existing mortgage on our facilities in The Woodlands, Texas.  The loan agreement provides for a $12.9 million mortgage on the property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $15.0 million.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until April 9, 2020, during which the purchaser may </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June 1, 2015 through December 31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease.&#160;&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Including the lease and debt obligations described above, we had incurred the following contractual obligations as of December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:36.325%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.751%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments due by period (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual Obligations</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 1 year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2-3 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-5 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">More than 5 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest payment obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">298.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements will be substantial and will depend on many factors, including our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen&#8217;s ability to successfully commercialize XERMELO outside of the United States and Japan and our receipt of any milestone payments and royalties; the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to continue commercializing XERMELO in the United States; to successfully complete our nonclinical and clinical development efforts with respect to telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Disclosure about Market Risk</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase.&#160;&#160;We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk.&#160;&#160;We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">We had approximately $271.7 million in cash and cash equivalents and short-term investments as of&#160;December&#160;31, 2019.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are not subject to interest rate sensitivity on our outstanding Convertible Notes and our BioPharma Term Loan as each generally have a fixed rate of 5.25% and 9% per annum, respectively.  The Convertible Notes interest is payable in cash semi-annually in arrears and matures in December 2021, unless earlier converted or repurchased in accordance with their terms.  The BioPharma Term Loan bears interest payable quarterly in arrears, and provides for interest-only payments followed by payment of principal at maturity in December 2022.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160; </span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_76"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 7A.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 7. Management&#8217;s Discussion and Analysis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_79"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 8.&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Statements and Supplementary Data</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The financial statements required by this Item are incorporated under Item 15 in Part IV of this report.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_82"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_85"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9A.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Controls and Procedures</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2019 to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Management Report on Internal Control over Financial Reporting</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act).</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2019.&#160;&#160;In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Internal Control-Integrated Framework </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2013 Framework)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on such assessment using those criteria, management concluded that, as of December&#160;31, 2019, our internal control over financial reporting was effective.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subsequent to our evaluation described above, there were no significant changes in internal controls or other factors during the fiscal quarter ended December 31, 2019 that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_127"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have audited Lexicon Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Internal Control&#8212;Integrated Framework</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework (the COSO criteria). In our opinion, Lexicon Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated March&#160;12, 2020 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-indent:24.5pt;"><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Houston, Texas</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">March&#160;12, 2020</span></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_88"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 9B.&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Information</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_91"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART III</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_94"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 10.&#160; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is hereby incorporated by reference from (a) the information appearing under the captions &#8220;Election of Directors,&#8221; &#8220;Stock Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2019 and (b)&#160;the information appearing under Item&#160;1 in Part&#160;I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of this report.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_97"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 11.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Executive Compensation</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2019. Notwithstanding the foregoing, in accordance with the instructions to Item 407(e)(5) of Regulation S-K, the information contained in our proxy statement under the sub-heading &#8220;Compensation Committee Report&#8221; shall not be deemed to be filed as part of or incorporated by reference into this annual report on Form 10-K.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_100"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 12.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Stock Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_103"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 13.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Transactions with Related Persons&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_106"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 14.&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principal Accounting Fees and Services</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information required by this Item as to the fees we pay our principal accountant is hereby incorporated by reference from the information appearing under the caption &#8220;Ratification and Approval of Independent Auditors&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on December&#160;31, 2019.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_109"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART IV</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_112"></div><div style="margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Exhibits and Financial Statement Schedules</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">Documents filed as a part of this report:</span></div><div style="text-indent:-36pt;padding-left:108pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:91.128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.872%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_124">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_124">F-1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_130">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_130">F-2</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_136">Consolidated Statements of Comprehensive </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_136">Income (</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_136">Loss</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_136">F-3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_142">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_142">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_142">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_145">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_145">F-5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_148">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_148">F-6</a></span></div></td></tr></table></div><div style="text-indent:-36pt;padding-left:108pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Financial Statement Schedules&#160;</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All other financial statement schedules are omitted because they are not applicable or not required, or because the required information is included in the financial statements or notes thereto.</span></div><div style="text-indent:-36pt;padding-left:108pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Exhibits</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:9.876%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.045%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh31amendedandrestatedcer.htm">Amended and Restated Certificate of Incorporation</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000027/exh31-01.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form&#160;8-K dated May 20, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000016/exh32secondamendedandresta.htm">Second Amended and Restated Bylaws </a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated April 26, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w1.htm">Securities Purchase Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000118/exh10_1.htm">Amendment</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated October 7, 2009, to Securities Purchase Agreement, dated June&#160;17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w3.htm">Registration Rights Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095013407013586/h47609cexv10w4.htm">Stockholders&#8217; Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012310024973/h70210exv10w1.htm">Supplement to Transaction Agreements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000005/exhibit101.htm">Supplement No. 2 to Transaction Agreements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.7</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312514428223/d825616dex41.htm">Indenture</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> related to the 5.25% Convertible Senior Notes due 2021, dated as of November&#160;26, 2014, with Wells Fargo Bank, N.A. (filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000119312514428223/d825616dex41.htm">Form of 5.25% Convertible Senior Notes due 2021</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit A to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh101coatsofferletteramen.htm">Offer Letter</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated July 1, 2014, with Lonnel Coats, as amended (filed as Exhibit 10.1 to the Company's Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282212000010/exh105-xlapuertaofferletter.htm">Offer Letter</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 10, 2011, with Pablo Lapuerta, M.D. (filed as Exhibit 10.5 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2011 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000013/exh104tyleofferletter.htm">Offer Letter</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 23, 2016, with Praveen Tyle, Ph.D. (filed as Exhibit 10.4 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2016 and incorporated by reference herein).</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:9.876%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.045%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh104-santiniofferlettera.htm">Offer Lette</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh104-santiniofferlettera.htm">r</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 16, 2015, with Alexander A. Santini, as amended (filed as Exhibit 10.4 to the Company's Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Employment Agreement with Jeffrey L. Wade, J.D.</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012900000465/0000950129-00-000465.txt">Form of Indemnification Agreement with Officers and Directors</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000028/exhibit103-summaryofnonxem.htm">Summary of Non-Employee Director Compensation</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*10.8</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh1082017equityincent.htm">2017 Equity Incentive Plan</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, as amended.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh1092017non-employeedire.htm">2017 Non-Employee Directors&#8217; Equity Incentive Plan</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, as amended (filed as Exhibit 10.9 to the Company's Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282218000008/exh1011officerstockoptiona.htm">Form of Stock Option Agreement with Officers</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> under the 2017 Equity Incentive Plan (filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2017 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*10.11</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh1011officerrestrict.htm">Form of Restricted Stock Unit Agreement with Officers</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282218000008/exh1012officerrestrictedst.htm">Form of Notice of Stock Option Grant to Directors</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282218000008/exh1012officerrestrictedst.htm">Form of Notice of Restricted Stock Unit Grant to Directors</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> under the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.14</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000068/exh1014collaborationandlic.htm">Collaboration and License Agreement,</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> dated November 5, 2015, with Sanofi (filed as Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K/A for the period ended December 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.15</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000054/exhibit101-amendment1tolic.htm">Amendment No. 1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated July 1, 2017, to Collaboration and License Agreement, dated November 5, 2015, with Sanofi (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2017 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#167;10.16</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000028/exh101terminationsettlemen.htm">Confidential Termination and Settlement Agreement and Mutual Releases</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated September 9, 2019, with Sanofi-Aventis Deutschland GmbH (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.17</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282214000066/exh101licenseandcollaborat.htm">License and Collaboration Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated October 21, 2014, with Ipsen Pharma SAS (filed as Exhibit 10.1 to the amendment to the Company&#8217;s Quarterly Report on Form 10-Q/A for the period ended September 30, 2014, as filed on December 23, 2014, and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.18</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh101ipsenagreement.htm">First Amendment</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 17, 2015, to License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*10.19</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh1019amendmentno2toi.htm">Second Amendment</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated January 28, 2020, to License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh102bmsagreement.htm">Collaboration and License Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282215000025/exh103bmsagreeementamendme.htm">First Amendment</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated May 30, 2006, to Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2015 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.22</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282216000081/secondamendmenttocollabora.htm">Second Amendment,</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> dated November 2, 2016, to Collaboration and License Agreement, dated December 17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated November 2, 2016 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.23</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/1062822/000095012906002238/h33572exv10w22.txt">Second Amended and Restated Collaboration and License Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.22 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.24</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282209000109/exh10_1.htm">Amendment</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated June 8, 2009, to Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A dated June 8, 2009 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.25</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000045/exh101commercialsupplyagr.htm">Commercial Supply Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated June 6, 2016, with Catalent CTS, LLC (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q/A for the period ended March 31, 2017 and incorporated by reference herein).</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:9.876%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.045%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.26</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh1023amendno1catalentcom.htm">Amendment One to Commercial Supply Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated April 4, 2018, with Catalent CTS, LLC (filed as Exhibit 10.23 to the Company's Annual Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.27</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282219000007/exh1024amendno2catalentcom.htm">Amendment Two to Commercial Supply Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated April 27, 2018, with Catalent CTS, LLC (filed as Exhibit 10.24 to the Company's Annual  Report on Form 10-K for the period ended December 31, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.28</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282218000030/loanagreement08-30x2018.htm">Term Loan and Security Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated August 30, 2018, between Lex-Gen Woodlands, L.P. and Revere Credit Opportunities Fund III, LP (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated August 30, 2018 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;10.29</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282217000056/loanagrredacted12-04x2017.htm">Loan Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated December 4, 2017, with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated December 4, 2017 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.30</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282220000002/a2020purchaseandsaleagreem.htm">Real Estate Purchase and Sale Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated January 20, 2020, between Lex-Gen Woodlands, L.P. and FFC Equity Holdings, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated January 10, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282211000021/exh211subsidiaries.htm">Subsidiaries </a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2010 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*23.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh231ernstyoungconsent.htm">Consent of Independent Registered Public Accounting Firm</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*24.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i54910e5d8bdb46bf84d5ecc54d3bafab_118">Power of Attorney</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (contained in signature page).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh311certificationofp.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh312certificationofp.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh321certificationofp.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:1.996%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.804%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confidential treatment has been requested for a portion of this exhibit.&#160;&#160;The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#167;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Portions of the exhibit have been omitted.</span></td></tr></table></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_115"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 16.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Form 10-K Summary</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_118"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Signatures</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.095%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.710%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.778%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lexicon Pharmaceuticals, Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/s/ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">LONNEL COATS</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">/s/ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">JEFFREY L. WADE</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Power of Attorney</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lonnel Coats and Jeffrey L. Wade, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:27.136%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:37.385%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.551%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Signature</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ LONNEL COATS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ JEFFREY L. WADE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ JAMES F. TESSMER</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President, Finance and Accounting<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">James F. Tessmer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ RAYMOND DEBBANE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman of the Board of Directors</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raymond Debbane</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ PHILIPPE J. AMOUYAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Philippe J. Amouyal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ SAMUEL L. BARKER</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ ROBERT J. LEFKOWITZ</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Robert J. Lefkowitz, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ ALAN S. NIES</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alan S. Nies, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ FRANK P. PALANTONI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Frank P. Palantoni</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ CHRISTOPHER J. SOBECKI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ JUDITH L. SWAIN</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 12, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Judith L. Swain, M.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_121"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_124"></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the Shareholders and the Board of Directors of Lexicon Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have audited the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2019 and 2018, the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with US generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Internal Control-Integrated Framework</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated March&#160;12, 2020 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Adoption of ASU No. 2014-09 </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method for accounting for revenues in 2018 due to the adoption of ASU No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div style="text-indent:24.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">/s/ Ernst &amp; Young LLP</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have served as the Company&#8217;s auditor since 2002.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Houston, Texas</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">March&#160;12, 2020</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_130"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except par value)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:75.565%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.997%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.705%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzQtMS0xLTEtMA_470f9656-e69f-493b-87c1-a4bd97255e4a">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzQtMy0xLTEtMA_4c122e70-109a-4a86-8ae0-f01a966eb408">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzUtMS0xLTEtMA_ebaafcae-f9ce-4548-84f2-943d23e9dfb7">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzUtMy0xLTEtMA_625fbf20-c8ee-4665-9554-069389b558ba">79,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net of allowances of $4</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzYtMS0xLTEtMA_b401e581-7724-46ae-8751-261196fe573b">56,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzYtMy0xLTEtMA_be866871-7a76-4295-967d-42b4f45b32e6">5,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzctMS0xLTEtMA_89e2c4d3-bd39-451a-b7d8-505b867d0dee">4,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzctMy0xLTEtMA_a78787d1-5063-4ed0-946c-a65f7e0f4184">4,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzktMS0xLTEtMA_f4a693d7-4e26-47ee-8b49-b89c68fc774a">5,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzktMy0xLTEtMA_aa076f81-c1bf-4c74-bab4-48ed324ceb9c">2,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEwLTEtMS0xLTA_05df7288-a495-42f4-8cf5-9299324c7596">337,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEwLTMtMS0xLTA_b1dbdd0e-c62c-4849-8fae-9ba182110948">173,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzExLTEtMS0xLTA_ac2d6234-c12e-4ae9-b45d-4a7c21bb490c">14,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzExLTMtMS0xLTA_57ef7ccc-7a01-4c21-9ec2-d398b8ba6b92">15,865</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEyLTEtMS0xLTA_caffacf2-a815-456f-974c-bd5a0c14704d">44,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEyLTMtMS0xLTA_a0b3872c-d816-458c-94d7-cf66d65da958">44,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEzLTEtMS0xLTA_23d09b18-2369-43a8-a118-9275988bf8cc">19,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEzLTMtMS0xLTA_30a45576-9e77-4990-9f3e-e0174d77a1ca">50,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE0LTEtMS0xLTA_1895ff6d-553d-47e8-ab99-fbccc1c09ef2">1,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE0LTMtMS0xLTA_b9fcf15c-49b2-4611-9813-90caedc096f3">285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE1LTEtMS0xLTA_764aeb81-9674-4206-a755-d5e3599f0513">417,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE1LTMtMS0xLTA_5705c5fe-15c5-4101-b062-0fac591ee9e3">284,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Equity&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE4LTEtMS0xLTA_00c6535a-2e92-4524-83fd-c6f538e9dace">12,178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE4LTMtMS0xLTA_aab9fb66-cf6e-478d-b117-f7d7cbbf02a1">12,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE5LTEtMS0xLTA_7222ca89-b973-4ccb-aa3c-b588f8b8762c">42,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE5LTMtMS0xLTA_060404e3-fb10-4a34-ad73-d908f0d79482">21,245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIwLTEtMS0xLTA_136f1fa7-d4c2-43ba-849b-493e611a3cf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIwLTMtMS0xLTA_57a17285-ef7b-48f5-ba5d-1034f5d85d54">2,339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term debt, net of deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIxLTEtMS0xLTA_f2b3180c-aeee-4f4a-9269-a802a56a3ec7">11,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIxLTMtMS0xLTA_0208c277-e4b2-4f1a-8a31-e0267d0191b1">1,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIyLTEtMS0xLTA_cffec199-b55b-4a2c-ba08-ff5c3044ee07">65,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIyLTMtMS0xLTA_40d4c700-bebe-43bd-a5a3-5d554e3956ce">36,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIzLTEtMS0xLTA_b41e396e-6c0f-4e23-8dc0-f3321e31684f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIzLTMtMS0xLTA_c2939ba1-706a-4410-ba70-e58af400d3f0">23,651</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI0LTEtMS0xLTA_6bca4ac8-a652-4d97-a878-735771ca582f">234,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI0LTMtMS0xLTA_ddef8250-3918-452b-8dbb-aab9d0c95f2f">243,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI1LTEtMS0xLTA_857925ba-d7fe-499f-b308-fa727dfe7a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI1LTMtMS0xLTA_6bdb8c2e-ccd0-4641-9a01-a5d0c622607f">6,014</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI2LTEtMS0xLTA_8a19ea60-5f73-4233-b608-07c2f46910b7">1,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI2LTMtMS0xLTA_13bdb4d7-c085-4530-b2e1-590b9fef2cda">238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI3LTEtMS0xLTA_f938e11b-0efc-4fb8-9740-1fcae9fc0b71">300,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI3LTMtMS0xLTA_1f6fa5f5-c437-41f3-a572-3ea8ea9e36dd">310,541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI4LTEtMS0xLTA_7660847a-6aae-44b8-bd30-a18e82ea065c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI4LTMtMS0xLTA_0bc81fa3-47ba-40a4-9000-65a43bf735a1"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' Equity (Deficit):</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMwLTEtMS0xLTA_f15bcad7-103b-4fce-9fd4-15b97424dd87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMwLTMtMS0xLTA_f07fc23d-8064-44cd-945e-35da40235e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:20.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMxLTEtMS0xLTA_6b641a30-cb90-4146-b83c-8db2ee1f7fe0">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMxLTMtMS0xLTA_1f5e29d5-ed32-4d9f-93a9-8b0168e4dc4c">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMyLTEtMS0xLTA_865726b9-8c84-4f1e-85fb-f6023921a833">1,462,172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMyLTMtMS0xLTA_19e48642-b7ce-43c6-831f-2a571e171889">1,447,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMzLTEtMS0xLTA_ad032f13-3ea4-43ff-9a6c-089826e2353b">1,341,444</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMzLTMtMS0xLTA_5c21046c-9fb9-40bf-a2da-fc16dc7f73c7">1,471,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive gain (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM0LTEtMS0xLTA_ddca8266-d06d-4336-aff8-a40a34c871a6">84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM0LTMtMS0xLTA_acc02871-50c6-4b01-b57e-f568a678e1d4">12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock, at cost, 407 and 236 shares, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM1LTEtMS0xLTA_eac5b8ad-7ed9-43c5-b8aa-85cef08476ce">3,817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM1LTMtMS0xLTA_a2901ae3-44ba-43dc-acfb-08a93dd1b10d">2,876</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM2LTEtMS0xLTA_69e7c43d-1f44-43a1-8fa1-c3c06de4a0e9">117,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM2LTMtMS0xLTA_96c79051-6b80-413e-ba67-533a2875ce1e">26,405</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity (deficit)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM3LTEtMS0xLTA_054ced6f-bf84-4f43-b8f5-653596e2021c">417,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM3LTMtMS0xLTA_a27a8c82-74a5-4230-b207-beffaf39bc97">284,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_136"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except per share amounts)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:55.562%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.658%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtMS0xLTEtMA_072dc8a8-f96c-4627-9e7f-022937f8cb5e">32,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtMy0xLTEtMA_48632b6b-b8d1-4776-8c09-0bf7239fb780">26,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtNS0xLTEtMA_afdb4063-3694-4c44-852b-4d8b26a3e9be">15,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaborative agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtMS0xLTEtMA_dd0077e0-4b63-464a-8944-cb40e6f14cb4">289,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtMy0xLTEtMA_5274aa60-05b7-4379-a321-a1fb3f3ebd10">36,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtNS0xLTEtMA_d69e97b7-e21c-4d1e-b86f-5bff936686d6">75,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties and other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtMS0xLTEtMA_cb3d2c00-8f8d-4587-ad01-f0fca1b85cd3">511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtMy0xLTEtMA_95567b44-aeb7-4bc0-9742-71f6c268e1ea">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtNS0xLTEtMA_2ecc7f98-36df-487c-9948-1ae9f06b4c37">178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtMS0xLTEtMA_88242b4a-499d-4faf-b743-9f26fe9d3c29">322,073</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtMy0xLTEtMA_b3ce0228-81d5-4662-976e-c98e3f88f8b8">63,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtNS0xLTEtMA_f07f208e-7de8-4e6d-8085-7ef6128eee30">91,689</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtMS0xLTEtMA_050e2436-b192-41e7-945a-1ea83d43b503">3,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtMy0xLTEtMA_d46d1331-accb-4f3b-9b50-2f4b09bc76be">2,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtNS0xLTEtMA_1b0ca802-cac7-4aae-8f33-0c0a2e86103f">1,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:15.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development, including stock-based compensation of $7,096, $6,010 and $4,905, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktMS0xLTEtMA_052c562b-28a2-419b-9cbe-61514d141a63">91,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktMy0xLTEtMA_dd3d8929-7db5-444d-b1a0-487c46bc330d">100,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktNS0xLTEtMA_c0ca8f28-175a-4e72-b149-89ec13ec6472">152,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase in fair value of Symphony Icon, Inc. purchase liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTEtMS0xLTA_f6e9bbb8-bf18-45d7-b293-1fb20737d977">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTMtMS0xLTA_9bf15b1d-51bd-4d76-a4fc-f40e1fd7da49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTUtMS0xLTA_f2b949dd-cf00-45ce-bef1-5d8298780f27">2,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:15.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative, including stock-based compensation of $7,122, $5,686 and $4,567, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTEtMS0xLTA_a7e6ca51-afb5-4c23-a91a-ed0f9d5a5753">56,835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTMtMS0xLTA_808f3375-fccb-43ac-99bf-1f3f9ed2e03f">63,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTUtMS0xLTA_ac270c92-3479-4960-926d-4bdeb0117271">66,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment loss on intangible asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTEtMS0xLTA_fcb423ad-ccea-45ed-a44c-842c8e137a3c">28,638</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTMtMS0xLTA_e16cda3a-a66f-4529-beb5-6ee9d3e73ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTUtMS0xLTA_268cb7ad-9172-4538-a3dc-a14eeb47a67a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTEtMS0xLTA_15351ec7-5404-4529-94f1-58298660510c">180,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTMtMS0xLTA_d6023644-e0d9-42bd-8130-0ca4e2d33d0b">166,488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTUtMS0xLTA_e88d2d20-0e7c-46b7-ac02-817626ae46c6">222,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTEtMS0xLTA_39dcbe9b-ade1-4d05-b9f3-abb97b9280d2">141,445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTMtMS0xLTA_81629865-4ad7-4154-9961-3561aa699f41">103,279</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTUtMS0xLTA_01ca4617-0e3f-4800-939b-2e0fda709ad5">130,624</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTEtMS0xLTA_76bd2ad5-0366-48d6-89fd-012aa78f0935">20,676</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTMtMS0xLTA_59a240f6-4d90-4b3c-91eb-8cb0c91b9ffc">20,777</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTUtMS0xLTA_4b388367-4e28-42cb-8648-cb7adcc55604">6,984</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTEtMS0xLTA_a17b8110-e32b-4b79-9fb4-90fe120a663f">3,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTMtMS0xLTA_a42de3e2-555a-4fac-8b9a-dd89938ae84b">3,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTUtMS0xLTA_767a5d68-633d-47ba-bbdf-c6b6f11aec2c">1,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) before taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTEtMS0xLTA_f2dc1af2-5ae5-4fc2-a614-d41be86246ba">124,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTMtMS0xLTA_59d4a0f6-1f52-4900-8e88-4c7b452df3f5">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTUtMS0xLTA_25cfa142-1c2c-4ce6-b1df-e0b39de26425">135,654</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTEtMS0xLTA_96091e38-3cc3-49e8-a057-66823a51cad2">6,014</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTMtMS0xLTA_5df4890e-00d3-4858-9911-0d9dabcbb84d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTUtMS0xLTA_c8f04333-d64b-48af-bc68-3cab6b0cb632">12,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTEtMS0xLTA_6c5d41e7-865e-43f0-908d-59aa72b23077">130,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTMtMS0xLTA_484f61d7-3e01-4b63-972b-bd5c79f4c190">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTUtMS0xLTA_0fd409f1-e3fd-410f-bcbe-cda289a98b7c">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net income (loss) per common share, basic </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTEtMS0xLTA_f791fb8c-77dc-4236-b37c-59c0a1be3a71">1.23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTMtMS0xLTA_76709444-c25b-4d23-af7b-834a84cb5adb">1.14</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTUtMS0xLTA_28464be8-b096-4e40-80d4-d0f6f87c1b74">1.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net income (loss) per common share, diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTEtMS0xLTEyMTQ_a2e799f8-7328-4eab-9711-6faaef0eb39e">1.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTMtMS0xLTEyMDM_9e520714-323f-4bab-9bab-f2fb9f9d71a5">1.14</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTUtMS0xLTEyMDc_3c605a3f-9b28-470c-aa13-1e54c5dd351c">1.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net income (loss) per common share, basic</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTEtMS0xLTA_4c75eb7d-5f2d-4e59-b17d-e49ea205450d">106,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTMtMS0xLTA_40943b64-dcaf-43f0-8784-fef208a162e1">105,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTUtMS0xLTA_455ff887-31a7-45e3-9031-c80c26a78418">105,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net income (loss) per common share, diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTEtMS0xLTM4Mzc_5b465964-450e-4d3f-b15a-a3d2177ec977">116,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTMtMS0xLTEyMTA_d096207e-2935-4cb7-970b-7a919faf8d91">105,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTUtMS0xLTEyMTA_15a343cc-2dc1-4873-8abf-ff0ff6e134ff">105,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Unrealized gain (loss) on investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTEtMS0xLTA_fa2db7d8-ba8a-4df4-a7aa-c6b8dcd7856c">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTMtMS0xLTA_3704fb7a-474e-4e4a-af5e-4ea36881918d">210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTUtMS0xLTA_6c32fea5-4e00-49cc-a68b-3df46c73c35f">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Comprehensive income (loss)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTEtMS0xLTA_15208ab3-23e3-433e-83f4-32eeac835455">130,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTMtMS0xLTA_b9538d68-88a6-4a93-b492-b2fab62f842d">120,338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTUtMS0xLTA_867c2dd3-8c05-4352-a4d9-331bf9013162">123,020</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_142"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.444%;"><tr><td style="width:1.0%;"></td><td style="width:31.100%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.703%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.240%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.614%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.262%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.498%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.385%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Paid-In</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2016</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMS0xLTEtMA_fb96056d-59ef-4517-b001-77a659e05b84">104,582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMy0xLTEtMA_cd4b2f06-a2ee-4ad9-82b8-0b04db9c6790">105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a26c1b854e6492a9cee1d79baa36f4f_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtNS0xLTEtMA_d65b1aa1-bc67-4b52-9ab1-5a010318beea">1,411,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ebb2384f82444fdb95c578d086dd541_I20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtNy0xLTEtMA_be279761-ed5b-4457-bbbe-6a9cf75cc855">1,240,257</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2837d1af8744496a83b9465b01d9c7af_I20161231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtOS0xLTEtMA_0c7ae350-7572-43cc-95d7-4a8477391fb3">195</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i129f3fad6d374d8db3b6389a173ed459_I20161231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMTEtMS0xLTA_5a12a737-ebda-4b1c-b962-7863c44f866c">3,368</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57757fd132344fe38d2ce518c20bb378_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMTMtMS0xLTA_aea7d69b-2951-4a24-a8dd-217dc3a18267">167,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect of change in accounting principle</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMy0xLTEtMA_cea38f58-0ef7-4260-8beb-ea0a6da518c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtNS0xLTEtMA_08623649-625c-4680-b58f-56172a5fcc38">9,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtNy0xLTEtMA_76594541-237c-4242-9ca4-0675571c8bcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtOS0xLTEtMA_f1e43b74-de44-47e9-9774-df9a85f07b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMTEtMS0xLTA_fe31c018-8886-49bc-91a1-9748eb3ea9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMTMtMS0xLTA_1cb88160-896f-4ec5-97da-ef7d4a550deb">9,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock to designees of Symphony Icon Holdings LLC</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMS0xLTEtMA_6df66641-5d11-48f3-af58-39ade4b6000b">469</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMy0xLTEtMA_bedd244b-b0ed-446d-8a63-1725a82c95e1">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctNS0xLTEtMA_4166a6ed-fa90-4f8d-aed3-80507d60be93">5,485</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctNy0xLTEtMA_81d5390c-0d18-47a3-81c8-01f6aba16aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctOS0xLTEtMA_023f6548-3518-47b8-b397-3e8ae3ab60ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMTEtMS0xLTA_99ca9ad8-70a4-4ace-8008-48acdfc4a513">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMTMtMS0xLTA_faac9c9d-c728-4273-aae9-dcca99e305ab">5,486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of treasury stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,143)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMy0xLTEtMA_2a5a4ee1-2218-46d8-a96a-72da070a8bcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktNS0xLTEtMA_db5798cb-b681-4dc0-8554-e507b5b54e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktNy0xLTEtMA_20505957-5a04-4bb5-8e33-781450514848">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktOS0xLTEtMA_dc5ae173-efe4-4039-a687-9a1f11f42347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMTEtMS0xLTA_dc9e77e3-57e8-4462-9691-6443635ff27d">1,679</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMTMtMS0xLTA_e8f8167f-fed6-4555-8097-277638582ed2">1,679</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTMtMS0xLTA_86094483-2d0d-496e-9409-fe2f6a3a5a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTUtMS0xLTA_2e35629a-b0a5-4bd8-8ef8-a54c369336e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTctMS0xLTA_2fff3f81-6c78-4022-b548-ecb16cc44511">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTktMS0xLTA_e5444d81-e188-422e-a6ea-db6e22a227f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTExLTEtMS0w_f1d02f90-41b3-4295-b962-a7be7451f9ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTEzLTEtMS0w_6a4a6d96-3c21-4fac-814a-a281b258ef51">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized loss on investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTMtMS0xLTA_217f97f3-ad9c-418f-ab2f-893547353570">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTUtMS0xLTA_038baaba-e275-4889-97ff-5f3d8a888c68">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTctMS0xLTA_f5a01415-42c1-4c91-bb5e-9049d9e20eab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTktMS0xLTA_644361de-3587-47da-b242-165413ba3359">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTExLTEtMS0w_a648daa6-2e78-4ecc-8917-68dd205d3056">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTEzLTEtMS0w_dba315f9-fe86-47e4-b4d9-557657ef7872">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTEtMS0xLTA_f68ea4e1-ab83-4a40-ac6f-f1c5fbd8da86">105,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTMtMS0xLTA_108aa149-fecf-4ef8-a4b9-c55936120e03">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8cccc7e982e4621be9e20764d4dfc15_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTUtMS0xLTA_eb248c92-cc3e-44b6-b497-dcbd3dd605bd">1,435,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iffcd61f6da4749d4b7cc1ab6f3055a80_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTctMS0xLTA_f4166c04-8a28-4029-a674-0f77f5e427ec">1,365,241</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5028bb7c1904d74ad203e9136d8d368_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTktMS0xLTA_7daf448b-7b3b-4a1f-9706-1dd5e6c9f840">222</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i017c2651d77947d4bb01b4651850b16e_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTExLTEtMS0w_0f469d3f-4e59-4e88-841c-72d620121c42">1,904</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2be9572e894e461092c842e6748a2b74_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTEzLTEtMS0w_d1a0e722-fa9c-4ef2-a564-d69979e17c64">68,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Cumulative effect of change in accounting principle</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTUtMS0xLTA_83d40fe9-c6e5-48b0-a689-0f69eeb253cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTctMS0xLTA_e9bedc3e-73dd-46cd-bfc0-656d84f8f56d">14,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTktMS0xLTA_79dad369-59e6-4d74-81b1-2e84c0b20660">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTExLTEtMS0w_23ed9ea5-9afa-4b3c-88b0-280503c773a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTEzLTEtMS0w_2a1ffab6-599e-4824-9547-f650cfed48f2">14,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTMtMS0xLTA_a2ef1c7b-4f46-4a4e-86ab-dbfd26be8f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTUtMS0xLTA_7499d485-146b-4235-afc9-0a3739fb2c40">11,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTctMS0xLTA_7ba333ac-ce19-4ffa-9028-2b0baf73c178">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTktMS0xLTA_cb2a273b-348c-4f2f-89d7-585d798e2ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTExLTEtMS0w_aec9c6f2-0ea5-441c-be41-4682d09ba03e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTEzLTEtMS0w_fe4bd1f7-34d9-4a20-8ee6-5d93470db0f2">11,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTEtMS0xLTA_da0757fd-45ba-4c37-8757-42a47bd88e05">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTMtMS0xLTA_96a28715-ec39-474f-848e-f59493e0e249">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTUtMS0xLTA_78a4e530-24bb-4e63-859c-2303ad107ded">732</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTctMS0xLTA_2543e2bc-7b66-4ac0-a3cc-3acc11bc87a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTktMS0xLTA_848681b9-188a-4377-9f5b-98d72eb53848">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTExLTEtMS0w_84d2973f-562d-4b08-91a6-288a66cd173b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTEzLTEtMS0w_69cf734b-b5f5-4ae6-bf07-1ef427c2635c">732</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTMtMS0xLTA_4e67beb2-f735-467f-ad5e-15db3902805e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTUtMS0xLTA_727a0089-0b61-45f9-adac-862601e24bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTctMS0xLTA_27584c1a-c8c8-4c28-8e17-008e3f32232b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTktMS0xLTA_167b996e-2e21-4d77-98e9-9ef400049bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTExLTEtMS0w_a3d7923e-0702-4bdb-8629-f0ecad99382c">972</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTEzLTEtMS0w_a5fa4a80-7f26-4797-b6f3-69e2015fdf2f">972</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTMtMS0xLTA_8f13eb46-0b60-4e7b-8f70-f9a614ec7b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTUtMS0xLTA_93977f2f-5ade-45e7-9733-311a7f5ee6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTctMS0xLTA_8e87df8c-2219-4bf9-9fe7-1b880e9157f6">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTktMS0xLTA_10efe281-406f-4c81-b2e3-8d2cff067276">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTExLTEtMS0w_a7a2821f-7b75-48cb-bbd9-0863ec5c5f8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTEzLTEtMS0w_f6c97d24-df5b-4fd0-ada8-6bb6a14868a2">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized gain on investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTMtMS0xLTA_1ce56a3d-5d45-4861-ae2d-6292bdf96336">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTUtMS0xLTA_3ef0b11b-2eb9-4dcf-b6dd-5ba044385566">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTctMS0xLTA_4203437d-f33a-4575-aad9-223ca66eee93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTktMS0xLTA_0797cb61-0034-44b5-8769-c616f98c7801">210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTExLTEtMS0w_4ec5d47f-1925-4713-be8d-2facffc6ead2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTEzLTEtMS0w_b2632e2f-5634-463c-99c6-911ea2652037">210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTEtMS0xLTA_f31bde63-548d-431f-8039-ff4539895d34">106,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTMtMS0xLTA_36a5f62b-2d0c-45d7-a759-b9f5dda04b04">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2402ec5193524658955d7c90d3a16896_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTUtMS0xLTA_0cc1085c-bbdf-4568-bcb2-0026f9559a92">1,447,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5b2e221d098b491cbeaab0aa52d099ae_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTctMS0xLTA_aadf3863-c9c7-48a9-9d5d-35b1e259dcc2">1,471,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9e0a311a22b411e9fd8665266ff4e44_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTktMS0xLTA_4bbbd659-7c5b-45b1-8e37-3df40dd2614a">12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44b4b3353a5c41bbaa44ce871c92bba3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTExLTEtMS0w_a95c9828-d60e-4c4e-a0ee-b6b9c4f26af4">2,876</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTEzLTEtMS0w_1bb740b9-cf71-4e0a-8010-e1f0557a2fb7">26,405</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTMtMS0xLTA_d95cf5d4-006b-473f-9da5-5367a129f383">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTUtMS0xLTA_8f9bbc47-2aab-445a-9cf6-4f86809e3fc0">14,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTctMS0xLTA_3bee7e66-a781-4509-9da2-8049aac323b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTktMS0xLTA_9765bc75-bcda-4c6a-9184-e4f16842069f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTExLTEtMS0w_7334c509-d452-4fb5-924c-0061924ec8a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTEzLTEtMS0w_d478b19a-3a54-41e2-81df-62933e3ab3c4">14,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock under Equity Incentive Plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTEtMS0xLTA_bf9e2a07-9e04-41eb-8e7b-964e0141fb0d">517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTMtMS0xLTA_8b547d50-49b8-4409-a6ff-2ef47cbad673">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTUtMS0xLTA_dda3fdba-c6af-4ac0-99f7-5fccbc284d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTctMS0xLTA_92dd6883-1d7e-4b34-9d92-f1c6c04d273d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTktMS0xLTA_b37af37c-cbc9-4b98-b65f-65694cda3c36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTExLTEtMS0w_bd83a6b4-9b97-4ffa-9c8c-bdbb6fd39d5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTEzLTEtMS0w_6d837ef3-d213-442d-8088-542834f6be80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTMtMS0xLTA_ceaa3038-dbfd-414e-b346-10e7dc0821ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTUtMS0xLTA_c7b1df09-ed12-441e-9df3-007258692304">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTctMS0xLTA_5eea2bba-d241-44af-8782-def26e905424">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTktMS0xLTA_0f27feaf-6181-4f7d-ad7a-596df02b48f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTExLTEtMS0w_120319b8-52d2-4b74-bbce-09410f2122b2">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTEzLTEtMS0w_39e99ce3-a216-42e1-82fc-b9cc5764bd8c">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTMtMS0xLTA_d20a2336-9c5d-4437-9d42-5108477e47fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTUtMS0xLTA_b090a9e5-67a6-47f1-aff5-4f02200503e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTctMS0xLTA_07d910ae-6326-49d8-9aac-4369b298f7c2">130,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTktMS0xLTA_41d118f2-6fae-430c-b23a-aa9ea9269788">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTExLTEtMS0w_e61cccc3-dec8-46a2-8d8b-3db9cb7f884b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTEzLTEtMS0w_98dba59d-9ee3-42d3-92f4-c08e535a7eb5">130,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized gain on investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTMtMS0xLTA_34379ce4-a5e5-4211-bd85-cbb3b93fcc70">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTUtMS0xLTA_a44d84b0-1aab-4cc9-940a-7eec84c7ba6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTctMS0xLTA_3992f0bb-d62d-4fa8-b29c-f199358c462c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTktMS0xLTA_8da1d27d-2214-4086-9308-17adc3d699d9">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTExLTEtMS0w_1df3c2c5-586b-4ac5-834c-774e49ed4bcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTEzLTEtMS0w_bcc0c74b-aa23-4d7b-a142-d66c19ee554f">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7501ea3be2a741529ff3306e73060964_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTEtMS0xLTA_548b0054-982b-469c-b341-5208a208177f">106,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7501ea3be2a741529ff3306e73060964_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTMtMS0xLTA_ffb1e97e-43a0-4a02-9a42-b43aff6b943d">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98be0b7d6a10477d8c718994e04dc1c1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTUtMS0xLTA_c70f1167-e000-4d5f-881b-cf9ba33da31f">1,462,172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if0c089f26a424433a6a985286efbaae5_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTctMS0xLTA_4da22bba-0177-4c01-8e9d-7d82a42fbdf3">1,341,444</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ae9845aba89468b8e79334b8836b87a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTktMS0xLTA_ab6f93f8-e932-4ba2-9949-a84ce2fc268a">84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2669261eb809451d87dbe16b0e36331d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTExLTEtMS0w_eed8daeb-3cf2-4395-ae5e-f74411a0ce02">3,817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTEzLTEtMS0w_a1e1fbad-1b6c-4c00-9bf5-1536ef82fac8">117,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_145"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.722%;"><tr><td style="width:1.0%;"></td><td style="width:64.434%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.724%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.496%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.724%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.496%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.726%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtMS0xLTEtMA_10ac9e33-bf71-4fd1-9595-daa3b4e27efb">130,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtMy0xLTEtMA_4a7eec2f-2108-4617-a155-8bf71475a084">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtNS0xLTEtMA_fb05856d-2460-4af9-9487-426b4d616f16">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtMS0xLTEtMA_c957f12c-fbfe-430c-be55-c11fb2a1c50a">3,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtMy0xLTEtMA_9045b5a3-a032-4f3a-be64-296b4c91250c">3,683</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtNS0xLTEtMA_083e50ca-8fb8-407e-8e28-95d6abd14c15">3,399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment loss on intangible asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value of Symphony Icon, Inc. purchase liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctMS0xLTEtMA_6bb7ff4d-a0b9-412e-af53-c311cff042fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctMy0xLTEtMA_10006dab-79f6-4f13-ae73-e14db485e07f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctNS0xLTEtMA_23d7b4c5-ee2d-4aab-9f54-c7685808ec39">2,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtMS0xLTEtMA_3bc002d0-7e57-4cf7-8438-3087baac7e15">14,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtMy0xLTEtMA_91c74a7f-6ab2-4d36-8c69-134dd3ab4d5f">11,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtNS0xLTEtMA_93879224-7434-436b-8158-64a1748ccd3b">9,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on disposal of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktMS0xLTEtMA_6b68bd42-1ca6-4976-8bf5-1b8b873cb4b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktMy0xLTEtMA_2b6d4387-369c-4632-bae3-6882f9db7146">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktNS0xLTEtMA_c2b7676c-6c21-499f-9161-32364c4d9b4a">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTEtMS0xLTA_138dd801-eb01-42c2-ac9f-200a4bfc918b">1,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTMtMS0xLTA_9e23519d-578a-4d7d-9526-eb0a009df157">1,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTUtMS0xLTA_a26e8490-f3cf-48f3-8521-8b16b2b527da">599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTEtMS0xLTA_69df239c-48a9-42c9-a813-80aad03e43a0">6,014</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTMtMS0xLTA_daa86c90-0b89-49dd-b08a-25a647cbafcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTUtMS0xLTA_3efcdd88-65f9-4538-9ef4-9ee5cd19ea97">12,661</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Increase) decrease in accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTEtMS0xLTA_0f4a00b2-4901-4d41-ad27-222f76c28a09">50,608</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTMtMS0xLTA_00abc5e1-babf-48ad-914f-70b708577b71">1,099</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTUtMS0xLTA_5e61b1a7-e4b5-4537-b548-94e1bb2b1f6e">166</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Increase) decrease in inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTEtMS0xLTA_84fa292c-f6b3-43b4-9932-0d321ec37f72">437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTMtMS0xLTA_791cc215-53fd-45a0-b7a4-54418bf76f58">2,732</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTUtMS0xLTA_6773c173-98f7-4759-bcee-27a5a4d906b1"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTUtMS0xLTA_790e54f3-fa17-4c42-95f6-833f3e226823">1,948</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Increase) decrease in prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTEtMS0xLTA_ce1382f1-3ff3-44be-a852-e2c581ef4af2">2,652</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTMtMS0xLTA_170dbfac-98b5-4da0-a915-6f89892bb00e">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTUtMS0xLTA_81d06708-6ae8-4042-82ff-51a2d2f29ee1">557</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTEtMS0xLTA_92a1655e-96a8-4b60-8356-c6ab36166e6d">429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTMtMS0xLTA_d2cdb2cc-201b-4bc6-b679-ac0341562584">144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTUtMS0xLTA_cda8da00-1232-4b4e-b3bd-10546774b1cf">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase (decrease) in accounts payable and other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTEtMS0xLTA_b814f2bf-6031-47c5-a1ed-5141ba69d33c">20,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTMtMS0xLTA_2c53d336-7eaf-4a89-bf72-d227fa3386f9">19,913</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTUtMS0xLTA_4b5996bc-422f-476a-b728-7ea59fa77ada">11,875</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in deferred revenue&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTEtMS0xLTA_79504142-ce55-4d49-8397-f86c3e7ec5c5">25,990</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTMtMS0xLTA_9bdcca3b-9fa5-4555-8339-ab4df85e309f">22,940</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTUtMS0xLTA_eeb1b301-48e9-46ed-965f-ea9476c41ef6">51,133</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTEtMS0xLTA_257a7825-d75e-4a8d-bed4-e57f8a01c430">113,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTMtMS0xLTA_735866ed-bd0d-49b5-85b2-f5fdcb1638ed">148,607</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTUtMS0xLTA_a955d11e-81c1-4569-bbb4-2d9d4d846fd4">185,394</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTEtMS0xLTA_5998f925-cf7f-41de-b4a9-d4133a467098">70</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTMtMS0xLTA_bc39f4c0-3652-41b7-b152-7c37923e194a">95</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTUtMS0xLTA_7e97b931-1a44-426b-8c6f-8953283d6e65">228</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTEtMS0xLTA_abf616f6-e18b-4fa8-a893-663e83580da9">322,385</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTMtMS0xLTA_cc32e8b7-5778-46c9-8a0c-e44b9a09c7c2">119,987</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTUtMS0xLTA_ac7c3170-4571-4b2b-8d92-5dbbf3ab202e">267,873</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of investments&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTEtMS0xLTA_519b95b0-a4fc-4021-8b2a-d2568eb99066">166,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTMtMS0xLTA_f60aae56-39e2-495b-b809-4628dbc5e44b">289,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTUtMS0xLTA_8941dfbb-99e0-4dda-996e-14760a86b5b7">318,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTEtMS0xLTA_75fa1d95-3c68-439d-bd9e-fb9f2daf80b8">155,855</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTMtMS0xLTA_b3371dc0-207c-4979-9f46-4f3f8cd8449b">169,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTUtMS0xLTA_c338ac6e-12f5-4c31-8b4d-3b2492822d3a">50,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTEtMS0xLTA_a87db889-7946-459c-a9f6-cbf35c85aedd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTMtMS0xLTA_eab36738-0027-4f43-ba60-9d05be3bc4da">732</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTUtMS0xLTA_2162f78e-b442-49dd-96c3-25281d92c072">7,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTEtMS0xLTA_536f588e-e6bf-4542-958c-874527c85f2f">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTMtMS0xLTA_40d1fcf2-8b64-4703-8b45-b2dee410c11d">972</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTUtMS0xLTA_bcc6494c-6bf2-4395-a317-566de5b80c15">1,679</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from debt borrowings, net of fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTEtMS0xLTA_a2051e25-4c8d-463c-9a3d-1ff384a9102a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTMtMS0xLTA_201d225c-7182-475e-b0fe-ff2f03903f19">12,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTUtMS0xLTA_293e1154-7a72-4241-a180-15e255519025">145,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of debt borrowings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTEtMS0xLTA_ab58fd69-1a3f-4d7e-b0a9-9a7d409a6626">1,285</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTMtMS0xLTA_370b2d94-c393-43cc-8a25-f61f8507fffa">14,533</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTUtMS0xLTA_5ed14cdc-b7c1-4a49-bd2d-ffa32c232426">2,280</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTEtMS0xLTA_b7a41ccf-8275-4f0a-9811-78d3f1317714">2,226</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTMtMS0xLTA_4200d289-d770-48c0-9eeb-f5d8ad1fb790">2,244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTUtMS0xLTA_4f63bd37-9d64-4b5b-942c-48a31e1ce9b3">149,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTEtMS0xLTA_9cd5c41a-b0db-4909-acfa-f570a6221d3c">44,274</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTMtMS0xLTA_3d85c995-0d79-4c23-a982-0448931f3edc">18,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTUtMS0xLTA_387e00c4-1716-4d2e-833c-d4a331b92a15">15,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTEtMS0xLTA_698220f0-d859-4d59-ada3-83348804c2d1">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2be9572e894e461092c842e6748a2b74_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTMtMS0xLTA_8a1314c7-685f-4d7e-85e4-09ee4aea1e76">61,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57757fd132344fe38d2ce518c20bb378_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTUtMS0xLTA_c151b00d-f4bb-41fa-a472-c00e212b8783">46,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTEtMS0xLTA_bf4342c4-1020-4894-aaaa-3218986c3d65">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTMtMS0xLTA_b0297638-3189-49a1-98d8-1b88f0f75032">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2be9572e894e461092c842e6748a2b74_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTUtMS0xLTA_9fec6770-9a99-45f2-992a-1776422c4332">61,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTEtMS0xLTA_b81da75f-1609-493c-be17-66aa38b9af7e">19,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTMtMS0xLTA_610799e7-0457-4906-84e3-1762579afbfd">16,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTUtMS0xLTA_ae1e5aed-25c3-4115-8800-e1de2ac309c7">5,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock issued in satisfaction of Symphony Icon payment obligation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lxrx:SharesIssuedToSymphonyDesigneesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTEtMS0xLTA_67393143-f0a1-4cb9-a591-6ce0cbc3cf6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lxrx:SymphonyContingentPaymentInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTMtMS0xLTA_a4894f2f-d9cf-48e7-95f5-f0acf62239aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SharesIssuedToSymphonyDesigneesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTUtMS0xLTA_b3bbf9b9-e96c-4528-89fc-a8cbef887f3d">10,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_148"></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Consolidated Financial Statements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">December&#160;31, 2019 </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_151"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTEvZnJhZzo4OGM1YmNmNGU3ZjU0MTM2OWJjZTExNmZmM2QxOWExNC90ZXh0cmVnaW9uOjg4YzViY2Y0ZTdmNTQxMzY5YmNlMTE2ZmYzZDE5YTE0XzE0ODM_6ccd27e6-d8f9-4af7-b524-9854e8b83d93" continuedAt="ie11881281b06490f8d10395f715d63d5" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="ie11881281b06490f8d10395f715d63d5"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen Pharma SAS&#8217;s (&#8220;Ipsen&#8221;) ability to successfully commercialize XERMELO outside of the United States and Japan and Lexicon&#8217;s receipt of any milestone payments and royalties; the success of its ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin; general and industry-specific economic conditions which may affect research and development expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div></ix:continuation><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_154"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTk0_abce00dd-a726-4678-96ab-0c7852902cf1" continuedAt="i48626715d70b4493a4ec742d444c9974" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i48626715d70b4493a4ec742d444c9974" continuedAt="if93e45d2d76545c3979df66f4035ee12"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTE5_4365b836-56c2-4f57-9957-661ad9d93d22" continuedAt="i3ec5d9471f594ee894d8086776c8bee0" escape="true">Basis of Presentation:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"><ix:continuation id="i3ec5d9471f594ee894d8086776c8bee0"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. In 2018, accounts payable included $<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:PriorYearReclassOfAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2Njg3NTY_945aa197-e5f9-46d1-a39e-47040c476237">5.7</ix:nonFraction>&#160;million related to its accrual for clinical studies.  The Company has reclassified this amount to accrued liabilities in the consolidated balance sheet for comparable presentation of accounts payable and accrued liabilities.</ix:continuation>   </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODky_98927cb9-9ea1-4a55-afe0-c0eb419f7d97" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTcx_173669ea-d7e8-4596-a22b-a734ede6f1f4" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2019 and December&#160;31, 2018, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTAy_e9933e57-5f6f-400b-8d46-d93c7857e57f" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</span></ix:nonNumeric></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODk0_e8b4c312-1dd0-40f7-bc49-e81dd0ef65d2" continuedAt="i57a91457cda445338f72a8fe91be7820" escape="true">Inventory: </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i57a91457cda445338f72a8fe91be7820"> Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.</ix:continuation> Inventory consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if93e45d2d76545c3979df66f4035ee12" continuedAt="i6de561af728344d0b00e631a0c38f663"><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.403%;"><tr><td style="width:1.0%;"></td><td style="width:50.791%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.504%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.999%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.506%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzItMS0xLTEtMA_64a7f11b-920e-4898-9f05-74a1a505d19b">3,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzItMy0xLTEtMA_9d8cc269-ad0f-4da5-aae1-e5d6596015ea">3,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzMtMS0xLTEtMA_45da0cc0-5812-4f52-acc1-6dcfb08eb12a">153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzMtMy0xLTEtMA_bb625a0b-30da-4f56-9613-68063916db24">232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzQtMS0xLTEtMA_b4f2989c-718c-4da4-aede-762a720827ba">908</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzQtMy0xLTEtMA_10f5ad35-0070-402b-a083-57a939907668">884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzUtMS0xLTEtMA_13cf9d8a-0467-427e-a638-34f2e483becb">4,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzUtMy0xLTEtMA_db1e9816-e21e-494b-a2c7-27ff724cf599">4,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTIx_614189d6-573d-4438-b622-5e2bdd0c88f1" continuedAt="i5e472a09f7b34cf1b0ed8b21e400c02a" escape="true">Concentration of Credit Risk:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5e472a09f7b34cf1b0ed8b21e400c02a"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</ix:continuation>&#160;&#160;In 2019, customers in Germany and the United States represented <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI4NDg_7f3cc48a-3e4c-4a78-bce2-ad035bf985f7">89</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI4NTU_7bf76795-e69c-4bfd-8ce9-759b20b9adb7">10</ix:nonFraction>% of revenue, respectively.  In 2018, customers in Germany and the United States represented <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI5NDY_5b1ec4fd-4f9f-4fe2-9e35-c7d37da0086b">53</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI5NTM_f338bb25-4998-4048-bfc1-ad6dae8ba18a">40</ix:nonFraction>%, respectively.  In 2017, customers in Germany, France and the United States represented <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMwMzM_7ccfb857-20e5-461a-b34c-bdb07c05155b">65</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2Njg3NzI_e82d3295-f611-46d8-98df-4b3a298b8bb2">18</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMwNDA_e6afc2be-4b02-4dbd-9ccf-80d763ee25f5">17</ix:nonFraction>% of revenue, respectively.&#160;&#160;At December&#160;31, 2019, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODk4_9e0312cd-9503-41ff-84f4-120a996fb54b" continuedAt="id21df0cefc7a421399ded4a7023a40dd" escape="true">Segment Information and Significant Customers:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id21df0cefc7a421399ded4a7023a40dd"> Lexicon operates in <ix:nonFraction unitRef="segment" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMyMzM_2c0cec60-24f9-448b-a3ee-454ca025e477">one</ix:nonFraction> business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.</ix:continuation>  In 2019, Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) represented <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="lxrx:EntityWideRevenueSanofiPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzM3ODM_426f828d-9911-4685-b3a7-69b2d3f33636">89</ix:nonFraction>% of revenues and no other individual customer represented more than 10% of revenues.  In 2018, Sanofi represented <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" name="lxrx:EntityWideRevenueSanofiPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzM5Njg_fc563be8-0014-40b6-a718-226bb599b8b9">53</ix:nonFraction>% of revenues and two independent specialty pharmacies, Biologics, Inc. and Diplomate Pharmacy, represented <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="INF" name="lxrx:LXRXBiologicscustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU4NTQ_a356f408-4fb4-48fc-8707-22f27334cfd5">25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="INF" name="lxrx:LXRXDiplomatcustomerconcentration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU4NjE_aa1a4754-2fb9-4337-b45f-316d7fea8c58">14</ix:nonFraction>% of revenues, respectively.  In 2017, Sanofi and Ipsen represented <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="lxrx:EntityWideRevenueSanofiPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzQwMzI_76592578-ebb0-4ede-a0d6-1dde72d12498">65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="INF" name="lxrx:EntityWideRevenueIpsenPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU5Mzk_1b133355-65ca-4e8d-8c45-180696b6d0a6">18</ix:nonFraction>% of revenues, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODgz_c8a9e7df-83e9-4ef6-8da8-7aca7bd5bb01" continuedAt="i41c41258be4248d0b2c9ec1d13b42881" escape="true">Intangible Assets:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i41c41258be4248d0b2c9ec1d13b42881">  Intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.</ix:continuation>  During 2017, intangible assets relating to XERMELO of $<ix:nonFraction unitRef="usd" contextRef="i0e9da8ecf2c54fbe8f306aa71dd97256_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:XERMELOIntangibleAssetsFiniteLived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzQ0MjM_a8903fd0-afc2-4b77-92b4-6800b061859f">24.7</ix:nonFraction> million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company has recorded $1.8 million in amortization expense related to this asset in each of the years ended December&#160;31, 2019 and 2018, respectively, and $1.5 million for the year ended December&#160;31, 2017.  Amortization expense is recorded as cost of sales in the accompanying consolidated statements of comprehensive income (loss). </span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTE2_1a858cbb-f82a-4508-87b9-42250c66a6a8" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated future amortization expense for intangible assets as of December&#160;31, 2019 is as follows:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"><tr><td style="width:1.0%;"></td><td style="width:78.472%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.528%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzItMS0xLTEtMA_f6a2ed4a-e05f-4f21-8a0e-e64ccf506bf8">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzMtMS0xLTEtMA_a684e233-2b29-4d45-8e59-333d20505b02">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzQtMS0xLTEtMA_f44e1787-d274-466a-ae7b-b549a296f057">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzUtMS0xLTEtMA_04ee992b-611d-4dfb-ada3-2c0ada416141">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzYtMS0xLTEtMA_bb3b2877-fdc5-4a35-bb66-076159815875">1,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzctMS0xLTEtMA_7f825e68-26da-4afa-9875-fdd07efd0c2c">10,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzgtMS0xLTEtMA_8196d718-fc8e-4f01-8d25-0759bf9ea78c">19,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODg1_5693529c-b953-4aa9-8af4-2659d9b11641" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property and Equipment:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b">three</span> to <ix:nonNumeric contextRef="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTg_40aaa522-acdc-49dc-92e5-0c17126b9713">40</ix:nonNumeric> years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i6de561af728344d0b00e631a0c38f663" continuedAt="ia207d3af5bd14166a02d0b219fbf869b"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODc2_6b616497-b372-4233-93da-fb9f2ab16377" continuedAt="i5ea2f3272c4f44a8ae8a3be0778dc84b" escape="true">Impairment of Long-Lived Assets:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5ea2f3272c4f44a8ae8a3be0778dc84b">&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzYwNDA_be2ddde1-1488-411d-aaa4-87e8b35d1a33">no</ix:nonFraction> impairments of long-lived assets, including finite-lived intangible assets, in 2019, 2018 or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTkx_96ae33e4-c0be-4d31-920d-2342c4c397fa" escape="true">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.</ix:nonNumeric>  Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 13) and Lexicon's resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIxOTkwMjMyOTY2NDY_0b586ba8-6d4a-4bf3-9b28-abf1f8a9fd5b">28.6</ix:nonFraction>&#160;million to IPR&amp;D for the year ended December&#160;31, 2019.  The impairment reduced the remaining book value to zero. There were no impairments of indefinite-lived intangible assets in 2018  or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQ2_3148372b-434b-4c6d-bd93-f79be0db9c0c" continuedAt="i0a909da63b0d47cdb5b5e724773f763c" escape="true">Goodwill Impairment:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0a909da63b0d47cdb5b5e724773f763c">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</ix:continuation>&#160;&#160;There was <ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzc3NTk_35f6a524-8ac5-44e9-a9c4-3011818b0e01">no</ix:nonFraction> impairment of goodwill in 2019, 2018 or 2017.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQy_27061921-0294-4909-a027-bbc5485b5cbc" continuedAt="i25c632f5f066484c8ed8f4ecc8d1957f" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customer Credits:  The Company&#8217;s customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expects that its customers will earn prompt payment discounts.  As a result, the Company deducts the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ia207d3af5bd14166a02d0b219fbf869b" continuedAt="i967026e7926f44deaf639be1f6d0bb33"><ix:continuation id="i25c632f5f066484c8ed8f4ecc8d1957f"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenues in the period of adjustment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The Company adopted ASU NO. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;, on January 1, 2018, using the modified retrospective method.  In its adoption, the Company recorded a $14.2 million cumulative-effect adjustment to its accumulated deficit related to a contract with the Texas Institute for Genomic Medicine. Subsequent to adoption, the Company was notified that all performance obligations related to the contract have been fulfilled. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i967026e7926f44deaf639be1f6d0bb33" continuedAt="i60d7b8a897b840439a8ddf50bd16787c"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTYy_a649f10c-a2c9-4797-a9c7-2f7f82ffde3b" continuedAt="i2052063f900d4e4fa065bc0ab6729c76" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2052063f900d4e4fa065bc0ab6729c76"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during 2017 once the FDA approved XERMELO as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive income (loss).  As a result, cost of sales for approximately the next <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:durwordsen" name="lxrx:CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE2MzA3_e7a220c1-a06b-4b74-b6bd-47f2d5805e17">twelve months</ix:nonNumeric> will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of <ix:nonNumeric contextRef="id200f3fdbfab4a1d8d40cdc784c65d06_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE2NjE3_16c1c44e-7fdc-42c4-8435-389f53394821">14</ix:nonNumeric> years.</ix:continuation> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQ3_8e2dc647-7faf-4faa-b8f4-c2a738a2f1ac" continuedAt="i5096a0f76f514e418cbde119ad6a0082" escape="true">Research and Development Expenses:</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5096a0f76f514e418cbde119ad6a0082"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company's estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease was based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTcz_64356422-6efb-409c-b529-e82b746370a2" continuedAt="iee86ca927c1e4d57b8550e76f7f3180c" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE4ODgz_72afcd1b-2df1-443e-b4d8-8ef7db27829b">24.0</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE4OTU2_179c9abe-101a-4dfd-9afa-9dd652dcfb1b">1.1</ix:nonNumeric>&#160;years.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iee86ca927c1e4d57b8550e76f7f3180c">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended December&#160;31, 2019, 2018 and 2017, respectively:</span></div></ix:continuation><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTUw_f836b363-66b1-4206-8a85-cf26138bbebc" continuedAt="i345d325170dd49bdad3a1a54b7f0e80f" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i60d7b8a897b840439a8ddf50bd16787c"><div style="margin-bottom:6pt;"><ix:continuation id="i345d325170dd49bdad3a1a54b7f0e80f"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItMS0xLTEtMA_ac707baa-7973-4164-9bbc-bfd90023fc1a">88</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItMy0xLTEtMA_420d7836-d0fa-40a2-ace7-251a10d5a1f6">2.2</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItNS0xLTEtMA_bbb35456-9df6-48f6-8b08-15ba340017c2">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItNy0xLTEtMA_61bc59de-d22a-4c6f-b515-3643aa7e884c">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtMS0xLTEtMA_1db9fe27-d225-410d-9b89-307853197dcb">77</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtMy0xLTEtMA_c65ac751-7ff4-4636-bc22-91f113705bb8">2.6</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtNS0xLTEtMA_85c061f1-d80c-4852-bf45-054b7bd140d5">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtNy0xLTEtMA_3d03f1df-5419-4fc1-a189-200de7a1d41c">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtMS0xLTEtMA_8d4df040-116b-4dec-b9e5-af4418ede1b6">58</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtMy0xLTEtMA_e38e398e-3d71-4b40-bbc6-e9f98731321d">2.6</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtNS0xLTEtMA_982b4374-1e58-454e-9e57-73e35a7c1efd">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtNy0xLTEtMA_00867f44-e177-43ba-81c3-be78ab268cf4">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtMS0xLTEtMA_4f64af9d-0f88-4078-8dea-4f63feb8026a">63</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtMy0xLTEtMA_57a374fd-cea6-4d04-bd95-4d068844bc31">2.8</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtNS0xLTEtMA_add89eb9-dccc-40eb-93c6-efd0fd3351a7">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtNy0xLTEtMA_67934225-72f5-4353-80fa-4999011aa7a1">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017:</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtMS0xLTEtMA_f8c61866-9393-4103-81e1-0cecbb91db72">61</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtMy0xLTEtMA_99f61c86-beae-4064-a854-1efc74295dc6">1.7</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtNS0xLTEtMA_963a44b9-e84b-48b0-b20e-460a812a3b28">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtNy0xLTEtMA_01b62e79-09fb-460b-8c18-ab7826404025">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktMS0xLTEtMA_fdcdd044-4220-4213-8232-bd301ce15fe3">70</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktMy0xLTEtMA_2b99b92e-bbbd-4c77-b493-891c333f91c3">2.2</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktNS0xLTEtMA_26ac7d53-c1c0-476d-a28f-10510c06bf60">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231" decimals="0" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktNy0xLTEtMA_fbf80fee-91fd-4dca-8a1b-7d521d5dbdbe">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:continuation></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NzgxNzY_0347b4f4-8290-44f5-80aa-c7efed01e5e7" continuedAt="ic20db21d1493434db4dd82e74d24ef11" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Income Taxes:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method,  deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2019, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December 31, 2019, and positive evidence, including the income during the year ended December 31, 2019 and projections of future income. After assessing both the negative evidence and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December 31, 2019 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total deferred tax asset balance subject to the valuation allowance was approximately $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NzgxNzE_e828dc25-78b6-4642-b0df-0f5b782c88bf">333.6</ix:nonFraction>&#160;million at December 31, 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. </span></div></ix:nonNumeric><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"><ix:continuation id="ic20db21d1493434db4dd82e74d24ef11">The Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent, reduction of certain tax credits, limitations on, or deductibility of interest expense and executive compensation, and limitations on the use of net operating loss carryforwards.</ix:continuation> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQz_82b5d085-85e1-44dc-ad57-25e9e94a8249" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Income (Loss) per Common Share:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></ix:nonNumeric></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_160"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjAvZnJhZzo2MDMwMjRkZjczYWQ0OGFjODA0MGU0ZjhhMzcxMzY4ZC90ZXh0cmVnaW9uOjYwMzAyNGRmNzNhZDQ4YWM4MDQwZTRmOGEzNzEzNjhkXzY4Mzk_af0b684e-583c-4684-80fb-fa606613fc25" continuedAt="ide365e6b44144f558a30a8efcee26321" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="ide365e6b44144f558a30a8efcee26321" continuedAt="i8a27527e7645411f869518723522d095"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the  Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement was effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. This ASU was required to be adopted using a modified retrospective approach.  Management adopted ASU 2016-02 on the effective date of January 1, 2019 and elected the practical expedient that allows entities to not apply the new guidance in the comparative periods they present in their financial statements in the year of adoption.  Consequently, prior year financial information has not been updated and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019.  Upon adoption, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iead7811281254bcbb2692b1ba9a8a25b_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjAvZnJhZzo2MDMwMjRkZjczYWQ0OGFjODA0MGU0ZjhhMzcxMzY4ZC90ZXh0cmVnaW9uOjYwMzAyNGRmNzNhZDQ4YWM4MDQwZTRmOGEzNzEzNjhkXzUzNzA_2ec58214-f9b2-47ef-9d79-c36026c1c94e">2.1</ix:nonFraction> million for right-of-use assets and corresponding liabilities on the consolidated balance sheet, </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i8a27527e7645411f869518723522d095"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">primarily related to leases of office space.  The adoption of this ASU on January 1, 2019 did not have a material impact on Lexicon&#8217;s consolidated financial statements. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pronouncements Not Yet Adopted.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In November 2018, the FASB issued ASU No. 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606".  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_166"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzM0Nw_5311a8c2-a9c6-4065-a0c6-7ad8882b01ca" continuedAt="i3fae2179ad734b1290c58a9fbae47e1b" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3fae2179ad734b1290c58a9fbae47e1b" continuedAt="i42352e6378f64072a59f99b02a4827c1"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of cash and cash equivalents and investments held at December&#160;31, 2019 and 2018 are as follows:</span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzM0Mw_48fa1a1a-641f-4fe6-8063-52fbb6c9090b" escape="true"><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"></td><td style="width:41.827%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.585%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtMS0xLTEtMA_3742e855-5a6a-4a69-8652-3c54ab24466f">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtMy0xLTEtMA_bac7fd4a-554f-4047-be83-f855dfcb592a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtNS0xLTEtMA_9f6ef387-141c-4db1-9506-631e98681129">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtNy0xLTEtMA_07e2e40d-0318-43fa-bdb3-c2da4e28b1bc">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtMS0xLTEtMA_c0267828-faea-4197-afbc-9db837a12ce6">235,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtMy0xLTEtMA_da56f28e-d91a-4269-99ac-7f03012c87fc">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtNS0xLTEtMA_c2685689-420a-4bb1-bd80-3fc5acb44bb0">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtNy0xLTEtMA_39ceefa7-781e-42b0-8003-a3270c2bb7fa">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctMS0xLTEtMA_31c311a8-cd81-4713-9d31-110367224f90">235,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctMy0xLTEtMA_5764aaa3-1a49-41c4-8004-89ec4c1eb878">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctNS0xLTEtMA_15eb84ac-54a6-4b80-95ff-fe5267b9789b">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctNy0xLTEtMA_8ec48b83-4492-4087-9847-3f502cc49570">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtMS0xLTEtMA_71851602-0f43-4df1-a552-5792167bedc6">271,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtMy0xLTEtMA_bac1420c-45d2-4f7d-9edd-219236cd3803">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtNS0xLTEtMA_bbb25108-5317-4e46-a7dd-6b65c15e116f">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtNy0xLTEtMA_51673b25-ae4a-49e4-9275-b7a57c420881">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"></td><td style="width:41.981%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.431%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtMS0xLTEtMA_ea75cf48-e2d2-4b25-9b72-d77e023b11d6">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtMy0xLTEtMA_8eab78b2-b634-4e14-8a9c-11169024a6b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtNS0xLTEtMA_b6edfbeb-9885-484d-94ba-80bfcf80670e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtNy0xLTEtMA_e0e1f457-de13-4eca-9668-3f501656adbe">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtMS0xLTEtMA_73d52683-9a32-4458-9031-15bf28832ba6">73,983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtMy0xLTEtMA_b406a222-f7a8-4c36-bbda-6d65cb53bf7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtNS0xLTEtMA_7db1f0d4-490e-4106-b0a0-4ea739b98c38">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtNy0xLTEtMA_256d713a-42e2-49c9-a399-ce8be702d4f6">73,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtMS0xLTEtMA_60d49e5d-dbe2-4c26-8482-ee5db059e198">5,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtMy0xLTEtMA_03ce8993-f8a0-4774-911f-4a76efabbf45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtNS0xLTEtMA_f24e1da7-449f-4a4e-b79f-97003206e974">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtNy0xLTEtMA_b4f5d8ca-1029-4338-9c1e-a47cf86fe395">5,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctMS0xLTEtMA_eb7aca64-91e0-476b-98c7-a4e41aa21723">79,678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctMy0xLTEtMA_9a547088-a03c-44d4-932f-4419503e0c8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctNS0xLTEtMA_617f813d-6ac2-4b35-a552-df3da4d44850">12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctNy0xLTEtMA_452df47c-9b1f-410f-aeae-2d068695f752">79,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtMS0xLTEtMA_df566745-05c6-4f18-a4d7-c8a41319df75">160,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtMy0xLTEtMA_4fbb73a2-aa2e-4a52-ad08-29e1f72dfc24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtNS0xLTEtMA_a783f020-c802-430c-883b-7223de8947d0">12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtNy0xLTEtMA_5bf3c6a2-71e5-4342-bdd7-bcb1b977c4dd">160,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i42352e6378f64072a59f99b02a4827c1">There were <ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzE2NA_d6384062-fb12-4494-adae-6afe6684fb5e">no</ix:nonFraction> realized gains or losses for the years ended December&#160;31, 2019 and 2018.</ix:continuation>  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_169"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90ZXh0cmVnaW9uOjgxYjVmMmMzOTNiMzQwOGJhZDQ0ZDEzZTBkMGQxZDM2XzI5MTk_4705b11f-94fa-46bf-a611-54e46b46495c" continuedAt="ib390bcf36b6341109303fe4edaf2c4e1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib390bcf36b6341109303fe4edaf2c4e1" continuedAt="i5f8552780a0b43a8a7b3d930267fd5ab"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; significant unobservable inputs </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2019 and 2018.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90ZXh0cmVnaW9uOjgxYjVmMmMzOTNiMzQwOGJhZDQ0ZDEzZTBkMGQxZDM2XzI5MTA_8cd77480-06e3-4e0f-98c0-bbc68f20bbec" escape="true"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtMS0xLTEtMA_837a609a-9358-446b-b4f7-03a97a38e57c">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtMy0xLTEtMA_228a6e1c-ed99-41b0-8765-ede31a3123b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtNS0xLTEtMA_fb1481d6-9e4e-4707-80ee-631931b0d8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtNy0xLTEtMA_9c5b58fe-98f6-4648-b2e1-9ac854a2012b">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtMS0xLTEtMA_490eab61-b4d9-46eb-be85-bcb6d8fd6aef">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtMy0xLTEtMA_5277c868-ca47-4895-8ba1-85b95406a3a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtNS0xLTEtMA_48b228b5-4be6-469a-8b95-1daad5f7cc47">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtNy0xLTEtMA_6c635b45-8559-416d-a367-efa3a782c304">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctMS0xLTEtMA_a61be7bc-3e71-4533-9c03-28ec77cf8ece">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctMy0xLTEtMA_bc889476-8af5-4c9e-9b09-3b2cfbcd15e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctNS0xLTEtMA_a4bd03d1-e261-4c20-84c4-d638172b5872">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctNy0xLTEtMA_433c0568-0e4e-4ae4-b756-053bbe8260e1">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtMS0xLTEtMA_ea4748bd-d30a-4b55-a27b-70e7023cec32">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtMy0xLTEtMA_1d910fc5-5b04-4218-8054-c151c197be52">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91d5f1656d844951addb1fa04625751d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtNS0xLTEtMA_80bf5a6b-7b92-4740-92a7-5a8674133e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtNy0xLTEtMA_a4dfe099-8f4a-4167-b7eb-f9de5bd0f422">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtMS0xLTEtMA_534d8721-d568-4cfc-b20a-8fa24a615a5d">73,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtMy0xLTEtMA_29e81a70-67de-4e20-b535-48b996cc4a67">5,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91d5f1656d844951addb1fa04625751d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtNS0xLTEtMA_cf39365b-3070-46d1-8af5-1c60d54960b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtNy0xLTEtMA_571f986c-01db-4992-bb4e-c922d6726a73">79,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctMS0xLTEtMA_7198b166-f935-4b2d-aaae-3802cc9af0b4">154,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctMy0xLTEtMA_4d8d1208-a3e7-4808-b243-6c96d360c057">5,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91d5f1656d844951addb1fa04625751d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctNS0xLTEtMA_62b6c0e2-2abe-471a-88fc-e419e255d016">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctNy0xLTEtMA_314e81b6-6b75-4b50-bd4a-192be01f989b">160,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2019 or 2018. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div></ix:continuation><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5f8552780a0b43a8a7b3d930267fd5ab">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</ix:continuation>  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 9, Debt Obligations, for fair value measurements of debt obligations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_172"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90ZXh0cmVnaW9uOmZiMjYzYzk3ZWE5MDRlMjNiZDI5NDhjM2RjNDhlOGExXzEwMA_0f3801e3-1ad0-486e-b96e-55c1814f079a" continuedAt="ibd16c49bd3fa44f2b3603ec3419f6f00" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="ibd16c49bd3fa44f2b3603ec3419f6f00"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment at December&#160;31, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90ZXh0cmVnaW9uOmZiMjYzYzk3ZWE5MDRlMjNiZDI5NDhjM2RjNDhlOGExXzg4_61ba7044-e2a5-4d86-8d18-6d3680bf9acf" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:55.331%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.278%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.372%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.278%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.639%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Lives</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In Years</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-5</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94d65b504af44fc3a8e21bcd23052cfd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzMtNS0xLTEtMA_5ceb1c7e-d5a5-4fd8-a6ae-99214008c45e">4,587</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i326024d73cea4d15aa9ac4c2c5c24f6a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzMtNy0xLTEtMA_12f7540c-ca87-47d9-b0ee-f7b961796286">4,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-7</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c3e10389e3543398ede188dc42287b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzQtNS0xLTEtMA_242803b3-e2b5-4039-9139-ac5fb5f0845a">5,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3b8f069656465fb49124367dada928_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzQtNy0xLTEtMA_c9686df1-dfe2-44d8-bd23-7563197b3801">5,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i490ae890935942b1b6b3556c3099574e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzUtNS0xLTEtMA_ebb5ddbe-f6ac-4f81-b5ee-a23e1b5c5745">3,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4b49290934c41a6aad3724b4c80bbd6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzUtNy0xLTEtMA_1f139a74-13d2-4e32-9d16-20307d8e2d62">3,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b062ad588146aca58efd416bfc6a9b_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzYtNS0xLTEtMA_c308ecca-d287-4ed3-bfae-3b67a4811366">417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2bcb52391538408c8580e9d00fbeb629_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzYtNy0xLTEtMA_ef9706a1-5def-42ca-9319-f09ee456277d">416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15-40</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1340081d4b804484b5d1dca5c73bf782_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzctNS0xLTEtMA_3a6b3182-eabc-43ed-b883-b34117acaabe">59,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9476eb367804eba9e26e39f94e0c1d3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzctNy0xLTEtMA_0f3b0c51-e596-4991-a925-ab62206a85ae">59,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i428262586cfe46008e720b64332fe571_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzgtNS0xLTEtMA_05eab823-63e9-4f9b-ad2b-79466af185a4">2,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c95eef01a704b3a945e493cf9b53436_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzgtNy0xLTEtMA_f367eb09-763d-4e4a-a020-489f0581ba4b">2,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzktNS0xLTEtMA_0f21a987-f567-446d-b267-190ed907356b">75,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzktNy0xLTEtMA_1f78d0de-5fe5-4d0d-80a7-bd1ac8a14e55">75,871</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzEwLTUtMS0xLTA_8714c9d9-f014-4d12-b222-3c28c217a7ae">61,741</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzEwLTctMS0xLTA_a597925f-1887-40f7-8705-bbd7d5596844">60,006</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzExLTUtMS0xLTA_00355a84-5c7b-41fc-a52d-18557a7c016e">14,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzExLTctMS0xLTA_1fa2ff42-e8b3-4d2b-8339-4a3a0fce6385">15,865</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_178"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4NzM_b8048332-9b24-4a5a-bed2-b0762f884a15" continuedAt="i8825a5b36f1e4187a907d0a79c22891d" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i8825a5b36f1e4187a907d0a79c22891d" continuedAt="i12821102338a448fb7567974d2162ced"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2019 and 2018 are as follows:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4ODI_16b97296-1cd0-4749-9e29-d9a57eaef825" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzQtMS0xLTEtMA_a120e494-a4ff-453c-b706-ce19027d98ba">193,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzQtMy0xLTEtMA_d571458d-82d6-4941-a355-b98ed1fcb00c">206,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzUtMS0xLTEtMA_9341e6d2-dc53-42e4-9cb3-f55e44b7dbc0">46,306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzUtMy0xLTEtMA_30c8a3c6-b761-41e4-bde2-007927ddb189">47,087</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzYtMS0xLTEtMA_80b5c03e-4257-4228-bfec-8a59077fa986">24,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzYtMy0xLTEtMA_40e48420-6993-4f6c-b3e1-d5a5fb1bf568">24,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzctMS0xLTEtMA_e45ba0e0-d9f1-42c0-b541-e09af6b1c8e1">58,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzctMy0xLTEtMA_65d73c8d-75d4-491d-82a0-0fd86b72de6a">71,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzgtMS0xLTEtMA_6346e0de-5ce1-44e1-a8be-44e10d27478c">5,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzgtMy0xLTEtMA_cba5eafb-a728-4617-966d-a0434055b8c5">4,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzktMS0xLTEtMA_2e150d50-0cbf-42e6-a0ff-cd307aa656d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzktMy0xLTEtMA_08357ad1-a67f-42ef-ba50-b657b1e7b5c7">5,458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:DeferredTaxAssetsSection163j_LXRX" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEwLTMtMS0xLTA_20f30b96-8509-4193-8db1-8596ea72c9c6">3,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzExLTEtMS0xLTA_17686f2e-8db6-44ae-b339-b7d2111af358">5,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzExLTMtMS0xLTA_e5cc619b-aed2-41ea-89bb-dc17c087fe8b">6,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEyLTEtMS0xLTA_7299d423-595b-4cc1-97bb-a794d2eb371a">333,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEyLTMtMS0xLTA_7e49bdfb-2840-48aa-9a49-a28f95761fd9">369,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability related to acquisition of Symphony Icon</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE0LTEtMS0xLTA_b4bd2e48-2219-416f-8d7d-ab531c418d3d">4,140</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE0LTMtMS0xLTA_796ee3b6-adeb-4a98-94c6-85d1ed865e8b">10,525</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE1LTEtMS0xLTA_9c31baa1-0048-49e2-b27d-640e527fd988">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE1LTMtMS0xLTA_16b8122f-aee7-4777-acaf-72f54c53bf8c">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE2LTEtMS0xLTA_9e5e4d71-7cf3-4648-9eb2-7cdfacadde5d">4,143</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE2LTMtMS0xLTA_71d4f81f-f736-4b30-8a18-8778787940f8">10,527</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE3LTEtMS0xLTA_33d4f072-9399-4bba-9064-ed3c3eccedbb">329,426</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE3LTMtMS0xLTA_3763377c-e7de-47a8-8591-3f646e02161a">364,702</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE4LTEtMS0xLTA_3a190b86-4c12-4cdf-92fb-3bff6e612fb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE4LTMtMS0xLTA_da0d29a7-eed1-4d50-bea3-f7a0f96a5aa0">6,014</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i12821102338a448fb7567974d2162ced" continuedAt="ia312c505bbdd4256a54d32f0888254cf"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets associated with net operating losses (NOLs), deferred revenue and interest decreased in 2019 due to the Termination Agreement (as defined in Note 13) with Sanofi.  Refer to Note 13, Collaboration and License Agreements, for additional information.  The $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEyMDk0NjI3OTEwODkx_ee02e742-6481-4beb-a87c-b874842a05e5">4.1</ix:nonFraction>&#160;million deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEzNzQzODk1MzU4MjM5_cab194eb-d0e1-4498-bcd0-5781da47e792" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.783%;"><tr><td style="width:1.0%;"></td><td style="width:51.021%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.839%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.537%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.239%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected income tax expense (benefit) at <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjc4_bf4a7fd6-8cb4-4567-8a8a-c825344ac4db">21</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjgz_28e93f05-c1d4-4d56-b8b7-26d153af5f7a">21</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjg4_f408a711-e792-4bdc-b525-fedd217a6613">35</ix:nonFraction>%, respectively</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMS0xLTEtNzc5OA_629e4a46-3a55-4a85-8542-5f48468be604">26,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMy0xLTEtNzgwMQ_49fb2373-27f8-42c0-80f0-60913c227499">25,315</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtNS0xLTEtNzgwNA_ae09b129-5ae7-4d75-a866-8c643316d619">47,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtMS0xLTEtNzc5OA_bbef9b31-58cb-454b-8aaa-080edaf05e69">445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtMy0xLTEtNzgwMQ_d6194c75-325b-4b27-9cf2-895d7d5c92a2">809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtNS0xLTEtNzgwNA_b78c1a96-ab54-40b9-b24d-d1d388fc9795">2,324</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtMS0xLTEtNzc5OA_4bbf4088-ab79-4209-acb0-0e235cbf950e">1,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtMy0xLTEtNzgwMQ_6204c559-e8a6-44a2-b2eb-1410472a1ec4">1,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtNS0xLTEtNzgwNA_816ef7b3-7683-448b-a9da-2fec6df9e089">1,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtMS0xLTEtNzc5OA_184b7bcf-5ba4-47bb-b982-fda83bb72a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtMy0xLTEtNzgwMQ_4716ac83-cfb1-48fe-bc6b-5746f9dd99e3">978</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtNS0xLTEtNzgwNA_4ee1e218-52f4-46c3-a065-5e24d0ba4929">1,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctMS0xLTEtNzc5OA_cd25728b-2c5d-4071-9821-b8581f3c6cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctMy0xLTEtNzgwMQ_00613283-8177-463a-a4eb-b02f92737887">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctNS0xLTEtNzgwNA_819e092a-6004-4181-bbfb-c83ab6642e32">189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred true-up</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtMS0xLTEtNzc5OA_ed2ad472-cf21-4311-91ae-cbc025d8f624">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtMy0xLTEtNzgwMQ_933acafd-2387-47bc-967c-fabd72b52fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtNS0xLTEtNzgwNA_6da0c8e6-64eb-44ad-9fbb-fc9c4c290d86">5,316</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktMS0xLTEtNzc5OA_99c78259-1acc-4e05-b3f8-f8a65a4b16c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktMy0xLTEtNzgwMQ_d5079e0d-1891-44a7-ac9c-63182879d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktNS0xLTEtNzgwNA_46c370d9-7a77-47c5-a744-4b01e0131eff">169,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Symphony Icon fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTEtMS0xLTc3OTg_05598669-6e04-487b-86f9-cc8d95c70ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTMtMS0xLTc4MDE_23cc7fbe-8a68-4917-9115-052bd14c26da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" name="lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTUtMS0xLTc4MDQ_a43f4ac2-622e-4da6-a298-43ee863a085f">735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTEtMS0xLTc3OTg_6904dcc4-a8fd-40f0-b5de-c424726e8cc1">35,276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTMtMS0xLTc4MDE_72e6e3f2-7d2b-43b7-91d8-8bf34cfe45d7">25,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTUtMS0xLTc4MDQ_7886b73c-0e9b-490f-9369-268d6c74615d">126,634</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTEtMS0xLTc3OTg_25f9708a-d4dd-45c2-bcd7-e5837f26ca74">1,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTMtMS0xLTc4MDE_4eaed4f1-b755-41e9-ab4c-a52d6ee097f0">115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTUtMS0xLTc4MDQ_05335f6f-0ad2-4309-8c10-b0f5398f7429">372</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTEtMS0xLTc3OTg_67cf3318-35bd-4281-94f8-f0572445afdf">6,014</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTMtMS0xLTc4MDE_b656a60e-b7eb-41d7-b5d4-f5f5af84ab4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTUtMS0xLTc4MDQ_05cb5759-8c83-4918-ad40-841ef7256cb7">12,661</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, Lexicon had both federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI2MzA_b1b4dd8b-ec46-4ee5-9171-6341c36d65bc">879.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI2Mzc_a7993fe7-413e-4e94-80ee-aadfa9255ae6">83.0</ix:nonFraction> million, respectively.&#160;&#160;In 2019, federal NOLs decreased by $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:FederalNetOperatingLossChange" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI3NDg3NzkwODAyMDg_a99697c8-50ec-4ea8-950c-fde91fd1714f">62.2</ix:nonFraction>&#160;million primarily due to utilization against taxable income.  The state NOL carryforwards decreased due to a legislative change from pre-apportionment to post-apportionment reporting in New Jersey.  The federal and state NOL carryforwards will begin to expire in 2022.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEyMDk0NjI3OTEwODk5_b348d296-137d-4a32-90d2-43a06f9c4c4f">46.3</ix:nonFraction>&#160;million begin to expire in 2020.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&#160;&#160;Utilization of the NOL, R&amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Although NOLs were utilized in 2019, based on the federal tax law limits and the Company's cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2019, the valuation allowance decreased $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzM2NDc_47005b17-113f-469a-9a86-a22d9d425758">35.3</ix:nonFraction> million, primarily due to the Company&#8217;s utilization of NOLs and decreases to deferred revenue and interest deferred tax assets.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Lexicon recorded an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2MzUyNTE_8e59543d-ccbe-45ff-9558-af3fa2360b54">6.0</ix:nonFraction>&#160;million in the year ended December&#160;31, 2019 despite reporting pretax income for the year. The result reflects the impact of the impairment of intangible assets associated with Symphony Icon and the benefit from the utilization of federal NOLs for which a tax benefit had not previously been recognized, partially offset by nondeductible expenses.  There were <ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQyNjE_2693de93-c51d-4a2f-87bf-305c46da42a5">no</ix:nonFraction> income tax benefits in the year ended December&#160;31, 2018.  Income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzg0NjA_6f40cdfc-de26-4140-a8d1-4928e42de975">12.7</ix:nonFraction>&#160;million were recorded for the year ended December&#160;31, 2017.  Of the $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0MTA_6f40cdfc-de26-4140-a8d1-4928e42de975">12.7</ix:nonFraction>&#160;million tax benefits, $<ix:nonFraction unitRef="usd" contextRef="i518a6981e36c42a6a7263b4a8fad852d_I20170227" decimals="-5" format="ixt:numdotdecimal" name="lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0Mjg_4a32e122-3298-4f18-8db6-4a63b7e2af5a">8.7</ix:nonFraction>&#160;million is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO and $<ix:nonFraction unitRef="usd" contextRef="i2be9572e894e461092c842e6748a2b74_I20171231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0NDU_4dade6a1-5b82-4b5f-a286-84a33cf7f182">4.0</ix:nonFraction>&#160;million was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  As of December&#160;31, 2019 and 2018, the Company did not have any unrecognized tax benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia312c505bbdd4256a54d32f0888254cf">expense.&#160;&#160;As of December&#160;31, 2019 and 2018, the Company had <ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4MDA_78fe434d-6976-4962-89ba-d2483e3956d6">no</ix:nonFraction> accruals for interest or penalties related to income tax matters.</ix:continuation></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_184"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzEzMzI_3f326d0f-c540-4a70-a2f7-3b5fbf687792" continuedAt="ibf0fb339daa14a9f975235490bcd7312" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="ibf0fb339daa14a9f975235490bcd7312"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="i8c6df2280ae0495591132f2f5d361b8e_I20010712" decimals="-5" format="ixt:numdotdecimal" name="lxrx:CoelacanthGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzQ2NQ_1e216948-ddd5-4c80-accb-07f9002b7f4f">25.8</ix:nonFraction> million, which represents the excess of the $<ix:nonFraction unitRef="usd" contextRef="i8c6df2280ae0495591132f2f5d361b8e_I20010712" decimals="-5" format="ixt:numdotdecimal" name="lxrx:CoelacanthPurchasePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzUwNA_c73df68c-b4b5-4f1d-a3f9-7cc51e013604">36.0</ix:nonFraction> million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $<ix:nonFraction unitRef="usd" contextRef="i9ef4d236906043df99288d5dec2fccfc_I20100730" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SymphonyIconGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzgxNg_ae46fc06-b818-44b0-98cb-8f483ab2250b">18.7</ix:nonFraction> million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_187"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzcxMDU_987806be-4d80-4dae-b9be-2d83d68c1304" continuedAt="i7b2cde4a57de4dbcb70bf9bf29f484b2" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="i7b2cde4a57de4dbcb70bf9bf29f484b2" continuedAt="ib0f1d1bb2cf747d795351721a02c630e"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Convertible Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzk3_19773d91-c9c0-4fc2-9c9c-48d1bb475293">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEzNw_7a759e72-55de-4a88-8108-db4190b84462">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="4" name="lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY0Ng_7a759e72-55de-4a88-8108-db4190b84462">5.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially <ix:nonFraction unitRef="number" contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEzNzQ_7e03e478-a660-4d16-a2f8-812747c963b7">118.4553</ix:nonFraction> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzE0OTE_0b045b52-37a5-42b6-8b23-99f99150e24c">8.442</ix:nonFraction> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="INF" name="lxrx:DebtInstrumentRepurchasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzIxMDE_29336b3d-cc87-4095-8655-813c8cdfe25b">100</ix:nonFraction>% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Convertible Notes, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzIzNDQ_6e214616-76e2-44b5-9f4d-e59c34e0d586">3.4</ix:nonFraction> million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI1ODY_709f0024-f6ab-4884-930f-af1897447d75">seven</span>-year term of the Convertible Notes.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI2ODc_70c3d47f-ba85-424f-9fc5-9e2d26cf6891">0.9</ix:nonFraction>&#160;million, which offsets long-term debt on the consolidated balance sheets. As of December&#160;31, 2019, the carrying value of the Convertible Notes was $86.6&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI4MDE_5753530f-b0de-48b6-9a3f-56829df04c31">64.8</ix:nonFraction>&#160;million as of December&#160;31, 2019 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ib0f1d1bb2cf747d795351721a02c630e" continuedAt="i5b104c8d8bb14456a1cd8c11f41bb09a"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mortgage Loan. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with <ix:nonFraction unitRef="usd" contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzMzNjU_065fea12-bcd1-42a8-a06b-edc7c2875b7f">no</ix:nonFraction> recognition of gain or loss on the transaction.  The loan agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="i505f2df038f048d09e005588782957fa_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtInstrument_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0NTE_77df5558-b7ac-4c6d-91cb-6f83c750f633">12.9</ix:nonFraction> million mortgage on the Property and has a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0ODk_cd815874-61d3-4e93-b842-9068c8947236">two</span>-year term with a <ix:nonNumeric contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM1MDk_7875bfb6-ed46-423d-80c0-c0d20f1ca3a5">10</ix:nonNumeric>-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i505f2df038f048d09e005588782957fa_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2NDA_9839f01a-8846-4264-8acd-31312770f838">5.5</ix:nonFraction>% and (b) <ix:nonFraction unitRef="number" contextRef="i505f2df038f048d09e005588782957fa_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2NTE_b4b01247-98f6-4266-a196-5c491ea72b0c">7.5</ix:nonFraction>% and provides for a balloon payment of $<ix:nonFraction unitRef="usd" contextRef="i505f2df038f048d09e005588782957fa_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtBalloonPayment_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2OTI_cbaa6182-aa4d-4413-b442-9f1117bd3216">10.3</ix:nonFraction> million due in August 2020.  Lexicon incurred $<ix:nonFraction unitRef="usd" contextRef="i505f2df038f048d09e005588782957fa_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtIssueCosts_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM3MzM_54f28d98-9a01-4bd8-a53f-1011bf5717a6">0.4</ix:nonFraction> million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the consolidated balance sheets and will be amortized as interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM5MTI_05762f89-6afe-4eba-b7d3-725a92223b9e">two</span>-year term of the loan agreement.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtIssueCosts_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQwMTA_60b79463-1e53-43b8-ab2a-62974b3775fa">0.1</ix:nonFraction> million.  The consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MortgageLoansOnRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQwNzI_8572977e-6e8c-4c67-82c8-8da3b664535c">11.0</ix:nonFraction>&#160;million&#160;as of December&#160;31, 2019.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:BuildingsCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQxOTg_f379f034-7bd4-4071-8256-fbac1853d752">59.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:LandCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQyMDU_62430f3e-5cad-489b-a598-0fc90442e9b2">2.7</ix:nonFraction> million, respectively, before accumulated depreciation, as of December&#160;31, 2019.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lexicon&#8217;s wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until April 9, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BioPharma Term Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $<ix:nonFraction unitRef="usd" contextRef="ia8d9306784934680a1912cb049ecc58c_I20171218" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEwOTk1MTE2MzUwMTI_21e93269-579c-46a4-b462-738e1fab5fd8">150</ix:nonFraction> million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan matures in December 2022, bears interest at <ix:nonFraction unitRef="number" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQ4NDk_836110d5-6947-440a-9428-b3cb80c5c180">9</ix:nonFraction>% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.   </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the BioPharma Term Loan, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia8d9306784934680a1912cb049ecc58c_I20171218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzYyOTE_fc82acc7-b12e-476b-b84e-e35212387c5b">4.1</ix:nonFraction> million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY1MzU_04b7db4d-7fa9-457a-afc5-ab80eee00947">five</span>-year term of the BioPharma Term Loan.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY2Mzg_cd9004e4-796b-4be8-8f89-4299ce6bdb2d">2.4</ix:nonFraction> million, which offsets long-term debt on the consolidated balance sheets.  As of December&#160;31, 2019, the carrying value of the BioPharma Term Loan was $147.6&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate. </span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i5b104c8d8bb14456a1cd8c11f41bb09a"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzcwOTk_f27c0f27-111f-4be3-a6b6-a26e8b2157d9" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:79.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.156%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzItMS0xLTEtMA_1e7cc976-0335-4870-9c78-ec10800931cd">11,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzMtMS0xLTEtMA_d1a852ce-8140-4fab-8c02-f487e9432720">87,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzQtMS0xLTEtMA_1e95270a-4bb9-49c5-8aaf-cdfc888baf49">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzUtMS0xLTEtMA_003a3e36-2124-4db6-b68c-a386fc001463">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzYtMS0xLTEtMA_71dc0719-bfc6-4f11-9e25-76c70a50d757">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzctMS0xLTEtMA_17c6b095-08f8-4fd7-bcb7-fc0028de4a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzgtMS0xLTEtMA_026ed374-0a85-46ce-a830-eda9f09a0328">248,630</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzktMS0xLTEtMA_a5aaef03-f742-4c10-9507-ac8b96b6e5ac">3,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzEwLTEtMS0xLTA_f088d668-edca-4213-a6a8-def493250fca">11,012</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzExLTEtMS0xLTA_f4ef8575-b5ff-4d41-b5c3-fd942f0fa98a">234,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_193"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzI2ODE_fd8fd906-e1a5-44b7-8ddd-56693f82532e" continuedAt="i5eeac5f3645f40b8918f06488e4acbe8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5eeac5f3645f40b8918f06488e4acbe8" continuedAt="i3c5ec2488e514993b6e78aaa17e77b43"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Lease Obligations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;&#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  As disclosed in Note 3, Lexicon adopted ASU 2016-02, "Leases", on January 1, 2019.  As of December&#160;31, 2019, the office space lease right-of-use (ROU) asset had a balance of $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4NjA_aac13a2b-4d13-4325-9194-52c938f0eb7b">1.7</ix:nonFraction> million, which is included in other assets in the consolidated balance sheet, and current and non-current liabilities relating to the ROU asset were $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4NzY_574407bc-9bbc-432b-9686-49ae1259b537">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4Nzg_4b4d1022-f80f-4535-aa6d-b59c53247620">1.1</ix:nonFraction>&#160;million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.  The discount rate used to record the office space lease was Lexicon's estimated borrowing rate of 9%.  Lexicon elected to apply the short-term lease exception to all leases one year or less.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzI2OTI_dc378fb1-b0d6-4813-ac50-048265701696" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:79.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.156%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzItMS0xLTEtMA_5a8fb076-8f99-4361-b6a2-42541fd213c4">620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzMtMS0xLTEtMA_465f72aa-e69b-4264-a2e2-8ca9595b72fc">632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzQtMS0xLTEtMA_c3bb2526-9009-4101-b589-2391721746ec">645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzUtMS0xLTEtMA_9088bc26-1659-4736-a47f-e8098a33ac3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzYtMS0xLTEtMA_2c3b014a-d7fe-46fe-a632-8ae88f90a0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzctMS0xLTEtMA_32e5c7fd-bc57-4b22-a2d2-472e1b40a435">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzgtMS0xLTEtMA_474d1c7d-bf64-43f0-8efa-5395d6b56a16">1,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount of lease payments representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" sign="-" name="lxrx:InterestOnLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzktMS0xLTEtNDA2MQ_3e2e3540-be77-4079-b173-53eca1c2f091">242</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:PresentValueOfFutureLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzEwLTEtMS0xLTQwNzI_2cc31a41-5389-4236-a67d-95f5dbcda914">1,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" sign="-" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzExLTEtMS0xLTQwNzc_7126dedc-d0d9-4568-8f79-3944168788e8">553</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzEyLTEtMS0xLTQwODA_e0d1db1a-f238-43af-aa6e-63fcf524cf1a">1,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employment Arrangements:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNjU_271664d5-aa24-4596-adff-6eaadc2549e8">six</span> or <ix:nonNumeric contextRef="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231" format="ixt-sec:durmonth" name="lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNzE_2b4193b3-93a6-4a06-ad6c-6190ba3ad675">12</ix:nonNumeric> months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i3c5ec2488e514993b6e78aaa17e77b43"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Proceedings:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div></ix:continuation><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_199"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4ODQ_5bc8f307-aec8-4cb8-a291-68a329036248" continuedAt="id901720954ee4cc0a2d307b52235dcf7" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="id901720954ee4cc0a2d307b52235dcf7" continuedAt="i07e14413571f40aaa7b7511f60059092"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity Incentive Plans</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Equity Incentive Plan:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of <ix:nonFraction unitRef="number" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzc0OQ_93a9ba8a-a0d1-410e-9d89-03d5d637ab8d">100</ix:nonFraction>% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of <ix:nonNumeric contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzk0NA_dfe2a8bb-1afb-4fa4-bbad-e85f99cbd1f2">four years</ix:nonNumeric>; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of <ix:nonNumeric contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwODM_7cea93c0-df8b-4540-ae95-c85326929930">ten years</ix:nonNumeric> from the date of grant.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEyNjc_d1424696-e8a8-474b-a9f2-6c65e092ade8">20,000,000</ix:nonFraction> shares at December&#160;31, 2019.&#160;&#160;In the first quarter of 2020, the Company amended the 2017 Equity Incentive Plan, subject to stockholder approval, to increase the aggregate number of shares that may be issued under the plan to 30,000,000 shares.  As of December&#160;31, 2019, options to purchase <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:OptionsOutstandingEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEzODM_c56a9755-b149-49a7-abcb-810f86b4b2ce">7,456,905</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEzOTc_09b6b755-e4e5-4ae8-8eda-0e043ea15a89">2,801,928</ix:nonFraction> restricted stock units were outstanding, <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:StockOptionsExercisedEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE0NDE_5fee111f-962e-491d-957a-2cf3aad50b8d">1,909,515</ix:nonFraction> shares had been issued upon the exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE1MDM_74ed0c6d-5cf1-4ac1-8bb3-fd1c6b575fdd">1,968,979</ix:nonFraction> shares had been issued pursuant to restricted stock units and <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE1Njg_bf217bbb-4e35-4ccc-a69d-5a03151198a1">113,940</ix:nonFraction> shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:Totalvalueofsharesbynonemployeeinayear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzIxNjM_ca86333e-041e-436a-94b4-36c077f515f6">500,000</ix:nonFraction> during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of <ix:nonNumeric contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI1MTU_01201b2c-a22b-4d44-9cdf-1eedc08feba4">ten years</ix:nonNumeric> from the date of grant.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI2OTE_a413458f-5ff9-4c4c-b82a-b32e9fea899e">600,000</ix:nonFraction> shares.&#160;&#160;As of December&#160;31, 2019, stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4MTM_43790527-cf18-4516-a00f-c7b345e19f7a">237,850</ix:nonFraction> shares were outstanding, <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt-sec:numwordsen" name="lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4NDE_30bd3491-b587-419e-923f-ae8bc3fafa15">none</ix:nonFraction> had been issued upon the exercise of stock options, 27,728 restricted stock units were outstanding and <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4OTk_6d0c1712-cf11-4370-8321-8120fa9d6e1c">103,208</ix:nonFraction> shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan. </span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i07e14413571f40aaa7b7511f60059092"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Option Activity:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4Nzg_d3a6c232-aff0-4643-b597-504ebd1fa0a6" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:34.749%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.814%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMi0xLTEtMA_046a1ce5-1d0b-4d69-9846-fba8830c69a5">6,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItNC0xLTEtMA_9d9820f0-1be0-4f3c-8325-97dcf878b3cc">10.68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItNi0xLTEtMA_c316bdad-5eb5-404f-b6e0-4bf34d4fecdb">4,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItOC0xLTEtMA_0896a1c6-974f-42e3-8466-81443d5e7522">11.17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i676db318ef444ad296e217ae53030a14_I20161231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMTAtMS0xLTA_6d3a4dee-629e-461f-8f4c-9b62659c5805">4,834</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i676db318ef444ad296e217ae53030a14_I20161231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMTItMS0xLTA_532ae5ba-a33f-4a0d-8cc3-b1c38b194972">11.24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMi0xLTEtMA_6450b09d-8808-46f5-8000-3fe0062e3e36">2,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtNC0xLTEtMA_075dadc5-b8a2-462e-b161-84bf38cc597a">5.06</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtNi0xLTEtMA_664cd09a-a1f9-419b-8c68-52f0f4a3c8a4">1,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtOC0xLTEtMA_64c66066-31ca-4b9e-8da5-7c2fd0d999b2">10.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMTAtMS0xLTA_5513a191-c8b6-4af6-94c2-1e421a22bec3">892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMTItMS0xLTA_2d5b39ff-e53a-4668-b02f-751312d93d3f">14.31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMi0xLTEtMA_17b5df2a-b1ed-4987-ab0b-747177382d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtNC0xLTEtMA_0d33613c-7017-4909-9da9-b6eed42cac7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtNi0xLTEtMA_bb3ed39f-10af-4a38-a82c-5663edd33e39">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtOC0xLTEtMA_258cc76f-9669-4356-993c-e835331f0200">7.55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMTAtMS0xLTA_31a3a8b0-6e0e-4a79-8cca-a4991854b854">458</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMTItMS0xLTA_0cbf09a0-f36a-46de-b4db-9d599dc43b15">11.97</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMi0xLTEtMA_b2d0f386-479c-4c03-a336-860c530e29bb">212</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtNC0xLTEtMA_c4285959-9e8a-4203-9b0f-969755c983b1">9.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtNi0xLTEtMA_f7adb8c6-22cb-4cbf-96e2-02456a362b2a">239</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtOC0xLTEtMA_75251291-8eae-4f20-ab9f-c2833fa8a991">14.21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMTAtMS0xLTA_a788b89c-4c44-4785-b573-b091b7a06559">157</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMTItMS0xLTA_f0506f54-e139-4125-8a94-44ed3c04e076">26.42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMi0xLTEtMA_5c14819c-1a1c-4efa-9ca2-f9eda56f2acd">680</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtNC0xLTEtMA_2e024f84-97c2-4736-a9ed-6358fa29e1e8">10.42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtNi0xLTEtMA_03329881-5059-4199-9366-8a101f458d56">389</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtOC0xLTEtMA_f05dbcd5-9fe5-4cd8-87d1-e01d0e2a2191">12.04</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMTAtMS0xLTA_63e8639c-22ee-4086-a712-7d1462847ee5">150</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMTItMS0xLTA_e2040ecd-aa26-4389-b674-c718bdf38352">13.84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i82e588be725e4af58a772fca835425ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMi0xLTEtMA_d232c3bc-dfb2-49f8-9cb7-45784d9861a8">7,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i82e588be725e4af58a772fca835425ca_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctNC0xLTEtMA_73801c5b-2c82-4f6d-a3b0-118509068065">8.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctNi0xLTEtMA_4ee88ae2-b23e-46ef-8a38-7f9f792d6298">6,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctOC0xLTEtMA_ec9e6129-66af-47bb-83ac-6b4fef940bc5">10.68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMTAtMS0xLTA_6115fafa-871d-4ea6-b526-cb6c0b33a539">4,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMTItMS0xLTA_f6c16901-717d-45e8-8adb-72d249a53851">11.17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i82e588be725e4af58a772fca835425ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMi0xLTEtMA_b67c5aac-a42a-4266-bfd8-e06bc4d6bcd6">4,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i82e588be725e4af58a772fca835425ca_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtNC0xLTEtMA_43e38dda-6b17-4ade-be47-d7ab582c685e">10.56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtNi0xLTEtMA_1c61485f-81e9-4fac-9152-6c42272907f2">3,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtOC0xLTEtMA_660a87f4-0625-4eba-b3d6-b098caa44ed8">10.72</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMTAtMS0xLTA_e5a5d82c-c25c-40eb-a6e6-96524705db7b">3,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMTItMS0xLTA_bd07991a-2592-4ce6-bb9a-ad4ee05d1744">10.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2019, 2018 and 2017 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyMzY_fe745eab-9f4e-4e72-a13d-3019fb108b19">3.18</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyNDA_34b71b6f-c7d9-4467-9476-fe2682f1de7a">5.63</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyNDc_d56bb967-4a9a-45b8-b26f-d186f0db4b63">8.59</ix:nonFraction>, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2018 and 2017 were $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMzNjU_4268b397-a4ff-4401-bb19-645427edce6e">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMzNzI_bf6e190a-f949-41f7-a637-2ce2f36d61c5">2.0</ix:nonFraction> million, respectively.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM0ODg_bca17b93-3e5a-45b0-999b-48f9929b4c21">6.8</ix:nonNumeric> and <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM0OTU_8ffaf2cf-297b-4412-affa-e05ed741032b">5.3</ix:nonNumeric> years, respectively, as of December&#160;31, 2019.&#160;&#160;At December&#160;31, 2019, the aggregate intrinsic value of the outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM2Mzg_7e7f9858-a6a4-4124-ac6a-b96405ccc443">0.2</ix:nonFraction> million.  At December&#160;31, 2019, there was <ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM2NDU_dac6d08f-809c-45c6-9855-5249c2feca09">no</ix:nonFraction> intrinsic value of exercisable stock options. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December&#160;31, 2019, Lexicon granted its non-employee directors <ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzQyNTY_218488b1-c387-4079-a460-dd21c8f3998a">27,728</ix:nonFraction> restricted stock units and during the year ended December&#160;31, 2018 and 2017, granted its non-employee directors <ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4MzU_630ca565-d09d-4505-9e37-0137e3808fba">20,512</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="0" format="ixt:numdotdecimal" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4Mzg_7917c7b3-2abf-4dc5-b042-60e1b39417d9">10,248</ix:nonFraction> shares, respectively, of restricted stock awards.  The restricted stock in 2019, 2018 and 2017 had weighted average grant date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM5MzY_056c8550-8c7f-47b4-b9c2-37a284ce0165">5.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4NDE_4e4aed34-4be2-43ab-b0e6-17d0f5d473b9">7.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" name="lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4NDQ_45ea6582-7d93-453f-bf30-77cc797bd43e">15.61</ix:nonFraction> per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date and vesting of restricted stock awards is immediate.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the years ended December&#160;31, 2019, 2018 and 2017, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxODc_3e3d37a1-a8e6-4c56-8f56-a53ef432e351">three</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxOTM_6c3cd917-a52f-4bb3-8628-3b363616b2f4">four</span> annual installments.  The total fair value of shares vested in 2019, 2018 and 2017 was $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyODY_14629ea9-8729-415a-a731-9569acbcbc75">2.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyOTA_4c3e461a-6be0-412c-b755-0cd0f91a1ccb">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyOTk_1feba533-0ad4-4e1a-911e-9851da00c242">4.7</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4ODI_99ae8d1f-e78d-41b5-b22b-0a2dc7030d3c" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:65.203%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzItMi0xLTEtMA_ab4cb4e9-04cb-4759-8693-71b3dda5a52d">1,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzItNC0xLTEtMA_8e274f17-430d-45f9-9473-1d66731cb997">10.17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzMtMi0xLTEtMA_19822f4c-eb60-43f7-aeac-5c42004a1fcb">2,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzMtNC0xLTEtMA_25d2dd14-edf8-4bce-a947-3e2f42ea5035">5.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzQtMi0xLTEtMA_d67a2fba-4fb4-4408-8364-5540c1c83dfd">517</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzQtNC0xLTEtMA_7b89a566-f3a8-420b-912b-52f55938362f">9.60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzUtMi0xLTEtMA_89562bb4-2a28-4aac-8e16-8f11030585fe">385</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzUtNC0xLTEtMA_dc626dd1-b9ef-4e8e-845c-60ab1445a95e">6.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2cf18c961781453a902022b81e8fb9be_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzYtMi0xLTEtMA_2a748afb-25a7-4591-9199-94fc37a7b49d">2,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cf18c961781453a902022b81e8fb9be_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzYtNC0xLTEtMA_f666793e-2c08-43f6-b21d-3057d790ebef">6.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ0MTk_1ecf2f6e-0d19-438e-b5f1-a0a91af6d2d6">10,524,411</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and <ix:nonFraction unitRef="shares" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ1Njk_c539f71b-84ea-4868-895e-5a97dff3434a">5,979,947</ix:nonFraction> additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div></ix:continuation><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_202"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzY1MA_0e789609-c10e-4977-b6d3-b92a47de4145" continuedAt="icc87d4cfaf27434aa89b918f510b8ff4" escape="true">Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="icc87d4cfaf27434aa89b918f510b8ff4"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ2Ng_b4dfffd7-c687-4d11-9196-9cf6e6bae477">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ3MA_84069b5d-6eb3-4793-a9b9-32b750879d96">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ3Nw_66906275-c9ad-44eb-9d5e-e6fa70346c59">1.0</ix:nonFraction> million in the years ended December&#160;31, 2019, 2018 and 2017, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzYyOA_b159658f-ba94-40d2-bf42-41b82bcb07e0">four</span> years of service.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_205"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzIwMTUy_7df0a4cf-c75a-4ee5-b6a2-f78c0d9badfb" continuedAt="i243f1474b408463db8e140351abf194e" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i243f1474b408463db8e140351abf194e" continuedAt="i8273d7b81d9d4bb4939bb17ebf98510f"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sanofi.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development and commercialization of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#8220;Termination Agreement&#8221;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SettlementPaymentFromTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NDg3OTU_383f8c22-5a0c-4e09-8f7c-35cc4f0880e6">208</ix:nonFraction>&#160;million in September 2019, $<ix:nonFraction unitRef="usd" contextRef="iea1681c8bfaf4cb7885ec38236a3a489_D20200301-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SettlementPaymentFromTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTUxNDg_4f1add72-31d3-4b85-8345-1fadb4b86d74">26</ix:nonFraction>&#160;million in March 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement) and is obligated to pay an additional $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SettlementPaymentObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NDg4MDc_3557a631-85cc-4094-8300-3ff91a167dd0">26</ix:nonFraction>&#160;million within twelve months of the Settlement Date, and neither party will owe additional payments pursuant to the Sanofi Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  The following is a summary description of the Sanofi Agreement without giving effect to the Termination Agreement. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Sanofi Agreement, Lexicon had granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party could (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such countries.  Among the specified exceptions was a right Lexicon retained to pursue the development of its development candidate LX2761, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE2ODg_a38ea5c1-9fdb-407a-a11f-6848e794e1e2">300</ix:nonFraction> million.  In addition, Lexicon was eligible to receive from Sanofi (a) up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3NzU_d4f2db62-6d85-4176-b9f3-26e05cf0f395">110</ix:nonFraction> million upon the achievement of <ix:nonFraction unitRef="milestone" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="INF" format="ixt-sec:numwordsen" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MDI_29de12d8-457f-400a-9621-ab0cbb30cc7e">four</ix:nonFraction> development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE5NTk_797c18ea-0b06-4d02-83e7-43bdb7bf2364">220</ix:nonFraction> million upon the achievement of <ix:nonFraction unitRef="milestone" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="INF" format="ixt-sec:numwordsen" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE5ODY_f885f9c2-c180-4333-9bae-5fe1803e7596">four</ix:nonFraction> regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiOutcomesStudyMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzIzNjA_69552584-bcd6-4482-8b3d-858a3c602337">100</ix:nonFraction> million upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiSalesMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzI2Mjc_71916b43-7cdc-429a-a1a4-ced49614b98b">990</ix:nonFraction> million upon the achievement of <ix:nonFraction unitRef="milestone" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="INF" format="ixt-sec:numwordsen" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzI2NTQ_8be1a32f-5be9-4fe1-a44b-22823b8fc480">six</ix:nonFraction> commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believed that each of the development and regulatory milestones under the Sanofi Agreement was substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments were deemed constrained and were not recognized as revenue.  Commercial milestones would have been accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon was also entitled to tiered, escalating royalties ranging from low double digit percentages to <ix:nonFraction unitRef="number" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="INF" format="ixt-sec:numwordsen" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzMzNjY_dfd29ab1-a699-4434-b892-2fc92f99c389">forty</ix:nonFraction> percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i8273d7b81d9d4bb4939bb17ebf98510f" continuedAt="ie0e8ccb600794a5583d7d87216bfde33"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon continued to be responsible for all clinical development activities relating to type 1 diabetes and exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon would have funded <ix:nonFraction unitRef="number" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="INF" format="ixt-sec:numwordsen" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQwMTI_85b8328f-bb95-4499-933d-be77b02cddb8">forty</ix:nonFraction> percent of the commercialization costs relating to such co-promotion activities. Sanofi was responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and would have been solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon shared in the funding of a portion of the planned type 2 diabetes development costs over the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ0ODM_07c80404-0919-4d69-96df-eb1aa3ad8777">three</span> years of the collaboration, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ1MzY_692d5424-e14b-4a5c-8cd3-130974d967c5">100</ix:nonFraction> million, which was satisfied in 2018. Sanofi would have booked sales worldwide in all indications.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The parties were responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The parties&#8217; activities under the Sanofi Agreement were governed by a joint steering committee and certain other governance committees which reflected equal or other appropriate representation from both parties. If the applicable governance committee was not able to make a decision by consensus and the parties were not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi would have final decision-making authority, subject to limitations specified in the Sanofi Agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Sanofi Agreement would have expired upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country was the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and <ix:nonNumeric contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" format="ixt-sec:duryear" name="lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzU3Mzc_176e4513-0f49-4c0c-8f4d-47ffd56dd119">10</ix:nonNumeric> years following the first commercial sale in the applicable country. Either party could terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi could terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzY4Nzk_a38ea5c1-9fdb-407a-a11f-6848e794e1e2">300</ix:nonFraction> million upfront payment: </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The funding Lexicon will provide for development relating to type 2 diabetes.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it was an exclusive license that gave Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it was possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Sanofi Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company was recognizing as revenue the amount allocated to the development services for type 1 diabetes over the period of time Lexicon performed services, which was expected to be through 2027, and recognized as revenue the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon provided the funding, which was completed in 2018.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzgyNTM_a38ea5c1-9fdb-407a-a11f-6848e794e1e2">300</ix:nonFraction> million upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ie0e8ccb600794a5583d7d87216bfde33" continuedAt="ib64cc4cc486b4159af7054ea91de34f2"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk1MzQ_692d5424-e14b-4a5c-8cd3-130974d967c5">100</ix:nonFraction> million in funding.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the allocation of the Sanofi Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2MDQ_cecff7a5-883e-437f-a7b2-045d4ae6ba74">126.8</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SanofiUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2MTQ_a38ea5c1-9fdb-407a-a11f-6848e794e1e2">300</ix:nonFraction> million upfront payment for the license in 2015.  The Company was recognizing the $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2OTA_d68fe752-8dcb-4d78-8f19-ae6831578ba8">113.8</ix:nonFraction> million allocated to the development services performance obligation and the $<ix:nonFraction unitRef="usd" contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueAllocatedtoFundingDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk3NjI_1712e2e1-da00-4127-8b45-7618fbb31e5c">59.4</ix:nonFraction> million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SanofiDeferredRevenueFromTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTM2OTY_5dfc89a6-15bc-46a4-8647-57956a79634a">23.5</ix:nonFraction>&#160;million allocated to Lexicon's performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SanofiTerminationAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTM3MDk_cf455856-6b9e-45ff-8b0e-ccd24cc3a200">260</ix:nonFraction>&#160;million, representing the full cash consideration from the Termination Agreement.  The Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjIz_c165e424-c422-4fdd-b48a-ca6db58c76a9">286</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjI3_671e604e-696e-4e22-a7db-213f6cd6fcfd">33.2</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjM1_2005b64d-dc4c-4114-866a-f00263404042">60.1</ix:nonFraction> million for the years ended December&#160;31, 2019,  2018 and 2017, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ipsen.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalPaymentsToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMDg5_52e4be76-f85f-4463-9aad-9c9a7835c3fc">47.2</ix:nonFraction> million through December&#160;31, 2019, consisting of $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMTE4_78912b41-c168-427a-9ad4-5b1a9d70516f">24.5</ix:nonFraction> million in upfront payments, a $<ix:nonFraction unitRef="usd" contextRef="iefd14d4f858f4035ae6b02237f016ab7_D20160801-20160831" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMTQ0_ac9cd4a1-3514-43f0-8295-39163ef86ea9">6.4</ix:nonFraction> million milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $<ix:nonFraction unitRef="usd" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMzUz_734d873f-b086-4b63-85e5-04932c3d601c">5.1</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $<ix:nonFraction unitRef="usd" contextRef="ib9b309ec36344fefbc30f63b0cbe55bb_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNTIz_ddfa5171-92bb-458e-b575-581f19ce5d59">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $<ix:nonFraction unitRef="usd" contextRef="iefb28917800949f293202b0888b3e175_D20171101-20171130" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNTg1_c56c5964-0e35-47f5-a863-f048379f66a3">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $<ix:nonFraction unitRef="usd" contextRef="i3b945f8014e44862a193e174495bd0fb_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNjYx_a688a365-0dd3-44c7-b074-dda71f011330">1.3</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen's first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumRegulatoryAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyODIz_66e8e72f-4182-4938-9405-0fcbec7ee9a6">9.6</ix:nonFraction>&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-6" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyOTM0_ed76e7be-e10f-4127-9a09-746ddc89704c">72</ix:nonFraction>&#160;million upon the achievement of specified sales milestones.  Milestone payments are deemed constrained. Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEzNzE5_78912b41-c168-427a-9ad4-5b1a9d70516f">24.5</ix:nonFraction> million upfront payment: </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed </span></div><div style="text-indent:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Territory;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for XERMELO;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to participate in committees which govern the development of XERMELO</span></div><div style="padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">until commercialization; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ib64cc4cc486b4159af7054ea91de34f2" continuedAt="i7c6d25d6af9f4aaaa96bf6e38d4050fa"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, which was completed in 2018.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE1ODAy_78912b41-c168-427a-9ad4-5b1a9d70516f">24.5</ix:nonFraction> million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7c6d25d6af9f4aaaa96bf6e38d4050fa" continuedAt="i4937ba3396944e95ba76a4b3862c861c">As a result of the allocation, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MTc2_a3a6961d-6c4d-4bfc-a92b-4d10bb88e368">21.2</ix:nonFraction> million of the </ix:continuation></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4937ba3396944e95ba76a4b3862c861c">$<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MTg2_78912b41-c168-427a-9ad4-5b1a9d70516f">24.5</ix:nonFraction> million upfront payment for the license in 2014, and an additional $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MjQ4_79872391-915e-40cb-ae56-bb8876a48699">1.4</ix:nonFraction> million in 2015 upon entering into the amendment.  The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MzI1_09dc9e6c-e459-428c-a719-91476e3c212e">1.7</ix:nonFraction> million allocated to the development services deliverable over the estimated period of performance as development occurs, and recognized the $<ix:nonFraction unitRef="usd" contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3NDY1_ea8b251c-8c0c-4c9c-b592-d37c26c107b0">0.1</ix:nonFraction> million allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  During 2019, the milestone earned when Ipsen made its first commercial sale in Canada was determined to be a distinct performance obligation relating to the development activities and accordingly, was recognized as revenue without further allocation to the remaining performance obligations.  Revenue recognized under the Agreement was $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjQw_f6f035ae-cc13-44bd-800e-b442fc7b6a7f">4.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjQ0_127b73ab-297d-44a1-aa50-97b0a980452f">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjUx_5cfafe5c-2a3a-4be4-9d38-67077abce144">16.2</ix:nonFraction> million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $0.3&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRoyaltyIncome_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MzUw_b2dce147-a231-4591-b205-10d1180451be">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRoyaltyIncome_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MzU3_2856e575-60ea-4ec0-b173-2c7e4eaf9aac">0.1</ix:nonFraction> million, respectively, of royalties from Ipsen.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $1.3 million,  $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:Ipsenproductsales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4NDQ3_56da7e28-8fae-4607-906b-e8e06f8032cf">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:Ipsenproductsales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4NDU0_2e375cb5-d476-456e-a8ad-c6ad784658b4">0.8</ix:nonFraction> million, respectively, from sales of bulk tablets of XERMELO to Ipsen.</ix:continuation> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_2047"></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">14. <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NzYx_e5c2f4d0-98cd-4e03-8fe7-2af6ad28c0fe" continuedAt="i9fe144e4380a4feea3e126ca1e56db43" escape="true">Earnings (Loss) Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9fe144e4380a4feea3e126ca1e56db43"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NzYy_23b1e414-5dda-46bb-8eac-7456678dcc05" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of Lexicon's earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"></td><td style="width:40.042%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.420%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.867%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.052%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.468%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except per share amounts)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTEtMS0xLTQxMzY_4ff83943-32cf-4955-a848-6b8b632421ab">130,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTMtMS0xLTQxMzY_db58e5a3-4e5a-4441-827b-bb314e0c8658">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTUtMS0xLTQxMzY_8fda6339-398e-4d45-900c-cb05707dd7d7">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTEtMS0xLTQxMzY_547112a6-538a-4975-8f38-94d3be061f03">5,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTMtMS0xLTQxMzY_52e34885-0ba6-4ab7-8ada-77594d65c65a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTUtMS0xLTQxMzY_146cca89-054b-45de-a3b9-3dfe740b70af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTEtMS0xLTQxMzY_eb4dbbac-e10a-43c3-8bf1-3c2d98878388">135,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTMtMS0xLTQxMzY_4024d2ab-ccbf-467f-b7b0-15e28cd0a5dd">120,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTUtMS0xLTQxMzY_fa5c1588-15a0-4146-a1a9-b2dee254062f">122,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTEtMS0xLTQxMzk_88937ab3-2dc8-43ab-8d0d-33bead17e6a5">106,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTMtMS0xLTQxMzk_8f609501-bb4a-4193-b148-dfa71ba023b2">105,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTUtMS0xLTQxMzk_c71624ef-516f-4e2e-a359-253d40a721a4">105,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add effect of potential dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Share based awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC0xLTEtMS00MTM5_d8eca35f-09cb-4d57-9f5a-431ddb254050">164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC0zLTEtMS00MTM5_f7758787-e120-4ef2-9f62-cefae778554c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC01LTEtMS00MTM5_5bf5309c-0863-4ff5-8705-699e3bcb789d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS0xLTEtMS00MTM5_3bb9840a-b77a-48eb-aa1f-da8fab9844bd">10,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS0zLTEtMS00MTM5_37904723-682b-4745-af2d-c29056115f4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS01LTEtMS00MTM5_e5a06cf8-abdb-496c-9ce1-d4928f9fd3e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi0xLTEtMS00MTM5_2932b4fe-95d0-429a-b85c-a5531195feec">116,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi0zLTEtMS00MTM5_940c989c-8570-43bb-92cd-6ebbb23a4453">105,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi01LTEtMS00MTM5_da6cebc2-fbe0-4535-b5fd-beb1ee81d152">105,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC0xLTEtMS00MTQy_cccccc7f-aece-476a-895b-3901aa86e8fe">1.23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC0zLTEtMS00MTQy_9c60dd6a-db20-401d-a0e4-a5e674e40097">1.14</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC01LTEtMS00MTQy_b2a1723d-43ef-45b0-b28e-0a582301f22e">1.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS0xLTEtMS00MTQy_6c5d2848-1f07-41fa-b488-fa5b28097165">1.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS0zLTEtMS00MTQy_4d3d733d-aa4e-4a23-aec2-60ef71fe455c">1.14</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS01LTEtMS00MTQy_42b5e653-a08f-447c-bad9-a64d5e7e9ccf">1.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was <ix:nonFraction unitRef="shares" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NjYx_76b6f6a3-4817-4a07-ba4e-9be28f5826ce">8,206,390</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4Njc0_f0d7a508-f8ab-4962-a28f-ed651d0515c2">7,438,134</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4Njk2_e6490612-15fe-4252-8f92-586abdc2b6a4">5,907,643</ix:nonFraction>, respectively, for the years ended December&#160;31, 2019, 2018 and 2017.  For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div id="i54910e5d8bdb46bf84d5ecc54d3bafab_208"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">15.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzEwMDE_fc70560f-237f-4be0-87a3-6d73d8fe1209" continuedAt="ia01e5a1274bd4ac7b1a6a9088d54f1d4" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ia01e5a1274bd4ac7b1a6a9088d54f1d4" continuedAt="i654be05b753d44de8bfdd73c3571f65f"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzk5Nw_5860121a-ccf2-4542-b2a6-1c07c263e1d6" continuedAt="i74329fa3715d434d915628b5d7034ecb" escape="true">The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018:</ix:nonNumeric></span></div><ix:continuation id="i74329fa3715d434d915628b5d7034ecb"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtMS0xLTEtMA_b084c9f4-ff02-4693-bbb4-d7eaf131940d">9,216</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtMy0xLTEtMA_58f8b7d6-64c1-4212-af6d-be79a7dfbbba">9,682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtNS0xLTEtMA_a902e59c-dbf6-43ae-a815-2f8ebc4a63f3">294,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtNy0xLTEtMA_be05d76c-187c-43e7-982f-5176f7e015a1">8,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtMS0xLTEtMA_fbf6d39e-d0bc-45d1-a55f-705991bd2f0f">17,469</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtMy0xLTEtMA_361ce8d3-2a0b-4c9e-b2b0-8436fa6020c1">18,545</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtNS0xLTEtMA_937acdf8-f0e0-498f-b287-759fe53b91ce">224,676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtNy0xLTEtMA_f9a43d4f-7fb6-4187-89c9-62407504241e">47,217</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtMS0xLTEtMA_5522a1cb-2a4c-43a1-ae62-d6b9ea17f657">21,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtMy0xLTEtMA_cc1512f6-cb0a-47b7-aa97-f219bae02da4">23,018</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtNS0xLTEtMA_6ca956e6-e9a8-4b5e-8842-d8b7ff963787">226,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtNy0xLTEtMA_30048e70-3f3e-4172-abcf-2a9718e09d18">51,138</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctMS0xLTEtMA_9b9b9ea3-24b4-43e5-98e5-74b689ad73b7">0.21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctMy0xLTEtMA_4739c7d2-d5d1-46da-bf49-cc2b76087dcf">0.22</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctNS0xLTEtMA_044627e8-dd52-41e0-b7f4-0ff5e7418d2a">2.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctNy0xLTEtMA_6220b8a0-b4c7-49d3-af03-9a402046efa9">0.48</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMS0xLTEtMTI0Ng_4159a958-8d28-4c5b-b4f0-3d43ad5bfe0d">0.21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMy0xLTEtMTI0Ng_3a5b717c-8987-4b75-983b-caaca1664cfc">0.22</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNS0xLTEtMTI0Ng_57206c1c-29ec-4d67-bd64-055df558f3e2">1.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNy0xLTEtNDE0OQ_0d08b9e7-1a85-4c48-8fb2-b060653d1ee1">0.48</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Shares used in computing net income (loss) per common share, basic </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMS0xLTEtMA_9fe45697-36b0-4608-920d-3bb4f9e05032">106,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMy0xLTEtMA_4f3d8c76-d60d-49ce-b4c0-c547e987d790">106,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNS0xLTEtMA_19b51dab-950d-4308-923a-2bd1ecb68435">106,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNy0xLTEtMA_fe58f428-5709-4186-b68f-b33dbc3fa8fe">106,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTEtMS0xLTEyNDM_2b002f4a-015b-4846-9fc8-06d02cbe9398">106,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTMtMS0xLTEyNDM_41ced991-5610-4336-8fa3-b13050589612">106,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTUtMS0xLTEyNDA_d0939aec-fa64-4032-9786-10df2cb5603c">116,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTctMS0xLTQxNTI_788ad2ec-6879-4191-ae1b-e5512ea695d3">106,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTEtMS0xLTA_b930916d-ba61-4969-8dfa-5a8bd4892847">25,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTMtMS0xLTA_785d1dfe-e68e-4048-9dad-e24b646b7f99">13,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTUtMS0xLTA_6a340f4e-c52e-4b13-9225-2afc78c1e22b">6,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTctMS0xLTA_06347f24-4aba-431a-8d8a-6605a62b41e7">17,071</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTEtMS0xLTA_289a64a4-a4c6-44da-a114-9404f45c8283">37,713</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTMtMS0xLTA_1e5be2cc-2959-44e2-a1b7-71dce3a2d961">30,272</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTUtMS0xLTA_c228bc65-8d2d-4e58-bba9-3c85e6c98c12">22,927</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTctMS0xLTA_3d2146f9-9cee-4d50-8eb8-63ec8c476bc6">12,367</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTEtMS0xLTA_d927e587-4528-41af-95a7-91fb5a0e6878">41,821</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTMtMS0xLTA_78e95ea8-b596-431c-af52-a39eb477f51f">34,549</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTUtMS0xLTA_0c07e283-5c6b-4822-8d9b-d4df8e418e88">27,396</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTctMS0xLTA_4583ebef-a49d-44c3-a0cf-5566f752d093">16,782</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTEtMS0xLTA_8dbb6f0b-390e-4780-9374-d754d2e85bfd">0.40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTMtMS0xLTA_7836a4be-9ee2-4ed6-8fcf-9a7be9f0112a">0.33</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTUtMS0xLTA_171b9019-95b0-4453-9830-e5d823b20600">0.26</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTctMS0xLTA_3f0fce2c-dfee-4457-85e9-184065f3c361">0.16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net loss per common share, basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTEtMS0xLTA_090fe152-dd7f-4146-aa15-8b049278d0ce">105,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTMtMS0xLTA_6559abe5-678c-4189-b3d6-c4e901eb1a9c">105,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTUtMS0xLTA_0ff7ecb5-eba7-4dbd-ac6a-54416d68fc95">105,881</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTctMS0xLTA_61207ec3-0efe-4a16-a1cb-e32e1440e73b">105,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Revenues for the three months ended September 30, 2019 include $<ix:nonFraction unitRef="usd" contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SanofiTerminationAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzE2NDkyNjc0NDMyMjc_cf455856-6b9e-45ff-8b0e-ccd24cc3a200">260</ix:nonFraction>&#160;million from the Sanofi Termination Agreement, as defined in Note 13.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i654be05b753d44de8bfdd73c3571f65f">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>exh1082017equityincent.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie158650cce594273a4a64a478bb22d46_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.8</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LEXICON PHARMACEUTICALS, INC.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2017 EQUITY INCENTIVE PLAN</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Plan initially was established as the Lexicon Genetics Incorporated 1995 Stock Option Plan (the &#8220;1995 Stock Option Plan&#8221;), which was adopted by the Board and approved by the Company&#8217;s stockholders on September 13, 1995.  The 1995 Stock Option Plan was subsequently amended and restated in its entirety and renamed the Lexicon Genetics Incorporated 2000 Equity Incentive Plan (the &#8220;2000 Equity Incentive Plan&#8221;), which was adopted by the Board on February 3, 2000 and approved by the Company&#8217;s stockholders on March 15, 2000 and May 19, 2004. The 2000 Equity Incentive Plan was subsequently amended and restated in its entirety and renamed the Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), which was adopted by the Board on February 27, 2009 and approved by the Company&#8217;s stockholders on April 23, 2009.  The Equity Incentive Plan, as amended, was subsequently amended and restated in its entirety and renamed the 2017 Equity Incentive Plan (the &#8220;2017 Equity Incentive Plan&#8221;), which was adopted by the Board on February 9, 2017 and approved by the Company's stockholders on April 27, 2017.  A subsequent amendment to the 2017 Equity Incentive Plan was adopted by the Board on February 7, 2019 and approved by the Company's stockholders on April 25, 2019.  The 2017 Equity Incentive Plan was subsequently amended by the Board, effective February 6, 2020, to remove the provisions formerly required by Section 162(m) of the Code.  The terms of this 2017 Equity Incentive Plan, as amended, shall supersede the terms of the 1995 Stock Option Plan, the 2000 Equity Incentive Plan and the Equity Incentive Plan in their entirety&#59; provided, however, that nothing herein shall operate or be construed as modifying the terms of an Incentive Stock Option granted under the 1995 Stock Option Plan, the 2000 Equity Incentive Plan or the Equity Incentive Plan in a manner that would treat the option as being a new grant for purpose of Section 424(h) of the Code.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURPOSES.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;ELIGIBLE STOCK AWARD RECIPIENTS. The persons eligible to receive Stock Awards are the Employees, Directors and Consultants of the Company and its Affiliates.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;AVAILABLE STOCK AWARDS. The purpose of the Plan is to provide a means by which eligible recipients of Stock Awards may be given an opportunity to benefit from increases in value of the Common Stock through the granting of the following Stock Awards&#58; (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Bonus Awards, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Stock Appreciation Rights and (vii) Performance Stock Awards.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;GENERAL PURPOSE. The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Stock Awards, to secure and retain the services of new members of this group and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Affiliates.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.&#160;DEFINITIONS.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) &#160;&#8220;AFFILIATE&#8221; means any parent corporation or subsidiary corporation of the Company, whether now or hereafter existing, as those terms are defined in Sections&#160;424(e) and (f), respectively, of the Code.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;&#8220;BOARD&#8221; means the Board of Directors of the Company.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;&#8220;CODE&#8221; means the Internal Revenue Code of 1986, as amended.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;&#8220;COMMITTEE&#8221; means a committee of one or more members of the Board appointed by the Board in accordance with subsection 3(c).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)&#160;&#8220;COMMON STOCK&#8221; means the common stock, par value $.001 per share, of the Company.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)&#160;&#8220;COMPANY&#8221; means Lexicon Pharmaceuticals, Inc. a Delaware corporation.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)&#160;&#8220;CONSULTANT&#8221; means any person other than a Director or Employee who is engaged by the Company or an Affiliate to render consulting or advisory services and who is compensated for such services.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(h)&#160;&#8220;CONTINUOUS SERVICE&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. The Participant&#8217;s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or a Director will not constitute an interruption of Continuous Service. The Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave. </font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;&#8220;DIRECTOR&#8221; means a member of the Board of Directors of the Company.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(j)&#160;&#8220;DISABILITY&#8221; means the permanent and total disability of a person within the meaning of Section 22(e)(3) of the Code.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(k)&#160;&#8220;EMPLOYEE&#8221; means any person (which may include a Director) who is employed by the Company or an Affiliate.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(l)&#160;&#8220;EXCHANGE ACT&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(m)&#160;&#8220;FAIR MARKET VALUE&#8221; means, as of any date, the value of the Common Stock determined as follows&#58;</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;If the Common Stock is listed on any established stock exchange or traded on the Nasdaq Stock Market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the day of determination, as reported in The Wall Street Journal or such other source as the Board deems reliable.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160; In the absence of such markets for the Common Stock, the Fair Market Value shall be determined in good faith by the Board in such manner as it deems appropriate and as is consistent with the requirements of Section 409A of the Code.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(n)&#160;&#8220;INCENTIVE STOCK OPTION&#8221; means an option to purchase Common Stock that is intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(o)&#160;&#8220;NON-EMPLOYEE DIRECTOR&#8221; means a Director who either (i) is not a current Employee or Officer of the Company or its parent or a subsidiary, does not receive compensation (directly or indirectly) from the Company or its parent for a subsidiary for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;Regulation S-K&#8221;)), does not possess an interest in any other transaction as to which disclosure would be required under Item 404(a) of Regulation S-K and is not engaged in a business relationship as to which disclosure would be required under Item 404(b) of Regulation S-K&#59; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(p)&#160;&#8220;NONSTATUTORY STOCK OPTION&#8221; means an option to purchase Common Stock other than an Incentive Stock Option.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(q&#160;)&#8220;OFFICER&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(r)&#160;&#8220;OPTION&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option granted pursuant to Section 6 of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(s)&#160;&#8220;OPTION AGREEMENT&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(t)&#160;&#8220;OPTIONHOLDER&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(u)&#160;&#8220;PARTICIPANT&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;&#8220;PERFORMANCE STOCK AWARD&#8221; means a right to receive a Stock Award based upon performance criteria specified by the Committee.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(w)&#160;&#8220;PLAN&#8221; means this Lexicon Pharmaceuticals, Inc. 2017 Equity Incentive Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(x)&#160;&#8220;RESTRICTED STOCK AWARD&#8221; means a right to purchase restricted Common Stock granted pursuant to Section 7(b) of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(y)&#160;&#8220;RESTRICTED STOCK UNIT AWARD&#8221; means a right to receive shares of Common Stock (or a cash payment equal to the Fair Market Value thereof) granted pursuant to Section 7(c) of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(z)&#160;&#8220;RULE 16B-3&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b&#30;3, as in effect from time to time.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(aa)&#160;&#8220;SECURITIES ACT&#8221; means the Securities Act of 1933, as amended.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(bb)&#160;&#8220;STOCK APPRECIATION RIGHT&#8221; means a right to receive an amount equal to any appreciation or increase in the Fair Market Value of Common Stock over a specified period of time granted pursuant to Section 7(d) of the Plan, payable in shares of Common Stock or cash.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(cc)&#160;&#8220;STOCK AWARD&#8221; means any right granted under the Plan, including an Option, a Stock Bonus Award, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or a Performance Stock Award.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(dd)&#160;&#8220;STOCK AWARD AGREEMENT&#8221; means a written agreement between the Company and a holder of a Stock Award evidencing the terms and conditions of an individual Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ee)&#160;&#8220;STOCK BONUS AWARD&#8221; means an award of Common Stock granted pursuant to Section&#160;7(a) of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ff)&#160;&#8220;TEN PERCENT STOCKHOLDER&#8221; means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any of its Affiliates.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;ADMINISTRATION.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;ADMINISTRATION BY BOARD. The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided in subsection 3(c).</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;POWERS OF BOARD. The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;To determine from time to time which of the persons eligible under the Plan shall be granted Stock Awards&#59; when and how each Stock Award shall be granted&#59; what type or combination of types of Stock Award shall be granted&#59; the provisions of each Stock Award granted (which need not be identical), including the time or times when a person shall be permitted to receive Common Stock pursuant to a Stock Award&#59; and the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement or other agreement evidencing a Stock Award, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;To amend the Plan or a Stock Award as provided in Section 13.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)&#160;To terminate or suspend the Plan as provided in Section 14.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company that are not in conflict with the provisions of the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;DELEGATION TO COMMITTEE.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;GENERAL. The Board may delegate administration of the Plan to a Committee or Committees of one (1) or more members of the Board, and the term &#8220;Committee&#8221; shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;COMMITTEE COMPOSITION WHEN COMMON STOCK IS PUBLICLY TRADED.  At such time as the Common Stock is publicly traded, in the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">discretion of the Board, a Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. Within the scope of such authority, the Board or the Committee may) delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Stock Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;EFFECT OF BOARD&#8217;S DECISION. All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SHARES SUBJECT TO THE PLAN.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;SHARE RESERVE. Subject to the provisions of Section 12 relating to adjustments upon changes in Common Stock, the Common Stock that may be issued pursuant to Stock Awards shall not exceed in the aggregate twenty million (20,000,000) shares and the Common Stock that may be issued pursuant to Incentive Stock Options shall not exceed in the aggregate twenty million (20,000,000) shares. </font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;REVERSION OF SHARES TO THE SHARE RESERVE. If any Stock Award shall for any reason expire or otherwise terminate, in whole or in part, without having been exercised in full or shares of Common Stock issued to a Participant pursuant to a Stock Award are forfeited to or repurchased by the Company, including any repurchase or forfeiture caused by the failure to meet a contingency or condition required for the vesting of such shares, the shares of Common Stock not issued under such Stock Award or forfeited to or repurchased by the Company shall revert to and again become available for issuance under the Plan&#59; provided, however, that shares subject to a Stock Award that are not delivered to a Participant because (i) such Participant&#8217;s right to purchase such shares subject to an Option are surrendered in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise,&#8221; or (ii) such shares are withheld in satisfaction of the withholding of taxes incurred in connection with the exercise of an Option or Stock Appreciation Right, or the issuance of shares under a Stock Bonus Award, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Award, the shares so surrendered or withheld shall not remain available for subsequent issuance under the Plan.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;SOURCE OF SHARES. The shares of Common Stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or otherwise.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ELIGIBILITY.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;ELIGIBILITY FOR SPECIFIC STOCK AWARDS. Incentive Stock Options may be granted only to Employees.  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;TEN PERCENT STOCKHOLDERS.  A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock at the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OPTION PROVISIONS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. The provisions of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions&#58;</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;TERM. Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, no Option shall be exercisable after the expiration of ten (10) years from the date it was granted. </font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;EXERCISE PRICE. Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, the exercise price of each Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;CONSIDERATION. The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations, either (i) in cash at the time the Option is exercised or (ii) at the discretion of the Board (1) by delivery to the Company of other Common Stock, (2) according to a deferred payment or other similar arrangement with the Optionholder, (3) by surrender of Optionholder&#8217;s right to purchase shares subject to an Option (valued, for such purposes, as the Fair Market Value of such surrendered shares on the date of exercise less the exercise price for such surrendered shares) in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise&#8221; of such Option, or (4)&#160;in any other form of legal consideration that may be acceptable to the Board.  At any time that the Company is incorporated in Delaware, payment of the Common Stock&#8217;s &#8220;par value,&#8221; as defined in the Delaware General Corporation Law, shall not be made by deferred payment.  In the case of any deferred payment arrangement, interest shall be compounded at least annually and shall be charged at the minimum rate of interest necessary to avoid the treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;TRANSFERABILITY. An Incentive Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. A Nonstatutory Stock Option shall be transferable to the extent provided in the Option Agreement&#59; provided that, if the Nonstatutory Stock Option does not provide for transferability, then the Nonstatutory Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)&#160;VESTING GENERALLY. The total number of shares of Common Stock subject to an Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. </font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)&#160;TERMINATION OF CONTINUOUS SERVICE. In the event an Optionholder&#8217;s Continuous Service terminates (other than upon the Optionholder&#8217;s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (i) the date three (3) months following the termination of the Optionholder&#8217;s Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement.  If, after termination, the Optionholder </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">does not exercise his or her Option within the time specified in the Option Agreement, the Option shall terminate.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(g)&#160;EXTENSION OF TERMINATION DATE. An Optionholder&#8217;s Option Agreement may also provide that if the exercise of the Option following the termination of the Optionholder&#8217;s Continuous Service (other than upon the Optionholder&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of the term of the Option set forth in subsection 6(a) or (ii) the expiration of a period of three (3) months after the termination of the Optionholder&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(h)&#160;DISABILITY OF OPTIONHOLDER. In the event that an Optionholder&#8217;s Continuous Service terminates as a result of the Optionholder&#8217;s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination (or such longer or shorter period specified in the Option Agreement,) or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein, the Option shall terminate.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;DEATH OF OPTIONHOLDER. In the event (i) an Optionholder&#8217;s Continuous Service terminates as a result of the Optionholder&#8217;s death or (ii) the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder&#8217;s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder&#8217;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholder&#8217;s death pursuant to subsection 6(d), but only within the period ending on the earlier of (1) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the Option Agreement) or (2) the expiration of the term of such Option as set forth in the Option Agreement. If, after death, the Option is not exercised within the time specified herein, the Option shall terminate.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">STOCK BONUS AWARD, RESTRICTED STOCK AWARD, RESTRICTED STOCK UNIT AWARD AND STOCK APPRECIATION RIGHT PROVISIONS.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;STOCK BONUS AWARDS. Each Stock Bonus Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Stock Bonus Award agreements may change from time to time, and the terms and conditions of separate Stock Bonus Award agreements need not be identical, but each Stock Bonus Award agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;CONSIDERATION. A Stock Bonus Award may be granted in consideration for past services actually rendered to the Company or an Affiliate for its benefit.  Unless otherwise provided in the Stock Bonus Award agreement, no further consideration will be payable by Participant upon grant of the Stock Bonus Award.  Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its discretion and permissible under applicable law.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;VESTING. Shares of Common Stock awarded under the Stock Bonus Award agreement may, but need not, be subject to a share repurchase option or forfeiture </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">restrictions in favor of the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event a Participant&#8217;s Continuous Service terminates, the Company may reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the Stock Bonus Award agreement.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)&#160;TRANSFERABILITY. Rights to acquire shares of Common Stock under the Stock Bonus Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Bonus Award agreement, as the Board shall determine in its discretion, so long as Common Stock awarded under the Stock Bonus Award agreement remains subject to the terms of the Stock Bonus Award agreement.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;RESTRICTED STOCK AWARDS. Each Restricted Stock Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of the Restricted Stock Award agreement may change from time to time, and the terms and conditions of separate Restricted Stock Award agreements need not be identical, but each Restricted Stock Award agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;CONSIDERATION. Unless otherwise provided in the Restricted Stock Award agreement, no further consideration will be payable by Participant upon grant of the Restricted Stock Award.  Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its discretion and permissible under applicable law.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;VESTING. Shares of Common Stock acquired under the Restricted Stock Award agreement may, but need not, be subject to a share repurchase option in favor of the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event a Participant&#8217;s Continuous Service terminates, the Company may repurchase or otherwise reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the Restricted Stock Award agreement.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)&#160;TRANSFERABILITY. Rights to acquire shares of Common Stock under the Restricted Stock Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award agreement, as the Board shall determine in its discretion, so long as Common Stock awarded under the Restricted Stock Award agreement remains subject to the terms of the Restricted Stock Award agreement.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;RESTRICTED STOCK UNIT AWARDS. Each Restricted Stock Unit Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award agreements need not be identical, provided, however, that each Restricted Stock Unit Award agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;CONSIDERATION. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;VESTING. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;PAYMENT. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award agreement.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)&#160;DIVIDEND EQUIVALENTS. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Restricted Stock Unit Award agreement to which they relate.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. Except as otherwise provided in the applicable Restricted Stock Unit Award agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service. </font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)&#160;TRANSFERABILITY. Rights under the Restricted Stock Unit Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Unit Award agreement, as the Board shall determine in its discretion.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;STOCK APPRECIATION RIGHTS. Each Stock Appreciation Right agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of the Stock Appreciation Right agreements may change from time to time, and the terms and conditions of separate Stock Appreciation Right agreements need not be identical, but each Stock Appreciation Right agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions&#58;</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)&#160;CALCULATION OF APPRECIATION.  Each Stock Appreciation Right will be denominated in shares of Common Stock equivalents. The appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (i)&#160;the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to the number of shares of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right on such date, over (ii)&#160;an amount (the strike price) that will be determined by the Board at the time of grant of the Stock Appreciation Right for such number of shares of Common Stock, provided that the strike price of a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock Appreciation Right shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock equal to the number of shares of Common Stock equivalents subject to the Stock Appreciation Right on the date the Stock Appreciation Right is granted.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)&#160;VESTING. At the time of the grant of a Stock Appreciation Right, the Board may impose such restrictions or conditions to the vesting of such Stock Appreciation Right as it, in its sole discretion, deems appropriate.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii)&#160;EXERCISE. To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right agreement evidencing such Stock Appreciation Right.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv)&#160;PAYMENT. The appreciation distribution in respect to a Stock Appreciation Right may be paid in cash, shares of Common Stock, a combination of cash and shares of Common Stock or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right agreement evidencing such Stock Appreciation Right.</font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v)&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event that a Participant&#8217;s Continuous Service terminates, the Participant may exercise his or her Stock Appreciation Right (to the extent that the Participant was entitled to exercise such Stock Appreciation Right as of the date of termination) but only within such period of time ending on the earlier of (i)&#160;the date three (3)&#160;months following the termination of the Participant&#8217;s Continuous Service (or such longer or shorter period specified in the Stock Appreciation Right agreement), or (ii)&#160;the expiration of the term of the Stock Appreciation Right as set forth in the Stock Appreciation Right agreement. If, after termination, the Participant does not exercise his or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right agreement (as applicable), the Stock Appreciation Right shall terminate. </font></div><div style="text-indent:27pt;padding-left:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(vi)&#160;TRANSFERABILITY. Rights under the Stock Appreciation Right agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Appreciation Right agreement, as the Board shall determine in its discretion.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PERFORMANCE STOCK AWARDS. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Committee is authorized to designate any of the Stock Awards granted under the Plan as Performance Stock Awards.  The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions applicable to a Performance Stock Award, and may exercise its discretion to reduce or increase the number of shares issuable under any Performance Stock Award.  Performance conditions may differ for Performance Stock Awards granted to any one Participant or to different Participants.  The performance period applicable to any Performance Stock Award shall be set by the Committee in its discretion, but shall not exceed ten years.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVENANTS OF THE COMPANY.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;AVAILABILITY OF SHARES. During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Stock Awards.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;SECURITIES LAW COMPLIANCE. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards&#59; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">USE OF PROCEEDS FROM STOCK.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proceeds from the sale of Common Stock pursuant to Stock Awards shall constitute general funds of the Company.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MISCELLANEOUS.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;ACCELERATION OF EXERCISABILITY AND VESTING. Subject to the limitations of Section 8, the Board shall have the power to accelerate the time at which a Stock Award may first be exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;STOCKHOLDER RIGHTS. No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;NO EMPLOYMENT OR OTHER SERVICE RIGHTS. Nothing in the Plan or any instrument executed or Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;INCENTIVE STOCK OPTION $100,000 LIMITATION. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof which exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)&#160; INVESTMENT ASSURANCES. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and&#47;or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award&#59; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (1) the issuance of the shares of Common Stock upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act or (2) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)&#160;WITHHOLDING OBLIGATIONS. To the extent provided by the terms of a Stock Award Agreement, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under a Stock Award by any of the following means (in addition to the Company&#8217;s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means&#58; (i) tendering a cash payment&#59; (ii) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Stock Award&#59; or (iii) delivering to the Company owned and unencumbered shares of Common Stock.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ADJUSTMENTS UPON CHANGES IN STOCK.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;CAPITALIZATION ADJUSTMENTS.  If any change is made in the Common Stock subject to the Plan, or subject to any Stock Award, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan will be appropriately adjusted in the class(es) and the number of securities subject to the Plan pursuant to subsection 4(a) and the maximum number of securities subject to award to any person pursuant to subsection 5(c), and the outstanding Stock Awards will be appropriately adjusted in the class(es) and number of securities and price per share of Common Stock subject to such outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. For clarity, the conversion of any convertible securities of the Company shall not be treated as a transaction &#8220;without receipt of consideration&#8221; by the Company.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;DISSOLUTION OR LIQUIDATION.  In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards shall terminate immediately prior to such event.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;ASSET SALE, MERGER, CONSOLIDATION OR REVERSE MERGER.  In the event of (i) a sale, lease or other disposition of all or substantially all of the assets of the Company, (ii) a merger or consolidation in which the Company is not the surviving corporation or (iii) a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, then any surviving corporation or acquiring corporation shall assume any Stock Awards outstanding under the Plan or shall substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in the transaction described in this subsection 12(c) for those outstanding under the Plan). In the event any surviving corporation or acquiring corporation fails to assume such Stock Awards or to substitute similar stock awards for those outstanding under the Plan, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated, the vesting of such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not exercised (if applicable) at or prior to such event. With </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">respect to any other Stock Awards outstanding under the Plan, such Stock Awards shall terminate if not exercised (if applicable) prior to such event.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMENDMENT OF THE PLAN AND STOCK AWARDS.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;AMENDMENT OF PLAN. The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 12 relating to adjustments upon changes in Common Stock, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy the requirements of Section 422 of the Code, Rule 16b-3 or any Nasdaq or securities exchange listing requirements.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;STOCKHOLDER APPROVAL.  The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;CONTEMPLATED AMENDMENTS. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options and&#47;or to bring the Plan and&#47;or Incentive Stock Options granted under it into compliance therewith.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;NO IMPAIRMENT OF RIGHTS. Rights under any Stock Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(e)&#160;AMENDMENT OF STOCK AWARDS. The Board at any time, and from time to time, may amend the terms of any one or more Stock Awards&#59; provided, however, that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(f)&#160;SUBSTITUTE AWARDS&#59; NO REPRICING.  Stock Awards may be granted in substitution or exchange for any other Stock Award granted under the Plan or under another plan of the Company or an Affiliate or any other right of an eligible person to receive payment from the Company or an Affiliate.  Stock Awards may also be granted under the Plan in substitution for awards held by individuals who become eligible persons as a result of a merger, consolidation or acquisition of another entity or the assets of another entity by or with the Company or an Affiliate (&#8220;Substitute Awards&#8221;).  Such Substitute Awards referred to in the immediately preceding sentence that are Options or Stock Appreciation Rights may have an exercise price that is less than the Fair Market Value of a share of Common Stock on the date of the substitution if such substitution complies with applicable laws (including rules regarding nonqualified deferred compensation) and exchange rules.  Except as provided in this Section 13(f) or in Section 12, without the approval of the stockholders of the Company, the terms of outstanding Stock Awards may not be amended to (i) reduce the exercise price or grant price of an outstanding Option or Stock Appreciation Right, (ii) grant a new Option, Stock Appreciation Right or other Stock Award in substitution for, or upon the cancellation of, any previously granted Option or Stock Appreciation Right that has the effect of reducing the exercise price or grant price thereof, (iii) exchange any Option or Stock Appreciation Right for Common Stock, cash or other consideration when the exercise price or grant price per share of Common Stock under such Option or Stock Appreciation Right exceeds the Fair Market Value of a share of Common Stock.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;PLAN TERM. The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the day before the tenth (10th) anniversary of the date the Plan is adopted by the Board or approved by the stockholders of the Company, whichever is </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">earlier. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="text-indent:31.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;NO IMPAIRMENT OF RIGHTS. Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the Participant.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">15&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Plan shall become effective upon its adoption by the Board, but no Stock Award shall be exercised (or, in the case of a stock bonus, shall be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board.</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CHOICE OF LAW.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state&#8217;s conflict of laws rules.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>exh1011officerrestrict.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icb1971589e7e4134bc1875076028c8d4_1"></div><div style="height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.11</font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">(Officer Restricted Stock Unit)</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Restricted Stock Unit Agreement (this &#8220;Agreement&#8221;), effective as of ___________ (the &#8220;Grant Date&#8221;), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ______________ (&#8220;Employee&#8221;).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">To carry out the purposes of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;Plan&#8221;) and the determination of the compensation committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s board of directors (the &#8220;Board&#8221;) to grant Employee a Restricted Stock Unit Award (as defined in the Plan) under the Plan, subject to the terms and conditions of this Agreement, of shares of the Company&#8217;s Common Stock, par value $0.001 per share (&#8220;Stock&#8221;), in order to provide Employee with incentives to exert maximum efforts for the Company&#8217;s success by providing Employee the opportunity to benefit from increases in the value of the Stock, and in consideration of the mutual agreements and other matters set forth herein and in the Plan, the Company and Employee hereby agree as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Grant of Restricted Stock Unit Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  The Company hereby grants to Employee a Restricted Stock Unit Award, on the terms and conditions set forth in this Agreement and in the Plan, consisting of the right to receive an aggregate of ___________ shares of Stock (the &#8220;Shares&#8221;).</font></div><div style="text-indent:54pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Vesting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  (a) Subject to the terms and conditions set forth in this Agreement and the Plan, the right of Employee to receive the Shares shall vest with respect to ______ of the total number of Shares on _____________&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> that, if not already vested in accordance with the foregoing, the right of Employee to receive the Shares shall become vested upon (i) a termination of Employee&#8217;s Continuous Service (as defined in the Plan) by the Company without Cause (as defined below) or by Employee for Good Reason (as defined below) that occurs after the occurrence of a Change in Control (as defined below) or (ii) the termination of Employee&#8217;s Continuous Service as a result of Employee&#8217;s death or Disability (as defined in the Plan).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;For purposes of the foregoing&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:25.63pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(i) A &#8220;Change in Control&#8221; shall be deemed to have occurred if any of the following shall have taken place&#58; (A) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) other than Invus, L.P. and its affiliates (collectively, &#8220;Invus&#8221;) is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (B) Invus becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act, or any successor provisions thereto), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then-outstanding voting securities&#59; (C) the consummation of a reorganization, merger, or consolidation, in each case with respect to which persons who were stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the reorganized, merged or consolidated Company&#8217;s then-outstanding securities entitled to vote generally in the election of directors in substantially the same proportions as their ownership of the Company&#8217;s outstanding voting securities prior to such reorganization, merger or consolidation&#59; (D) a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">liquidation or dissolution of the Company or the sale of all or substantially all of the Company&#8217;s assets&#59; or (E) following the election or removal of directors, a majority of the Board consists of individuals who were not members of the Board two years before such election or removal, unless the election of each director who is not a director at the beginning of such two-year period has been approved in advance by directors representing at least a majority of the directors then in office who were directors at the beginning of the two-year period&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">, that notwithstanding the foregoing, neither the execution by the Company of the Securities Purchase Agreement and Stockholders&#8217; Agreement with Invus, L.P., each dated June 15, 2007 (as amended, supplemented or otherwise modified, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Invus Transaction Agreements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), nor the consummation of the transactions contemplated in the Invus Transaction Agreements, including, without limitation, the acquisition by Invus of the Initial Shares and the Rights Shares (as defined in the Invus Transaction Agreements), the election of any representatives of Invus to the board of directors of the Company, or the acquisition by Invus of additional shares of Stock, as permitted or contemplated under the Invus Transaction Agreements, will constitute a &#8220;Change in Control.&#8221;  The Compensation Committee, in its discretion, may deem any other corporate event affecting the Company to be a &#8220;Change in Control&#8221; hereunder.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:22.58pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(ii) &#8220;Cause&#8221; means a termination of Employee&#8217;s employment directly resulting from (A)&#160;Employee having engaged in intentional misconduct causing a material violation by the Company of any state or federal laws, (B) Employee having engaged in a theft of Company funds or Company assets or in a material act of fraud upon the Company, (C)&#160;an act of personal dishonesty taken by Employee that was intended to result in personal enrichment of Employee at the expense of the Company, (D) Employee&#8217;s final conviction (or the entry of any plea other than not guilty) in a court of competent jurisdiction of a felony, or (E)&#160;a breach by Employee of any contractual or fiduciary obligation to the Company, if such breach results in a material injury to the Company.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:19.53pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(iii) &#8220;Good Reason&#8221; means the occurrence of any of the following events without Employee&#8217;s express written consent&#58; (A) a material diminution in Employee&#8217;s base salary, (B) a material diminution in Employee&#8217;s authority, duties, or responsibilities, or (C) any other action or inaction that constitutes a material breach by the Company of any contractual obligation to Employee.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Forfeiture upon Termination of Service</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  Simultaneously with termination of Employee&#8217;s Continuous Service for any reason other than as a result of Employee&#8217;s death or Disability (as defined in the Plan) prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, Employee shall automatically forfeit all rights to receive the Shares, unless and except to the extent otherwise agreed by the Company, in its sole discretion.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Issuance of Shares upon Vesting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  Subject to the provisions of Sections 3 and 6 of this Agreement, upon vesting of the Shares in accordance with Section 2 of this Agreement, the Company shall (a) provide Employee with prompt notice of such vesting event and (b) issue the Shares to Employee for no additional consideration.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Non-Transferability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  Employee&#8217;s rights under this Agreement, including with respect to any Shares as to which the interest of Employee has not vested in accordance with Section 2 of this Agreement, may not be transferred by Employee otherwise than by will or the laws of descent and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">distribution or pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Withholding of Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.   Employee shall be liable for any and all federal, state or local taxes, including withholding taxes, arising out of the grant or vesting of Shares hereunder.  Unless Employee elects otherwise as provided below, Employee shall satisfy such withholding tax obligation by forfeiting to the Company that number of Shares having a Fair Market Value (as defined in the Plan) equal to the Company&#8217;s withholding obligation relating to such grant or vesting of Shares hereunder.  Employee may alternatively elect to satisfy such withholding tax obligation by making a cash payment to the Company equal to the Company&#8217;s minimum withholding obligation, in which case Employee shall (a) provide the Company with written notice of such election and (b) pay to the Company in immediately available funds an amount equal to the Company&#8217;s minimum withholding obligation, in each case by no later than the date giving rise to such withholding tax obligation.  No Shares shall be issued to Employee unless and until Employee shall have paid or otherwise satisfied the withholding tax obligations with respect thereto.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Dividend Equivalents&#59; Voting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  If the Board declares any dividends with respect to the Stock prior to the vesting of Employee&#8217;s rights to receive the Shares in accordance with Section 2 of this Agreement, dividend equivalents shall be credited to Employee in respect of the Shares and shall be converted into additional shares of Stock covered by this Agreement and such additional shares shall be subject to all of the terms and conditions of the underlying Shares.  Employee shall have no voting rights with respect to the Restricted Stock Unit Award or the Shares subject thereto until such time as the Shares are issued to Employee pursuant to Section 4 of this Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">No Right to Continued Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">. Nothing in this Agreement or the Plan shall confer upon Employee any right to continue in the employ of the Company or shall interfere with or restrict in any way the right of the Company, which is hereby expressly reserved, to terminate Employee&#8217;s employment at any time for any reason whatsoever, with or without cause and with or without advance notice.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">2017 Equity Incentive Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  The Plan, a copy of which is available for inspection by Employee at the Company&#8217;s principal executive office during business hours, is incorporated by reference in this Agreement.  This Agreement is subject to, and the Company and Employee agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Agreement and the Plan, the terms of the Plan shall control.  Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Agreement, and the determinations of the administrator of the Plan shall be final and binding on Employee and the Company.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.25pt;">Binding Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under Employee. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.25pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.  This Agreement and all actions taken hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and Employee has executed this Agreement effective for all purposes as of the Grant Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Lexicon Pharmaceuticals, Inc.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">__________________________________</font></div><div style="text-indent:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lonnel Coats</font></div><div style="text-indent:216pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">President and Chief Executive Officer</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Employee</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:216pt;text-align:justify;"><font><br></font></div><div style="text-indent:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">______________________________________</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:180pt;text-align:justify;"><font><br></font></div><div style="text-indent:216pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>exh1019amendmentno2toi.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib24c1eb661bb4a50ad247f6b7561cbb4_1"></div><div style="height:63.35pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 10.19</font></div></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECOND AMENDMENT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">TO LICENSE AND COLLABORATION AGREEMENT</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Second Amendment to License and Collaboration Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;) is entered into effective as of the last date set forth on the signature page hereof (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;) by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at 8800 Technology Forest Place, The Woodlands, Texas 77381 U.S.A. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Lexicon</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), and IPSEN PHARMA SAS, a French corporation with its principal offices at 65 Quai Georges Gorse, Boulogne-Billancourt 92100, France (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Ipsen</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Capitalized terms not otherwise defined herein shall have the meaning given to such terms in the Collaboration Agreement.  Unless otherwise expressly stated herein, the Sections referred to herein refer to the Sections in the Collaboration Agreement.</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;R E C I T A L S</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, Lexicon and Ipsen are parties to that certain License and Collaboration Agreement dated October 21, 2014, as amended March 17, 2015 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Collaboration Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, Lexicon and Ipsen desire to amend the Collaboration Agreement to reflect (a) the dissolution of the JDC and JCC and assumption of the JDC&#8217;s and JCC&#8217;s responsibilities by the JSC, (b) certain modifications to the JSC&#8217;s meeting schedule, (c) the elimination of the obligation of the Executive Officers of the Parties to meet once per year and (d) certain modifications to the Parties&#8217; reporting obligations&#59;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, Lexicon and Ipsen hereby agree as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.&#160;The JDC and JCC are hereby dissolved, with all responsibilities of the JDC set forth in Section 2.2(e) of the Collaboration Agreement and all responsibilities of the JCC set forth in Section 2.3(e) of the Collaboration Agreement being hereby assumed by the JSC and added to the JSC&#8217;s responsibilities set forth in Section 2.1(b) of the Collaboration Agreement.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.&#160;Section 2.1(h)(i) of the Collaboration Agreement is hereby amended so that, after the receipt of the first Marketing Authorization for a Licensed Product from the EMA (or from the applicable Regulatory Authority in the first Major EU Country), the JSC shall meet once per year rather than twice per year, at such time as may be agreed by the Parties.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3.&#160;Section 2.4 of the Collaboration Agreement is hereby deleted in its entirety and shall have no further force or effect.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.&#160;The third sentence in Section 5.1(a) is hereby amended to recite &#8220;Ipsen shall submit an updated Commercialization Plan for JSC review and approval at least fifteen (15) days prior to the annual meeting of the JSC during the Term.&#8221;</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:63.35pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.&#160;Section 6.2 of the Collaboration Agreement is hereby amended so that the written reports to be provided by each Party to the other Party following the first filing of an MAA with the EMA (or the applicable Regulatory Authority in the first Major EU Country) will be provided on an annual basis rather than within thirty (30) days after the end of each six (6) month period during each calendar year.  Such written reports shall set forth in reasonable detail such Party&#8217;s and its Affiliates&#8217; and sublicensees&#8217; (a) activities and progress during the preceding twelve (12) month period in carrying out the Commercialization Plan, including information concerning the preparations for commercial launch of the Licensed Products, First Commercial Sale, achievement of sales level event milestones and the territories in which the foregoing activities are conducted, such information to be provided separately for each Licensed Product, and (b) any planned commercialization activities in the next twelve (12) month period, including expected timelines.  Such written reports shall be provided by each Party to the other Party at least fifteen (15) days prior to the annual meeting of the JSC contemplated by Section 2.1(h)(i) of the Collaboration Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.&#160;This Amendment shall not amend or modify the covenants, terms, conditions, rights and obligations of the parties under the Collaboration Agreement, except as specifically set forth herein.  The Collaboration Agreement shall continue in full force and effect in accordance with its terms as amended by this Amendment.</font></div><div style="text-align:justify;margin-top:12pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.</font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute and deliver this Amendment as of the Amendment Effective Date.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">IPSEN PHARMA SAS</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Signature of Authorized Representative)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Printed Name&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">LEXICON PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Signature of Authorized Representative)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Printed Name&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Title&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="padding-right:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">-2-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exh231ernstyoungconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie6b6ff686eb44bdcb47d01d7b2ef3903_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 23.1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Registration Statements (Form S-8 Nos. 333-41532, 333-168678, 333-183020, 333-210145, 333-217873 and 333-234569) pertaining to the 2017 Equity Incentive Plan and to the 2017 Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Registration Statement (Form S-3 No. 333-234568) of Lexicon Pharmaceuticals, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our reports dated March&#160;12, 2020, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended December&#160;31, 2019.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Houston, Texas</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March&#160;12, 2020 </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exh311certificationofp.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4098ad6db709413b8c23ec94b036848f_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.935%;"><tr><td style="width:1.0%;"></td><td style="width:2.662%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.662%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.787%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.889%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">c)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">d)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; March&#160;12, 2020 </font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:52.319%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.681%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Lonnel Coats</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exh312certificationofp.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie599049f1b964105be1a2e7d72d87cd5_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"><tr><td style="width:1.0%;"></td><td style="width:2.566%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.566%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.669%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.199%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">c)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">d)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)&#58;</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b)</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; March&#160;12, 2020 </font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:52.319%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.681%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Jeffrey L. Wade</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Office</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">r</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exh321certificationofp.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9cbe045f6822456284a162e3fcb57ff2_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.959%;"><tr><td style="width:1.0%;"></td><td style="width:5.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lexicon's Annual Report on Form 10-K for the year ended December 31, 2019, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.</font></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 12th day of March, 2020.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:52.319%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.245%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.436%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Lonnel Coats</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:52.319%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.245%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.436%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Jeffrey L. Wade</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>lxrx-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lexpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetParentheticals" roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals">
        <link:definition>1002003 - Statement - Balance Sheet Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofComprehensiveLossParentheticalsParentheticals" roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals">
        <link:definition>1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.lexpharma.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleassetDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCostofSalesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1">
        <link:definition>2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2">
        <link:definition>2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements">
        <link:definition>2115103 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsTables" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables">
        <link:definition>2316302 - Disclosure - Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>2417411 - Disclosure - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2118104 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails">
        <link:definition>2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2121105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2322304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2423413 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2">
        <link:definition>2424414 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lexpharma.com/role/PropertyandEquipment">
        <link:definition>2125106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables">
        <link:definition>2326305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails">
        <link:definition>2427415 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lexpharma.com/role/IncomeTaxes">
        <link:definition>2128107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lexpharma.com/role/IncomeTaxesTables">
        <link:definition>2329306 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1">
        <link:definition>2430416 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2">
        <link:definition>2431417 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3">
        <link:definition>2432418 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.lexpharma.com/role/Goodwill">
        <link:definition>2133108 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.lexpharma.com/role/GoodwillTables">
        <link:definition>2334307 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.lexpharma.com/role/GoodwillDetails">
        <link:definition>2435419 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2136109 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables">
        <link:definition>2337308 - Disclosure - Debt Obligations Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsNarrativeDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails">
        <link:definition>2438420 - Disclosure - Debt Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails1" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1">
        <link:definition>2439421 - Disclosure - Debt Obligations (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2140110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>2341309 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails2" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2">
        <link:definition>2443423 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards">
        <link:definition>2144111 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables">
        <link:definition>2345310 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsNarrativeDetails" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails">
        <link:definition>2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails2" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2">
        <link:definition>2447425 - Disclosure - Equity Incentive Awards (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails3" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3">
        <link:definition>2448426 - Disclosure - Equity Incentive Awards (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails4" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4">
        <link:definition>2449427 - Disclosure - Equity Incentive Awards (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlan" roleURI="http://www.lexpharma.com/role/BenefitPlan">
        <link:definition>2150112 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanTables" roleURI="http://www.lexpharma.com/role/BenefitPlanTables">
        <link:definition>2351311 - Disclosure - Benefit Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanDetails" roleURI="http://www.lexpharma.com/role/BenefitPlanDetails">
        <link:definition>2452428 - Disclosure - Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2153113 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2454429 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.lexpharma.com/role/EarningsPerShare">
        <link:definition>2155114 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.lexpharma.com/role/EarningsPerShareTables">
        <link:definition>2356312 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails">
        <link:definition>2457430 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2158115 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2359313 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails">
        <link:definition>2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_OptionsOutstandingEquityIncentivePlan" abstract="false" name="OptionsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_SanofiSalesMilestonePayments" abstract="false" name="SanofiSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PriorYearReclassOfAccrual" abstract="false" name="PriorYearReclassOfAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" abstract="false" name="RestrictedStockUnitsOutstandingEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" abstract="false" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsSection163j_LXRX" abstract="false" name="DeferredTaxAssetsSection163j_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BalanceSheetParentheticalsAbstract" abstract="true" name="BalanceSheetParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" abstract="false" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_EntityWideRevenueIpsenPercentage" abstract="false" name="EntityWideRevenueIpsenPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_XERMELOIntangibleAssetsFiniteLived" abstract="false" name="XERMELOIntangibleAssetsFiniteLived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LXRXDiplomatcustomerconcentration" abstract="false" name="LXRXDiplomatcustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_EquityIncentiveAwardsAbstract" abstract="true" name="EquityIncentiveAwardsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiDevelopmentMilestones" abstract="false" name="SanofiDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" abstract="false" name="StockOptionExercisePriceAsPercentOfValueOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoFundingDeliverable" abstract="false" name="SanofiRevenueAllocatedtoFundingDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" abstract="false" name="ChangeInFairValueOfSymphonyIconIncPurchaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiOutcomesStudyMilestone" abstract="false" name="SanofiOutcomesStudyMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" abstract="false" name="CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenTotalUpfrontPayments" abstract="false" name="IpsenTotalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedEquityIncentivePlan" abstract="false" name="StockOptionsExercisedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SettlementPaymentObligation" abstract="false" name="SettlementPaymentObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" abstract="false" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SymphonyContingentPaymentInCash" abstract="false" name="SymphonyContingentPaymentInCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CommitmentsAndContingenciesAbstract" abstract="true" name="CommitmentsAndContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiUpfrontPayment" abstract="false" name="SanofiUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="SanofiRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" abstract="false" name="DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CoelacanthGoodwill" abstract="false" name="CoelacanthGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" abstract="false" name="DeferredTaxLiabilityfromReclassifiedIntangibleAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PresentValueOfFutureLeasePayments" abstract="false" name="PresentValueOfFutureLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BenefitPlanAbstract" abstract="true" name="BenefitPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DefinedContributionPlanRequisiteServicePeriod" abstract="false" name="DefinedContributionPlanRequisiteServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" abstract="false" name="SanofiCommercializationCostsFundedbyLexiconMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" abstract="false" name="SanofiRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PropertyAndEquipmentAbstract" abstract="true" name="PropertyAndEquipmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvertibleDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_LXRXBiologicscustomerconcentration" abstract="false" name="LXRXBiologicscustomerconcentration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_SanofiTerminationAgreement" abstract="false" name="SanofiTerminationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FederalNetOperatingLossChange" abstract="false" name="FederalNetOperatingLossChange" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_SymphonyIconGoodwill" abstract="false" name="SymphonyIconGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BuildingsCollateral" abstract="false" name="BuildingsCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_GoodwillAbstract" abstract="true" name="GoodwillAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" abstract="false" name="DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtInstrumentRepurchasePercentage" abstract="false" name="DebtInstrumentRepurchasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtIssueCosts_Revere_LXRX" abstract="false" name="MortgageDebtIssueCosts_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_InterestOnLeasePayments" abstract="false" name="InterestOnLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiDeferredRevenueFromTermination" abstract="false" name="SanofiDeferredRevenueFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" abstract="false" name="DeferredCompensationArrangementWithIndividualPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_Totalvalueofsharesbynonemployeeinayear" abstract="false" name="Totalvalueofsharesbynonemployeeinayear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_EntityWideRevenueSanofiPercentage" abstract="false" name="EntityWideRevenueSanofiPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lxrx_Ipsenproductsales" abstract="false" name="Ipsenproductsales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" abstract="false" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_IpsenTotalPaymentsToDate" abstract="false" name="IpsenTotalPaymentsToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" abstract="false" name="TotalSharesThatMayBeIssuedEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_LandCollateral" abstract="false" name="LandCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CoelacanthPurchasePrice" abstract="false" name="CoelacanthPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRoyaltyIncome_LXRX" abstract="false" name="IpsenRoyaltyIncome_LXRX" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRegulatoryMilestones" abstract="false" name="SanofiRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" abstract="false" name="SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" abstract="false" name="EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesIssuedToSymphonyDesigneesValue" abstract="false" name="SharesIssuedToSymphonyDesigneesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_OrganizationAndOperationsAbstract" abstract="true" name="OrganizationAndOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsParentheticalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>lxrx-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1317c397-7e42-4936-ae67-f869b6a1d75e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_PreferredStockValue_1317c397-7e42-4936-ae67-f869b6a1d75e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dd6708b0-11d6-434b-9b18-1b597bf96a10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_CommonStockValue_dd6708b0-11d6-434b-9b18-1b597bf96a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ab66f66a-5a9c-46c9-92bb-266c0e09e707" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ab66f66a-5a9c-46c9-92bb-266c0e09e707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df925c64-34c6-4eb3-9bd5-7fefc986b5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df925c64-34c6-4eb3-9bd5-7fefc986b5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d1626f82-fbdb-488d-9797-dc24f9a01d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d1626f82-fbdb-488d-9797-dc24f9a01d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a2f16dad-34e1-476c-a619-2aef74c91c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d4df9cc-bcfb-4ef4-8c1c-feb95c7a13a1" xlink:to="loc_us-gaap_TreasuryStockValue_a2f16dad-34e1-476c-a619-2aef74c91c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65598aa-e6c3-4827-bc6a-925d0387d638" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e06ebedc-26fc-4089-b14b-7df586c65a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65598aa-e6c3-4827-bc6a-925d0387d638" xlink:to="loc_us-gaap_StockholdersEquity_e06ebedc-26fc-4089-b14b-7df586c65a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb751021-a5d5-4e65-904d-96a49e8b446e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65598aa-e6c3-4827-bc6a-925d0387d638" xlink:to="loc_us-gaap_Liabilities_eb751021-a5d5-4e65-904d-96a49e8b446e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c9d016c-cabb-4d21-9db4-9aed33324a91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1c9d016c-cabb-4d21-9db4-9aed33324a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f78cdd31-cc9d-4bbc-a2fe-a28dde4de551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:to="loc_us-gaap_ShortTermInvestments_f78cdd31-cc9d-4bbc-a2fe-a28dde4de551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2d26879d-39ce-4361-b10e-174b2e56e782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2d26879d-39ce-4361-b10e-174b2e56e782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ad5a0d7d-3c13-47b3-bb29-7806fcac7001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:to="loc_us-gaap_InventoryNet_ad5a0d7d-3c13-47b3-bb29-7806fcac7001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9d0f979a-d5ca-4a9d-83f0-98fb10ff56bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c5aa1ea-c7cd-48e0-a255-7e3ae625669b" xlink:to="loc_us-gaap_OtherAssetsCurrent_9d0f979a-d5ca-4a9d-83f0-98fb10ff56bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c74a0e1e-47e3-42e0-8219-d01991d968d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:to="loc_us-gaap_LiabilitiesCurrent_c74a0e1e-47e3-42e0-8219-d01991d968d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_83f3a6ef-29c9-448b-88ce-979ffa832cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_83f3a6ef-29c9-448b-88ce-979ffa832cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6c29273f-09d7-4393-b822-2e938f34886b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6c29273f-09d7-4393-b822-2e938f34886b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3a97612b-0716-483b-aeb4-48502ae2d232" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3a97612b-0716-483b-aeb4-48502ae2d232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8fbb017a-22f4-433c-b433-7494c9aabbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a42c08a1-40db-47f2-b68b-c521148e0670" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8fbb017a-22f4-433c-b433-7494c9aabbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6e69989a-0316-4043-91bf-dc97dd596048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3dc28efd-3736-4339-a102-d38c0a4ee46f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e69989a-0316-4043-91bf-dc97dd596048" xlink:to="loc_us-gaap_AccountsPayableCurrent_3dc28efd-3736-4339-a102-d38c0a4ee46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a5dc0b98-fbe3-4aa7-8902-4f65c39db5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e69989a-0316-4043-91bf-dc97dd596048" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a5dc0b98-fbe3-4aa7-8902-4f65c39db5f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_87b7e38c-7595-4a99-b0e5-075a4f567727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e69989a-0316-4043-91bf-dc97dd596048" xlink:to="loc_us-gaap_DeferredRevenueCurrent_87b7e38c-7595-4a99-b0e5-075a4f567727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8c93ef21-b303-4eb9-9e9b-4335dc7a035a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6e69989a-0316-4043-91bf-dc97dd596048" xlink:to="loc_us-gaap_LongTermDebtCurrent_8c93ef21-b303-4eb9-9e9b-4335dc7a035a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_74c02e78-a6d2-4b16-afe3-bdb8927f2d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:to="loc_us-gaap_AssetsCurrent_74c02e78-a6d2-4b16-afe3-bdb8927f2d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_196926bc-15d6-4817-a465-034a974e1cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_196926bc-15d6-4817-a465-034a974e1cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc98eac0-fe8a-46c0-9065-d8237a9932cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:to="loc_us-gaap_Goodwill_dc98eac0-fe8a-46c0-9065-d8237a9932cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_fda5409f-dec8-4828-a60e-91b0267cc239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_fda5409f-dec8-4828-a60e-91b0267cc239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2a63a693-4bf9-4725-a002-85bcb3318473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_22a02820-a1ca-4002-bfc8-006805cabafa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2a63a693-4bf9-4725-a002-85bcb3318473" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BalanceSheetParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_165c9301-7d79-4f60-abb9-5b44c3376c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8f923e8c-584c-4340-9f7b-6f0a5d27c205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_165c9301-7d79-4f60-abb9-5b44c3376c17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8f923e8c-584c-4340-9f7b-6f0a5d27c205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_39598215-b651-4749-a9fe-1e122487ec89" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_165c9301-7d79-4f60-abb9-5b44c3376c17" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_39598215-b651-4749-a9fe-1e122487ec89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_45097421-2278-4a61-9d9c-15b94b3bca95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_165c9301-7d79-4f60-abb9-5b44c3376c17" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_45097421-2278-4a61-9d9c-15b94b3bca95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_75c50e78-2838-4e96-bdbe-30673afea0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_165c9301-7d79-4f60-abb9-5b44c3376c17" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_75c50e78-2838-4e96-bdbe-30673afea0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_110578db-0d7e-42e2-8944-ebcdce929d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_937ee66a-f816-48ae-8d68-ac71f210c059" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_110578db-0d7e-42e2-8944-ebcdce929d3e" xlink:to="loc_us-gaap_Revenues_937ee66a-f816-48ae-8d68-ac71f210c059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2564c9b1-a1bf-4f2d-986c-3beb1e4e25e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_110578db-0d7e-42e2-8944-ebcdce929d3e" xlink:to="loc_us-gaap_OperatingExpenses_2564c9b1-a1bf-4f2d-986c-3beb1e4e25e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03932c77-a90e-4772-b2b4-43ea9ad21645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13037cee-f77f-452d-8b7a-fd24572f7f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_03932c77-a90e-4772-b2b4-43ea9ad21645" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13037cee-f77f-452d-8b7a-fd24572f7f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1b16607-1a19-40a3-b77a-35493dce92b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_03932c77-a90e-4772-b2b4-43ea9ad21645" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1b16607-1a19-40a3-b77a-35493dce92b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2314ea2d-0c8f-458f-a19d-80f478a37931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da2fec26-02f6-4eef-928b-7dd5241c2e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_2314ea2d-0c8f-458f-a19d-80f478a37931" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da2fec26-02f6-4eef-928b-7dd5241c2e1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1ebf7229-aab8-434f-8a47-cc03b42a799c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_2314ea2d-0c8f-458f-a19d-80f478a37931" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1ebf7229-aab8-434f-8a47-cc03b42a799c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_b2044d8e-eb35-40a8-9c27-dc3ae67b4868" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_2314ea2d-0c8f-458f-a19d-80f478a37931" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_b2044d8e-eb35-40a8-9c27-dc3ae67b4868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ab189e6b-9345-49a2-967b-8cbf29a66dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8e27a511-6974-4912-b79b-9c3389e0db1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ab189e6b-9345-49a2-967b-8cbf29a66dad" xlink:to="loc_us-gaap_OperatingIncomeLoss_8e27a511-6974-4912-b79b-9c3389e0db1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7a02d093-5b9f-4364-9ece-8768131af014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ab189e6b-9345-49a2-967b-8cbf29a66dad" xlink:to="loc_us-gaap_InterestExpense_7a02d093-5b9f-4364-9ece-8768131af014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ebd8b870-835c-4d36-bc9d-e3cb4471ae85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ab189e6b-9345-49a2-967b-8cbf29a66dad" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ebd8b870-835c-4d36-bc9d-e3cb4471ae85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d224e5-a527-406f-a517-077243bd6f57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6398a38c-e765-49a6-a0b7-c34e79ccb7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d224e5-a527-406f-a517-077243bd6f57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6398a38c-e765-49a6-a0b7-c34e79ccb7ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ae1b425d-f4be-49e1-a219-504d027300c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d224e5-a527-406f-a517-077243bd6f57" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ae1b425d-f4be-49e1-a219-504d027300c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67764024-f2d5-4055-8b53-f869638c7446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d224e5-a527-406f-a517-077243bd6f57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67764024-f2d5-4055-8b53-f869638c7446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bdcb0f32-de21-4ab1-a4d5-ef1262b13bba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8d224e5-a527-406f-a517-077243bd6f57" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bdcb0f32-de21-4ab1-a4d5-ef1262b13bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a2db92f-c384-4a23-9557-ade6bf7d3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e89d249-86ae-4394-acad-6abc06974cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a2db92f-c384-4a23-9557-ade6bf7d3fb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e89d249-86ae-4394-acad-6abc06974cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b5ed5730-7ee4-4df2-8a38-672a89c9fa45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a2db92f-c384-4a23-9557-ade6bf7d3fb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b5ed5730-7ee4-4df2-8a38-672a89c9fa45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a95cea7d-dee8-4f11-882c-9613a53d9ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6a2db92f-c384-4a23-9557-ade6bf7d3fb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a95cea7d-dee8-4f11-882c-9613a53d9ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496ad1fa-4bb6-452b-9562-fda34a2dee0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99169846-506e-4eba-9240-1371a989e026" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496ad1fa-4bb6-452b-9562-fda34a2dee0a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99169846-506e-4eba-9240-1371a989e026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_909e61ee-dd5d-4ef0-849e-267e6ee012ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496ad1fa-4bb6-452b-9562-fda34a2dee0a" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_909e61ee-dd5d-4ef0-849e-267e6ee012ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_103845e3-70f9-4f66-9a5d-3fac39daa904" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_496ad1fa-4bb6-452b-9562-fda34a2dee0a" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_103845e3-70f9-4f66-9a5d-3fac39daa904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d70bf82d-560e-4718-a3d8-92f73ef88be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_ProfitLoss_d70bf82d-560e-4718-a3d8-92f73ef88be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6904c8a9-c672-4197-84a8-b7291845be5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6904c8a9-c672-4197-84a8-b7291845be5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_b26d174a-bc05-481b-9a8e-45bb90fdfd1e" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_b26d174a-bc05-481b-9a8e-45bb90fdfd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bd336dd6-2dcb-4b19-b6e0-6eead61633ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_ShareBasedCompensation_bd336dd6-2dcb-4b19-b6e0-6eead61633ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_668c045b-90da-4f03-ae48-6bb8bc85ba1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_668c045b-90da-4f03-ae48-6bb8bc85ba1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_81f34e26-cf83-4c56-b1b0-678131278ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_81f34e26-cf83-4c56-b1b0-678131278ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be33db76-27e3-46b3-9605-ce4e03fe7d27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_be33db76-27e3-46b3-9605-ce4e03fe7d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a634ffd5-43bf-48f9-bd76-cec1f95d6f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a634ffd5-43bf-48f9-bd76-cec1f95d6f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_009f976a-9723-41c2-a203-f47d62d6ecbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_009f976a-9723-41c2-a203-f47d62d6ecbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_19a2edd5-1748-455f-af27-4bb7f43f4864" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_19a2edd5-1748-455f-af27-4bb7f43f4864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_440c9f42-d3dc-403d-af43-a832c13091d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_440c9f42-d3dc-403d-af43-a832c13091d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_2ba99b9d-0a08-498a-bee7-764dd276c5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_2ba99b9d-0a08-498a-bee7-764dd276c5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_12f517ce-1d44-418f-8b27-39956a7f999a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_618b106e-19a7-44d0-b44b-5a93157ab795" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_12f517ce-1d44-418f-8b27-39956a7f999a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#OrganizationandOperations"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestments"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1eea16dc-b4d5-4bd7-b55e-77f5adadf576" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_557f467b-657a-4f86-9add-a4a7e6544b5f" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1eea16dc-b4d5-4bd7-b55e-77f5adadf576" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_557f467b-657a-4f86-9add-a4a7e6544b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_bd78e3a8-d9ca-4019-a12f-ae3e5119969d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1eea16dc-b4d5-4bd7-b55e-77f5adadf576" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_bd78e3a8-d9ca-4019-a12f-ae3e5119969d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c0e561cc-a481-40bc-a322-73e150dee238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c0e561cc-a481-40bc-a322-73e150dee238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_830dca53-a22f-4eac-bcd5-03f3b4bc22a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_830dca53-a22f-4eac-bcd5-03f3b4bc22a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_8508474c-a6c9-480d-8768-a0f6072b15f6" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_8508474c-a6c9-480d-8768-a0f6072b15f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a15c7e59-b366-4f71-a9d8-75a50ea8973e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a15c7e59-b366-4f71-a9d8-75a50ea8973e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b05b5b0f-00ab-4b36-b704-235a38e77058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b05b5b0f-00ab-4b36-b704-235a38e77058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_10e4231b-ac66-4957-a3d1-93fcb7782c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_10e4231b-ac66-4957-a3d1-93fcb7782c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d2c42682-e1e5-4f46-8b2f-767f7736c555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d2c42682-e1e5-4f46-8b2f-767f7736c555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_c0a34218-5402-4361-a6f8-6ebda4c31b89" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bec821f6-9119-4434-8034-fad1489db903" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_c0a34218-5402-4361-a6f8-6ebda4c31b89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails3"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:type="simple" xlink:href="lxrx-20191231.xsd#Goodwill"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligations"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDebtObligationsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwards"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlan"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>lxrx-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended" id="i861ff5d266aa4816b741aa41dbe5a245_e0771773-00d7-44db-9384-fd9aadfd7f06"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="idb5dfd98186a49d1b4f751225a856d8b_3962eb52-911b-4b63-aabe-1940a2a464e7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23e0720-07ea-4b8d-9075-c405b044b0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23e0720-07ea-4b8d-9075-c405b044b0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5a662f29-d68e-4ebe-abfb-3e540250567d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_ShortTermInvestments_5a662f29-d68e-4ebe-abfb-3e540250567d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3e9be66a-0897-4ccd-a1e2-cda6054f2f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3e9be66a-0897-4ccd-a1e2-cda6054f2f3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c5273ef1-5eda-4954-9c1f-218bfcceda2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_InventoryNet_c5273ef1-5eda-4954-9c1f-218bfcceda2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ba7ca694-11fd-4336-ab17-e4482f78a949" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_OtherAssetsCurrent_ba7ca694-11fd-4336-ab17-e4482f78a949" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1e2f32c1-0ac5-438f-9bfe-20ab3eb33b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_AssetsCurrent_1e2f32c1-0ac5-438f-9bfe-20ab3eb33b5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82cb1af1-1831-4683-afe0-0925f7ada1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_82cb1af1-1831-4683-afe0-0925f7ada1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a59d6ec2-fea5-41a0-a3a7-4ec21dce8a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Goodwill_a59d6ec2-fea5-41a0-a3a7-4ec21dce8a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_cbaef37d-2d52-4f67-82ea-5ffa3bc3e11e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_cbaef37d-2d52-4f67-82ea-5ffa3bc3e11e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ef4df63-e9d2-4448-93f6-259e543b1a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ef4df63-e9d2-4448-93f6-259e543b1a0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_70d4d595-00dd-466f-9ab3-cdb3c4339d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Assets_70d4d595-00dd-466f-9ab3-cdb3c4339d3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0d80c98d-3642-4302-9150-d002ff6dea45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_AccountsPayableCurrent_0d80c98d-3642-4302-9150-d002ff6dea45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfb98e78-2bf7-4d7d-9b86-19fdc8d29648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfb98e78-2bf7-4d7d-9b86-19fdc8d29648" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_66b3c615-2eb2-46eb-85d1-f631b75eaae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_DeferredRevenueCurrent_66b3c615-2eb2-46eb-85d1-f631b75eaae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d7bc7f9f-e6c6-4a4c-b003-4437f7276a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_LongTermDebtCurrent_d7bc7f9f-e6c6-4a4c-b003-4437f7276a83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b15db15-81ab-4198-a990-44d018c5ec53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b15db15-81ab-4198-a990-44d018c5ec53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_ae84eb10-89f5-4f18-97fe-ef83dc9aa3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_ae84eb10-89f5-4f18-97fe-ef83dc9aa3d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7c65889c-1044-4180-bd2b-dd8ec49e2127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7c65889c-1044-4180-bd2b-dd8ec49e2127" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_7d615465-b98e-4288-a583-21c6006d1e24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_7d615465-b98e-4288-a583-21c6006d1e24" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b14bd5ff-d1a5-4c53-b629-7605f66d267d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b14bd5ff-d1a5-4c53-b629-7605f66d267d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d47854a7-7794-4ec0-82e5-4fd28e75a07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Liabilities_d47854a7-7794-4ec0-82e5-4fd28e75a07f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7d856d59-165d-4450-a635-edb22c513222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7d856d59-165d-4450-a635-edb22c513222" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4e0b0299-311d-4565-8f60-43f1102dd74c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_PreferredStockValue_4e0b0299-311d-4565-8f60-43f1102dd74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b99fe5c7-0af9-4854-aa20-2a50333f33fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_CommonStockValue_b99fe5c7-0af9-4854-aa20-2a50333f33fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4adff5d1-4d6a-4c6e-9bcc-395b2d40ba27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4adff5d1-4d6a-4c6e-9bcc-395b2d40ba27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1ff120ba-0c35-4c49-b7ba-0efce33db1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1ff120ba-0c35-4c49-b7ba-0efce33db1c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_962fc6b2-3953-4769-9096-0d03f12edbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_962fc6b2-3953-4769-9096-0d03f12edbe6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c9c04eb3-2e31-4536-8258-6f4be0a3623c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_TreasuryStockValue_c9c04eb3-2e31-4536-8258-6f4be0a3623c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_24f5387c-d8c1-4a2c-9203-145e58b549df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_StockholdersEquity_24f5387c-d8c1-4a2c-9203-145e58b549df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe0244c1-cda1-4370-b212-735eaa20d69b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe0244c1-cda1-4370-b212-735eaa20d69b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:to="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_161fe665-f538-4f93-a9d2-8e0ab24ad886_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:to="loc_srt_ScenarioUnspecifiedDomain_161fe665-f538-4f93-a9d2-8e0ab24ad886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ceb1ca5-ce5a-4d13-8be8-9079ee7c82b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ceb1ca5-ce5a-4d13-8be8-9079ee7c82b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_424e555e-e43b-41d6-87e6-57008cffc4d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:to="loc_us-gaap_ClassOfStockDomain_424e555e-e43b-41d6-87e6-57008cffc4d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eef15b06-9e34-481e-bd91-6e9d00435c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:to="loc_us-gaap_ClassOfStockDomain_eef15b06-9e34-481e-bd91-6e9d00435c6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BalanceSheetParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended" id="i388ae72befb741ebab627b5436714579_042661f4-e812-44cc-84d3-c354fc19b28c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_04c0ce63-fdf7-4a6c-bae5-71505374e615" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_04c0ce63-fdf7-4a6c-bae5-71505374e615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac237b01-211e-46dc-9ca4-a41b38902121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac237b01-211e-46dc-9ca4-a41b38902121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_951bd15a-81e5-4a57-baaa-3b2a1e81ddba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_951bd15a-81e5-4a57-baaa-3b2a1e81ddba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2cb9d5dd-4866-47e2-9889-ab08c810b508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2cb9d5dd-4866-47e2-9889-ab08c810b508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_366f6a62-1bbb-41b4-9086-cc00af1a7a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_366f6a62-1bbb-41b4-9086-cc00af1a7a63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13a3c36b-b37a-418b-b224-e5b97c2b7aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13a3c36b-b37a-418b-b224-e5b97c2b7aa7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0672a023-9586-41bd-a363-55a0c3ed3eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0672a023-9586-41bd-a363-55a0c3ed3eb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_103aefd9-5c84-404c-8c21-df1655c79329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_103aefd9-5c84-404c-8c21-df1655c79329" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c67a547-abd6-4867-b331-387d4048d703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_4c67a547-abd6-4867-b331-387d4048d703" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_9f9b5e69-0091-4dd1-ac69-5cdbdce6267d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_TreasuryStockShares_9f9b5e69-0091-4dd1-ac69-5cdbdce6267d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af523c4c-f67e-4ed2-8c44-74b420f2e0d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:to="loc_us-gaap_EquityComponentDomain_af523c4c-f67e-4ed2-8c44-74b420f2e0d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:to="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86b3416a-5fde-4bd3-bf4b-1c2f8d982564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:to="loc_us-gaap_CommonStockMember_86b3416a-5fde-4bd3-bf4b-1c2f8d982564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0e465b43-39f4-4208-b0b1-e80c26b56b13_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0e465b43-39f4-4208-b0b1-e80c26b56b13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_effcc5ab-a264-4f83-9307-c4c5b096b1c2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:to="loc_srt_ScenarioUnspecifiedDomain_effcc5ab-a264-4f83-9307-c4c5b096b1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a05ce9e2-b5ef-4865-ba15-8838e2932a11_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:to="loc_us-gaap_ClassOfStockDomain_a05ce9e2-b5ef-4865-ba15-8838e2932a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_849bacd4-a14f-48e7-b831-9c39ae739083" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:to="loc_us-gaap_ClassOfStockDomain_849bacd4-a14f-48e7-b831-9c39ae739083" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="ic12372d4cde04ae2848cc660574301c6_9162d5dd-5db5-4747-813c-18952d3f6091">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28f62c7d-ef68-4ff3-b91b-a167f5e9e6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28f62c7d-ef68-4ff3-b91b-a167f5e9e6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33d9f8e9-94c6-4f70-b4d6-ee929e0efa40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33d9f8e9-94c6-4f70-b4d6-ee929e0efa40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_01af013f-d7b5-4c5a-b99d-a75fd1fb341e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_01af013f-d7b5-4c5a-b99d-a75fd1fb341e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6fa9e18a-407b-4dff-8ec4-a3339a3918ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_Revenues_6fa9e18a-407b-4dff-8ec4-a3339a3918ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5963b461-5200-456c-b8c7-bfcb464809e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5963b461-5200-456c-b8c7-bfcb464809e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3f82c28-009d-4466-95ee-b9e83cc3ae04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3f82c28-009d-4466-95ee-b9e83cc3ae04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_4e438119-e037-4df9-989f-e9324c2c0b72" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_4e438119-e037-4df9-989f-e9324c2c0b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d8876f68-a4d4-43f2-bbc0-66a2ab4b218d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d8876f68-a4d4-43f2-bbc0-66a2ab4b218d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_06824084-1595-4159-9b1d-e622a202c690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_OperatingExpenses_06824084-1595-4159-9b1d-e622a202c690" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_520b9d69-420a-4c1f-9920-e093bdd236b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OperatingIncomeLoss_520b9d69-420a-4c1f-9920-e093bdd236b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_064ded76-8cf9-435e-8e1a-c60d80887ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_InterestExpense_064ded76-8cf9-435e-8e1a-c60d80887ad3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_48a4a772-960f-4b39-9b61-821f057337ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_48a4a772-960f-4b39-9b61-821f057337ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1156246c-632c-4697-a90d-4bacc12cc778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1156246c-632c-4697-a90d-4bacc12cc778" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_288acd38-cf67-40d1-b49b-9fc271a189df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_288acd38-cf67-40d1-b49b-9fc271a189df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_252d75f7-e19f-483c-9bdc-22c4630b2ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_NetIncomeLoss_252d75f7-e19f-483c-9bdc-22c4630b2ecb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6f9a3ea5-500b-458e-9676-68227f7947fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6f9a3ea5-500b-458e-9676-68227f7947fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_89c406f9-4c7f-4391-8ef1-941b45efa4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_89c406f9-4c7f-4391-8ef1-941b45efa4b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cfdaed8c-be9c-423e-a466-088c7eb40115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cfdaed8c-be9c-423e-a466-088c7eb40115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_40e8977e-a9e3-4a59-b7f7-d7a328810c98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_EarningsPerShareBasic_40e8977e-a9e3-4a59-b7f7-d7a328810c98" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2f02c66b-8c2d-4344-b93a-3f73ecf173c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2f02c66b-8c2d-4344-b93a-3f73ecf173c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_54f74abf-75ff-4780-8d0c-fc601f8a8ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_54f74abf-75ff-4780-8d0c-fc601f8a8ea1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0717214-422b-4933-ad45-c131e5e9a4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0717214-422b-4933-ad45-c131e5e9a4a1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_7d41b1a1-95e4-4b93-b733-b2f3b3d105a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_7d41b1a1-95e4-4b93-b733-b2f3b3d105a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:to="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_303b7d35-948e-4268-9a8e-0245d53f0eff_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:to="loc_srt_ScenarioUnspecifiedDomain_303b7d35-948e-4268-9a8e-0245d53f0eff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2b8c8797-5cdf-484e-b55f-e4bb6f7f6bfe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2b8c8797-5cdf-484e-b55f-e4bb6f7f6bfe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended" id="idb18947d85af41dbb5e4cde4ccb16408_9a857358-10a7-431f-87b5-6a7c90476dc3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7c12f25f-e8e8-4d70-a5ae-9f4883146159" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7c12f25f-e8e8-4d70-a5ae-9f4883146159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_a1fd6d81-0a0e-4010-9015-99ff8808ec1f" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_a1fd6d81-0a0e-4010-9015-99ff8808ec1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:to="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:to="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9e717313-b890-43bb-bc1e-f798fca07b49_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9e717313-b890-43bb-bc1e-f798fca07b49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a5878263-726b-4718-9f3b-798595760187" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a5878263-726b-4718-9f3b-798595760187" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if105821d17a24062b27cf00957285483_77000338-83ac-4c03-8a08-8ceadce164a2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_3ae17df0-eb66-4537-ae98-8dd88cfa453e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_3ae17df0-eb66-4537-ae98-8dd88cfa453e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a2e2f25-8e9c-4e63-bd81-7097fe20a410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a2e2f25-8e9c-4e63-bd81-7097fe20a410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca07f788-68db-48fb-a85c-ba855d7e306d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StockholdersEquity_ca07f788-68db-48fb-a85c-ba855d7e306d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb7171f1-9249-4693-bce8-a9c2b4589004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb7171f1-9249-4693-bce8-a9c2b4589004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_e0562a58-89a6-4d82-a3ba-acc896bfd163" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_e0562a58-89a6-4d82-a3ba-acc896bfd163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_932adf75-a16f-48fa-888e-01a9b32a9c83" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyContingentPaymentInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_932adf75-a16f-48fa-888e-01a9b32a9c83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_eb654758-e9d3-4eb8-ad63-d8282bcbf3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_eb654758-e9d3-4eb8-ad63-d8282bcbf3cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bd2654af-af4c-4f7c-acf4-eae76ef711bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bd2654af-af4c-4f7c-acf4-eae76ef711bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9e6ac520-6c39-4578-a0a8-71b0e7e89dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9e6ac520-6c39-4578-a0a8-71b0e7e89dd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_729d22df-ffa8-46a4-9973-af213ae674f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_NetIncomeLoss_729d22df-ffa8-46a4-9973-af213ae674f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b193fc79-87bf-4f64-b160-b89fe26c2410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b193fc79-87bf-4f64-b160-b89fe26c2410" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_689ee446-b81a-4e09-8b6b-7fac3a1e266d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c0519ac-8790-4c90-880d-f7ee058b1044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_423b749f-47b5-4368-8dde-cc4177e0424f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:to="loc_us-gaap_EquityComponentDomain_423b749f-47b5-4368-8dde-cc4177e0424f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:to="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f6ba88ef-33fd-4142-8648-af1b3e9ac30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_CommonStockMember_f6ba88ef-33fd-4142-8648-af1b3e9ac30f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df28a122-cf38-482d-b8b0-b9f75011c364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df28a122-cf38-482d-b8b0-b9f75011c364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91e97b47-5cff-41d1-8a11-508680f1add7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_RetainedEarningsMember_91e97b47-5cff-41d1-8a11-508680f1add7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b275d65a-a62a-439e-8a70-fd27c2f0100f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b275d65a-a62a-439e-8a70-fd27c2f0100f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f2894745-f2ea-468e-ac30-af4069d7271c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_TreasuryStockMember_f2894745-f2ea-468e-ac30-af4069d7271c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i8ba8094bdaf4473082f5b0d2bb9789a2_31498213-4d3e-4287-82a2-c3727cbd795e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a9b72ce-fe09-4e6b-88c6-e01b3dd251ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_ProfitLoss_6a9b72ce-fe09-4e6b-88c6-e01b3dd251ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ccb28bb9-db3b-4a6d-bac3-689964fec04e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ccb28bb9-db3b-4a6d-bac3-689964fec04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_eceba35d-cc19-4905-a6de-c290e676746b" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_eceba35d-cc19-4905-a6de-c290e676746b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e9cad782-9743-44ae-987a-6c977cacec39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_ShareBasedCompensation_e9cad782-9743-44ae-987a-6c977cacec39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_c29ef3a9-f2c9-427d-ab68-c6e31592c1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_c29ef3a9-f2c9-427d-ab68-c6e31592c1f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1574bc71-1161-45dd-b823-8111902bb450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1574bc71-1161-45dd-b823-8111902bb450" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a8bf6-d793-4c7b-8801-eb311843ad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a8bf6-d793-4c7b-8801-eb311843ad7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6916f656-39a4-4abc-aad6-8f183baa83f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6916f656-39a4-4abc-aad6-8f183baa83f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c46ec029-47a7-4b89-9a43-8e9b2ed4dc58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c46ec029-47a7-4b89-9a43-8e9b2ed4dc58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b066af5e-6c14-4dc0-8f19-75129c267b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b066af5e-6c14-4dc0-8f19-75129c267b9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02223200-8982-4482-ad34-f5c0f56ab2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02223200-8982-4482-ad34-f5c0f56ab2ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26aceadc-1b96-48e4-b6c1-254b9890c3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26aceadc-1b96-48e4-b6c1-254b9890c3fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45cb4caa-4ec3-492f-8e6d-c94e38cae4be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45cb4caa-4ec3-492f-8e6d-c94e38cae4be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_79046090-6a8d-4bff-ba75-8b5791eda2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_79046090-6a8d-4bff-ba75-8b5791eda2cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b65be901-c548-474f-80dc-2f7bd695babb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b65be901-c548-474f-80dc-2f7bd695babb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e2d7f6a7-122e-440b-b435-a4326268c4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e2d7f6a7-122e-440b-b435-a4326268c4d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_266ba451-a1c6-4984-aea7-3c0d0cc2fa79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_266ba451-a1c6-4984-aea7-3c0d0cc2fa79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ce3dff3-0b39-4da0-989c-4b6298bdb3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ce3dff3-0b39-4da0-989c-4b6298bdb3b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9a6c5f9-a42f-4608-8049-a50366d3407f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9a6c5f9-a42f-4608-8049-a50366d3407f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e3ac9f9-7787-4a03-80bd-27850fcfe358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e3ac9f9-7787-4a03-80bd-27850fcfe358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ee7521-79db-40fe-b110-e51724f00079" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ee7521-79db-40fe-b110-e51724f00079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fce637b8-dcdd-40b1-b4b5-51ad33108a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fce637b8-dcdd-40b1-b4b5-51ad33108a76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37c7c3a0-c9d1-4ab2-ba91-1a820aa36f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37c7c3a0-c9d1-4ab2-ba91-1a820aa36f5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_e7b740f8-aa8c-4443-a32e-7b781de75627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_e7b740f8-aa8c-4443-a32e-7b781de75627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccabf126-1ec0-4dbb-858b-926492abaf38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccabf126-1ec0-4dbb-858b-926492abaf38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a803ac-4eea-4c56-b520-841aabf9c36e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_bdf879f0-5cec-4a21-9323-cd1bb5861f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:to="loc_us-gaap_InterestPaidNet_bdf879f0-5cec-4a21-9323-cd1bb5861f1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_6040abd1-a2d2-4f54-ae98-c08c96efb1f4" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_6040abd1-a2d2-4f54-ae98-c08c96efb1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_3a88c8ac-d85b-454c-b2a5-d5cf9f4539fd" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyContingentPaymentInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_3a88c8ac-d85b-454c-b2a5-d5cf9f4539fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:to="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_91ba0485-d223-41f4-b57b-600f8e3d01bb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_91ba0485-d223-41f4-b57b-600f8e3d01bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fbf091cd-cf5b-4f56-919d-fc7e09ed4b46" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fbf091cd-cf5b-4f56-919d-fc7e09ed4b46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#OrganizationandOperations"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="extended" id="i2bb36de5cb6f4d958cc7dfb82dae5c07_0ccfde04-17b8-4bb2-8cb5-738453d0c35b"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="if98b10f7f4644f44bf91a1f349c37dd7_229783ea-d020-4097-8942-9c6461ab43be"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i85f63a6377ca4d05832c6d3a042f354a_eb9e9eae-39df-4905-a4cb-e3852b98214e"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i21f325bd5571402e824df876b4ed339a_22616967-c80f-446c-8754-6d5f5b5251dc"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" id="i7c2b380b86ac4d75bb2052835b110938_4df9f394-d182-40d5-9c43-7ef506777d44"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended" id="i01eb59d7ed134f69ba7ac86f3e7dd0b0_72d52b7a-7b7e-4bc7-b08c-5235b76ddebb"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="extended" id="i9cb731734bbd4e3aaa08cc90e6722823_dc8541a2-920d-4902-b982-626beaacfc1e"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended" id="i1943f6db62724de1ad67183125924709_52420030-755f-44f4-8388-bfdb197c16a9">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_767c5166-6d52-40a1-a561-1355d9a6e0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_767c5166-6d52-40a1-a561-1355d9a6e0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c6e4582f-1bc0-44a4-a956-535e00c79b79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c6e4582f-1bc0-44a4-a956-535e00c79b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_703c4124-f1a1-4281-afd6-8f5be80a2036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_703c4124-f1a1-4281-afd6-8f5be80a2036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c65d2af-d222-4cf8-9f7e-2492e2eed351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c65d2af-d222-4cf8-9f7e-2492e2eed351" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_85a1f88b-49cd-4cc7-bf6b-41c9ffa6d57e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_85a1f88b-49cd-4cc7-bf6b-41c9ffa6d57e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_85997775-5c8a-408b-91bd-dc3accafcf24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_85997775-5c8a-408b-91bd-dc3accafcf24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cdbba60c-ac31-4328-b299-1149b7ec9de9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cdbba60c-ac31-4328-b299-1149b7ec9de9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f91e0843-1ad8-45fd-b1ef-854586a856cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f91e0843-1ad8-45fd-b1ef-854586a856cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8f31f9-acd3-4101-882e-26931fa81e60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8f31f9-acd3-4101-882e-26931fa81e60" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="iaaf8d34a3a8240f4821f4dff5b4cfb2b_8a7e71cb-5b07-4878-8466-e860c02d610e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8effe865-1fef-4fc5-a65f-5edf5840d624" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8effe865-1fef-4fc5-a65f-5edf5840d624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:to="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2acef425-015b-4f5f-a9c8-75057121791c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:to="loc_srt_RangeMember_2acef425-015b-4f5f-a9c8-75057121791c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:to="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db7ce864-5911-45f0-81d9-7c65abe001b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:to="loc_srt_MinimumMember_db7ce864-5911-45f0-81d9-7c65abe001b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ccc5f7de-bc97-4ffa-a5e4-69b58af1666a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:to="loc_srt_MaximumMember_ccc5f7de-bc97-4ffa-a5e4-69b58af1666a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended" id="i72413bea2d3e4abfb363a1cc5f65594f_efee798d-2529-454f-b9b2-e5fc005d2576"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended" id="i3bd66229dc054f72abf842c0372d85a1_a18ae878-f09c-423f-bdd1-5f0e4a902897"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended" id="ia7fcc357d9ff428b8179d7ab34e86f85_1785d912-fae7-4c0f-b07f-61edd8eb26b6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fce4da0-460f-4588-adb7-4562d48f7625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fce4da0-460f-4588-adb7-4562d48f7625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0edc254-16ee-4d6d-980e-445cbc4340fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a0edc254-16ee-4d6d-980e-445cbc4340fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bc18c4c7-9946-4269-9194-d10696f4b34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bc18c4c7-9946-4269-9194-d10696f4b34f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended" id="iafe2b944d95b434fa173f81b46b30440_bc9adad3-ee27-4bac-920b-579b8bd4e624">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_3bef328e-eda9-4d03-a28a-220304d991ae" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_3bef328e-eda9-4d03-a28a-220304d991ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_8342ca1c-917b-48ce-b307-42eff378b491" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_8342ca1c-917b-48ce-b307-42eff378b491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e2fbbb49-0245-4321-919e-8b754c7d45b1" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e2fbbb49-0245-4321-919e-8b754c7d45b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_1709e78c-f9e0-4b45-9aac-e12c5f325af9" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_1709e78c-f9e0-4b45-9aac-e12c5f325af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9e73e2dc-d83a-47d8-8edb-b68c8a0fb2e9" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9e73e2dc-d83a-47d8-8edb-b68c8a0fb2e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_bf6acedd-aed7-4e91-92be-a45f5b6a4ca8" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_bf6acedd-aed7-4e91-92be-a45f5b6a4ca8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_9dd76a81-dd21-4257-8826-271cf4d68e75" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_9dd76a81-dd21-4257-8826-271cf4d68e75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_a7c5a2ed-3d38-41d1-adc6-a506a5fa3dbb" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_a7c5a2ed-3d38-41d1-adc6-a506a5fa3dbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f83a43c1-a1a0-4429-8125-588f450646c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f83a43c1-a1a0-4429-8125-588f450646c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:to="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a294d38d-ca77-42e3-8f13-5f89f026bea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:to="loc_us-gaap_StockOptionMember_a294d38d-ca77-42e3-8f13-5f89f026bea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2f59a8e1-87a6-4138-87de-1678986c4f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2f59a8e1-87a6-4138-87de-1678986c4f14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="extended" id="i997be3b2f71745c0ab1996d85224d27b_542081ee-d45d-4abe-a99d-e5ebeeee56cc"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended" id="i39a8f79478e64f2aa00529a4bc246dc4_bbe0c9a2-8a40-441c-9d1c-849ab1c09736"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" id="i4def0fa6337642a38894bb017cb0e1ac_9dac8b60-208c-474c-a96e-de997c343afc"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" id="i27f36631c4e34ab4bee05bcb5099acfb_908103fd-7c3f-4b1a-9841-fed3d4a77c8d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcad7413-f621-4ffb-8f3d-c107d4461372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcad7413-f621-4ffb-8f3d-c107d4461372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46219a93-1f00-4b1f-98ea-67e1993f8b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:to="loc_us-gaap_OperatingLeaseLiability_46219a93-1f00-4b1f-98ea-67e1993f8b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_482e6c60-ad09-4bd8-8be7-fe1991c40a68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:to="loc_us-gaap_TypeOfAdoptionMember_482e6c60-ad09-4bd8-8be7-fe1991c40a68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e8e5489f-f344-476b-bace-08c73ec23f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e8e5489f-f344-476b-bace-08c73ec23f6e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestments"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended" id="icf9620ba233a4857a1b9c4372759ac0e_ff94523d-245b-4edb-a200-057f47c82a2a"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended" id="icc6c3ea890bf4bd0be22840744753d0a_8bf0613a-88c5-44b1-99c4-11fd94ffbeac"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="i2ee60d582e95444b93be5ac09526e17d_58241fb0-3b62-4a82-8be5-2a686fe9b4b3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_d28c7606-424c-4221-8c2b-3cbfea5dbeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_d28c7606-424c-4221-8c2b-3cbfea5dbeb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_22dbce89-b21f-4b67-9e87-1e2e6f85f277" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_22dbce89-b21f-4b67-9e87-1e2e6f85f277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e66f7006-23f0-47e3-ac8c-74cd45f878c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e66f7006-23f0-47e3-ac8c-74cd45f878c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1f0ba568-158d-454b-b70b-d46a1420838f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1f0ba568-158d-454b-b70b-d46a1420838f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_901e0e67-956f-462f-90bc-315d8e96ef5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_901e0e67-956f-462f-90bc-315d8e96ef5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:to="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ca6bf134-1715-4133-8c11-a3cee4351f13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ca6bf134-1715-4133-8c11-a3cee4351f13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c89ca0c6-26f7-4111-b39c-3b613a7fb5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_CashMember_c89ca0c6-26f7-4111-b39c-3b613a7fb5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6d4265ef-68be-4940-9264-142197122532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6d4265ef-68be-4940-9264-142197122532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_595c6289-ec22-44f5-b3bb-fcbe8e85712a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_595c6289-ec22-44f5-b3bb-fcbe8e85712a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6373a795-5270-4f87-8656-62a03e1df23b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6373a795-5270-4f87-8656-62a03e1df23b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_fe4f0f4d-2d2a-45a4-94fe-3e95defee62c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_InvestmentsMember_fe4f0f4d-2d2a-45a4-94fe-3e95defee62c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" id="i4ec6dec6ca894fe48a8308049f96e6e9_947231f2-2d7e-4723-b82e-0e250bb80903"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i9618914df87c4c6ea8dc19c3938ca597_5cb40096-6e2f-47a0-89a5-a8e48cb04c57"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i7da76679fc684c6083551fcb471c7c67_1ae3d175-4b4d-4254-8cec-b5c5c4967d1f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8649d0b9-3f64-4528-911e-0b2c12d6924e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8649d0b9-3f64-4528-911e-0b2c12d6924e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0c9cbc82-67e5-4886-b206-0f87359ce08f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0c9cbc82-67e5-4886-b206-0f87359ce08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_456e040f-cf85-48b5-b21a-92abe969e38b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_456e040f-cf85-48b5-b21a-92abe969e38b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e8d090d-5105-49e3-acb0-861a3089e068_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e8d090d-5105-49e3-acb0-861a3089e068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8c93dd3-6d28-4b5c-9aa4-b5982e48fb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8c93dd3-6d28-4b5c-9aa4-b5982e48fb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71e30b14-19b3-439a-b918-7b9244275d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71e30b14-19b3-439a-b918-7b9244275d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f708c41d-4159-431e-82de-d3ecd4b72fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f708c41d-4159-431e-82de-d3ecd4b72fc2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="if179e38d497e40a4a4c366d2e6b1543f_45f460fe-a38a-40f3-aae1-16cdde24d8d7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_39d7e36d-481b-498f-ad2d-24d33de7a5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_39d7e36d-481b-498f-ad2d-24d33de7a5e4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eed0d451-5e3f-4b76-a662-1bf7834cb3bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eed0d451-5e3f-4b76-a662-1bf7834cb3bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d64a332-a6ab-45db-b9f4-b0f8094f26a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d64a332-a6ab-45db-b9f4-b0f8094f26a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="extended" id="i489063bfa9b04d0dbee6f3a744d4426a_4566070d-01aa-452e-bee6-1e1d3600cacf"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="extended" id="ia08bf3e0fabd4b84af7072721f572f9d_02f3c38f-c6ea-4c1c-aaed-671ffd85ed27"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ibb92760beaed4fac90514cf4a0cd0c86_cf726308-497e-424c-a6b7-d036cf26f903">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_02d23279-b4ab-45ef-a365-a3cfb38c7603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_02d23279-b4ab-45ef-a365-a3cfb38c7603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34d204e5-c0cc-4c90-be85-7ec40d8bc842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34d204e5-c0cc-4c90-be85-7ec40d8bc842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7308ae8-d87d-450c-8e3f-515de245209d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7308ae8-d87d-450c-8e3f-515de245209d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5437f343-752a-4efd-a7e9-ecc370517337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5437f343-752a-4efd-a7e9-ecc370517337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dc90899-d4e8-4b6b-98aa-e1522e15690a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3dc90899-d4e8-4b6b-98aa-e1522e15690a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f1fa8b42-320a-4e35-aa86-eb90088068f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_ComputerEquipmentMember_f1fa8b42-320a-4e35-aa86-eb90088068f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f0b94e0d-2c57-4183-b3d3-57ce6e881969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f0b94e0d-2c57-4183-b3d3-57ce6e881969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0a3d8bdb-c732-4b3e-bbc1-74316a21dfad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_EquipmentMember_0a3d8bdb-c732-4b3e-bbc1-74316a21dfad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_65ec78c0-aabc-4715-926b-07a9ac39a712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_65ec78c0-aabc-4715-926b-07a9ac39a712" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_9cc210a7-466f-4fd1-9c4f-5b613d30550c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_9cc210a7-466f-4fd1-9c4f-5b613d30550c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3654c9fc-9e96-4e1b-904b-cbd9734d3be3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_LandMember_3654c9fc-9e96-4e1b-904b-cbd9734d3be3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:to="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_764fde62-8e9a-4412-b2b6-caa3a0f5d33e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:to="loc_srt_RangeMember_764fde62-8e9a-4412-b2b6-caa3a0f5d33e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:to="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a148d9ab-e1e8-40b4-b28b-a55440992073" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:to="loc_srt_MinimumMember_a148d9ab-e1e8-40b4-b28b-a55440992073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76ab00b2-db86-4763-825b-de9e0ca28136" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:to="loc_srt_MaximumMember_76ab00b2-db86-4763-825b-de9e0ca28136" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended" id="i70e6049eecba451385722962eaca3152_cdb6e847-2cb8-418e-8e5c-5855717b24b2"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended" id="i8e26d42088dc4e7dac3b44a1a8af71ee_b6d3d5f5-9d10-4c1f-ab47-ed86f44fa201"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended" id="i11e638f27fdd4cca85ddb3dfb50f8ed3_a74d7834-8295-46e1-95dc-fcb3b388c26b">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1dec8a33-2f99-4d5e-a8ba-92a645533fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1dec8a33-2f99-4d5e-a8ba-92a645533fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_65b99697-a999-4b4d-a787-ded98b24fd50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_65b99697-a999-4b4d-a787-ded98b24fd50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_ad13dec2-a08e-4ab1-bc42-0fef97b58077" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_ad13dec2-a08e-4ab1-bc42-0fef97b58077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8e078e43-64e6-4f0c-887d-e80263247a98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8e078e43-64e6-4f0c-887d-e80263247a98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4101deb0-1bb5-4c4c-88c5-b9ceb5d22b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4101deb0-1bb5-4c4c-88c5-b9ceb5d22b14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_77010bbd-9e2f-429b-8842-2b9d72ac59ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_77010bbd-9e2f-429b-8842-2b9d72ac59ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_82795ace-3609-481d-945a-4fe73d334def" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_82795ace-3609-481d-945a-4fe73d334def" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e366f576-55fa-44db-894a-95e9863b8732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e366f576-55fa-44db-894a-95e9863b8732" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f494ffab-ea62-497c-80ce-6983ce49bc08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f494ffab-ea62-497c-80ce-6983ce49bc08" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_3f93ec57-2be1-4607-994b-44f145acc2fa" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_3f93ec57-2be1-4607-994b-44f145acc2fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_a464fd1d-8fa3-4cd9-9524-ded089f4811b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_a464fd1d-8fa3-4cd9-9524-ded089f4811b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c25270bf-b36f-4b94-9cc0-6d306692171c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c25270bf-b36f-4b94-9cc0-6d306692171c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16146d82-ccbf-42c3-9619-e7c430c46931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16146d82-ccbf-42c3-9619-e7c430c46931" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7de0e8d6-47ad-4ed4-996c-b412a88ee700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7de0e8d6-47ad-4ed4-996c-b412a88ee700" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f3dd9111-40e8-4cba-8273-25b2ebe4b4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f3dd9111-40e8-4cba-8273-25b2ebe4b4b9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_d4f1e481-3994-4ade-83c8-b237a5db1423_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_d4f1e481-3994-4ade-83c8-b237a5db1423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3a9d3355-ad00-423b-9445-f0f19bc748c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3a9d3355-ad00-423b-9445-f0f19bc748c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" id="i7b5945ebd7514d8b899935fd8ff4d15a_9d7c4213-95ff-4671-a765-7d9bd3e88ada">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_2a36f06c-84da-4619-be13-8603043afd86" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_2a36f06c-84da-4619-be13-8603043afd86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_87238e91-68ab-4e05-ae32-6d8831e0076b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_87238e91-68ab-4e05-ae32-6d8831e0076b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FederalNetOperatingLossChange_ba4a811d-f64c-473d-86c5-34c265f327c6" xlink:href="lxrx-20191231.xsd#lxrx_FederalNetOperatingLossChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_lxrx_FederalNetOperatingLossChange_ba4a811d-f64c-473d-86c5-34c265f327c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c1693a47-9993-4491-a68e-f3004b59ff1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c1693a47-9993-4491-a68e-f3004b59ff1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_884f9d1b-7eba-4bb6-8a1a-6e2620c8eb98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_884f9d1b-7eba-4bb6-8a1a-6e2620c8eb98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails3"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="extended" id="i5eae6484b4304626aad77b11e65b46ac_b3273bbc-2ae2-403f-af1a-9d18e8480605"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:type="simple" xlink:href="lxrx-20191231.xsd#Goodwill"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended" id="i9309380c163044239920b444c3fda988_6c5d49aa-71c8-491c-aae0-6646f157fc1f"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended" id="iebaffb6e71024fe4a850679072d190a7_e93b4efa-b6d4-4e6c-a69d-fba824cdfe2d"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended" id="id0fcb07f86fa4f18a89702ca618593a4_db168fc3-26e6-4dc9-bf36-38ba3e7e686e"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligations"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" id="i99c18ccc19d94cc2963ea37c4364c0d1_2b22fca5-6eb6-49c3-930d-3c9f0cd30364"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDebtObligationsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended" id="id960596036a64bf5b050df196194efad_0f7c8b8b-f751-42af-933b-42e22745754d"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended" id="i58c0320be4cc4bb091990ba5e8b57a37_1ded7775-436b-4288-aaba-390de4da6b45">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_792dc5f9-067f-4580-a7e0-192a17e6a871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_792dc5f9-067f-4580-a7e0-192a17e6a871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_b56204c7-fbe7-4eb2-ba18-e5eeafd68d2c" xlink:href="lxrx-20191231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_b56204c7-fbe7-4eb2-ba18-e5eeafd68d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3f5d99cb-dd8d-4aa0-b577-55a3dd4ea172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3f5d99cb-dd8d-4aa0-b577-55a3dd4ea172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_71636335-1cb1-450c-b4a8-50b83bde9e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_71636335-1cb1-450c-b4a8-50b83bde9e66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_e5e4bf01-1c76-48c6-bb14-d5154cdf9b9b" xlink:href="lxrx-20191231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_e5e4bf01-1c76-48c6-bb14-d5154cdf9b9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_66d60bb3-eeaa-4cfc-bc6a-311265131a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_66d60bb3-eeaa-4cfc-bc6a-311265131a0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_503cabe7-c02f-41ec-a319-31d6cad4dc24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentTerm_503cabe7-c02f-41ec-a319-31d6cad4dc24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_8db3fedd-3ddd-440b-bb7d-7846f089438b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_8db3fedd-3ddd-440b-bb7d-7846f089438b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1d715282-d8ab-4c0d-a8aa-7afa44626cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1d715282-d8ab-4c0d-a8aa-7afa44626cc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0abfb4b6-79be-4ac3-ac4a-c4952ef6c1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0abfb4b6-79be-4ac3-ac4a-c4952ef6c1db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_4e9b8e36-d5e7-4cf4-b967-46c2fde6df20" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_4e9b8e36-d5e7-4cf4-b967-46c2fde6df20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1269b0b8-f290-4d33-a208-50db175eeb71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1269b0b8-f290-4d33-a208-50db175eeb71" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_38a81877-def9-42db-a895-9421a78ee436" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_38a81877-def9-42db-a895-9421a78ee436" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_f43aac5a-f885-4dc1-b1fb-34280018c93a" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_f43aac5a-f885-4dc1-b1fb-34280018c93a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_6b5fbcb4-0b8f-4266-bcae-bff436630922" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_6b5fbcb4-0b8f-4266-bcae-bff436630922" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db5792eb-9220-4770-b8bb-d7d46459a0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db5792eb-9220-4770-b8bb-d7d46459a0d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_2e223930-0efd-413b-9b58-df772e238ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_2e223930-0efd-413b-9b58-df772e238ba2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral_931826f0-5fcb-4d38-beef-e888b5d4691a" xlink:href="lxrx-20191231.xsd#lxrx_BuildingsCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_BuildingsCollateral_931826f0-5fcb-4d38-beef-e888b5d4691a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral_26f35288-d5af-4e5c-9e66-cee518ff5f92" xlink:href="lxrx-20191231.xsd#lxrx_LandCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_LandCollateral_26f35288-d5af-4e5c-9e66-cee518ff5f92" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4baf7528-ca79-4cf7-9858-8852863a83d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4baf7528-ca79-4cf7-9858-8852863a83d3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_82bc0c8d-fb05-4706-ab6b-fb4b141f2c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_82bc0c8d-fb05-4706-ab6b-fb4b141f2c68" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_fe75a23b-09f9-46cd-89f1-9727fd0f4df2" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_fe75a23b-09f9-46cd-89f1-9727fd0f4df2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4a014621-9c27-4a35-b690-8150f11e1fda_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4a014621-9c27-4a35-b690-8150f11e1fda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b17a614-b707-4e6f-97f1-bf5d0d5b7a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b17a614-b707-4e6f-97f1-bf5d0d5b7a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:to="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_73214885-48c5-41bf-8249-179e91d5f972_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_73214885-48c5-41bf-8249-179e91d5f972_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2bf76273-dd56-4029-9e55-b049f2dbbe9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2bf76273-dd56-4029-9e55-b049f2dbbe9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended" id="i36d5c8b05c63461b8571eeba26118a52_4bb964b3-4462-4819-a240-76c463aa133f"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="i49299f9c5555468c94debb62b1006987_9431fa84-9116-4db1-a4f5-aba18df7baee"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i0755adbf15574687a98acf86ca858b3c_4d8c9772-33e1-4cac-8e74-2eb464ce0435"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i049ddde46fa04e8d9e30ae6cabf7c7ff_79bc870d-95b1-4200-b224-e25a92501254">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_0a5d363f-116b-45ef-b0d4-118068167e21" xlink:href="lxrx-20191231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_0a5d363f-116b-45ef-b0d4-118068167e21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:to="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54250c42-b281-41d0-96b3-f3f3d5aabda8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:to="loc_srt_RangeMember_54250c42-b281-41d0-96b3-f3f3d5aabda8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:to="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a946c46c-adca-4ee0-9143-eb77bcc64358" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:to="loc_srt_MinimumMember_a946c46c-adca-4ee0-9143-eb77bcc64358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10c43aa7-12ee-4de5-89fd-7a8370dda39c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:to="loc_srt_MaximumMember_10c43aa7-12ee-4de5-89fd-7a8370dda39c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended" id="i420e40d7ac6e4cd8b894780b7d319ddb_de3b6ef6-9e7b-4471-8ad8-eb07dcd8553a"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwards"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended" id="i8d67fddfc9b14746a5f108494f9918e5_536d33d7-f11f-4568-8a2e-8857c6a293ba"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended" id="iafc12a8d19084534acb1f4807f1c06d2_b282af10-f4fc-4cba-ae7b-6337cf65a779"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended" id="ibfe73905527c483f85168785012b5ad3_15a5f9ca-2c09-481a-b410-c66469a1975a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_6a00eca0-0dcf-4a89-b862-004093e9ca85" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_6a00eca0-0dcf-4a89-b862-004093e9ca85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_81768178-b3d2-4b9c-b644-d9253aecd17e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_81768178-b3d2-4b9c-b644-d9253aecd17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d7e4b71-4da2-45d1-9f2b-d1f806df51c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d7e4b71-4da2-45d1-9f2b-d1f806df51c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_be681fe7-8cd7-4789-8ba1-6cae7ab1a192" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_be681fe7-8cd7-4789-8ba1-6cae7ab1a192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_a6dfd685-36d2-4868-9771-4eea53997631" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_a6dfd685-36d2-4868-9771-4eea53997631" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6f60c063-286a-4de3-859e-ba212927cb07" xlink:href="lxrx-20191231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6f60c063-286a-4de3-859e-ba212927cb07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_901074fe-354f-47f5-8f21-a17268542a1e" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_901074fe-354f-47f5-8f21-a17268542a1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_0e0c60dc-6f35-4e3d-a87e-5fb9d2ea2642" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_0e0c60dc-6f35-4e3d-a87e-5fb9d2ea2642" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_4ffa787c-dacc-4a96-801b-b70436b55d97" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_4ffa787c-dacc-4a96-801b-b70436b55d97" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_4d11fa29-8da9-4743-afa0-bccdd3255ca8" xlink:href="lxrx-20191231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_4d11fa29-8da9-4743-afa0-bccdd3255ca8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_ee9d17a0-b3d2-4289-b591-6e93dea2c743" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_ee9d17a0-b3d2-4289-b591-6e93dea2c743" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8324404b-628c-48ef-80fd-b609bbcd2767" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8324404b-628c-48ef-80fd-b609bbcd2767" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_6559ef7d-4b22-4e7b-ad23-910c51cb42a7" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_6559ef7d-4b22-4e7b-ad23-910c51cb42a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_74d0ed98-d65b-425b-ae5f-ce76046d6a94" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_74d0ed98-d65b-425b-ae5f-ce76046d6a94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55ae37ed-0295-49f0-9998-9894be432092" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55ae37ed-0295-49f0-9998-9894be432092" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_55bd8709-6a56-4224-8522-0c4005fb12f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_55bd8709-6a56-4224-8522-0c4005fb12f0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:to="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbd74672-d0ec-4355-8c1d-f3646841b8c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbd74672-d0ec-4355-8c1d-f3646841b8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88a1bb19-b279-450f-aff7-dc4b66b74d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88a1bb19-b279-450f-aff7-dc4b66b74d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a359024d-c5b0-4ed9-88f8-997ab726bd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:to="loc_us-gaap_RestrictedStockMember_a359024d-c5b0-4ed9-88f8-997ab726bd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:to="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93f3f887-53c8-4b2c-b697-a3bf49a51cf0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:to="loc_srt_RangeMember_93f3f887-53c8-4b2c-b697-a3bf49a51cf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:to="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07b45ec8-8f09-42e1-a77d-69c6cde95c71" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:to="loc_srt_MinimumMember_07b45ec8-8f09-42e1-a77d-69c6cde95c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b6e2a7e-a9ac-4a9a-a384-353f79d7f76a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:to="loc_srt_MaximumMember_5b6e2a7e-a9ac-4a9a-a384-353f79d7f76a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended" id="i851e23eba6164bafaa7ad7171558bac7_3641c724-7913-4cae-90fa-6ffad16b16ab">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4168f721-899b-4da1-85b2-047cff914437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4168f721-899b-4da1-85b2-047cff914437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300290e8-acbe-47cf-9f2c-65e22ed55be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300290e8-acbe-47cf-9f2c-65e22ed55be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24eb0dfa-d43f-4c5d-bea5-844d43fc87d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24eb0dfa-d43f-4c5d-bea5-844d43fc87d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1e8d2ca7-d6c2-4779-bbc7-1440524892fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1e8d2ca7-d6c2-4779-bbc7-1440524892fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_860dc658-c415-416b-a61b-8b101248d8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_860dc658-c415-416b-a61b-8b101248d8ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b6ca27d-b4f1-4b8f-a278-b331ddb12e18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b6ca27d-b4f1-4b8f-a278-b331ddb12e18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bde76914-1115-4314-99d9-2884ed942954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bde76914-1115-4314-99d9-2884ed942954" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d5dd6150-bd1b-4323-95b4-aa953210b6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d5dd6150-bd1b-4323-95b4-aa953210b6ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_44202f88-43e2-4646-a53f-1a01ae44b50b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_44202f88-43e2-4646-a53f-1a01ae44b50b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb62031e-1a6c-42cc-8feb-634818eb37e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb62031e-1a6c-42cc-8feb-634818eb37e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ffd50e9-a337-44ec-8bfa-70825314cace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ffd50e9-a337-44ec-8bfa-70825314cace" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae9c5f92-62f0-4e1e-b857-5a4b580fe302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae9c5f92-62f0-4e1e-b857-5a4b580fe302" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8083ce79-cf2e-4199-ad62-cf4f9eeaaf6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8083ce79-cf2e-4199-ad62-cf4f9eeaaf6d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_48f023fd-aca9-4b5c-a719-263114016880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_48f023fd-aca9-4b5c-a719-263114016880" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1945bcd8-aa10-4d1d-88d0-1811c68a8b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1945bcd8-aa10-4d1d-88d0-1811c68a8b2d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17ff77b8-bdf9-44a6-97d7-6a8776a09690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17ff77b8-bdf9-44a6-97d7-6a8776a09690" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cef084dc-4a51-4d39-9388-97a9571740c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cef084dc-4a51-4d39-9388-97a9571740c7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9f17bef3-532a-40a4-a07d-d3f228af9af3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9f17bef3-532a-40a4-a07d-d3f228af9af3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:to="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97cc5fae-513e-4baf-9997-895aed7f2700_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97cc5fae-513e-4baf-9997-895aed7f2700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa4f887c-5e8d-4b25-a554-1f2ef5e6824c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa4f887c-5e8d-4b25-a554-1f2ef5e6824c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended" id="i931ea746cb6d41e6af6ca89916f90e5c_73ab5bc1-ac23-4c73-b870-b5de17d461de">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd1ddc52-2cbb-4f1f-811c-c8e4cb2007cb" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd1ddc52-2cbb-4f1f-811c-c8e4cb2007cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_829c8f1f-11ac-461f-ae10-4318d4bbc268" xlink:href="lxrx-20191231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_829c8f1f-11ac-461f-ae10-4318d4bbc268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c87f729d-b505-4196-849b-9d4a36ef7316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c87f729d-b505-4196-849b-9d4a36ef7316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_addb3f08-f512-451e-b35d-78b2c03736ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:to="loc_us-gaap_PlanNameDomain_addb3f08-f512-451e-b35d-78b2c03736ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_658c4777-1404-4935-bd06-2d894ae35ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:to="loc_us-gaap_PlanNameDomain_658c4777-1404-4935-bd06-2d894ae35ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20507e9-b56d-47fb-90c6-6999531fa02d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f20507e9-b56d-47fb-90c6-6999531fa02d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1231b748-7cbe-46bb-baf1-886b9f684b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1231b748-7cbe-46bb-baf1-886b9f684b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ced95b7d-0850-4a2b-96d2-10fe99ca5739_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:to="loc_us-gaap_ClassOfStockDomain_ced95b7d-0850-4a2b-96d2-10fe99ca5739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ed694f4-05d4-4b9a-887a-3490fd4d2a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:to="loc_us-gaap_ClassOfStockDomain_8ed694f4-05d4-4b9a-887a-3490fd4d2a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2536105e-154e-4cfa-a478-1538c02040c0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:to="loc_srt_RangeMember_2536105e-154e-4cfa-a478-1538c02040c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b614979e-40ee-4daf-b027-c2d3f93891b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:to="loc_srt_RangeMember_b614979e-40ee-4daf-b027-c2d3f93891b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended" id="ib9e9d07ab4424b70ab55f0d15891d19c_3cd668c6-d4c8-4638-a766-f078d42b6ee0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05872cc3-2980-4bee-aece-fd154f43adda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05872cc3-2980-4bee-aece-fd154f43adda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_418eac8e-a3a9-4446-8945-e6f1adbfa8de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_418eac8e-a3a9-4446-8945-e6f1adbfa8de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f394ed3-0297-43e1-a355-a6f3be168bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f394ed3-0297-43e1-a355-a6f3be168bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4d0489b-26a3-4d8b-abc2-89563509bb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4d0489b-26a3-4d8b-abc2-89563509bb4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3b43c2dc-27d9-4883-80d9-92724b79f557" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3b43c2dc-27d9-4883-80d9-92724b79f557" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d0266a2-6b87-4cfb-826e-adf0b7ee4b22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d0266a2-6b87-4cfb-826e-adf0b7ee4b22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3de8e933-4e78-4e89-9f5e-cff8d59e09da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3de8e933-4e78-4e89-9f5e-cff8d59e09da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_2d479094-4444-4165-b2cd-058b1a21959d" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_2d479094-4444-4165-b2cd-058b1a21959d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:to="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a50ce0-f9d1-4345-b806-4979e4b4bf88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a50ce0-f9d1-4345-b806-4979e4b4bf88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_503b0bee-7147-480c-ad25-d76e6234b7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_503b0bee-7147-480c-ad25-d76e6234b7e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlan"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended" id="ice927283461e4c4bb9fdba5ec2055d2d_14e49c83-391f-4839-b4f9-764680a59a78"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended" id="iaf3fb8399dfc4d3682cd0372b7cb8e40_0df6b6dd-85f7-4def-9eb6-7543755db3a3"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended" id="i5b7f21dcc26148c39487471028f0f657_325c55d9-f4b5-474f-a8ef-70db5a78f54b"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="i73f53a55e73b4ec19606f586b077f1ae_87f2a6fb-5a5e-446f-8df4-1ff900413317"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i8bf79f53c178495f97fd879f96e5ed57_85efac77-18a1-4730-b8b6-45de72377042">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_70c5b590-736c-4bf3-8b39-1e03adce94c0" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:to="loc_lxrx_SettlementPaymentFromTermination_70c5b590-736c-4bf3-8b39-1e03adce94c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:to="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f6f0dd42-197f-49e9-9adf-edbb643fc337_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f6f0dd42-197f-49e9-9adf-edbb643fc337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_07ae89ad-9dd0-48cc-9eeb-9fd7c4d6d636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:to="loc_us-gaap_SubsequentEventMember_07ae89ad-9dd0-48cc-9eeb-9fd7c4d6d636" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended" id="i30c9b401239c46a28869f8c496226b5a_8011ec22-d1e8-4e73-8942-88e6e9ba673b"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended" id="i454c77f374eb44418df80bac7467dfe3_f653d7ea-650e-48f1-aa00-da72aa23967f"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended" id="ia3ca8c27c9be4095802b21eff52c42b0_ed4616b3-0172-4032-a0a4-a65119436a8e"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" id="i03c433ca38944eb1942457e55493f30f_abb440bb-5889-492d-bee9-d19bb0b73849"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="i08f7f47fa7844883a0c2dfb22c488d18_c03a5545-21e6-4ce7-a39d-92b03d85d72d"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended" id="iab31fc0b34b341579dece6677b2626f4_547dfb33-f992-44e3-848f-108f64b68cb6">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_58b970ea-c6e0-43b9-80f8-9b8748a385c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_Revenues_58b970ea-c6e0-43b9-80f8-9b8748a385c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5634857e-b844-49ad-9c23-fda6e45f9cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_OperatingIncomeLoss_5634857e-b844-49ad-9c23-fda6e45f9cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb979920-5245-4d34-8919-ea0c971a5454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_NetIncomeLoss_eb979920-5245-4d34-8919-ea0c971a5454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_09289830-d592-4dfb-b8c9-93c4d929deb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_09289830-d592-4dfb-b8c9-93c4d929deb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_882f3bd8-332b-4a22-9ca6-36fe411f62a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_882f3bd8-332b-4a22-9ca6-36fe411f62a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d024f0e8-e89d-4d26-b98c-2b52e7ef2bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d024f0e8-e89d-4d26-b98c-2b52e7ef2bfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3045be8-1548-4e49-a29c-e41addc1ea8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3045be8-1548-4e49-a29c-e41addc1ea8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3feedc04-9323-4b35-adeb-42a69ff859c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3feedc04-9323-4b35-adeb-42a69ff859c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_764c59c8-bff4-48c0-9ac2-6f153d37df85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareBasic_764c59c8-bff4-48c0-9ac2-6f153d37df85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80dff2e7-6615-415d-af97-309e436cd685_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80dff2e7-6615-415d-af97-309e436cd685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dddbaa12-0bf0-4206-8852-7ca89c06be6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dddbaa12-0bf0-4206-8852-7ca89c06be6f" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>lxrx-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37f45f78-d5e7-4c2e-925a-2bc8bac2a79e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7da376a1-f92d-4f58-9ad1-63f82d324fd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_7efc5e57-abe3-4416-bb27-d3fd743e1b10_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4f4e9498-0f48-42c9-9fb4-a8610f267264_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_39a62829-c175-49ec-b5cc-5c1bfb69ae54_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f781c10b-86b0-4091-a08c-02e27b635472_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_13690aef-1718-4d1c-ac91-57cf2b2327b8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e328f460-62a8-4c2c-9d11-6d9e70cf4ad8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_3e1d9aef-4908-4b92-88a1-4224728cd235_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6afad005-883c-4a14-929e-a046962a03df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_edd244c3-1bc3-49f0-ad96-6fad3516afcf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_93350a53-6825-42ec-aa73-533b238e741b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_864e9240-0dd8-48be-b22e-3d51e12ef1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6820741f-eb0c-415f-ad08-ba44420c86bf_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentObligation_50fa0a7d-ca18-4736-81b0-7de548d780ed_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment Obligation</link:label>
    <link:label id="lab_lxrx_SettlementPaymentObligation_label_en-US" xlink:label="lab_lxrx_SettlementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment Obligation</link:label>
    <link:label id="lab_lxrx_SettlementPaymentObligation_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentObligation" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentObligation" xlink:to="lab_lxrx_SettlementPaymentObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_85290278-df21-4950-90e1-985dd5f9ef37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_34734ce4-becf-4ac4-bbe0-9ca7b13cb5b8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_99d3742d-d85a-4668-87ac-506c9af665f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BuildingsCollateral_1b317575-8893-4ada-9400-4fae0c407209_terseLabel_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_label_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_documentation_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The buildings that serve as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral" xlink:href="lxrx-20191231.xsd#lxrx_BuildingsCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BuildingsCollateral" xlink:to="lab_lxrx_BuildingsCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_592c10ae-79d9-4f3a-86ae-1828f192629d_negatedTerseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_396def0d-7989-45a7-96a4-1d99331aa9af_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:to="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_16dc381a-50f2-4af8-a284-5eb1beb5d110_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_bd0751a5-1526-42a9-bb39-5c349ed31360_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_99f08767-5296-40cf-b4ac-e61c3e232c4c_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac4626df-6bef-45b4-8f7f-82a9b3b1cfd9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2be485e9-1d91-4876-9e7f-e9603559bc35_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7ad62726-7521-4e6a-b928-f9e61357002b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_4e381409-c206-4df2-a97e-3fc3fc699f95_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_52b74281-ce34-4263-b609-7094cdd6760c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_bee63f54-c7c8-4438-a251-b91f9daf98fe_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercial milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b0649575-ae9f-4a0a-8b04-20322b157bd2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0f5198c2-9e31-4eb2-8399-5c1724b789c1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_46fa865d-8443-4d14-b6b1-f94683c6f15d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d2917f2d-80dd-411d-ba00-1a807f25a070_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1436cb15-366c-4955-a3d9-41c4cc5dce03_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_14762148-05e8-47f5-b419-1a9f6140b9cd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0d55d18c-81fb-4450-aee1-5652bdcdc466_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_faa2851d-b108-45e8-b4f8-f8a723d8163d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_53791c08-084d-4eca-98f1-0a660ef6df81_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8b4e24fa-36b0-4e3f-b114-5e9c5eb0977f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3147c9cb-6171-48e5-a51f-031b8b5cc939_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_54e0f831-6b69-4b27-9348-ccff7fd41d33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_61fa14c6-b7f1-46af-acaf-ede339c3d7c1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_56814385-e88e-4014-9e6b-ce1c2633fe5c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_dc7aa233-1d38-4af8-a70f-a8c4eb6bbe50_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_4b5d3508-0b7a-47ba-830f-834bba89a8a8_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f329a270-7101-4bdb-9085-e990bd821147_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_df6856ac-3214-4920-beb9-3398009d86a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_221adce2-1541-4ba2-9490-1c51c53d9672_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_bb50aa30-706b-4623-8c18-58fbd834ac88_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers attributed to France as a percentage of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_58934467-d27e-4fb7-af75-13a004921a79_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_53700da8-41be-4ef3-aa6b-83346652a8e6_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e7836608-d62a-4409-91e2-524f6419aac2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_84a13e12-395d-44c0-8772-4bc6e592c329_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7c6abd8b-5dca-4cd1-9aab-d8a44fbe8704_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_82a19da0-f0a5-46a1-98f0-ac1bbc19e114_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_1ee734a6-f364-4555-9ed4-84e2ca62a47b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbc655e0-9110-415c-91bc-4b1f5b25a217_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1196b3b4-062f-4e5e-a42e-a2a94a5a7e48_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_708e4f84-d20e-4cab-beb9-d71cfc8ada21_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_691c9cd4-af4a-4468-aca2-2a792bfef0ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity (Deficit):</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6ec30c49-1f45-436e-9ddd-215d8e36cfb5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f1ac38cc-2909-4575-a494-b19662855f92_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c30e2490-bc30-447f-b413-0cd38d03e784_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_381d62b3-1e82-479a-b65d-a9b9f8c2a0db_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of gain or loss on extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_f8821d92-50b0-459e-bf66-150216a869f7_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_95af92fd-4efe-4ff0-ab96-086bdbeb0419_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_766c429d-8d5f-4ca3-88ab-05e89c22bff5_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3447e89a-c1f7-4fbf-80c3-a9cfdf07e911_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f4b948f4-9a68-4bda-9121-c5f35ae78bfa_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_52978a4f-855f-4be6-92e5-a79379bebe50_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e9d6ce9d-1415-40d7-8c02-c34e5e919587_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8431f3a0-cc8b-40ae-a867-212af2fbc019_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_d6d75567-e5ac-44d1-8de7-950c7fe20348_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FederalNetOperatingLossChange_8c056445-3ccb-4b74-87c7-eda0c01659e1_terseLabel_en-US" xlink:label="lab_lxrx_FederalNetOperatingLossChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Change</link:label>
    <link:label id="lab_lxrx_FederalNetOperatingLossChange_label_en-US" xlink:label="lab_lxrx_FederalNetOperatingLossChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Change</link:label>
    <link:label id="lab_lxrx_FederalNetOperatingLossChange_documentation_en-US" xlink:label="lab_lxrx_FederalNetOperatingLossChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FederalNetOperatingLossChange" xlink:href="lxrx-20191231.xsd#lxrx_FederalNetOperatingLossChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FederalNetOperatingLossChange" xlink:to="lab_lxrx_FederalNetOperatingLossChange" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_762c9ac7-ff84-4517-b221-c26daaed7cf4_terseLabel_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXDiplomatcustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:href="lxrx-20191231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXDiplomatcustomerconcentration" xlink:to="lab_lxrx_LXRXDiplomatcustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_911bf000-d277-4582-a768-859848608696_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Sanofi Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueSanofiPercentage_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:href="lxrx-20191231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueSanofiPercentage" xlink:to="lab_lxrx_EntityWideRevenueSanofiPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_4e9cf201-cc72-4ce1-8e03-cc38493bc30c_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5ee88789-16da-4477-b500-190879a8d856_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f4e66286-32c2-48cc-b92a-5e37f1f47241_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_4a922ad6-a02e-4be9-976a-0469f6154315_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_2a81ee89-33a6-4d2b-bd47-784ab9784263_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_564b30a1-c1a4-4165-843b-55987969cc7a_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f5f52ebf-6290-4ad7-a884-c9c131337c57_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_39df911d-3db0-4e01-9fa6-7afe96b57293_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a74e0a7f-c1ca-40d2-8bb7-e78be40dbf4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_0b674e97-b9c9-4e72-ae0a-90afa9b8b80c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_65053e46-db90-4f32-828b-ae76f455469b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_1d8682e1-b795-463d-ab78-ada88829abf2_terseLabel_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_label_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_documentation_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:href="lxrx-20191231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract" xlink:to="lab_lxrx_CommitmentsAndContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_872495e8-a2fa-4687-bfc4-077fe76130cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_96635708-fb85-4b00-91ab-6c1ac39b6b58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 407 and 236 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ce595e97-7350-4ef5-b21f-7b194160fda0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_d965fb11-a294-4699-9ed7-43aa8b5532b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0165636a-e511-4a11-850e-1656d8d27fab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_165487e9-82db-4029-a84c-4bcd3d4898f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_24638908-2adb-4199-a016-011a5ac3925c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22f2e5a1-95b0-4596-b0cb-97c9dfa6b42e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_aa34b835-90f7-49f5-8138-40a6fae57ec9_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_589c5fe5-9272-4e88-b3a6-f0775f624165_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a0590d05-f361-4012-99a7-59ff662fb8d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_fa1fcf6d-b12f-4772-bb5a-68ecd9164fa5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bbe71812-be80-44ee-a9b8-2f52621cb999_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b371d570-5066-4ed6-897d-bc34c9791ce3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c9deb7c4-faaa-4429-ae2a-247bf9811f95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de19045b-0259-4dbb-928f-951f10af2a5c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_dc0aa0c4-b039-445c-b595-68592711f7fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_abf08773-ddae-437c-b817-2f32f48f4cc8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ff5f26a8-ee8a-41b2-8fe9-0367acf160d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90d284a3-af7a-48d2-82a8-241e657e175c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_686a6739-68d8-4e7a-b8d0-57ecc3535384_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_00caa73a-85ee-465f-9e2c-ec719fb2460d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_38a698c4-aa00-4a7c-a4fc-43ad1db10bc8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e4dc4ba9-8eef-4a72-83dd-28b68eb1bfc3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_8301c363-276d-4ad9-ac08-a0bab5d301e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b699ca1f-6371-4647-b958-2eb279d78c17_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f883b129-96c2-41f1-b82e-773c631e927b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_30167faf-b87a-41ff-925b-37e6f0647fd2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5661dad5-8afc-43c6-ace5-d051e7b82c4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_243ee4c8-ba3d-4a46-8189-62259d2311d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7bd8f8db-a2e6-486f-b834-fc4372e072cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Ipsenproductsales_3157e1d2-54f7-4bdc-b75d-5ea05535fc70_terseLabel_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_label_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen product sales</link:label>
    <link:label id="lab_lxrx_Ipsenproductsales_documentation_en-US" xlink:label="lab_lxrx_Ipsenproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales" xlink:href="lxrx-20191231.xsd#lxrx_Ipsenproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Ipsenproductsales" xlink:to="lab_lxrx_Ipsenproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f9eaf5e1-b2ac-4273-96da-c3f333b1433d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ff27b0e6-837d-497f-851f-b5652132329a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_69320bc6-e849-4bb9-8aaf-6d20b2d960fd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4e702999-722d-4368-bf29-9bda9a1ae7a2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_557f674e-374f-405b-850c-23ffeb4e426d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PriorYearReclassOfAccrual_6e8f3ba1-5162-48cb-ab16-f5fedef1f9f0_terseLabel_en-US" xlink:label="lab_lxrx_PriorYearReclassOfAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Reclass of Accrual</link:label>
    <link:label id="lab_lxrx_PriorYearReclassOfAccrual_label_en-US" xlink:label="lab_lxrx_PriorYearReclassOfAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Reclass of Accrual</link:label>
    <link:label id="lab_lxrx_PriorYearReclassOfAccrual_documentation_en-US" xlink:label="lab_lxrx_PriorYearReclassOfAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Reclass of Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PriorYearReclassOfAccrual" xlink:href="lxrx-20191231.xsd#lxrx_PriorYearReclassOfAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PriorYearReclassOfAccrual" xlink:to="lab_lxrx_PriorYearReclassOfAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_e116b650-a8ff-4cef-802a-c6c148f8fb4e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b994f899-6594-48bb-bfc7-00db4644bf4a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_decb1e7a-f354-4364-90fe-9d78d076d83d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_646788ce-cd4e-4155-8e23-771256c1ab42_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_22c3d2ab-d407-4a83-b799-1dc105eeb9c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a1a81cdc-a77b-4726-bf76-0608f6e4a1ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_520fd8f0-50fe-45d8-8fd8-6d0f9c2d1fe8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_82240bc1-a56b-4e0b-befd-e0a01f14f3bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $4</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_fdd03427-a497-4824-a59d-b5b3319db53e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_1aa98123-0d8f-4c68-b457-cd8bbf4d4f98_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_693b4da0-43ef-4e76-ab60-02d08d3f5e2f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cc549dbe-e105-4ccd-a6ca-473978fd37d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_20e5de4c-9916-4704-a9af-d69a9d82fc1c_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_label_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments To Date</link:label>
    <link:label id="lab_lxrx_IpsenTotalPaymentsToDate_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPaymentsToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate" xlink:href="lxrx-20191231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPaymentsToDate" xlink:to="lab_lxrx_IpsenTotalPaymentsToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthGoodwill_095faa30-bb62-4a77-84cf-af00070a0832_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_label_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_documentation_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill" xlink:href="lxrx-20191231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthGoodwill" xlink:to="lab_lxrx_CoelacanthGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_18cf2bb6-3441-42a8-8e8e-6f5fbf24b44e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_19813615-f5e7-446d-ab20-f2f4d0bcfc3e_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments to Symphony Icon Holdings in the form of cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyContingentPaymentInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentInCash" xlink:to="lab_lxrx_SymphonyContingentPaymentInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ef6e18a4-3171-4a3d-b701-ed895e34741c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cfc9dc39-cc28-4a78-9f93-31156d26e771_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_11751db4-9300-47d3-a9f6-7d669ff88e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cf820a53-78a5-429c-a9e9-54854c0b5a52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_523b86a3-dd6f-499b-8796-bc25f4d7f7e3_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:to="lab_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_0fd8e259-e80a-485a-bca5-d4387cca474b_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_515788ca-6a2b-4337-b2ae-4de58753c63d_terseLabel_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_label_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Sales Milestone Payments</link:label>
    <link:label id="lab_lxrx_SanofiSalesMilestonePayments_documentation_en-US" xlink:label="lab_lxrx_SanofiSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments" xlink:href="lxrx-20191231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiSalesMilestonePayments" xlink:to="lab_lxrx_SanofiSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c50b36e3-f061-487f-8e8d-5d62035a3314_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f5e6de3a-70f7-4c82-91cb-b9a41f9cdcfe_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f5e6e3eb-c020-4a12-b26c-3a85c7c06df2_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_18f8836e-093c-4e3d-8f4d-6c5cabe4c04e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d20f8de9-9666-44d1-9c15-6606a8f50b47_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2dcec39e-7036-4eab-9647-4d51bee17b6e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_ab20bcb7-e3d7-4d3e-b3dd-d080898e940d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2bb810ab-a842-446a-996b-9a67522f3075_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_78397bb8-9de6-4c8e-a6a0-112300616dda_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_212e0ebc-2f14-4a43-b857-1315c93a9219_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6b0a410b-bc09-4c96-a22c-9b0132572c76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4013238-7973-4214-9812-ebe36a9a4e40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ca2d3bd-41ab-4a06-840e-23b82f7f5cd4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_d360d898-1c34-409f-8910-f78ea03f48fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7f9433b1-6d65-45af-9886-cee5eb74f2c1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_b30fc5f4-5e46-41ad-ae0c-2c5422d643ef_terseLabel_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_label_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:label id="lab_lxrx_PresentValueOfFutureLeasePayments_documentation_en-US" xlink:label="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present Value of Future Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:href="lxrx-20191231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PresentValueOfFutureLeasePayments" xlink:to="lab_lxrx_PresentValueOfFutureLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_83dfed28-d781-4e7b-9180-9c1fad058c1b_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cd3769a2-0eae-4966-b809-26c05083c4c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c96451ab-a78f-4c9f-afd4-d7a45c65d246_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9191f98b-7fa6-413b-9ff1-0054c57f1ddf_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_04f1cf48-a7e6-444e-ac91-7926337a584a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_b667fe17-7b38-4536-911f-b0b672f586db_terseLabel_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_label_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration</link:label>
    <link:label id="lab_lxrx_LXRXBiologicscustomerconcentration_documentation_en-US" xlink:label="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:href="lxrx-20191231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LXRXBiologicscustomerconcentration" xlink:to="lab_lxrx_LXRXBiologicscustomerconcentration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_1b535b53-bbe6-4563-aba3-576665555756_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_bf908c86-b74e-4b0e-8151-820a33f3f73f_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments" xlink:href="lxrx-20191231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6b929924-f7a6-4de8-aed3-ae1b12628171_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment_bbe02a82-88af-4f38-bb5a-fc1598bb045b_terseLabel_en-US" xlink:label="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment</link:label>
    <link:label id="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment_label_en-US" xlink:label="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment</link:label>
    <link:label id="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment_documentation_en-US" xlink:label="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:href="lxrx-20191231.xsd#lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:to="lab_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_dfc36f7b-389b-4b79-b736-fcf79ae77930_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4ce71903-98a5-4488-9a9a-4b8b8521b809_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c97194a2-c70b-4564-8c03-0284ba58dad2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8743bca9-4fff-4b11-9554-33e1029511d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2951beb2-3300-42dc-ab47-ba29105f2e73_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_02c2e670-40b9-4e4a-a4e7-809b1d6577d8_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_f6679c83-b230-4c30-b1b2-470194007299_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_917777b0-2bb0-45fd-801f-9e094356f6a3_verboseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in satisfaction of Symphony Icon base payment obligation</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_label_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued to Symphony Designees, Value</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:to="lab_lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_cabcb64d-c20f-47dc-891b-a7ce70e965a4_terseLabel_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_label_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Commercialization Costs Funded by Lexicon Maximum Amount</link:label>
    <link:label id="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_documentation_en-US" xlink:label="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:href="lxrx-20191231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:to="lab_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_1f503d3d-0b57-46c0-8d06-fe16c84316f2_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_369beff3-6d76-4b1e-9403-404e6d0c3283_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e5902b33-4d50-478c-9ff3-d40c48d71823_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c8c2bec9-23e3-4cf3-9c97-a2c59f19a34f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_aa6f4b97-964c-405f-a42b-839dc0f48012_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7076bc96-44d1-4c31-a2fb-834650a9923d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_09b3627c-bd1e-4884-aefd-b82c5dde925a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_878e774e-bded-4f9a-bbdf-7863f48ea0d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_cf51acd3-177e-4f7d-8e25-ab6d90c55fff_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_910693f2-b465-45d7-b2e5-34504d6ec91c_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8b552ec4-411a-4c08-ab4c-fa3495649a65_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_c701728f-4602-4dca-87d0-4ebafcb61c2f_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2d1a185d-98d1-4348-aa3b-4fb1b361eef9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_824841cd-fabb-46ce-a7f8-18e69ca9f3a7_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9c3b2fe0-b469-4de2-b205-8dc21e5b7287_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_16d945c3-69dc-4c1f-a1c5-64e8a8330841_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_22f16f26-412d-40bb-99e1-0f81f3e0bd3d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b45b3167-6e77-4faa-94d4-0f973cc13d7b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_eda0455a-6aa4-4dcf-b331-a6c4b98fd6d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9b15fede-ffc1-4378-aeea-38afed701f5e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_c54e9070-bf4d-46fc-8809-44c8078aca54_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_11ea7826-3907-4f52-aa1a-3cafae93b9b3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1bbe7f2f-0f65-4ed5-99ad-83f2532d7c0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Federal</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_09ce7e5a-4cc5-402f-9502-7b9eadbb0cb0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a83695d6-6062-47b5-bc7a-c5fc0deebe5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_5d4e9751-c528-4a5a-a2ee-d47413303032_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_235f503e-621a-46d9-bcb9-977428b9a324_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0cea88b5-6f79-41e6-8026-b5487c3bc74a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_99b35511-cc70-4932-88cc-5ce9bce6bd1f_terseLabel_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_label_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Outcomes Study Milestone</link:label>
    <link:label id="lab_lxrx_SanofiOutcomesStudyMilestone_documentation_en-US" xlink:label="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:href="lxrx-20191231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiOutcomesStudyMilestone" xlink:to="lab_lxrx_SanofiOutcomesStudyMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_d238a700-983e-4725-a52b-138902c29e06_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_211c9ce5-ba72-435c-b08c-5400f6715fe4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1e7cdcf5-800b-48cd-8db9-efe627754c30_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f1d544a0-9a9b-4550-a7fd-ae76180fcd1e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5aad55e8-321c-4075-83af-9235119fa798_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a508b10a-b649-4121-afb1-9bf573eca1f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_6c9d64d1-9a59-4c63-a84e-c8c00cdb4975_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_35e684c6-e7b1-4026-bc45-0616aa7bf72a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b99fa623-549e-41a8-9bbe-556e9ed5725b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5e7d9f85-24c8-4ef3-b0e7-a35c48fde65c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4878b70d-55c0-4d60-822c-9c8524fc0593_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_5440d126-9fab-45d3-8486-a11e8473beb3_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_label_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_documentation_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice" xlink:href="lxrx-20191231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthPurchasePrice" xlink:to="lab_lxrx_CoelacanthPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_843285dd-c923-4b1a-85e8-232f55df4120_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ae616264-e779-4388-b30c-8e19fdec21c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_38ce3ed6-3487-40da-8817-ceda81fa16fc_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_e7449f38-9171-45c8-8f40-cb7ca8643e2e_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_SanofiRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRegulatoryMilestones" xlink:to="lab_lxrx_SanofiRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_214ea339-3dba-4aa3-825d-609c3e9e3a32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f0a14dd1-69ce-4954-9338-4eaa0d6728e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca2f6051-3fba-40e9-abb8-69985956cd0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a575277d-b87f-4053-922d-7c21b8db2b81_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_ee856d69-5c4e-4a25-a6fa-70853abf5f14_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d9e86b1f-c213-4a57-b692-8db5301a03b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_b2275eaa-659f-4255-b03a-ad7f352a3988_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5ecc8531-3475-4a8e-9a13-8651f7f957aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_21780681-853d-4154-a8cc-66b06b960188_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_2487d976-c103-4278-b5e1-d0fc554b4a57_terseLabel_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_label_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:label id="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_documentation_en-US" xlink:label="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement With Individual, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:href="lxrx-20191231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:to="lab_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9db4ebc1-f260-4316-a5e8-ccc7bd7a84ea_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_9734ae7e-abf6-4ca7-9636-d8cc41847ff1_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage" xlink:href="lxrx-20191231.xsd#lxrx_EntityWideRevenueIpsenPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueIpsenPercentage" xlink:to="lab_lxrx_EntityWideRevenueIpsenPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f9032c3c-6a39-42d2-85f5-f74c8278307f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_f83569db-2775-42f7-b1dc-233e43f8440a_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_0296c8bb-73c9-4185-83b2-4e72c30a3a09_verboseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5e4c686b-bd03-4f74-9055-56162206c1b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_94962f1c-9c55-4a3b-87e1-1f9bba260c12_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Policy</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_288c0acf-aad7-4800-a55d-171e144940b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e987862b-26e9-4ded-86a7-846de7458b88_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_37cffd7e-da32-47f5-b356-61e231796206_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c442c885-d4ca-49ac-97e1-b8b8c386785c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_32ecf02e-1a1f-44e1-abdb-582ac941d8d1_terseLabel_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of Symphony Icon, Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_label_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Symphony Icon Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_documentation_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:to="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b9e26e97-462e-4726-8208-8f4f1fbbd3ab_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_5e94657b-582c-4826-b83b-d257d60837ed_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase shares outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:to="lab_lxrx_OptionsOutstandingEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_36d79d3c-e7a8-42a2-953b-bbbdf8262278_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_756a912f-61a7-4fb3-be40-388f14890b18_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_5117f5f1-ed07-4ae4-9d9c-24c559f13239_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and Other Accounts Receivable, Policy</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fe3f4db5-d891-4b99-8a55-6d3ebda8ff7b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_87bedf01-05ac-4834-b5ed-a512a42928bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_423637c7-6688-48f1-ae21-95afa378756c_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_2476e000-6eb3-4663-ba5c-3ab1a403f5b8_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_28859a51-ad52-433c-8e2d-588cf45d047a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_360574cc-a2bf-487a-92a2-1c837b5f5c82_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77202920-b79e-4b0b-a9bb-994c8b47e3df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_e196dc34-64a7-423b-aa02-9fe3e2722a1e_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5d69a9e3-d048-4ea8-9dde-5919d5834068_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_cc5ce627-d672-4c24-b5dd-3703889d6d35_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX</link:label>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_label_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX</link:label>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_documentation_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRoyaltyIncome_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRoyaltyIncome_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRoyaltyIncome_LXRX" xlink:to="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f8c49e2-c13f-4232-83fb-ec5813461b0d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_d4cc4632-8096-4bd7-9073-c45f3c0d994c_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:href="lxrx-20191231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_584ef3f3-c1fc-4b48-9f92-2b6ad8ac4e27_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6f152e89-4033-4655-8bb7-d06e42fbab32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_06ad9622-a4bf-4886-8518-70b6d0aac164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_1fa6727f-e89d-4269-8490-8b24c94aee29_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to Funding Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoFundingDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_49ce1f06-a1ac-4ff7-8057-bb4863b1ffd0_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5d47b3fd-76a1-46e3-8b09-c6c4a53d0b5b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_4a609998-b984-4196-a072-16372d78a413_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a311b9f5-f1a8-4554-8e91-abb79986b65b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e3c80d87-a65f-494a-9cef-28023602e605_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_afcbf7c4-ab79-4e8e-898d-92cc700a0a31_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_b5ee2fb3-9c7f-4474-8991-02b18d085292_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_label_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX</link:label>
    <link:label id="lab_lxrx_DeferredTaxAssetsSection163j_LXRX_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:to="lab_lxrx_DeferredTaxAssetsSection163j_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_f8cd1839-5ff4-426e-9099-967049023c41_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3899440e-a5b9-4419-8959-f0a5b4e9da3d_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4813f3e9-8193-4c7a-9e51-c792699b4a15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_29a289a8-a914-4418-a91f-1c225a73de93_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_4ea08a92-65f3-46c2-b02c-7be287797aad_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_731bb71f-82ac-4fcb-a0ea-f73916bb36bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_011433f8-007d-454b-9ab5-99d50abbee52_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_940e2584-c61b-4828-b2f0-55140e9983e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_259bd8d0-bdb1-4530-acb2-e6a399c3db5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_fe754b43-3aa2-4728-979b-9a9eb033c7fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fcb929b0-9ed0-422e-9c36-c467960f0749_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ae4a842d-68ed-4261-9b5f-fe46d57010ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0172a5c3-b335-4a85-b19f-c451255081b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1c3ff88-d074-41b4-96e7-de401b4f8408_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_31bf366b-3471-490e-9610-beba85a91300_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20191231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_890c4943-2b9b-4a17-aa69-41c08af13b9f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_419e7e1b-6635-455b-986e-de0ea84ea205_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_94fd873b-7daf-4dc7-9de1-5497ef1d9139_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_adcdfd51-4ca9-4e98-9821-3af293a53d6f_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_0726b7d3-f1b9-4852-a586-cf76b89452b1_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bcd55141-2c5f-446a-b685-fe3457ad51a2_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_42c2d599-5597-4f89-95ec-bbd6278cd5b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_40874669-9466-42e5-bbd6-7f5183cdffe5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e9c062ed-b97e-4715-ad98-9170757d3091_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_63e3cab3-0e1a-4c3f-a39e-a6000a2accef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_40dcf6e4-cd70-4b57-ae91-873d37ba11ad_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_a223c684-a676-4111-a306-48450917b51f_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_5151359b-573a-4a56-af1b-3638dd1781fe_terseLabel_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase price</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_label_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:label id="lab_lxrx_DebtInstrumentRepurchasePercentage_documentation_en-US" xlink:label="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:href="lxrx-20191231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtInstrumentRepurchasePercentage" xlink:to="lab_lxrx_DebtInstrumentRepurchasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_4d0cb633-c011-450c-aa98-9f2736d8a504_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_92bf15f9-8967-4790-b14f-137b1d12a5a7_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_7fadd375-278e-4d39-a3a3-214062893c7c_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Intangible Asset - Upon approval by FDA, the indefinite-lived intangible asset was reclassified finite-lived asset and the tax effect was to book to a deferred tax liability with offset to accumulated deferred tax benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:to="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_b41eedd5-0f84-4f41-ba47-953093edd4c1_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_06345309-7e36-4178-8dbb-23da329d2827_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_23c004dd-d2b7-4291-b31b-c11146ceabb3_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_12817f31-9201-4d32-b24c-25b2ab7c03ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42dec202-04be-4117-bb30-15e7727911c7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b1eebe81-4a4b-4bde-b6dc-b6b817d5a7c0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b953307c-1c09-46e9-bfaa-792b2bc777e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_52dbdca3-f69f-41dd-9307-942a20930077_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of regulatory milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8dec2946-31a4-419e-b111-dafb20bfe41a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_37af6684-779e-48b1-8184-c8cf7ef95998_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_25b1dba2-268f-43b7-b24d-61193cce0039_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c0438895-8fed-4d4f-9d86-ef15f5afb077_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_487c69f4-9416-4017-bef2-778e0b53d7f3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_261c8ff4-da48-4199-a7c6-f6f5a19f7199_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_0d53787b-cf29-4b45-87fc-4b50803f42be_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9e6070a2-d6f4-43c7-8b35-d5074fb424c5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_52356810-281a-4a3e-aa05-82cc85b4bbdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_43b13c76-1209-4a36-a13c-6a1fa8238592_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_4e359ed7-eecf-4f55-b9fe-3a251160afac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_c77c7dbf-4081-4cff-95bb-d5a3b869adc9_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_be9b4b12-1d37-4252-8029-db190cb53b34_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_05f6ff6c-661a-4367-a0ea-3667cfc3ddc2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_32eb6a9c-2cda-4f2c-a33f-c6e9fc1331e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c3d18693-f987-446c-85ba-1b95435137f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_323c1988-4b9d-46a0-b41d-f96169b3d894_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_97a45ed9-8878-4825-9eb1-4b5611ddf254_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_e2fd1a7a-d48a-4a11-bd18-4e5e658d1e59_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_603e6440-52c5-4dac-959d-09958559e593_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e42cbed-10f8-47ee-a592-87e487e6c3b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_81bc3dd3-1881-4104-84a4-6b56d75e6918_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a89ac598-eac9-4de2-b7a5-1a920c2bb7e8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f54bb8cc-a484-4de0-9892-f329fe973958_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_43847b2a-5a9f-4ae8-bd45-d879e86d05eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_545bb3ac-4e9b-4497-8a66-9577e83ecbfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6fcfd757-aa3e-42f6-a89e-5077567ca1d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_caab33ae-b602-4d00-aeb7-155c4a41602b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_72686174-1c3d-43e1-a47c-6be7969f51c2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_acb5f1d0-b759-43a1-990e-1055d4902cbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_27087009-a0be-491a-9d53-c79ad58ebc7d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_020b5258-c7d4-4a04-ae4b-f7d0980947ff_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_97bf10ba-84ca-4431-beaa-8162cb006a43_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3af5ed73-3c9f-4de8-ba30-ba3d0fea7f90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_ac8ef44f-9f45-4f0f-9050-c77154d3e2f4_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_473fec6c-7456-40bb-9f2e-7f83ee2ca4ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_089b62e5-dc0e-42c6-90f8-4a2c266dc232_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_91607d3b-9afe-42e7-9755-3c9365bf03ef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_b33f444f-9cbd-4fc1-8d79-bfb7ada5ef59_terseLabel_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_label_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year</link:label>
    <link:label id="lab_lxrx_Totalvalueofsharesbynonemployeeinayear_documentation_en-US" xlink:label="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:href="lxrx-20191231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:to="lab_lxrx_Totalvalueofsharesbynonemployeeinayear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_889c97ae-7911-48da-917b-5a71ef04845e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_44640a06-7e6b-4ba5-a901-3bac6adcd363_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e9cad9f6-3e9a-4bf5-91bf-5a7a06d93111_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5f30f45a-8c8c-4bf9-bdd8-05043645016b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LandCollateral_ece05ca5-2196-44ec-b82e-d2f38e9e2298_terseLabel_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_label_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_documentation_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The land that serves as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral" xlink:href="lxrx-20191231.xsd#lxrx_LandCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LandCollateral" xlink:to="lab_lxrx_LandCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_3cd7a362-94b7-4721-8930-81b09f52ac93_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_7a060d5c-b222-4281-9cdd-3f041926b259_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a6e0c94f-0a37-46b2-b109-9a4e1e34d172_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_645c6fd1-4ddd-482a-93bc-8a698f5b1f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6e04c434-eaa4-421c-8ab3-ee7de65c1e57_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3f3b3f69-e676-4437-aadd-3ae692436f2e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GoodwillAbstract_3b3d2ede-bc7c-4a93-8296-8713b4c4eece_terseLabel_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_label_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_documentation_en-US" xlink:label="lab_lxrx_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract" xlink:href="lxrx-20191231.xsd#lxrx_GoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GoodwillAbstract" xlink:to="lab_lxrx_GoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64ba50cb-e6a0-4201-8b70-e60d5800b168_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_813122b8-b43b-4632-b025-736af69ac0db_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_cdce104e-f2a7-443c-b699-164de621897b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5917340e-aeae-4fad-9252-96fe3f37f05e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fdaebed3-343d-4c1e-8a38-c97ebd2878cc_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a9a4ad17-61ba-4e94-96c3-bdec1c5a81b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f229117c-57fe-4987-a3da-a939a8462f51_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e307cab7-7f17-4e4a-8e2c-e4222095c893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d85e41be-69c8-4c9a-be25-6250e8f931c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e62a7d9f-2f7f-4ffb-9f6b-d7b136b9ea74_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_825dca35-7a1f-4f51-8e72-aea380567d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_af88ffee-9f22-4978-9f0b-1ba34e8823f8_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability from Reclassified Indefinite-lived Intangible - remeasured amount calculated using the tax rate of 21 percent from 35 percent and relating to the deferred tax liability associated with the indefinite-lived intangible asset associated with the Symphony Icon acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:to="lab_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_a305f4b8-5434-4165-9a3d-e15bc2144ce6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_7df5cde8-6730-44a8-84fd-5b66f11c2ed4_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_label_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:label id="lab_lxrx_SanofiDeferredRevenueFromTermination_documentation_en-US" xlink:label="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Deferred Revenue from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:href="lxrx-20191231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDeferredRevenueFromTermination" xlink:to="lab_lxrx_SanofiDeferredRevenueFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_a2795609-6c61-44ad-9e08-0b4fa96741c5_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_df3221a9-eb52-4f3f-a3e4-8ecdb1da7961_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aad7e5fa-7f83-4ad7-91f6-720b89adbd25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_31035d7d-73ae-47fc-a2d1-f9100ca42b35_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3666aa1b-9bf5-42fd-9759-bd2175e9caf9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_0ea19e89-2a54-4f59-b9b8-7c86a30b1ee3_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstate_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstate" xlink:to="lab_us-gaap_MortgageLoansOnRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_29a09507-a4e5-4ec6-8678-88044a63a655_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7aaf4091-1afc-4087-8eb5-5cd58c27c361_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5308be5-c3fc-4ef7-87ff-a47b99485edb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b56338a9-c36e-4326-8d3c-9fadad58a573_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_e02ebc58-590e-499c-a05c-9647cf12c310_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_459f7932-275e-4b9f-9333-924f7bf035e5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_aef01096-25e0-4b42-ae33-dbe08dc4a9b7_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_label_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_documentation_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:to="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9e0f0d37-2692-4930-9d18-d762e6901b04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_ca2201b3-d832-4098-ac91-8cfcaf6b8f3e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_da27f7e1-766f-4c1f-8d61-ad27f9013d32_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_b5094a86-5d67-4fcf-b7a4-b7f679768e1f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ca935f87-0ad6-4d9b-9eda-bc76180c7b10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c8e4c9f6-419b-4fae-a19f-614143bac760_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d8906b58-6ba5-4979-957c-928e6f581356_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b00ff64f-eb86-41de-bae5-ca31d4974ff3_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_04c30026-7fdd-469d-9034-6848e14204c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_90e866d5-ab32-4369-be7b-c03405931483_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9474a16c-9680-41ec-9fd4-f281bb918079_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3eec7189-ff95-4acc-a9f6-b49ba9ca2940_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c960f911-df8f-4105-a109-73ae34edd25f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3abecca-e108-4695-bef9-3f7446e21bba_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_0cf41b3b-cb1b-4a8b-bdd7-49ee9ebc057a_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:to="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_4563583f-fe75-45b5-8a62-77e9ea36ff91_terseLabel_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_label_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Upfront Payment</link:label>
    <link:label id="lab_lxrx_SanofiUpfrontPayment_documentation_en-US" xlink:label="lab_lxrx_SanofiUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment" xlink:href="lxrx-20191231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiUpfrontPayment" xlink:to="lab_lxrx_SanofiUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_82aad372-c180-4a4e-9721-cee335678078_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_8cdb4584-4dd6-49e4-8e12-deb9d971fe58_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_b1acc122-7410-4e45-addd-8d2f172056e0_terseLabel_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_label_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_documentation_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract" xlink:to="lab_lxrx_EquityIncentiveAwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_94bc1a0a-6259-410f-b33c-4affc218bdf2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative, including stock-based compensation of $7,122, $5,686, and $4,567, respectively</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5d0f5290-9c16-4d81-a2ec-4bd65a845f36_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_439368d2-ba7e-4fe6-8d76-39d6fa74a987_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_8b50f05c-9d5f-4c02-a331-6731f079a8d2_terseLabel_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years of service</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_label_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:label id="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod_documentation_en-US" xlink:label="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:href="lxrx-20191231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:to="lab_lxrx_DefinedContributionPlanRequisiteServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a682dd6f-6810-4352-97be-48ccfc1aec3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d27c4aee-09e8-4422-a1cd-48466041cd1f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5fb35d3c-8522-47b6-8283-26b2571fb3ff_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_40d64b2d-37a4-401e-bffb-74d1fe864848_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_da06c491-6f04-40ae-bd27-adbad7261d18_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9c5118e8-9e7b-4dc6-9d9b-5f3e55ffe586_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e5ce074c-8160-4782-bf8b-db9c2301fad2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_936eb62a-7ae6-4a8f-8c3f-c2d9555afa4a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_5f71aec2-a80e-4fa5-b377-a9733d4cc79e_terseLabel_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_label_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_documentation_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract" xlink:to="lab_lxrx_BalanceSheetParentheticalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_8744316c-fbcc-44ed-9161-03bc06d127ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_20191313-0539-4a7d-92b1-5d58c278b57e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39123b5e-24f8-4adf-9cfc-4994c27e6eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_04a1933c-ccb0-4509-b553-0e6f97d80801_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2612bba3-85e6-40ac-875e-fc4e574301be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_935f2b3c-e76b-4739-b457-8a133ac7d887_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_8a4b4fe5-6fd9-4eb6-ba9b-8ff0f36e247a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8b199a31-456c-421f-b8f7-ec35ab932e40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_de950261-cb89-4099-85b5-7f15bb04f61b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:to="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cd78c958-b2ea-4095-8793-ac5dc5f26be9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_bd5e01c1-9650-404b-b4db-60136afe2603_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_7372bb40-7a92-47ac-9275-a325745b5cb0_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded commercialization costs</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_60905ff6-e604-4365-bc73-500b87d7e5f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94ed8fa1-9dee-4324-b364-27fffd2d4929_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f24de25-82a9-4184-b004-6933291078af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8da598bc-01de-4347-a99c-7e92292cd2af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0342e433-d62f-4af7-b271-280016abe6b1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48b529fb-1e0d-4c30-8312-918a97972066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5b83d7a5-8f88-49e2-b679-fe640918b946_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f6f7e4d0-cc16-4852-803f-2fd63479f89b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_3deecdbc-bd4b-4a90-be05-d33011cd8bf4_terseLabel_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XERMELO Intangible Assets Finite Lived</link:label>
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_label_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XERMELO Intangible Assets Finite Lived</link:label>
    <link:label id="lab_lxrx_XERMELOIntangibleAssetsFiniteLived_documentation_en-US" xlink:label="lab_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets relating to XERMELO that were reclassified from indefinite-lived to finite-lived once the FDA approved XERMELO.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:href="lxrx-20191231.xsd#lxrx_XERMELOIntangibleAssetsFiniteLived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:to="lab_lxrx_XERMELOIntangibleAssetsFiniteLived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_bf3f77af-3917-415a-bcfb-60f5001df5a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials_44843e6a-50f1-44a4-974b-e52ff2d2218d_terseLabel_en-US" xlink:label="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periot to reflect a lower average per unit cost of materials</link:label>
    <link:label id="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials_label_en-US" xlink:label="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold, Period Reflecting Lower Average Per Unit Cost Of Materials</link:label>
    <link:label id="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials_documentation_en-US" xlink:label="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold, Period Reflecting Lower Average Per Unit Cost Of Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:href="lxrx-20191231.xsd#lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:to="lab_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_523eac84-48cc-4fb6-bc45-0a0330990956_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_d33139ac-fdef-45b8-b91a-ff7a35d75146_terseLabel_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_label_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:label id="lab_lxrx_SanofiTerminationAgreement_documentation_en-US" xlink:label="lab_lxrx_SanofiTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement" xlink:href="lxrx-20191231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiTerminationAgreement" xlink:to="lab_lxrx_SanofiTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_183a6ec5-9eb2-4f49-9165-8a07bea083ae_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9dcb089e-55f4-4cdc-a206-e718ce57385a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_914f34d8-bfdd-4034-8199-7851c96024f9_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BenefitPlanAbstract_3d5001aa-7a35-4527-abb8-c7639d9c7864_terseLabel_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_label_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_documentation_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract" xlink:href="lxrx-20191231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BenefitPlanAbstract" xlink:to="lab_lxrx_BenefitPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_95d382e0-9753-44a6-ae4b-c252afda562e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ab0129e-892d-454d-9626-29d37abb617a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_1ebfeabd-0999-4fd8-8aca-db1818d120e5_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_137a605a-d0e7-49c2-ad9e-681c8384c1af_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_78cc2caf-28c4-4f6b-abcf-4c7e344c358e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_05f72a55-b1e6-49bc-9190-b2a618cf81e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ef559abf-db71-41aa-a005-5100c90b1e33_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4601156a-4e8e-485e-9d7a-d8670c2fd64f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $7,096, $6,010, and $4,905, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_1efc20f7-7ad5-495f-9244-f54b088bb774_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_cbb3c12c-f5b5-4898-8da3-fc7e9fa150cf_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_ad4f3051-890f-4485-997f-b2fb1cd243e8_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_0dc9532b-3c7d-4ea1-a4c5-50f019608e0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_91fdf213-37de-4831-acd8-cdb2a0620c45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_70820b9e-91bb-44f2-85e4-9feb94b85856_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InterestOnLeasePayments_85d86e01-d1d7-46b1-a2e2-2c518082a409_terseLabel_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_label_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:label id="lab_lxrx_InterestOnLeasePayments_documentation_en-US" xlink:label="lab_lxrx_InterestOnLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments" xlink:href="lxrx-20191231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InterestOnLeasePayments" xlink:to="lab_lxrx_InterestOnLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1947f3b8-d260-4666-88c3-a1627eb6b2c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ba36104e-0c32-45e0-91df-03752acb6d08_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_af0986af-639a-4156-b23c-0ea4ee3c361e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2d90941d-11b6-403e-ac61-956ab8374184_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_e6a4bdc2-e27c-4169-9592-0a7e99c4d54a_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_label_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_documentation_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyIconGoodwill" xlink:to="lab_lxrx_SymphonyIconGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_16c74588-d09a-4684-be18-48c7c4c7116d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_194d5349-8197-437d-b48f-464f58a172a8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e1e8fad0-f072-4337-8282-4e3b1ec723ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e7cfd6bd-abf0-4611-8c89-c1d892bfd99b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_d288d2f9-e878-43f5-89fd-a596e88835d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0f297de2-bbf1-43b8-9ad1-d1e6a9533426_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7db56041-4ef8-491b-b9ee-c1b2dd3f610f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_55cc292c-e6c0-406e-ba09-eeaf88925da3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d336961c-1751-4dd3-8b4e-4d7b31aefbd0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bfdc7ca7-97be-4ecf-9c70-32e1c58a744f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9eceef15-e8a0-4019-a6e6-eac2bad99eab_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d521c9b9-de61-4d1b-b4b2-7dcc358c6f95_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fef5e61f-8340-40b9-b5b0-0d56e227ccf9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_10eb0117-adbc-40fe-a3f1-85b15aeea270_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e664e46c-c1c8-4b62-adb3-259e51e08091_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d862d84f-89f1-48f0-838d-882d10910511_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_114e1ecc-a34d-4420-8037-fbbf7e264fe2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6749d16d-aa1d-40dd-896a-6be87c51b654_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_7edb3293-6a6f-4308-a979-9c2f7e52b919_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a817ed72-4375-49d9-b5ad-730eb001286b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_db1f2646-f782-4e75-92dc-919eae234a39_terseLabel_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development costs period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_label_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:label id="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_documentation_en-US" xlink:label="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:to="lab_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9b0c5f11-bc9c-4c15-8fd2-843337f95823_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_728d2dac-acf3-4c62-8cb4-a21282e1c2c5_terseLabel_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_label_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract" xlink:href="lxrx-20191231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract" xlink:to="lab_lxrx_OrganizationAndOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0bad4a4b-708f-4e03-b677-2a2607994cb8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0ab8c659-3079-4fd9-aa70-ccf741aea215_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_78517206-5e19-4a45-94f5-9bec47064b9e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2c7ac6f9-f638-4dee-a911-4bf956fd824c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b141f503-bd34-4ff9-9c07-c902dfa930e5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_84752a29-6132-48e1-931f-eb3424358589_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, State</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c946e6ad-e02d-4e61-a1f8-52bda90f4bc2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cce22d7b-1692-4e9d-946f-eb881cb63b68_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_4746c74e-3b43-4b31-9f6e-2108bdaa1d3d_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b1d66d4-0812-4dde-b119-b9ef46888da8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ad11a379-c1a7-48a6-a152-6f06b2a7b998_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cbaba275-7e6d-41c6-8b84-fcd7ac35e420_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7fb2bd2b-5f8a-4586-bcd0-f0d65c2c306a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b8fc3ebb-7cc0-4a7f-8b0b-ba793238bd42_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_b93790db-3f8b-48a5-a5e7-93d74f41d7e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_35a7ff2e-b44e-46b3-8be8-9b13947138a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_f1460297-04b8-4209-a0ce-4bb8bec8e8f1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_f24bbb96-1010-47b0-928a-b1826884597f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_b8bc3062-cea6-4428-a7b7-7c79452cbb0d_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_label_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Development Milestones</link:label>
    <link:label id="lab_lxrx_SanofiDevelopmentMilestones_documentation_en-US" xlink:label="lab_lxrx_SanofiDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones" xlink:href="lxrx-20191231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDevelopmentMilestones" xlink:to="lab_lxrx_SanofiDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_66abeb4f-a74c-4cfa-a1a6-4acb94ff97ed_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b3a4ecfb-d2a6-4241-a09d-fba66b9e51d7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9cfb6e5e-da87-4ae1-b86c-89087de7fcf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_5f2f8a71-e1bf-4857-b109-ed2ea7ee4334_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_5a22be4b-4f37-4e4c-b0bb-b6f62ab357b5_terseLabel_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_label_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_documentation_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract" xlink:href="lxrx-20191231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract" xlink:to="lab_lxrx_PropertyAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_3f33b842-4437-4217-917c-30e35d46b2f5_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_cea2d89c-56e7-4706-b165-b7aa6e056f31_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lxrx-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:75b0cead-5a5c-47f6-aad5-4e99b1d51247,g:4c8ac387-8b41-4d23-b70d-137f96384742-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/CoverPage" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c20b8e77-3e97-47f8-89d6-6418ebec37f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentType_c20b8e77-3e97-47f8-89d6-6418ebec37f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_98ee622a-8d6e-4b57-b5f6-b0db69c323d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentAnnualReport_98ee622a-8d6e-4b57-b5f6-b0db69c323d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4e4dcfc9-b477-4ddf-84fd-23d0b291b86f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentPeriodEndDate_4e4dcfc9-b477-4ddf-84fd-23d0b291b86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_15369edb-d19e-485b-a623-4302fa369aab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentTransitionReport_15369edb-d19e-485b-a623-4302fa369aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_abf399bf-5c06-467d-a82c-a753d6c36f7d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityFileNumber_abf399bf-5c06-467d-a82c-a753d6c36f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a939d5f1-93ec-44fb-acc2-d1aecfffae9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a939d5f1-93ec-44fb-acc2-d1aecfffae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6682737b-61cf-4e0f-8261-8d73dc159fc9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityTaxIdentificationNumber_6682737b-61cf-4e0f-8261-8d73dc159fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_530465ee-0175-4b71-8b2b-10040c070de8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityAddressAddressLine1_530465ee-0175-4b71-8b2b-10040c070de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_88aeda63-1d4f-4020-b8a3-c8a0a86781f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_CityAreaCode_88aeda63-1d4f-4020-b8a3-c8a0a86781f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_af5dd38f-d6ae-49be-9670-e1dfcd17cfbf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_LocalPhoneNumber_af5dd38f-d6ae-49be-9670-e1dfcd17cfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2e48e80d-b98e-428c-b6a0-34ae1a4e71a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityAddressCityOrTown_2e48e80d-b98e-428c-b6a0-34ae1a4e71a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2303cea6-b605-40b8-8461-182b9d17c508" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityAddressStateOrProvince_2303cea6-b605-40b8-8461-182b9d17c508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_237d6c4f-58b8-4d9d-a9d1-fab888fc8c96" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityAddressPostalZipCode_237d6c4f-58b8-4d9d-a9d1-fab888fc8c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6a504130-6d1e-4197-98d5-61fef3c2ff0f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_Security12bTitle_6a504130-6d1e-4197-98d5-61fef3c2ff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e8a162d2-86fa-4477-beec-a27206468537" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_SecurityExchangeName_e8a162d2-86fa-4477-beec-a27206468537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3db9a679-3a85-4bef-b328-f0dd1c92b866" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3db9a679-3a85-4bef-b328-f0dd1c92b866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_70feb8d7-02b4-4384-9f31-bc5c0dd6ad52" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityVoluntaryFilers_70feb8d7-02b4-4384-9f31-bc5c0dd6ad52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1b305354-8981-4290-8fff-ff5d9f63cb8d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityCurrentReportingStatus_1b305354-8981-4290-8fff-ff5d9f63cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_73ac7927-5291-43aa-b11c-cb24e97590b5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityInteractiveDataCurrent_73ac7927-5291-43aa-b11c-cb24e97590b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f486b8fc-b6c8-4871-afa3-16e286afb08f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityFilerCategory_f486b8fc-b6c8-4871-afa3-16e286afb08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f91860ad-ddef-4872-aa38-947e60f14c70" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntitySmallBusiness_f91860ad-ddef-4872-aa38-947e60f14c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fdd2b48d-1950-4feb-a302-30f916a950d6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityEmergingGrowthCompany_fdd2b48d-1950-4feb-a302-30f916a950d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_08f1891b-ce9d-4de1-83bc-2da342e48fdc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityShellCompany_08f1891b-ce9d-4de1-83bc-2da342e48fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7c88fb7a-341a-4ce1-9af0-87a3a307ce4e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityPublicFloat_7c88fb7a-341a-4ce1-9af0-87a3a307ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c4bde18f-1482-4e39-8c0d-2a1f3f24757f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c4bde18f-1482-4e39-8c0d-2a1f3f24757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3564c109-1070-4840-89f3-78491a2b8ccf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityRegistrantName_3564c109-1070-4840-89f3-78491a2b8ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f8d8ff88-959b-42ed-bf04-65cc74400846" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityCentralIndexKey_f8d8ff88-959b-42ed-bf04-65cc74400846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_74032c35-d742-4037-aff8-e6f15dc71657" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_CurrentFiscalYearEndDate_74032c35-d742-4037-aff8-e6f15dc71657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c52ac64e-500f-46dd-a28f-f3fdc3cf0227" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentFiscalYearFocus_c52ac64e-500f-46dd-a28f-f3fdc3cf0227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6cf2ccb9-a48e-4add-b31c-472cd4068c0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6cf2ccb9-a48e-4add-b31c-472cd4068c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dd618d09-aca6-4847-a500-e05c94cfa6fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_AmendmentFlag_dd618d09-aca6-4847-a500-e05c94cfa6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_20a61314-7aab-46fd-99db-89feba660a6e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_TradingSymbol_20a61314-7aab-46fd-99db-89feba660a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f7b940f4-754b-4981-8dd1-194b18646a4e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bb9ba72-3ff1-441b-862e-3566a2d556b6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f7b940f4-754b-4981-8dd1-194b18646a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8762422a-869e-480f-8050-ae3bf6be51a6" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8762422a-869e-480f-8050-ae3bf6be51a6" xlink:to="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:to="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ceb1ca5-ce5a-4d13-8be8-9079ee7c82b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_161fe665-f538-4f93-a9d2-8e0ab24ad886" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ceb1ca5-ce5a-4d13-8be8-9079ee7c82b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:to="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eef15b06-9e34-481e-bd91-6e9d00435c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_424e555e-e43b-41d6-87e6-57008cffc4d6" xlink:to="loc_us-gaap_ClassOfStockDomain_eef15b06-9e34-481e-bd91-6e9d00435c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f829e5f4-771e-4d18-869e-026f220d1aba" xlink:to="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23e0720-07ea-4b8d-9075-c405b044b0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f23e0720-07ea-4b8d-9075-c405b044b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5a662f29-d68e-4ebe-abfb-3e540250567d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_ShortTermInvestments_5a662f29-d68e-4ebe-abfb-3e540250567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3e9be66a-0897-4ccd-a1e2-cda6054f2f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3e9be66a-0897-4ccd-a1e2-cda6054f2f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c5273ef1-5eda-4954-9c1f-218bfcceda2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_InventoryNet_c5273ef1-5eda-4954-9c1f-218bfcceda2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ba7ca694-11fd-4336-ab17-e4482f78a949" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_OtherAssetsCurrent_ba7ca694-11fd-4336-ab17-e4482f78a949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1e2f32c1-0ac5-438f-9bfe-20ab3eb33b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_748bb84e-a10b-4223-a4ff-384e653441b3" xlink:to="loc_us-gaap_AssetsCurrent_1e2f32c1-0ac5-438f-9bfe-20ab3eb33b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82cb1af1-1831-4683-afe0-0925f7ada1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_82cb1af1-1831-4683-afe0-0925f7ada1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a59d6ec2-fea5-41a0-a3a7-4ec21dce8a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Goodwill_a59d6ec2-fea5-41a0-a3a7-4ec21dce8a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_cbaef37d-2d52-4f67-82ea-5ffa3bc3e11e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_cbaef37d-2d52-4f67-82ea-5ffa3bc3e11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ef4df63-e9d2-4448-93f6-259e543b1a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ef4df63-e9d2-4448-93f6-259e543b1a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_70d4d595-00dd-466f-9ab3-cdb3c4339d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Assets_70d4d595-00dd-466f-9ab3-cdb3c4339d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0d80c98d-3642-4302-9150-d002ff6dea45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_AccountsPayableCurrent_0d80c98d-3642-4302-9150-d002ff6dea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfb98e78-2bf7-4d7d-9b86-19fdc8d29648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfb98e78-2bf7-4d7d-9b86-19fdc8d29648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_66b3c615-2eb2-46eb-85d1-f631b75eaae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_DeferredRevenueCurrent_66b3c615-2eb2-46eb-85d1-f631b75eaae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d7bc7f9f-e6c6-4a4c-b003-4437f7276a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_LongTermDebtCurrent_d7bc7f9f-e6c6-4a4c-b003-4437f7276a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b15db15-81ab-4198-a990-44d018c5ec53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81cabb49-4f8b-4389-922a-cc2c8d8c1408" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b15db15-81ab-4198-a990-44d018c5ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_ae84eb10-89f5-4f18-97fe-ef83dc9aa3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_ae84eb10-89f5-4f18-97fe-ef83dc9aa3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7c65889c-1044-4180-bd2b-dd8ec49e2127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7c65889c-1044-4180-bd2b-dd8ec49e2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_7d615465-b98e-4288-a583-21c6006d1e24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_7d615465-b98e-4288-a583-21c6006d1e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b14bd5ff-d1a5-4c53-b629-7605f66d267d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b14bd5ff-d1a5-4c53-b629-7605f66d267d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d47854a7-7794-4ec0-82e5-4fd28e75a07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_Liabilities_d47854a7-7794-4ec0-82e5-4fd28e75a07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7d856d59-165d-4450-a635-edb22c513222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7d856d59-165d-4450-a635-edb22c513222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4e0b0299-311d-4565-8f60-43f1102dd74c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_PreferredStockValue_4e0b0299-311d-4565-8f60-43f1102dd74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b99fe5c7-0af9-4854-aa20-2a50333f33fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_CommonStockValue_b99fe5c7-0af9-4854-aa20-2a50333f33fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4adff5d1-4d6a-4c6e-9bcc-395b2d40ba27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4adff5d1-4d6a-4c6e-9bcc-395b2d40ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1ff120ba-0c35-4c49-b7ba-0efce33db1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1ff120ba-0c35-4c49-b7ba-0efce33db1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_962fc6b2-3953-4769-9096-0d03f12edbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_962fc6b2-3953-4769-9096-0d03f12edbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c9c04eb3-2e31-4536-8258-6f4be0a3623c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_TreasuryStockValue_c9c04eb3-2e31-4536-8258-6f4be0a3623c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_24f5387c-d8c1-4a2c-9203-145e58b549df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec33b0a9-1409-4e48-be3d-f93bdefd44c7" xlink:to="loc_us-gaap_StockholdersEquity_24f5387c-d8c1-4a2c-9203-145e58b549df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe0244c1-cda1-4370-b212-735eaa20d69b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fcba5e4-4aea-4aff-817b-df0e35efcae7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fe0244c1-cda1-4370-b212-735eaa20d69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BalanceSheetParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_49182380-dbc7-43e8-a82d-024910948568" xlink:href="lxrx-20191231.xsd#lxrx_BalanceSheetParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_49182380-dbc7-43e8-a82d-024910948568" xlink:to="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af523c4c-f67e-4ed2-8c44-74b420f2e0d4" xlink:to="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86b3416a-5fde-4bd3-bf4b-1c2f8d982564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_911fdefb-1d44-4154-ac9c-20c2912906d6" xlink:to="loc_us-gaap_CommonStockMember_86b3416a-5fde-4bd3-bf4b-1c2f8d982564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_effcc5ab-a264-4f83-9307-c4c5b096b1c2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_0e465b43-39f4-4208-b0b1-e80c26b56b13" xlink:to="loc_srt_ScenarioUnspecifiedDomain_effcc5ab-a264-4f83-9307-c4c5b096b1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_849bacd4-a14f-48e7-b831-9c39ae739083" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a05ce9e2-b5ef-4865-ba15-8838e2932a11" xlink:to="loc_us-gaap_ClassOfStockDomain_849bacd4-a14f-48e7-b831-9c39ae739083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9507e18a-9150-433b-b527-4eec9cd5bb1e" xlink:to="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_04c0ce63-fdf7-4a6c-bae5-71505374e615" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_04c0ce63-fdf7-4a6c-bae5-71505374e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac237b01-211e-46dc-9ca4-a41b38902121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac237b01-211e-46dc-9ca4-a41b38902121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_951bd15a-81e5-4a57-baaa-3b2a1e81ddba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_951bd15a-81e5-4a57-baaa-3b2a1e81ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2cb9d5dd-4866-47e2-9889-ab08c810b508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2cb9d5dd-4866-47e2-9889-ab08c810b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_366f6a62-1bbb-41b4-9086-cc00af1a7a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_366f6a62-1bbb-41b4-9086-cc00af1a7a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13a3c36b-b37a-418b-b224-e5b97c2b7aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13a3c36b-b37a-418b-b224-e5b97c2b7aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0672a023-9586-41bd-a363-55a0c3ed3eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0672a023-9586-41bd-a363-55a0c3ed3eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_103aefd9-5c84-404c-8c21-df1655c79329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_103aefd9-5c84-404c-8c21-df1655c79329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c67a547-abd6-4867-b331-387d4048d703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_4c67a547-abd6-4867-b331-387d4048d703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_9f9b5e69-0091-4dd1-ac69-5cdbdce6267d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78da7c3d-f7b8-4ff2-a547-228fac99d5bc" xlink:to="loc_us-gaap_TreasuryStockShares_9f9b5e69-0091-4dd1-ac69-5cdbdce6267d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_52c64e5f-0b7e-4e20-8dbb-e5b7fdd17317" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_52c64e5f-0b7e-4e20-8dbb-e5b7fdd17317" xlink:to="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:to="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2b8c8797-5cdf-484e-b55f-e4bb6f7f6bfe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_303b7d35-948e-4268-9a8e-0245d53f0eff" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2b8c8797-5cdf-484e-b55f-e4bb6f7f6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_41de0d94-97a9-43f6-b1e2-3a5eafa9cdd2" xlink:to="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28f62c7d-ef68-4ff3-b91b-a167f5e9e6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28f62c7d-ef68-4ff3-b91b-a167f5e9e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33d9f8e9-94c6-4f70-b4d6-ee929e0efa40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33d9f8e9-94c6-4f70-b4d6-ee929e0efa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_01af013f-d7b5-4c5a-b99d-a75fd1fb341e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_01af013f-d7b5-4c5a-b99d-a75fd1fb341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6fa9e18a-407b-4dff-8ec4-a3339a3918ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd456c55-5426-45b6-b79e-ef5f9b353691" xlink:to="loc_us-gaap_Revenues_6fa9e18a-407b-4dff-8ec4-a3339a3918ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5963b461-5200-456c-b8c7-bfcb464809e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5963b461-5200-456c-b8c7-bfcb464809e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3f82c28-009d-4466-95ee-b9e83cc3ae04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3f82c28-009d-4466-95ee-b9e83cc3ae04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_4e438119-e037-4df9-989f-e9324c2c0b72" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_4e438119-e037-4df9-989f-e9324c2c0b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d8876f68-a4d4-43f2-bbc0-66a2ab4b218d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d8876f68-a4d4-43f2-bbc0-66a2ab4b218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_06824084-1595-4159-9b1d-e622a202c690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cbdb994a-8b00-44b6-8a72-7a9357a79d1c" xlink:to="loc_us-gaap_OperatingExpenses_06824084-1595-4159-9b1d-e622a202c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_520b9d69-420a-4c1f-9920-e093bdd236b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OperatingIncomeLoss_520b9d69-420a-4c1f-9920-e093bdd236b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_064ded76-8cf9-435e-8e1a-c60d80887ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_InterestExpense_064ded76-8cf9-435e-8e1a-c60d80887ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_48a4a772-960f-4b39-9b61-821f057337ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_48a4a772-960f-4b39-9b61-821f057337ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1156246c-632c-4697-a90d-4bacc12cc778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1156246c-632c-4697-a90d-4bacc12cc778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_288acd38-cf67-40d1-b49b-9fc271a189df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_288acd38-cf67-40d1-b49b-9fc271a189df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_252d75f7-e19f-483c-9bdc-22c4630b2ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_NetIncomeLoss_252d75f7-e19f-483c-9bdc-22c4630b2ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6f9a3ea5-500b-458e-9676-68227f7947fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6f9a3ea5-500b-458e-9676-68227f7947fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_89c406f9-4c7f-4391-8ef1-941b45efa4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_89c406f9-4c7f-4391-8ef1-941b45efa4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cfdaed8c-be9c-423e-a466-088c7eb40115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7fa50b0e-3ce9-417c-b3f4-4d625da7b66b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cfdaed8c-be9c-423e-a466-088c7eb40115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_40e8977e-a9e3-4a59-b7f7-d7a328810c98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_EarningsPerShareBasic_40e8977e-a9e3-4a59-b7f7-d7a328810c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2f02c66b-8c2d-4344-b93a-3f73ecf173c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2f02c66b-8c2d-4344-b93a-3f73ecf173c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_54f74abf-75ff-4780-8d0c-fc601f8a8ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_54f74abf-75ff-4780-8d0c-fc601f8a8ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0717214-422b-4933-ad45-c131e5e9a4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0717214-422b-4933-ad45-c131e5e9a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_7d41b1a1-95e4-4b93-b733-b2f3b3d105a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fffa907a-1d18-48e7-940d-56b840294307" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_7d41b1a1-95e4-4b93-b733-b2f3b3d105a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="simple" xlink:href="lxrx-20191231.xsd#StatementsofComprehensiveLossParentheticalsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_80c3bf05-358d-46ca-8e80-e378b12bf6d8" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_80c3bf05-358d-46ca-8e80-e378b12bf6d8" xlink:to="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:to="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a5878263-726b-4718-9f3b-798595760187" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9e717313-b890-43bb-bc1e-f798fca07b49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a5878263-726b-4718-9f3b-798595760187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8dab0537-5870-4100-acd8-a004889d6711" xlink:to="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7c12f25f-e8e8-4d70-a5ae-9f4883146159" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7c12f25f-e8e8-4d70-a5ae-9f4883146159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_a1fd6d81-0a0e-4010-9015-99ff8808ec1f" xlink:href="lxrx-20191231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2cce5d26-9612-4e7d-a1f9-f18702463d26" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_a1fd6d81-0a0e-4010-9015-99ff8808ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_79c2a748-2a58-4d6c-a966-1648b633bbaf" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_79c2a748-2a58-4d6c-a966-1648b633bbaf" xlink:to="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_423b749f-47b5-4368-8dde-cc4177e0424f" xlink:to="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f6ba88ef-33fd-4142-8648-af1b3e9ac30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_CommonStockMember_f6ba88ef-33fd-4142-8648-af1b3e9ac30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df28a122-cf38-482d-b8b0-b9f75011c364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df28a122-cf38-482d-b8b0-b9f75011c364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91e97b47-5cff-41d1-8a11-508680f1add7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_RetainedEarningsMember_91e97b47-5cff-41d1-8a11-508680f1add7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b275d65a-a62a-439e-8a70-fd27c2f0100f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b275d65a-a62a-439e-8a70-fd27c2f0100f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f2894745-f2ea-468e-ac30-af4069d7271c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f967d1c-c896-4319-a2b8-3d32a505da03" xlink:to="loc_us-gaap_TreasuryStockMember_f2894745-f2ea-468e-ac30-af4069d7271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3260f7a9-4931-4ad0-a9b0-847f041e7f4d" xlink:to="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_3ae17df0-eb66-4537-ae98-8dd88cfa453e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_3ae17df0-eb66-4537-ae98-8dd88cfa453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a2e2f25-8e9c-4e63-bd81-7097fe20a410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a2e2f25-8e9c-4e63-bd81-7097fe20a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca07f788-68db-48fb-a85c-ba855d7e306d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StockholdersEquity_ca07f788-68db-48fb-a85c-ba855d7e306d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb7171f1-9249-4693-bce8-a9c2b4589004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb7171f1-9249-4693-bce8-a9c2b4589004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_e0562a58-89a6-4d82-a3ba-acc896bfd163" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_e0562a58-89a6-4d82-a3ba-acc896bfd163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_932adf75-a16f-48fa-888e-01a9b32a9c83" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyContingentPaymentInCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_932adf75-a16f-48fa-888e-01a9b32a9c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_eb654758-e9d3-4eb8-ad63-d8282bcbf3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_eb654758-e9d3-4eb8-ad63-d8282bcbf3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bd2654af-af4c-4f7c-acf4-eae76ef711bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bd2654af-af4c-4f7c-acf4-eae76ef711bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9e6ac520-6c39-4578-a0a8-71b0e7e89dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9e6ac520-6c39-4578-a0a8-71b0e7e89dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_729d22df-ffa8-46a4-9973-af213ae674f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_NetIncomeLoss_729d22df-ffa8-46a4-9973-af213ae674f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b193fc79-87bf-4f64-b160-b89fe26c2410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b193fc79-87bf-4f64-b160-b89fe26c2410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_689ee446-b81a-4e09-8b6b-7fac3a1e266d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_689ee446-b81a-4e09-8b6b-7fac3a1e266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c0519ac-8790-4c90-880d-f7ee058b1044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f637cbf3-f504-4775-9f1e-cd74946b1225" xlink:to="loc_us-gaap_StockholdersEquity_5c0519ac-8790-4c90-880d-f7ee058b1044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lxrx-20191231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3227cd6f-6193-45d2-a230-552666ee8afa" xlink:href="lxrx-20191231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3227cd6f-6193-45d2-a230-552666ee8afa" xlink:to="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:to="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fbf091cd-cf5b-4f56-919d-fc7e09ed4b46" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_91ba0485-d223-41f4-b57b-600f8e3d01bb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fbf091cd-cf5b-4f56-919d-fc7e09ed4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e0ba451a-82b2-4c7f-9181-bf4d8211938b" xlink:to="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a9b72ce-fe09-4e6b-88c6-e01b3dd251ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_ProfitLoss_6a9b72ce-fe09-4e6b-88c6-e01b3dd251ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ccb28bb9-db3b-4a6d-bac3-689964fec04e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ccb28bb9-db3b-4a6d-bac3-689964fec04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_eceba35d-cc19-4905-a6de-c290e676746b" xlink:href="lxrx-20191231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_eceba35d-cc19-4905-a6de-c290e676746b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e9cad782-9743-44ae-987a-6c977cacec39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_ShareBasedCompensation_e9cad782-9743-44ae-987a-6c977cacec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_c29ef3a9-f2c9-427d-ab68-c6e31592c1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_c29ef3a9-f2c9-427d-ab68-c6e31592c1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1574bc71-1161-45dd-b823-8111902bb450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1574bc71-1161-45dd-b823-8111902bb450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a8bf6-d793-4c7b-8801-eb311843ad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a8bf6-d793-4c7b-8801-eb311843ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4820037-3a94-4dff-b408-1be833647773" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6916f656-39a4-4abc-aad6-8f183baa83f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6916f656-39a4-4abc-aad6-8f183baa83f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c46ec029-47a7-4b89-9a43-8e9b2ed4dc58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c46ec029-47a7-4b89-9a43-8e9b2ed4dc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b066af5e-6c14-4dc0-8f19-75129c267b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b066af5e-6c14-4dc0-8f19-75129c267b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02223200-8982-4482-ad34-f5c0f56ab2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_02223200-8982-4482-ad34-f5c0f56ab2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26aceadc-1b96-48e4-b6c1-254b9890c3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_26aceadc-1b96-48e4-b6c1-254b9890c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45cb4caa-4ec3-492f-8e6d-c94e38cae4be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e58a9d1e-5bb5-4af4-a01f-bb4ee897ce6d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45cb4caa-4ec3-492f-8e6d-c94e38cae4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_79046090-6a8d-4bff-ba75-8b5791eda2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8d851051-48d7-4878-9ca3-e3638f101a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_79046090-6a8d-4bff-ba75-8b5791eda2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b65be901-c548-474f-80dc-2f7bd695babb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b65be901-c548-474f-80dc-2f7bd695babb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e2d7f6a7-122e-440b-b435-a4326268c4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e2d7f6a7-122e-440b-b435-a4326268c4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_266ba451-a1c6-4984-aea7-3c0d0cc2fa79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_266ba451-a1c6-4984-aea7-3c0d0cc2fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ce3dff3-0b39-4da0-989c-4b6298bdb3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_434c1c93-533f-406e-8d69-ca5762a61698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ce3dff3-0b39-4da0-989c-4b6298bdb3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9a6c5f9-a42f-4608-8049-a50366d3407f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9a6c5f9-a42f-4608-8049-a50366d3407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e3ac9f9-7787-4a03-80bd-27850fcfe358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e3ac9f9-7787-4a03-80bd-27850fcfe358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ee7521-79db-40fe-b110-e51724f00079" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ee7521-79db-40fe-b110-e51724f00079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fce637b8-dcdd-40b1-b4b5-51ad33108a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fce637b8-dcdd-40b1-b4b5-51ad33108a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37c7c3a0-c9d1-4ab2-ba91-1a820aa36f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af5487dd-bd49-44fd-96a9-f0c3e5d67b2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37c7c3a0-c9d1-4ab2-ba91-1a820aa36f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_e7b740f8-aa8c-4443-a32e-7b781de75627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_e7b740f8-aa8c-4443-a32e-7b781de75627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccabf126-1ec0-4dbb-858b-926492abaf38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccabf126-1ec0-4dbb-858b-926492abaf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a803ac-4eea-4c56-b520-841aabf9c36e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a803ac-4eea-4c56-b520-841aabf9c36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_bdf879f0-5cec-4a21-9323-cd1bb5861f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b99d3416-c386-454e-b971-47c97121ac9b" xlink:to="loc_us-gaap_InterestPaidNet_bdf879f0-5cec-4a21-9323-cd1bb5861f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8d6455c-4b17-4281-987e-f6e1f0a7d2d5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_6040abd1-a2d2-4f54-ae98-c08c96efb1f4" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_6040abd1-a2d2-4f54-ae98-c08c96efb1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_3a88c8ac-d85b-454c-b2a5-d5cf9f4539fd" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyContingentPaymentInCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d498363a-594b-4546-841e-53c0c5e54901" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_3a88c8ac-d85b-454c-b2a5-d5cf9f4539fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_27a20c9c-a9cd-4833-9b93-12ec3cb4bdb6" xlink:href="lxrx-20191231.xsd#lxrx_OrganizationAndOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d130277a-a335-4805-8534-46174146e60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_27a20c9c-a9cd-4833-9b93-12ec3cb4bdb6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d130277a-a335-4805-8534-46174146e60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cff929ca-45fa-42cb-b34c-f6985924f2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_182980e2-f837-43cc-ac04-d07c67b1a227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cff929ca-45fa-42cb-b34c-f6985924f2d2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_182980e2-f837-43cc-ac04-d07c67b1a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a4b67bf3-d31b-40a5-984a-f06d61ac37b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a4b67bf3-d31b-40a5-984a-f06d61ac37b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_917c2fd7-34fb-4d51-a3be-1879693f6f35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_UseOfEstimates_917c2fd7-34fb-4d51-a3be-1879693f6f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0217b2af-b479-4b14-b181-e4d402b94a18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0217b2af-b479-4b14-b181-e4d402b94a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_10e2b62d-9167-4992-b020-273fe43922a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_10e2b62d-9167-4992-b020-273fe43922a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_40ac00ae-57e7-4e73-9a06-62c62b3fb9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_40ac00ae-57e7-4e73-9a06-62c62b3fb9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_19810b3a-1822-479e-9d55-6960feee7119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_19810b3a-1822-479e-9d55-6960feee7119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_79ea32ee-c375-4d80-ab36-af94f87721b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_79ea32ee-c375-4d80-ab36-af94f87721b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_7c114caf-8cd1-47c2-bd3c-a5e6a7e475dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_7c114caf-8cd1-47c2-bd3c-a5e6a7e475dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1a2201ae-dd7a-4145-9b15-f3d0296482e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1a2201ae-dd7a-4145-9b15-f3d0296482e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1afdd7f0-ca09-460f-9f06-dfa860dc5c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1afdd7f0-ca09-460f-9f06-dfa860dc5c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0c9a3b35-d880-4cc5-a4e6-8ae49be52c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0c9a3b35-d880-4cc5-a4e6-8ae49be52c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_75eef6d7-3241-4dc4-86d6-66be14f97e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_75eef6d7-3241-4dc4-86d6-66be14f97e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_c0b16bfd-d935-49e1-a39f-fee04b9551b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_c0b16bfd-d935-49e1-a39f-fee04b9551b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_316e4a0f-ab29-424f-bddd-9cb8eb36fe68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_316e4a0f-ab29-424f-bddd-9cb8eb36fe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9a3f44ab-f8c4-4f2c-a9b0-67d3c7a79895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9a3f44ab-f8c4-4f2c-a9b0-67d3c7a79895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ceee89d-69b4-4b58-aec0-a444c22f7f27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ceee89d-69b4-4b58-aec0-a444c22f7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_f1a82e6a-b7a9-4d54-a524-7a3647f180f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_f1a82e6a-b7a9-4d54-a524-7a3647f180f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_151e21f9-d917-4bb5-8757-6745c611f467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ab0ec60-bd29-412d-a8d3-863479d13ef8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_151e21f9-d917-4bb5-8757-6745c611f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a9c9288-3827-46ba-a9a8-ec25781f12c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_f0bbf5bf-6741-47d3-af4a-0016e63f3bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a9c9288-3827-46ba-a9a8-ec25781f12c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_f0bbf5bf-6741-47d3-af4a-0016e63f3bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e5bf45a5-932a-4441-b2da-9cb99fc28270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a9c9288-3827-46ba-a9a8-ec25781f12c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e5bf45a5-932a-4441-b2da-9cb99fc28270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_e1ba6594-f55b-4c3e-83e8-a7f9ff992e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:to="loc_us-gaap_InventoryRawMaterials_e1ba6594-f55b-4c3e-83e8-a7f9ff992e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_58794e52-6c41-4e66-a0e5-dd4963142b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:to="loc_us-gaap_InventoryWorkInProcess_58794e52-6c41-4e66-a0e5-dd4963142b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2272e7fe-9635-438d-aaf7-036e5a54603f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:to="loc_us-gaap_InventoryFinishedGoods_2272e7fe-9635-438d-aaf7-036e5a54603f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_15ea6451-99f0-4390-8e3d-790de6285479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:to="loc_us-gaap_InventoryGross_15ea6451-99f0-4390-8e3d-790de6285479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PriorYearReclassOfAccrual_c71bb72b-cffe-41fb-996c-931daa46bd3a" xlink:href="lxrx-20191231.xsd#lxrx_PriorYearReclassOfAccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d60d0bdc-65d6-48c0-85e2-1e1cfa4b4014" xlink:to="loc_lxrx_PriorYearReclassOfAccrual_c71bb72b-cffe-41fb-996c-931daa46bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_556922cf-54e4-4706-a89e-bbc9287fcd2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_b483613f-1da3-4c14-bab3-c80d463e74bc" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_556922cf-54e4-4706-a89e-bbc9287fcd2f" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_b483613f-1da3-4c14-bab3-c80d463e74bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_520ffca3-537c-484c-b2c7-fb284797162f" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_556922cf-54e4-4706-a89e-bbc9287fcd2f" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_520ffca3-537c-484c-b2c7-fb284797162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_3ecb0327-26b5-4867-8381-d93489a2a843" xlink:href="lxrx-20191231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_556922cf-54e4-4706-a89e-bbc9287fcd2f" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany_3ecb0327-26b5-4867-8381-d93489a2a843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ca4db0d9-4bc8-4cde-8de4-77f830359786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ca4db0d9-4bc8-4cde-8de4-77f830359786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueSanofiPercentage_2bc28cc1-a90e-4c61-9582-79d5a3f3bdf5" xlink:href="lxrx-20191231.xsd#lxrx_EntityWideRevenueSanofiPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:to="loc_lxrx_EntityWideRevenueSanofiPercentage_2bc28cc1-a90e-4c61-9582-79d5a3f3bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXBiologicscustomerconcentration_9258d00d-a841-47ac-b54b-b1f5b984378f" xlink:href="lxrx-20191231.xsd#lxrx_LXRXBiologicscustomerconcentration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:to="loc_lxrx_LXRXBiologicscustomerconcentration_9258d00d-a841-47ac-b54b-b1f5b984378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LXRXDiplomatcustomerconcentration_ca9d08d7-d1ad-4226-a3ab-ae4c45b276f0" xlink:href="lxrx-20191231.xsd#lxrx_LXRXDiplomatcustomerconcentration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:to="loc_lxrx_LXRXDiplomatcustomerconcentration_ca9d08d7-d1ad-4226-a3ab-ae4c45b276f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_b62d1835-1c4f-4d88-8636-a04ae4acbc41" xlink:href="lxrx-20191231.xsd#lxrx_EntityWideRevenueIpsenPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a041ee-c853-4c40-ad69-d1fac693d7e3" xlink:to="loc_lxrx_EntityWideRevenueIpsenPercentage_b62d1835-1c4f-4d88-8636-a04ae4acbc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesIntangibleassetDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ef202e5-866c-4661-ab19-52072ca02964" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ef202e5-866c-4661-ab19-52072ca02964" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8f31f9-acd3-4101-882e-26931fa81e60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f91e0843-1ad8-45fd-b1ef-854586a856cb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8f31f9-acd3-4101-882e-26931fa81e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_73ce773f-a628-448f-985c-560f18683d5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_767c5166-6d52-40a1-a561-1355d9a6e0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_767c5166-6d52-40a1-a561-1355d9a6e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c6e4582f-1bc0-44a4-a956-535e00c79b79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c6e4582f-1bc0-44a4-a956-535e00c79b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_703c4124-f1a1-4281-afd6-8f5be80a2036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_703c4124-f1a1-4281-afd6-8f5be80a2036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c65d2af-d222-4cf8-9f7e-2492e2eed351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c65d2af-d222-4cf8-9f7e-2492e2eed351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_85a1f88b-49cd-4cc7-bf6b-41c9ffa6d57e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_85a1f88b-49cd-4cc7-bf6b-41c9ffa6d57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_85997775-5c8a-408b-91bd-dc3accafcf24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_85997775-5c8a-408b-91bd-dc3accafcf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cdbba60c-ac31-4328-b299-1149b7ec9de9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_afd69c19-82cf-4cd4-9ae9-8c0cf868a4b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cdbba60c-ac31-4328-b299-1149b7ec9de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_bf3c69a5-5319-4011-be4d-cfae051e6702" xlink:href="lxrx-20191231.xsd#lxrx_XERMELOIntangibleAssetsFiniteLived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ef202e5-866c-4661-ab19-52072ca02964" xlink:to="loc_lxrx_XERMELOIntangibleAssetsFiniteLived_bf3c69a5-5319-4011-be4d-cfae051e6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fbd9746-bd32-4f9a-8f3c-068bec2f8b26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fbd9746-bd32-4f9a-8f3c-068bec2f8b26" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:to="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2acef425-015b-4f5f-a9c8-75057121791c" xlink:to="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db7ce864-5911-45f0-81d9-7c65abe001b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:to="loc_srt_MinimumMember_db7ce864-5911-45f0-81d9-7c65abe001b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ccc5f7de-bc97-4ffa-a5e4-69b58af1666a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8682939b-24d3-4330-828a-f59d0683955b" xlink:to="loc_srt_MaximumMember_ccc5f7de-bc97-4ffa-a5e4-69b58af1666a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_752ebca4-61e2-4bf9-be63-b6e09b16d11a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8effe865-1fef-4fc5-a65f-5edf5840d624" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e86834f-36d8-47d0-b523-1f4fe024189a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8effe865-1fef-4fc5-a65f-5edf5840d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2f19b881-5156-4eb5-b3bf-d1e13419e497" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1af93537-eb93-43e7-805b-01ae87eab9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f19b881-5156-4eb5-b3bf-d1e13419e497" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1af93537-eb93-43e7-805b-01ae87eab9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9b3a9e71-087b-4554-aa4e-9e42c55aa621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f19b881-5156-4eb5-b3bf-d1e13419e497" xlink:to="loc_us-gaap_AssetImpairmentCharges_9b3a9e71-087b-4554-aa4e-9e42c55aa621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_17587db6-0ca0-42f0-80e9-fef7859802c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f19b881-5156-4eb5-b3bf-d1e13419e497" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_17587db6-0ca0-42f0-80e9-fef7859802c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bd86c52-ec0a-4754-88b1-409194e70d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3b04b911-1464-45d3-ba2d-29f5dc2bc3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bd86c52-ec0a-4754-88b1-409194e70d6b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3b04b911-1464-45d3-ba2d-29f5dc2bc3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesCostofSalesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_956f5775-46c1-423d-9b6b-ab6c76a3c361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials_37ed2cf0-74e2-4df5-adeb-cbd2ce02104e" xlink:href="lxrx-20191231.xsd#lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_956f5775-46c1-423d-9b6b-ab6c76a3c361" xlink:to="loc_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials_37ed2cf0-74e2-4df5-adeb-cbd2ce02104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_956f5775-46c1-423d-9b6b-ab6c76a3c361" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a0edc254-16ee-4d6d-980e-445cbc4340fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bc18c4c7-9946-4269-9194-d10696f4b34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_549f8c83-f378-4757-9a4d-429114a7465b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bc18c4c7-9946-4269-9194-d10696f4b34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3a6f345-d32b-412d-8d10-b292dbd1010f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fce4da0-460f-4588-adb7-4562d48f7625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dc76aef8-10e5-4042-99c5-c87b6bc6c2c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7fce4da0-460f-4588-adb7-4562d48f7625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_107519df-334f-45fe-b741-19ac275af320" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_107519df-334f-45fe-b741-19ac275af320" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:to="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9debb2c7-11fb-4f10-bb1b-1ab507f89dfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a294d38d-ca77-42e3-8f13-5f89f026bea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e351972-5edc-43d6-bb66-2c78806b3abf" xlink:to="loc_us-gaap_StockOptionMember_a294d38d-ca77-42e3-8f13-5f89f026bea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2f59a8e1-87a6-4138-87de-1678986c4f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bae99eb1-6f07-4bb7-a56d-0791fadf9d9b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2f59a8e1-87a6-4138-87de-1678986c4f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4436a6be-71b3-4669-b3ef-091ac3d0a7e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_3bef328e-eda9-4d03-a28a-220304d991ae" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_3bef328e-eda9-4d03-a28a-220304d991ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_8342ca1c-917b-48ce-b307-42eff378b491" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_8342ca1c-917b-48ce-b307-42eff378b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e2fbbb49-0245-4321-919e-8b754c7d45b1" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e2fbbb49-0245-4321-919e-8b754c7d45b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_1709e78c-f9e0-4b45-9aac-e12c5f325af9" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_1709e78c-f9e0-4b45-9aac-e12c5f325af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9e73e2dc-d83a-47d8-8edb-b68c8a0fb2e9" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9e73e2dc-d83a-47d8-8edb-b68c8a0fb2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_bf6acedd-aed7-4e91-92be-a45f5b6a4ca8" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_bf6acedd-aed7-4e91-92be-a45f5b6a4ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_9dd76a81-dd21-4257-8826-271cf4d68e75" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_9dd76a81-dd21-4257-8826-271cf4d68e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_a7c5a2ed-3d38-41d1-adc6-a506a5fa3dbb" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_a7c5a2ed-3d38-41d1-adc6-a506a5fa3dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f83a43c1-a1a0-4429-8125-588f450646c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75cd55b9-00da-457a-96a7-7844626b7a2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f83a43c1-a1a0-4429-8125-588f450646c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_936cba80-47cc-4070-a1ea-332a71599a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62aecb56-86a7-4bc9-ab69-e700d648c251" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_936cba80-47cc-4070-a1ea-332a71599a4c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62aecb56-86a7-4bc9-ab69-e700d648c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68c187bb-7cc8-4b2e-aaab-99b1d3549714" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_936cba80-47cc-4070-a1ea-332a71599a4c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68c187bb-7cc8-4b2e-aaab-99b1d3549714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_f5bad5c6-85b8-4a89-b8e8-c584acd1d579" xlink:href="lxrx-20191231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9b3b58f6-81e9-4d8f-aef8-e46a98377f63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_f5bad5c6-85b8-4a89-b8e8-c584acd1d579" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9b3b58f6-81e9-4d8f-aef8-e46a98377f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#RecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_6f0d8c2c-611d-4f99-a645-a5ac5adf8fbb" xlink:href="lxrx-20191231.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_6f0d8c2c-611d-4f99-a645-a5ac5adf8fbb" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_482e6c60-ad09-4bd8-8be7-fe1991c40a68" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e8e5489f-f344-476b-bace-08c73ec23f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4b16203b-9b92-4455-a761-6e3d9b92b9d9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e8e5489f-f344-476b-bace-08c73ec23f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_91d6d41b-8fb2-4d55-9dde-53afc10de8d1" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcad7413-f621-4ffb-8f3d-c107d4461372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcad7413-f621-4ffb-8f3d-c107d4461372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46219a93-1f00-4b1f-98ea-67e1993f8b53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_844746d2-5b1a-4695-bb94-d48e8cb293f4" xlink:to="loc_us-gaap_OperatingLeaseLiability_46219a93-1f00-4b1f-98ea-67e1993f8b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c6675b79-0a5d-497b-bd7d-34e2ea81c3cc" xlink:href="lxrx-20191231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_14bf9ed8-8498-47c2-89b4-0e3c21125a96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c6675b79-0a5d-497b-bd7d-34e2ea81c3cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_14bf9ed8-8498-47c2-89b4-0e3c21125a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b8b88757-0119-43fc-a48e-7671124896ea" xlink:href="lxrx-20191231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7e925087-eec0-4a9e-87b2-5aa5cc355ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b8b88757-0119-43fc-a48e-7671124896ea" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_7e925087-eec0-4a9e-87b2-5aa5cc355ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CashandCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_21529bee-3cf3-4ca4-a241-27ebe1216015" xlink:href="lxrx-20191231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_21529bee-3cf3-4ca4-a241-27ebe1216015" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:to="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ca6bf134-1715-4133-8c11-a3cee4351f13" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c89ca0c6-26f7-4111-b39c-3b613a7fb5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_CashMember_c89ca0c6-26f7-4111-b39c-3b613a7fb5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6d4265ef-68be-4940-9264-142197122532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6d4265ef-68be-4940-9264-142197122532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_595c6289-ec22-44f5-b3bb-fcbe8e85712a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_595c6289-ec22-44f5-b3bb-fcbe8e85712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6373a795-5270-4f87-8656-62a03e1df23b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6373a795-5270-4f87-8656-62a03e1df23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_fe4f0f4d-2d2a-45a4-94fe-3e95defee62c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b3e4f956-0cae-4385-ac74-0e28390caa75" xlink:to="loc_us-gaap_InvestmentsMember_fe4f0f4d-2d2a-45a4-94fe-3e95defee62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_bdf1b847-09db-46e0-9039-e5d6c9409a93" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_d28c7606-424c-4221-8c2b-3cbfea5dbeb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_d28c7606-424c-4221-8c2b-3cbfea5dbeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_22dbce89-b21f-4b67-9e87-1e2e6f85f277" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_22dbce89-b21f-4b67-9e87-1e2e6f85f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e66f7006-23f0-47e3-ac8c-74cd45f878c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e66f7006-23f0-47e3-ac8c-74cd45f878c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1f0ba568-158d-454b-b70b-d46a1420838f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1f0ba568-158d-454b-b70b-d46a1420838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_901e0e67-956f-462f-90bc-315d8e96ef5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_27d2bbc2-28ce-4500-93f6-b129ad1029c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_901e0e67-956f-462f-90bc-315d8e96ef5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_90efe289-e9bd-40db-915c-aa733f0c1078" xlink:href="lxrx-20191231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d9e6f274-00dc-4f1d-9ef4-6333d5007fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_90efe289-e9bd-40db-915c-aa733f0c1078" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d9e6f274-00dc-4f1d-9ef4-6333d5007fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_e3f29047-9ee5-4bbf-b5e8-3a8d0b42f22e" xlink:href="lxrx-20191231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_435fcd43-deb6-4572-af3b-c67e8cccc9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_e3f29047-9ee5-4bbf-b5e8-3a8d0b42f22e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_435fcd43-deb6-4572-af3b-c67e8cccc9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_f984f14c-19f8-4936-ba8f-40519b4aa575" xlink:href="lxrx-20191231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_f984f14c-19f8-4936-ba8f-40519b4aa575" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e8d090d-5105-49e3-acb0-861a3089e068" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8c93dd3-6d28-4b5c-9aa4-b5982e48fb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8c93dd3-6d28-4b5c-9aa4-b5982e48fb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_71e30b14-19b3-439a-b918-7b9244275d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_71e30b14-19b3-439a-b918-7b9244275d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f708c41d-4159-431e-82de-d3ecd4b72fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a17ab927-86ad-4b04-b3b6-17c3242e5a65" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f708c41d-4159-431e-82de-d3ecd4b72fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e13bd07a-d2cb-41d2-ae45-6e0d886e4f0a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8649d0b9-3f64-4528-911e-0b2c12d6924e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8649d0b9-3f64-4528-911e-0b2c12d6924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0c9cbc82-67e5-4886-b206-0f87359ce08f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0c9cbc82-67e5-4886-b206-0f87359ce08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_456e040f-cf85-48b5-b21a-92abe969e38b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a00bb5a1-060f-4024-a4dd-90dd478b74f6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_456e040f-cf85-48b5-b21a-92abe969e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_1c8f536f-e90b-46e7-81df-dd411e6e83e1" xlink:href="lxrx-20191231.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_1c8f536f-e90b-46e7-81df-dd411e6e83e1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d64a332-a6ab-45db-b9f4-b0f8094f26a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eed0d451-5e3f-4b76-a662-1bf7834cb3bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0d64a332-a6ab-45db-b9f4-b0f8094f26a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_39d7e36d-481b-498f-ad2d-24d33de7a5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51a982ff-56db-4aca-b88a-13a2dd7d6dbc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_39d7e36d-481b-498f-ad2d-24d33de7a5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_be7e001a-31ff-4eef-a81c-2149461fac25" xlink:href="lxrx-20191231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_041496eb-dd78-41ab-800a-c91c51d96197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_be7e001a-31ff-4eef-a81c-2149461fac25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_041496eb-dd78-41ab-800a-c91c51d96197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_a64893a1-cb38-46fa-802d-1e9078e7c623" xlink:href="lxrx-20191231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b7126879-891d-43c1-80ec-a1216e33af86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_a64893a1-cb38-46fa-802d-1e9078e7c623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b7126879-891d-43c1-80ec-a1216e33af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_0519421f-f6cd-42c6-b452-0ea492f06336" xlink:href="lxrx-20191231.xsd#lxrx_PropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_0519421f-f6cd-42c6-b452-0ea492f06336" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3dc90899-d4e8-4b6b-98aa-e1522e15690a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f1fa8b42-320a-4e35-aa86-eb90088068f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_ComputerEquipmentMember_f1fa8b42-320a-4e35-aa86-eb90088068f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f0b94e0d-2c57-4183-b3d3-57ce6e881969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f0b94e0d-2c57-4183-b3d3-57ce6e881969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0a3d8bdb-c732-4b3e-bbc1-74316a21dfad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_EquipmentMember_0a3d8bdb-c732-4b3e-bbc1-74316a21dfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_65ec78c0-aabc-4715-926b-07a9ac39a712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_65ec78c0-aabc-4715-926b-07a9ac39a712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_9cc210a7-466f-4fd1-9c4f-5b613d30550c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_9cc210a7-466f-4fd1-9c4f-5b613d30550c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3654c9fc-9e96-4e1b-904b-cbd9734d3be3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e6c524ae-2551-49ea-bd25-7168aa3c989b" xlink:to="loc_us-gaap_LandMember_3654c9fc-9e96-4e1b-904b-cbd9734d3be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:to="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_764fde62-8e9a-4412-b2b6-caa3a0f5d33e" xlink:to="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a148d9ab-e1e8-40b4-b28b-a55440992073" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:to="loc_srt_MinimumMember_a148d9ab-e1e8-40b4-b28b-a55440992073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76ab00b2-db86-4763-825b-de9e0ca28136" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4064cec2-fdb2-4323-8739-8fb83b39db94" xlink:to="loc_srt_MaximumMember_76ab00b2-db86-4763-825b-de9e0ca28136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e51d4681-273e-4f98-b5ff-19023b1b3815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_02d23279-b4ab-45ef-a365-a3cfb38c7603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_02d23279-b4ab-45ef-a365-a3cfb38c7603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34d204e5-c0cc-4c90-be85-7ec40d8bc842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34d204e5-c0cc-4c90-be85-7ec40d8bc842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7308ae8-d87d-450c-8e3f-515de245209d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a7308ae8-d87d-450c-8e3f-515de245209d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5437f343-752a-4efd-a7e9-ecc370517337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3ce3723-8373-4287-856f-69c4bf126d24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5437f343-752a-4efd-a7e9-ecc370517337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef52a4e7-1502-43bb-b3e2-9469b550fd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5fdfa6f0-96cc-46e8-bf4f-5067a16d2c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef52a4e7-1502-43bb-b3e2-9469b550fd2e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5fdfa6f0-96cc-46e8-bf4f-5067a16d2c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1aaf097b-8aa9-4c2c-8cd5-e3d5cb650da7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0d51d80-6346-40a8-a188-852e1271f0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1aaf097b-8aa9-4c2c-8cd5-e3d5cb650da7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0d51d80-6346-40a8-a188-852e1271f0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a813686c-476d-4ad2-9fb8-21d28e7d16cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1aaf097b-8aa9-4c2c-8cd5-e3d5cb650da7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a813686c-476d-4ad2-9fb8-21d28e7d16cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5c2a2c66-c44b-4c5f-aad7-52915c5ce882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5c2a2c66-c44b-4c5f-aad7-52915c5ce882" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_3a9d3355-ad00-423b-9445-f0f19bc748c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_d4f1e481-3994-4ade-83c8-b237a5db1423" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_3a9d3355-ad00-423b-9445-f0f19bc748c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_1bb3c8bd-8861-4e5d-bab0-33df404a8dc0" xlink:to="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1dec8a33-2f99-4d5e-a8ba-92a645533fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1dec8a33-2f99-4d5e-a8ba-92a645533fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_65b99697-a999-4b4d-a787-ded98b24fd50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_65b99697-a999-4b4d-a787-ded98b24fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_ad13dec2-a08e-4ab1-bc42-0fef97b58077" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug_ad13dec2-a08e-4ab1-bc42-0fef97b58077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8e078e43-64e6-4f0c-887d-e80263247a98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8e078e43-64e6-4f0c-887d-e80263247a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4101deb0-1bb5-4c4c-88c5-b9ceb5d22b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4101deb0-1bb5-4c4c-88c5-b9ceb5d22b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_77010bbd-9e2f-429b-8842-2b9d72ac59ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_77010bbd-9e2f-429b-8842-2b9d72ac59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_82795ace-3609-481d-945a-4fe73d334def" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxAssetsSection163j_LXRX"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxAssetsSection163j_LXRX_82795ace-3609-481d-945a-4fe73d334def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e366f576-55fa-44db-894a-95e9863b8732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e366f576-55fa-44db-894a-95e9863b8732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f494ffab-ea62-497c-80ce-6983ce49bc08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f494ffab-ea62-497c-80ce-6983ce49bc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_3f93ec57-2be1-4607-994b-44f145acc2fa" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_3f93ec57-2be1-4607-994b-44f145acc2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_a464fd1d-8fa3-4cd9-9524-ded089f4811b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_a464fd1d-8fa3-4cd9-9524-ded089f4811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c25270bf-b36f-4b94-9cc0-6d306692171c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c25270bf-b36f-4b94-9cc0-6d306692171c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16146d82-ccbf-42c3-9619-e7c430c46931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16146d82-ccbf-42c3-9619-e7c430c46931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7de0e8d6-47ad-4ed4-996c-b412a88ee700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7de0e8d6-47ad-4ed4-996c-b412a88ee700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f3dd9111-40e8-4cba-8273-25b2ebe4b4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c7b61bf8-bba1-491d-8927-abe7884112a8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f3dd9111-40e8-4cba-8273-25b2ebe4b4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_0118a04b-3151-4578-b735-313916e1b791" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset_0118a04b-3151-4578-b735-313916e1b791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_f0cbabac-91a9-4561-9f97-a1f7c0254dd7" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible_f0cbabac-91a9-4561-9f97-a1f7c0254dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d58fb1dc-e306-48f0-8cf1-ee4a8976b134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d58fb1dc-e306-48f0-8cf1-ee4a8976b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_01d66c36-aab5-4bd4-8651-4f6ba77d0459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_01d66c36-aab5-4bd4-8651-4f6ba77d0459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_26aa95da-8f30-45b4-8aff-4c0fe26706ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_26aa95da-8f30-45b4-8aff-4c0fe26706ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0866a69e-3265-42a0-952e-3ea2303c0a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0866a69e-3265-42a0-952e-3ea2303c0a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_94422154-21f1-4fa1-a583-5c36abc212f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_94422154-21f1-4fa1-a583-5c36abc212f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49c01325-2078-4bec-89b9-5604d7a0ecb3" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_884f9d1b-7eba-4bb6-8a1a-6e2620c8eb98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c1693a47-9993-4491-a68e-f3004b59ff1a" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_884f9d1b-7eba-4bb6-8a1a-6e2620c8eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_cba098a5-1e30-4e43-b1a6-c38872e06bf7" xlink:to="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_2a36f06c-84da-4619-be13-8603043afd86" xlink:href="lxrx-20191231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_2a36f06c-84da-4619-be13-8603043afd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_87238e91-68ab-4e05-ae32-6d8831e0076b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_87238e91-68ab-4e05-ae32-6d8831e0076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FederalNetOperatingLossChange_ba4a811d-f64c-473d-86c5-34c265f327c6" xlink:href="lxrx-20191231.xsd#lxrx_FederalNetOperatingLossChange"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_3f61736e-b632-407d-bfa2-29dbf6667e3f" xlink:to="loc_lxrx_FederalNetOperatingLossChange_ba4a811d-f64c-473d-86c5-34c265f327c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#IncomeTaxesDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1b3640fc-1126-4866-a673-0071d8abc209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1b3640fc-1126-4866-a673-0071d8abc209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b67812e3-b2a7-42d5-bfd0-97a1223c84aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_b67812e3-b2a7-42d5-bfd0-97a1223c84aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_0038c4d2-9f2d-4a21-9691-9e4e950df066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_0038c4d2-9f2d-4a21-9691-9e4e950df066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_233adcf8-0955-4da1-9e3b-1563a43bbc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_233adcf8-0955-4da1-9e3b-1563a43bbc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0422fea4-44a1-4532-bb18-ac09fc8ea8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0422fea4-44a1-4532-bb18-ac09fc8ea8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_6bee6f6a-a6df-4da9-bd3f-fce9b254e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_6bee6f6a-a6df-4da9-bd3f-fce9b254e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment_691b03f1-2cc5-40c9-b6f5-577ff26a38c1" xlink:href="lxrx-20191231.xsd#lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment_691b03f1-2cc5-40c9-b6f5-577ff26a38c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_cb387dd3-8c5f-4e76-966b-54b27991b74f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_cb387dd3-8c5f-4e76-966b-54b27991b74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8bf993c8-628a-4583-a426-a5f9372f2d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8bf993c8-628a-4583-a426-a5f9372f2d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_db8df2bf-3355-481a-b71c-5321b717db77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_db8df2bf-3355-481a-b71c-5321b717db77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1fe00a51-0501-4d3e-a4b3-dc0b69bf992e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1fe00a51-0501-4d3e-a4b3-dc0b69bf992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bde88636-2856-4982-be8e-861d259e4b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3afb403e-5669-48bb-96e6-804fd5f3da00" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bde88636-2856-4982-be8e-861d259e4b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:type="simple" xlink:href="lxrx-20191231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_e0b3777b-1a1f-4825-8322-091ed584eb4a" xlink:href="lxrx-20191231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1be83fa0-388a-41b6-8cd5-e2c4bcd60de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_e0b3777b-1a1f-4825-8322-091ed584eb4a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1be83fa0-388a-41b6-8cd5-e2c4bcd60de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GoodwillAbstract_458ad6cb-aaf6-43af-b39e-5139e490e3d4" xlink:href="lxrx-20191231.xsd#lxrx_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthGoodwill_b427982c-82db-489b-8e7b-c7072b2fad82" xlink:href="lxrx-20191231.xsd#lxrx_CoelacanthGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_458ad6cb-aaf6-43af-b39e-5139e490e3d4" xlink:to="loc_lxrx_CoelacanthGoodwill_b427982c-82db-489b-8e7b-c7072b2fad82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CoelacanthPurchasePrice_582b1931-0929-4609-be08-c727bd963818" xlink:href="lxrx-20191231.xsd#lxrx_CoelacanthPurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_458ad6cb-aaf6-43af-b39e-5139e490e3d4" xlink:to="loc_lxrx_CoelacanthPurchasePrice_582b1931-0929-4609-be08-c727bd963818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SymphonyIconGoodwill_19d97284-d849-442b-816c-61c80745d8df" xlink:href="lxrx-20191231.xsd#lxrx_SymphonyIconGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_458ad6cb-aaf6-43af-b39e-5139e490e3d4" xlink:to="loc_lxrx_SymphonyIconGoodwill_19d97284-d849-442b-816c-61c80745d8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_800bad7c-31ea-40de-a570-cf541a307d87" xlink:href="lxrx-20191231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1742df97-36de-450a-8c25-018909a57717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_800bad7c-31ea-40de-a570-cf541a307d87" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1742df97-36de-450a-8c25-018909a57717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_ea8287dc-fb5d-4f69-a4ac-76bced762b95" xlink:href="lxrx-20191231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2ecfec5a-0b46-42cd-b6e0-7e0df8444a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_ea8287dc-fb5d-4f69-a4ac-76bced762b95" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2ecfec5a-0b46-42cd-b6e0-7e0df8444a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_fd1322f4-712a-4cf3-8fad-916fe3272dee" xlink:href="lxrx-20191231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_fd1322f4-712a-4cf3-8fad-916fe3272dee" xlink:to="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b17a614-b707-4e6f-97f1-bf5d0d5b7a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4a014621-9c27-4a35-b690-8150f11e1fda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b17a614-b707-4e6f-97f1-bf5d0d5b7a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:to="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2bf76273-dd56-4029-9e55-b049f2dbbe9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_73214885-48c5-41bf-8249-179e91d5f972" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2bf76273-dd56-4029-9e55-b049f2dbbe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_262b5bb7-0853-447f-bf7b-c16f0617e9cc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_792dc5f9-067f-4580-a7e0-192a17e6a871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_792dc5f9-067f-4580-a7e0-192a17e6a871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_b56204c7-fbe7-4eb2-ba18-e5eeafd68d2c" xlink:href="lxrx-20191231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_b56204c7-fbe7-4eb2-ba18-e5eeafd68d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3f5d99cb-dd8d-4aa0-b577-55a3dd4ea172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3f5d99cb-dd8d-4aa0-b577-55a3dd4ea172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_71636335-1cb1-450c-b4a8-50b83bde9e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_71636335-1cb1-450c-b4a8-50b83bde9e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtInstrumentRepurchasePercentage_e5e4bf01-1c76-48c6-bb14-d5154cdf9b9b" xlink:href="lxrx-20191231.xsd#lxrx_DebtInstrumentRepurchasePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_DebtInstrumentRepurchasePercentage_e5e4bf01-1c76-48c6-bb14-d5154cdf9b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_66d60bb3-eeaa-4cfc-bc6a-311265131a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_66d60bb3-eeaa-4cfc-bc6a-311265131a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_503cabe7-c02f-41ec-a319-31d6cad4dc24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentTerm_503cabe7-c02f-41ec-a319-31d6cad4dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_8db3fedd-3ddd-440b-bb7d-7846f089438b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_8db3fedd-3ddd-440b-bb7d-7846f089438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1d715282-d8ab-4c0d-a8aa-7afa44626cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1d715282-d8ab-4c0d-a8aa-7afa44626cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0abfb4b6-79be-4ac3-ac4a-c4952ef6c1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0abfb4b6-79be-4ac3-ac4a-c4952ef6c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_4e9b8e36-d5e7-4cf4-b967-46c2fde6df20" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_4e9b8e36-d5e7-4cf4-b967-46c2fde6df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1269b0b8-f290-4d33-a208-50db175eeb71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1269b0b8-f290-4d33-a208-50db175eeb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_38a81877-def9-42db-a895-9421a78ee436" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_38a81877-def9-42db-a895-9421a78ee436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_f43aac5a-f885-4dc1-b1fb-34280018c93a" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_f43aac5a-f885-4dc1-b1fb-34280018c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_6b5fbcb4-0b8f-4266-bcae-bff436630922" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_6b5fbcb4-0b8f-4266-bcae-bff436630922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db5792eb-9220-4770-b8bb-d7d46459a0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_db5792eb-9220-4770-b8bb-d7d46459a0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstate_2e223930-0efd-413b-9b58-df772e238ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MortgageLoansOnRealEstate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_MortgageLoansOnRealEstate_2e223930-0efd-413b-9b58-df772e238ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral_931826f0-5fcb-4d38-beef-e888b5d4691a" xlink:href="lxrx-20191231.xsd#lxrx_BuildingsCollateral"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_BuildingsCollateral_931826f0-5fcb-4d38-beef-e888b5d4691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral_26f35288-d5af-4e5c-9e66-cee518ff5f92" xlink:href="lxrx-20191231.xsd#lxrx_LandCollateral"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_LandCollateral_26f35288-d5af-4e5c-9e66-cee518ff5f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4baf7528-ca79-4cf7-9858-8852863a83d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4baf7528-ca79-4cf7-9858-8852863a83d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_82bc0c8d-fb05-4706-ab6b-fb4b141f2c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_82bc0c8d-fb05-4706-ab6b-fb4b141f2c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_fe75a23b-09f9-46cd-89f1-9727fd0f4df2" xlink:href="lxrx-20191231.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6cb25b5e-9320-4ee9-bccc-8d83e364e775" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_fe75a23b-09f9-46cd-89f1-9727fd0f4df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="simple" xlink:href="lxrx-20191231.xsd#DebtObligationsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:href="lxrx-20191231.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e75d0487-6380-473b-a5e3-cbc9a998eb51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e75d0487-6380-473b-a5e3-cbc9a998eb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bad2f420-930c-4c7d-8bf0-edebb8c07fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bad2f420-930c-4c7d-8bf0-edebb8c07fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7ab5399e-04ab-4553-91a5-0125ab9e2220" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7ab5399e-04ab-4553-91a5-0125ab9e2220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ba7b04e1-2aea-41d1-b897-f33a6d6cd243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ba7b04e1-2aea-41d1-b897-f33a6d6cd243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_24715f5d-b165-477e-804b-bada6922ed08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_24715f5d-b165-477e-804b-bada6922ed08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_13e36980-a05d-4fb7-9b6e-486e022651aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_13e36980-a05d-4fb7-9b6e-486e022651aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ab0fc3b5-a944-40a6-a71a-6130703cc716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebt_ab0fc3b5-a944-40a6-a71a-6130703cc716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9429e5ad-2101-46d6-bc1a-605728c4a60e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9429e5ad-2101-46d6-bc1a-605728c4a60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d2e86e8e-c345-415b-95eb-e1a33594cde7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtCurrent_d2e86e8e-c345-415b-95eb-e1a33594cde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c24fee84-05de-4d06-8c65-ab617c12ee8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_bc5680f4-709e-4b54-973d-1a8242e24f30" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c24fee84-05de-4d06-8c65-ab617c12ee8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_7349b17e-e9b7-4e2f-b9eb-b00cb1c2e10b" xlink:href="lxrx-20191231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e613a9bf-f6bf-4f47-96f8-a0f29327844f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_7349b17e-e9b7-4e2f-b9eb-b00cb1c2e10b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e613a9bf-f6bf-4f47-96f8-a0f29327844f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_24400b91-9bc0-425f-9c1c-1a6c0863583d" xlink:href="lxrx-20191231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3a98f60d-655c-41a5-9c6b-f4ac23fac40f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_24400b91-9bc0-425f-9c1c-1a6c0863583d" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3a98f60d-655c-41a5-9c6b-f4ac23fac40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_9929b840-38ee-4f73-9983-81f8b2c01f0b" xlink:href="lxrx-20191231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_9929b840-38ee-4f73-9983-81f8b2c01f0b" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:to="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_54250c42-b281-41d0-96b3-f3f3d5aabda8" xlink:to="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a946c46c-adca-4ee0-9143-eb77bcc64358" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:to="loc_srt_MinimumMember_a946c46c-adca-4ee0-9143-eb77bcc64358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10c43aa7-12ee-4de5-89fd-7a8370dda39c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57d2479b-4631-42a8-8efb-ed31a4df0d83" xlink:to="loc_srt_MaximumMember_10c43aa7-12ee-4de5-89fd-7a8370dda39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_15c2ab89-0344-440d-bc13-0fdf172bd87d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_0a5d363f-116b-45ef-b0d4-118068167e21" xlink:href="lxrx-20191231.xsd#lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_a9783308-4146-443d-9a12-d4a1b22d38e3" xlink:to="loc_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod_0a5d363f-116b-45ef-b0d4-118068167e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CommitmentsandContingenciesDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:href="lxrx-20191231.xsd#lxrx_CommitmentsAndContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_18d973ed-68d3-4524-bfd3-6a022aa1802a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_18d973ed-68d3-4524-bfd3-6a022aa1802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f74ede57-de5d-4771-9b62-51e580db171d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f74ede57-de5d-4771-9b62-51e580db171d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_43ee8c48-4047-40a3-b13f-5fa112c80a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_43ee8c48-4047-40a3-b13f-5fa112c80a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a46dd095-aaf1-4580-9f8d-b07455adeeba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a46dd095-aaf1-4580-9f8d-b07455adeeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_e94354af-53e7-4e49-83aa-4d7643cd2389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_e94354af-53e7-4e49-83aa-4d7643cd2389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36dd4b18-f486-4e8f-bf35-c3dbbf4b08a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36dd4b18-f486-4e8f-bf35-c3dbbf4b08a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_86bb9c00-90ca-47a3-a0ce-e60b9e4e30e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_86bb9c00-90ca-47a3-a0ce-e60b9e4e30e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InterestOnLeasePayments_1dab70ce-56d9-41af-8415-a82b9c1472b2" xlink:href="lxrx-20191231.xsd#lxrx_InterestOnLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_lxrx_InterestOnLeasePayments_1dab70ce-56d9-41af-8415-a82b9c1472b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PresentValueOfFutureLeasePayments_6139a0dd-9fef-4311-9538-31339834c54e" xlink:href="lxrx-20191231.xsd#lxrx_PresentValueOfFutureLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_lxrx_PresentValueOfFutureLeasePayments_6139a0dd-9fef-4311-9538-31339834c54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_22f2faac-33de-4afb-9a52-c0be915335e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_22f2faac-33de-4afb-9a52-c0be915335e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cd05d3df-3874-4ff3-acaf-948cd144a8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cd05d3df-3874-4ff3-acaf-948cd144a8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c0dbf61-03e8-45cc-ab2b-7808b905e8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_fed53904-0611-43b4-be0b-2e4b182b00a6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c0dbf61-03e8-45cc-ab2b-7808b905e8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_9e240ec0-c511-4770-8df1-74643bdd1c61" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b96c5079-9742-423c-9c69-d246761cc516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_9e240ec0-c511-4770-8df1-74643bdd1c61" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b96c5079-9742-423c-9c69-d246761cc516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_f806d0b0-047e-4105-9a3b-b8e3a34dd0d4" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1b4ece05-ab6e-419b-ba29-dae7ea03bbb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_f806d0b0-047e-4105-9a3b-b8e3a34dd0d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1b4ece05-ab6e-419b-ba29-dae7ea03bbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4d202f2c-4a41-495c-a9b7-2cf63a73c375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_f806d0b0-047e-4105-9a3b-b8e3a34dd0d4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4d202f2c-4a41-495c-a9b7-2cf63a73c375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_02e87bac-77ac-4de1-9a8e-2349c44724f8" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_02e87bac-77ac-4de1-9a8e-2349c44724f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:to="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dbd74672-d0ec-4355-8c1d-f3646841b8c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88a1bb19-b279-450f-aff7-dc4b66b74d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88a1bb19-b279-450f-aff7-dc4b66b74d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a359024d-c5b0-4ed9-88f8-997ab726bd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e0d7973-daa3-4497-8dd6-c8014090925a" xlink:to="loc_us-gaap_RestrictedStockMember_a359024d-c5b0-4ed9-88f8-997ab726bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:to="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_93f3f887-53c8-4b2c-b697-a3bf49a51cf0" xlink:to="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07b45ec8-8f09-42e1-a77d-69c6cde95c71" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:to="loc_srt_MinimumMember_07b45ec8-8f09-42e1-a77d-69c6cde95c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b6e2a7e-a9ac-4a9a-a384-353f79d7f76a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb242457-f229-4574-9d6f-3769c5930a62" xlink:to="loc_srt_MaximumMember_5b6e2a7e-a9ac-4a9a-a384-353f79d7f76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf9d202-98cc-4d71-84ee-3f804b3f357a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_6a00eca0-0dcf-4a89-b862-004093e9ca85" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_6a00eca0-0dcf-4a89-b862-004093e9ca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_81768178-b3d2-4b9c-b644-d9253aecd17e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_81768178-b3d2-4b9c-b644-d9253aecd17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d7e4b71-4da2-45d1-9f2b-d1f806df51c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d7e4b71-4da2-45d1-9f2b-d1f806df51c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_be681fe7-8cd7-4789-8ba1-6cae7ab1a192" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_be681fe7-8cd7-4789-8ba1-6cae7ab1a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_a6dfd685-36d2-4868-9771-4eea53997631" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_a6dfd685-36d2-4868-9771-4eea53997631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6f60c063-286a-4de3-859e-ba212927cb07" xlink:href="lxrx-20191231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_6f60c063-286a-4de3-859e-ba212927cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_901074fe-354f-47f5-8f21-a17268542a1e" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_901074fe-354f-47f5-8f21-a17268542a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_0e0c60dc-6f35-4e3d-a87e-5fb9d2ea2642" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_0e0c60dc-6f35-4e3d-a87e-5fb9d2ea2642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_4ffa787c-dacc-4a96-801b-b70436b55d97" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_4ffa787c-dacc-4a96-801b-b70436b55d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_4d11fa29-8da9-4743-afa0-bccdd3255ca8" xlink:href="lxrx-20191231.xsd#lxrx_Totalvalueofsharesbynonemployeeinayear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_Totalvalueofsharesbynonemployeeinayear_4d11fa29-8da9-4743-afa0-bccdd3255ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_ee9d17a0-b3d2-4289-b591-6e93dea2c743" xlink:href="lxrx-20191231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_ee9d17a0-b3d2-4289-b591-6e93dea2c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8324404b-628c-48ef-80fd-b609bbcd2767" xlink:href="lxrx-20191231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_8324404b-628c-48ef-80fd-b609bbcd2767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_6559ef7d-4b22-4e7b-ad23-910c51cb42a7" xlink:href="lxrx-20191231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_6559ef7d-4b22-4e7b-ad23-910c51cb42a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_74d0ed98-d65b-425b-ae5f-ce76046d6a94" xlink:href="lxrx-20191231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_74d0ed98-d65b-425b-ae5f-ce76046d6a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55ae37ed-0295-49f0-9998-9894be432092" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55ae37ed-0295-49f0-9998-9894be432092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_55bd8709-6a56-4224-8522-0c4005fb12f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_146aee96-5358-4174-93d4-be780c39f413" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_55bd8709-6a56-4224-8522-0c4005fb12f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_3c5c9388-7722-48b3-b58a-19a4979ca97f" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_3c5c9388-7722-48b3-b58a-19a4979ca97f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:to="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_97cc5fae-513e-4baf-9997-895aed7f2700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa4f887c-5e8d-4b25-a554-1f2ef5e6824c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17f2c6e9-b534-40f8-a3fc-787fd60c411c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa4f887c-5e8d-4b25-a554-1f2ef5e6824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46bac301-56c1-4a7e-99a4-cbaa2015fb29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4168f721-899b-4da1-85b2-047cff914437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4168f721-899b-4da1-85b2-047cff914437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300290e8-acbe-47cf-9f2c-65e22ed55be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300290e8-acbe-47cf-9f2c-65e22ed55be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24eb0dfa-d43f-4c5d-bea5-844d43fc87d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24eb0dfa-d43f-4c5d-bea5-844d43fc87d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1e8d2ca7-d6c2-4779-bbc7-1440524892fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1e8d2ca7-d6c2-4779-bbc7-1440524892fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_860dc658-c415-416b-a61b-8b101248d8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_860dc658-c415-416b-a61b-8b101248d8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b6ca27d-b4f1-4b8f-a278-b331ddb12e18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b6ca27d-b4f1-4b8f-a278-b331ddb12e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bde76914-1115-4314-99d9-2884ed942954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bde76914-1115-4314-99d9-2884ed942954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d5dd6150-bd1b-4323-95b4-aa953210b6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d5dd6150-bd1b-4323-95b4-aa953210b6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_44202f88-43e2-4646-a53f-1a01ae44b50b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_44202f88-43e2-4646-a53f-1a01ae44b50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb62031e-1a6c-42cc-8feb-634818eb37e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb62031e-1a6c-42cc-8feb-634818eb37e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ffd50e9-a337-44ec-8bfa-70825314cace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ffd50e9-a337-44ec-8bfa-70825314cace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae9c5f92-62f0-4e1e-b857-5a4b580fe302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae9c5f92-62f0-4e1e-b857-5a4b580fe302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8083ce79-cf2e-4199-ad62-cf4f9eeaaf6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8083ce79-cf2e-4199-ad62-cf4f9eeaaf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_48f023fd-aca9-4b5c-a719-263114016880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_48f023fd-aca9-4b5c-a719-263114016880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1945bcd8-aa10-4d1d-88d0-1811c68a8b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1945bcd8-aa10-4d1d-88d0-1811c68a8b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17ff77b8-bdf9-44a6-97d7-6a8776a09690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17ff77b8-bdf9-44a6-97d7-6a8776a09690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cef084dc-4a51-4d39-9388-97a9571740c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cef084dc-4a51-4d39-9388-97a9571740c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9f17bef3-532a-40a4-a07d-d3f228af9af3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1707bcb3-5d56-4570-acdb-8b926898e6ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9f17bef3-532a-40a4-a07d-d3f228af9af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails3"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_6abc7532-c809-467d-8bb6-a92a7aa4c730" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_6abc7532-c809-467d-8bb6-a92a7aa4c730" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_658c4777-1404-4935-bd06-2d894ae35ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_addb3f08-f512-451e-b35d-78b2c03736ed" xlink:to="loc_us-gaap_PlanNameDomain_658c4777-1404-4935-bd06-2d894ae35ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1231b748-7cbe-46bb-baf1-886b9f684b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f20507e9-b56d-47fb-90c6-6999531fa02d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1231b748-7cbe-46bb-baf1-886b9f684b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8ed694f4-05d4-4b9a-887a-3490fd4d2a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ced95b7d-0850-4a2b-96d2-10fe99ca5739" xlink:to="loc_us-gaap_ClassOfStockDomain_8ed694f4-05d4-4b9a-887a-3490fd4d2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b614979e-40ee-4daf-b027-c2d3f93891b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2536105e-154e-4cfa-a478-1538c02040c0" xlink:to="loc_srt_RangeMember_b614979e-40ee-4daf-b027-c2d3f93891b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd41b89-d00d-4016-9812-90b4a8f7dc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd1ddc52-2cbb-4f1f-811c-c8e4cb2007cb" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_dd1ddc52-2cbb-4f1f-811c-c8e4cb2007cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_829c8f1f-11ac-461f-ae10-4318d4bbc268" xlink:href="lxrx-20191231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_829c8f1f-11ac-461f-ae10-4318d4bbc268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c87f729d-b505-4196-849b-9d4a36ef7316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d042748-f76b-436d-9030-47020307b591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c87f729d-b505-4196-849b-9d4a36ef7316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EquityIncentiveAwardsDetails4"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_67802fa9-62f4-458b-adae-0bb4aa660090" xlink:href="lxrx-20191231.xsd#lxrx_EquityIncentiveAwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_67802fa9-62f4-458b-adae-0bb4aa660090" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:to="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d6a50ce0-f9d1-4345-b806-4979e4b4bf88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_503b0bee-7147-480c-ad25-d76e6234b7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86bf0171-4f25-4286-8f25-f54f091c4a09" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_503b0bee-7147-480c-ad25-d76e6234b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faee3cc5-57a5-4704-83cf-8ac0e4845895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05872cc3-2980-4bee-aece-fd154f43adda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05872cc3-2980-4bee-aece-fd154f43adda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_418eac8e-a3a9-4446-8945-e6f1adbfa8de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_418eac8e-a3a9-4446-8945-e6f1adbfa8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f394ed3-0297-43e1-a355-a6f3be168bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7f394ed3-0297-43e1-a355-a6f3be168bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4d0489b-26a3-4d8b-abc2-89563509bb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4d0489b-26a3-4d8b-abc2-89563509bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3b43c2dc-27d9-4883-80d9-92724b79f557" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3b43c2dc-27d9-4883-80d9-92724b79f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d0266a2-6b87-4cfb-826e-adf0b7ee4b22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d0266a2-6b87-4cfb-826e-adf0b7ee4b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3de8e933-4e78-4e89-9f5e-cff8d59e09da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3de8e933-4e78-4e89-9f5e-cff8d59e09da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_2d479094-4444-4165-b2cd-058b1a21959d" xlink:href="lxrx-20191231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c3523fe-ede4-4f33-9bda-b29752dbbabf" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_2d479094-4444-4165-b2cd-058b1a21959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlan"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_9a473eb1-0f42-4068-8f95-0aac156a5ef5" xlink:href="lxrx-20191231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_917d0bdd-96ff-4a57-8762-9f61e477fec4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_9a473eb1-0f42-4068-8f95-0aac156a5ef5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_917d0bdd-96ff-4a57-8762-9f61e477fec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#BenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BenefitPlanAbstract_682c03d9-11ab-43ce-9de8-7bf540c99902" xlink:href="lxrx-20191231.xsd#lxrx_BenefitPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_8997a8b9-1458-4415-bf5e-aed3e68edc5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_682c03d9-11ab-43ce-9de8-7bf540c99902" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_8997a8b9-1458-4415-bf5e-aed3e68edc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_9f3e345c-429e-45c6-8bc7-44c080f0d153" xlink:href="lxrx-20191231.xsd#lxrx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_682c03d9-11ab-43ce-9de8-7bf540c99902" xlink:to="loc_lxrx_DefinedContributionPlanRequisiteServicePeriod_9f3e345c-429e-45c6-8bc7-44c080f0d153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_38f70237-6d55-4e67-88a6-7ec289b44bd3" xlink:href="lxrx-20191231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_caa55256-2217-4144-874e-7d47fc2f4766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_38f70237-6d55-4e67-88a6-7ec289b44bd3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_caa55256-2217-4144-874e-7d47fc2f4766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:href="lxrx-20191231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiUpfrontPayment_76876b38-90b9-4eb8-b472-1afb24623b36" xlink:href="lxrx-20191231.xsd#lxrx_SanofiUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiUpfrontPayment_76876b38-90b9-4eb8-b472-1afb24623b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDevelopmentMilestones_1751d4de-0306-4cbc-904c-cc32101d8d26" xlink:href="lxrx-20191231.xsd#lxrx_SanofiDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiDevelopmentMilestones_1751d4de-0306-4cbc-904c-cc32101d8d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_6fa54a81-bbe6-4942-b04a-9a787cf70661" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones_6fa54a81-bbe6-4942-b04a-9a787cf70661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRegulatoryMilestones_5e2e7567-943f-47e8-acc7-661b07025fc7" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRegulatoryMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiRegulatoryMilestones_5e2e7567-943f-47e8-acc7-661b07025fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_1cb483a4-7f5a-493b-9f76-21a07196de8c" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones_1cb483a4-7f5a-493b-9f76-21a07196de8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiOutcomesStudyMilestone_9fd88c2c-bcc0-4a0f-a61f-5b7ace45a5fe" xlink:href="lxrx-20191231.xsd#lxrx_SanofiOutcomesStudyMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiOutcomesStudyMilestone_9fd88c2c-bcc0-4a0f-a61f-5b7ace45a5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiSalesMilestonePayments_d2ded97a-e784-4b6b-9cb2-4b51994cf6e5" xlink:href="lxrx-20191231.xsd#lxrx_SanofiSalesMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiSalesMilestonePayments_d2ded97a-e784-4b6b-9cb2-4b51994cf6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_bbf04d42-5d35-4055-b0e4-f78f97cbde9f" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones_bbf04d42-5d35-4055-b0e4-f78f97cbde9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_23671dfd-645a-4942-bb62-a4ab61fb8f7a" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage_23671dfd-645a-4942-bb62-a4ab61fb8f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_48d51be2-d94b-4893-8dda-8d517e4c3735" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage_48d51be2-d94b-4893-8dda-8d517e4c3735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_d4658ade-3aeb-4b7a-80d1-327d6d4c4238" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod_d4658ade-3aeb-4b7a-80d1-327d6d4c4238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_21d95cd5-f9b5-46d3-8675-86b02a4bfd89" xlink:href="lxrx-20191231.xsd#lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount_21d95cd5-f9b5-46d3-8675-86b02a4bfd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_cfb0599b-8a2d-4bdf-9369-999c2ea60902" xlink:href="lxrx-20191231.xsd#lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_cfb0599b-8a2d-4bdf-9369-999c2ea60902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_779ff1b4-e2dc-40a0-ad05-8af8fafecaa8" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable_779ff1b4-e2dc-40a0-ad05-8af8fafecaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_c4379fbf-8d7d-436c-aaf1-5feea36fc77a" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable_c4379fbf-8d7d-436c-aaf1-5feea36fc77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_9a4d1af5-a335-4b26-81c1-61db5496208a" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiRevenueRecognized_9a4d1af5-a335-4b26-81c1-61db5496208a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_66919074-3d92-4bcf-8384-ba4f62d5a9d6" xlink:href="lxrx-20191231.xsd#lxrx_SanofiRevenueAllocatedtoFundingDeliverable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiRevenueAllocatedtoFundingDeliverable_66919074-3d92-4bcf-8384-ba4f62d5a9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPaymentsToDate_c0af16ae-9102-4e39-b554-d5076338f22a" xlink:href="lxrx-20191231.xsd#lxrx_IpsenTotalPaymentsToDate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenTotalPaymentsToDate_c0af16ae-9102-4e39-b554-d5076338f22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_b59ad1a4-2156-4f75-a590-48862ad800b0" xlink:href="lxrx-20191231.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_b59ad1a4-2156-4f75-a590-48862ad800b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_0a3e8135-6d63-48d6-aa94-f74731413a14" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_0a3e8135-6d63-48d6-aa94-f74731413a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_0e26293a-a119-46f5-8bd9-3308297ae846" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_0e26293a-a119-46f5-8bd9-3308297ae846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_2af00d46-e83a-497d-8910-96b3d0a53ec9" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_2af00d46-e83a-497d-8910-96b3d0a53ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_107f60cd-0a31-4299-b639-6de303e0c3c0" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_107f60cd-0a31-4299-b639-6de303e0c3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_a9d75fbe-524e-4cde-ad69-e27088ee26d2" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_a9d75fbe-524e-4cde-ad69-e27088ee26d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_4a3e8d1c-4d98-4dd3-a64c-041a9d38b12c" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenRevenueRecognized_4a3e8d1c-4d98-4dd3-a64c-041a9d38b12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRoyaltyIncome_LXRX_74a1389b-7930-40ba-987d-b0f53eeb4b8d" xlink:href="lxrx-20191231.xsd#lxrx_IpsenRoyaltyIncome_LXRX"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenRoyaltyIncome_LXRX_74a1389b-7930-40ba-987d-b0f53eeb4b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Ipsenproductsales_cd1f7076-8edb-4bbb-987f-8672dfa7a20c" xlink:href="lxrx-20191231.xsd#lxrx_Ipsenproductsales"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_Ipsenproductsales_cd1f7076-8edb-4bbb-987f-8672dfa7a20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_dd334549-3aa5-48ce-9f62-70c77e8e4295" xlink:href="lxrx-20191231.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_dd334549-3aa5-48ce-9f62-70c77e8e4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_fa228e2b-a6b7-463e-8666-234b6c2ebdfa" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SettlementPaymentFromTermination_fa228e2b-a6b7-463e-8666-234b6c2ebdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentObligation_0b8e73d3-154e-4176-a0e7-ee2ab976666b" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentObligation"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SettlementPaymentObligation_0b8e73d3-154e-4176-a0e7-ee2ab976666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiTerminationAgreement_7f7c16e1-5b94-4b89-bc77-15134205fef5" xlink:href="lxrx-20191231.xsd#lxrx_SanofiTerminationAgreement"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiTerminationAgreement_7f7c16e1-5b94-4b89-bc77-15134205fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDeferredRevenueFromTermination_1fed5f60-8463-4a57-94be-bad8f11b21be" xlink:href="lxrx-20191231.xsd#lxrx_SanofiDeferredRevenueFromTermination"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_lxrx_SanofiDeferredRevenueFromTermination_1fed5f60-8463-4a57-94be-bad8f11b21be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_d75b941e-b23f-40cb-a2f8-d03c386a58d2" xlink:to="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f6f0dd42-197f-49e9-9adf-edbb643fc337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_07ae89ad-9dd0-48cc-9eeb-9fd7c4d6d636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e3be16c-5680-4165-8418-306d68e6c319" xlink:to="loc_us-gaap_SubsequentEventMember_07ae89ad-9dd0-48cc-9eeb-9fd7c4d6d636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5c0adebc-360f-4b1a-906b-61e0cf41c8e2" xlink:to="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_70c5b590-736c-4bf3-8b39-1e03adce94c0" xlink:href="lxrx-20191231.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_439e994a-4cd7-4d88-8b94-555603555d0a" xlink:to="loc_lxrx_SettlementPaymentFromTermination_70c5b590-736c-4bf3-8b39-1e03adce94c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9f7aac0e-f28c-4801-bfce-37c4892ee90f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_383a2bad-7b4d-4dcb-80b1-9d02f4e6678e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9f7aac0e-f28c-4801-bfce-37c4892ee90f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_383a2bad-7b4d-4dcb-80b1-9d02f4e6678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4940a161-e2ad-4d31-bc67-c3d821c1008f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_206452eb-5c4b-4c5a-bbfa-18aebf0f9e02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4940a161-e2ad-4d31-bc67-c3d821c1008f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_206452eb-5c4b-4c5a-bbfa-18aebf0f9e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e72423e6-4299-4320-9e82-e58a96989777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_NetIncomeLoss_e72423e6-4299-4320-9e82-e58a96989777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_f1f1bba3-a227-463b-b07d-fe52dfe43dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_f1f1bba3-a227-463b-b07d-fe52dfe43dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_025e0024-2ca2-458c-8563-66617ac102c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_025e0024-2ca2-458c-8563-66617ac102c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f2fa4cea-149f-463d-a589-91cba0f2536a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f2fa4cea-149f-463d-a589-91cba0f2536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_6509a319-7556-4ab4-8903-056df9486221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_6509a319-7556-4ab4-8903-056df9486221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c2f648df-8bdc-4464-85cd-5317b518ff4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c2f648df-8bdc-4464-85cd-5317b518ff4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_225d5e62-16b0-4cab-a4f9-39da3bc000e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_EarningsPerShareBasic_225d5e62-16b0-4cab-a4f9-39da3bc000e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cd616c13-eaab-47fb-b8a9-d6866ed271d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cd616c13-eaab-47fb-b8a9-d6866ed271d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bf6035b-8415-4a61-b70c-5ae1e5531b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bf6035b-8415-4a61-b70c-5ae1e5531b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_37b0cd11-d3c9-4710-aad5-35ea04a3b78e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_37b0cd11-d3c9-4710-aad5-35ea04a3b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b7c76470-0236-4dd0-a22c-33cb5f04c1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c92027d8-b033-4465-a673-b642e3f80652" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b7c76470-0236-4dd0-a22c-33cb5f04c1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b7866154-e06f-448a-97c0-165168a871bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2ffeeca4-740b-4fcc-9c94-4b670dcece30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b7866154-e06f-448a-97c0-165168a871bd" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2ffeeca4-740b-4fcc-9c94-4b670dcece30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_39cdca43-dee4-4d0d-9ebb-de6a38538659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7704c2d7-99cd-48d8-a81c-7b037b68a9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_39cdca43-dee4-4d0d-9ebb-de6a38538659" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7704c2d7-99cd-48d8-a81c-7b037b68a9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="lxrx-20191231.xsd#SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_42834400-f64e-4694-b2d4-4300bcc2fdab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_42834400-f64e-4694-b2d4-4300bcc2fdab" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dddbaa12-0bf0-4206-8852-7ca89c06be6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80dff2e7-6615-415d-af97-309e436cd685" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dddbaa12-0bf0-4206-8852-7ca89c06be6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_d80ac581-5331-426d-a560-70c51dc4acdb" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_58b970ea-c6e0-43b9-80f8-9b8748a385c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_Revenues_58b970ea-c6e0-43b9-80f8-9b8748a385c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5634857e-b844-49ad-9c23-fda6e45f9cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_OperatingIncomeLoss_5634857e-b844-49ad-9c23-fda6e45f9cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb979920-5245-4d34-8919-ea0c971a5454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_NetIncomeLoss_eb979920-5245-4d34-8919-ea0c971a5454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_09289830-d592-4dfb-b8c9-93c4d929deb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_09289830-d592-4dfb-b8c9-93c4d929deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_882f3bd8-332b-4a22-9ca6-36fe411f62a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_882f3bd8-332b-4a22-9ca6-36fe411f62a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d024f0e8-e89d-4d26-b98c-2b52e7ef2bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d024f0e8-e89d-4d26-b98c-2b52e7ef2bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3045be8-1548-4e49-a29c-e41addc1ea8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3045be8-1548-4e49-a29c-e41addc1ea8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3feedc04-9323-4b35-adeb-42a69ff859c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3feedc04-9323-4b35-adeb-42a69ff859c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_764c59c8-bff4-48c0-9ac2-6f153d37df85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2e24845a-48f8-4c44-bec3-716ff8c24354" xlink:to="loc_us-gaap_EarningsPerShareBasic_764c59c8-bff4-48c0-9ac2-6f153d37df85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>lxrx-20191231_g1.jpg
<TEXT>
begin 644 lxrx-20191231_g1.jpg
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1J7[%'[-WBWXO\
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
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M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M1110 4444 %%%%  0",$53T+PYX>\+V/]E^&="L].MC(TAM["U2&/>QRS;4
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MON.BOY:_UMX6H?[OD&'?G4JXN;_\DQ%./WQ:\CW/85WO5?R4?\F?#G_"2_\
M!Q5XU_Y!'PT_9/\ !,+\M_;NLZ]J5Q&/1?LP$9;Z\=:/^&:_^"\OC7_D9O\
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M/_';X.3>&-;\27!U+QH8IQJNOS7(4)'N&S>?E.>I'4<4 ?85%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M_P"!;4 3>,?^18O?^N!JYIW_ "#X/^N*_P A7/\ B7PEIECH-U=PW%T6CB)
M>Y8C\15FR\%Z5+9Q2M<WF6B4G%TV.E &[16/_P (/I'_ #\WO_@6U'_"#Z1_
MS\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1
M_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_
M .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[
M_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U
M &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L5CV7_([WO_ %Y1?S-'
M_"#Z1_S\WO\ X%M4&@Z?#IGBR\L[=Y&5;.,@R.6/))ZF@#?HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRD<,0*A9&/FU])T4 %%%% !7@O[7/_)</@9_V/<O_HBO>J\%_:Y_Y+A\#/\
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MJ/F.>U 'V%16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H
M7O\ WTM &Q7S'_P4Z_;GU[]DGX9Z/\./@3X?3Q+\;?BCJ)T'X2^$EVL9KU@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\ D'P?]<5_D*FH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M64\.ESIVFF^U&YO4L+4R -Y%NLZPH,84)M7Y56OH.@ KY _X+[_\H;?VA/\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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MDXNFQTJ7_A!](_Y^;W_P+:M+3O\ D'P?]<5_D*FH Q_^$'TC_GYO?_ MJ/\
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M#0=/ATSQ9>6=N\C*MG&09'+'DD]36_6/9?\ ([WO_7E%_,T ;%%%% !1110
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M?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*FJ'3O^0?!_P!<5_D*FH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\#_\ ((E_Z_9O_0JV*Q_
M_P#R")?^OV;_ -"K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "OE?
M_@IW\:?B+\+M$\,>&O!NK6D>G>);;5+;7M/O]'M;V"^A5;9?+DCN8I%*%99
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MOV\-._X\OC+X$U+'3^T?#LT.?KY1_P XKP#]M'_@G%\:_P!M!M-\3_$OP?\
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M HHHH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F: -BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C3X6_\%1_ VN^!
MM9TC]OCX"^)OAIH<_B'6M#A\9^*O"[S^#M?T^&^N+2.:2^3S8;*.:&,%DO\
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M4 8__"2ZO_T*%[_WTM4?$NO:G<Z#=03>&+J%6B(,KLN%]S735F^,?^18O?\
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MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
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MU[E'U]K.RDO^O2J/R/C?]=Z>9>[D.&GC/[Z_=T/7VT[*:\Z*JOR-3Q]^V?\
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M>6:1_ *Y@#S$/&VOWQ,PQ]T?Z1Q7H/P@^#OPU^ O]H_\*G^$%[I7]J^3]O\
M^)E-/YOE;]G^ND?;CS'Z8SGG.!7:^)?^0OH__7Z?_036Q2P7"?"V68J.)P>
MHTJD;VE"E",E=-.TE%-73:=GJFT&7<#\%Y/C(XO 99AZ-6-^6<*-.$E=-.TH
MQ35TVG9ZIM;,Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBBOH#Z@P-2U
M.76=.GT?6/ $UW:74+0W5K<I')'-&P(9&5LAE()!!X(-?#/Q#_X)K?'+]E#Q
M]J'[17_!'OQ ?A_J-_<F[\3_  2\1,9O!GB9OXO+A#;M-N"!A9(B%X51Y2;B
M?T%HKZ/A[BK..&JD_JDDZ516J4II3I58KI4IR]V5NCTE%ZPE&5F8U:%.LES;
MK9K=>C/D']D[_@KGX ^-WQ$/[,?Q_P#A-K/P>^-UFH6^^&OC&=(VOFY_>Z;<
MG;'J$38)4I\Q )"E1O/U-_PDNK_]"A>_]]+7G7[8?["W[,7[=OP]7X>_M(?#
M:WU9+5C)HNM6[&WU/1IS@B>TND_>0N"%. 2C;0'5AQ7R@/B9_P %&O\ @D6?
ML?QYM]=_:6_9\L^(_'^E6PD\:>$+4=]0@!_XF<"+]Z=3O #N[( L9^H_L'AS
MC/W^'I+#8M[X2I/W9O\ ZAJTG[S?2C6:J;*%2M)V,?:UL/I5UC_,O_;E^JT\
MD?>;>(]5=2C^#KP@C!!9<$5EZAI7A_5\_P!J_!^WNL]?M%C ^?S!JC^SG^TY
M\!/VM_AA9?&3]G+XHZ5XL\.WPPE]ID^3#)@$Q31L \$H!&8Y%5QD9'-=W7YQ
MF&75<-B)X7&T7&I!M2A.-I1:W3C)7375-&M2CAL5#WXJ2?=)H\UU#X-_!?5<
MG4?V8?#TI/5V\/VF[\]F:PM1_96_9PU3/VG]F*Q7/7[.GD_^BV%>ST5X-?AO
MAW$_QL'2EZTX/\T>+B.$N%,9_'P%"?\ BI4W^<3P"?\ 8B_9G:0SV/P'U.RD
M/62R\07:'\O.Q^E,_P"&// UL/\ B0ZC\2]*QT_L_P 8R+CZ;MU?05%>>^!^
M#KWC@*4?\,(Q_P#24CRWX;\ WO#*Z$'_ '*<8?\ I"B?/O\ PS'XQL?^0!^T
M'\9(/[JWGBB.Y5?8!HQQ0?@M^TW8?\@#]J3Q='CI_:.@65W^>XC-?05%'^I?
M#Z^"$X?X*U:'_I-1"_XA[PM'^'"I#_!B,13_ /2*L3Y_7P;^W1IW-K^T%:ZC
MCMJ'@6UBS]?*>O./VNV_;&@_9V\0V_Q0U/PI=^'S]D^WR6>F30W7_'W#L*?,
M4'[S9G(Z9QSBOL>N+_:'^$'_  OKX/:Q\)_^$A_LK^U?L_\ I_V3S_*\JXCF
M^YO3=GR]OWAC.><8KQ>)."8XGAW&4,#6KNI.E4C&+Q%62E)P:C%^UG)6;LG=
MI6>K/GN+O#N.+X3S##9=7Q,JLZ%6,(2Q5:<9RE3DHQE[:I)6DVD^9I6>K2U/
MR/KU/]BGP]H/BK]ISPOHGB;PQ#K-E))=/+IMQ&'28I:32)E6X8!E5L'@[>:]
MVUC_ ())_P!DZ7/J7_#0'F>2F[9_PBF,_C]JKN_V</\ @G/_ ,*-^+.B?%__
M (7%_:G]FI.W]G?\(]Y'F>=;20_ZS[0^,>9G[ISMQQG(_F/ACP<\0,%Q+@L1
MC< O8PK4Y3O4HR7(IQ<KI5&VN5.Z2=]K,_CG@WP!\4<OXOR[%9AEB6'IUZ,J
MEZN'DO9QJ1<[Q55N2Y4[I)M[69]"PZ_J-O$MO;^"[I(T4*B(4 4#@  =!3_^
M$EU?_H4+W_OI:V**_N!))61_HXDDK(Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M:V**!F/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 8_@?_D$2_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5;% !1110 4444
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M* "BBB@#-\8_\BQ>_P#7 U<T[_D'P?\ 7%?Y"J?C'_D6+W_K@:N:=_R#X/\
MKBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_
M ->47\S6Q6/9?\CO>_\ 7E%_,T ;%%%% !1110 4444 %%%% !1110 4444
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M>^%%]_P4$\>:#\"->^'GAZ:*]\:?!/0K:^.I:1H[RJI*:JY"W-S$KCS9%01
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MJ:L*RL_&ALXC%K-F%\I=H-L<@8^M2_8O&_\ T&[+_P !C_C0!L45C_8O&_\
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ME]"%&G_+"*BK]W9*[?5O5]38HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&NX](V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M_'*/^&G?V:_^CA? W_A66?\ \<KP[_AR#_P2;_Z,4\#?^ LO_P <H_X<@_\
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M0.223T% 'YF_L6V5FG_!SI^V;?I9H9A\+?!@$BH Q#:=I^1GWV)_WR/2O4?
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M\0Z^<X T?PQ=OGZ;T6D_X;!UK53M\(_LI_%&]S]R6\\/+:1/[AGD/'OBO:@
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M^P:M8>7]KM/['O)?+WQK(OS1PLIRCJ>">N#SD5B_\/#?V/?^BO\ _EOZA_\
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M[P]IL-AHVE64>V*UMXD"(BCV ')R2>223FOQ4_85_:4_:P\4?%/PUX]_9\^
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MWLZ-<> [.=OSN3,?UKUWP9^PO\'_  1&(?#O[0/C'24"X\KPU?6^F1D>FV"
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M2,DZCJU95ZSBM6H1A+"4;RV]^,E%-NTFE?\ FK7Q]XT3QZ/BBGB:\'B(:O\
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M )39\N_\/A?@CH''Q<_9Q^.?@(K_ *UO%?PON8T3U.86DR/>M[PA_P %A/\
M@FSXU<1:9^U7HEI)G#1ZW8WFG%&[@_:H8P,?7%?0G_"8^&/^@U!_WU6!XO\
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MV?8M%?''_#OSQIX3^;X0_P#!57XYZ9M_U47B?7X-<B3V"31)Q[9H_P"%1_\
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M#R+#2[6%69(YI0C23RN52 21H9)'61 #[/HHHH **** "BBB@ HHHH ****
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MQ&+E&=948RC"=2-.%+G:G.;YG3IP4FG9\M[7;;A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHKWCYHA_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"L[Q=8V
M4?AJ\>.SB5A"<%8P"*UZS?&/_(L7O_7 T 3:?I]@UA 390DF%<DQCT%3?V=I
M_P#SXP_]^A1IW_(/@_ZXK_(5-0!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%>:?&_P#8G_9+_:0@DC^-?[/OA?7II%VG49M,
M6*]4>BW,6V9?^ N*]1HK*M0HXB')5BI+LTFON9W9=F>991BEB<!7G1J+:4)2
MA)>DHM-?>?($G_!+#Q7\(6-[^Q-^VQ\0_AV(^;?PWKTT?B+1(P/X%M;SE,]"
MV]B!CTI#\5?^"K/[/WR?%K]E/P+\8]'A^_K7PQUDZ;J*QC^.2SO%(ED_V(<#
MGKQ7V!17G?V/1I?[K.5+_"_=_P# 9<T5\DC[3_B(V9X_3/,-0QRZNM3M5?FZ
M]%TJ\GVYZDE?H];_ "MX)_X*V_L7:GKL?@GXS?V_\)/$;\-H7Q4\+RZ4X(X)
M\XAH H/=I%SUQ7TCX3\0^ /'NB1>)O VN:/K6FW S!J&DW,5S!(/]F2,E3^!
MI?&WP_\  ?Q+T*3PM\1_!.D>(-,F_P!;IVMZ;%=0/QCF.564_E7S=XL_X) ?
MLHC7)O&?P!O_ !A\'?$,IW-JWPO\43Z>KL,X#0,7AV<\JJ+D9%'_  M8?^2J
MOG"7_MT6_P#P%!;PSSC9XC 3??EQ5*_JO8U81^5>7KT^HO[.T_\ Y\8?^_0H
M_L[3_P#GQA_[]"ODK_A67_!7C]GWYOAW\?/ 7QNT:'II?CW16T75O+'1([FU
M)BD?MYDW7KBG+_P53U#X1L++]M[]C3XE?"HQ\7/B"WT[^WM"C[$_;;('ZX$9
MX_4_MC#TM,3"5+_$O=_\#C>'WR#_ (AOF^.][),11QZZ*A4_>OTP]54\0W_A
MI-7Z[7^L_P"SM/\ ^?&'_OT*/[.T_P#Y\8?^_0K@/@C^US^S%^TA;)<? WXZ
M^&?$DC)O-EI^J)]KC7KE[=B)8_\ @2BO1:]*E6I5X*=.2DGU3NOO1\3C\NS#
M*L5+#8VC*E4CO&<7&2]8R2:^XPO!=E9RZ5(TMI$Q^V2C+1@\;JU_[.T__GQA
M_P"_0KQW]C+]K;X1?M5Z1XR_X57JXN3X/\9WFC:@"X/F[3F.Y3'6&4;MC=]C
M>E>T4J%>CB:2J4I*47LT7FF59CDN.G@L?2E2JPMS1DK-72:NO--/T9#_ &=I
M_P#SXP_]^A1_9VG_ //C#_WZ%<E\4_VBO@%\#K8W7QC^-/A;PNH7<$UW7H+5
MW&,_*DCAG/H "37@>K?\%D/V3-5U&70/@#H'Q ^+FJ1-L:Q^&W@:[O K]@9)
M5B3'<LI88YYKFQ&99?A)<M6K%/M=7^2W?W'LY/P3Q?G]+VV7X"K4IK>:A+V:
M\Y5&E"*\W)(^J?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"ODX?M+_P#!5#XPC;\%
M?V"?#G@*SD_X]];^+GC0.2#W>QL1YT>/0DT']CK_ (*+_%[]Y^T#_P %(;GP
MY9R_ZW0/A#X4AT[R\]=E_-F?V&5XZUS_ -JNK_N]"I/SY>1??-Q?W)GL_P"H
M5/!:YOFF%P_]U5?K$_3EPL:T4_*<H6ZM'U!XI\0> O VD/X@\;:WI&CV$7^L
MO=5N8K>%/J\A"C\Z^>_B+_P5E_X)X?#_ %+_ (1VQ^-5AXLUAV*VVD>!-+FU
MF:X8?PH]LC1$_5Q53PK_ ,$<OV(;#5X_%/Q0\,>(_B9K<?\ S&OB5XLNM4F?
MUW(62%L]\QU]"?#OX0?";X0Z;_8WPH^&'A[PS:;0IMO#^C06:$#U6)5!HOG=
M;90IK_MZ;^[W$OO8<GA?EGQ3Q6-DNRI86%_*3^LSDO\ MRFWY;GS&/V\/VK/
MBP?*_9A_X)=^-[BWEXBUKXH7UKX:A0=I?)D+R2IW 4@D&E_X4Q_P5U^,HSX^
M_:1^%GPDL9>MI\/?!SZQ>!/[KRZ@0BOCC='P.HKZ]HH_LRK5_P!XQ$Y>2:@O
M_)$I??)A_KS@<#IE&486B^DJD)8F?S^L2J4K_P"&C%>1\BVW_!';X+>-)%O?
MVHOCS\5OBU*S!IK+Q5XUFAT\'_IG;6OE^6O^SO->U?"7]BC]D;X%+$WPE_9P
M\':+/#CR[^WT&%KOCIFX=6E;\6->H45M0RK+<-/GITH\W=J\O_ G=_B>9FG'
MW&><X?ZOB\?5=+_GVI.%)>E*'+37RBB'^SM/_P"?&'_OT*/[.T__ )\8?^_0
MJ:BO0/D2'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@#"\1V5FFJZ2J6D0#7A# 1CD;36O\ V=I__/C#_P!^A6;X
ME_Y"^C_]?I_]!-;% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SX
MP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $
M/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A4U% $/]G:?_SXP_\ ?H5E>)OAI\./&D/V;QC\/]$U:/&/+U/2H9UQZ8=3
M6W12E&,E9JZ-*5:K0J*=.3C)=4[/[T>)^,O^";W[ _CS<WB+]D'X?[W^_-8>
M&H+.1CZE[=48GWS7G5__ ,$4OV 8;E]0\ > O$G@RZ<Y:Z\)^.=2MVW>H#SN
MH_  5]8T5Y]7*,JK.\Z$&^_*K_?:Y]=@O$7C_+8>SPV:XF$?Y56J<K]8\W*_
MFCY%/_!*SQ1X6/F?"+_@HS\?-&(YCMM:\50ZO;1^RQ30CCVR:/\ AD[_ (*C
M>"_F\%?\%(?#WB6)?]59>,OA#918]FFM7WM]<5]=5R7QW\!^,OBE\&_$GPW^
M'_Q$_P"$2U?7=)EL;3Q(-.-VVG^:-CRI$)8MSA"VT[QM8AN<8.%3)\'3@Y4E
M--+11J3C?RMS*/WZ'K83Q(XDQF*ITLPJ8><)22E.OA,/6Y4W9R;="571:OD?
M,[:7>A_/%_P4@_:V^-'[4WQZFL_B_P"+O#6L?\(0;C0]-N_!ME+;Z9<B.=_,
MNHEE9F)D8#Y^-RQQX  %?H1_P3@\1_MH_P#!3#X#QRZE^W?'X'TCP>\&A:OH
MW@WPE#_;=V(X$\NYFOIF+QM*N3YD8PSK)\H*UR6L?\&P_P#9.ESZE_PV]YGD
MINV?\*UQG\?[2KZ/_P"":?\ P2)\9?\ !/3XKW_Q*T;]K+_A)='U_1OL>M>&
MG\$FS6X((>&82_;I-KQMNP=ARLDB\;LC\^R7(^)Z><NMC:4O9U'[]JB3\KN,
M[M+MVN?U]XF>*7@;C/#2&6\,8ZC]<P<;X92P4Y1NVO:**JX=TZ<JBNU+2T[.
MZW/0?AW_ ,$@/V)/".MIXQ^(/@O5OB;XA&/,U_XH:[-K$TO?YXY"(&YYYCIO
M[3G_  1Z_86_:7EL_%$?PN_X5YXSTD Z#\0?A7*-!UC3G (5EEME"R[0< 2H
MX Z8KZAHK]CX>QN+X3QBQ>33>'J[<U-\K:>ZDU\2?VE*ZDM&FC^%,_XEXAXI
MM_:^+J5TME.;E&/^&+?+%+HHI)=#\_QJO_!8'_@G;^[\9^$-/_:Y^%UI_P Q
M;0+./2_'6FVX'62UYAU/:, >63-(<EBN:][_ &/?^"E/[$G[<#RZ#\&/B-:V
M_BNSW+JWP_\ $]E_9NO:=(H_>))9S8=]G1GB\R,'C=7T+7@G[87_  3-_8U_
M;B2+5?CA\)H%\366UM(\=^'9FT[7=.D7_5O%>PX=MAY5)-\8/.ROO/\ 6'A+
MB7W<^PGU>L_^8C"QC%-]ZN%;C2EYNC*@^K4V?,>QKT?X4KKM+]);_?<]U_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*^"_P#A"O\ @L=_P3MS+\./%MM^UM\+[3D:
M!XJNDTSQSIMNHZ17N##J149),H,LAPJJM>Q?LC_\%9OV//VN?$S_  ITKQ5J
M'@?XDVL@AU/X6?$G3VT;7K:? )B6"8XG(ZXA9R!R0M<.9<!9K0P4\PRRI#&X
M6*O*I0;ER+_I[2:C5H]KU(*#?PSEN7#%0<N2:Y9=GU]'L_DSZ2_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHKX<Z2'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*R].
MBCA\:7L<4:JHLX\*HP.IK:K'LO\ D=[W_KRB_F: -BBBB@ HHHH **** "BB
MB@ HHKRC]EG]L?X-_M>Q>,)?A'J_VD>"_%MSH6H[G!\TQ_<N8\=891N*-WV-
MZ5E.O1IU8TY22E*]EWMO;T._#Y5F.+P-?&T:4I4J/+[226D.=VAS/IS-67=G
MJ]%%%:G %%%% !117SS_ ,%._B=^U5\ /V.?B#^TK^RMXT\%6.J_#GP7J?B6
M[TCQOX7N=0MM3M[&W>ZFA5[>[@>"0Q1.$;#J7V@@ E@ ?0U%?)?_  2#_P""
MI/A'_@IO^SY/KFM^'QX3^*W@FZ&C_%KX>W*/%<:)JB;E9UBD_>"WE*.R;LE2
MKQ,2T3$]%\'/BC^UAXE_;\^)WP$\:?$OP;<>"/ OA3PSK.G0V'@J>#4KMM5?
M5$>&6=KYXPL7]F@AEBRWG8(79EP#Z2HHHH ***^)?^"XW[5G[5W[''P)\ ?%
M+]F?XEZ+H,>L?%[P]X;\0Q7OA9+Z[GM;VX*/Y$LTABAX7:0T#L0Q*NA H ^V
MJ*** "BBB@ JKK>AZ+XFT:[\.^)-(M=0T^_MWM[ZPOK=98;B%U*O'(C JZL"
M05(((.#7P1^TK^V;^W[X#_X+$?##_@G7\,_B9\,[+PI\3O NJ>(X->UKX;WE
M[?:8UG]K8VQ6/58$F#+!&!)A""S':<"K?[6'_!0O]L/_ ()B?''X4VW[8,/P
M]^(7PA^*_C6W\(KXR\$>&[W0=6\,ZK< F%KFTGOKV.\MV"R-NB:)U6-\J2%$
M@![_ /L_?\$]/@G^R+KU_/\ LEZWXB^'GAK5M4.HZK\.]%O8I_#TMRQ'F20V
MEW%*; N!AELWMT. 2I(%>[UY9\?_  %^U9XO^)7PQUO]GSX]Z1X0\,Z'XJ>Z
M^*&B:CX9COI?$NE>5A;2"5^;5P_.]<'Y@=V$,<GJ= !12.Z1H9)&"JHRS$X
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M.6;3;J%)9(W@N(95:WD&V19$:)_-W"10#Z\HHHH *\%_:Y_Y+A\#/^Q[E_\
M1%>]5X+^US_R7#X&?]CW+_Z(H ]ZHHHH **** "BBB@ HHHH **** "BBB@
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M:JY'Y[/T>WY/R/LBBFPS17$2SP2JZ.H9'1LA@>001U%.KX#8Z@HHHH ****
M"L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "BBB@#P3]H3X@_\%$O
M#GQ'ETS]FS]GGP#XD\,"TB:+4_$/BV2SN6F(/F*8U4@*#C![UQ'_  M__@L=
M_P!&>_"7_P .#-_\17UE17FU,OJU*CDL145^BY;+TO%O\3[7!<7X#!X2G0ED
M^$J.*2YYJOS2MUERUXQN^MHI>1\F_P#"W_\ @L=_T9[\)?\ PX,W_P 11_PM
M_P#X+'?]&>_"7_PX,W_Q%?65%1_9E;_H)J??#_Y ZO\ 7C+O^A'@O_ <1_\
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M$IO@+^Q=\</C[\0O@F#I7ACX]#2[G4O"%E%Y,6CWL":@ETUJZGY(IOMBNL8
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M!\=^'=;\5^/K&WN7A'B9;#3IGLM+D=""UL)H9)IX,E9E6-'!3<&Y']I#1?\
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MQ$M?BE\1--OKOPSXP\:^/=<N[_3W@N;O^Q-0BAO+J0:<K121B1+9(1<VY3S
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M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** .4URU\4
MKJ.FK=:I;.[7)$#+ 0%;;U/K6G]B\;_]!NR_\!C_ (T>)?\ D+Z/_P!?I_\
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M_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&N,^.G[-?@/\
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M_D*FJ'3O^0?!_P!<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'\#_\ ((E_Z_9O_0JV*Q_ _P#R")?^OV;_ -"K8H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#'\2_\ (7T?_K]/_H)K8K'\2_\ (7T?
M_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\8_\
M(L7O_7 U<T[_ )!\'_7%?Y"J?C'_ )%B]_ZX&KFG?\@^#_KBO\A0!-1110 4
M444 %%%% !1110 4444 %%%% !6=XM\'^$O'_AN\\&^._"^G:WH^HPF'4-*U
M>QCN;:YC/5)(I 5=3Z$$5HT54)SI34X.S6J:T::ZH&DT?#'C+_@C3<_ SQ/>
M?%O_ ()1_M):Y\!/$-U.;B_\&9;5/!VL29R1/ILY80%A\OF1']VI^2,53TS_
M (*T_'?]D+4H/!'_  5Y_9/O_A_;M,L$'QF^'<,^L^#KUBVU6E*!KC3BQ^['
M*'8X)(45]YU!J>F:;K>G3Z/K.G07=I=1-%<VMU"LD<J,,,K*P(92."#P:_0J
M?'TLVIJAQ/AECHK15&^3%17]W$)-SLME7C6BE\*CN<CPOLW>B^7RWC]W^5CY
M _;@_P""YG[!'[%7P6T+XN-\3;3XA3>+HI)/".B> =0M[V74$3 >9Y0_EP1*
MQ"LSG=NRJH[*P'R3^S#_ ,'9_P"RQ\3OC3'H'[0'P U[X;Z5JS1VD'B2+7(]
M6MK1MV!)=*L,,D4?/+(LI'<8R1^8_P#P<'?L_>$/V;_^"JGQ!\#_  U^%>F>
M#_"M[9:1J?AS2M%L5MK1HIM.M_/EBC7"JINUNAA0%!4@ 8KXKK^[/#[Z+?A'
MGO &&Q]=5JU3%TXU8U74<)TU4BI1BH0;I\T$TI<RG>2;LD^5?,8O.\?2Q3BK
M)1=K6WM^.OR/[@=,U/3=:TVWUG1M0@N[.[@2:TN[:421S1L RNC*2&4@@@C@
M@YJ>OD__ ((8R?$*7_@DI\#7^)_VC^T_^$/Q;_:L[O[/%S,+#K_#]C^S[?\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX+^US_R7#X&?]CW+_P"B*ZKXK>%/VL]7\7/>?!_XK^%](T4P($LM6T)[B82
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M[T >]45X+_PK[_@H?_T<%X$_\)=Z/^%??\%#_P#HX+P)_P"$N] 'O5%>"_\
M"OO^"A__ $<%X$_\)=Z/^%??\%#_ /HX+P)_X2[T >]45X+_ ,*^_P""A_\
MT<%X$_\ "7>C_A7W_!0__HX+P)_X2[T >Q>!_P#D$2_]?LW_ *%6Q7R3^SQ?
M_MY_%KP1=^)?#_QN\(6<%OKU[9/%>^&]SF2&4HS J,;2>0.M=Y_PK[_@H?\
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M_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWH ]B\2_\
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MA_\ T<%X$_\ "7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\
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M<%P &:&2<LC\'H1R*]?HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!YC^UC\1/COX"^&4%A^S#\/M+\1?$#Q)JT>D>%X_$<\L.D
M6$SQ2S/?:A)"#(MM##!*Y5!OE<1PJ5:4,/B/3OVV_P#@JQ^P7^W;\(_V>?\
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MC;Q'^SQ\5)/#>E_$&^MTBNM>TF42/9O<A %>X5(BS/U*RH&W,"[@'WI1110
M4444 %%%% !1110 4444 %>,_MC>._VL-)T+1?AC^Q5X.\.77COQ3<3!?$GC
MA;@Z'X:L(%4SWMRL&)+B7=)#%#;(RF1Y2Y(CAD->S4RXN+>SMY+N[G2**)"\
MLLC!510,DDG@ #O0!^=_[-/[<W_!2#]G3_@IAX5_X)J?\%,+3P#XOM_BOX;U
M+5OA1\4/AWI<]@LT]A ]Q=V5W;2L0I6*)R"N-I:+YI/-_=^L-^U_\9/VKOV]
MOB/^Q-^RCXWTKPEHOP2T+3)_B7X[O-"&J7-QK6I*\MGI5I"\B1)''!%))/,V
M]MQ$2K&09*G^#/PLA_;#_;HM/^"D.OV)7P7X"\)7GA?X$1SQX?5/MDBMJGB-
M1U6"=8XK6US_ *R".6?!2XA-> ?\$*[+4M)_X*$?\%#]+\2J5U3_ (:&CN6C
ME_UGV*8W\EHQ[[#$05]J /J#_@G'^W%K?[6FE?$;X5_%K1M-TOXI?!7Q]=^$
M/B)8Z,'6RNY8F)MM4M$D9I([:[A'F)&[,Z,LB%FV!VXCX'_MM_M7>+O^"QOC
M_P#8+^,'A'P5I/@_PU\&K;Q=X>;PY/=75W=/<:A#;AKBXG2(':!,-D<2@9R6
M?C'B_P#P21AU/5/^"VO_  41\5:0KIH/_"4>#K"0@?NY;Z&QNUDP>A92'W=Q
MY@SUKL_AW_RLT_$;_LT#2/\ U(&H ]I_;J\5?\%0+SQAX9^&W_!-3PE\+H)O
MLD^H>-_%_P 98]0_LJVB+".UM+1;$^9-<NRSN_!6)(X]Q4S)GQ+]F+]H;_@L
MUI7_  4I\,?L=_MGZ_\ LYZKH%U\.=3\8^)W^%6BZVMY8V4<RV5FK2WTRI&T
MUY(2H"/NCM+C[I (_0.OD7_@FF!\=_C/^T!^W[=@36OCSXAMX0\!W.,HWAKP
MT9-.CDB8\[)]2.JS\<$2(>P  /KJBBB@ HHHH **** "BBB@ HHHH *YWXN^
M/+OX7_"_7_B%IO@_4/$-WH^E37-CX?TE0;K5+A4/E6L6> \LFV,%L*"X+$ $
MUT5% 'Y;?MI_MB_\%V/^";'@*']O3]H;3O@9XY^$^G:K9K\1/AIX'TZ_AU'P
M[87,Z0K);7]PX^U.CR1QM(RA2SAO)"9:/ZB_;M_X*!ZI\$;;X,?"']G:PTS4
M_B5^T1XH@TCX>?V_!(]GIMD(DN+[6+J&-XY)HK6W=6\A71G>1%W*-Q%+_@H1
M\.X_^"@]S!_P3=T#?+X4NM8TS5?CUK<!(33M&MYXKZ#1D<?\OU_)% -@.8;3
MS97QYMNLWSY_P4"TBXT?_@XX_8'U'5;=8/#C>&?'5GI2E=L"7B:-<Y1 !@-^
M\M  /]GTH ^@?#7[7OQ>_9Q_X*"^$/V OVJ_&.F>*K7XM>$;[6/A1X\L]#73
M)YM1TX;]1TB[@21XG(@:.XBF3R_E+1.K,%D;#_X*]_MR?M9_L0-\&-4^"?A+
MP3+X:^(7QR\-^"/$.K:S<7-QJ-O'?S2-(8+952)!Y=NZ>:TLAS*,1#&X>/\
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M%\=/"'B/P$)=,3Q?J6@^$+BSU7Q=:6-Q%<1P2B6ZDAL3-);Q>>\8E+KYJQB
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\#?\
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M'B+_ (*1?M0?LA_#3]I)?VI?A/HE]\0_AQHOB7^RS\#[ZYBL);^PANO)W?\
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M9&XB@LY"X&);^ *V3@_=- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5!(4R,VT$@8KTVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795794768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,216&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,682&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294,448&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,469)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,545)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,217)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,797)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,018)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,138)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.48)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.48)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Shares used in computing net income (loss) per common share, basic </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,713)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,272)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,927)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,821)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,549)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,396)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,782)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.40)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.33)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.26)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net loss per common share, basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,881&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Revenues for the three months ended September 30, 2019 include $260&#160;million from the Sanofi Termination Agreement, as defined in Note 13.</span></div>For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792342512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786391408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DefinedContributionPlanRequisiteServicePeriod', window );">Years of service</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DefinedContributionPlanRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DefinedContributionPlanRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806510704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,788<span></span>
</td>
<td class="nump">$ 75,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,741)<span></span>
</td>
<td class="num">(60,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,047<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,587<span></span>
</td>
<td class="nump">4,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,279<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,212<span></span>
</td>
<td class="nump">59,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792322752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 24.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20191231.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 124,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 508,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 45,
    "http://www.lexpharma.com/20191231": 9,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 59
   },
   "keyCustom": 93,
   "keyStandard": 353,
   "memberCustom": 0,
   "memberStandard": 28,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lexpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115103 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Property and Equipment",
     "role": "http://www.lexpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Income Taxes",
     "role": "http://www.lexpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Goodwill",
     "role": "http://www.lexpharma.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Equity Incentive Awards",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - Benefit Plan",
     "role": "http://www.lexpharma.com/role/BenefitPlan",
     "shortName": "Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Earnings Per Share",
     "role": "http://www.lexpharma.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158115 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Debt Obligations Debt Obligations (Tables)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables",
     "shortName": "Debt Obligations Debt Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "if05c5deaf74d41e7aa9d53b249dbcc42_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheet Parentheticals",
     "role": "http://www.lexpharma.com/role/BalanceSheetParentheticals",
     "shortName": "Balance Sheet Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345310 - Disclosure - Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356312 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359313 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails",
     "shortName": "Summary of Significant Accounting Policies Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails",
     "shortName": "Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails",
     "shortName": "Summary of Significant Accounting Policies Intangible asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "Summary of Significant Accounting Policies Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
     "shortName": "Summary of Significant Accounting Policies - Cost of Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Recent Accounting Pronouncements (Details)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails",
     "shortName": "Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "iead7811281254bcbb2692b1ba9a8a25b_I20190101",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash and Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Income Taxes (Details 1)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i518a6981e36c42a6a7263b4a8fad852d_I20170227",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Income Taxes (Details 2)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i518a6981e36c42a6a7263b4a8fad852d_I20170227",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "role": "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals",
     "shortName": "Statements of Comprehensive Loss Parentheticals (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Income Taxes (Details 3)",
     "role": "http://www.lexpharma.com/role/IncomeTaxesDetails3",
     "shortName": "Income Taxes (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i8c6df2280ae0495591132f2f5d361b8e_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Goodwill (Details)",
     "role": "http://www.lexpharma.com/role/GoodwillDetails",
     "shortName": "Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i8c6df2280ae0495591132f2f5d361b8e_I20010712",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "lxrx:CoelacanthGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i337cde26133a4419842ffadf1b382833_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Debt Obligations - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
     "shortName": "Debt Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i337cde26133a4419842ffadf1b382833_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Debt Obligations (Details 1)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails1",
     "shortName": "Debt Obligations (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1d6ed6d282844c3dbc84721dd2091ae1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
     "shortName": "Equity Incentive Awards - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Equity Incentive Awards (Details 2)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
     "shortName": "Equity Incentive Awards (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Equity Incentive Awards (Details 3)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
     "shortName": "Equity Incentive Awards (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i2cf18c961781453a902022b81e8fb9be_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Equity Incentive Awards (Details 4)",
     "role": "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
     "shortName": "Equity Incentive Awards (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i2cf18c961781453a902022b81e8fb9be_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Benefit Plan (Details)",
     "role": "http://www.lexpharma.com/role/BenefitPlanDetails",
     "shortName": "Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i15195352c4e8468894a3f6db6b28643f_D20151101-20151130",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "lxrx:SanofiUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Collaboration and License Agreements (Details)",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i15195352c4e8468894a3f6db6b28643f_D20151101-20151130",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "lxrx:SanofiUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457430 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "role": "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.lexpharma.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20191231.htm",
      "contextRef": "i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "verboseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_BalanceSheetParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance Sheet Parentheticals [Abstract]",
        "label": "Balance Sheet Parentheticals [Abstract]",
        "terseLabel": "Balance Sheet Parentheticals [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_BenefitPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Benefit Plan [Abstract]",
        "label": "Benefit Plan [Abstract]",
        "terseLabel": "Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "BenefitPlanAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_BuildingsCollateral": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The buildings that serve as collateral for Lexicon's mortgage loan.",
        "label": "Buildings Collateral",
        "terseLabel": "Buildings Collateral"
       }
      }
     },
     "localname": "BuildingsCollateral",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.",
        "label": "Change in fair value of Symphony Icon Inc. purchase liability",
        "terseLabel": "Increase in fair value of Symphony Icon, Inc. purchase liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfSymphonyIconIncPurchaseLiability",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CoelacanthGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.",
        "label": "Coelacanth Goodwill",
        "terseLabel": "Coelacanth Goodwill"
       }
      }
     },
     "localname": "CoelacanthGoodwill",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CoelacanthPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.",
        "label": "Coelacanth Purchase Price",
        "terseLabel": "Coelacanth Purchase Price"
       }
      }
     },
     "localname": "CoelacanthPurchasePrice",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and Contingencies",
        "label": "Commitments and Contingencies [Abstract]",
        "terseLabel": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "label": "Consolidated Statements of Operations Parentheticals [Abstract]",
        "terseLabel": "Consolidated Statements of Operations Parentheticals [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsParentheticalsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.",
        "label": "Convertible Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Convertible Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost Of Goods And Services Sold, Period Reflecting Lower Average Per Unit Cost Of Materials",
        "label": "Cost Of Goods And Services Sold, Period Reflecting Lower Average Per Unit Cost Of Materials",
        "terseLabel": "Periot to reflect a lower average per unit cost of materials"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DebtInstrumentRepurchasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Percentage",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Repurchase price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Compensation Arrangement With Individual, Payment Period",
        "label": "Deferred Compensation Arrangement With Individual, Payment Period",
        "terseLabel": "Payment period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPaymentPeriod",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DeferredTaxAssetsSection163j_LXRX": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017",
        "label": "Deferred Tax Assets, Section 163j_LXRX",
        "terseLabel": "Deferred Tax Assets, Section 163j_LXRX"
       }
      }
     },
     "localname": "DeferredTaxAssetsSection163j_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.",
        "label": "Deferred Tax Liability Related to Acquisition of Symphony Icon",
        "negatedTerseLabel": "Deferred Tax Liability Related to Acquisition of Symphony Icon",
        "terseLabel": "Deferred Tax Liability Related to Acquisition of Symphony Icon"
       }
      }
     },
     "localname": "DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liability from Reclassified Indefinite-lived Intangible - remeasured amount calculated using the tax rate of 21 percent from 35 percent and relating to the deferred tax liability associated with the indefinite-lived intangible asset associated with the Symphony Icon acquisition",
        "label": "Deferred Tax Liability from Reclassified Indefinite-lived Intangible",
        "terseLabel": "Deferred Tax Liability from Reclassified Indefinite-lived Intangible"
       }
      }
     },
     "localname": "DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liability from Reclassified Intangible Asset - Upon approval by FDA, the indefinite-lived intangible asset was reclassified finite-lived asset and the tax effect was to book to a deferred tax liability with offset to accumulated deferred tax benefit.",
        "label": "Deferred Tax Liability from Reclassified Intangible Asset",
        "terseLabel": "Deferred Tax Liability from Reclassified Intangible Asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilityfromReclassifiedIntangibleAsset",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DefinedContributionPlanRequisiteServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Contribution Plan, Requisite Service Period",
        "label": "Defined Contribution Plan, Requisite Service Period",
        "terseLabel": "Years of service"
       }
      }
     },
     "localname": "DefinedContributionPlanRequisiteServicePeriod",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.",
        "label": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent",
        "terseLabel": "Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "label": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany",
        "terseLabel": "Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from external customers attributed to France as a percentage of total revenue.",
        "label": "Disclosure On Geographic Areas Revenue From External Customers Attributed to France",
        "terseLabel": "Disclosure On Geographic Areas Revenue From External Customers Attributed to France"
       }
      }
     },
     "localname": "DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment",
        "label": "Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment",
        "terseLabel": "Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_EntityWideRevenueIpsenPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.",
        "label": "Entity Wide Revenue Ipsen Percentage",
        "terseLabel": "Entity Wide Revenue Ipsen Percentage"
       }
      }
     },
     "localname": "EntityWideRevenueIpsenPercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EntityWideRevenueSanofiPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.",
        "label": "Entity Wide Revenue Sanofi Percentage",
        "terseLabel": "Entity Wide Revenue Sanofi Percentage"
       }
      }
     },
     "localname": "EntityWideRevenueSanofiPercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_EquityIncentiveAwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Awards [Abstract]",
        "label": "Equity Incentive Awards [Abstract]",
        "terseLabel": "Equity Incentive Awards [Abstract]"
       }
      }
     },
     "localname": "EquityIncentiveAwardsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_FederalNetOperatingLossChange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Federal Net Operating Loss Change",
        "label": "Federal Net Operating Loss Change",
        "terseLabel": "Federal Net Operating Loss Change"
       }
      }
     },
     "localname": "FederalNetOperatingLossChange",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_GoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill [Abstract]",
        "label": "Goodwill [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "localname": "GoodwillAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_InterestOnLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest on Lease Payments",
        "label": "Interest on Lease Payments",
        "terseLabel": "Interest on Lease Payments"
       }
      }
     },
     "localname": "InterestOnLeasePayments",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.",
        "label": "Ipsen Maximum Regulatory And Commercial Milestones",
        "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "IpsenMaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.",
        "label": "Ipsen Revenue Allocated to Committee Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Ipsen Revenue Allocated to License Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRoyaltyIncome_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.",
        "label": "Ipsen Royalty Income_LXRX",
        "terseLabel": "Ipsen Royalty Income_LXRX"
       }
      }
     },
     "localname": "IpsenRoyaltyIncome_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPaymentsToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.",
        "label": "Ipsen Total Payments To Date",
        "terseLabel": "Ipsen Total Payments To Date"
       }
      }
     },
     "localname": "IpsenTotalPaymentsToDate",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.",
        "label": "Ipsen Total Upfront Payments",
        "terseLabel": "Ipsen Total Upfront Payments"
       }
      }
     },
     "localname": "IpsenTotalUpfrontPayments",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Ipsenproductsales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.",
        "label": "Ipsen product sales",
        "terseLabel": "Ipsen product sales"
       }
      }
     },
     "localname": "Ipsenproductsales",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LXRXBiologicscustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues",
        "label": "LXRX Biologics customer concentration",
        "terseLabel": "Biologics customer concentration"
       }
      }
     },
     "localname": "LXRXBiologicscustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LXRXDiplomatcustomerconcentration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues",
        "label": "LXRX Diplomat customer concentration",
        "terseLabel": "LXRX Diplomat customer concentration"
       }
      }
     },
     "localname": "LXRXDiplomatcustomerconcentration",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LandCollateral": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The land that serves as collateral for Lexicon's mortgage loan.",
        "label": "Land Collateral",
        "terseLabel": "Land Collateral"
       }
      }
     },
     "localname": "LandCollateral",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtIssueCosts_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement",
        "label": "Mortgage Debt Issue Costs_Revere_LXRX",
        "terseLabel": "Mortgage Debt Issue Costs_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtIssueCosts_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OptionsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Equity Incentive Plan.",
        "label": "Options Outstanding, Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Options Outstanding, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Options Outstanding, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_OrganizationAndOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and Operations [Abstract]",
        "label": "Organization and Operations [Abstract]",
        "terseLabel": "Organization and Operations [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_PresentValueOfFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present Value of Future Lease Payments",
        "label": "Present Value of Future Lease Payments",
        "terseLabel": "Present Value of Future Lease Payments"
       }
      }
     },
     "localname": "PresentValueOfFutureLeasePayments",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PriorYearReclassOfAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prior Year Reclass of Accrual",
        "label": "Prior Year Reclass of Accrual",
        "terseLabel": "Prior Year Reclass of Accrual"
       }
      }
     },
     "localname": "PriorYearReclassOfAccrual",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property and Equipment [Abstract]",
        "label": "Property and Equipment [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyAndEquipmentAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20191231",
     "xbrltype": "stringItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage",
        "terseLabel": "Funded commercialization costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Development Costs Period",
        "terseLabel": "Development costs period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones",
        "terseLabel": "Number of commercial milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones",
        "terseLabel": "Number of development milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones",
        "terseLabel": "Number of regulatory milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage",
        "terseLabel": "Royalties percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted stock units outstanding under the Equity Incentive Plan.",
        "label": "Restricted Stock Units Outstanding, Equity Incentive Plan",
        "terseLabel": "Restricted Stock Units Outstanding, Equity Incentive Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsOutstandingEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.",
        "label": "Sanofi Commercialization Costs Funded by Lexicon Maximum Amount",
        "terseLabel": "Sanofi Development Costs Funded by Lexicon Maximum Amount"
       }
      }
     },
     "localname": "SanofiCommercializationCostsFundedbyLexiconMaximumAmount",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDeferredRevenueFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Deferred Revenue from Termination",
        "label": "Sanofi Deferred Revenue from Termination",
        "terseLabel": "Sanofi Deferred Revenue from Termination"
       }
      }
     },
     "localname": "SanofiDeferredRevenueFromTermination",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.",
        "label": "Sanofi Development Milestones",
        "terseLabel": "Sanofi Development Milestones"
       }
      }
     },
     "localname": "SanofiDevelopmentMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiOutcomesStudyMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.",
        "label": "Sanofi Outcomes Study Milestone",
        "terseLabel": "Sanofi Outcomes Study Milestone"
       }
      }
     },
     "localname": "SanofiOutcomesStudyMilestone",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.",
        "label": "Sanofi Regulatory Milestones",
        "terseLabel": "Sanofi Regulatory Milestones"
       }
      }
     },
     "localname": "SanofiRegulatoryMilestones",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Sanofi Revenue Allocated to Development Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoFundingDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.",
        "label": "Sanofi Revenue Allocated to Funding Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to Funding Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoFundingDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Sanofi Revenue Allocated to License Deliverable",
        "terseLabel": "Sanofi Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "SanofiRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.",
        "label": "Sanofi Sales Milestone Payments",
        "terseLabel": "Sanofi Sales Milestone Payments"
       }
      }
     },
     "localname": "SanofiSalesMilestonePayments",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiTerminationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Termination Agreement",
        "label": "Sanofi Termination Agreement",
        "terseLabel": "Sanofi Termination Agreement"
       }
      }
     },
     "localname": "SanofiTerminationAgreement",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.",
        "label": "Sanofi Upfront Payment",
        "terseLabel": "Sanofi Upfront Payment"
       }
      }
     },
     "localname": "SanofiUpfrontPayment",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Settlement Payment Obligation",
        "label": "Settlement Payment Obligation",
        "terseLabel": "Settlement Payment Obligation"
       }
      }
     },
     "localname": "SettlementPaymentObligation",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued pursuant to restricted stock units under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.",
        "label": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan",
        "terseLabel": "Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan"
       }
      }
     },
     "localname": "SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesIssuedToSymphonyDesigneesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.",
        "label": "Shares Issued to Symphony Designees, Value",
        "terseLabel": "Issuance of common stock to designees of Symphony Icon Holdings LLC, value",
        "verboseLabel": "Common stock issued in satisfaction of Symphony Icon base payment obligation"
       }
      }
     },
     "localname": "SharesIssuedToSymphonyDesigneesValue",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense associated with general and administrative expense.",
        "label": "Stock-based compensation expense associated with general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with general and administrative expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.",
        "label": "Stock Option Exercise Price as Percent of Value of Common Stock",
        "terseLabel": "Stock Option Exercise Price as Percent of Value of Common Stock"
       }
      }
     },
     "localname": "StockOptionExercisePriceAsPercentOfValueOfCommonStock",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_StockOptionsExercisedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Equity Incentive Plan.",
        "label": "Stock Options Exercised, Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Stock Options Exercised, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SymphonyContingentPaymentInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent payments to Symphony Icon Holdings in the form of cash.",
        "label": "Symphony Contingent Payment In Cash",
        "terseLabel": "Symphony Contingent Payment In Cash"
       }
      }
     },
     "localname": "SymphonyContingentPaymentInCash",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SymphonyIconGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.",
        "label": "Symphony Icon Goodwill",
        "terseLabel": "Symphony Icon Goodwill"
       }
      }
     },
     "localname": "SymphonyIconGoodwill",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/GoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.",
        "label": "Total Shares That May be Issued, Equity Incentive Plan",
        "terseLabel": "Total Shares That May be Issued, Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.",
        "label": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan",
        "terseLabel": "Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan"
       }
      }
     },
     "localname": "TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_Totalvalueofsharesbynonemployeeinayear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year",
        "label": "Total value of shares by nonemployee in a year",
        "terseLabel": "Total value of shares by nonemployee in a year"
       }
      }
     },
     "localname": "Totalvalueofsharesbynonemployeeinayear",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_XERMELOIntangibleAssetsFiniteLived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets relating to XERMELO that were reclassified from indefinite-lived to finite-lived once the FDA approved XERMELO.",
        "label": "XERMELO Intangible Assets Finite Lived",
        "terseLabel": "XERMELO Intangible Assets Finite Lived"
       }
      }
     },
     "localname": "XERMELOIntangibleAssetsFiniteLived",
     "nsuri": "http://www.lexpharma.com/20191231",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r97",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Schedule of Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r180",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r19",
      "r137",
      "r138",
      "r201"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $4"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive gain (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r211",
      "r213",
      "r242",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r25",
      "r143",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r86",
      "r300"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r86",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r317",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r50"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Assets, Current [Abstract]"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities, Fair Value Disclosure"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Available-for-sale Securities, Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Available-for-sale Securities, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r215",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r27",
      "r88"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r89",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r179",
      "r326",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration Risk Disclosure"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r280",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r208",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r269",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current State and Local Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r12",
      "r13",
      "r318",
      "r320",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r38",
      "r191",
      "r192",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "Debt Instrument, Convertible, If-converted Value in Excess of Principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r96",
      "r191",
      "r193",
      "r194",
      "r195",
      "r298",
      "r299",
      "r301",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r31",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r95",
      "r270",
      "r272"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income Tax Benefit",
        "verboseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2",
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r261",
      "r319",
      "r332"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred Tax Liabilities, Gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r248",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred Tax Assets, Deferred Income"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r248",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Deferred Tax Assets, In Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r247",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r247",
      "r267",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Operating Loss Carryforwards, State"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r248",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred Tax Assets, Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r266",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r247",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r254",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r253",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r248",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/IncomeTaxesDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r86",
      "r132"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r101",
      "r107",
      "r110",
      "r111",
      "r112",
      "r116",
      "r329",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r101",
      "r107",
      "r110",
      "r111",
      "r112",
      "r116",
      "r329",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r256",
      "r257",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r244",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' Equity (Deficit):"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r289",
      "r295",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r289",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r290",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r290",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r290",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r290",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxNoteTable": {
     "auth_ref": [
      "r347",
      "r349",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments.",
        "label": "Federal Income Tax Note [Table]",
        "terseLabel": "Federal Income Tax Note [Table]"
       }
      }
     },
     "localname": "FederalIncomeTaxNoteTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r162",
      "r165",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r86",
      "r170",
      "r174"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r86",
      "r187",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Recognition of gain or loss on extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative, including stock-based compensation of $7,122, $5,686, and $4,567, respectively"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r152",
      "r154"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r91",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r156",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Policy"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r86",
      "r153",
      "r155",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r86",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r86",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r168",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r101",
      "r316",
      "r327",
      "r343"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income (loss) before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Information by Financial Statement Line Item [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r91",
      "r251",
      "r252",
      "r259",
      "r260",
      "r265",
      "r273",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r250",
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r249",
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r94",
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Increase (decrease) in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "(Increase) decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r109",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r108",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r91",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r131",
      "r297",
      "r300",
      "r330"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, Gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r47",
      "r149"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r48",
      "r91",
      "r118",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory, Raw Materials, Gross"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r346",
      "r348",
      "r350",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r346",
      "r348",
      "r350",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investments, Owned, Federal Income Tax Note [Line Items]",
        "terseLabel": "Investments, Owned, Federal Income Tax Note [Line Items]"
       }
      }
     },
     "localname": "InvestmentsOwnedFederalIncomeTaxNoteLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r321",
      "r338"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r184",
      "r320",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal after Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Four"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Three"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r98",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Two"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of deferred financing costs",
        "verboseLabel": "Long-term Debt, Excluding Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/DebtObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r39",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageLoansOnRealEstate": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.",
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate",
        "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r59",
      "r66",
      "r87",
      "r114",
      "r328",
      "r341"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.",
        "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification",
        "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (Loss) From Operations",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2",
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Operating Leases, Future Minimum Payments Due"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards, Federal"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r215",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r57",
      "r59",
      "r81",
      "r133",
      "r135",
      "r279",
      "r281",
      "r282",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r173",
      "r339"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively",
        "verboseLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r91",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of assets",
        "verboseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails",
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of debt borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r246",
      "r355"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $7,096, $6,010, and $4,905, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r196",
      "r337"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition, Policy"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r64",
      "r129",
      "r130",
      "r134"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/PropertyandEquipmentDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r215",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r221",
      "r233",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting Disclosure"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r223",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r212",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r91",
      "r215",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans Policy"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r11",
      "r322",
      "r323",
      "r325",
      "r334"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-term Lease Commitment, Amount",
        "terseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r190",
      "r196",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r196",
      "r214",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r145"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade and Other Accounts Receivable, Policy"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r42",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r42",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/BalanceSheetParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r42",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost, 407 and 236 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r190",
      "r196",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r206",
      "r208",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails1",
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Change in Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing net loss per common share, basic and diluted",
        "verboseLabel": "Weighted Average Number of Shares Outstanding, Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r104",
      "r105",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted Average Number of Shares Issued, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.lexpharma.com/role/EarningsPerShareDetails",
      "http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918705-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.8)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.11)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13.7)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Column G))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r359": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r361": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r362": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787905664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage', window );">Convertible Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.4553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtInstrumentRepurchasePercentage', window );">Repurchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognition of gain or loss on extinguishment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInstrument_Revere_LXRX', window );">Mortgage Debt Instrument_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX', window );">Mortgage Debt Interest Rate_Base_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtBalloonPayment_LXRX', window );">Mortgage Debt Balloon Payment_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtIssueCosts_Revere_LXRX', window );">Mortgage Debt Issue Costs_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstate', window );">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BuildingsCollateral', window );">Buildings Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LandCollateral', window );">Land Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX', window );">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BuildingsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The buildings that serve as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BuildingsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtInstrumentRepurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtInstrumentRepurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LandCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The land that serves as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LandCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtBalloonPayment_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtBalloonPayment_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInstrument_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInstrument_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRate_Base_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtIssueCosts_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtIssueCosts_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 310<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-29(Column G))<br> -URI http://asc.fasb.org/extlink&amp;oid=6589523&amp;loc=d3e617274-123014<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797199920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock', window );">Stock Option Exercise Price as Percent of Value of Common Stock</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan', window );">Total Shares That May be Issued, Equity Incentive Plan</a></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingEquityIncentivePlan', window );">Options Outstanding, Equity Incentive Plan</a></td>
<td class="nump">7,456,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Equity Incentive Plan</a></td>
<td class="nump">2,801,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedEquityIncentivePlan', window );">Stock Options Exercised, Equity Incentive Plan</a></td>
<td class="nump">1,909,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</a></td>
<td class="nump">1,968,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan', window );">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</a></td>
<td class="nump">113,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Totalvalueofsharesbynonemployeeinayear', window );">Total value of shares by nonemployee in a year | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan', window );">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Options Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">237,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan', window );">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</a></td>
<td class="nump">103,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">10,524,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">5,979,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units outstanding under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Totalvalueofsharesbynonemployeeinayear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total value of shares by nonemployee in a year - represents amounts under which non-employee director may be granted awards under the Non-Employee Directors Equity Incentive Plan such that the aggregate grant date fair value may not exceed $500,000 in any calendar year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Totalvalueofsharesbynonemployeeinayear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806984416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Intangible asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_XERMELOIntangibleAssetsFiniteLived', window );">XERMELO Intangible Assets Finite Lived</a></td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_XERMELOIntangibleAssetsFiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets relating to XERMELO that were reclassified from indefinite-lived to finite-lived once the FDA approved XERMELO.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_XERMELOIntangibleAssetsFiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795773104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Information</a></td>
<td class="text">The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018:<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quarter Ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues (1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,216&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,682&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294,448&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,469)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,545)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,217)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,797)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,018)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,138)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.48)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per common share, diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.48)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;Shares used in computing net income (loss) per common share, basic </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,713)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,272)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,927)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,821)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,549)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,396)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,782)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.40)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.33)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.26)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net loss per common share, basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,881&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792249168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss Parentheticals (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 7,096<span></span>
</td>
<td class="nump">$ 6,010<span></span>
</td>
<td class="nump">$ 4,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense', window );">Stock-based compensation expense associated with general and administrative expense</a></td>
<td class="nump">$ 7,122<span></span>
</td>
<td class="nump">$ 5,686<span></span>
</td>
<td class="nump">$ 4,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792281760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Equity Incentive Plans</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Equity Incentive Plan:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 20,000,000 shares at December&#160;31, 2019.&#160;&#160;In the first quarter of 2020, the Company amended the 2017 Equity Incentive Plan, subject to stockholder approval, to increase the aggregate number of shares that may be issued under the plan to 30,000,000 shares.  As of December&#160;31, 2019, options to purchase 7,456,905 shares and 2,801,928 restricted stock units were outstanding, 1,909,515 shares had been issued upon the exercise of stock options, 1,968,979 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Non-Employee Directors&#8217; Equity Incentive Plan:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#8217;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate 600,000 shares.&#160;&#160;As of December&#160;31, 2019, stock options to purchase 237,850 shares were outstanding, none had been issued upon the exercise of stock options, 27,728 restricted stock units were outstanding and 103,208 shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Option Activity:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The following is a summary of stock option activity under Lexicon&#8217;s equity incentive plans:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:34.749%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.814%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,834&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(458)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(212)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(239)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(157)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(680)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(389)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2019, 2018 and 2017 were $3.18, $5.63 and&#160;$8.59, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2018 and 2017 were $0.2 million and $2.0 million, respectively.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 6.8 and 5.3 years, respectively, as of December&#160;31, 2019.&#160;&#160;At December&#160;31, 2019, the aggregate intrinsic value of the outstanding stock options was $0.2 million.  At December&#160;31, 2019, there was no intrinsic value of exercisable stock options. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Bonus and Restricted Stock Unit Activity:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the year ended December&#160;31, 2019, Lexicon granted its non-employee directors 27,728 restricted stock units and during the year ended December&#160;31, 2018 and 2017, granted its non-employee directors 20,512 and 10,248 shares, respectively, of restricted stock awards.  The restricted stock in 2019, 2018 and 2017 had weighted average grant date fair values of $5.67, $7.80 and $15.61 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date and vesting of restricted stock awards is immediate.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the years ended December&#160;31, 2019, 2018 and 2017, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxODc_3e3d37a1-a8e6-4c56-8f56-a53ef432e351">three</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxOTM_6c3cd917-a52f-4bb3-8628-3b363616b2f4">four</span> annual installments.  The total fair value of shares vested in 2019, 2018 and 2017 was $2.9&#160;million, $3.3&#160;million and $4.7&#160;million, respectively.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.203%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(517)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(385)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Aggregate Shares Reserved for Issuance</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, an aggregate of 10,524,411 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 5,979,947 additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805766016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 06, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s 2020 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2019, are incorporated by reference into Part III of this annual report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,969,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795805136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text">Recent Accounting Pronouncements<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the  Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement was effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. This ASU was required to be adopted using a modified retrospective approach.  Management adopted ASU 2016-02 on the effective date of January 1, 2019 and elected the practical expedient that allows entities to not apply the new guidance in the comparative periods they present in their financial statements in the year of adoption.  Consequently, prior year financial information has not been updated and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019.  Upon adoption, the Company recognized $2.1 million for right-of-use assets and corresponding liabilities on the consolidated balance sheet, </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">primarily related to leases of office space.  The adoption of this ASU on January 1, 2019 did not have a material impact on Lexicon&#8217;s consolidated financial statements. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pronouncements Not Yet Adopted.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In November 2018, the FASB issued ASU No. 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606".  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792363120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Basis of Presentation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. In 2018, accounts payable included $5.7&#160;million related to its accrual for clinical studies.  The Company has reclassified this amount to accrued liabilities in the consolidated balance sheet for comparable presentation of accounts payable and accrued liabilities.   </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2019 and December&#160;31, 2018, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. Inventory consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.403%;"><tr><td style="width:1.0%;"/><td style="width:50.791%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.504%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.999%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.506%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">232&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Concentration of Credit Risk:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In 2019, customers in Germany and the United States represented 89% and 10% of revenue, respectively.  In 2018, customers in Germany and the United States represented 53% and 40%, respectively.  In 2017, customers in Germany, France and the United States represented 65%, 18% and 17% of revenue, respectively.&#160;&#160;At December&#160;31, 2019, management believes that the Company has no significant concentrations of credit risk.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Segment Information and Significant Customers:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2019, Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) represented 89% of revenues and no other individual customer represented more than 10% of revenues.  In 2018, Sanofi represented 53% of revenues and two independent specialty pharmacies, Biologics, Inc. and Diplomate Pharmacy, represented 25% and 14% of revenues, respectively.  In 2017, Sanofi and Ipsen represented 65% and 18% of revenues, respectively. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangible Assets:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company has recorded $1.8 million in amortization expense related to this asset in each of the years ended December&#160;31, 2019 and 2018, respectively, and $1.5 million for the year ended December&#160;31, 2017.  Amortization expense is recorded as cost of sales in the accompanying consolidated statements of comprehensive income (loss). </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated future amortization expense for intangible assets as of December&#160;31, 2019 is as follows:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"><tr><td style="width:1.0%;"/><td style="width:78.472%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.528%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,716&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property and Equipment:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Impairment of Long-Lived Assets:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. There were no impairments of long-lived assets, including finite-lived intangible assets, in 2019, 2018 or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 13) and Lexicon's resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;D for the year ended December&#160;31, 2019.  The impairment reduced the remaining book value to zero. There were no impairments of indefinite-lived intangible assets in 2018  or 2017. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill Impairment:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2019, 2018 or 2017.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customer Credits:  The Company&#8217;s customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expects that its customers will earn prompt payment discounts.  As a result, the Company deducts the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenues in the period of adjustment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The Company adopted ASU NO. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;, on January 1, 2018, using the modified retrospective method.  In its adoption, the Company recorded a $14.2 million cumulative-effect adjustment to its accumulated deficit related to a contract with the Texas Institute for Genomic Medicine. Subsequent to adoption, the Company was notified that all performance obligations related to the contract have been fulfilled. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of Sales: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during 2017 once the FDA approved XERMELO as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive income (loss).  As a result, cost of sales for approximately the next twelve months will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company's estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease was based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $24.0 million, which is expected to be recognized over a weighted-average period of 1.1&#160;years.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended December&#160;31, 2019, 2018 and 2017, respectively:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017:</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Income Taxes:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method,  deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2019, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December 31, 2019, and positive evidence, including the income during the year ended December 31, 2019 and projections of future income. After assessing both the negative evidence and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December 31, 2019 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total deferred tax asset balance subject to the valuation allowance was approximately $333.6&#160;million at December 31, 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent, reduction of certain tax credits, limitations on, or deductibility of interest expense and executive compensation, and limitations on the use of net operating loss carryforwards. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Income (Loss) per Common Share:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795813488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at December&#160;31, 2019 and 2018 are as follows:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,087&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability related to acquisition of Symphony Icon</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,140)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,525)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,143)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,527)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(329,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(364,702)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,014)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred tax assets associated with net operating losses (NOLs), deferred revenue and interest decreased in 2019 due to the Termination Agreement (as defined in Note 13) with Sanofi.  Refer to Note 13, Collaboration and License Agreements, for additional information.  The $4.1&#160;million deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.783%;"><tr><td style="width:1.0%;"/><td style="width:51.021%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.839%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.682%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.537%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.682%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected income tax expense (benefit) at 21%, 21% and 35%, respectively</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,315)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,479)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,324)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(978)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred true-up</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,316)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Symphony Icon fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,634)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(372)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,014)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,661)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, Lexicon had both federal and state NOL carryforwards of approximately $879.7 million and $83.0 million, respectively.&#160;&#160;In 2019, federal NOLs decreased by $62.2&#160;million primarily due to utilization against taxable income.  The state NOL carryforwards decreased due to a legislative change from pre-apportionment to post-apportionment reporting in New Jersey.  The federal and state NOL carryforwards will begin to expire in 2022.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately $46.3&#160;million begin to expire in 2020.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&#160;&#160;Utilization of the NOL, R&amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Although NOLs were utilized in 2019, based on the federal tax law limits and the Company's cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2019, the valuation allowance decreased $35.3 million, primarily due to the Company&#8217;s utilization of NOLs and decreases to deferred revenue and interest deferred tax assets.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Lexicon recorded an income tax benefit of $6.0&#160;million in the year ended December&#160;31, 2019 despite reporting pretax income for the year. The result reflects the impact of the impairment of intangible assets associated with Symphony Icon and the benefit from the utilization of federal NOLs for which a tax benefit had not previously been recognized, partially offset by nondeductible expenses.  There were no income tax benefits in the year ended December&#160;31, 2018.  Income tax benefits of $12.7&#160;million were recorded for the year ended December&#160;31, 2017.  Of the $12.7&#160;million tax benefits, $8.7&#160;million is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO and $4.0&#160;million was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  As of December&#160;31, 2019 and 2018, the Company did not have any unrecognized tax benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax </span></div>expense.&#160;&#160;As of December&#160;31, 2019 and 2018, the Company had no accruals for interest or penalties related to income tax matters.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6664538128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</a></td>
<td class="nump">$ 11,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term Debt, Maturities, Repayments of Principal in Year Two</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term Debt, Maturities, Repayments of Principal in Year Three</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term Debt, Maturities, Repayments of Principal in Year Four</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term Debt, Maturities, Repayments of Principal in Year Five</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Long-term Debt, Maturities, Repayments of Principal after Year Five</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Gross</a></td>
<td class="nump">248,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Debt Issuance Expense</a></td>
<td class="num">(3,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
<td class="num">(11,012)<span></span>
</td>
<td class="num">$ (1,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
<td class="nump">$ 234,171<span></span>
</td>
<td class="nump">$ 243,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794503664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 2) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="nump">6,152<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.95<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="nump">$ 11.17<span></span>
</td>
<td class="nump">$ 11.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 14.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7.55<span></span>
</td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.95<span></span>
</td>
<td class="nump">$ 14.21<span></span>
</td>
<td class="nump">$ 26.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="nump">$ 12.04<span></span>
</td>
<td class="nump">$ 13.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="nump">$ 10.72<span></span>
</td>
<td class="nump">$ 10.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6665629424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details) - segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueSanofiPercentage', window );">Entity Wide Revenue Sanofi Percentage</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LXRXBiologicscustomerconcentration', window );">Biologics customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LXRXDiplomatcustomerconcentration', window );">LXRX Diplomat customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueIpsenPercentage', window );">Entity Wide Revenue Ipsen Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueIpsenPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EntityWideRevenueIpsenPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueSanofiPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue generated from Sanofi that accounts for 10 percent or more of an entity's revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EntityWideRevenueSanofiPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXBiologicscustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>LXRX Biologics customer concentration - represents percent of revenue that Biologics contributes to total revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXBiologicscustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LXRXDiplomatcustomerconcentration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>LXRX Diplomat customer concentration - represents the percent of revenue that Diplomat contributes to revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LXRXDiplomatcustomerconcentration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795701856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of Lexicon's earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:40.042%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.420%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.867%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.052%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.468%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except per share amounts)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add effect of potential dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Share based awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792333344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of cash and cash equivalents and investments held at December&#160;31, 2019 and 2018 are as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:41.827%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:41.981%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.431%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>There were no realized gains or losses for the years ended December&#160;31, 2019 and 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795796064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OrganizationAndOperationsAbstract', window );"><strong>Organization and Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen Pharma SAS&#8217;s (&#8220;Ipsen&#8221;) ability to successfully commercialize XERMELO outside of the United States and Japan and Lexicon&#8217;s receipt of any milestone payments and royalties; the success of its ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin; general and industry-specific economic conditions which may affect research and development expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795794768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6807511664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 32,331<span></span>
</td>
<td class="nump">$ 26,583<span></span>
</td>
<td class="nump">$ 15,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">289,231<span></span>
</td>
<td class="nump">36,271<span></span>
</td>
<td class="nump">75,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">322,073<span></span>
</td>
<td class="nump">63,209<span></span>
</td>
<td class="nump">91,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">3,231<span></span>
</td>
<td class="nump">2,491<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $7,096, $6,010, and $4,905, respectively</a></td>
<td class="nump">91,924<span></span>
</td>
<td class="nump">100,243<span></span>
</td>
<td class="nump">152,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative, including stock-based compensation of $7,122, $5,686, and $4,567, respectively</a></td>
<td class="nump">56,835<span></span>
</td>
<td class="nump">63,754<span></span>
</td>
<td class="nump">66,090<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">180,628<span></span>
</td>
<td class="nump">166,488<span></span>
</td>
<td class="nump">222,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">141,445<span></span>
</td>
<td class="num">(103,279)<span></span>
</td>
<td class="num">(130,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20,676)<span></span>
</td>
<td class="num">(20,777)<span></span>
</td>
<td class="num">(6,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before taxes</a></td>
<td class="nump">124,119<span></span>
</td>
<td class="num">(120,548)<span></span>
</td>
<td class="num">(135,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">6,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">130,133<span></span>
</td>
<td class="num">(120,548)<span></span>
</td>
<td class="num">(122,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 130,229<span></span>
</td>
<td class="num">$ (120,338)<span></span>
</td>
<td class="num">$ (123,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 28,638<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">116,747<span></span>
</td>
<td class="nump">105,830<span></span>
</td>
<td class="nump">105,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">106,218<span></span>
</td>
<td class="nump">105,830<span></span>
</td>
<td class="nump">105,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795803408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
<td class="text">Benefit Plan<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $1.2 million, $1.0 million and $1.0 million in the years ended December&#160;31, 2019, 2018 and 2017, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzYyOA_b159658f-ba94-40d2-bf42-41b82bcb07e0">four</span> years of service.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805630368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy</a></td>
<td class="text">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. In 2018, accounts payable included $5.7&#160;million related to its accrual for clinical studies.  The Company has reclassified this amount to accrued liabilities in the consolidated balance sheet for comparable presentation of accounts payable and accrued liabilities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2019 and December&#160;31, 2018, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text">Inventory:  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure</a></td>
<td class="text">Concentration of Credit Risk: Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
<td class="text">Segment Information and Significant Customers: Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text">Intangible Assets:  Intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property and Equipment:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b">three</span> to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy</a></td>
<td class="text">Impairment of Long-Lived Assets:&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy</a></td>
<td class="text">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customer Credits:  The Company&#8217;s customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expects that its customers will earn prompt payment discounts.  As a result, the Company deducts the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#8217;s estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#8217;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenues in the period of adjustment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of Sales:  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during 2017 once the FDA approved XERMELO as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive income (loss).  As a result, cost of sales for approximately the next twelve months will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
<td class="text">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company's estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease was based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $24.0 million, which is expected to be recognized over a weighted-average period of 1.1&#160;years.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div>The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Income (Loss) per Common Share:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy</a></td>
<td class="text">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#8217;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Income Taxes:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method,  deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;">The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2019, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December 31, 2019, and positive evidence, including the income during the year ended December 31, 2019 and projections of future income. After assessing both the negative evidence and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December 31, 2019 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total deferred tax asset balance subject to the valuation allowance was approximately $333.6&#160;million at December 31, 2019.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. </span></div>The Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent, reduction of certain tax credits, limitations on, or deductibility of interest expense and executive compensation, and limitations on the use of net operating loss carryforwards.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787952576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:55.331%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:3.278%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.372%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:3.278%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Lives</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In Years</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-5</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,644&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15-40</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,741)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,006)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808526624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiUpfrontPayment', window );">Sanofi Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiDevelopmentMilestones', window );">Sanofi Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones', window );">Number of development milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRegulatoryMilestones', window );">Sanofi Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones', window );">Number of regulatory milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiOutcomesStudyMilestone', window );">Sanofi Outcomes Study Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiSalesMilestonePayments', window );">Sanofi Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones', window );">Number of commercial milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage', window );">Funded commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod', window );">Development costs period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount', window );">Sanofi Development Costs Funded by Lexicon Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable', window );">Sanofi Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable', window );">Sanofi Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueRecognized', window );">Sanofi Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 33,200<span></span>
</td>
<td class="nump">$ 60,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable', window );">Sanofi Revenue Allocated to Funding Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalPaymentsToDate', window );">Ipsen Total Payments To Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalUpfrontPayments', window );">Ipsen Total Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePaymentReceived', window );">Ipsen Milestone Payment Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable', window );">Ipsen Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones', window );">Ipsen Maximum Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable', window );">Ipsen Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable', window );">Ipsen Revenue Allocated to Committee Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRoyaltyIncome_LXRX', window );">Ipsen Royalty Income_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Ipsenproductsales', window );">Ipsen product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumSalesMilestones', window );">Ipsen Maximum Sales Milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentObligation', window );">Settlement Payment Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiTerminationAgreement', window );">Sanofi Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiDeferredRevenueFromTermination', window );">Sanofi Deferred Revenue from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRoyaltyIncome_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRoyaltyIncome_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalPaymentsToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalPaymentsToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Ipsenproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Ipsenproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Commercial Costs, Funded Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Development Costs Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Number Of Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Royalties Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiDeferredRevenueFromTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sanofi Deferred Revenue from Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiDeferredRevenueFromTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiOutcomesStudyMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiOutcomesStudyMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoFundingDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoFundingDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sanofi Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SettlementPaymentFromTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment from Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SettlementPaymentFromTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SettlementPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SettlementPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>124</ContextCount>
  <ElementCount>446</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheet Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/StatementsofComprehensiveLossParentheticalsParentheticals</Role>
      <ShortName>Statements of Comprehensive Loss Parentheticals (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115103 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158115 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Debt Obligations Debt Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables</Role>
      <ShortName>Debt Obligations Debt Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345310 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwards</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2356312 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2359313 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandSignficantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies Intangible asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleassetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Intangible asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Cost of Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesCostofSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cost of Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414410 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails</Role>
      <ShortName>Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Cash and Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/Goodwill</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Debt Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsNarrativeDetails</Role>
      <ShortName>Debt Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Debt Obligations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails1</Role>
      <ShortName>Debt Obligations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligationsDebtObligationsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Equity Incentive Awards - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsNarrativeDetails</Role>
      <ShortName>Equity Incentive Awards - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Equity Incentive Awards (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2</Role>
      <ShortName>Equity Incentive Awards (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Equity Incentive Awards (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3</Role>
      <ShortName>Equity Incentive Awards (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Equity Incentive Awards (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4</Role>
      <ShortName>Equity Incentive Awards (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlanDetails</Role>
      <ShortName>Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/BenefitPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2457430 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lxrx-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2460431 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedQuarterlyFinancialInformationDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lxrx-20191231.htm">lxrx-20191231.htm</File>
    <File>exh1011officerrestrict.htm</File>
    <File>exh1019amendmentno2toi.htm</File>
    <File>exh1082017equityincent.htm</File>
    <File>exh231ernstyoungconsent.htm</File>
    <File>exh311certificationofp.htm</File>
    <File>exh312certificationofp.htm</File>
    <File>exh321certificationofp.htm</File>
    <File>lxrx-20191231.xsd</File>
    <File>lxrx-20191231_cal.xml</File>
    <File>lxrx-20191231_def.xml</File>
    <File>lxrx-20191231_lab.xml</File>
    <File>lxrx-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lxrx-20191231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805947152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 36,112<span></span>
</td>
<td class="nump">$ 80,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">235,547<span></span>
</td>
<td class="nump">79,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">271,659<span></span>
</td>
<td class="nump">160,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">80,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">235,547<span></span>
</td>
<td class="nump">73,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">271,659<span></span>
</td>
<td class="nump">154,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786341760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792453808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 4) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,830<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">2,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</a></td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792358016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 30, 2010</div></th>
<th class="th"><div>Jul. 12, 2001</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthGoodwill', window );">Coelacanth Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthPurchasePrice', window );">Coelacanth Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyIconGoodwill', window );">Symphony Icon Goodwill</a></td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon. This represents the purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CoelacanthPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyIconGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyIconGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786014512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Operating Leases, Future Minimum Payments, Due in Five Years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Operating Leases, Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InterestOnLeasePayments', window );">Interest on Lease Payments</a></td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PresentValueOfFutureLeasePayments', window );">Present Value of Future Lease Payments</a></td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InterestOnLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest on Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InterestOnLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PresentValueOfFutureLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present Value of Future Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PresentValueOfFutureLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792333344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment at December&#160;31, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:55.331%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:3.278%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.372%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:3.278%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Lives</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In Years</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-5</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,587&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,557&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,644&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-7</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15-40</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Accumulated depreciation and amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61,741)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,006)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795773968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Lease Obligations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;&#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  As disclosed in Note 3, Lexicon adopted ASU 2016-02, "Leases", on January 1, 2019.  As of December&#160;31, 2019, the office space lease right-of-use (ROU) asset had a balance of $1.7 million, which is included in other assets in the consolidated balance sheet, and current and non-current liabilities relating to the ROU asset were $0.6&#160;million and $1.1&#160;million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.  The discount rate used to record the office space lease was Lexicon's estimated borrowing rate of 9%.  Lexicon elected to apply the short-term lease exception to all leases one year or less.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:79.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.156%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount of lease payments representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(242)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(553)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employment Arrangements:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNjU_271664d5-aa24-4596-adff-6eaadc2549e8">six</span> or 12 months and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of a specified termination of the officer&#8217;s employment.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Proceedings:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806045424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2016</a></td>
<td class="nump">$ 167,507<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 1,411,222<span></span>
</td>
<td class="num">$ (1,240,257)<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
<td class="num">$ (3,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,472<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
<td class="nump">10,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">5,486<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,679)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(122,993)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(122,993)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2017</a></td>
<td class="nump">68,265<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,435,526<span></span>
</td>
<td class="num">(1,365,241)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</a></td>
<td class="nump">14,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,212<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,696<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentInCash', window );">Symphony Contingent Payment In Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(972)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,548)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(120,548)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2018</a></td>
<td class="num">(26,405)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,447,954<span></span>
</td>
<td class="num">(1,471,577)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,218<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">14,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">130,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 117,101<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 1,462,172<span></span>
</td>
<td class="num">$ (1,341,444)<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="num">$ (3,817)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments to Symphony Icon Holdings in the form of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806838752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,112<span></span>
</td>
<td class="nump">$ 80,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">235,547<span></span>
</td>
<td class="nump">79,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $4</a></td>
<td class="nump">56,532<span></span>
</td>
<td class="nump">5,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,243<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">337,754<span></span>
</td>
<td class="nump">173,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $61,741 and $60,006, respectively</a></td>
<td class="nump">14,047<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">19,716<span></span>
</td>
<td class="nump">50,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">417,715<span></span>
</td>
<td class="nump">284,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,178<span></span>
</td>
<td class="nump">12,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">42,151<span></span>
</td>
<td class="nump">21,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred financing costs</a></td>
<td class="nump">11,012<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,341<span></span>
</td>
<td class="nump">36,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred financing costs</a></td>
<td class="nump">234,171<span></span>
</td>
<td class="nump">243,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">300,614<span></span>
</td>
<td class="nump">310,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 106,679 and 106,162 shares issued, respectively</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,462,172<span></span>
</td>
<td class="nump">1,447,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,341,444)<span></span>
</td>
<td class="num">(1,471,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 407 and 236 shares, respectively</a></td>
<td class="num">(3,817)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">117,101<span></span>
</td>
<td class="num">(26,405)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity (deficit)</a></td>
<td class="nump">$ 417,715<span></span>
</td>
<td class="nump">$ 284,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6665629424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">$ 3,182<span></span>
</td>
<td class="nump">$ 3,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 4,243<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PriorYearReclassOfAccrual', window );">Prior Year Reclass of Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PriorYearReclassOfAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior Year Reclass of Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PriorYearReclassOfAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795756400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:79.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.156%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: amount of lease payments representing interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(242)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of future lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: short-term operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(553)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MX7<1]H-U._>/C<^"NH5?=Z&_ %!+ P04    " !-BVQ0F5R<(Q &  "<)P
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M7()92J:HXA0M*+,4IR.E_EK0W$&B+%$R/A7'9\&^O3D;[Y0'^MD@R="[U$Y
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MRL>,9I4+Q3Z5D\ERK#F#FC.P$ ()<I@@]P?-2@PZ!X/V:LJ'.,YE2?D097E
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M*+E]8"QK<06X_H%I+1\8!EW*@(DQ-C$&)J:EB8U0>BW^7EKT"E!W="_7T3J
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M/>\HF8K_#%=0(3PJ"3E*5"ZMI.R=1SVQ!"E:O(Z[-&D?QIO=_01;!_ )P&?
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MBKL-@6V@Z5!TP 8$';8]*S9]077Q)#GN_GZ4['ANYA>+I'D.#RDJ&XU]=2V
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MCVC;:<TFQYM^?D%L><;%7U!+ P04    " !-BVQ0CDF*<[4!  #2 P  &0
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M-N#+IOXWU@9 *=D=CE"''VPQ%#0A'M_@V4UC-AG!]O,/8LLW+G\"4$L#!!0
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MV/_:& \H97>%(]3B!UL,";4/QT]XMM.8388W_?R#V/*-B]]02P,$%     @
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M_V"+H:!VX?C1G\TT9I/AL)]_$%N^<?$;4$L#!!0    ( $V+;%"Y A8]M $
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M"BH7CK?^;,8Q&PV'W?2#V/R-\T]02P,$%     @ 38ML4)&CT#.V 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL?5/;;M0P$/T5RQ]09[TI
M+*LD4K<(@032JHCR[$TF%]678#N;\O>,G30$&O7%]HSGG#DS'F>CL4^N!?#D
M64GM<MIZWQ\9<V4+2K@;TX/&F]I8)3R:MF&NMR"J"%*2\21YQY3H-"VRZ#O;
M(C.#EYV&LR5N4$K8WR>09LSICKXX'KJF]<'!BJP7#7P'_Z,_6[38PE)U"K3K
MC"86ZIS>[8ZG-,3'@,<.1K<ZDU#)Q9BG8'RI<IH$02"A](%!X':%>Y R$*&,
M7S,G75(&X/K\POXIUHZU7(2#>R-_=I5O<WJ@I():#-(_F/$SS/7<4C(7_Q6N
M(#$\*,$<I9$NKJ0<G#=J9D$I2CQ/>Z?C/DXWM^D,VP;P&< 7P"'F85.BJ/RC
M\*+(K!F)G7K?B_#$NR/'WI3!&5L1[U"\0^^UX/M#QJZ!:(XY33%\%;-;(ABR
M+RGX5HH3?P7GV_#]IL)]A.__4?AAFR#=)$@C0?IFB1LQ:?)?$K;JJ0+;Q&ER
MI#2#CI.\\BX#>\?CF_P-GZ;]F[!-IQVY&(\O&_M?&^,!I20W.$(M?K#%D%#[
M<'R/9SN-V61XT\\_B"W?N/@#4$L#!!0    ( $V+;% "W7JHG0(  *P*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'56VX[:,!#]E2@?L(D-N8 @
M$FQ5M5(KH:W:/ALP$&T2I[:![=_7<;+9U!R_Q)><.6=LSXQF=1?R55TXU\%;
M735J'5ZT;I=1I X77C/U)%K>F#\G(6NFS5*>(]5*SH[6J*XB&L=I5+.R"8N5
MW=O)8B6NNBH;OI.!NM8UDW^WO!+W=4C"]XV7\GS1W494K%IVYC^X_MGNI%E%
M(\NQK'FC2M$$DI_6X88LM]0:6,2ODM_59!YT1]D+\=HMOA[78=QYQ"M^T!T%
M,\.-/_.JZIB,'W\&TG#4[ RG\W?VS_;PYC![IOBSJ'Z71WU9AWD8'/F)72O]
M(NY?^'"@) R&TW_C-UX9>.>)T3B(2MEO<+@J+>J!Q;A2L[=^+!L[WOL_63J8
M80,Z&-#1(+<Z42]D/?_$-"M64MP#V5]^R[HW)DMJ[N;0;=JKL/^,\\KLW@HZ
M)ZOHUA$-F&V/H1/,!R(R[*,$11);^F!.L?D,>CBSYK.I>1QC@CDDF%N"^7]'
MI,X1$6:&11(HD@""N2.", D62:%("@A21P1A,BR209$,$.2.",(LL$@.1?)'
M@B1V1!#&$W@+*+( !.[#(XSGX4F,,R@&%.[30Y#G[8DG4PF@<%\?@CS/3V"Z
M;@A]I"#NM2%0DGMT<%Z3&:!8N#H E'JRG^#T)R"WTX<2AT">,D5P!2 @O=.9
MJX- <X\.+@($9'B:N#H(E'IT<!T@(,G3S-5!(%\<X%) 0)ZG#W$ 0)DO#G U
M("#5LX<X0"!/'%!<#RA(]<R- PCRQ '%]8""5,_<.( @-PZB2;-0<WFV;9(*
M#N+:V!YMLCNV8AMJFXT/>-_'?6?R7#8JV MM6A;;6)R$T-SX$C^9V+^8UG%<
M5/RDNVEFYK+OG_J%%NW0&T9C@UK\ U!+ P04    " !-BVQ0WOEVDL8!   W
M!   &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6QM5-MNXR 0_17$!Q2'
M)$T:V9::5M6NM)6BKG;WF=CCB\K%"SAN_[Z 7:\WY<4PPSEG+C!.!Z5?30-@
MT9O@TF2XL;8[$&**!@0S-ZH#Z4XJI06SSM0U,9T&5@:2X(0FR2T1K)4X3X/O
MI/-4]9:W$DX:F5X(IM^/P-60X17^=+RT=6.]@^1IQVKX"?97=]+.(K-*V0J0
MIE42::@R?+\Z'+<>'P"_6QC,8H]\)6>E7KWQO<QPXA,"#H7U"LPM%W@ SKV0
M2^/OI(GGD)ZXW'^J/X7:72UG9N!!\3]M:9L,[S$JH6(]MR]J^ 93/5N,IN)_
MP 6X@_M,7(Q"<1.^J.B-56)2<:D(]C:NK0SK,)[L;B=:G$ G IT)^Q"'C(%"
MYH_,LCS5:D!Z['W'_!6O#M3UIO#.T(IPYI(WSGO)Z6Z7DHL7FC#'$4,7F-6,
M($Y]#D%C(8[T"YW&Z>MHANM 7R_I21(7V$0%-D%@\U^)^ZL28YB[>)!M-,CV
MJ\ ^N0H2PUQWDBPN3H"NPY,UJ%"]#..R\,Y3<4_#Q?^#CR/US'3=2H/.RKKG
M$RZY4LJ"2R6Y<;DT;HIG@T-E_7;G]GI\RZ-A53>-*9G_%?D'4$L#!!0    (
M $V+;%!K[]R;M@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;&U3VV[<(!#]%<0'!"_K)*N5;2F;*FJE5EJE:OO,VF,;!8P+>)W^?0?L.&[J
M%V"&<\Y<&++1V!?7 GCRJE7G<MIZWQ\9<V4+6K@;TT.'-[6Q6G@T;<-<;T%4
MD:05XTERQ[20'2VRZ#O;(C.#5[*#LR5NT%K8/R=09LSICKXYGF73^N!@1=:+
M!KZ#_]&?+5IL4:FDALY)TQ$+=4X?=L=3&O 1\%/"Z%9G$BJY&/,2C"]53I.0
M$"@H?5 0N%WA$90*0IC&[UF3+B$#<7U^4W^*M6,M%^'@T:A?LO)M3@^45%"+
M0?EG,WZ&N9Y;2N;BO\(5%,)#)ABC-,K%E92#\T;/*IB*%J_3+KNXC]/-'9]I
MVP0^$_A".,0X; H4,_\DO"@R:T9BI][W(CSQ[LBQ-V5PQE;$.TS>H?=:\ //
MV#4(S9C3A.$KS&Y!,%1?0O"M$"?^'YUOT_>;&>XC?;^F)_?; NFF0!H%TG]*
MW'\H<0N3?@C"5CW58)LX38Z49NCB)*^\R\ ^Q$=D[_!IVK\)V\C.D8OQ^+*Q
M_[4Q'C"5Y 9'J,4/MA@*:A^.]WBVTYA-AC?]_(/8\HV+OU!+ P04    " !-
MBVQ0-E@)4K<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6QM
M4]MNW" 0_17$!P2;W22KE6TIFRAJI59:I6K[S-IC&P6,"WB=_GT'[+ANZA=@
MAG/.7!BRT=A7UP)X\J95YW+:>M\?&7-E"UJX&]-#AS>UL5IX-&W#7&]!5)&D
M%>-)<L>TD!TMLN@[VR(S@U>R@[,E;M!:V-\G4&;,:4K?'2^R:7UPL"+K10/?
MP'_OSQ8MMJA44D/GI.F(A3JG#^GQM _X"/@A872K,PF57(QY#<;G*J=)2 @4
ME#XH"-RN\ A*!2%,X]>L29>0@;@^OZL_Q]JQEHMP\&C43UGY-J<'2BJHQ:#\
MBQD_P5S/+25S\5_@"@KA(1.,41KEXDK*P7FC9Q5,18NW:9==W,?I9G>8:=L$
M/A/X0CC$.&P*%#-_$EX4F34CL5/O>Q&>.#UR[$T9G+$5\0Z3=^B]%OQPF[%K
M$)HQIPG#5YAT03!47T+PK1 G_A^=;]-WFQGN(GVWIJ?)ML!^4V ?!?;_E'CW
MH<0MS/V'(&S54PVVB=/D2&F&+D[RRKL,[ ./;_(7/DW[5V$;V3ER,1Y?-O:_
M-L8#II+<X BU^,$60T'MP_$>SW8:L\GPII]_$%N^<?$'4$L#!!0    ( $V+
M;%!\;3..MP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;&U3
MVVZ<,!#]%<L?$(,A[68%2-E$52NUTBI5TV<O#&#%%VJ;)?W[VH90FO)B>\;G
MG+EX7$S:O-@>P*%7*90M<>_<<"3$UCU(9F_T ,K?M-I(YKQI.F(' ZR))"D(
M39(/1#*N<%5$W]E4A1Z=X K.!ME12F9^GT#HJ<0I?G,\\:YWP4&J8F =? ?W
M8S@;;Y%5I>$2E.5:(0-MB>_3XRD/^ AXYC#9S1F%2BY:OP3C2U/B)"0$ FH7
M%)C?KO  0@0AG\:O11.O(0-Q>WY3_Q1K][5<F(4'+7[RQO4E/F#40,M&X9[T
M]!F6>FXQ6HK_"E<0'AXR\3%J+6Q<43U:I^6BXE.1['7>N8K[--]D^4+;)]"%
M0%?"(<8A<Z"8^2-SK"J,GI"9>S^P\,3ID?K>U,$96Q'O?/+6>Z\5/1P*<@U"
M"^8T8^@&DZX(XM77$'0OQ(G^1Z?[]&PWPRS2LRT]S?8%\EV!/ KD_Y1X]Z[$
M'<Q=\BX(V?14@NGB-%E4ZU'%2=YXUX&]I_%-_L+G:?_&3,>511?M_,O&_K=:
M._"I)#=^A'K_P59#0.O"\:,_FWG,9L/I8?E!9/W&U1]02P,$%     @ 38ML
M4,42"4;# 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL;53_
M;YP@%/]7"'] .?'LNHN:]-HL6[(EER[K?N;TJ:0@#O#L_OL!6NNN_"+P^'QY
M#WCFD](OI@.PZ%6*WA2XLW8X$&*J#B0S-VJ WNTT2DMFW5*WQ P:6!U(4A"Z
MV]T2R7B/RSS$3KK,U6@%[^&DD1FE9/KO$82:"IS@M\ 3;SOK Z3,!];"3["_
MAI-V*[*JU%Q";[CJD8:FP/?)X9AY?  \<YC,9HY\)6>E7OSB6UW@G4\(!%36
M*S W7. !A/!"+HT_BR9>+3UQ.W]3_Q)J=[6<F8$')7[SVG8%OL.HAH:-PCZI
MZ2LL]608+<5_APL(!_>9.(]*"1.^J!J-57)1<:E(]CJ/O _C-.]DZ4*+$^A"
MH"OA+OB0V2AD_L@L*W.M)J3GLQ^8O^+D0-W95#X8CB+LN>2-BUY*^CG)R<4+
M+9CCC*$;S#N"./75@L8LCO0#G<;I:33#--#3+3VYC0OLHP+[(+#_KT1Z56(,
MD\9-LJA)%A'87YG$,-F5"=E<G 3=AB=K4*7&/K3+)KIVQ3T-%_\.GUOJ!],M
M[PTZ*^N>3[CD1BD++I7=C<NE<UV\+@0TUD\_N;F>W_*\L&I8VI2L_XKR'U!+
M P04    " !-BVQ0<+Q"';<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6QU4UENVS 0O0K! X0V[3JN(0F(4Q0MT !&BB;?M#1:$"XJ25G)
M[3ND9$5-U1^2,WSOS<)ATAO[XFH 3UZ5U"ZEM??M@3&7UZ"$NS$M:+PIC57"
MHVDKYEH+HH@D)1E?K79,B4;3+(F^D\T2TWG9:#A9XCJEA'T[@C1]2M?TZGAL
MJMH'!\N25E3P$_RO]F318I-*T2C0KC&:6"A3>K<^'+<!'P%/#?1N=B:ADK,Q
M+\'X7J1T%1("";D/"@*W"]R#E$$(T_@]:M(I9"#.SU?UK[%VK.4L'-P;^=P4
MOD[IGI("2M%)_VCZ;S#6\XF2L?@?< &)\) )QLB-='$E>>>\4:,*IJ+$Z[ W
M.N[]<+.[TI8)?"3PB;"/!#8$BIE_$5YDB34]L4/O6Q&>>'W@V)L\.&,KXATF
M[]![R?CG7<(N06C$' <,GV'6$X*A^A2"+X4X\G_H?)F^6<QP$^F;.9W_)_YV
M46 ;!;9_E7C[H<0ES/Y#$#;KJ0);Q6ER)#>=CI,\\TX#>\?CF[S#AVE_$+9J
MM"-GX_%E8_]+8SQ@*JL;'*$:/]AD2"A].-[BV0YC-AC>M.,/8M,WSOX 4$L#
M!!0    ( $V+;%#!Y491MP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;&U3VV[<(!#]%<0'!"_KILG*MI1-5:52*ZU2-7EF[;&- AX'\#K]
M^P)V'"OU"S##.6<N#-F(YL6V (Z\:=79G+;.]0?&;-F"%O8*>^C\38U&"^=-
MTS#;&Q!5)&G%>))<,RUD1XLL^DZFR'!P2G9P,L0.6@OS]P@*QYSNZ+OC43:M
M"PY69+UHX#>X/_W)>(LM*I74T%F)'3%0Y_1N=SBF 1\!3Q)&NSJ34,D9\248
M/ZJ<)B$A4%"ZH"#\=H%[4"H(^31>9TVZA S$]?E=_7NLW==R%A;N43W+RK4Y
MO:&D@EH,RCWB^ !S/5\HF8O_"1=0'AXR\3%*5#:NI!RL0SVK^%2T>)MVV<5]
MG&ZNTYFV3> S@2^$FQB'38%BYM^$$T5F<"1FZGTOPA/O#MSWI@S.V(IXYY.W
MWGLI^.UMQBY!:,8<)PQ?878+@GGU)03?"G'D_]'Y-GV_F>$^TO=K.D^W!=)-
M@30*I"N!?9)\*G$+\[E(MNJI!M/$:;*DQ*&+D[SR+@-[Q^.;?,"G:?\E3",[
M2\[H_,O&_M>(#GPJR94?H=9_L,504+MP_.K/9AJSR7#8SS^(+=^X^ =02P,$
M%     @ 38ML4,2J,8K# 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL;53OCIP@$'\5P@,<+JY[EXV:W-[ETB9MLKFF[6=61R4'8@'7Z]L7
MT+-VRQ>!X?=G!ACS2>DWTP%8]"Y%;PK<63L<"3%5!Y*9.S5 [W8:I26S;JE;
M8@8-K XD*0A-D@.1C/>XS$/LK,M<C5;P'LX:F5%*IG^?0*BIP#O\$7CE;6=]
M@)3YP%KX!O;[<-9N15:5FDOH#5<]TM 4^'%W/&4>'P _.$QF,T>^DHM2;W[Q
MN2YPXA," 97U"LP-5W@"(;R02^/7HHE72T_<SC_47T+MKI8+,_"DQ$]>VZ[
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M2G>@_$VMC63.FZ8AMC/ JDB2@M DN2&2<86++/J.ILAT[P17<#3(]E(R\WD
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M5'?5W*B&,0G*T'M07JUZ8Y> 0"/U-%5S/KTT4R#9,#^B:'G)BW]02P,$%
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M:R"L7[F^>]YX::I:Z@U4Y!VNX ?(G]V6JQ6:7/8-A58TK'4X'%;NL[_<^";
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MNFE$D#:)JE9JI6BK;I\=,@EH;4QM)VS_OKX0E@"B+]@SG'/FC,&3M5R\R1)
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MH-%VFYF]7*9I,;08UX>";*]5^0=02P,$%     @ 38ML4.K5$#*= @  EPH
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MEX  ,LQ"C/EO@1C?, LQ$_L(N?#!X (2YD8 (7,G/ .E#Z"QXXFC# $2YFZ
M(/-3;T&ET'0,*843CL&3<8,\8)ZEZ1B EJ[I&(*0Z1B"O G'\"F*?$#"-QT#
MT/VN> )*'T!CQ_"QC8 S>1F8CB%H9CI^ DH?0)UCY^9VK@@[Z<J'6QD]UT)=
M<C>C0W6UT?6#,9ZHJDO?^O]ENI+M!V:GHN;6G@I9.^@;_DBI(-*C^R)OF5Q6
MB4.G)$>AF@O99EVIU'4$;?HRT!EJT?@?4$L#!!0    ( $V+;%#FNU(OS $
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M,B6Y!L'-!>:X"[B^X8"X$D+S6_>*6PO,\19P7<-A<243++BO &8L\8T4N+/
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M:FVW.[.7\SC.@1;#\M*0];DK_@)02P,$%     @ 38ML4(8>JI]N @  /@@
M !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULC99M;YLP$,>_"N+]BFT>
M$Q&DI-.T29M4=>KVVB%.0 7,;"=TWWZVH8S (?5-L<W=_W?G<G=).RY>9<&8
M<M[JJI$[MU"JW7J>S M64_G 6];H-V<N:JKT5EP\V0I&3]:IKCR"4.35M&S<
M++5G3R)+^5559<.>A".O=4W%WP.K>+=SL?M^\%Q>"F4.O"QMZ87]9.JE?1)Z
MYXTJI[)FC2QYXPAVWKE[O#W@T#A8BU\EZ^1D[9A4CIR_FLVWT\Y%)B)6L5P9
M":H?-_;(JLHHZ3C^#*+NR#2.T_6[^A>;O$[F2"5[Y-7O\J2*G9NXSHF=Z;52
MS[S[RH:$0M<9LO_.;JS2YB82S<AY)>U?)[]*Q>M!18=2T[?^63;VV?5OHFAP
M@QW(X$!&!]+GTH-LY)^IHEDJ>.>(_O);:O['>$OTW>3FT%Z%?:>#E_KTEH6!
MGWHW(S38''H;,K'!HX6GU4<$@1 'LG#W-S$LX(,Q^E; GP@0$L " 2@06('@
M+LE@EF1O$UJ;QMI$!,&0$(2$ "2<07J;: KQ"0R)0$@$0*(9)%I")H'<06(0
M$@.0> :)%Y"5RTI 1 (@DADB^2AB R(V &(S0VP^BL (KAZTA(1H7CYH0<')
M6@7@E3+%  C/07@!^D2"E>\+@\6ZQP0 D3F(+#.*PI5O#,-%C7T M.@\_C*C
MJ=4]""Y^#%1_.*_^P>@N(XS6K@YN 'C9 0*TN+IPT6=PC.9?G3=IWS43%SNX
MI)/S:V.GYN1T'(Y[8MO_?_-^LOZ@XE(VTCERI8>(;?5GSA73P: ''4:AA_FX
MJ=A9F66LUZ*?:/U&\7:8UM[XDR'[!U!+ P04    " !-BVQ0YJW]\@H#  !K
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R5EV%OFS 0AO\*X@<4
MSF ;JB12TVG:I$VJ.FW[3!,G007,P$FZ?S]C*&/VN5KSH8!SOL?G\+Z^KJZR
M>^Y/0JC@I:Z:?AV>E&IOHZC?G41=]#>R%8W^YB"[NE#ZL3M&?=N)8F\FU55$
MXIA%=5$VX69EQAZZS4J>554VXJ$+^G-=%]WOK:CD=1U"^#KP6!Y/:AB(-JNV
M.(IO0GUO'SK]%,U9]F4MFKZ43=")PSJ\@]LMX<,$$_&C%-=^<1\,I3Q)^3P\
M?-ZOPWA8D:C$3@TI"GVYB'M154,FO8Y?4])P9@X3E_>OV3^:XG4Q3T4O[F7U
ML]RKTSK,PF O#L6Y4H_R^DE,!=$PF*K_(BZBTN'#2C1C)ZO>_ UVYU[)>LJB
MEU(7+^.U;,SU.N5_G89/(-,$,D\8-R<:06;E'PI5;%:=O ;=N/EM,?S&<$OT
MWNR&0;,5YCN]^%Z/7C:4TE5T&1)-,=LQABQB8(Z(=/8903#$ECC3*65X@@1=
M8V(2)(L$"?>L($43I"9!^L\*N%4D$A-G.(2B$(I ,@LRQC 3TY@8K1_SP4D,
M)3&$E%LDYI!X2ED>4QS$41!W02RV0-PM*8LA)YZ]RU!0AH#  F4."/(XI^"I
M*$=!.0(B%BA'0"S+>8Z#(,:%%2.HQ%96[+(@R5//ZP >#0."2FW4&$07*/K&
MFP>HEN^ ("C'+XA3%7L+A:L>$@3%;%3BOGX)SZ@/A?L#(.)GMD%,04N4CX(;
M!" .P6R' -<B($Z(SXH =PA +(+9%@&N1T!,29J"QUP!=PE ;(+;-@&N3U M
MJ3SE'A9N%( XA>\L -P"(/__XX3@VB:(MKEM(TA0PCWG'L&%31!A<]M#D*"$
MIAX.KFJ"J)K[4N!J)>\XI FN0H*HT-U5-RCQ=1,$UR%!=,@]IPC!]478.ZK%
M54,PU3C5ND'N.Q0M>KU:=$?3Y?;!3IX;TV(O1N=.^HZ87O%O^-B&?RVZ8]GT
MP9-4NN,T?>%!2B7T6N(;O6TGW?G/#Y4XJ.&6Z_MN;'_'!R7;J;6/YO\O-G\
M4$L#!!0    ( $V+;%#M[!Y'T@,  +@0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;(U848^C-A#^*XCW F,PX%42:;/9JB==I=6=KGUF$R=!!S@%
M9W/]]S7@Y<AXV%X> CC?S'PSV-_86=U4^[T[2ZF]'W75=&O_K/7E(0R[_5G6
M11>HBVS,+T?5UH4VC^TI["ZM+ Z#45V%+(K2L"[*QM^LAK&7=K-25UV5C7QI
MO>Y:UT7[[U96ZK;VP7\?^%*>SKH?"#>K2W&27Z7^=GEIS5,X>3F4M6RZ4C5>
M*X]K_Q$>GEG<&PR(OTIYZV;W7I_*JU+?^X=/A[4?]8QD)?>Z=U&8RYM\DE75
M>S(\_K%._2EF;SB_?_?^^Y"\2>:UZ.23JOXN#_J\]G/?.\AC<:WT%W7[0]J$
MN._9[#_+-UD9>,_$Q-BKJAN^O?VUTZJV7@R5NO@Q7LMFN-ZL_W<SVH!9 S89
M,/ZA06P-XLD D@\-$FN0_*H!MP8<&81C[D,Q=X4N-JM6W;QVG ^7HI]V\,#-
MZ]KW@\/;&7XS]>S,Z-N&9^DJ?.L=6<QVQ+ 9!B9$:+Q/(1@58LL<<W8?X,E%
MI/P>LG,A /$]YMG%\"RCF<9D,>+!07SG(*<=)*2#9'"0W#D0J)HC)ALPS8")
M \A115P0#U*4[\X%Y0$7-%].\N4NWSQ"5$:,F$6) O0"=R.&SS",II&2-%*"
M!J"R49B%(!D9)",<H(IN*4Q"!\G)(#GA $WE;?YA0>^""#*(((+@-2N<-Q+1
M(2"B=2$BIO+"LH<%:8%?7TY 2L<C,"+5#,O3"$IGN6:I0%5_(E I<#R1"50B
M4C07GRE4'B],%*"U!F(BM1RG%A-+7"1B_L%YNB80!6F.$R5@$$"&,R5A;"E5
M6A6!D,4<RZ(%S6O*DMAYBRX*!*0X.1>5BX4E!K0R B&-(L*<.2'348HYN^H(
M$6;L>H(DB)<6'"VC0&BDP#IJ02FI#):P"_E-9)@Q 4KXTO*F)1D(O14,$\X^
MD#)+.'.JEP4<;R$(E)G+8F&' +3  Z'P K<1"[JK#0.\ZR%1L<"L"13P)=)T
MPP"B8X@$DQ9.><3_:8UK8F8M YR""V-ID"PL2$8W)$8T)"SR6PNZ*U;J[&@H
M5(P%:4>A@"]T44:W0 8$:=RJ+0@I=N)LD@D8"Z($TR9@<;"TBV%TWV5$W\4*
ML&5$%V095FP"%:<,ZQ^%BI8V[XSNJ(SHJ )W5$:V1XXUFX9E>+M PV;3<N0=
MSDYCM6Q/P]&X\_;JVNC^P#(;G8[?CZP_S:'Q+3SLQD/T3S?CF?[/HCV53>>]
M*FW.BL.)[JB4EH:E2<_WSK(X3 ^5/.K^-C/W[7B6'A^TNMC_"<+ISXK-?U!+
M P04    " !-BVQ08Q*0C30"  !!!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U."YX;6Q]5=N.FS 0_17$!\3<22*"M FJ6JF5HJW:/CMD$M :3&TG;/^^
MOA"6->R^Q/9PSIDS YYD/64OO (0SFM#6KYS*R&Z+4*\K*#!?$4[:.63"V4-
M%O+(KHAW#/!9DQJ" L]+4(/KULTS'3NR/*,W0>H6CLSAMZ;![-\>".UWKN\^
M L_UM1(J@/*LPU?X">)7=V3RA$:5<]U RVO:.@PN._?)WQ:)PFO [QIZ/MD[
MJI(3I2_J\.V\<SUE" B40BE@N=SA (0H(6GC[Z#ICBD5<;I_J'_1M<M:3IC#
M@9(_]5E4.W?M.F>XX!L1S[3_"D,]L>L,Q7^'.Q )5TYDCI(2KG^=\L8%;085
M::7!KV:M6[WV@_Z#MDP(!D(P$OSD4T(X$,(W0O0I(1H(D45 IA3=FP(+G&>,
M]@XS;[?#ZB/RMY'L?JF"NMGZF6P/E]%['F\V&;HKH0&S-YA@@O%'!)+J8XI@
M*<4^F-&#]PD.<T02OX<4<XCOA\LNPL5"0RT03@M-U\L"T:) I 6BJ4G/LSIE
M,(G&M*;4- W65KD+*"_VK:84<Y3O!=$'EN-%R_&"9=^R;##I)$V\2E++\1R4
MKJRJBCG&ETH??"G)HM]DP:_5EKW!Q-/F;>SW<)B#PM &%7-0E$Y QB^:7*0&
MV%4/*>Z4]-8*]3U.HN,<? K41;3B>SD?S3A[DS'#]0=FU[KESHD*><WU9;Q0
M*D!Z]%;27B7G^7@@<!%JF\H],U/-' 3MAH&-QG^-_#]02P,$%     @ 38ML
M4,E2>411 @  00<  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL?55=
MCYLP$/PKB/>"S7<B@G1)5;52*T577?OLD$U 9S"UG7#]]S6&<!R8O@3;S.[,
M;,QNVC+^*@H :;U5M!8[NY"RV;JNR NHB'!8 [5Z<V&\(E)M^=45#0=RUD$5
M=3V$(K<B96UGJ3X[\BQE-TG+&H[<$K>J(OSO'BAK=S:V'P?/Y;60W8&;I0VY
MPD^0+\V1JYT[9CF7%=2B9+7%X;*SG_#V@'6 1OPJH163M=59.3'VVFV^G7<V
MZA0!A5QV*8AZW.$ E':9E(X_0U)[Y.P"I^M']B_:O#)S(@(.C/XNS[+8V8EM
MG>%";E0^L_8K#(9"VQK<?X<[4 7OE"B.G%&A?ZW\)B2KABQ*2D7>^F=9ZV<[
MY'^$F0.\(< ; W#TWP!_"/#? P)MOE>FK7XFDF0I9ZW%^W^K(=VEP%M?%3/O
M#G7M]#OE5JC3>Q8A/W7O7:(!L^\QW@2#1X2KLH\4GHEB[RW"O8\$AR4B"LT,
MOM&$K^/]27P8)^8$@3%!H!,$'ZH0S*K08R*-J7L;B8]F3I8@["6164IHE!(:
MI(0S*3TFGK!$CC\#'98@C!P<F[5$1BV104LTTQ(MRQ($*XYC(TML8(EG+/'"
M3.B@E3N2&%D2 TLR8TD67CZ%:Q7;&%DV!I;-C&6S\+)Q5@J&D?FC14L:C.9?
M+5JZ\9.5FN&5[H -1'A.A W7<<[C3AI2!?RJ>[>P<G:K]>"8G([SX<G3#>T=
MW@^7'X1?RUI8)R956]3-Z\*8!*4%.>K6%VJ>C1L*%]DM8[7F?5/O-Y(UP\!R
MQZF9_0-02P,$%     @ 38ML4.#4NM7] 0  / 4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL?53;CILP$/T5Q ?$W--&!&F3:-5*K11MU?;9@>&B
MM3%KF[#]^_K"LH2@O&![?,Z9,X/M=&#\5=0 TGFGI!5[MY:RVR$D\AHH%AO6
M0:MV2L8IEFK)*R0Z#K@P)$I0X'D)HKAIW2PUL3//4M9+TK1PYH[H*<7\WP$(
M&_:N[WX$7IJJECJ LK3#%?P"^;L[<[5"DTK14&A%PUJ'0[EWG_S=*=9X _C3
MP"!F<T=7<F'L52^^%WO7TX: 0"ZU E;#%8Y B!92-MY&37=*J8GS^8?ZLZE=
MU7+! HZ,_&T*6>_=+ZY30(E[(E_8\ W&>F+7&8O_ 5<@"JZ=J!PY(\)\G;P7
MDM%115FA^-V.36O&P>Y$VY&V3@A&0C 1_.0A(1P)X2<A>DB(1D*T("!;BNG-
M"4N<I9P-#K=_M\/Z$/F[2'4_UT'3;+.GVB-4])HE?I"BJQ8:,0>+"688?T(@
MI3ZE"-92'(([^B+!\1Z1Q+>0TSW$]\-U%^%JH:$1".<N0F]=(%H5B(Q =-.I
M<-$IB_EJ,*UUN5D6:S'Q'+.H]1'BQFB\:C1>,1HMC-YCPFVR2()F9X@"K\S]
M%$[.^E;J7S&+3D_ 4Z#/X")^4$^#O<F?,O9=^8EYU;3"N3"I3K@YAR5C$I1%
M;Z,\UNHIFQ8$2JFG6S7G]D+;A63=^%:AZ<',_@-02P,$%     @ 38ML4%D:
MWBG#!   R1@  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULE9GM4NLV
M$(9O)9,+./9J)=EF0F8(E, !9IC3:?O;$$$RQXY3VY#3NZ\_1&I+NQF7'R16
MWM4K>5=/9&5Q+,J?U=:8>O8KS_;5Y7Q;UX>+(*A>MR9/JV_%P>R;3]Z*,D_K
MYK)\#ZI#:=)-%Y1G@0A#'>3I;C]?+KJVYW*Y*#[J;+<WS^6L^LCSM/QG9;+B
M>#F'^5?#C]W[MFX;@N7BD+Z;WTW]Q^&Y;*Z"4R^;76[VU:[8STKS=CF_@HLG
M*=J 3O'GSARKP?M9.Y67HOC97MQO+N=A.R*3F=>Z[2)M7C[-M<FRMJ=F''_;
M3N<GSS9P^/ZK]]MN\LUD7M+*7!?97[M-O;V<Q_/9QKRE'UG]HSC>&3LA-9_9
MV3^:3Y,U\G8DC<=KD57=_]GK1U47N>VE&4J>_NI?=_ON]=A_$D4VC X0-D"<
M @2<#4 ;@%,#I V04P.4#5!3 [0-T%,#(AL0G0(P/!L0VX!XJD-B Y*I 1!^
M92Z<'')*-DP.^4HW3,XW?"4<W(P'?2UVQ7V3UNER41;'6=FOST/:8@ NFJBF
M\[:U6R[=ATV!5TWKYU*#6@2?;4]6L^HU8J!!%8XUWWV-!CW6//@:."F"9IBG
ML0IRK"M!>$1CCVM*$X\U-Y0F&6M^(S3"F?,MI8&Q9DUIQ%AS1VEPK+FG--+)
M :5Q<OG@:S!Q[N$CU8^3RR=*$]'91+KRL.L!!ST(1+H'2?<@NQ[D: Q.KM>]
M1G6:?3_?L/VCC11MI @CIV#6RC,"X(TT;:1](W2J;MUK],!(TAX1[1$1'F[5
M1MYDA. G$]-&,6'DE/XZGCJ9A/9(" ]GZ:P3/S-G2J!%/0G*D+!R5N#:BH9>
M27+&BX,R$%[*]0+OWFG&AN;I%0C"1KLVO@@%DR1@ECH@812Y1KZ(-V*(  02
MT$4"(4+%W3J&"$ @ 5TD ,&$<Y7'0 $(*DB7"H0(%7?W&#( @0;IH@%\-@!@
MS$Z*@0,0=) N'<#' PC->S&0 ((2TJ'$ _B8$+$>)JO_<B1TB,*5/1$R'0(W
M<L% 1Q#0D2YTA \=E4C6BF&.()@CO=V#SQP9"=:*X8X@N",=[MQ9T2@?4K%6
M#'D$01[I[1G1+VET,WI#J$9E;_>-4U2WA$I+5_6=4"F^A!@D"@*),G9OMO3R
M*L KZD="!GRA,>@4!#IEX@Y(>4Z)9IT8< H"G.Z#RYWP]U,0L4X,.05!3@6N
M$T%.UHC!IB"PJ82[2HE=5>(GDU!ICV-6-1JTYE<\0V!!$%BY!+:BX8"\5?A(
MB-B;B Q5D:"J<JCZ8$4C(^_V/*+/7O;K"1GR(D%>Y9#WWHH !DZ18(P8[B+!
M7>4^I%O1" 5AS&Y:D'NZ(\"K(M<+?2_-6S&$0X)P*G:M",)I?B^&#+R0@)=*
M7"\?7@+9KRYDZ(7:>T#6FNN#X1)27/(R3CSMG<LX@R8DT*29 QYD.(')_S@4
M8%:WI%:W,^>5]-?MF<J3S,J5,#U%DEF4<L*B7$EB,T0,-Q@<^^6F?._.Q*O9
M:_&QK]MA#EI/Y^Y7W;&[T[Z"BWL@VA_@XJD_9ORO^_Z0_RDMWW?[:O92U'61
M=R>*;T51FV;TX;=FW%N3;DX7F7FKV[=1\[[L#]?[B[HXV!\.@M.O%\M_ 5!+
M P04    " !-BVQ0DIM&"1,$  #U$@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970V,BYX;6R-F-N2HCH4AE^%XGZ$)"2!+K6J/?1!G:JNWK5GKFF-AQH.;L!V
M]MM/.&C+RL+A1B%^_\J?E44,&9[3[%>^5ZJP?L=1DH_L?5$<'QPG7^]5'.:#
M]*@2_<LVS>*PT+?9SLF/F0HWE2B.'.JZPHG#0V*/AU7;6S8>IJ<B.B3J+;/R
M4QR'V?\3%:7GD4WL2\/[8;<OR@9G/#R&._6/*OX]OF7ZSKE&V1QBE>2'-+$R
MM1W9C^1A1;Q24!$_#NJ<WUQ;Y5 ^TO17>?.Z&=ENZ4A%:EV4(4+]]:FF*HK*
M2-K'?TU0^]IG*;R]OD1_J@:O!_,1YFJ:1C\/FV(_LGW;VJAM>(J*]_3\HIH!
M<=MJ1K]2GRK2>.E$][%.H[SZM-:GO$CC)HJV$H>_Z^]#4GV?F_@7&2Z@C8!>
M!;KO>P+6"-B7P+LK\!J!UU? &P'O*Q"-0/05R$8@^PK\1N#W%02-(.@K(.YE
MYMPOB;@ON4XVZ=W+9;H)!1*G+JRJ4F=A$8Z'67JVLOIA.X;E,TT>M$H'+UNK
MVJ]^U-6:Z];/L1!TZ'R6D1IF4C/TEB&BS2Q,AEP)1UNX^J"HCPDU],#%U"28
MY[:9F<EX;6)N$D*P-O.$,+R-/&-A0%<O& /BO&(,3.U?4[/\N^&5B1#"\!EB
M>*6P*@*[M<$$'L'#(WA5!*\U6 EJK69XQ205\XUKISXH!A.C5+@^2-T,B4:9
M2T"T.881&0!O3PA&A/3!;#QCT20+@+<7!&,>]P)0(0CF$9\24"0F1O1 &2CM
M)38$ZG(/9&2%<C0(.DJ&XQ/.D0D'/2VXT1-W854L30@\^:M[1,NJP*T*Q"J8
MBJ>:$;<Y=GF@MSPN</.,DKY/#/(%)SW?(%]14N?SEFR-5.(CE>9()>AK(<V^
MA&=86IH8G)9[1,NLCYOU$;.P]'TD,4QPTZX)0KOWB);= +<;&'8)@RM<@-@5
M5%+#[Q0AB:CF ?[O]8XY1TF] !CD NU=>M+,*Q:3^\STN4))RF1G#9>[*'3;
MXB*9!G_ DP:2MZN8.X!KW13!Z(" E7.&!Z-@\9]W8+!F$8P,*%RML6!D0, X
M5QV8[$AIUTZ0("GE,*6D7TI-C P"#E.*!C-3BF-&2K$^X3YUB07#4HIC72G%
M-[6/A"++%X6^J?%0^-05+("/&0)*C_E&W:\0D >N%%['OS?IV/$1AMAGT#Y#
M=AZ<&HL$PN%;#QSLWGN0CMTF,;>;QCYRTD!]5N/^Z*P_.L=1=$'NB$K,O<(2
M1?$E&4?1-=FY>:N,5;:KSD]R:YV>DJ)\,[AIO9[1/-+RK12T3\C#*T':%^69
M3O46^Q6^/A#Z'F:[0Y);'VFAWX:K%]9MFA9*C\ =Z%+9JW!SO8G4MB@OI;[.
MZH.8^J9(C\TADW,]Z1K_ 5!+ P04    " !-BVQ0^+=M_$($  #G$P  &0
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M#*V0IT )IQ=79]P:)L@G2;5SCA9GUXR Z726G%X.KQ"_T\D8D IEZ]U32.U
MD00I#T@BJ).C= J$L9= BUG#VW@O+I$@I%=7@ 8QC8ZTX=/1Y97%['J?8UVS
MZ#'<-5"/CWK!$LG:?FX$%',*4FQ(YHQ1PE3F;;][,9E)>!OB<C<5FP'C@F7
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MR50J8HV)VX?6B6OZ1OYH3ODG2Z%R3:RC3&E5A/C5'LO^^80.!&[Q[;8U8UX
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M.1F-O.KF7)EPUQAJJ:L@BYT]X@UFXNRJLB-ERH12ZDE^<;3P.(X63@D+>O8
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M.1TQ;FW_;.MZ"7+:H L!5QYDF*/=L[TULAS$,T7 ]0L7%W^MZG ?:+2?8ZB
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M8.N[^QVH%V6N[$J]T[ $[V<&7$/A@H:++N.]5KZA.L.PYRT'S ;?Y_H]2PP
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MCR-@>1H,WZ-UZS&Z8]A2\6T9F=1/ 2718O6%!S2+T5NYCTVP=(AT[YPWD5%
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MA.-=%4=GDE-[.5;B@0!73^0_LUZKPL9B^*!'H[I20%WJ$Z\[=VE\G.TZ8'
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M_4]T+LY/O\X>R0HOI:GD4+EJCQ//PH4VSM*A;!?-^35FJ;RRIV%V[]/O.)C
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MXD)@*'I3K[HSQUUS6^1U-:N]+NOOI M*LA3J7:V7P]NQ:1Q\+7%&FG;<9 .
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MN_Z<S\9_72W> %!+ 0(4 Q0    ( $V+;% ?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $V+;% GZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 38ML4'<^"ZGN    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 38ML4)E<G",0!@  G"<  !,
M         ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !-
MBVQ0A")H5'8#   K$0  &               @ 'W"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 38ML4-?T&<P_!   =!0  !@
M         ( !HPP  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( $V+;%#OHX 2;0(  +@(   8              "  1@1  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !-BVQ0 9[71UP$  !B%
M&               @ &[$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 38ML4.%;]L8% @  304  !@              ( !31@  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $V+;%# +!DE/@4
M )<>   8              "  8@:  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !-BVQ0]3&%YC %  #A&0  &               @ '\
M'P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 38ML4*0W
MV&RU 0  T@,  !@              ( !8B4  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( $V+;%!^R[\)M0$  -(#   8
M  "  4TG  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !-
MBVQ0C2BR[K(!  #2 P  &0              @ $X*0  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $V+;%".28ISM0$  -(#   9
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M970Q-2YX;6Q02P$"% ,4    " !-BVQ0&;X^&K,!  #2 P  &0
M    @ &[-   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M $V+;%"FX?,PM $  -(#   9              "  :4V  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 38ML4,F:QY6U 0  T@,  !D
M             ( !D#@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !-BVQ0&C6NO[0!  #2 P  &0              @ %\.@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $V+;%"1,':MM $
M -(#   9              "  6<\  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 38ML4+D"%CVT 0  T@,  !D              ( !
M4CX  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !-BVQ0
MD:/0,[8!  #2 P  &0              @ $]0   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( $V+;% "W7JHG0(  *P*   9
M      "  2I"  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 38ML4-[Y=I+& 0  -P0  !D              ( !_D0  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !-BVQ0:^_<F[8!  #2 P
M&0              @ '[1@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( $V+;% V6 E2MP$  -(#   9              "  >A(  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 38ML4'QM,XZW
M 0  T@,  !D              ( !UDH  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !-BVQ0Q1()1L,!   W!   &0
M@ '$3   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $V+
M;%!PO$(=MP$  -(#   9              "  ;Y.  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 38ML4,'E1E&W 0  T@,  !D
M         ( !K%   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !-BVQ0Q*HQBL,!   W!   &0              @ &:4@  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $V+;%"O3^=]MP$  -(#
M   9              "  914  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ 38ML4"*RE,2W 0  T@,  !D              ( !@E8
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !-BVQ0;OK"
M> 8"  #5!0  &0              @ %P6   >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( $V+;%!;EW'.# (  .T%   9
M  "  :U:  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M38ML4+DZ)X8C @  ;08  !D              ( !\%P  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !-BVQ0/&0\RS "  #^!@  &0
M            @ %*7P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( $V+;%"QS53*!@(  !T&   9              "  ;%A  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 38ML4#*]7RT8 @
M!08  !D              ( ![F,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !-BVQ0B\"(3>@!  #5!   &0              @ $]
M9@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $V+;%"O
MF)E:V@$  +D$   9              "  5QH  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ 38ML4.K5$#*= @  EPH  !D
M     ( !;6H  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $V+;% 2X<Q45P0  .L7   9              "
M 1EX  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 38ML
M4-VB)+\L P  B0P  !D              ( !IWP  'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !-BVQ0A[( 6+8"  "-"0  &0
M        @ $*@   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( $V+;% DN]TG$P,  'P,   9              "  ?>"  !X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 38ML4 ')!H70 0  >@0
M !D              ( !088  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !-BVQ0-V0=]GD#   *#P  &0              @ %(B
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( $V+;%#\WI%&
M3 (  )X'   9              "  ?B+  !X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ 38ML4)\ ;RO@ 0  ^@0  !D
M ( !>XX  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !-
MBVQ0AAZJGVX"   ^"   &0              @ &2D   >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $V+;%#FK?WR"@,  &L,   9
M          "  3>3  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#
M%     @ 38ML4.WL'D?2 P  N!   !D              ( !>)8  'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !-BVQ08Q*0C30"  !!
M!@  &0              @ &!F@  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;%!+ 0(4 Q0    ( $V+;%#)4GE$40(  $$'   9              "  >R<
M  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 38ML4.#4
MNM7] 0  / 4  !D              ( !=)\  'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6Q02P$"% ,4    " !-BVQ061K>*<,$  #)&   &0
M    @ &HH0  >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M $V+;%"2FT8)$P0  /42   9              "  :*F  !X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ 38ML4/BW;?Q"!   YQ,  !D
M             ( ![*H  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !-BVQ0*\C&7LN*  !(,P( %               @ %EKP  >&PO
M<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !-BVQ07MT  6T"  "\#
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:+GAM;%!+!08     2 !( *H3  !W1@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787804320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795812336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations Debt Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:79.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.156%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,447)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,012)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795796064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings (Loss) Per Share<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of Lexicon's earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:40.042%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.420%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.867%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.052%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.468%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands, except per share amounts)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Add interest expense on Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add effect of potential dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Share based awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Convertible Notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) per share - diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 8,206,390, 7,438,134 and 5,907,643, respectively, for the years ended December&#160;31, 2019, 2018 and 2017.  For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792301920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:41.827%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"/><td style="width:41.981%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.425%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.571%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.431%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792453808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792260448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794008496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Deferred Tax Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 193,270<span></span>
</td>
<td class="nump">$ 206,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">46,306<span></span>
</td>
<td class="nump">47,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug', window );">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug</a></td>
<td class="nump">24,524<span></span>
</td>
<td class="nump">24,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, In Process Research and Development</a></td>
<td class="nump">58,596<span></span>
</td>
<td class="nump">71,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">4,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Tax Assets, Deferred Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxAssetsSection163j_LXRX', window );">Deferred Tax Assets, Section 163j_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
<td class="nump">5,533<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">333,569<span></span>
</td>
<td class="nump">369,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon', window );">Deferred Tax Liability Related to Acquisition of Symphony Icon</a></td>
<td class="num">(4,140)<span></span>
</td>
<td class="num">(10,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
<td class="num">(4,143)<span></span>
</td>
<td class="num">(10,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="num">(329,426)<span></span>
</td>
<td class="num">(364,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="num">$ (6,014)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (12,661)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsSection163j_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Section 163j_LXRX - represents the disallowed interest expense deduction as a result of adoption of the Tax Act in 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsSection163j_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible orphan drug credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794995520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 294,448<span></span>
</td>
<td class="nump">$ 9,682<span></span>
</td>
<td class="nump">$ 9,216<span></span>
</td>
<td class="nump">$ 17,071<span></span>
</td>
<td class="nump">$ 6,966<span></span>
</td>
<td class="nump">$ 13,798<span></span>
</td>
<td class="nump">$ 25,374<span></span>
</td>
<td class="nump">$ 322,073<span></span>
</td>
<td class="nump">$ 63,209<span></span>
</td>
<td class="nump">$ 91,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (Loss) From Operations</a></td>
<td class="num">(47,217)<span></span>
</td>
<td class="nump">224,676<span></span>
</td>
<td class="num">(18,545)<span></span>
</td>
<td class="num">(17,469)<span></span>
</td>
<td class="num">(12,367)<span></span>
</td>
<td class="num">(22,927)<span></span>
</td>
<td class="num">(30,272)<span></span>
</td>
<td class="num">(37,713)<span></span>
</td>
<td class="nump">141,445<span></span>
</td>
<td class="num">(103,279)<span></span>
</td>
<td class="num">(130,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,138)<span></span>
</td>
<td class="nump">$ 226,086<span></span>
</td>
<td class="num">$ (23,018)<span></span>
</td>
<td class="num">$ (21,797)<span></span>
</td>
<td class="num">$ (16,782)<span></span>
</td>
<td class="num">$ (27,396)<span></span>
</td>
<td class="num">$ (34,549)<span></span>
</td>
<td class="num">$ (41,821)<span></span>
</td>
<td class="nump">$ 130,133<span></span>
</td>
<td class="num">$ (120,548)<span></span>
</td>
<td class="num">$ (122,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Earnings Per Share, Basic and Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Number of Shares Outstanding, Basic and Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,920<span></span>
</td>
<td class="nump">105,881<span></span>
</td>
<td class="nump">105,848<span></span>
</td>
<td class="nump">105,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,218<span></span>
</td>
<td class="nump">105,830<span></span>
</td>
<td class="nump">105,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">116,640<span></span>
</td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,747<span></span>
</td>
<td class="nump">105,830<span></span>
</td>
<td class="nump">105,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001062822-20-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-20-000015-xbrl.zip
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M9-G]LOF-DF?U' <8O!G8/$P^P'[N'_X=7TY!V2HIHQ%1.E?TR$PM+-YH2T7
MM6P7'(3)@9?XM'NIG-["D>WW.Y;SSX-MA[TOQ+:S'3=X9HHT#=X-W9;2$Y[)
M_]*U#DN%G@A-',"'52)C=P<X)S@H7L2-6$&8BZF$6U95#?R"*\ E,&X0VTU5
M$F,NI\$(F8+%0&5),/TD%26Y2+7;:5HAB<4*(5.G-A+M#L&!#@J!>XD</W&9
M=)?8?@]V!T)$[*B(ZU3 [SNWI"(*N.MY8NTDS"?8!"16@R5<>@P@$FO&ZAE1
MN&F*$8Z82WH:'S4<0!S()6;H2# Y32ZU%7XSE;-U8K-18G[?9C@Y.T<<N=99
M@F.F$.A$BX2C::S6MJLE[ZWVU_@()BQR<3I2>:[2D]YJ;?R.*K+]>ZK#T'PB
M=D<@,9]W26A.>++@2[-U_V+\_<O6SP$6)/*WPJL?B$ L#>U():OKU=OEG U/
M+!('=P^7ZF),%]M%E!N(DIWU0GA^L5-!#W5-T2"CJ9KSI*8T6*E*^:]*(]IV
MDU UP6>NR""AV89(L>!)Q6IA')8*#(]-_<U\H=A2<(W>!W&EU9 62CK@61),
MK3=UFBRHIY%F!!! <5]YE=L:STA,9):Y_)J%/ NUB].CG940&TTY$@+@B<_0
M/[EP,9Y3K C15&E :DX'QD\@JLI;&%2^@6:,R@]4\2UY4S[11B8%4'4J7]((
M7T8S.S8@!EE"WQS,>R-;D GI(*S 8E%D5;<1K*_"Y8^%!G@$?K^>J+JIN'>G
MN94G""-48'+'23^YS?\K,@!AP*5!KW=$" W<&:"Q&(MQLUE"0UAW2Z![(6'V
M5,5R+/&9"NI[_)NS(>^Y]=:B6>IOX]9,! Z:Q[\T#-9]L3)S)K\),LDHE.LS
M!,A$"A%?7B8_-K$!L6>4%#%)L,\D)3(%1;:8! ?@$7@FBQ-0GNUX;O;+3*+'
M\6DPGV.]QG48?[4E([.)J)W.BG&OP7MNB[)PV8[B$L(M]>ZZ!^QXS[EN08@B
M;"-DLXC200@XP_Q5G@>D6G*Z#'8V,WLAP2WC)@)8!; %;F)=&J#K(ZQ0FUIM
M *#  8-CP H1!$X61/(EI0QL<H LDF\F 9;.R;[8IA9GPKQIHB+T!HH\01@%
MT'KO5STB-/80?/: I-"@>WC\;))"<B>P'C.YGMVIX!B W)D\%72!O$,(GFWB
M%#>:V@JVW[ED7EG(YW.\*[()GUC=E"#5F=.!%,1*97$!<6C$;2LOXAJ@!#5^
M+E7"U_@XBO!SJDUJ-A;8GI"PA"] !3#-L&%^CD.-*7'DQQO#)E$Z)_0B$("U
MJ8$J1=PFG,::%R[Y7E-^B-3M\K%X:A^U436\"AHT59DPV(Q!2;-JQIR\_X(;
MRYS8!IDN*0T4A$%$IB%4IRVH%@P<FA.WJ,)BQ29A8+>RFV K.5F*N;169-N9
M+AA<!Q:#+^?5Q!FBW4DADWRY8UD3J4(3,=1DA#O+?@7@86)96E;8GT0YXPBQ
M@&,1P\@-($65#VY6"OJ!@=AA@ML+&#^2'*D:@<99D7 F.2Q2.ISM1K7,,XW]
MDQD0MVR\^]6M3/]U]_#YI)XK9J92!*H;FY9B3UNBF9R)":AAU2+=HK^&!S1Z
M*]NI1,V5(1-=;GT,D".SB!ED8F6H$0)DB'=!RJP%N?^KO #R,!#KL+A Q-VQ
MP:298:Q*)2-_$5-YI=?D(?($7;3_)D-0NF]3):/4EQ9;6%.9FI9X>E^:,UO$
M=?]9=EY\I_088L4"0GYR4L.Z9W>ES\>_<FK,N)$I6'*>"5689.G*Z ^O\XY=
M64#;FG3%I_V9%> R_TI-E2+T6*V,JFW\TE[K;^D<<"4R-FCK90T.U);FP"(I
M#.$B2M2-K310PF[3K"'OA2&6N(W$+'3"@ 02Y@C!/#5FQ@U;%*(%HQ)1"1E@
M$U]LSZIL'SQ+VW-I3,&=4W?23#;H:76#-3K!*A5$LI\N%[)/JO*J32-IS17]
M_P/*7?7V5K^Q5ZV]HQRNIC-*)$J[!82)/1TN. >:MT=8P39%S>I4.U'17&:J
MFJ^HM8&_@(D6N3E\E@I]I;)=RC:-8>^M^WO\RR0E7N=S?2ZMKF8A3;E2'T?%
M\]E'4Q;,47,P7M?8M5D-Q[&T@X'R^C; C?J.^35\?>0RK\!W;7UM&2<'1TP(
M9K2T>3\7P6,:A+*4PD1>X;]F6??)'@,=//2<\]>L4#\]>PD(,==R5/@H>%9H
MQ Y6Y]AO$,I2P8C%V"L$#HU9$24O3 >K&BA\B/T9[-*[VZ MUX!"M2UK76;4
M/NNJ8\NR@^SH@!+PH8[E5$D7B7!=0V0U7HXXMFWDJV?I^#Z!I<;ZJ$-P0W[[
M^%=)?J\9#H(C220?)640C!X![[C$>:=,I2<*@D:6\UMAFB[1\\+=Y%I2PAXS
M<T[C[/E.&*4"?)WC+&LZC/UDP\Q )97A3#6Z-![>NB[OE0@7"U5FO+3PMD%<
M-?\U"N$OW:SE?5W-O7F4PE4,./N.2\U^X/JSR-G/=#QR;=0OT%@UA@^HHTI>
MA31KS"Q5M(Q[<B]P G$"3\"K9-QVJEI&TGCW9T_*/]OE1MQ _,!M@:?!J8WK
M2V5&)U;;UTE) 0N8J/FPL9'54*9YYB#D=1OA3"C;^D@&J&Y2C)F(2F<AGW.9
M6!6@6@^F?5)0VOP/+ZULJQPA;&-8KG6))6K*0;V:2!(I38!-W;4KL,=7JGGJ
MPT9K<2U&JZ1K8"4R:?*6.K1G7#8:,:QPH&-% M?381I V+;.OCC %J-[]"P=
MX#EVUPD\EOU;(><\P6*,[0C[63VA7,YEM0L0&)"X/A+LL;,+;$JZ-0;V;.O7
M2>AZRM \>=:7MB"">%#F#6L@L[" >KX)[4/YJLKF0MNP-%<;^E'@27C0YWA7
MCCF2#5M].\Q3^2A#I5%T_;<9A!/');+7$MY= 3)DT#+EVYX=Q]OV;M.')1RT
M]P;6$VK-F[.DMF43)-$U9@=>ZE9+7(U<_+X>K.[KB^ULT=#C9VD[P8-?^R/U
MKAHE_/<M[(?G'ON:T79> 6I 35L]ZJS*+[ XY02-'@/RH<1WV9F"%3?/A\CQ
M(9R7H*=:>L_M@)1;&V/?,FFXK:F35I,Y19#(;?TI'*&M%:,LZ)3&?V_!=0O8
MKB6AY]2*JD(M4;3T%Y0=3SRG&<DD-$J)"P@CC!)S/+7B*?4M"Q$=F46#U[SC
M6[TMMGVQ#"WR]_I96H;UGW=Z_*L-GS*Q7SC ]J\9*7#0M4J@17TMY)5=J-GL
M5VM&6P"ULDC.L,_-=K?C851[A"$N--JA$?8(8LP#*H2G1"0BJ]!\2EA%"S09
MJ%DK1HMHKUDQ6?'_JA-ZBUL_262_161[6$>X(3!;Y[[@!OG5A>VV=F_N&O@X
M&<T$+9K_@-N=7Y2PLU2&+<TO=?6NU"Y77G MUS$&MV!/.1Y;61V/L%9H;7+F
M&QYW)</*J'7DVOHELC#_7;,";VUC(GW43MIC$'6'4MNBE]:"]L]!]9Z3Z1QT
M!]9TOG<"$<3M\2_26<R:4@=1]P).F,E^I E[MOQI _?!-M_M[,\SFV:NRV=S
M_0G>A"_&!7;^0*B+K8L35_$,G8 O.M.F,\_J&VI!9[[',)Z.^'W@B\>_P#9]
M\?+MCR#9_OF0$R_U:4)KM3C ^6'R6&L_Q>,KY3;=X[YTYC^1^J(F;=MS><4^
M70ZO+FYNV*=_75Q?_/A=O4,)FQ\HZHF;6,9"I[C 0@7A.WBD_M%';LH[C9?+
MS^12](76SG\KAH<M++^1^R6_Q+/YO9?^B@W=UT^NO\*?"^L_3>7=^'GH1Z,R
MSX'3[Y>U3U8]7E(WGF_^Y<X_SWH3'_HMLP\JRT0"KI"7Q[_OP9BG<>[KH=]?
M^*@%]@L[_'8VE6+,+D)>Q_W/"%YLSI\HKAY(?57F/'<V_T%[>;?-_#/"BII%
MZ1_WOM".O2#H+WZ&Z/<AZ#W[_[FB_^/6V_\'4$L#!!0    ( $Z+;%"7KZUN
ML@H  (%-   :    97AH,3 Q.6%M96YD;65N=&YO,G1O:2YH=&WM7&MOVS@6
M_;Z_XDZ*G7$ O_-LD@G@.FZ;05X;N\CNIP4ET3:GLBB05!SWU^\A*=O*PTG3
M%ELG=8$HM411]WW.)>4<_'9TWN[]YZ)#0S.*Z>+3NY/C-JU5:K6KC7:M=M0[
MHH^]TQ/:K-8;U%,LT<((F;"X5NN<K=':T)ATKU8;C\?5\495JD&M=UFS4VW6
M8BDUKT8F6CL\L&=PY"PZ_,?!;Y4*'<DP&_'$4*@X,SRB3(MD0%<1UY^I4LE'
MM64Z46(P--2L-^MT)=5G<<W\=2-,S ^G\QS4_.>#FGO(02"CR>%!)*Y)1'^N
MB:"Y&39XL+W="()-ME5G47-SI[\=[&QM-T*<^F\#0M8PW-^CS23F?ZX-N7WV
MWO9&=6,K-?MC$9GA7J->_^?^VJUQAM^8"HO%(-ESTMK+?0GE\NL!"S\/E,R2
MJ!+*6*H]-0A*S:VM\O2'ZM7Z^KZ_]J;N_NW;"2I]-A+Q9.^/GAAQ36=\3)=R
MQ)(_RAJ>J&BN1-\/U.(+WVLT(*7[./:2[V">6"2\DFO2:#K9.S=#$0A#C7JU
M\?:@9N^8:G_/!HMT@XG5X>U[?^1=(7S*U;(;LMMIGY\=4>NT<W:$G][KT:QW
M3B@$G;-NAUK0L'U^<M)Z=W[9ZAV?GU'KPV6G\Z"^7^UED42PP][&-L0I&.?O
M3!O1GRR-=3876&<H-'5Y*).(6B@_D2ME1M*)@'LU)X8+;1G'+)"*V8))K8'B
MW TKF2&GW]_L-IOU_:F1EE=9YYP(JGH]]@AR<66'P0XSW9=?C[5#9_+&_CK!
M=RX'@3HB@=-XO\]#(Z[A-DVR3]8_,=.&(B 3:6ZH+Y49$KQH+VD$*C.9XI2R
M :<A)L)-K]&KU)E9Y@BF6'ZU"DX.)BX) V[&G"=TTOGW,6HU77QL79ZVVIU/
MO>-VZZ1;IN.S=K5,C(YXS,8,3H5-TFG2C@7<+HRF5(DD%"F+$1]]Y+@F9FAW
MMUZG'@^'";0;3.B]5!Q1<Q&SD)>IAWBXDC**(8;&1WZ#Z-K9V=AMT*=JM]JJ
M4NEUA,L)OQ&HA,NOQ3PZRBXVCB^ZG6E$4+?5M6'P7O$D'#XC"+:WZ%\9$_2!
M@_SBU >I-+S_3F:("0CP3@ %DE!FRM#;)LAC&<_ "?Y:W'^<:OZBG%_]$<SD
MU5.<-DN%@<1?@)+ RI&F1!J20#DU%F X$>_CILC!GTA(#UD<TY !*BP0CCA+
M;#\W '8DEACI#%GEYQ$>1A?0HRK1IR3F6A>>Q6]25%8=3V LURSZAY;=/%V+
M4#+1I'B?*POJ>%PNE3ME/]\:^(0 WTYJEY+@+\R&QG9]_^N/E]2A-AU3CUIT
M0MWO-=(+R8+G6NGJ8^>R8Y$D!T6/,[9"$G.$41D!\5Q$ CQ"K@Q#.'Y-VQ"Y
MR#\/C0P0T\U&F9KUQF;9<E9F"1LNGC*%+&OLN$M;KXF2+C#*\FLUAYW?WVR]
MW?^&U%BEU,*4BK@6R"IDD\N QZJZ'00TB($!5&+K;F@DM)9QY@;F;=]?1VTW
M_U]M_YMIG8W2.R.L1QL[^WHZ<O89()4"8$0@8N'R'$V(NZ?;+E,I6)_E^TA&
M @R2>3S*\0FC9C.-.#<6/W4XY%$6@U"60B\TC\5()*PHD@S@_UMG.C<\S%S?
M=NZ8JIKUM1?S"F2?@9X63#1%09EPIIQ"I>@).?,I<EFA-)BR$W8NAUX%^[<%
M^]GY%5I%&_'OSR\[94M50AM1J(2W' P^- (S\B'H"%=F,C0FH03?8@F:%=QF
M75@@2_?SQUZQ?;)-$HLC?>2.'%OG[:Z<]WSG-:K^=^]N(5%\:FI?<JYY5/9M
MI27-]ZI&H1;-%Y\0"3F!I6:U6>+KTV&+"IXK7X]-WUXX_<973!]PF_+3"+)E
M$J$VKW?^\5'DZ?C=\G9/I@6"-&S1?%R0Y]'UUQ5PS3S@B@8;KI?$D\X3>N:Y
MG#IJSTA!)_O&MDRX6?&0B]1,Y^H+I8VEF)\]-+4R,Y1*?/%SPWG$ICPVH@LE
MHPQ0VU=RY!'IM$4EC)F=8&D: UF"F-,E'V0Q,U)-II.:R;1)FS[U;]S;^02%
MLL2HR7IY%F>^\7P RZ#TT&G",--8%"Z5[;J-;TCA/EOX1FR"@/:%<!;%.<[]
MR@&V<2_ -K\^M"(><^/6V-WJ&2Z"K!F_+%M8+D@D]3/E?(4@@IO@:;\B_QV=
M>''M9<E19K. &F8H%(QC%Q!L+!=JX192FZT_D+B.UX;"S#H]#^W>P#H+1L)"
M 66I[Q_;<C3B*A1V9<>[[B)F/GUM-BE^+:"7*]YIJN0U. 62)>9V.Z0O4!LP
M=ZFQM8YV=.)61.5L?84EB:4@4^HZA1G,&F7*GK$?>UR-JGE+]&P7/N[X5/IW
M$_841S4!^2UNV.<VWVGZV1ZZC06N&^#[@31&CO;J]S?\%XI1/ [5;&HVX)5
M<?:YXLKJ'HO',-O:LUXR>.*9+SCRM^Y4E^UJ\YN!R]TU!G(@<_*6Q#4L@>7*
M\EI$OJYSAJIO"_MD&K5NE3$_Y?GO-%0]]/1!47PT(TU.6RW/VXJ0]OUHACF1
MK$51'4V?9E3 -/0NXIF5P4TIK-BEC7J>CW/PMNTP9';Z:G%#I>UU=',)1 <*
M"AE-<](-"%F,\<RC8Y6H:['QKC'SBE(D:HAL+1.G=<31;<0>59TQ;S7)MOZW
M^M:4*$*SSM$!08:FT9&&^7E;Z)C==O3<T Z#809V";A82E)+4"+W:<S!J5&7
MFG>4M.T34VKB/)B9/+0>JH"VU0KCS$TG$F@X\M="2RI44GAFRE3>#]NB&<YF
MHYAE=NLHC^"[5$B7Z;WS_OSYU&6VLX<'!+_V\8V;-4YJ5-QK'A,..(G<X]K(
MI-#NP<UP#V*+N^7L\5"$/B@A$Q](*V[1@FY;,[%BV,[#.:FHY)T\T5Y''D^<
MBBY$[JKC=] L/6?)A%)8T+::X3W;%J3(<R!!E5KHL:(;^$W*K<".I=GRH1\/
MS6>E^O>#FFVP^0B:&_^\YY+P)[:A5AWV \?M&5="09R_IN#];_>G_#H@W.=6
MKCR/GZV)E/T&5-GE@L-\_-^]GN83J[!^-5MGR9?+W%KT8]XL(UQ#CFX)W81&
MW+IEL]CN6,T*IE^'00SW'@$XKXJ-+9%DC@'V,YSPS-@*Z:FQO<#"4*K(;27/
MMJC]#EMA2\#U,D5C/2OL1DP-1%(Q,H7'X-+\<TZ0-I:(8BQXC>VY ?82-A1V
MJDLEY:.67RI)'WN9;UY,\K4 [I;0??L:6I[&E2T&J!@.6% ?/.C.L">R&1Q9
MV@981I:PN$P!. >2I3#<R %W,#1+=&2:P8- ^?@,WC72%P_61F4_9$OZ5WMY
MX?B,KHY[9YUNE]SVT?G[\JUR[A8>0I990H/S0H%7HE:S?$D+9T$MP#=A M=)
MNE8BCPCGI B$Y-HAPJW8F;\_N.@=NA>YFK0@Q>^^/_4-JBVUV@N"Z]W$;9#0
M\M>V1[?4GPN-J^//.KZ:I<Y2=_;J-,ID:UYM+V]5V_575"PNE$@LBS@#HJ_*
MQB]_?&'1V[/?J5N%[>JX2@B?$);"K_)A=?Q_Y\.+[:$6M(Z/?AWKM=E@U4>N
MCLMP7/61+[=8K/K(U?%IFK"<<;#J(U?'54*L^LC5\2?FPY-?5/[I+]?.WYJ-
M[/M?%>5#</?V#O3+^'9UI5E9_()PS?]Q,O=GT@[_!U!+ P04    " !.BVQ0
M-4="<GHV  "7= $ &@   &5X:#$P.#(P,3=E<75I='EI;F-E;G0N:'1M[7UK
M4]M8MNCW^RMTNL^9@2I!@)"DT^F3*@=$XADPC&V2R?UR2[:WL2:RY)9DB.?7
MW_783SULAY#IA-94]71CRUM[K[7V>C]^^Z_3RY/AQZO FQ7SV+NZ?G/>/?%^
MVGORY,/3DR=/3H>GWKOAQ;EWO']PZ VS,,FC(DJ3,'[R).C]Y/TT*XK%KT^>
MW-W=[=\]W4^SFR?#_A-<ZOA)G*:YV)\4DY]>_X:?P/^+</+Z__SV7WM[WFDZ
M7LY%4GCC3(2%F'C+/$INO \3D7_R]O;D4R?I8I5%-[/".SHX.O ^I-FGZ#;D
M[XNHB,5KM<YO3_COWY[02WX;I9/5Z]\FT:T73?[WIT@</OOE^;.#\5@\>WE\
M].)I>!P^/PZ/7_PR&AT=38Z?_[]#V.03>)Q_DQ>K6/SO3S.![_[UQ=&B>'47
M38K9KX<'!__SZB?GH4)\+O;".+I)?J6MXM?3%$XFOQ^%XT\W6;I,)GOC-$ZS
M7[.;T<[1LV>^^L<[V#_8?<7?_7Q _WN%"^Q-PWD4KW[]ZS":B]SKB3NOG\[#
MY*]^#FC8RT463?G!//JW^/40=TE_WLEMPSIQE(@]>8S#(]I[\'D6C:+".SS8
M_^6W)_@#=?+*^:VCC0'&(OO#SG:PW=G.@W]V3RY[WM6[3O^B<Q)<#[LGG?.!
M[W5[)_ON8=<><QYF-U&R-TJ+(ITS9+_SDQ\='+[P@G]<=X<?\;!!;]A]'WA7
MYYW>^F-'R02._.O3Y_ :"P[_6N9%-%U]SX XK@?$<!;EWE4<)EZ4 *L*XWCE
MW86Y)_(B',51/@-> W\6,^&=B\_1.$V\MR(1133.O6XR3K-%FA%#.GSY\IDW
M*-+Q)^]R@3R/5]W!7_[EYU^.C@Y>U3]"7QZ^VO6]NUDTGM';PTFZP$5'*WKS
MFS3,8!L)_+-89.FM^>8DG2_"9(5K'+YXE0.48?59&D]$EGOP@H& =>8CD7F'
M3WW:X[[G#>&'#=O%E^?+42Y^7P*> 18A<,N)X)=G"!3<5@30*@!&21%EHEC)
M+Q-X=K(%I(X I5[P^S*"7\(7N,JMJ$*K^;&M(09;.!.C;!EF*P^.3RO>!XH7
M80:O.7QF+7$1K@"&],'Q/D%TS;$>!JJ;0?9PT#IZ04=[>2]P=199%'M'#/&7
MDN!J]^;CW9+ \!\(3,S:MB"OIL?N!3 B!5AQ#;S^V@BI%_QC@%3' @ ?G[2>
M(MUTM*TVR>]9B]3F33[C'TMT;MA*+1KM??F>F$[%F'ZE]_?<)\7-Q_-F8@[;
MHQ_@1J,<>%3N3=-L+C)8,X/5 ?^TZ #7@8T>/C_:F>]ZZ50>:"+D9D%&SW/^
M'+A]\]9=<LQG( W@) N @YCP5JR5FGBH+U'5R T0^LWW&<@;OHPR3>!_^?G9
MRU<, ]K6++T3MR+#UX2%EZ1P)M"$9R(3\%/><PI;AKOBI9DW$AYPXKS(EBS(
MYND$!#7^PCD.O-CLPSG2#2CQI' #4+*O.7::K3]UZ($T3^@=<*Z[=!D#F%#;
MIY^E_"8XP4C@[D,O 0V -H=$X2V6(%]R@6=1Y'!\=+PS<\EA*^5FC[2;13B9
MP(OV8C'](?6=!L7O4,/@C]CEB^V4LK_\?/C\X-4?N=%MP7EUW;^Z' 2#[2CK
MZ>'^LS)I'1W19S\6<37@;2?<9=0%Y]VWW3?G@3<87I[\W>M\Z/1/O7YPTKWJ
M@JDQ8(4)^2KR= &GCD:Q8*X_%H8%=>Y 4@!'SICY!O-%G*Z$R'WO%%CCN$A!
M0"$W/8%EEG$!O" WUYW$&7V-ZD)G.HWB")ABWJ**4#62J.J\[W3/.R5<*0P9
MIHHP94Z=(YZD.$*F+6 ;*(596=+(!/Q$BTA(E#CXG(/N#'+I!A"-TA!X.Y@&
MQ3)!N0!KC\!JF$; UK-T#H(!/3XYG!Q$Q&T8+X6%X3E:.+1R,0/8WLSH"Q(*
M*"/D@],TCM,[_,#>!8C57UYY.]%N@^ #(MN)X-L>2L^P6 *QK6H>@"?XPS=I
MLLSEVOC-[:[7!Y4UB\8H/>TWP[=U7U[#^:TG],(=4-0 EB')M#[BD(D>'H%G
MKD2&.E$(9W!>TE(Y4?E84OG;H!?T.^>>Y-=,WI)'^$B]3,86H8/^)\2GG)E2
M$;):!I]EM]%8Z"?QL O\8UMF1KIM+L9+X&ELN=2NC<K-G QWH[?RNTA[-!<P
M4L1+NC%HJW 'U5[@,?%99 5<N,_1?#E'E1LN&C]);UR.X7T/QC,?M>)TM,^4
M=!J<=7O=8?>RUPI])?0]!HVTK#MG9]WS;F<82$-:WBVDK 6(<G3B2V<0<C0B
MVE$>32*T )UO'*I$:US WQF8/'?X*[1XPBE8,$#D48X,WV=/'4HL-FQ0<9B
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M*%J95\*5.YP;&.8S;Q&N2$T3Z.M7,J8:%B(C*9WN;L#GN,5G%9__+N'S^CP
MJ_7-WE,7?<:3XYBGIJ^&FZ/!N7>R0I.#L&J%O_S\].#54PJ]@MW,?52DQQU.
M1DB&?[?8X>K$T$7/(#BY[G>'W6"P,6G&Y,H\;7-EJO6 I8) *4ZNKK#/0X?L
MV'[W[;N*8ES5JG1T1C,ILF+MNG>*_' G )7(4)O X7KT;@6%F;0>!FI:E%+F
M)5V4];QNXO ZK,99H2;N<9>=.K8+FT2>V]('5SB.:^FC1JX!LIDHJKV&&/0F
M6UD;O;Y6QJW&"_AA?=.%VF],QP6S6K7; KN\&OHLM+CFPLM)(ZX?Q)GE22\6
MI6C9-MB]W%KV K9OR_[\6SJXVJ!R,RD]_9&"RG^J.RY$W1U_<]F['M1S=2^\
MDW4.VUJ,O/X+&=]MS0RWNK54WCH,>MY5T,?D,#8<UWJ-T5F8WL$G:!M&N57Q
M!I_6:D#8'V/BU$'LRL0P&>-'IDM5\Q0S14X.[T(NX^T<'OR/_B478XS3^8B2
M#6]3JMI<I'>2GP-S'<=A+N/=,O6LDJ,D\ZSA7VUGFC++E)UI.J<7W5YW,.R3
M\MW>&J<CG0L<[\U'CQJ8V.5^+.C#R3Q*,(/5**"@C\:<TX*J:1'%3M9R+-"0
MS_4/9?<:6:\H/;YD/^HZ2\JJW;)5Q)\*6\JDO+K\$/0'WN59$Y:X3!<+OY"/
M^)9NYG/MM\DIB"- 0:C4,U^FT(.6G^=V9UE+X+0U&4Y-QC"UZE4K;B:90R7!
M5VF#YIIR1IE66D"I)=_+5U@1RSUR9^F=)\IZ>7D!]1LL7%XM*-&518TI4H:/
MRST(&Y8IW&;#\)O*^]6^97%;(H1.OD-+A&(3N[;%2B(0X80^/$(0'U )9KT3
M+&%$7C&Q?2..YF1+:<<,XMVKE)ADJ8I-&_P4E)@OVUV9++AP+8"HF1P"P^HP
MU]9HF!H-N"2JSS)G(J*Q!4RF,+2/'SM],%UW1U3XJKF?+G#RV><H\YMNTT]-
M"4]3F5_M"B&+;_JZ1\!G4-(BU=03-$')0;%,<YQFF(W(%6T"W<J^E\ZC/#<N
M.%7>,5ZI!55S9YGE66]$HP;'O1[T1Y;I'KJN&KL9M(0([YS*2B)EDJ,*"Q<0
M_>.80D[]!19B$LF&Z?/PDS ;G"YQLH/N.=Z2+O4NU;3+9&:CTV4')>U%)^=M
MF97ZN %Y:^"H.X=PP1NP6!NL35 \;J&H4S1P9DB&8UA\U;^4N!6+'615N6Z!
MRBY9_BH<(_>KUA,V\P<,PJ4%LX@1IZESOGJE'RJ53F%9*'>?048_C:.Q5>%6
MKT>V2KW3ZO T. _>LODUO/1T<[Z6]K6F+;L4V^8.=XMA&[-L8MIMN5USDSLG
MR3]RU>5PYW!W;:=#7ZN0R,94N8)>1WF6I)V\6,0K%:M3_;XRN_<PY;WQY5P6
MLS3#%)T9#7  _5>=:;+O=:?E@Y%_2GY?,:2=3"K+'/3EU4PD5]67LQEJOC$A
M<TZ!*-(I0D=ZN"HS2URUGGU816H01'L%6]0TF)1.J_(^;NW76L?!1'D&UK^E
MSJT8X ZK?%/89#+F=NB%GETE-23;0BY,?]R1W7+*$(B]SUUM0ML#1E)&'S!%
MC#=PSW/F@75EOO5,D#P?LN.[&E!3-2)M,)?)/QREJ N7#A"RFDJ_ENJQK#4R
MD%B/_9;Q&/-%<V/DRU>7 VIP[7UX%_0\NV.EUQW(F8_G'[UAOW,:G.+0HH+I
MA'%A2-KNX+!8@D$S1HY![1FT.=(&R>Z!M^,?*4CV2.^.:>E6EJ$6DV*CFE@E
M-8*+61C<I5H.]])D3U=IZWY@?EUW8:L4T/M@_)OY.%V8GA!:U/IVJ[&LQ#QA
M7[LEJ?5E/9$QG*0TXOHC,//5@A_>P<.:' \("CCE*52:@[UT@:XR*^Z^OBBL
MU;>=+MC!V5EP,M1.=-F1<."=!B?= 4:(O YY4:QV+D1XTG$E/4LRP0$]6]P]
M'XAG(BI=0JP&(DYG30MY(*$C..-H9:N,N+SV-4YA&['OC:)$)OO0JT'ERJGO
M8D+!0DDG;>#OM7$;_!&[?'2SO ;O.OU@X VNW_P-[PW8J,-W/!.W92Q.+)4
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M014A479]?5(996Z/5BIXM*I,D)U*+Y,;.M\YVI5)9"KJ3E5=%$31$2 =ZHD
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M(*7O1RM5JK<6T#LRO#DPSF+%*BB>N8O0(H=-^0&>\R7[%4F'>7W( N^K8-4
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MC$W215&>,*-*4+;S]?H<>D9+"E=L([OWB>P^;2.[WP$:Y! :ZMJSSD(LV4=
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MW(JN),9>=7'$KB1R0++3L+4_[F-_'-_/_G@R2B<K^->LF,>O_S]02P,$%
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M:L+*]Q0:FVOR";IA86%<.GUW_<,+7UR7#WZ3H?SK/P_A/E1Q_%]02P,$%
M  @ 3HML4'9M3+NI!0  ["<  !H   !E>&@S,C%C97)T:69I8V%T:6]N;V9P
M+FAT;>U::6_:2!C^OK_B+='FD, G$*XBI82H[*8)2NA&^VDU>,9XML;CG1E"
MV%^_K\>&DJM->J@T2Z0@>\[W?-[']G1>'9_W1G\.^Q#I:0S#]V].!STH56S[
MRN_9]O'H&-Z.WIU"U7)<&$F2**ZY2$ALV_VS$I0BK=.6;<_G<VON6T).[-&%
MG2U5M6,A%+.HIJ5N)VO!7T9H]Y?.JTH%CD4PF[)$0R 9T8S"3/%D E>4J0]0
MJ12C>B)=2#Z)-'B.Y\"5D!_X-<G[-=<QZR[7Z=CY?<<VFW3&@BZZ'<JO@=/7
M)=X,QLRIUL)ZP_.JM;K7J!*W[C$_#,:UPS#T_G)12!N'YW.47L3L=2EBV=ZM
MJF<=UE+=GG.JHY;K.+^V2V9<MQ.*1.-F$B?GE_D:JY7R$<OUQB3X,)%BEM!*
M(&(A6W(RWO=JM?+R'QS+.6CG?3N.^6MG"U1",N7QHK4WXE.FX(S-X4),2;)7
M5NB1BF*2A_E Q?]E*")*:V[GA0:X3LP35BDT<CVCP^Z.6W?:MT5?4U^S&UTA
M,9\D+>.$3.N-4.?P877Z-Q$?<PV^9[GWE-H0T;_:$P$&.Y.;[HI>_V(T.!GT
MCD:#\[.?4*VO<!-/*.K2\NNXY)J"?\^4YN%BTS4<SJ2:$91/"[AD08;UT'3J
M($+0$8-+(L<D8:IR?A.S!1P%.NOQ',>#?;<![ZU+JV>!Z]><,A %A(H4P?V@
M#*<B25B,@$ZT*L-0\B3@*8FA?\."F>;7#,[#D =,9NN=LAL>X,;#B,@I"1@.
M"$B,\P9)8,'^[@ZBN-,N1ID[MXU[D(3";RP,)4IV:L$5H6Q]JQ.>$+S$J_M;
ME8&1((*(239> /9EOD*-B=[=J36>DYA3(B<\J8R%UF+:RH( /:[).&;+.<6(
MF(6Z169:+*<8C,U;QD)2)K.(B$FJ6&MYL1Y0V?SV>L1E'J9<I3%9M'AB?&OV
M+>I6T[6:M:8I71KKE:9+>8JR9N5ES=;T?F?-JOONX]V?G/MC%FY@S?8;3YQL
M&X/D1D%3JY0DKTM^Z9DY>M<WUUD48=P6;7E$M%-"*3*=W/TNNFS9D+O?S0-F
M*?,#TBS':Y&VO/1F-;^(N*SIVPB,&SQ1VG5 ^PSD/!FZ;B/>$S4J=5UKE:M;
M$WZ9"0M(W%-PE"0SA,L+E@J)0)_ B9!3<)W*[Q *:0K"@A$)# &(PC$+V'2,
ML.J[92P);C-'9"PD\X@CN.J(*^@9:$43F<J"#41K1%Z<CN5BG<#!?K9\ ?5#
MU$=0'A2B?(3\<!;'B-=BFL8<[3#G.C)B2?;/C$N6/1FH#.954<I<?Y\< ,J^
M:JCMTX-5=<-:)/'YAF6B!!%))FQ9XMRF7S7ZW JO+7"\F*CW-@HXGN7S#;+B
M"+.()P@.TSS!$4<T029"L=6DV)U,AI!PB1F<2J:R7"UGXT@< \['D0@^V)%B
MKF)/-CU<<3A<F9I7$09D<-0LSE-=I$R:S=4:O[/NIZUMR-'7L?@''OU?UN/
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M[>9I?*83^]>MGV[$-H^OYK!F8#$H4JD45J;, LJ5W,O44L9)AJ1%(EM:R=Z
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M&0;#@BE9\,!,\,"%0*VAH*0928%H,8<7,#N0/4L!SA&$-+;&\:45?A\> #C
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M 7W5NS5<$:R[3D#=@IIL'=8!D35A\.,V8*VKZO;@"VNMM=KU7;C_M"+8J-F
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M[N+1'H#R!E=B9C[H%ITR-DT_S=ST(G//R)?>0KJQ209(?A8O>='.5B]^EP^
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MGWO#^7"#[NMT]@!DFG@(UBA*SD?XQO"+Z UMP[P9/UD_/@:'^C9.L_1>VGO
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M2M*D8 HTV20@"H;U*,+9Y&8S-^4XZ)B;))J<WU>TPC?!:#M7X77-A^LCD=&
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M&91W9/OOE^7Y^!2NY#1Y_!3^ARVXIY]L>3XF8Q8LSQ-^Y%/XQYT;G@_(TGP
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M4F>E<LVBG7<-UW%/L;F]:;HVWO<+>RVUWJ"61V._.=22<-MT_6U2XR8PRWF
MS@P6[J+FYB5>#,-Q4CE<.![[3 T4^#[(+K+%3Z?(GD1WK\5WH34R%SP^;T4_
M][35D(U2IG",+QVH:+H&I$T6]S&N*ZQ4-%87+;=*C"]88M5"'54FSE5Q)XH\
M3M[,?8O+*]>P3L>;A.9/D2[OAP0)B_;8)$$CLU&IUR/K56=SFR3!%V:_&9$(
MGB6N462S^<26+'?*/XF)9JT;#X4E&TLM/(&D27=!+RHA+QNKHK+<]M1!45D
MO+6VR(7,(.F6L:6P39O84&2&K;P%MNMEF)N@V[Y'=-OK:$QO%>*FIX?&%DWD
M9[3D>L Y%L@#]NEVXGIZLE?@I_U>+"N7L9<^[L&LR%RAK&LCC:M;"E*R(Q7Z
M7*>^SEZNPU _B>>1D_"1\HCM@N#WI]$[$+%Q68?&QN9;RAS]U7<@>J>02UFC
M5\&WY8TV_67BW\]8]Z6J^$QI\%A3K^"^(%2)O(,U@Y/28"=E3'1'B7[O.UUF
MS9H"(5$?-;VA-\@>=@+/N"BV FDJU6<ED_ZC\).-Q"XIO"]_&4DI1/K8E,R;
M0F3V+LJ,3$ZU.R(SHX\8@\]1A$*;"I%1S0UM\98AOBW"#]'(<&VTLG;4!NV6
MTH3>T*9Q_$LZKQ$.:#76?6WM43SQH>,QQ<4 H96 )^0R4\*<(@Z5=ZIHJ2,G
M=VME7B/"UE$'06H?=\1=H_I13>]]2,?7-GP1ZZ@W?"WV^C XK@U0L]4<57>"
M\>P59X[@4;!(3:V^BO>2<PEWEESV6KK+C/N=^[=I\)!)1ME(I$ VU?PM:A"#
M**2*$YE0'X>\8 <;\ZPQ0D&>@[%3-E$QO9.*3ZB1+0+ZA5X0H3Q<X@Y\01'
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MB]Q]B@]+ABCNC>-7 ?&;,7Q^)(5L99E5-P_C+ ;8K3F&A%E\R**?E#7H_2B
M39BR]>@)V2"]8V?B==VXFDR<S(IO>((L"V:G*: X+GS>')5WV 5:S1O"+L)I
M=F!'LJ70@][>2-(/]XS18FK;*$C(VBNO,M"P[\%N^I!RC0\NKPUQ:@,:T]Q"
M(R"H\>U5A8<WI[80E+"%TR=8/<MC(?=&"%[BJR32NV!G2[SWNK&Z,#Y#$2^#
M&-,'!,HM$2BG!P3*SHM%F61%VC=PH- I@!.PK.$D@++\7JF$4_'9O:L>WXX,
MXE,,(KNZZ(?SA<+GE9"",W>$]>#PFDJP]F+1I?*-8+C[^ 0E#/(&CUQ7(>92
M'?+*N5QCM+6"4&N*!2Q<AB^8=8A@K]R,[FU4LY[T(G*"L>3=?<PP09@:)4(U
M/_Z\6Q2U9&_4]^YW7/.Z@]&.I'\TD$?E"_CRK2NSP>YEIINR'%L)#$KT=%X1
MC_H"_56SD?$P>J^1A<S^C58*=_#B:$)H:M$8VR[\^HJ*%;!*0<DZ5]Q(AQ>_
M9?J*8E4$X@HA>6F+CXA>7<T][X"6+K3"!B_YH\"B+0]@)HM9<GJB#Z!H4'@$
M+,YSB6T+L&6]9..3PWH6G$Q^'R;-(B'OW2>V2,%(# =OXUW(:XZ]LKNR,B3@
M;83W#IX"%W*L5FZQ7/7$#>$='-"<-6*[8 8.43JAB-<;Z9D9V\  C"0U2*E!
MXONF*UEL+XN?-+(D(Q>L"HE,UB-48@2:*2HBV>PYCBRJV2YG)BY9]E'"&;6Z
M)4J2_M$)Z.0->O"\C:KV/)S:[EF$TY[S8.U&#$ ] MX@^1Y=-B:W'I3V#?EM
M;9V=_AD#^$$)UMV*B*;8"\RYYEMBH6'&])+&LP?UL,<T46-@C0YZ3/Z#I>83
M57BZO#"UR7=X$ZO9_%ZT!8:H.II?[^Y1N4BEUQ>%\:-^1700Y$]4S<UG7DRQ
M3Q"G5"88BM_]=OB:7G$W-+#M4P>,8U.'P$6U;6!?HKG/:C6^IT(CR2J:DMGH
MJ+18I+9-0\<LRYOFU327!B B!Q8!/0W6+!:.9:XUR8^V5@7 HR=VX\)0QS7H
MF,"8"#0IO=:Y#V1]5[Y,*3I%(R]<;SQ:3G0( ;8N.O@3U5QS932F@PH?N; W
MN,AK:KY<5)?(^*5QJA8DA /W8$=*GCBDEBFZ.INQ/H&'$9S,I:;MN@+(*,%P
MA!BH O0MR9/Q5I#6FM-]I%V_=B?PW)1NJ:DYZK"-!!9ICT/EBR,M0LTQ?)[I
M[!14VW/X? >[\)R GQ2)%D_-_T8DUO\<NFP8S_2R:#E.61NI'S45<S@BBG_#
M&S#8I>$ LWG;FZMO7*.&C%= ,8:!LE.-Y$-5 9MDK=H_>IWAV9O6';:KT:34
M$;M^:C=$%&_P^;*8H)>@,=TH.12(;RB<[D"3UMA[L5?+O<S6E+"4$G1J*>NT
MP2.L"<@-6G\(J"7=SFPC5.UD 4F>[B!C5*LO)$IH9QOV)J+M)%UE=PQUMJOF
MI"KBF,$@;ZTEF!*O]LY_R#CB3Z;9$I5M*4]X*Y% CO. J1J%,GI#VJUIRRU/
M_X&@9$\(2H+]Z(]IZ%V0J3@/.*&"KRPED'!NRN2J;LH\: 7XTMR52W_NA^&G
M'C>]6.MQS%T.:/0D(AWA6M88A8A0[76$8;A3;JF#/'Y^WGIV[R.6 79T$*.-
M.8>0_"!$?=LM%AEEY,T5,Q2UH 7CRF#5[NU2X&^9><&(;/:;):",'F1L3X>Z
ML\ZC<NU@L,]ZA)19VXIS)*X!Q:7@ZJSA,TVF!#A8EP0.;+;TYC9[@52^)!DZ
M]F;(CJR%!M9%;1+J53U5,I H2*3U.W2S'[C ]GBHM[UJ([)RT4+!J!UXC:NZ
M+CVHC?@<6?L1 KG95KE-\0L#[0GW>';+]-]^;@3G\8SEC8PM;?).,#NGIP\]
M? C+N?'(,8[$ *[@<Z_KW#65\CZ<,^#L]-FS)]XPF99P!<TD2MJ+U(-N<0N-
M$UWOG%B3?(*.5)WE'!YB9VY&D>P='P7N":8QRC5WA\W]8VXX*/&8:O689+Z>
MI?FZKQ,0A=+L7)0A7,T1:M5<MK#N<T78Y 4"2J-OX@Q,BOWKK-@@M?Z'3X=>
M_'>0=KBGH@ENZ%$=&E,G;[H5(BKT!$:8J0,-1R\4;KL<;^R>T"ODX%1@^!Y"
MD>A<36&:*S*9N4Q_+,BOP9ZHG"RU]#J,&1VP^N!;0D5Q2^T*-FWS<9+\*C14
M:-S4*YR%(*P&EY:IM=-.$0K&TH])?L'T<6XV4-K/S")L&Z$RT%TYX1>4U@?]
MY2JDB4-X:K_)B-F-FI%.O2]@1EAU)^QD%H7C7/*R V/1P1A@?*C:P\#0/1+4
ME%_U0IM_1,^GQTHXT2;+R/!@.(E!_P?AX$7U#2T&='X:#@<E@.%K[B\=L*T1
MA)6JE3G0AH@T3)HNRXS#!?2/P -$.5:I(B[KZH+%I(5=7.GM0+>/Q_ZAF%BY
M^>HCV/^BZI=8="***6*FC.I<N(T#=6 QZ+ZH!XAU2RA<_?H<0XFNH).LM%Y3
MCG\BM1,5Z3G["T]V<)S\RU?HC'X@I:?']&>JW?S$""U=8%^R<ZHOHE&]?(W=
M7.@4//?L@#/%5E/9R5L+__V!ROC_U6IJNATDI@GSCZXBI74/@*E; J;.#H"I
MG1<+H7Y"(%IH)DA_5[06EBJ7GS\3)/-,>BH5ERW%N? ; 4<^+7*![_HC'7#<
M5O8-&W&Z\46$*FZIW*:Z*-U&#:* "]#1A2#@R[*OIQ:.RG28%<+6O?\XA7.%
MW*(_%6XZQXSIRA5\.G^NFZML[7-H+U^>RYI5ZNC& PFD*ZGX5U8),0,8$=I@
M\>^%>%[V2V98X161?J34M*]$8Q2+T3J\-QO5G]91HGKN2B07E0EM&U<,@!E:
M#[VE]4T_M4:3Q\_ET_P>\K_H3;\1':].=>L&4T&C!$RIEDJ(7:V=YJB.46TS
MINV4"@$[2*P/F[E&X5BLFG_!7Y$Y]IH_^HX_"G/^Y?4[6:<-]PZN:X>AMZNY
MB^D[BLH3P](,UFXE)1@Z_&SCM$D*U]'(L2A ;CAM29<KT" L-!J7O UL=9L'
M\%H*T^[*SYTF"%X"7! L/B,"P>G>T?F+O,-CMMYV?.6V1.J)15EMJPGN_J?E
M2HXEBY%Y&U;+]G!J$5ZQ&NSR<^YOYO)HA\F6?4X+\"OC^)Y)ES?*1"G&:6P^
M9@Y<KB_$A? T=BF$0-6SX]9&[G7!PD.TMB?:+U\MF5U@(Z) C>6_%DQ<<)V6
MQ%O $!J4 Z$8DI9OZH4Q:VW+#!9Z(,-:;5#(:O_@K%K1XA-IKX4K@KR*=L,V
MJGYA;4)DUW5GO^WS.&\^[E+$2#L@(A7+SQ1'7PWTTE=OUS]7>-BV;1#/27>!
M?>AAEZ"%MX:C>XE)K3JRAD7-$G*E=Y.4V95E469LX/5C8\5@X8.4S6O=REYX
MC9LS'"I5PF;LY'8D .MDDC$7;3WH:<YV-'V/?BZ+#ZY<AZQB4+PJJ\2=H^:W
M+9Q@OUT<S&A0_>(KG$ ZBAC7E\#Q05"H6!8KJJ'FJ> +J:Q>6];)G(H%/HF(
M-2QYNY1LB-?OCTYO(S&R07+4^K6#>>+*,PL:_A)C.P)T#&BG0#B]PI'K]+&T
M2CF[:ACLA9HX-DX1,_\KK;'DKBS=FGE"Q*# #RG+T+%<^>POBXN"=YR76JFI
MD3VP#6TW!5(.8R?ZL "XVB"-7TMCABV10V)M\B6"MKHT0A)SJ>D;4UGG6^L&
MC/XL='6:VJ"^O+RG/TSCTCX$?*.1Q40?QVC]C$7&AH69Y+R,F^!%%>740F66
M1#,\!L[3:1391543'Z)0Z!7,5!HMP0#;BYC>>5,K@#9W$TX2Q44I MDG$!?R
M??/2P&0>X4!/M=:X:4T<>#C]VPXZ&PP[5;QR?\BFS(;R03PU@UC71J8,S1-&
M%+2UF2L4*5JT-!MED-5T5UE%S0%F2_(Y+D*^!KCM/,06](CD!^@;3$:&@4?.
M>RY$ YIJNE$-.B"2Z,.#JX'4;JCV9>LR)'SU*FJ<%JE4VF"'&)]\O!JM=KA1
MYLP=.KJ1Z6 G(U7H"0FUGX"!9-.KT^CZU,L*(]0&YFUN*HXLLZBJ>4=L_$JQ
M^K6;9T9#;CBFB:O^7:]-P)_(/57?:069S05S!?CJIJ721@%+HVMUKWO.YYPZ
MFV!89M7V>XHTJ;2H\VU%HEX,MC! JHSU(A]6:H>3A=YY8,4=F8S<[V!Y=%.A
M#"T^RO29BQ9?X0+?[ZR8@>F$'Q"%XL^;RX/Q%[6^&+DLF!A(,PYP]NPVL.'*
M3\<UJ\)S[:)Y3<3$OK"9=/6@4C>J:9&1IE8C=K@$A]SV/<IM_Q! $"'-?>/Y
M?F&J\-6  LA@19AE)QRN69-UTA%BHGV*Q!_J-=.\S*1'%E(E4>!0&'NP!H@M
M623KZ)H$'H2)(0EM7#EBJA]RG^&-QH^X<L+(,,.LI"UE\B1EGGM0'Y[:#B.@
MYAOUC&8%GF[M7Q^B<DCRM*1J*$^*(?1J6&LI-ZOH2.),\LVKI:B3V,$#OP>_
MT]>8I#"RP' 6.)?_SFI2]N0<*8_^J91'Z YT&#YE&QA&."\F!58KC]&SMS5Q
MP)&-Z$-N*=?PBH&XS-9<3 06H*Q(&N \0H7'/Z5,U8-Z7@Q8^-JJ:\BD$O.D
M:Z9SJ8Z+NV^)(0937(A=>HF\8YIU)L6K24F=NA%"7WQEO5A+QQ2XF+2ZXUL&
M>LFS1NCL!B14_&?Z("RF6Z$IRN*DDANO^J:.<J )BKQ#Q $:=4H$1EETI*_&
MK,N:F/#P;[0AX'<@!P[[UDQ=CG_$+(Z,;\9[Q>QP^"2=?.IGGOH+/[%TFUQ$
MDP1^0YHV<@WC0>Y*CI#&%O00I^*9P1*,,UQFI78GL''!;%)?!LFU2R96 @/E
M2'3:*1P'#Z!=2^U.*6T@;>,SF@ 7W6^3#+;.JC5_'5]J&0!YF.(M1C8S4;@K
M;[OG82(? ME?V)Q*/3TRTZ5B):=E3H5/U<WJP&;Z<[=P#3J<XZQR]A[AW_JK
M84)=L' # J"6OV)OI-$KQI_=X4LQ]8I#(LRV!*OXJ0R<Z06R4M]Y#ZLOR[J5
M;BGLS5./PD  GB1O>D@MNMA0?%(!\AC?->5A]O$ZPS=369OIA+GAW1'/TZ)N
M5[U#@7'1!F.X-4=*/DHK)^[2)22<$0B,V0/@K,!W%@;DI4S_PQU(![3$8Y=^
M3 SL@21LB<$\M&GE6^SK:AI?GD]I9?57 ND] #IN">AX< !T[+Y8SYX])M@
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M"Q7<T*;)ED6.3;Z10_I2Z$H]^6MH-%@WVMG::PED(E\5)==,&R+N>)2[S?]
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M^M%((8WQ@3,-:#VE@-%8:@!L),O7'G_16F)$B%]B<B+I*H4_7O5:V>(C&*P
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MY."5\(]0Q>PE+ 0]JE%<G#X17*YUZ_4Z_Y*C?L8TJ2N)!_+4- :88'MY==W
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M"/9% (\X6NL+!VH*=38\$N8'FG?%&EL7@,S=>.K1D"-HQ!52KF.K.11V\D)
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MYA]AX-'[Y,Z>!DA?GH'UWKH'P5K:K,4,I"*7DUOJ<I**N@?G&162#!2B.%O
M5)\X;6E- ,Q6FH@,.\SE,>P,??DRFV7,@CY@K1"B5W:5Q$C 0OA8E'?Z-SEQ
M_$,0@ES8&D=.=R0[ _^)6&'V=!A(H(^MME""]DKU,39OR,V'@#']A2E']8E8
MRZFS:T5=SY&N7F4\6C@)]0,J[D54X"WTS+24:XL-:3AGG&,NM:0#'PR+(G7L
M-FTRW4"3/,BR4_[&"5SKX9L67C-PDE/%*7,1#'^!<&D-W -&,0CY,#\-Q1B'
MIS9$,HA<'(.*PBZ^T"8;=*-(,BTEYDBC'^H=J0AYCT;:ANT3ED/>O,,[UVX
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MEJ8T8%,26%]A"RC4Z77<&2%US63K4N3@IBT(4;W(,5JV5%ZV(ZGK<IZAMAI
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M=8)!8EM4@Y19A]@HB0H6#W$)%^+=]<PTE$&[Y4<]V0,9A53="T[2A^:WVB<
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M&? /LH%?K^SCB^G9^?'4U&P@L[F=9TBT"O-=\R?7,VZI-]Q:;LBVC(-6P9+
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M% --6)OP)IV_?EDRX& ?6)7<::0ZV YV*&/N;X].-A9"S19XLNTM]>-,RK#
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MJELD#EW! )V-RU046",W7T(NT64T*3$NU*LN_-EH.SP;F%C-:IE!I73OX)U
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MFRW#_V<!V<$<U.2')EDLL$\GI)?WP-:X>I6VQC_*>PWQ0UB=!VJ*\[\,3$(
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MFL?+#:Z(!'VF5*%/U$H/+[5=W9(VS;"IG!%%Y[6HJ[?^5N6UND.F?*0<WW:
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M4&/7TV=(/S\;E?5(5,:8PM=!OG<V (NG9\]0S! $/ CX&)9N<CZ-I],@X$'
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M)5LH$0$R&=\'3VB@S9/&_C S$>VL'BT.'=[NW_BI7T @E_R2N,%NA!_H74:
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MBQ@6,2QB5)7E*X<8G6=(97_CB+%%YQG5*3U2A9^VC(BM&/!T=&H_0]$G6S3
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M!<1G<P]'=3F;3,=1.'-.7-P5:B_@U; ??#3%Z6\93_P0BT]O<#10;$<@\)@
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M;I!1;3&VU;L%1J6[^*07]D'%K? 5RSBO\C3Q@VOV7'^-Q41BI&%%YK9^)CO
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MRCDY.7D#[+WANO9K5D.ATZYW;2D3BM5PCDUF]!EG/K,]?60*KO^")@[Y+=X
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MLZ[1-X6X"+S[]FYOGP+8KHJ_XVM58-)E%9A+Z4)+,K8/M;3E!IS<Q2) LQ)
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M\<$@IEE5EJ8HR_/WE]FD>I[N7:_?1VNPG#6XN"9."%XP[LJR"<F!D"F"$R*
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M+#EVM&LM108@ Y !#Y8!WS40N,>6]RU?YGC_X_V_R_<_1@)( :0 4@ I@!1
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M4%)942P>#WRC?>\1C C&-DQ=^R1[",9-;+S,17AE(KE3OCB*WFH0.=>3=2:
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ME#'/]O;++^OM:8>T0]JU8>J6H=T*-&M(NTW0;JY'XS99&Q('QZ@"P1(%PW(
M;T.06HEBL@+2;MTRM!5)]W9(P'&4)IW>( S/TKH$&SLM-%Z;8&/7]:*HI-^.
M!=X^P48AUD$#K)^&XS$Z)<LY)1?7>ARR,F6<*[!!1A"":[!1,)#_/WOOWMRV
MK?4+?Q6-W^>\IYT1O D0)('VC&?2).W),W6<)L[3G?Z3P=5F(DO>I!3'^?1G
M+9"4J(N=./%%MM&9.K9$$B#6PF]=L19-!"\*QPNO8XY\Q+R(>7>=F1$Q[\<P
M;Y&"H1.9*.DRDA<*[+#"4Z*\SPCW"6-)DB6I*R+F1<R+F'=;*1B7MBV(P/=C
MP+=(N$@**VFB' %M'(!/6D&P;2#A:2XUDP(HR';V:)H,:9I&X(O %X'OCA(N
M(N;]&.8M,BLXM2">/".Y!^#C:6*(9JDB"C1 A6*L$"(J>Q'S(N;==>&@B'D_
MAGF]O J74P/_I02H( C/L46T%9JD5DNC"R\$CUZ]"'H1]+:C,5]$OA]$OD6.
MA116JTQ:(IU+"6<V)9)Y3DPB7)9FJG ZBR;N=B=;W$ :V@/J<?9V7#E8@2_.
M#HY4.1X C)7C3ZYM['FSS<P>=/9=++P1TTL?-(-O7Q['P?3855CPL'+';ER7
MGURC!RTP[O].1KBB?P#2H7)T,'[CS*PJIZ6KGU1E#5_U2RF"(G7@#]7GJ$-=
M38?ZTD\)27E:2.,X49G+0(6BE*#-3XS6J9:I-Z:XU;*)$3XC?&X#Z;8O)23"
MY]; YR*[1'%N!=<)H4IIPHV11/)$D<(Y([@IM,IOU?<6X3/"YS:0;OL*?$3X
MW!KX7.2HI%(RGVA-;,XLX5X)HIDTQ%,ITTP8GC,3X3/"9X3/F\Q1B4"YI4"Y
M2&P15E'+"DL8HYSP1.1$IHD@M%#6I#:7TLJ=/9E'C(P8&3'RCG):(G)N#7+V
MRXY8GQIF,I*)7&/[Z8R(E!M2%-QQZ2S7)NJ8$3\C?MYB^9&(E-N#E(MT&@#"
MQ!1<$Z582K@MX#?*&1CGN:'2N2SC/BJ9L7M6O/0^7+I=E7'D13)[>[;I;VJD
MQL8-U'3PS!EWHETU2.EP@")M.VKEZ$EE715&@-4;U)-1:0?_7WC)YIMVK!2^
MM).9'KE!MPH/13FIL75FO:*?%%E"G4JU8ZK@-&/2^S1-<E? CT3F_/V+'\[:
M?1HZ785R::%[9WTPF]93-<8UC%K'U;0.VFH<35UP+G229)Q(P< \RZ7!;C&4
M9.C6A/]I48#209-\F!=RZW)XKV%';BD:;N?!AUL37M<)M5M%U_]Z )OEWDBK
M=5/Z^T75AO;2QV DNZI^_I]9.3V/4NC*4FB1!NF]IDX6>&98)82KA!&IP/35
M\+?WN98\M4$*10D4)5"40%$"W5\))(5VB2YLKFC"B\(*4U A)7<)MX8:>@W&
M4A1.UR"<^EWD$D]I7A '/$&XS3P1@FIBO-0J3:U**9I(0YZS(2U8%%%11$41
M%474EHFHJ_0[\(E)A/0L!QV<\S15N9(B8R)W7BOELHME5 U+";]%876[PFJ1
MTLNM8J'/7T*+@G"34"*<M 04#0;4]-KZ%(55RD%@<7ZSW0^BG(IR*LJI[=XL
MVR:GKB"F<N6DX)G22DB>"RU<(=.4:R'27(M"16?>+8J@1;*TTKF7J1?$R10;
MC2E&P+Z51 EN'/.&Y4+M[(EUV1,-I2B H@"* NC^&$HLSR7+J=,BD3RC5A16
M.YKKQ*5YFE(;#:4MDU+]NHW."JN<)JGQ(*92F1$P;1WQ!>>4JL2XA.WLI4-!
MBV@E12$5A5044MNSIE<Z/9 [FULFF.#<I%8;P0M&K66)I,K%@-.VB*;%20!%
M'?5:64)U;M")EQ"I?49HEN;."^:5$3M[E!9#FJPW,(UFU&V?)/C75,%;=(4@
MPX^[*&I)DZ]5M60!QU9>HYOT4M'.AJ+& 9!4=U6D<_$^8>!?RBG,RGS+&QX>
MNX$R9G("LSX'AAJ,)U,84%7P,9;PG+JC2HT&IZJ:#B9^,#UVM4/4#+RJILX.
M?#E68U/"1?44/@CU/G?OTY)]'PL$K,ZXI(G+K-!6\UQ[P6WFC,FX3;7R2K^G
M/-O9L JGD[I$!/JE<B,U+3^Y7\]*.SUNBJFVXW.V6V1K=6+G=RH-))A-W:\M
M1B3]1VRH+7N?UOQWPE<JQO9^'E<+A#YR1%=.?23*PVO]HD9GZKS>^=?2V[>/
M3G,8>VV)FG78^S^Z@ILV#'DO5K'8O(I_NL\E[-3!JV,%VHEQLR"!ZN'@Q=A\
MTP;],*NGI3_?FO=\,"!].=V>]M'US1Q3$7Z?JOIX\/MH<E8_G-?]Z<48Q,ID
M!@^Q]<^/DB^[%SI1U5$Y[K2^O '_H#%U-[57!/-5S::3[I9&#0R?M*HCO.9(
MG=;NE^Z7->.Z7W(<7ZD[G%>.P\N$<5O$E'*W8"R 9GM0KYU/"ZB[#:"N:-#-
MESG?Y2F_^/M+;[[T2P&3^MX')[OTLB^YS+_SW@<XXTL>O'3O=AWDO-!?M=E*
MDMMA)?67CF;7O7:M1+BB-;K1<?8#2UO<PM*^<ZH:/ =PLTMG9+_!9_IX#DG?
M0&&3>[.WKGWI'L_6NO28^;45TKF&)8M$OU:BBTCTQT?TXL;[*MV:AK?1(+WI
M)0P6NT>+?>"KR<E@<NHJ-45'*\8@/H4Z4;_<E)2ZGJCJCW+N1GMY:\3_W;1#
MC(2-A(V$O5]M_/(F'K/MZ_C230=E*%(X^&DTJ>MKS<#Z,9-QNQ;J6K-M?J0.
MX&4I,W>R,EO:D/95-?'E=,NZT;[MDF;8RV>8*/-/N7_XEK[[^WGR[L/O'PX.
M1Q_@6?S@V=O/^R?_\_'=H>'_O)DGS;"7)_O\GP_[=/]P-&J3:]*#9\_Y_M__
M?;(/X^]_>'WR\N\79^M),^_8NR_')_M?WGX^^/LMVW_V%_OG@^'[AT>?X?W.
M#OYX<?[RCW?TW8??,&FF/7'P?+K_Y#U-E)$N38GV!27<6TID)C-BE4HU=ZQP
M7M]F+]H;JZ"Y+5)L"^H,1\B/D']]N?R"BH3+C!:)9EP+IW6:PU]:<LHRS67
M?-%AOKB>I/X(_M\/_N=S\.<*&[XQ3QA-!.$Y+8BB648$"@->9"H1',"?)<.,
MBYM-YH^X'W$_XOY=K\Q5<#^G*C4V5<H5C MGM%$IR](B2:RF/FD:X!4=[A<1
M]^\8]U\NE'ZODTQDN26,YU@VT&/[3U$0SG+-;4YS3W/$?38$NRWB_M9YK6[
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M$)XP2H1FBEB6Y6#92IGD.9A!>3[,D_4$E[L^H[GMTBM&?!\%0-ZJ0R@"Y"T
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M)%8#?# >^ AVVU,B*8+=C8/=PH[GB:7>>$:$SCGA19)BPD-&-+/.<9H82BV
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MFD:YQ;JM!D;@[@OR(G&!-WX%]ET=%GZ*"]^?8WB7.@19WNZ"X,+L!Y !YP/
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MQJ9*N8)QX8PV*F596B2)U=0G:>"XHN.X(N+.S7/6_MG^E_WWA3%>BZR 97?
M7D G@C85T58GA4DRFF6 .WFVB;/N,PM,)PVG/V8.6.D;].7%>R>831FH.#ZG
M%/L&"2*%!7FD4\6DT A"H.*LI^9]CQ3:+H:(4NA2K'CY[,E[ERMOF'; #@DC
MW&I+), '$8DM\M0YEOD,N&.]J=0E"O!2:?OI!:42A_T^*-J-2GA46Z)VNN8=
M6'8&7.JLB1V?HBO[P@:T[@C9[74HJE^.CZ(GNRV6R]]+EZ24&=C]69(23CU
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MT+% .!,YI__\X-0VGR$;+,W==7-OJAJ7]>#8C9J62[,:#X5C!ZNJ*ILCW^&
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M@><%"'='(V#+-U>A=Q!4#E,BB#=_!Z=9I^,U+]8<<_@,9D*GR#=RZ \WGIR
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MEJ:2@YZ[LT?Y!7U(-I1OCIKN+6NZKUOA!U#?"WFT#7,?<=G=O]+WPC%K<EX
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M3T9],""O:!%@3Z<FMEE-KQ/2,:B#/8*^^-[N@JC 2OJ?:X,QXV&X%(F1,<A
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MX.R>37]HG7H")7;W=CS>/=W K>Y6=[>;ID!TNML[>X>MS^_$UI]_'VZU+X9
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MIA4BG'C$@R/(""R19"0:+=,R>I.Y(7-#YH;,#<V+'KT>#](Q(YD [DH ,^<
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M<R\(3V2<?""<? *7+^/DL^&D/\-)*XPR5)2(Z+3L&)<*:84%<BZH((210).
MDW@5X\O+\C)./K?OM_SIP*TXRLG IE#X2TC&+?OQ/'<XOY?!]= ?NTZ\/LK=
M+-U^QL-]'D:N#34=F^5A7VL* EED:_!NUN#W>:\98R:$U1P)KQSBI/3("AK
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M^3A-=IV#Q269*OB$B/=QBGA>;&]\D=1$;KE$S J!N-4":<$I$B777&H7)>;
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MO/T?/#6>9Q2Y'*Q^S@C8_\0$!-H:4^%5+FF;,M"&QEIL7%W[O\7&>\/&63>
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M@#D^BR(2 0K0/N)CE,$RVNE%">8</#6 XY+B)$ERX@!Z80BBT'12A<&9A"*
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MRE.2W+KUM;Z&06FZS>=FS+YNL]BUY\XW]N8L<9QAC+4G[M;!/6J#%AD-2O/
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MC@,0\$K1]]$L+L-_1W7RZ=R,;W0ZS8Y<ZDJ96YS;./"4DSZG5&$38D!5:$*
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MF6MG^7N:[CTG\'N,YE[/=&4?8W/]5,3@4#_%_\I_MBO\(O9NVV+JMI.X/WT
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MQ&@N!'4&"X29PHJ(9+1'$.)$'/&73!P_DC@./GX/!')$?*&LY0C@PF) M*!
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MX4?HR76^RE3W2"V7KC'U/3;9W!M"&C%R&49*@MH_>'MDF?".4P2$-8&@+!=
M^$*"@" "%Y0+K40LE(FO@I&;67B7J_@3J_NSHJ;WI>21*2E1$MX[W3F*?;,=
M<@6P"D) "L2!T(0"S@KAM<:%HV9CB\I-<@M"JO6*%;0S56XF.LK4S-Z\IS(
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MFE95F\NPQ^0'J(2F?F5N=3V[1%*;\Z2L+^[D@LXW(:;+G>((2FND8P8X0F7
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M3GFIE+E:U9J%E';4:J8YSM,R$0^+-<6TWD7[=@75'Q=G*D=Q\A._:F+;V_Z
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MM2M2Y# 1@@*H ]<B2G,@E%6 <QIX%J.&457V@"S0SYEE99:5659F6>O+LA[
MOI99UMJQK%D#7$&8,4I( "G1@%#K@,): FR]XP1J#I7/+&O-K7 O.\CR;2K9
MZVRKMS;1EK<(MUVOM7Q"Q]/U:_;\.>:CFB9C1G[GJ_O+F?$@58-^Y[TSH_U>
MJA4Q7T!B/Q9]SNSR=NRRF#=).DUL+-$/7 $5(-A@(+0O #;(2B&XP")&CN!
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M^]57U;NN-?VOUZH_*#N\78+%O9=T3?GH&IJ.J]B&S#]ORS__FC,>,T,M$D2
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MLF!M1F#&R(R1&2/7U5J=,?+!,+(N#/SA^][!SA$785=1P$@F>+1<R]C9L-#
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M3/.G[MN+\)^3T5EWZ_\'4$L#!!0    ( $Z+;% HHGH/"!0  -_N   1
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M+Q.LXKU*WY[B&?KPV_\#4$L#!!0    ( $Z+;% IF)0J@1@  #T$ 0 5
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M<H)\>.>/"][Y]V>79_#3L^GP]&QT_;N3#O)/ST87W07VRQSCBU[_\>7+S[\
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M_R*E81F['[WSP_1Z_-*?#6=^-/!!ZZRU1R?$H1.BHR..AT"XUI$"=6"H:4&
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MM?(T/D6D^;2A6%6&W)X&.VJAQ3080#"*4<Z(5_-DH%;$48G66'OIP 8IVQC
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MW97@,#@91(C>-3$G#^ ZI#"MKD&IJ9"*Q3"FL[>Y!)/SFT70?1I&F'Z8C-+
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M_?WN6RU;2J""6LK9AQLP.@Q^SC$26ER.ZB'P!UJL(LK'H&XNI/ZIGZW:W8/
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ME&6K&L_;]7[WGU<JN.Y2"*]B]_O4QN/EL:JKJX,9Y4<I'_;S=_\/4$L#!!0
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M2IX\QN-<"CF%S$X#<NPC_@?+[*REI0_-[*A&F9TU>&N9'8. 5GL=-86;5EJ
M[%RL%ZE-U!;2()*GJ&),3 )6/T05!J3(>B'=H]>>6VXZW$#_=3+)7X97;M,^
M,KS\NWT(;C.0-6D%Q8/RG)A.TM)2U;8?46N=5,D0O!^0AYUU &!.I#K^:CE@
MC#-KM2W"N))$ER%N%R /[WJP]H0^);=#OP-ZBTN)%IW@4A>D",5PZP)W,HO
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M* LAY-@+M#>!2V_;V)A\1==2H2&]3^^1Y4MU_Z%F'Y E^*E>?21,%53*!*O
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MG__F,X%A]IJ]ULR:]5UK9NTP)AD+P#X30V-#@&47"W"5^0,PO@.\9SS@;IZ
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MV_Y3AGN6TH!4F%=?/]]56@)VH90!$$W-$_%[-?$<]!X&(.!OM0CO,&<_$TR
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M!;P/"?W]NF$9]_V7I-XLI\L\+HK4^O)/X"W_V6LF%$S/T/<L,P V47";8N-
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MMK3_EV/GY!92.OR^O 25EF0'3J*//>90>_YU+(T4\;BTJ/:>1UW*TUF/W*
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MG!GP#_+Y'.MSXX,F,37(J/'S<=M<YR<?MM>F:0Y-[N9/2\[9MESE'/AKLV:
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MX@P&82(?SV'TR#-,<9D+JNE[K<T</,\$<>E+P)TI7UD/Z!)@OYC1A4J"%<P
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M&]Y:TWM()8*^V*)7LPAM&UM=)%<JYS\<G&J18OWT/B4^9[8A>[Y@%?WW,H^
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MU0;6V\,48;:KZ0[('BC) CQ#I5307[1R4B]Y8@5TI?!M)MV_V&W$VI^$+9G
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M+'3VG)4BG1./@G08G'+>)4 7X]@!>GG['XSNN_84KW;24%%5[1L X4W:?$,
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M%X ER5G&HWA1F"8]L]U0D2PTOO.>!1/TOLCX#Y:M)WGDM]HP>,WFINP@9#4
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M'3J& :;Q#\Q3&S*2@CI':^ J55U^'NRW<6&IQ[3<FT+\M+YV;_ST+6,0_>'
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M);)X&%=G@X/<VH':&L>P #L;',D@F+SE#.]<GS1I1RDJ0Y%[3%"TFN+&0G/
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M*3XL_WJ^B((,G6:";D^C$_;D/[]\-EZC?=-1FZ]+(0]J83BZJ0,E_PU0WII
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M8VGHUG96KP80B@P#Z'@_ 9V0IL4$M<H0EU?5\B7QON8'Z"PJ$KE#K]61Z>K
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M,K,83F#0[7CQKJC"??,>#ME,8LW3K'*_=[8X49'!PX:2K0/1L*J(*"QR((K
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MDGD'99O//3TRVBN>G%Q2X"VO]G:7Z*UM99JT4YJ%YG<$_"@W*0^R(>(OX @
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M#GP;="I](R\;%F4WJ?,I-(['(4%"V6'\&VQRH!4FTRR'EALT$*8;HZ\/LQ3
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MI>X:GF?Q;U8G[Z+:/2E-%68HRPN]??*07H?,+&MP/'1?PA8:<.N+P%KI (G
M*!ZFRK+ZN"W8D)&'^=Q36#^<.+;UK*;!%5)&.,>JPW>@#X8@R^'Y*$(G&R+M
M-@(K+WFCKEA56>DL^L7Z]G)% V"G%&?8>>9=A@CS.=X3":J//>.\>C_0O1Q
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MI-9"NG&9/B[8,0T:L=Z5 9_PO$I+C<XW9^4AHIHU996J\5'/W&"]=6N<'Q1
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M/+_4L+.K0_IYGY';E:@$Y<U3(S/^RPU8@ QHB.XPFX!S5@=YVY@D:5Y$8HA
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MA#R\\K2+J[U3NG-AWZ?3\HKO^VOE18V'0_XG6W[^M_U_::B-R?\ 4$L#!!0
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M0IX6KX04>:[$(5^NBT*4Q5_(<E5Q^/5RF7W6!+]0JQ$*9!1#'H@((N8)B+V
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M?#^"U","(BZ". I\%IJ5<3K;TTR7N4I8L)9V'5UHS;0G\#5>P"Y';9KE:FS
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M5*5M?Z._94Z?F\_X%_)%D=GC]:/.X[Y@A#(:(@Z9YTAEM7*F*\?HI&Q,1([
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MT-0,XP E+0TX.UV.&J.Q5/AL"E[6$)VL>7$ME9K*O'KMA/ ZKY_GA>6?;]Y
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ME,>)]9[LR"!3^S:;OK&MG&!+4 ??\1B>%GN( 5#R_ '[!,C!YQT J)%<T:.
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M=)[':KXD2LU?%_I_B[)A(/VK*.[NU7773TJ=.V'^^$Y9VG5$8L818RC5*UB
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M02LK,,*"C;0.+M(I<"U\TH$@\VP91D'+P64<"+61G,*;$GQFRTJ?0RASA:[
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MF<0"$A(H_RQB+$\HHI1;,<IZEW1JIM5H :E6 VRKNIW$ICDUMZ]K]6U(VZY
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ML10P)E$2AFE )'':=(XG^M16^W7[AZ,;D89&<*W]%5CK?VB#TE#\[8( .A3
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MB8O#/X>?/G(0Z*2*^Z&@TY>/5/SVH7@2,YD@2G/&($$YTH8B@#C'$91QA*7
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MX"@F<:KW>WHESB1$2IK.WUD*8R)213-$";9J7.4V[-3(X>OZ\9&6S\;VV%,
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M3F-\X.JUJN<U\HQ;IM,#<B_J;OIX9O\R_<6R#K8U?D,YERI)"&4*"I:%$)D
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M[9CX8H4XHW$:!DC"@,<11(FIGQD*!8,X2R+*62H"/&\,#&V[E*M7POU8@E=
M'VB[CLG[?+DT=I>VS9ZU)3;$E% 5$)Q2!=.84(C")(4LBCD,)$52QEQ/F&RG
MY/U2O.J$;,9_I>F0^O<#3H2=-\L[M ,;%V?]Z#,#Z4;JYI#<8SZ9"TI>D\RL
M!AXW\\P%BQ?I:$XW7^%2KZVV19O]5I]VWZST_I:M5W7:;/'RB')W@%G-(T$"
M@D(!PY"EIJ^+A)2G(21)2AF.,Q1BJ[P0?R)-;9G?TPAL4CJ;H()]I4RD^[M\
ML:X#V)ND9D-Y)T-<]I3MX=2_;KX=//^CS>(8QP.C3V"_DP4OF'L_?KA.JO'/
M*+R@>/(@P\^3^\3*/C\^/13+YUN-PZ8"]ERF%#'!(RBCC&L+-"6:MTD$ YI)
M0C@2";(J+WUVA*EQ\49&8(0$&RE=8OY.P6CAB[H6G($I;AA<7,(6K\1G)/?3
MW1+\K_7B&<3!S!Q2!'N'%'^9$X0ZHE#O63[K 1^,=^JN"2AL3QF>%M(<#M2N
M?ZZ-NBK?G#8<3,!O8-=_H*H*GIO(@>9,X\2M_PCQ;YDY0%C4];%_/N3\X<5!
M0U,=NY2\N%^:8ASF?%N/M#2I\OHQVV>+34WM%?UK6P3MN1G2_+K.V,\%6!8K
MDYBW7JR X5"M/I=59?+V&KV?RMQ4WOY)*S-V?F].,O0":8;0PU;%HCY+$>9L
M1S]_"Z.WR,J.UZD["/+4C2/&*W;(?1A:V'5AO\W B[+8^H?-[]KT\X,PQJ5H
MV\!4I^,<WQ;5:AZF/$,)QE $QL>18@29##%$F&<<\2P,4Z>@P2&$G-HB=:*N
M_:S^>?L/K::SP^AX\VUNM)T=&)X'EQF5W;8-@[P9=AN)UY[O@=?=UYQJYPW&
MD'/A<\LQB)RC;D*&1/IX6S+H6'U+K&VC.G[(O0W0N[SBBZ):EWM5$4.B=RDQ
M(J:;< 91G G($%9ZJ4$JP33,(FJ5F==C[*FM&X?!,(8B-J$RV\ 8UZ,EAXFP
M=*(/ ^_0KO1]J0^RT'9R@^^#U)WL 9C?TFWVPX]<U<T9EY<%W]P?T8_0[IZD
M&65Y7Y^T?\GO'U9WZL^JZ3HVEZ'$BHH JB"+-(7%&<01UC_)F(629U&LG&K!
M=8XV-=*JQ8.%@NMJLTUUXZAN;.U8R1MB _/05LXF]L6DL[;H_5G)QG[TQSQ6
MH/CDFNX!1V47*]V/^<3N)D^;\\TOFK*W<YEQ)5(F(&7*!-2$(<0<$\A#@4G$
ME""$7;7//AQO:BQR<A^U_64C\Y5[WB/ >VY?^\/X&CM16P2OWTJ>QF707>'1
MD*^[P3NM_\6]VIG;^G','_+GF6HM=^6F=][^!?F2YT\+V9QUWJD;T63/_V]3
MQBM7.6_<_B+"6$2*0(DSK*T;E4!,E":JA*028QPGPBE 8! II\9G6LFS%8Q,
M*Z]=$\R#JUI=9WOGSQM]9^!08S<V'.;5L./05Y_P@9GW%>?:F;<'G0N?;#^,
MH*.N$8-B?;RR##M8S[(4)H>J+GY<5W\T3L9B60?!_957\T!%)!,R@HRI4*\K
M#$-"A4FPD2DE21RCR"I!TVJTJ:T/6V&W%6MW\H+O1F+7XA.=6-L1M3<$!R9<
M9\3<ZTK8(.&UGD3G@./6D;#1_47]"*N;KMXZ'[2T$RQ) Z2I0RIMEY*004:D
MU#MF%@D1JS0,5(^"$:='LWK[QZ\4<;#IVQ-W!O[H\"2YH.R\39YF-[Q^0%VS
M+1ZX5=Z9D5YK$VS10._"U;ZWO%6GW?,Q7\I;S5C5/$DXCTC$H4QY %&0FH/X
M0.]V)548DR@1U*G[T]423<U4Z=K>5)?W-^"[T0S4JCG:--=/[K4;U &F[!4W
MH]YFR^.VTQ'A<;:8MD)-9#OIB*']UM'UP3V3F!Z?:%XV6]5W>?545'1QISX6
MR_N/III#XRC]7"QR_KR+5A!QG)(TY##,$FT":H,/8H:D_BEC<4BE8B)P2EOJ
M(<34F'JG@_G0-UK4M5"T'K!69'LTT.CBF'[49Z;L.'AH_ >FW1[0@^_MGX.$
MG5R#I]?TH3YRC)LP= 52+U*$KGE67R>;?L9#L=!WM%U6YDP)GG&:09(QS8B2
M*TAX%L XDB%/,,V0Z4UHW^S]Y1!.S#=:S_=J3\Y_J5/05\_@%R%5SO/5KZ[^
MM!>P$LFE5&$"):9FIZ#?=YK*%$K*(T8%(5+?[UR!X3IPQRNW\(;JOYJ4D!^=
M^>:V8(HD"CEA! J9FO7;>&\0BV F.(\3S%-%$M?:"3Z@'+Y0@F<@;5V[UT S
M\.+Y]>"[;;V[QZFYGVFI:=6GB_<<(G[]NB]&&=F9>T[+EQ[<LU?V6Y@^Y*:2
M7KWNW2Y7>KYS/9/-"OB)_M^B?+N@5?6'?BW>%8\T7\Z55(GF @5QC R]:FY@
M"0M@())41E'&N;*JL-9S_*D9\XWXK>6X4V!K1-8Z@%H)8+0 WQL]''TLKK-D
M1S<#8C\P%_F'W9F9>H+GD[9<11B5TWKB<TQX?1_CHT7#<5&8I?CZ4)2K;[)\
M-,61JU7M?:F+KN]ER@22!6&802H8UP2I)*2Q"B%.6)A0*6F4.;D\KA=I:IQY
MW(5@]K(%@<FJJ16#6J!'L*?:-<T>>LVGI>4VZBP-S*X=D[(G?MLG8AC'B#\\
MA^LGT4NJ5VPV<0V*W9THKGIR3Z;NV_1GT^.V6I7KQGN^>I#EMP>Z;(I(5!^*
M4DE37?IV^;G>;,YEFB*)4@YYR#%$+(T,N<<P2HA,0AG@@(0]8AA&5&&B@1$>
M.M!MNU)OP0 U&J;]V+*M"Z(-PBTBYDBMP<1Q)1GQ?;-<<B;V^OQMFA8.\,JX
MKV_C3Y[7A7!$\<==,<>?EQ=+ZRN(T--WM.F?MTOEK?;.?G$:"8R4R4,)(<(J
M@#C& F(<B5"OF$$2ADZ>HJ[1IK;'V6N,^DE2(VN/W4LWOI8^'E^H#>W1V0&V
M)^E V?Y6H'CUU'0..*Y?QD;W%UX8JYN\>Z _;D/$PA#)4'(.:8P$1"C29!+$
M&52,J4Q&*5+2J9*]S:"3XY1.I^<5$7Q6,W"U2[D7KJ_J1QXHS,X%HY'<Q1]?
M)UC.!0D'Q_#+>_O6[?Y<%J;@XA=927VW*13^;M?4ZI-\9+*<IQDB(DP%I#34
MU!0(;>*0E,*429SQ)&1IXEB:VV+4J7'3[1*V4H.-V+6_<$]PUQK:-MC;D9)W
M1 =FI=LEN 0F^-Y([3,6S04EO[6K;08>N3RU Q8O*U"[W-R/FHPQUNP+%XOB
MIXE4>?-\7+:@SBG,I&!Q1&*8TE1!% <84I(12'BD#:<D8B1T.J^W'7AJ!+65
M&VP%-VZBE_4X>N5U6D^''6$- ?+ G.4-7V?><@7+)W59CSTJ>[DB<DQ@SO?W
MS1A]*J6INJU'TC\O9%OX\N:Q*%=MB] YQ:&FL+I@6Y9 ;6F9>",J8!:;<_8@
MC'#J6''I\J!3XZY]F6M#@.X)ZYH_:H&Y'4GY1G)@@MH7UY1<:@6N\;RQP;-'
MFJD]0'Z33BW&'3D%U1Z)EPFI#O?VZ-AQVDC;<[>_+9:KDO+5M^*S+%51/GXH
MRMJS7NU=;\KQ5NWQG6"ABE*40I75Y24U;Y%(<*@M+4EE%",:VS>A]2[>],AM
MMZGA1LRV_[)#5PS_4]C-@*\_,0-SY7;7>7.TZ]Q3SY1*;Q0$WPK0JF@.39O#
MU+JLW>[&6D^G@_>A/D[[9BFO.L,C=5IYI9EV:S,RV$1T]BCQ/^IX#4X&0^R@
M.\IPH_3UUVYBS;[I!]3[;<("GJ@PA(P3#A$/$XB5B"!&<1QGBB0X<JH;\7*(
MJ:VG.PF!$;&7.^,$D+:>UFO@&=RMZH1,#P?J.>7]>DM?C#*R:_2<EB_]H&>O
M[&&GWY7W=-G:^YIPVBK0Q;*Z855-,O,LPB(2E$/*5:R_]51_YIPA2*,PPB:I
M-N*)M=U]<;BI???[ M>;VIW(^DUOA;;D 4O +:QDKS .S ^O@*"#->H5R;'Z
M^%V'J)N5: U0I]5W^2GC67'6&AU89?9W];6R-)UI8O],<_&'7,T#1@6BB,$L
M, V!9!!#EF89C&B4!ADAB#.GUD!'SY\:S]9I,4]:-J -6I"WPKK:5X<0VAI7
MO8$9W+)J) -&M!EX_Q=?K(6I6/66/N4KNJA;86XNFH%=?XT;OLI_U!7F?)IA
M)V'R:X,=#C&R 792OY?6U^G+^GWTG\OV_*=.0*]# ><!99BG"8&Q_LPA4H)
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M,4$K)]@)ZA"?> [/[N_>%TI#N\ &!,@A;-,#4",%:]XNP1_%C[HX!=#TD\S
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M\7A:I3-?;]*^) F5.// F:4CTBG:"KY(L$YY'D1T*0T7I7R_]G8HZ3Y)>H!
MNP#$"Y+5,LQ>SS-^_=](3I/+KA1'OK3V$>ALS! +4V!T2E8IQIP:SB>]L?AV
MD.@^-WJ(2,<NZCM+OKR:KE*8_0>&Y<7[&:N8%$EJR/6E+GUC*?XN#M 4KG.R
MW.@A+MSN6W\[9'2<$QU$L)UX)%=,O**?K"9)BY",0M",431N<H8@Z$RD$S G
MF0H38@ALW+/\=M#H. LZA%B[0L;9R[LS)DPJ(J7H(:A:N1:(B2AY[10@4E;,
MD+<T1!1[+P';O6;L.!DZC&A'QL<1<9 W7,S"\21GPUTF'RFD8*J/1":/, [(
M=/(JE6!*&  3WRVZ'0XZ3H/N+\*1=?]Q&6HWD@_?3N)B-A$L&"ZY AL"^4*F
M9/ ^Q^HD8PS&T%\/D<OX;M'M=-]QDG-_$?818BQ.3NJK.0J8/WPBD:W>GJYK
M1Y7*TZ38Z!4KQ(U6Q$V]%'8Y<^!>1>Z,,F' Y-9#E&R'DN[3GH,)>S#H_///
MMR3ZAGYP0'^;^6HQF^9-4B;,:F>>#Y\0UZOO*=^VW\U]'S94_YNMB#VP'T[E
M:W+O4I?(<M8(M>F+838/W>OC0Z89!)2QF(B:!_.8P+9;:E^C<;J"XQ ^3S9U
M[9O'^B'.D")HX5%7W-I:KIJY.V.!"5.$8)F'>(?'<&$C2EC%#4;//_W,4.!L
MO;KXR4V+<3<9X_3,::#;"ZLQ@+1'/&!6R_45Y1\2S@/YQD=?IZL)KV7,QF@H
M6CI0Q<M:XB[ (0M1D*?LW!TYK%MPH06N086^NPF3>RD8!RE#J',QI&S'!L<Y
MW7_,5Y\Q3<L4\\O%29C.)S)AY"EH2*A#%8D$%]&!9]8CVN1$5(,!Y#XJQ@')
M0)I=#"WF$;%R:]^\F(75ZFW9.%$;T2BA4&N-@$J2W\2S 6?1@+:,N51*4G<5
M:@QX_MRD:)RV70,:F&%EW@%XKM-_#G_$PG5D!CQ*14<R"2=FS\&@SXPIJ9.Y
MHY;X<-3<)J63\^@P'2\&%7@'D+F4"\44^)J^7$U$23%H).(#DL4,A;PX;B/D
MPE!J+"G@':GT 0W-)2GCM(%K:6'VDW('.#E:K<C3/[]!NG3XK7(Q.H40.*NW
MBH*.:T6<2/J9T;+F#60+J-Q)32<&9D\5+X:6=P>@>1%6GX[FN?[QZ_]W.OT2
M9K6@Y6C](BR7WZ;SXW\+LU/:6$(BLX(!LU5,T>7JG)'#IA@94J4B"TT"ZZVH
M&Q=4 Z#@YHDUN$HZP-F'3XOE^B,N3U[/O^!JO2F;FNA@C"C"0S;U:@HCR2N6
M"!*U8D(S;>[J2CC ,78',>.ZRL.CZ&"!=P":HY1J^[S5>TQ(^X".^-]Q??'P
M1Z*/%(<&8*YV<TXIDYA00,K!,*V**/*.&X$!#K8'B!K7&QH>1(,IH ,PU7TP
MIU_Y1BS4H@DK*0P C9FLI]<*?.(%!'>QI$0_%$TLSW4BQFF4VPXL>PNX W"\
M77_"Y7<BF<1@4S!> ><E@Y+2D*WDEF)0Y42Q+GAU1Z^ZPR%RFY1QNNBV \J!
MPNX +M\33T:O2)$XL)!T?=1>P,=2)W6$*#%*&76;DVAGD Q>)MWPZ-E;Q/OC
M8[$.LT'P\6ZY^(S+];=WLU!G#N3JQW^N+E@UC4ZDR$.IW;8D!V4<2:4@.?)>
MZ&)#ID.T"5P>(JJ31/$P@?E@TN_ TOQUL<A_3F>S2= ^&TP""@;: 3PP"#*0
MWT4_XSFA"^*.I\&'H^:"@$X2?<,@9"^I=H"&S<GYFN0^/YZ2,WYF(S?N5@Q8
MI,T@LA:@BK'@!(E%EQ)D3!(Y;V)3[B-H7-]V8+0,(O5>T'-._6*>SH]68E[E
M8B1@O<55Y'"!E\6 T!ZUDF0L69/<WIW4C.OJML#-0?+N #1G]$\LRRIKKX&Q
M3 ZZ,>2 D>M%P7Z4B?QUG^4=!?I#^;CC.K=-[@UVDF@'+NV;:8C3V70]Q5MN
MON,IQ*@\64 7JW/NP=<2LY1$<MDEKNYJUWLX-NXG:9SA$(WP,I#D>[ EY^G$
M=^%;S25>!'<L.Y:\RR!-?=M6>V]XKAEDQD0I)F-0=_3(&BZ3^STYXUXG#:7L
M>Q*Y!TB^#_PL3VG56S*:Q%);GEL'(I8ZMXU\,A^= >Y+)N$(;U03$W0O1>,&
MU.U0-(#\.P#2R_-EW^,7G)]>;@=CZ.@U7(/ 2-O!8 2G:\]K(WFT&D- W@)%
M=Y,S;L3="$(#2+X#_+Q9S(_KW>I+C)?78=G&9(LO@"89.N)5@EA'-2LE;;'"
MFN":%-K<0<NXT7<CY!PJ\QY@<]MPBLAUIO\G=["^TN/>0?">$0>9<9<T)MT&
M-?N=6,U"[U:@.4SB'<1=-PSFM41"0*<P\DWG&$W"X0Z\+0A8G,S)AR#S4YQ6
M.R9O!F^^T2CJ&D;N/1B=:W;S&A<V&>V<3\"9(@%QQR!F0;+)#I/R*/A=W3B&
M/:YVA,[@S3E:!>R'2[P#W%QL@(_AZS4K>IV?3 Z;,OIRVA094NTD")X,8W5B
MB-CF==3>]N<^PD::^-;8#@VBA@Y@M4F*W\U)Y"IF3<+)O%[&T3D,T0@/UC!=
MC,FB43GH_22--"FNY7W$X:+O $37F)AD99U6P8*U7M6+6U8OX>K!G(5#JP.[
MJZWEH![T2,/BVN>;=Q)N!\YR[6HQ/:MUKA7TBWF=*('S5%FQV6F3M0=N="9O
MOSYZ-U(#YBA$TER*JP;6@[YAN)^FD>;'-<+-4,+OP+[4BJ'UM\L(%).4D06B
M7C$*0U$YB"@S%"]CQI*52DU\Y>_)&&F\7".T'"#B#@#R[F+=S;O2LQ<Y"EED
MPGO2(B>,:W+)7#$,E"R<,Y&S54VNR.^@9=P[K$-4>ZN4[S Y=P"5:YV6SNB/
MWA?4R0(+A>1!YRN$(!B(H)F4LM#_VKSWOD'(N%=4 X+D( EW@)"CG*=5[&'V
M+DSSZ_F+\'E*'M%$A5S'77%0V=0N] ;!QY1 >AU%5BR&-BF:>^@9]SYJ0+P,
M(>\.8/,>UX&.XOQK6,[)TUH=I71Z<CJKO9]>8IFFZ7K"2^&"Z 966P>KI#Q$
M6[^ELQFES)&G)I45CY,V[A75@& :6 L=X.H:!YN,01V.LL1/.%]-OV ==7""
M;Q:K6@#[MGP,7R?>D!]HHJC[1(*RQH-GW@#+C$YD02X^-NEZLR.=X]YO#6F^
M&NJG _A]7&)8G2Z_73O/DT],890@L+[9T-* $]J!*2HB"]*(-L6GMTD9MQ!U
M0! =*.7=<>+/<#+'XPK<CP-VQR$&/BUF)/G5F7PF0M769#9!O1RFL%0D\())
M$I-&[:)6/C?)"-XF9=PZU 'A<J"4.T@-7LMJ'LWS'?P49()$P.O[]3I(U#*(
M@@NPLI8?"9:-CXWSR'<2-M(@^?;)Y</5,!BLANX]?+WWZKN-F#_A>IK";*_F
MPP]\VC#=A[<E=XCVP_>O=6FHE.=.2,<@1XKAE40'P8D,! S/F:=XWKC'9+;E
M6@,W(/::6>0NG%51*[*W$+6HSPF13M>L8VSS#*^;!L0#:_>1#L2[B+L#S_:2
M^C-35_WVQ7QS75*;'(:BR<%2"8JQM3=/;:F:E *KHA*L"&2Y23G%@U1UTK!M
M#W7?AYR#9=\!D&[P<-[6TM?>&5@B\+RI+ZI93Y(+Z3T),HR>F3;=9^^DIA/@
M'*[M.Z^M#A%]!_BYEC#_#4\B+B?.1*FXJ4^7,XDD9@F1PC[@2127/<6!IHGQ
MN45)#S=7!VGW_KN)/40]=F?T.QN ,U1&1R5!^D+B$(SB2!8YH"-YF*A-Y-N4
MK#=NF_]47:WW.92&D>W8X+BWGSN6DI(.$8(PJE;M2_"262"3JR/SQ$/:IM+F
MQVJ;OY-FMVJ;OXN8.SAT[F_O'9A.Z%'0QL$"RM5:UE ?:#CI4'@I F_RD.&P
MMOE/U=1Z$*_W()EW )X[NK@[Y6-(F<YBKBH':"'6EDX^21_02L_:O+=[/FWS
M=]+QXVWS=Q%X!Y"Y(W%I70XVU92WC75T21$0M+(@A"ODT7G:3$WND?9LF]^^
ME&] "[.?E#O R=%LMOBS)JU>+98O%Z=Q74YGM_O>7G9,4(DE-!)*K@_=@TFT
MIU"#)=%I:14:WJ97Q2Y4=F*0]H3$S>ON9OKI 7S7JT6(B#3=J(F^GN%&7_-\
M=+)8KJ?_M?GYO9T-)R$):2/A1O Z^L+D1'8YD*VN/3:=9X*+)C[44 QT$M,-
M!-DQM-H!FK^OUGT7EF^7&\GF38'!.UQN1HW2><-CYCJ X_4I2=#D2(000$;R
M2-#QG-N,:=R.O$Z<_V&0V$ CW>'L;'[MT>GZTV(Y_2_,$Y$B":4V57/&@++D
M 7OG/(3(7'*<1=VF']G#9'7B\K7 U4$:Z!1/KU>K4^)$&E-,, )XC+5;1%1
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MS!UXNG?X<J70!F$V ,_<G973>,4R:!.=8L(KR9HD!/<L1GFJ>MI]3,I 4NX
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M;>1QMM$FG&LCE$E@I$B@C+= 4J= -8:4N$C)VB8YIX8\=?=X[3"+V(?N.SB
M+V;>7K)ZOIU_H3"F3-<3X5Q(63I(Q5 @S#*'J'P$7Y*P/'#7J,'_(W1U]^#M
M$#@.J8-##^Q!0/4[KJ^YI$*+;'6Q@-S7^D&9Z&#("81(RD@6!:8FW?Z_HZ*[
M)VV' &9_^79@<?Z&T^-/A+2C+V1LC_'WT]JJ]6W9/).Y]H+XE[":IIK]G<Y.
MZ;<GIO@@,6C0C$50VB$Y&N3$4G@L;+%>V3:C_/8CM[LG<(? [0DTUH%#N,V
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M!CJ]!QD&LZ-H^=!I+VWMY^^XGF@E;9%*@M5U_B:6#,%BG0V<I&6:6RF?]K4
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MA3W$+ N4A#X*K9"GMK4R7:B<;N)70P-\A*+&OI#LY._?>0OX[=]?Y/^\O+K
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M!->\>U2--*]N! _\&'5,]F6^SN+;?'^]J*-GYM_PQ3_"*A]4J_3PAX9Y?>]
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M:CMT5B#4/G<ZVI!0Z:#+LS'CLZN,DU)X6@,X@'RG 90/@6B_86 7\*QG65#
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MQ6>=H]0W-FRO7QN^X>(27UQL_S;FS?*.$%[AQ;Q6&=7VB-;Z4GA4@+4D7K'
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M=*Z:;"31GPWY7;X^YBDKN>(R<-4=)(\MTRUE^&QO\H<3\23 TLEA9RB,\#)
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MC?_G?_U_4$L! A0#%     @ 38ML4%%?A/]8$@  S&L  !H
M ( !     &5X:#$P,3%O9F9I8V5R<F5S=')I8W0N:'1M4$L! A0#%     @
M3HML4)>OK6ZR"@  @4T  !H              ( !D!(  &5X:#$P,3EA;65N
M9&UE;G1N;S)T;VDN:'1M4$L! A0#%     @ 3HML4#5'0G)Z-@  EW0! !H
M             ( !>AT  &5X:#$P.#(P,3=E<75I='EI;F-E;G0N:'1M4$L!
M A0#%     @ 3HML4&[*;+?> P  +P\  !L              ( !+%0  &5X
M:#(S,65R;G-T>6]U;F=C;VYS96YT+FAT;5!+ 0(4 Q0    ( $Z+;%#L!"3%
MI@@  .I"   :              "  4-8  !E>&@S,3%C97)T:69I8V%T:6]N
M;V9P+FAT;5!+ 0(4 Q0    ( $Z+;%#%!+R4S @   -#   :
M  "  2%A  !E>&@S,3)C97)T:69I8V%T:6]N;V9P+FAT;5!+ 0(4 Q0    (
M $Z+;%!V;4R[J04  .PG   :              "  25J  !E>&@S,C%C97)T
M:69I8V%T:6]N;V9P+FAT;5!+ 0(4 Q0    ( $Z+;%"G*OYA^3\# (D+)@ 1
M              "  09P  !L>')X+3(P,3DQ,C,Q+FAT;5!+ 0(4 Q0    (
M $Z+;% HHGH/"!0  -_N   1              "  2ZP P!L>')X+3(P,3DQ
M,C,Q+GAS9%!+ 0(4 Q0    ( $Z+;% IF)0J@1@  #T$ 0 5
M  "  67$ P!L>')X+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4    " !.BVQ0
MY ]XPIYE  "?+@0 %0              @ $9W0, ;'AR>"TR,#$Y,3(S,5]D
M968N>&UL4$L! A0#%     @ 3HML4'M*^C*>) $ ^6\! !0
M ( !ZD($ &QX<G@M,C Q.3$R,S%?9S$N:G!G4$L! A0#%     @ 3HML4,D=
MPFU, P$ RX(* !4              ( !NF<% &QX<G@M,C Q.3$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( $Z+;%!5KUB"RXD  $M%!@ 5              "
M 3EK!@!L>')X+3(P,3DQ,C,Q7W!R92YX;6Q02P4&      X #@#% P  -_4&
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795787568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sanofi.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development and commercialization of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#8220;Termination Agreement&#8221;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $208&#160;million in September 2019, $26&#160;million in March 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement) and is obligated to pay an additional $26&#160;million within twelve months of the Settlement Date, and neither party will owe additional payments pursuant to the Sanofi Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  The following is a summary description of the Sanofi Agreement without giving effect to the Termination Agreement. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Sanofi Agreement, Lexicon had granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party could (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such countries.  Among the specified exceptions was a right Lexicon retained to pursue the development of its development candidate LX2761, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $300 million.  In addition, Lexicon was eligible to receive from Sanofi (a) up to an aggregate of $110 million upon the achievement of four development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of $220 million upon the achievement of four regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) $100 million upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of $990 million upon the achievement of six commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believed that each of the development and regulatory milestones under the Sanofi Agreement was substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments were deemed constrained and were not recognized as revenue.  Commercial milestones would have been accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon was also entitled to tiered, escalating royalties ranging from low double digit percentages to forty percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon continued to be responsible for all clinical development activities relating to type 1 diabetes and exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon would have funded forty percent of the commercialization costs relating to such co-promotion activities. Sanofi was responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and would have been solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon shared in the funding of a portion of the planned type 2 diabetes development costs over the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ0ODM_07c80404-0919-4d69-96df-eb1aa3ad8777">three</span> years of the collaboration, up to an aggregate of $100 million, which was satisfied in 2018. Sanofi would have booked sales worldwide in all indications.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The parties were responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The parties&#8217; activities under the Sanofi Agreement were governed by a joint steering committee and certain other governance committees which reflected equal or other appropriate representation from both parties. If the applicable governance committee was not able to make a decision by consensus and the parties were not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi would have final decision-making authority, subject to limitations specified in the Sanofi Agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Sanofi Agreement would have expired upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country was the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and 10 years following the first commercial sale in the applicable country. Either party could terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi could terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $300 million upfront payment: </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The funding Lexicon will provide for development relating to type 2 diabetes.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it was an exclusive license that gave Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it was possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Sanofi Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company was recognizing as revenue the amount allocated to the development services for type 1 diabetes over the period of time Lexicon performed services, which was expected to be through 2027, and recognized as revenue the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon provided the funding, which was completed in 2018.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $300 million upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for $100 million in funding.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the allocation of the Sanofi Agreement, the Company recognized $126.8 million of the $300 million upfront payment for the license in 2015.  The Company was recognizing the $113.8 million allocated to the development services performance obligation and the $59.4 million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $23.5&#160;million allocated to Lexicon's performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $260&#160;million, representing the full cash consideration from the Termination Agreement.  The Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $286 million, $33.2 million and  $60.1 million for the years ended December&#160;31, 2019,  2018 and 2017, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ipsen.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $47.2 million through December&#160;31, 2019, consisting of $24.5 million in upfront payments, a $6.4 million milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen's first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;72&#160;million upon the achievement of specified sales milestones.  Milestone payments are deemed constrained. Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5 million upfront payment: </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed </span></div><div style="text-indent:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Territory;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for XERMELO;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to participate in committees which govern the development of XERMELO</span></div><div style="padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">until commercialization; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, which was completed in 2018.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $24.5 million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div>As a result of the allocation, the Company recognized $21.2 million of the $24.5 million upfront payment for the license in 2014, and an additional $1.4 million in 2015 upon entering into the amendment.  The Company recognized the $1.7 million allocated to the development services deliverable over the estimated period of performance as development occurs, and recognized the $0.1 million allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  During 2019, the milestone earned when Ipsen made its first commercial sale in Canada was determined to be a distinct performance obligation relating to the development activities and accordingly, was recognized as revenue without further allocation to the remaining performance obligations.  Revenue recognized under the Agreement was $4.9 million, $4.6 million and $16.2 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $0.3&#160;million, $0.3 million and $0.1 million, respectively, of royalties from Ipsen.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $1.3 million,  $1.6 million and $0.8 million, respectively, from sales of bulk tablets of XERMELO to Ipsen.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795775552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated future amortization expense for intangible assets as of December&#160;31, 2019 is as follows:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"><tr><td style="width:1.0%;"/><td style="width:78.472%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.528%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,766&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,716&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018:</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017:</span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795764176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,087&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,044&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">369,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability related to acquisition of Symphony Icon</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,140)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,525)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,143)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,527)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(329,426)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(364,702)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,014)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.783%;"><tr><td style="width:1.0%;"/><td style="width:51.021%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.839%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.682%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.537%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.682%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Expected income tax expense (benefit) at 21%, 21% and 35%, respectively</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,315)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(47,479)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,324)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(978)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Orphan drug credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(189)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred true-up</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,316)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax rate change</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Symphony Icon fair value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35,276)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,634)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(372)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,014)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,661)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806296416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 27, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset', window );">Deferred Tax Liability from Reclassified Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible', window );">Deferred Tax Liability from Reclassified Indefinite-lived Intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="num">$ (6,014)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (12,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change in Amount</a></td>
<td class="nump">35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
<td class="nump">879,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating Loss Carryforwards, State</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon', window );">Deferred Tax Liability Related to Acquisition of Symphony Icon</a></td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">10,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">46,306<span></span>
</td>
<td class="nump">$ 47,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FederalNetOperatingLossChange', window );">Federal Net Operating Loss Change</a></td>
<td class="nump">$ 62,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability from Reclassified Indefinite-lived Intangible - remeasured amount calculated using the tax rate of 21 percent from 35 percent and relating to the deferred tax liability associated with the indefinite-lived intangible asset associated with the Symphony Icon acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability from Reclassified Intangible Asset - Upon approval by FDA, the indefinite-lived intangible asset was reclassified finite-lived asset and the tax effect was to book to a deferred tax liability with offset to accumulated deferred tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityfromReclassifiedIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FederalNetOperatingLossChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Net Operating Loss Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FederalNetOperatingLossChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805991488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">$ 80,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">80,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">235,463<span></span>
</td>
<td class="nump">73,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">235,547<span></span>
</td>
<td class="nump">73,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">235,463<span></span>
</td>
<td class="nump">79,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">235,547<span></span>
</td>
<td class="nump">79,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">271,575<span></span>
</td>
<td class="nump">160,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
<td class="nump">$ 271,659<span></span>
</td>
<td class="nump">$ 160,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792575072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cost of Sales (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials', window );">Periot to reflect a lower average per unit cost of materials</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Goods And Services Sold, Period Reflecting Lower Average Per Unit Cost Of Materials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794745104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (51,138)<span></span>
</td>
<td class="nump">$ 226,086<span></span>
</td>
<td class="num">$ (23,018)<span></span>
</td>
<td class="num">$ (21,797)<span></span>
</td>
<td class="num">$ (16,782)<span></span>
</td>
<td class="num">$ (27,396)<span></span>
</td>
<td class="num">$ (34,549)<span></span>
</td>
<td class="num">$ (41,821)<span></span>
</td>
<td class="nump">$ 130,133<span></span>
</td>
<td class="num">$ (120,548)<span></span>
</td>
<td class="num">$ (122,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Debt Instrument, Convertible, If-converted Value in Excess of Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,067<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per common share, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,920,000<span></span>
</td>
<td class="nump">105,881,000<span></span>
</td>
<td class="nump">105,848,000<span></span>
</td>
<td class="nump">105,668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,365,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">106,272,000<span></span>
</td>
<td class="nump">116,640,000<span></span>
</td>
<td class="nump">106,272,000<span></span>
</td>
<td class="nump">106,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,747,000<span></span>
</td>
<td class="nump">105,830,000<span></span>
</td>
<td class="nump">105,237,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,206,390<span></span>
</td>
<td class="nump">7,438,134<span></span>
</td>
<td class="nump">5,907,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,200<span></span>
</td>
<td class="num">$ (120,548)<span></span>
</td>
<td class="num">$ (122,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted Average Number of Shares Issued, Basic</a></td>
<td class="nump">106,272,000<span></span>
</td>
<td class="nump">106,272,000<span></span>
</td>
<td class="nump">106,272,000<span></span>
</td>
<td class="nump">106,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,218,000<span></span>
</td>
<td class="nump">105,830,000<span></span>
</td>
<td class="nump">105,237,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1930-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6807146560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State and Local Tax Expense (Benefit)</a></td>
<td class="nump">$ 445<span></span>
</td>
<td class="num">$ (809)<span></span>
</td>
<td class="num">$ (2,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(978)<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="num">(35,276)<span></span>
</td>
<td class="nump">25,928<span></span>
</td>
<td class="num">(126,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</a></td>
<td class="nump">26,065<span></span>
</td>
<td class="num">(25,315)<span></span>
</td>
<td class="num">(47,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment', window );">Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="num">$ (6,014)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (12,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Symphony Icon FV Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794012704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod', window );">Payment period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Arrangement With Individual, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DeferredCompensationArrangementWithIndividualPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792664944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</a></td>
<td class="nump">27,728<span></span>
</td>
<td class="nump">20,512<span></span>
</td>
<td class="nump">10,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="nump">$ 15.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806606496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 130,133<span></span>
</td>
<td class="num">$ (120,548)<span></span>
</td>
<td class="num">$ (122,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,654<span></span>
</td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">3,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase in fair value of Symphony Icon, Inc. purchase liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,218<span></span>
</td>
<td class="nump">11,696<span></span>
</td>
<td class="nump">9,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(6,014)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="num">(50,608)<span></span>
</td>
<td class="num">(1,099)<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="nump">437<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
<td class="num">(1,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(2,652)<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="num">(557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) decrease in other assets</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and other liabilities</a></td>
<td class="nump">20,097<span></span>
</td>
<td class="num">(19,913)<span></span>
</td>
<td class="num">(11,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenue</a></td>
<td class="num">(25,990)<span></span>
</td>
<td class="num">(22,940)<span></span>
</td>
<td class="num">(51,133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">113,807<span></span>
</td>
<td class="num">(148,607)<span></span>
</td>
<td class="num">(185,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(322,385)<span></span>
</td>
<td class="num">(119,987)<span></span>
</td>
<td class="num">(267,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">166,600<span></span>
</td>
<td class="nump">289,658<span></span>
</td>
<td class="nump">318,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(155,855)<span></span>
</td>
<td class="nump">169,576<span></span>
</td>
<td class="nump">50,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(941)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
<td class="num">(1,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,529<span></span>
</td>
<td class="nump">145,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings</a></td>
<td class="num">(1,285)<span></span>
</td>
<td class="num">(14,533)<span></span>
</td>
<td class="num">(2,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2,226)<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
<td class="nump">149,933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(44,274)<span></span>
</td>
<td class="nump">18,725<span></span>
</td>
<td class="nump">15,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">80,386<span></span>
</td>
<td class="nump">61,661<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">80,386<span></span>
</td>
<td class="nump">61,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">19,211<span></span>
</td>
<td class="nump">16,465<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Common stock issued in satisfaction of Symphony Icon base payment obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentInCash', window );">Symphony Contingent Payment In Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments to Symphony Icon Holdings in the form of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786909200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 61,741<span></span>
</td>
<td class="nump">$ 60,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">106,679<span></span>
</td>
<td class="nump">106,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795805136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; significant unobservable inputs </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2019 and 2018.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets or liabilities at December&#160;31, 2019 or 2018. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div>The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795764752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text">Debt Obligations<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Convertible Notes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheets.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI1ODY_709f0024-f6ab-4884-930f-af1897447d75">seven</span>-year term of the Convertible Notes.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $0.9&#160;million, which offsets long-term debt on the consolidated balance sheets. As of December&#160;31, 2019, the carrying value of the Convertible Notes was $86.6&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Convertible Notes was $64.8&#160;million as of December&#160;31, 2019 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mortgage Loan. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provides for a $12.9 million mortgage on the Property and has a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0ODk_cd815874-61d3-4e93-b842-9068c8947236">two</span>-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.  Lexicon incurred $0.4 million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the consolidated balance sheets and will be amortized as interest expense over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM5MTI_05762f89-6afe-4eba-b7d3-725a92223b9e">two</span>-year term of the loan agreement.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $0.1 million.  The consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0&#160;million&#160;as of December&#160;31, 2019.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $59.2 million and $2.7 million, respectively, before accumulated depreciation, as of December&#160;31, 2019.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lexicon&#8217;s wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until April 9, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BioPharma Term Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $150 million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;).  The BioPharma Term Loan matures in December 2022, bears interest at 9% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.   </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY1MzU_04b7db4d-7fa9-457a-afc5-ab80eee00947">five</span>-year term of the BioPharma Term Loan.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $2.4 million, which offsets long-term debt on the consolidated balance sheets.  As of December&#160;31, 2019, the carrying value of the BioPharma Term Loan was $147.6&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table includes the aggregate scheduled future principal payments of the Company&#8217;s long-term debt as of December&#160;31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:79.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.156%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ending<br/>December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less deferred financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,447)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,012)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6666954064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 28,638<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>lxrx-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20191231"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20191231.xsd" xlink:type="simple"/>
    <context id="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5c88259cb8e4b92bfdfaa68b9ab937e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i52f9f923aa5d4203ae1082950c943805_I20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-03-06</instant>
        </period>
    </context>
    <context id="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7501ea3be2a741529ff3306e73060964_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i967751fea12e4973a32d9fe35e3e91d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8180495170b24b8ebb36517b94125b49_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i9a26c1b854e6492a9cee1d79baa36f4f_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i2ebb2384f82444fdb95c578d086dd541_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i2837d1af8744496a83b9465b01d9c7af_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i129f3fad6d374d8db3b6389a173ed459_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i57757fd132344fe38d2ce518c20bb378_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib8cccc7e982e4621be9e20764d4dfc15_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iffcd61f6da4749d4b7cc1ab6f3055a80_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if5028bb7c1904d74ad203e9136d8d368_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i017c2651d77947d4bb01b4651850b16e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2be9572e894e461092c842e6748a2b74_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2402ec5193524658955d7c90d3a16896_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5b2e221d098b491cbeaab0aa52d099ae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id9e0a311a22b411e9fd8665266ff4e44_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44b4b3353a5c41bbaa44ce871c92bba3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a257be715794239b4b42dbe56325b63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieac0714597ff49c483b52893312f674c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48208aca804f4529a47984a51825c00c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98be0b7d6a10477d8c718994e04dc1c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0c089f26a424433a6a985286efbaae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ae9845aba89468b8e79334b8836b87a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2669261eb809451d87dbe16b0e36331d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e9da8ecf2c54fbe8f306aa71dd97256_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id200f3fdbfab4a1d8d40cdc784c65d06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iead7811281254bcbb2692b1ba9a8a25b_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c449fb5ca67473f98ac63f3ac55af83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3eec56c8d824574affec4d66d71660d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f0a69895e164f97977732e2bfd75452_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0fe9e860df2f49179681c5585ac22f36_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if54c610d056a4769931c5fb35bdfbf57_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i52761b423ed94c999cfcf4ff49cffcae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if42edf1b0c174407b6dc7acf67878cbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafa3a2a02ed444c58bd99b8c7d318975_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2ec419047d94a2ba32418d003ec5498_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2edf8da90db84523a6fc9be2eb374ea8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idd0883ce436140d4aedbccded39fec5c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i91d5f1656d844951addb1fa04625751d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i94d65b504af44fc3a8e21bcd23052cfd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i326024d73cea4d15aa9ac4c2c5c24f6a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6c3e10389e3543398ede188dc42287b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a3b8f069656465fb49124367dada928_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i490ae890935942b1b6b3556c3099574e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4b49290934c41a6aad3724b4c80bbd6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i15b062ad588146aca58efd416bfc6a9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2bcb52391538408c8580e9d00fbeb629_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1340081d4b804484b5d1dca5c73bf782_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9476eb367804eba9e26e39f94e0c1d3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i428262586cfe46008e720b64332fe571_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c95eef01a704b3a945e493cf9b53436_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7aba92216bb9424f8d15c759003ae223_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3c89489e14d14a80a43bc37c4139f132_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib68552052df34ab5921379e6cebe42c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i826b9f0fff2b4a2999f965a6464b4373_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28f89df9133a45d3809aeee03abe338a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fe56801915047618583b6f63ff8c91c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24f85df61eb445838e80f6b878175cb2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5eaa1ca4276f4306939acd691adbae4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia58710b444204c06a40a6e1eec7042b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc7d3efc2a38441eae57d3f6c2f543cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i518a6981e36c42a6a7263b4a8fad852d_I20170227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-02-27</instant>
        </period>
    </context>
    <context id="i8c6df2280ae0495591132f2f5d361b8e_I20010712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2001-07-12</instant>
        </period>
    </context>
    <context id="i9ef4d236906043df99288d5dec2fccfc_I20100730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2010-07-30</instant>
        </period>
    </context>
    <context id="i337cde26133a4419842ffadf1b382833_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i505f2df038f048d09e005588782957fa_I20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-08-30</instant>
        </period>
    </context>
    <context id="ia8d9306784934680a1912cb049ecc58c_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="ie9d39defcce14b468b07992b453eadce_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc703c71a5994ba2b8a490586719cf93_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i17260f0b7b8f41c4812252456551f9ea_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i676db318ef444ad296e217ae53030a14_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i82e588be725e4af58a772fca835425ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93792b54ada2484d8b1bab2bf045cd99_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id86a6b1aaaba4df58235feed7b3ecf76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2cf18c961781453a902022b81e8fb9be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea1681c8bfaf4cb7885ec38236a3a489_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="iefd14d4f858f4035ae6b02237f016ab7_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib9b309ec36344fefbc30f63b0cbe55bb_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iefb28917800949f293202b0888b3e175_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i3b945f8014e44862a193e174495bd0fb_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ied0c7299e00945369d3ea72496353df9_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6e86892468984645956d23c25fe705dd_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>lxrx:segment</measure>
    </unit>
    <unit id="milestone">
        <measure>lxrx:milestone</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl81LTEtMS0xLTA_a69b9694-2b49-41d8-b5f7-dd9ecee8af16">0001062822</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl82LTEtMS0xLTA_3e7fb043-f487-4d78-bd6a-3c61230b5594">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMC0xLTEtMS0w_10951cd0-5a1b-4fef-8310-8e0d7dc3a28b">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMS0xLTEtMS0w_a6520e78-1cdb-4a77-b525-de6f9c622479">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl80L2ZyYWc6Y2Y0MzllZTVkMTE4NDI4Yzk2ZDU5NjE2NGI3MTAzMDgvdGFibGU6ZjQzMDQyMGVmNmM2NDk2NTgyM2UzZWY0NjVjZDhiMDIvdGFibGVyYW5nZTpmNDMwNDIwZWY2YzY0OTY1ODIzZTNlZjQ2NWNkOGIwMl8xMi0xLTEtMS0w_9b0682fc-fad1-455b-af93-91d69484911c">false</dei:AmendmentFlag>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzItMS0xLTEtMA_8ea96369-abfa-40b6-b59d-a408df885010"
      unitRef="usd">4000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzItMi0xLTEtMA_200f12c2-0b78-42d7-9ebe-3d9751b4ecef"
      unitRef="usd">4000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzMtMS0xLTEtMA_12a86c68-6207-4329-888d-aee45318bd87"
      unitRef="usd">61741000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzMtMi0xLTEtMA_c56f6097-8417-4296-b92c-7db16ad36b0d"
      unitRef="usd">60006000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzQtMS0xLTEtMA_7c42ac67-987b-41d2-b1a1-33e322da1e7e"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzQtMi0xLTEtMA_b56f876f-08d0-4500-a03d-7fbec7ad107e"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzUtMS0xLTEtMA_9a4be0ec-7dfc-4e47-a7cf-8473a165e16c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzUtMi0xLTEtMA_850a43b4-5236-4d6d-b900-8b6e5a2bd9db"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzYtMS0xLTEtMA_afff9bd4-b982-4e84-ae62-46d58b8bf47c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzYtMi0xLTEtMA_79fd79d5-bb1e-461a-b91e-eb7d20eb9f17"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzctMS0xLTEtMA_1cb6c44e-d652-40e7-b5b6-adb0722247aa"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzctMi0xLTEtMA_4169bd2a-5338-47c2-9a45-6c84172dd99d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzgtMS0xLTEtMA_028b51ef-c4d6-4cbf-8761-af3d8f15d7f5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzgtMi0xLTEtMA_03fac5fe-820d-4b5a-ba62-6d0f43e38cda"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzktMS0xLTEtMA_8f6d5986-4fbd-4639-932f-9037c84f724d"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzktMi0xLTEtMA_dc7475d4-e8ea-4381-81ce-69b4c1b458ef"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7501ea3be2a741529ff3306e73060964_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzEwLTEtMS0xLTA_bbb6662a-7a57-4f28-a8aa-728ed9fcd76e"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzEwLTItMS0xLTA_2854f468-3d8b-4ba4-a565-e43d1a5d042c"
      unitRef="shares">106162000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockShares
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzExLTEtMS0xLTA_525fe59c-bfa7-42e5-b934-3705e1bc472c"
      unitRef="shares">407000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzMvZnJhZzphNGViZjNiNmNjNjg0MzdmYmRiMDRiYmUzOWUyZGM1ZS90YWJsZTpmMTEzODgxMWQ5NmQ0Mzg2OTk4YzJhMGExMzllMTQwNi90YWJsZXJhbmdlOmYxMTM4ODExZDk2ZDQzODY5OThjMmEwYTEzOWUxNDA2XzExLTItMS0xLTA_899dc8d9-fde5-4f1a-9a4b-5c59591275fd"
      unitRef="shares">236000</us-gaap:TreasuryStockShares>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMS0xLTEtMA_87106309-86c8-4c5a-85e8-c3452708c067"
      unitRef="usd">7096000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMi0xLTEtMA_c915c111-f99f-4398-a21a-0b89d1521652"
      unitRef="usd">6010000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzItMy0xLTEtMA_448a2543-2a93-49eb-af4d-ebf853e94ad1"
      unitRef="usd">4905000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMS0xLTEtMA_14a71d00-4882-4b68-9fda-b9d4b2be78b8"
      unitRef="usd">7122000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMi0xLTEtMA_45c89cee-f28c-4b36-a76a-62ef79f70dad"
      unitRef="usd">5686000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzkvZnJhZzpiOTJiOTZjNTEzMjE0MGQ0YmI1OWUyNDM3Njg3N2NmNy90YWJsZTpjMzE3NDk0YjcwYTg0NDNhYWMxZmY5YmFmZjcyMGE4MC90YWJsZXJhbmdlOmMzMTc0OTRiNzBhODQ0M2FhYzFmZjliYWZmNzIwYTgwXzMtMy0xLTEtMA_6ae5b854-2c2a-41c8-8eef-ef87b641e3ef"
      unitRef="usd">4567000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzM1_da523249-8560-4c0a-a483-57694c053469"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzEzNg_3f425cae-a1fd-40af-af14-9aed1943090c"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzIxNw_bc439bbf-aab1-4f29-a66e-b683ef38a15d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzI4MA_ad1b657f-caae-42a2-a65b-0f0b8df15150"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzMyMw_39f2de35-20b7-4817-92e6-259093748f72"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTcvZnJhZzo1MGViOGZhZjEyNjQ0YTFhOWEwY2ZhNzMwNTMyMWVmNC90ZXh0cmVnaW9uOjUwZWI4ZmFmMTI2NDRhMWE5YTBjZmE3MzA1MzIxZWY0XzM1OA_326a2626-8c5c-45ae-b33f-d83d3879d3a8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingLeaseLiability
      contextRef="iead7811281254bcbb2692b1ba9a8a25b_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjMvZnJhZzphNTlhNzAyMDc2MTk0YTUxYjM5NzQ2NjM4NjBhNTFmMi90YWJsZToyYWMwZmU1OTEzMzk0MjUyOGYxMDU2ZTUyM2Y3NzExYi90YWJsZXJhbmdlOjJhYzBmZTU5MTMzOTQyNTI4ZjEwNTZlNTIzZjc3MTFiXzEtMi0xLTEtMA_389b0044-7dd2-45e0-b3c6-2369f7e1ee17"
      unitRef="usd">2100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7aba92216bb9424f8d15c759003ae223_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzMtNC0xLTEtMA_a588fa87-a839-486c-b9af-52eca205a69f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3c89489e14d14a80a43bc37c4139f132_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzMtNi0xLTEtMA_4b381142-89e6-4f83-a697-d19200a1cbd5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib68552052df34ab5921379e6cebe42c0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzQtNC0xLTEtMA_2bbb5d57-b0fe-43cf-b738-3db19cfdd825">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i826b9f0fff2b4a2999f965a6464b4373_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzQtNi0xLTEtMA_8b755bdb-2977-4ac4-9cb2-7e0af16c9588">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i28f89df9133a45d3809aeee03abe338a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzUtNC0xLTEtMA_57309094-8b57-4af6-b58c-ad3d23836da2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4fe56801915047618583b6f63ff8c91c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzUtNi0xLTEtMA_cfc109f1-d9e6-4648-b3f5-646189b6e4cc">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i24f85df61eb445838e80f6b878175cb2_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzYtNC0xLTEtMA_dfa7fc87-69fc-480e-8c12-cc80955f49a3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5eaa1ca4276f4306939acd691adbae4b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzYtNi0xLTEtMA_20363ce3-2307-4f50-9d33-c3f5c3f66af0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia58710b444204c06a40a6e1eec7042b4_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzctNC0xLTEtMA_0cbfe455-04cd-4d1e-a667-156e38637ea1">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibc7d3efc2a38441eae57d3f6c2f543cc_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzUvZnJhZzowYzQ3MGYwNzg0YTM0NTUyYTVhZGI1ZmQyZTc0NTRkZC90YWJsZTo4MzAyYTI1ZTBhNTc0ODcyOGJmMTUzNzhlOTA4YmUyNS90YWJsZXJhbmdlOjgzMDJhMjVlMGE1NzQ4NzI4YmYxNTM3OGU5MDhiZTI1XzctNi0xLTEtMA_f57c8757-e244-4a4c-acfa-979ea2113ac9">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODEvZnJhZzo2NGE1YWM5YjE4YzY0OTZkYWVmZTVhYzJkYjUyZTdmMC90ZXh0cmVnaW9uOjY0YTVhYzliMThjNjQ5NmRhZWZlNWFjMmRiNTJlN2YwXzcw_2af9e7ed-362a-49aa-9786-fe8350793bd6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DebtInstrumentTerm
      contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI1ODY_709f0024-f6ab-4884-930f-af1897447d75">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0ODk_cd815874-61d3-4e93-b842-9068c8947236">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM5MTI_05762f89-6afe-4eba-b7d3-725a92223b9e">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie9d39defcce14b468b07992b453eadce_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY1MzU_04b7db4d-7fa9-457a-afc5-ab80eee00947">P5Y</us-gaap:DebtInstrumentTerm>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="i8bdd8437aa5348e690e2fb92c8b4a327_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNjU_271664d5-aa24-4596-adff-6eaadc2549e8">P6M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i93792b54ada2484d8b1bab2bf045cd99_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxODc_3e3d37a1-a8e6-4c56-8f56-a53ef432e351">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id86a6b1aaaba4df58235feed7b3ecf76_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxOTM_6c3cd917-a52f-4bb3-8628-3b363616b2f4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lxrx:DefinedContributionPlanRequisiteServicePeriod
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzYyOA_b159658f-ba94-40d2-bf42-41b82bcb07e0">P4Y</lxrx:DefinedContributionPlanRequisiteServicePeriod>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ0ODM_07c80404-0919-4d69-96df-eb1aa3ad8777">P3Y</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod>
    <dei:DocumentType
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV81NDk3NTU4MTQyMzg0_884129dd-5f50-4bb6-a146-6d5be2057a95">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YmU1NWM1NDRiN2FkNDI4NGE0MDcwNzBkNDYwMTlmOWYvdGFibGVyYW5nZTpiZTU1YzU0NGI3YWQ0Mjg0YTQwNzA3MGQ0NjAxOWY5Zl8xLTAtMS0xLTQzNTE_1e111496-a6fa-4ee0-97e8-af3db3b5d161">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YmU1NWM1NDRiN2FkNDI4NGE0MDcwNzBkNDYwMTlmOWYvdGFibGVyYW5nZTpiZTU1YzU0NGI3YWQ0Mjg0YTQwNzA3MGQ0NjAxOWY5Zl8zLTItMS0xLTQ1NTU_d976a395-9f97-4392-a9e8-091c4e01b297">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YTA1YWY1ZmQ2MTM4NGM3Nzk5YmY5NDYzZTRiZDdlNDcvdGFibGVyYW5nZTphMDVhZjVmZDYxMzg0Yzc3OTliZjk0NjNlNGJkN2U0N18wLTAtMS0xLTQzNTM_aaef369c-4a3a-4e15-b617-99ff12fc0e31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTgz_ca35fecb-e234-4904-8687-3c3b38186f5b">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8xMDk5NTExNjMxNDcw_f36229e3-f119-4392-b238-21f7917f1ed9">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NDJjZWZmZDgzYWM4NGRiMjg2NzExMTQ1Mjc2MjczMWUvdGFibGVyYW5nZTo0MmNlZmZkODNhYzg0ZGIyODY3MTExNDUyNzYyNzMxZV8wLTEtMS0xLTQzNTU_cc82fff8-0aba-4925-810c-a67176b9b99b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NDJjZWZmZDgzYWM4NGRiMjg2NzExMTQ1Mjc2MjczMWUvdGFibGVyYW5nZTo0MmNlZmZkODNhYzg0ZGIyODY3MTExNDUyNzYyNzMxZV8wLTMtMS0xLTQzNTc_63b1f41b-79c7-4af2-8326-fd3972bdbb0f">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTEtMS0xLTQzNTk_570e65d1-3c75-4ab7-b8e6-ee2e765308a8">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:CityAreaCode
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTMtMS0xLTQzNjQ_b2fdf16d-a17b-4050-93f6-d778f0072938">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8wLTYtMS0xLTQ1NjE_6ec01671-2f0a-4639-87d2-df3fe11a63b2">863-3000</dei:LocalPhoneNumber>
    <dei:EntityAddressCityOrTown
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTEtMS0xLTQ1NjM_f6b7abbe-8940-45bc-8a79-c1cf95bdda98">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTItMS0xLTQ1NjU_079f6dc7-036b-4901-822c-f7da4474e17e">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6NzAxNjM1YmZlNjE1NDU3NDljZDNkYWQyZDBjY2Y5MzEvdGFibGVyYW5nZTo3MDE2MzViZmU2MTU0NTc0OWNkM2RhZDJkMGNjZjkzMV8xLTMtMS0xLTQ1Njc_68e3dda8-5a82-44e8-9df6-296e3a6a7aeb">77381</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTEtMS0xLTQzNjc_316d725b-8cd4-4b26-8f0b-5f228f9cc161">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTItMS0xLTc1Nzc_5ead25f9-a4e7-431a-aa04-6c7a6572ea49">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGFibGU6YWUzOGU1N2ZlYTc3NGY1MWE1MTY5OTBhZDIwYzdhYmIvdGFibGVyYW5nZTphZTM4ZTU3ZmVhNzc0ZjUxYTUxNjk5MGFkMjBjN2FiYl8xLTMtMS0xLTQzNjk_f47b355c-945d-4550-af2a-c23a13d0b941">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTM2_aba2aa1d-91e3-4f72-9862-81b0744c7070">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQw_1b0779fe-0688-429c-8dfa-38e429caed23">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQ0_d778554d-ce43-4bc5-9790-54b71d863cd7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTQ5_27d623f7-02ca-4f6b-a42e-0a7d949b70c6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTU0_d67f7cdd-b805-4772-abd6-dc7a94413d80">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTcz_89bd0c86-cc79-4da7-8e43-31d249298e00">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTc2_723637c3-db43-4ce9-bd19-c354ee0f1cbe">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTc5_03b231d5-26b6-4c05-9a29-0450eaf7d33d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ib5c88259cb8e4b92bfdfaa68b9ab937e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8yNzUy_9fe5f8aa-7cfd-495c-9713-16b36030ea2f"
      unitRef="usd">259500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i52f9f923aa5d4203ae1082950c943805_I20200306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV8zMDEx_77a85645-773a-4084-9fa6-172e70074f8f"
      unitRef="shares">106969973</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xL2ZyYWc6NzhhZWYzNDgyMWRhNDk4ZGJjN2Q3ODBjMDg5YTMzODEvdGV4dHJlZ2lvbjo3OGFlZjM0ODIxZGE0OThkYmM3ZDc4MGMwODlhMzM4MV80OTQ3ODAyMzI4NTgx_9710d433-1371-4311-8de2-49663d63dc1e">Certain sections of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s 2020 annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2019, are incorporated by reference into Part III of this annual report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzQtMS0xLTEtMA_470f9656-e69f-493b-87c1-a4bd97255e4a"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzQtMy0xLTEtMA_4c122e70-109a-4a86-8ae0-f01a966eb408"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzUtMS0xLTEtMA_ebaafcae-f9ce-4548-84f2-943d23e9dfb7"
      unitRef="usd">235547000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzUtMy0xLTEtMA_625fbf20-c8ee-4665-9554-069389b558ba"
      unitRef="usd">79666000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzYtMS0xLTEtMA_b401e581-7724-46ae-8751-261196fe573b"
      unitRef="usd">56532000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzYtMy0xLTEtMA_be866871-7a76-4295-967d-42b4f45b32e6"
      unitRef="usd">5924000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzctMS0xLTEtMA_89e2c4d3-bd39-451a-b7d8-505b867d0dee"
      unitRef="usd">4243000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzctMy0xLTEtMA_a78787d1-5063-4ed0-946c-a65f7e0f4184"
      unitRef="usd">4680000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzktMS0xLTEtMA_f4a693d7-4e26-47ee-8b49-b89c68fc774a"
      unitRef="usd">5320000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzktMy0xLTEtMA_aa076f81-c1bf-4c74-bab4-48ed324ceb9c"
      unitRef="usd">2668000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEwLTEtMS0xLTA_05df7288-a495-42f4-8cf5-9299324c7596"
      unitRef="usd">337754000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEwLTMtMS0xLTA_b1dbdd0e-c62c-4849-8fae-9ba182110948"
      unitRef="usd">173324000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzExLTEtMS0xLTA_ac2d6234-c12e-4ae9-b45d-4a7c21bb490c"
      unitRef="usd">14047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzExLTMtMS0xLTA_57ef7ccc-7a01-4c21-9ec2-d398b8ba6b92"
      unitRef="usd">15865000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEyLTEtMS0xLTA_caffacf2-a815-456f-974c-bd5a0c14704d"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEyLTMtMS0xLTA_a0b3872c-d816-458c-94d7-cf66d65da958"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEzLTEtMS0xLTA_23d09b18-2369-43a8-a118-9275988bf8cc"
      unitRef="usd">19716000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzEzLTMtMS0xLTA_30a45576-9e77-4990-9f3e-e0174d77a1ca"
      unitRef="usd">50119000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE0LTEtMS0xLTA_1895ff6d-553d-47e8-ab99-fbccc1c09ef2"
      unitRef="usd">1655000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE0LTMtMS0xLTA_b9fcf15c-49b2-4611-9813-90caedc096f3"
      unitRef="usd">285000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE1LTEtMS0xLTA_764aeb81-9674-4206-a755-d5e3599f0513"
      unitRef="usd">417715000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE1LTMtMS0xLTA_5705c5fe-15c5-4101-b062-0fac591ee9e3"
      unitRef="usd">284136000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE4LTEtMS0xLTA_00c6535a-2e92-4524-83fd-c6f538e9dace"
      unitRef="usd">12178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE4LTMtMS0xLTA_aab9fb66-cf6e-478d-b117-f7d7cbbf02a1"
      unitRef="usd">12052000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE5LTEtMS0xLTA_7222ca89-b973-4ccb-aa3c-b588f8b8762c"
      unitRef="usd">42151000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzE5LTMtMS0xLTA_060404e3-fb10-4a34-ad73-d908f0d79482"
      unitRef="usd">21245000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIwLTEtMS0xLTA_136f1fa7-d4c2-43ba-849b-493e611a3cf5"
      unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIwLTMtMS0xLTA_57a17285-ef7b-48f5-ba5d-1034f5d85d54"
      unitRef="usd">2339000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIxLTEtMS0xLTA_f2b3180c-aeee-4f4a-9269-a802a56a3ec7"
      unitRef="usd">11012000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIxLTMtMS0xLTA_0208c277-e4b2-4f1a-8a31-e0267d0191b1"
      unitRef="usd">1115000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIyLTEtMS0xLTA_cffec199-b55b-4a2c-ba08-ff5c3044ee07"
      unitRef="usd">65341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIyLTMtMS0xLTA_40d4c700-bebe-43bd-a5a3-5d554e3956ce"
      unitRef="usd">36751000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIzLTEtMS0xLTA_b41e396e-6c0f-4e23-8dc0-f3321e31684f"
      unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzIzLTMtMS0xLTA_c2939ba1-706a-4410-ba70-e58af400d3f0"
      unitRef="usd">23651000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI0LTEtMS0xLTA_6bca4ac8-a652-4d97-a878-735771ca582f"
      unitRef="usd">234171000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI0LTMtMS0xLTA_ddef8250-3918-452b-8dbb-aab9d0c95f2f"
      unitRef="usd">243887000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI1LTEtMS0xLTA_857925ba-d7fe-499f-b308-fa727dfe7a5f"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI1LTMtMS0xLTA_6bdb8c2e-ccd0-4641-9a01-a5d0c622607f"
      unitRef="usd">6014000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI2LTEtMS0xLTA_8a19ea60-5f73-4233-b608-07c2f46910b7"
      unitRef="usd">1102000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI2LTMtMS0xLTA_13bdb4d7-c085-4530-b2e1-590b9fef2cda"
      unitRef="usd">238000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI3LTEtMS0xLTA_f938e11b-0efc-4fb8-9740-1fcae9fc0b71"
      unitRef="usd">300614000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI3LTMtMS0xLTA_1f6fa5f5-c437-41f3-a572-3ea8ea9e36dd"
      unitRef="usd">310541000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI4LTEtMS0xLTA_7660847a-6aae-44b8-bd30-a18e82ea065c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzI4LTMtMS0xLTA_0bc81fa3-47ba-40a4-9000-65a43bf735a1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMwLTEtMS0xLTA_f15bcad7-103b-4fce-9fd4-15b97424dd87"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMwLTMtMS0xLTA_f07fc23d-8064-44cd-945e-35da40235e35"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMxLTEtMS0xLTA_6b641a30-cb90-4146-b83c-8db2ee1f7fe0"
      unitRef="usd">106000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMxLTMtMS0xLTA_1f5e29d5-ed32-4d9f-93a9-8b0168e4dc4c"
      unitRef="usd">106000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMyLTEtMS0xLTA_865726b9-8c84-4f1e-85fb-f6023921a833"
      unitRef="usd">1462172000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMyLTMtMS0xLTA_19e48642-b7ce-43c6-831f-2a571e171889"
      unitRef="usd">1447954000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMzLTEtMS0xLTA_ad032f13-3ea4-43ff-9a6c-089826e2353b"
      unitRef="usd">-1341444000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzMzLTMtMS0xLTA_5c21046c-9fb9-40bf-a2da-fc16dc7f73c7"
      unitRef="usd">-1471577000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM0LTEtMS0xLTA_ddca8266-d06d-4336-aff8-a40a34c871a6"
      unitRef="usd">84000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM0LTMtMS0xLTA_acc02871-50c6-4b01-b57e-f568a678e1d4"
      unitRef="usd">-12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM1LTEtMS0xLTA_eac5b8ad-7ed9-43c5-b8aa-85cef08476ce"
      unitRef="usd">3817000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM1LTMtMS0xLTA_a2901ae3-44ba-43dc-acfb-08a93dd1b10d"
      unitRef="usd">2876000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM2LTEtMS0xLTA_69e7c43d-1f44-43a1-8fa1-c3c06de4a0e9"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM2LTMtMS0xLTA_96c79051-6b80-413e-ba67-533a2875ce1e"
      unitRef="usd">-26405000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM3LTEtMS0xLTA_054ced6f-bf84-4f43-b8f5-653596e2021c"
      unitRef="usd">417715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzAvZnJhZzoxMTYwNjc2ODAzMTg0NjI3OWJjODMwYTk5ZTVlMmYxYy90YWJsZTpiYmY4NTk5NmE1YTQ0MWIzOGUxNTE4ZTk5NzY4Y2EyYi90YWJsZXJhbmdlOmJiZjg1OTk2YTVhNDQxYjM4ZTE1MThlOTk3NjhjYTJiXzM3LTMtMS0xLTA_a27a8c82-74a5-4230-b207-beffaf39bc97"
      unitRef="usd">284136000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtMS0xLTEtMA_072dc8a8-f96c-4627-9e7f-022937f8cb5e"
      unitRef="usd">32331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtMy0xLTEtMA_48632b6b-b8d1-4776-8c09-0bf7239fb780"
      unitRef="usd">26583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzMtNS0xLTEtMA_afdb4063-3694-4c44-852b-4d8b26a3e9be"
      unitRef="usd">15890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtMS0xLTEtMA_dd0077e0-4b63-464a-8944-cb40e6f14cb4"
      unitRef="usd">289231000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtMy0xLTEtMA_5274aa60-05b7-4379-a321-a1fb3f3ebd10"
      unitRef="usd">36271000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzQtNS0xLTEtMA_d69e97b7-e21c-4d1e-b86f-5bff936686d6"
      unitRef="usd">75621000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtMS0xLTEtMA_cb3d2c00-8f8d-4587-ad01-f0fca1b85cd3"
      unitRef="usd">511000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtMy0xLTEtMA_95567b44-aeb7-4bc0-9742-71f6c268e1ea"
      unitRef="usd">355000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzUtNS0xLTEtMA_2ecc7f98-36df-487c-9948-1ae9f06b4c37"
      unitRef="usd">178000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtMS0xLTEtMA_88242b4a-499d-4faf-b743-9f26fe9d3c29"
      unitRef="usd">322073000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtMy0xLTEtMA_b3ce0228-81d5-4662-976e-c98e3f88f8b8"
      unitRef="usd">63209000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzYtNS0xLTEtMA_f07f208e-7de8-4e6d-8085-7ef6128eee30"
      unitRef="usd">91689000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtMS0xLTEtMA_050e2436-b192-41e7-945a-1ea83d43b503"
      unitRef="usd">3231000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtMy0xLTEtMA_d46d1331-accb-4f3b-9b50-2f4b09bc76be"
      unitRef="usd">2491000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzgtNS0xLTEtMA_1b0ca802-cac7-4aae-8f33-0c0a2e86103f"
      unitRef="usd">1899000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktMS0xLTEtMA_052c562b-28a2-419b-9cbe-61514d141a63"
      unitRef="usd">91924000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktMy0xLTEtMA_dd3d8929-7db5-444d-b1a0-487c46bc330d"
      unitRef="usd">100243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzktNS0xLTEtMA_c0ca8f28-175a-4e72-b149-89ec13ec6472"
      unitRef="usd">152223000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTEtMS0xLTA_f6e9bbb8-bf18-45d7-b293-1fb20737d977"
      unitRef="usd">0</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTMtMS0xLTA_9bf15b1d-51bd-4d76-a4fc-f40e1fd7da49"
      unitRef="usd">0</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEwLTUtMS0xLTA_f2b949dd-cf00-45ce-bef1-5d8298780f27"
      unitRef="usd">2101000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTEtMS0xLTA_a7e6ca51-afb5-4c23-a91a-ed0f9d5a5753"
      unitRef="usd">56835000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTMtMS0xLTA_808f3375-fccb-43ac-99bf-1f3f9ed2e03f"
      unitRef="usd">63754000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzExLTUtMS0xLTA_ac270c92-3479-4960-926d-4bdeb0117271"
      unitRef="usd">66090000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTEtMS0xLTA_fcb423ad-ccea-45ed-a44c-842c8e137a3c"
      unitRef="usd">28638000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTMtMS0xLTA_e16cda3a-a66f-4529-beb5-6ee9d3e73ffa"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEyLTUtMS0xLTA_268cb7ad-9172-4538-a3dc-a14eeb47a67a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OperatingExpenses
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTEtMS0xLTA_15351ec7-5404-4529-94f1-58298660510c"
      unitRef="usd">180628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTMtMS0xLTA_d6023644-e0d9-42bd-8130-0ca4e2d33d0b"
      unitRef="usd">166488000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzEzLTUtMS0xLTA_e88d2d20-0e7c-46b7-ac02-817626ae46c6"
      unitRef="usd">222313000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTEtMS0xLTA_39dcbe9b-ade1-4d05-b9f3-abb97b9280d2"
      unitRef="usd">141445000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTMtMS0xLTA_81629865-4ad7-4154-9961-3561aa699f41"
      unitRef="usd">-103279000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE0LTUtMS0xLTA_01ca4617-0e3f-4800-939b-2e0fda709ad5"
      unitRef="usd">-130624000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTEtMS0xLTA_76bd2ad5-0366-48d6-89fd-012aa78f0935"
      unitRef="usd">20676000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTMtMS0xLTA_59a240f6-4d90-4b3c-91eb-8cb0c91b9ffc"
      unitRef="usd">20777000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE3LTUtMS0xLTA_4b388367-4e28-42cb-8648-cb7adcc55604"
      unitRef="usd">6984000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTEtMS0xLTA_a17b8110-e32b-4b79-9fb4-90fe120a663f"
      unitRef="usd">3350000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTMtMS0xLTA_a42de3e2-555a-4fac-8b9a-dd89938ae84b"
      unitRef="usd">3508000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE4LTUtMS0xLTA_767a5d68-633d-47ba-bbdf-c6b6f11aec2c"
      unitRef="usd">1954000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTEtMS0xLTA_f2dc1af2-5ae5-4fc2-a614-d41be86246ba"
      unitRef="usd">124119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTMtMS0xLTA_59d4a0f6-1f52-4900-8e88-4c7b452df3f5"
      unitRef="usd">-120548000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzE5LTUtMS0xLTA_25cfa142-1c2c-4ce6-b1df-e0b39de26425"
      unitRef="usd">-135654000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTEtMS0xLTA_96091e38-3cc3-49e8-a057-66823a51cad2"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTMtMS0xLTA_5df4890e-00d3-4858-9911-0d9dabcbb84d"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIwLTUtMS0xLTA_c8f04333-d64b-48af-bc68-3cab6b0cb632"
      unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTEtMS0xLTA_6c5d41e7-865e-43f0-908d-59aa72b23077"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTMtMS0xLTA_484f61d7-3e01-4b63-972b-bd5c79f4c190"
      unitRef="usd">-120548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIxLTUtMS0xLTA_0fd409f1-e3fd-410f-bcbe-cda289a98b7c"
      unitRef="usd">-122993000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTEtMS0xLTA_f791fb8c-77dc-4236-b37c-59c0a1be3a71"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTMtMS0xLTA_76709444-c25b-4d23-af7b-834a84cb5adb"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIyLTUtMS0xLTA_28464be8-b096-4e40-80d4-d0f6f87c1b74"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTEtMS0xLTEyMTQ_a2e799f8-7328-4eab-9711-6faaef0eb39e"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTMtMS0xLTEyMDM_9e520714-323f-4bab-9bab-f2fb9f9d71a5"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTUtMS0xLTEyMDc_3c605a3f-9b28-470c-aa13-1e54c5dd351c"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTEtMS0xLTA_4c75eb7d-5f2d-4e59-b17d-e49ea205450d"
      unitRef="shares">106218000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTMtMS0xLTA_40943b64-dcaf-43f0-8784-fef208a162e1"
      unitRef="shares">105830000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzIzLTUtMS0xLTA_455ff887-31a7-45e3-9031-c80c26a78418"
      unitRef="shares">105237000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTEtMS0xLTM4Mzc_5b465964-450e-4d3f-b15a-a3d2177ec977"
      unitRef="shares">116747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTMtMS0xLTEyMTA_d096207e-2935-4cb7-970b-7a919faf8d91"
      unitRef="shares">105830000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI1LTUtMS0xLTEyMTA_15a343cc-2dc1-4873-8abf-ff0ff6e134ff"
      unitRef="shares">105237000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTEtMS0xLTA_fa2db7d8-ba8a-4df4-a7aa-c6b8dcd7856c"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTMtMS0xLTA_3704fb7a-474e-4e4a-af5e-4ea36881918d"
      unitRef="usd">210000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI2LTUtMS0xLTA_6c32fea5-4e00-49cc-a68b-3df46c73c35f"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTEtMS0xLTA_15208ab3-23e3-433e-83f4-32eeac835455"
      unitRef="usd">130229000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTMtMS0xLTA_b9538d68-88a6-4a93-b492-b2fab62f842d"
      unitRef="usd">-120338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xMzYvZnJhZzo3ZTI1ODhkOGU1ZTc0Yzk3YTAyMWM4ODk4MjNmODEyYi90YWJsZTowMjE0M2I2NTE5N2E0NzQ2OGIwOGMxYzNmM2IwOGNmYi90YWJsZXJhbmdlOjAyMTQzYjY1MTk3YTQ3NDY4YjA4YzFjM2YzYjA4Y2ZiXzI3LTUtMS0xLTA_867c2dd3-8c05-4352-a4d9-331bf9013162"
      unitRef="usd">-123020000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMS0xLTEtMA_fb96056d-59ef-4517-b001-77a659e05b84"
      unitRef="shares">104582000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7c80e5b5de5d4cc6a656b10c2e7dffc2_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMy0xLTEtMA_cd4b2f06-a2ee-4ad9-82b8-0b04db9c6790"
      unitRef="usd">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a26c1b854e6492a9cee1d79baa36f4f_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtNS0xLTEtMA_d65b1aa1-bc67-4b52-9ab1-5a010318beea"
      unitRef="usd">1411222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ebb2384f82444fdb95c578d086dd541_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtNy0xLTEtMA_be279761-ed5b-4457-bbbe-6a9cf75cc855"
      unitRef="usd">-1240257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2837d1af8744496a83b9465b01d9c7af_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtOS0xLTEtMA_0c7ae350-7572-43cc-95d7-4a8477391fb3"
      unitRef="usd">-195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i129f3fad6d374d8db3b6389a173ed459_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMTEtMS0xLTA_5a12a737-ebda-4b1c-b962-7863c44f866c"
      unitRef="usd">-3368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57757fd132344fe38d2ce518c20bb378_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzQtMTMtMS0xLTA_aea7d69b-2951-4a24-a8dd-217dc3a18267"
      unitRef="usd">167507000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMy0xLTEtMA_cea38f58-0ef7-4260-8beb-ea0a6da518c0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtNS0xLTEtMA_08623649-625c-4680-b58f-56172a5fcc38"
      unitRef="usd">9472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtNy0xLTEtMA_76594541-237c-4242-9ca4-0675571c8bcf"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtOS0xLTEtMA_f1e43b74-de44-47e9-9774-df9a85f07b8a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMTEtMS0xLTA_fe31c018-8886-49bc-91a1-9748eb3ea9aa"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzUtMTMtMS0xLTA_1cb88160-896f-4ec5-97da-ef7d4a550deb"
      unitRef="usd">9472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMS0xLTEtMA_6df66641-5d11-48f3-af58-39ade4b6000b"
      unitRef="shares">469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMy0xLTEtMA_bedd244b-b0ed-446d-8a63-1725a82c95e1"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctNS0xLTEtMA_4166a6ed-fa90-4f8d-aed3-80507d60be93"
      unitRef="usd">5485000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctNy0xLTEtMA_81d5390c-0d18-47a3-81c8-01f6aba16aef"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctOS0xLTEtMA_023f6548-3518-47b8-b397-3e8ae3ab60ea"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMTEtMS0xLTA_99ca9ad8-70a4-4ace-8008-48acdfc4a513"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzctMTMtMS0xLTA_faac9c9d-c728-4273-aae9-dcca99e305ab"
      unitRef="usd">5486000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMy0xLTEtMA_2a5a4ee1-2218-46d8-a96a-72da070a8bcb"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktNS0xLTEtMA_db5798cb-b681-4dc0-8554-e507b5b54e8e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktNy0xLTEtMA_20505957-5a04-4bb5-8e33-781450514848"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktOS0xLTEtMA_dc5ae173-efe4-4039-a687-9a1f11f42347"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMTEtMS0xLTA_dc9e77e3-57e8-4462-9691-6443635ff27d"
      unitRef="usd">-1679000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzktMTMtMS0xLTA_e8f8167f-fed6-4555-8097-277638582ed2"
      unitRef="usd">1679000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTMtMS0xLTA_86094483-2d0d-496e-9409-fe2f6a3a5a36"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTUtMS0xLTA_2e35629a-b0a5-4bd8-8ef8-a54c369336e8"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTctMS0xLTA_2fff3f81-6c78-4022-b548-ecb16cc44511"
      unitRef="usd">-122993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTktMS0xLTA_e5444d81-e188-422e-a6ea-db6e22a227f2"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTExLTEtMS0w_f1d02f90-41b3-4295-b962-a7be7451f9ba"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEwLTEzLTEtMS0w_6a4a6d96-3c21-4fac-814a-a281b258ef51"
      unitRef="usd">-122993000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3869ec5153134120987567fd88cf4a1a_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTMtMS0xLTA_217f97f3-ad9c-418f-ab2f-893547353570"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia454818c396a4d7b92d8fd5c9c14b07f_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTUtMS0xLTA_038baaba-e275-4889-97ff-5f3d8a888c68"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5c780d015cec41a49df3470c3e2dc4ed_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTctMS0xLTA_f5a01415-42c1-4c91-bb5e-9049d9e20eab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i69abe0bd47b64c03a19bad0be6a53980_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTktMS0xLTA_644361de-3587-47da-b242-165413ba3359"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ied4f3c0787f1459d816ccd436fc57bdb_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTExLTEtMS0w_a648daa6-2e78-4ecc-8917-68dd205d3056"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzExLTEzLTEtMS0w_dba315f9-fe86-47e4-b4d9-557657ef7872"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTEtMS0xLTA_f68ea4e1-ab83-4a40-ac6f-f1c5fbd8da86"
      unitRef="shares">105711000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff34fcaca1154c2b8e86cffa8f0fd449_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTMtMS0xLTA_108aa149-fecf-4ef8-a4b9-c55936120e03"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8cccc7e982e4621be9e20764d4dfc15_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTUtMS0xLTA_eb248c92-cc3e-44b6-b497-dcbd3dd605bd"
      unitRef="usd">1435526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffcd61f6da4749d4b7cc1ab6f3055a80_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTctMS0xLTA_f4166c04-8a28-4029-a674-0f77f5e427ec"
      unitRef="usd">-1365241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5028bb7c1904d74ad203e9136d8d368_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTktMS0xLTA_7daf448b-7b3b-4a1f-9706-1dd5e6c9f840"
      unitRef="usd">-222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i017c2651d77947d4bb01b4651850b16e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTExLTEtMS0w_0f469d3f-4e59-4e88-841c-72d620121c42"
      unitRef="usd">-1904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2be9572e894e461092c842e6748a2b74_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzEzLTEzLTEtMS0w_d1a0e722-fa9c-4ef2-a564-d69979e17c64"
      unitRef="usd">68265000</us-gaap:StockholdersEquity>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTUtMS0xLTA_83d40fe9-c6e5-48b0-a689-0f69eeb253cf"
      unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTctMS0xLTA_e9bedc3e-73dd-46cd-bfc0-656d84f8f56d"
      unitRef="usd">14212000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTktMS0xLTA_79dad369-59e6-4d74-81b1-2e84c0b20660"
      unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTExLTEtMS0w_23ed9ea5-9afa-4b3c-88b0-280503c773a9"
      unitRef="usd">0</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE0LTEzLTEtMS0w_2a1ffab6-599e-4824-9547-f650cfed48f2"
      unitRef="usd">14212000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTMtMS0xLTA_a2ef1c7b-4f46-4a4e-86ab-dbfd26be8f7d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTUtMS0xLTA_7499d485-146b-4235-afc9-0a3739fb2c40"
      unitRef="usd">11696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTctMS0xLTA_7ba333ac-ce19-4ffa-9028-2b0baf73c178"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTktMS0xLTA_cb2a273b-348c-4f2f-89d7-585d798e2ee9"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTExLTEtMS0w_aec9c6f2-0ea5-441c-be41-4682d09ba03e"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE1LTEzLTEtMS0w_fe4bd1f7-34d9-4a20-8ee6-5d93470db0f2"
      unitRef="usd">11696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTEtMS0xLTA_da0757fd-45ba-4c37-8757-42a47bd88e05"
      unitRef="shares">451000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTMtMS0xLTA_96a28715-ec39-474f-848e-f59493e0e249"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTUtMS0xLTA_78a4e530-24bb-4e63-859c-2303ad107ded"
      unitRef="usd">732000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTctMS0xLTA_2543e2bc-7b66-4ac0-a3cc-3acc11bc87a6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTktMS0xLTA_848681b9-188a-4377-9f5b-98d72eb53848"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTExLTEtMS0w_84d2973f-562d-4b08-91a6-288a66cd173b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzE3LTEzLTEtMS0w_69cf734b-b5f5-4ae6-bf07-1ef427c2635c"
      unitRef="usd">732000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTMtMS0xLTA_4e67beb2-f735-467f-ad5e-15db3902805e"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTUtMS0xLTA_727a0089-0b61-45f9-adac-862601e24bf9"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTctMS0xLTA_27584c1a-c8c8-4c28-8e17-008e3f32232b"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTktMS0xLTA_167b996e-2e21-4d77-98e9-9ef400049bce"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTExLTEtMS0w_a3d7923e-0702-4bdb-8629-f0ecad99382c"
      unitRef="usd">972000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIwLTEzLTEtMS0w_a5fa4a80-7f26-4797-b6f3-69e2015fdf2f"
      unitRef="usd">972000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTMtMS0xLTA_8f13eb46-0b60-4e7b-8f70-f9a614ec7b26"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTUtMS0xLTA_93977f2f-5ade-45e7-9733-311a7f5ee6de"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTctMS0xLTA_8e87df8c-2219-4bf9-9fe7-1b880e9157f6"
      unitRef="usd">-120548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTktMS0xLTA_10efe281-406f-4c81-b2e3-8d2cff067276"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTExLTEtMS0w_a7a2821f-7b75-48cb-bbd9-0863ec5c5f8c"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIxLTEzLTEtMS0w_f6c97d24-df5b-4fd0-ada8-6bb6a14868a2"
      unitRef="usd">-120548000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie95ab05cc4bd426dba6730a15dd92129_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTMtMS0xLTA_1ce56a3d-5d45-4861-ae2d-6292bdf96336"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7778a65bc8a94ffe99b0564783df283b_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTUtMS0xLTA_3ef0b11b-2eb9-4dcf-b6dd-5ba044385566"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8e983d5a460d4a5db278cd66761d6065_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTctMS0xLTA_4203437d-f33a-4575-aad9-223ca66eee93"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icf271e9cb2d24f518719be1f4a8fd7b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTktMS0xLTA_0797cb61-0034-44b5-8769-c616f98c7801"
      unitRef="usd">210000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6f730b37fda648b0b259c6336cbec89d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTExLTEtMS0w_4ec5d47f-1925-4713-be8d-2facffc6ead2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzIyLTEzLTEtMS0w_b2632e2f-5634-463c-99c6-911ea2652037"
      unitRef="usd">210000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTEtMS0xLTA_f31bde63-548d-431f-8039-ff4539895d34"
      unitRef="shares">106162000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i967751fea12e4973a32d9fe35e3e91d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTMtMS0xLTA_36a5f62b-2d0c-45d7-a759-b9f5dda04b04"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2402ec5193524658955d7c90d3a16896_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTUtMS0xLTA_0cc1085c-bbdf-4568-bcb2-0026f9559a92"
      unitRef="usd">1447954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b2e221d098b491cbeaab0aa52d099ae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTctMS0xLTA_aadf3863-c9c7-48a9-9d5d-35b1e259dcc2"
      unitRef="usd">-1471577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9e0a311a22b411e9fd8665266ff4e44_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTktMS0xLTA_4bbbd659-7c5b-45b1-8e37-3df40dd2614a"
      unitRef="usd">-12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44b4b3353a5c41bbaa44ce871c92bba3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTExLTEtMS0w_a95c9828-d60e-4c4e-a0ee-b6b9c4f26af4"
      unitRef="usd">-2876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI0LTEzLTEtMS0w_1bb740b9-cf71-4e0a-8010-e1f0557a2fb7"
      unitRef="usd">-26405000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTMtMS0xLTA_d95cf5d4-006b-473f-9da5-5367a129f383"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTUtMS0xLTA_8f9bbc47-2aab-445a-9cf6-4f86809e3fc0"
      unitRef="usd">14218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTctMS0xLTA_3bee7e66-a781-4509-9da2-8049aac323b4"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTktMS0xLTA_9765bc75-bcda-4c6a-9184-e4f16842069f"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTExLTEtMS0w_7334c509-d452-4fb5-924c-0061924ec8a5"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI2LTEzLTEtMS0w_d478b19a-3a54-41e2-81df-62933e3ab3c4"
      unitRef="usd">14218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTEtMS0xLTA_bf9e2a07-9e04-41eb-8e7b-964e0141fb0d"
      unitRef="shares">517000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTMtMS0xLTA_8b547d50-49b8-4409-a6ff-2ef47cbad673"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTUtMS0xLTA_dda3fdba-c6af-4ac0-99f7-5fccbc284d94"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTctMS0xLTA_92dd6883-1d7e-4b34-9d92-f1c6c04d273d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTktMS0xLTA_b37af37c-cbc9-4b98-b65f-65694cda3c36"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTExLTEtMS0w_bd83a6b4-9b97-4ffa-9c8c-bdbb6fd39d5f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzI4LTEzLTEtMS0w_6d837ef3-d213-442d-8088-542834f6be80"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTMtMS0xLTA_ceaa3038-dbfd-414e-b346-10e7dc0821ca"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTUtMS0xLTA_c7b1df09-ed12-441e-9df3-007258692304"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTctMS0xLTA_5eea2bba-d241-44af-8782-def26e905424"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTktMS0xLTA_0f27feaf-6181-4f7d-ad7a-596df02b48f5"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTExLTEtMS0w_120319b8-52d2-4b74-bbce-09410f2122b2"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMxLTEzLTEtMS0w_39e99ce3-a216-42e1-82fc-b9cc5764bd8c"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTMtMS0xLTA_d20a2336-9c5d-4437-9d42-5108477e47fb"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTUtMS0xLTA_b090a9e5-67a6-47f1-aff5-4f02200503e7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTctMS0xLTA_07d910ae-6326-49d8-9aac-4369b298f7c2"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTktMS0xLTA_41d118f2-6fae-430c-b23a-aa9ea9269788"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTExLTEtMS0w_e61cccc3-dec8-46a2-8d8b-3db9cb7f884b"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMyLTEzLTEtMS0w_98dba59d-9ee3-42d3-92f4-c08e535a7eb5"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0a257be715794239b4b42dbe56325b63_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTMtMS0xLTA_34379ce4-a5e5-4211-bd85-cbb3b93fcc70"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ieac0714597ff49c483b52893312f674c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTUtMS0xLTA_a44d84b0-1aab-4cc9-940a-7eec84c7ba6b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9269d24780454c11824cf7cb9dcda553_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTctMS0xLTA_3992f0bb-d62d-4fa8-b29c-f199358c462c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48208aca804f4529a47984a51825c00c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTktMS0xLTA_8da1d27d-2214-4086-9308-17adc3d699d9"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i370f08d03fa945bd85076fdc73930f86_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTExLTEtMS0w_1df3c2c5-586b-4ac5-834c-774e49ed4bcc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzMzLTEzLTEtMS0w_bcc0c74b-aa23-4d7b-a142-d66c19ee554f"
      unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7501ea3be2a741529ff3306e73060964_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTEtMS0xLTA_548b0054-982b-469c-b341-5208a208177f"
      unitRef="shares">106679000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7501ea3be2a741529ff3306e73060964_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTMtMS0xLTA_ffb1e97e-43a0-4a02-9a42-b43aff6b943d"
      unitRef="usd">106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98be0b7d6a10477d8c718994e04dc1c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTUtMS0xLTA_c70f1167-e000-4d5f-881b-cf9ba33da31f"
      unitRef="usd">1462172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0c089f26a424433a6a985286efbaae5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTctMS0xLTA_4da22bba-0177-4c01-8e9d-7d82a42fbdf3"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ae9845aba89468b8e79334b8836b87a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTktMS0xLTA_ab6f93f8-e932-4ba2-9949-a84ce2fc268a"
      unitRef="usd">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2669261eb809451d87dbe16b0e36331d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTExLTEtMS0w_eed8daeb-3cf2-4395-ae5e-f74411a0ce02"
      unitRef="usd">-3817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDIvZnJhZzo0YzYwMDRmNTY2YTE0ZTM4OWUxNjA0NmY1NWU3NTk4Yi90YWJsZTo5YTA5ODMyMzIyOTQ0Mzc4YTZhM2FmZGViOTUxNjc5ZC90YWJsZXJhbmdlOjlhMDk4MzIzMjI5NDQzNzhhNmEzYWZkZWI5NTE2NzlkXzM1LTEzLTEtMS0w_a1e1fbad-1b6c-4c00-9bf5-1536ef82fac8"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtMS0xLTEtMA_10ac9e33-bf71-4fd1-9595-daa3b4e27efb"
      unitRef="usd">130133000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtMy0xLTEtMA_4a7eec2f-2108-4617-a155-8bf71475a084"
      unitRef="usd">-120548000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMtNS0xLTEtMA_fb05856d-2460-4af9-9487-426b4d616f16"
      unitRef="usd">-122993000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtMS0xLTEtMA_c957f12c-fbfe-430c-be55-c11fb2a1c50a"
      unitRef="usd">3654000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtMy0xLTEtMA_9045b5a3-a032-4f3a-be64-296b4c91250c"
      unitRef="usd">3683000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzUtNS0xLTEtMA_083e50ca-8fb8-407e-8e28-95d6abd14c15"
      unitRef="usd">3399000</us-gaap:DepreciationDepletionAndAmortization>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctMS0xLTEtMA_6bb7ff4d-a0b9-412e-af53-c311cff042fb"
      unitRef="usd">0</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctMy0xLTEtMA_10006dab-79f6-4f13-ae73-e14db485e07f"
      unitRef="usd">0</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzctNS0xLTEtMA_23d7b4c5-ee2d-4aab-9f54-c7685808ec39"
      unitRef="usd">2101000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
    <us-gaap:ShareBasedCompensation
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtMS0xLTEtMA_3bc002d0-7e57-4cf7-8438-3087baac7e15"
      unitRef="usd">14218000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtMy0xLTEtMA_91c74a7f-6ab2-4d36-8c69-134dd3ab4d5f"
      unitRef="usd">11696000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzgtNS0xLTEtMA_93879224-7434-436b-8158-64a1748ccd3b"
      unitRef="usd">9472000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktMS0xLTEtMA_6b68bd42-1ca6-4976-8bf5-1b8b873cb4b9"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktMy0xLTEtMA_2b6d4387-369c-4632-bae3-6882f9db7146"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzktNS0xLTEtMA_c2b7676c-6c21-499f-9161-32364c4d9b4a"
      unitRef="usd">-3000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTEtMS0xLTA_138dd801-eb01-42c2-ac9f-200a4bfc918b"
      unitRef="usd">1465000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTMtMS0xLTA_9e23519d-578a-4d7d-9526-eb0a009df157"
      unitRef="usd">1336000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEwLTUtMS0xLTA_a26e8490-f3cf-48f3-8521-8b16b2b527da"
      unitRef="usd">599000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTEtMS0xLTA_69df239c-48a9-42c9-a813-80aad03e43a0"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTMtMS0xLTA_daa86c90-0b89-49dd-b08a-25a647cbafcb"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzExLTUtMS0xLTA_3efcdd88-65f9-4538-9ef4-9ee5cd19ea97"
      unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTEtMS0xLTA_0f4a00b2-4901-4d41-ad27-222f76c28a09"
      unitRef="usd">50608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTMtMS0xLTA_00abc5e1-babf-48ad-914f-70b708577b71"
      unitRef="usd">1099000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzEzLTUtMS0xLTA_5e61b1a7-e4b5-4537-b548-94e1bb2b1f6e"
      unitRef="usd">-166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTEtMS0xLTA_84fa292c-f6b3-43b4-9932-0d321ec37f72"
      unitRef="usd">-437000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTMtMS0xLTA_791cc215-53fd-45a0-b7a4-54418bf76f58"
      unitRef="usd">2732000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTUtMS0xLTA_6773c173-98f7-4759-bcee-27a5a4d906b1"
      unitRef="usd">1948000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE0LTUtMS0xLTA_790e54f3-fa17-4c42-95f6-833f3e226823"
      unitRef="usd">1948000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTEtMS0xLTA_ce1382f1-3ff3-44be-a852-e2c581ef4af2"
      unitRef="usd">2652000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTMtMS0xLTA_170dbfac-98b5-4da0-a915-6f89892bb00e"
      unitRef="usd">-1766000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE1LTUtMS0xLTA_81d06708-6ae8-4042-82ff-51a2d2f29ee1"
      unitRef="usd">557000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTEtMS0xLTA_92a1655e-96a8-4b60-8356-c6ab36166e6d"
      unitRef="usd">-429000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTMtMS0xLTA_d2cdb2cc-201b-4bc6-b679-ac0341562584"
      unitRef="usd">-144000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE2LTUtMS0xLTA_cda8da00-1232-4b4e-b3bd-10546774b1cf"
      unitRef="usd">-33000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTEtMS0xLTA_b814f2bf-6031-47c5-a1ed-5141ba69d33c"
      unitRef="usd">20097000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTMtMS0xLTA_2c53d336-7eaf-4a89-bf72-d227fa3386f9"
      unitRef="usd">-19913000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE3LTUtMS0xLTA_4b5996bc-422f-476a-b728-7ea59fa77ada"
      unitRef="usd">-11875000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTEtMS0xLTA_79504142-ce55-4d49-8397-f86c3e7ec5c5"
      unitRef="usd">-25990000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTMtMS0xLTA_9bdcca3b-9fa5-4555-8339-ab4df85e309f"
      unitRef="usd">-22940000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE4LTUtMS0xLTA_eeb1b301-48e9-46ed-965f-ea9476c41ef6"
      unitRef="usd">-51133000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTEtMS0xLTA_257a7825-d75e-4a8d-bed4-e57f8a01c430"
      unitRef="usd">113807000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTMtMS0xLTA_735866ed-bd0d-49b5-85b2-f5fdcb1638ed"
      unitRef="usd">-148607000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzE5LTUtMS0xLTA_a955d11e-81c1-4569-bbb4-2d9d4d846fd4"
      unitRef="usd">-185394000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTEtMS0xLTA_5998f925-cf7f-41de-b4a9-d4133a467098"
      unitRef="usd">70000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTMtMS0xLTA_bc39f4c0-3652-41b7-b152-7c37923e194a"
      unitRef="usd">95000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIxLTUtMS0xLTA_7e97b931-1a44-426b-8c6f-8953283d6e65"
      unitRef="usd">228000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTEtMS0xLTA_abf616f6-e18b-4fa8-a893-663e83580da9"
      unitRef="usd">322385000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTMtMS0xLTA_cc32e8b7-5778-46c9-8a0c-e44b9a09c7c2"
      unitRef="usd">119987000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzIzLTUtMS0xLTA_ac7c3170-4571-4b2b-8d92-5dbbf3ab202e"
      unitRef="usd">267873000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTEtMS0xLTA_519b95b0-a4fc-4021-8b2a-d2568eb99066"
      unitRef="usd">166600000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTMtMS0xLTA_f60aae56-39e2-495b-b809-4628dbc5e44b"
      unitRef="usd">289658000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI0LTUtMS0xLTA_8941dfbb-99e0-4dda-996e-14760a86b5b7"
      unitRef="usd">318623000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTEtMS0xLTA_75fa1d95-3c68-439d-bd9e-fb9f2daf80b8"
      unitRef="usd">-155855000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTMtMS0xLTA_b3371dc0-207c-4979-9f46-4f3f8cd8449b"
      unitRef="usd">169576000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI1LTUtMS0xLTA_c338ac6e-12f5-4c31-8b4d-3b2492822d3a"
      unitRef="usd">50522000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTEtMS0xLTA_a87db889-7946-459c-a9f6-cbf35c85aedd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTMtMS0xLTA_eab36738-0027-4f43-ba60-9d05be3bc4da"
      unitRef="usd">732000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI3LTUtMS0xLTA_2162f78e-b442-49dd-96c3-25281d92c072"
      unitRef="usd">7987000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTEtMS0xLTA_536f588e-e6bf-4542-958c-874527c85f2f"
      unitRef="usd">941000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTMtMS0xLTA_40d1fcf2-8b64-4703-8b45-b2dee410c11d"
      unitRef="usd">972000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI4LTUtMS0xLTA_bcc6494c-6bf2-4395-a317-566de5b80c15"
      unitRef="usd">1679000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTEtMS0xLTA_a2051e25-4c8d-463c-9a3d-1ff384a9102a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTMtMS0xLTA_201d225c-7182-475e-b0fe-ff2f03903f19"
      unitRef="usd">12529000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzI5LTUtMS0xLTA_293e1154-7a72-4241-a180-15e255519025"
      unitRef="usd">145905000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTEtMS0xLTA_ab58fd69-1a3f-4d7e-b0a9-9a7d409a6626"
      unitRef="usd">1285000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTMtMS0xLTA_370b2d94-c393-43cc-8a25-f61f8507fffa"
      unitRef="usd">14533000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMwLTUtMS0xLTA_5ed14cdc-b7c1-4a49-bd2d-ffa32c232426"
      unitRef="usd">2280000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTEtMS0xLTA_b7a41ccf-8275-4f0a-9811-78d3f1317714"
      unitRef="usd">-2226000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTMtMS0xLTA_4200d289-d770-48c0-9eeb-f5d8ad1fb790"
      unitRef="usd">-2244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMyLTUtMS0xLTA_4f63bd37-9d64-4b5b-942c-48a31e1ce9b3"
      unitRef="usd">149933000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTEtMS0xLTA_9cd5c41a-b0db-4909-acfa-f570a6221d3c"
      unitRef="usd">-44274000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTMtMS0xLTA_3d85c995-0d79-4c23-a982-0448931f3edc"
      unitRef="usd">18725000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzMzLTUtMS0xLTA_387e00c4-1716-4d2e-833c-d4a331b92a15"
      unitRef="usd">15061000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTEtMS0xLTA_698220f0-d859-4d59-ada3-83348804c2d1"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2be9572e894e461092c842e6748a2b74_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTMtMS0xLTA_8a1314c7-685f-4d7e-85e4-09ee4aea1e76"
      unitRef="usd">61661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i57757fd132344fe38d2ce518c20bb378_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM0LTUtMS0xLTA_c151b00d-f4bb-41fa-a472-c00e212b8783"
      unitRef="usd">46600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTEtMS0xLTA_bf4342c4-1020-4894-aaaa-3218986c3d65"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTMtMS0xLTA_b0297638-3189-49a1-98d8-1b88f0f75032"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2be9572e894e461092c842e6748a2b74_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM1LTUtMS0xLTA_9fec6770-9a99-45f2-992a-1776422c4332"
      unitRef="usd">61661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTEtMS0xLTA_b81da75f-1609-493c-be17-66aa38b9af7e"
      unitRef="usd">19211000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTMtMS0xLTA_610799e7-0457-4906-84e3-1762579afbfd"
      unitRef="usd">16465000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzM4LTUtMS0xLTA_ae1e5aed-25c3-4115-8800-e1de2ac309c7"
      unitRef="usd">5870000</us-gaap:InterestPaidNet>
    <lxrx:SharesIssuedToSymphonyDesigneesValue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTEtMS0xLTA_67393143-f0a1-4cb9-a591-6ce0cbc3cf6b"
      unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
    <lxrx:SymphonyContingentPaymentInCash
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTMtMS0xLTA_a4894f2f-d9cf-48e7-95f5-f0acf62239aa"
      unitRef="usd">0</lxrx:SymphonyContingentPaymentInCash>
    <lxrx:SharesIssuedToSymphonyDesigneesValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNDUvZnJhZzo2NDE0ZTZiMTU1YWE0YjFjOTljMGU4ODUxMmVkYTc4ZS90YWJsZTo2NmM4ZjM1MTllNjA0NmY3ODE4MWJmMDhiMjRmNWIwZC90YWJsZXJhbmdlOjY2YzhmMzUxOWU2MDQ2Zjc4MTgxYmYwOGIyNGY1YjBkXzQyLTUtMS0xLTA_b3bbf9b9-e96c-4528-89fc-a8cbef887f3d"
      unitRef="usd">10499000</lxrx:SharesIssuedToSymphonyDesigneesValue>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTEvZnJhZzo4OGM1YmNmNGU3ZjU0MTM2OWJjZTExNmZmM2QxOWExNC90ZXh0cmVnaW9uOjg4YzViY2Y0ZTdmNTQxMzY5YmNlMTE2ZmYzZDE5YTE0XzE0ODM_6ccd27e6-d8f9-4af7-b524-9854e8b83d93">Organization and Operations&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under strategic collaborations and other research and development collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts and financing under debt and lease arrangements. The Company&#x2019;s future success is dependent upon many factors, including, but not limited to, its ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen Pharma SAS&#x2019;s (&#x201c;Ipsen&#x201d;) ability to successfully commercialize XERMELO outside of the United States and Japan and Lexicon&#x2019;s receipt of any milestone payments and royalties; the success of its ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; its success in establishing new collaborations and licenses, including for the development and commercialization of sotagliflozin; general and industry-specific economic conditions which may affect research and development expenditures; and its ability to obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTk0_abce00dd-a726-4678-96ab-0c7852902cf1">Summary of Significant Accounting Policies&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. In 2018, accounts payable included $5.7&#160;million related to its accrual for clinical studies.  The Company has reclassified this amount to accrued liabilities in the consolidated balance sheet for comparable presentation of accounts payable and accrued liabilities.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2019 and December&#160;31, 2018, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventory: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. Inventory consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.403%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.791%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.504%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.999%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.506%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Concentration of Credit Risk:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In 2019, customers in Germany and the United States represented 89% and 10% of revenue, respectively.  In 2018, customers in Germany and the United States represented 53% and 40%, respectively.  In 2017, customers in Germany, France and the United States represented 65%, 18% and 17% of revenue, respectively.&#160;&#160;At December&#160;31, 2019, management believes that the Company has no significant concentrations of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Segment Information and Significant Customers:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.  In 2019, Sanofi-Aventis Deutschland GmbH (&#x201c;Sanofi&#x201d;) represented 89% of revenues and no other individual customer represented more than 10% of revenues.  In 2018, Sanofi represented 53% of revenues and two independent specialty pharmacies, Biologics, Inc. and Diplomate Pharmacy, represented 25% and 14% of revenues, respectively.  In 2017, Sanofi and Ipsen represented 65% and 18% of revenues, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangible Assets:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  Intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.  During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the FDA.  The Company has recorded $1.8 million in amortization expense related to this asset in each of the years ended December&#160;31, 2019 and 2018, respectively, and $1.5 million for the year ended December&#160;31, 2017.  Amortization expense is recorded as cost of sales in the accompanying consolidated statements of comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimated future amortization expense for intangible assets as of December&#160;31, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.472%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.528%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ending&lt;br/&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. There were no impairments of long-lived assets, including finite-lived intangible assets, in 2019, 2018 or 2017. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#x2019;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.  Lexicon determined that a triggering event occurred upon execution of the Termination Agreement with Sanofi (as defined in Note 13) and Lexicon's resulting decision to substantially reallocate resources from the development of certain programs, including LX1031 and LX1033 for irritable bowel syndrome, to the development of sotagliflozin.  In connection with such triggering event, Lexicon determined that its LX1031 and LX1033 programs for irritable bowel syndrome, collectively an intangible asset, were considered to be impaired and recorded an impairment charge of $28.6&#160;million to IPR&amp;amp;D for the year ended December&#160;31, 2019.  The impairment reduced the remaining book value to zero. There were no impairments of indefinite-lived intangible assets in 2018  or 2017. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill Impairment:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in 2019, 2018 or 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of the Company&#x2019;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs are included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Customer Credits:  The Company&#x2019;s customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expects that its customers will earn prompt payment discounts.  As a result, the Company deducts the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;The Company adopted ASU NO. 2014-09, &#x201c;Revenue from Contracts with Customers&#x201d;, on January 1, 2018, using the modified retrospective method.  In its adoption, the Company recorded a $14.2 million cumulative-effect adjustment to its accumulated deficit related to a contract with the Texas Institute for Genomic Medicine. Subsequent to adoption, the Company was notified that all performance obligations related to the contract have been fulfilled. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during 2017 once the FDA approved XERMELO as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive income (loss).  As a result, cost of sales for approximately the next twelve months will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company's estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease was based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $24.0 million, which is expected to be recognized over a weighted-average period of 1.1&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended December&#160;31, 2019, 2018 and 2017, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.8%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;"&gt;Income Taxes:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method,  deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2019, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December 31, 2019, and positive evidence, including the income during the year ended December 31, 2019 and projections of future income. After assessing both the negative evidence and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December 31, 2019 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total deferred tax asset balance subject to the valuation allowance was approximately $333.6&#160;million at December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;The Tax Cuts and Jobs Act (the &#x201c;2017 Tax Act&#x201d;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent, reduction of certain tax credits, limitations on, or deductibility of interest expense and executive compensation, and limitations on the use of net operating loss carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Net Income (Loss) per Common Share:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTE5_4365b836-56c2-4f57-9957-661ad9d93d22">Basis of Presentation: The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. In 2018, accounts payable included $5.7&#160;million related to its accrual for clinical studies.  The Company has reclassified this amount to accrued liabilities in the consolidated balance sheet for comparable presentation of accounts payable and accrued liabilities.</us-gaap:ConsolidationPolicyTextBlock>
    <lxrx:PriorYearReclassOfAccrual
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2Njg3NTY_945aa197-e5f9-46d1-a39e-47040c476237"
      unitRef="usd">5700000</lxrx:PriorYearReclassOfAccrual>
    <us-gaap:UseOfEstimates
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODky_98927cb9-9ea1-4a55-afe0-c0eb419f7d97">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTcx_173669ea-d7e8-4596-a22b-a734ede6f1f4">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of December&#160;31, 2019 and December&#160;31, 2018, short-term investments consist of U.S. treasury bills and corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTAy_e9933e57-5f6f-400b-8d46-d93c7857e57f">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.&lt;/span&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODk0_e8b4c312-1dd0-40f7-bc49-e81dd0ef65d2">Inventory:  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzItMS0xLTEtMA_64a7f11b-920e-4898-9f05-74a1a505d19b"
      unitRef="usd">3182000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzItMy0xLTEtMA_9d8cc269-ad0f-4da5-aae1-e5d6596015ea"
      unitRef="usd">3564000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzMtMS0xLTEtMA_45da0cc0-5812-4f52-acc1-6dcfb08eb12a"
      unitRef="usd">153000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzMtMy0xLTEtMA_bb625a0b-30da-4f56-9613-68063916db24"
      unitRef="usd">232000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzQtMS0xLTEtMA_b4f2989c-718c-4da4-aede-762a720827ba"
      unitRef="usd">908000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzQtMy0xLTEtMA_10f5ad35-0070-402b-a083-57a939907668"
      unitRef="usd">884000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzUtMS0xLTEtMA_13cf9d8a-0467-427e-a638-34f2e483becb"
      unitRef="usd">4243000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTo1MGU4MWJjNzUwYzQ0YWY3OWQxYWJkM2ExZjkxNmUwMC90YWJsZXJhbmdlOjUwZTgxYmM3NTBjNDRhZjc5ZDFhYmQzYTFmOTE2ZTAwXzUtMy0xLTEtMA_db1e9816-e21e-494b-a2c7-27ff724cf599"
      unitRef="usd">4680000</us-gaap:InventoryGross>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTIx_614189d6-573d-4438-b622-5e2bdd0c88f1">Concentration of Credit Risk: Lexicon&#x2019;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#x2019;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI4NDg_7f3cc48a-3e4c-4a78-bce2-ad035bf985f7"
      unitRef="number">0.89</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI4NTU_7bf76795-e69c-4bfd-8ce9-759b20b9adb7"
      unitRef="number">0.10</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI5NDY_5b1ec4fd-4f9f-4fe2-9e35-c7d37da0086b"
      unitRef="number">0.53</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzI5NTM_f338bb25-4998-4048-bfc1-ad6dae8ba18a"
      unitRef="number">0.40</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMwMzM_7ccfb857-20e5-461a-b34c-bdb07c05155b"
      unitRef="number">0.65</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2Njg3NzI_e82d3295-f611-46d8-98df-4b3a298b8bb2"
      unitRef="number">0.18</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance>
    <lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMwNDA_e6afc2be-4b02-4dbd-9ccf-80d763ee25f5"
      unitRef="number">0.17</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODk4_9e0312cd-9503-41ff-84f4-120a996fb54b">Segment Information and Significant Customers: Lexicon operates in one business segment, which primarily focuses on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#x2019;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzMyMzM_2c0cec60-24f9-448b-a3ee-454ca025e477"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <lxrx:EntityWideRevenueSanofiPercentage
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzM3ODM_426f828d-9911-4685-b3a7-69b2d3f33636"
      unitRef="number">0.89</lxrx:EntityWideRevenueSanofiPercentage>
    <lxrx:EntityWideRevenueSanofiPercentage
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzM5Njg_fc563be8-0014-40b6-a718-226bb599b8b9"
      unitRef="number">0.53</lxrx:EntityWideRevenueSanofiPercentage>
    <lxrx:LXRXBiologicscustomerconcentration
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU4NTQ_a356f408-4fb4-48fc-8707-22f27334cfd5"
      unitRef="number">0.25</lxrx:LXRXBiologicscustomerconcentration>
    <lxrx:LXRXDiplomatcustomerconcentration
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU4NjE_aa1a4754-2fb9-4337-b45f-316d7fea8c58"
      unitRef="number">0.14</lxrx:LXRXDiplomatcustomerconcentration>
    <lxrx:EntityWideRevenueSanofiPercentage
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzQwMzI_76592578-ebb0-4ede-a0d6-1dde72d12498"
      unitRef="number">0.65</lxrx:EntityWideRevenueSanofiPercentage>
    <lxrx:EntityWideRevenueIpsenPercentage
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NTU5Mzk_1b133355-65ca-4e8d-8c45-180696b6d0a6"
      unitRef="number">0.18</lxrx:EntityWideRevenueIpsenPercentage>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODgz_c8a9e7df-83e9-4ef6-8da8-7aca7bd5bb01">Intangible Assets:  Intangible assets, net consist of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <lxrx:XERMELOIntangibleAssetsFiniteLived
      contextRef="i0e9da8ecf2c54fbe8f306aa71dd97256_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzQ0MjM_a8903fd0-afc2-4b77-92b4-6800b061859f"
      unitRef="usd">24700000</lxrx:XERMELOIntangibleAssetsFiniteLived>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTE2_1a858cbb-f82a-4508-87b9-42250c66a6a8">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimated future amortization expense for intangible assets as of December&#160;31, 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.836%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.472%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.528%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ending&lt;br/&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzItMS0xLTEtMA_f6a2ed4a-e05f-4f21-8a0e-e64ccf506bf8"
      unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzMtMS0xLTEtMA_a684e233-2b29-4d45-8e59-333d20505b02"
      unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzQtMS0xLTEtMA_f44e1787-d274-466a-ae7b-b549a296f057"
      unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzUtMS0xLTEtMA_04ee992b-611d-4dfb-ada3-2c0ada416141"
      unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzYtMS0xLTEtMA_bb3b2877-fdc5-4a35-bb66-076159815875"
      unitRef="usd">1766000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzctMS0xLTEtMA_7f825e68-26da-4afa-9875-fdd07efd0c2c"
      unitRef="usd">10886000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZToxNDc0YzIzYmExNjA0MTQzYjM3Y2ZmN2NjNzI3Njk3OC90YWJsZXJhbmdlOjE0NzRjMjNiYTE2MDQxNDNiMzdjZmY3Y2M3Mjc2OTc4XzgtMS0xLTEtMA_8196d718-fc8e-4f01-8d25-0759bf9ea78c"
      unitRef="usd">19716000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODg1_5693529c-b953-4aa9-8af4-2659d9b11641">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Property and Equipment:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Property and equipment that is held and used is carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTI_f6c62078-d254-4c54-a37d-9d4c2c58808b"&gt;three&lt;/span&gt; to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzUwNTg_40aaa522-acdc-49dc-92e5-0c17126b9713">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzODc2_6b616497-b372-4233-93da-fb9f2ab16377">Impairment of Long-Lived Assets:&#160;&#160;Long-lived assets, right-of-use assets for leases and finite-lived intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzYwNDA_be2ddde1-1488-411d-aaa4-87e8b35d1a33"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTkx_96ae33e4-c0be-4d31-920d-2342c4c397fa">Indefinite-lived intangible assets are also tested annually for impairment and whenever indicators of impairment are present.  When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its intangible assets.  If management believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of the intangible assets is less than its carrying amount, the Company calculates the asset&#x2019;s fair value.  If the carrying value of the asset exceeds its fair value, then the intangible asset is written down to its fair value.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIxOTkwMjMyOTY2NDY_0b586ba8-6d4a-4bf3-9b28-abf1f8a9fd5b"
      unitRef="usd">28600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQ2_3148372b-434b-4c6d-bd93-f79be0db9c0c">Goodwill Impairment:&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzc3NTk_35f6a524-8ac5-44e9-a9c4-3011818b0e01"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQy_27061921-0294-4909-a027-bbc5485b5cbc">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen.  Product revenues are recognized when the customer obtains control of the Company&#x2019;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the United States, as discussed below.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns. Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs are included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Customer Credits:  The Company&#x2019;s customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts.  The Company expects that its customers will earn prompt payment discounts.  As a result, the Company deducts the full amount of those discounts from total product sales when revenues are recognized.  Service fees are also deducted from product sales as they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rebates:  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program.  Rebate amounts are based upon contractual agreements or legal requirements with public sector (e.g., Medicaid) benefit providers.  Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers.  The allowance for rebates is based on statutory discount rates and expected utilization.  The Company&#x2019;s estimates for expected utilization of rebates are based on third party market research data and data received from the specialty pharmacies.  Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known unpaid rebates from the prior quarter.  If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Chargebacks:  Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor, who acts as a retailer.  Contracted customers, which currently consist primarily of Public Health Service Institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price.  The specialty pharmacy or distributor, in turn, charges back to Lexicon the difference between the price paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer.  The allowance for chargeback is based on known sales to contracted customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare Part D Coverage Gap:  The Medicare Part D prescription drug benefit mandates manufacturers to fund a portion of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients.  The Company&#x2019;s estimates for the expected Medicare Part D coverage gap are based on data received from the specialty pharmacies and projections based on historical data.  Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters.  If actual future funding varies from estimates, the Company may need to adjust prior period accruals, which would affect revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Co-payment assistance:  Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance.  The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTYy_a649f10c-a2c9-4797-a9c7-2f7f82ffde3b">Cost of Sales:  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The Company began capitalizing inventory during 2017 once the FDA approved XERMELO as the related costs were expected to be recoverable through the commercialization of the product.  Costs incurred prior to approval of XERMELO have been recorded as research and development expense in the consolidated statements of comprehensive income (loss).  As a result, cost of sales for approximately the next twelve months will reflect a lower average per unit cost of materials.  Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</us-gaap:CostOfSalesPolicyTextBlock>
    <lxrx:CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE2MzA3_e7a220c1-a06b-4b74-b6bd-47f2d5805e17">P12M</lxrx:CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id200f3fdbfab4a1d8d40cdc784c65d06_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE2NjE3_16c1c44e-7fdc-42c4-8435-389f53394821">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQ3_8e2dc647-7faf-4faa-b8f4-c2a738a2f1ac">Research and Development Expenses: Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company's estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease was based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that will conduct and manage the clinical studies on its behalf. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTcz_64356422-6efb-409c-b529-e82b746370a2">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive income (loss) for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of December&#160;31, 2019, stock-based compensation cost for all outstanding unvested options and restricted stock units was $24.0 million, which is expected to be recognized over a weighted-average period of 1.1&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE4ODgz_72afcd1b-2df1-443e-b4d8-8ef7db27829b"
      unitRef="usd">24000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzE4OTU2_179c9abe-101a-4dfd-9afa-9dd652dcfb1b">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTUw_f836b363-66b1-4206-8a85-cf26138bbebc">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.8%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2017:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItMS0xLTEtMA_ac707baa-7973-4164-9bbc-bfd90023fc1a"
      unitRef="number">0.88</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItMy0xLTEtMA_420d7836-d0fa-40a2-ace7-251a10d5a1f6"
      unitRef="number">0.022</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItNS0xLTEtMA_bbb35456-9df6-48f6-8b08-15ba340017c2">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzItNy0xLTEtMA_61bc59de-d22a-4c6f-b515-3643aa7e884c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtMS0xLTEtMA_1db9fe27-d225-410d-9b89-307853197dcb"
      unitRef="number">0.77</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtMy0xLTEtMA_c65ac751-7ff4-4636-bc22-91f113705bb8"
      unitRef="number">0.026</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtNS0xLTEtMA_85c061f1-d80c-4852-bf45-054b7bd140d5">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i342ae8c917454379af0d7a4110f8fa9e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzMtNy0xLTEtMA_3d03f1df-5419-4fc1-a189-200de7a1d41c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtMS0xLTEtMA_8d4df040-116b-4dec-b9e5-af4418ede1b6"
      unitRef="number">0.58</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtMy0xLTEtMA_e38e398e-3d71-4b40-bbc6-e9f98731321d"
      unitRef="number">0.026</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtNS0xLTEtMA_982b4374-1e58-454e-9e57-73e35a7c1efd">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzUtNy0xLTEtMA_00867f44-e177-43ba-81c3-be78ab268cf4"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtMS0xLTEtMA_4f64af9d-0f88-4078-8dea-4f63feb8026a"
      unitRef="number">0.63</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtMy0xLTEtMA_57a374fd-cea6-4d04-bd95-4d068844bc31"
      unitRef="number">0.028</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtNS0xLTEtMA_add89eb9-dccc-40eb-93c6-efd0fd3351a7">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i071ee1a4c02244e886416de15f7375a9_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzYtNy0xLTEtMA_67934225-72f5-4353-80fa-4999011aa7a1"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtMS0xLTEtMA_f8c61866-9393-4103-81e1-0cecbb91db72"
      unitRef="number">0.61</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtMy0xLTEtMA_99f61c86-beae-4064-a854-1efc74295dc6"
      unitRef="number">0.017</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtNS0xLTEtMA_963a44b9-e84b-48b0-b20e-460a812a3b28">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzgtNy0xLTEtMA_01b62e79-09fb-460b-8c18-ab7826404025"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktMS0xLTEtMA_fdcdd044-4220-4213-8232-bd301ce15fe3"
      unitRef="number">0.70</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktMy0xLTEtMA_2b99b92e-bbbd-4c77-b493-891c333f91c3"
      unitRef="number">0.022</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktNS0xLTEtMA_26ac7d53-c1c0-476d-a28f-10510c06bf60">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i1d9882a8ddfc4055b506f21ea7af230d_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90YWJsZTowNzMyMTg1OTllYWE0Y2U2YTRkODM2MDM0NTNkZDJlNS90YWJsZXJhbmdlOjA3MzIxODU5OWVhYTRjZTZhNGQ4MzYwMzQ1M2RkMmU1XzktNy0xLTEtMA_fbf80fee-91fd-4dca-8a1b-7d521d5dbdbe"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NzgxNzY_0347b4f4-8290-44f5-80aa-c7efed01e5e7">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;"&gt;Income Taxes:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt; The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. The Company uses the liability method in accounting for income taxes. Under this method,  deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;"&gt;The Company maintains a valuation allowance on net operating losses and other deferred tax assets. Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards and income tax credit carryforwards that are available for utilization in future periods. On a periodic basis, the valuation allowance is reassessed on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. In 2019, the Company reassessed the valuation allowance and considered negative evidence, including the cumulative losses over the three years ended December 31, 2019, and positive evidence, including the income during the year ended December 31, 2019 and projections of future income. After assessing both the negative evidence and the positive evidence, the Company concluded that it should continue to maintain the valuation allowance on net operating losses and other deferred tax assets as of December 31, 2019 given the significance of the weight of the negative evidence. Based on recent financial performance and future projections, the Company could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods. However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The total deferred tax asset balance subject to the valuation allowance was approximately $333.6&#160;million at December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Significant judgment is required in making these assessments to maintain or reverse valuation allowances and, to the extent future expectations change the Company would have to assess the recoverability of these deferred tax assets at that time. &lt;/span&gt;&lt;/div&gt;The Tax Cuts and Jobs Act (the &#x201c;2017 Tax Act&#x201d;) was enacted on December 22, 2017.  The 2017 Tax Act significantly changes U.S. corporate income tax laws, including a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent, reduction of certain tax credits, limitations on, or deductibility of interest expense and executive compensation, and limitations on the use of net operating loss carryforwards.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzEwOTk1MTE2NzgxNzE_e828dc25-78b6-4642-b0df-0f5b782c88bf"
      unitRef="usd">333600000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNTQvZnJhZzo3ZDdjNWUwZWRkZGY0NzMzYjcwZmY0ZGU2OTMzYWY4MC90ZXh0cmVnaW9uOjdkN2M1ZTBlZGRkZjQ3MzNiNzBmZjRkZTY5MzNhZjgwXzIzOTQz_82b5d085-85e1-44dc-ad57-25e9e94a8249">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Net Income (Loss) per Common Share:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units that could potentially dilute earnings per share in the future are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjAvZnJhZzo2MDMwMjRkZjczYWQ0OGFjODA0MGU0ZjhhMzcxMzY4ZC90ZXh0cmVnaW9uOjYwMzAyNGRmNzNhZDQ4YWM4MDQwZTRmOGEzNzEzNjhkXzY4Mzk_af0b684e-583c-4684-80fb-fa606613fc25">Recent Accounting Pronouncements&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the  Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement was effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. This ASU was required to be adopted using a modified retrospective approach.  Management adopted ASU 2016-02 on the effective date of January 1, 2019 and elected the practical expedient that allows entities to not apply the new guidance in the comparative periods they present in their financial statements in the year of adoption.  Consequently, prior year financial information has not been updated and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019.  Upon adoption, the Company recognized $2.1 million for right-of-use assets and corresponding liabilities on the consolidated balance sheet, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;primarily related to leases of office space.  The adoption of this ASU on January 1, 2019 did not have a material impact on Lexicon&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pronouncements Not Yet Adopted.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  In November 2018, the FASB issued ASU No. 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606".  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirements, and does not expect adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Intangibles-Goodwill and Other,&#x201d; which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iead7811281254bcbb2692b1ba9a8a25b_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjAvZnJhZzo2MDMwMjRkZjczYWQ0OGFjODA0MGU0ZjhhMzcxMzY4ZC90ZXh0cmVnaW9uOjYwMzAyNGRmNzNhZDQ4YWM4MDQwZTRmOGEzNzEzNjhkXzUzNzA_2ec58214-f9b2-47ef-9d79-c36026c1c94e"
      unitRef="usd">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzM0Nw_5311a8c2-a9c6-4065-a0c6-7ad8882b01ca">Cash and Cash Equivalents and Investments&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of cash and cash equivalents and investments held at December&#160;31, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.981%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.431%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There were no realized gains or losses for the years ended December&#160;31, 2019 and 2018.</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzM0Mw_48fa1a1a-641f-4fe6-8063-52fbb6c9090b">&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.827%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.981%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.425%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.571%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.431%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtMS0xLTEtMA_3742e855-5a6a-4a69-8652-3c54ab24466f"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtMy0xLTEtMA_bac7fd4a-554f-4047-be83-f855dfcb592a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtNS0xLTEtMA_9f6ef387-141c-4db1-9506-631e98681129"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i013dec9bd58e42ae9c6a8408e8dd7601_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzMtNy0xLTEtMA_07e2e40d-0318-43fa-bdb3-c2da4e28b1bc"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtMS0xLTEtMA_c0267828-faea-4197-afbc-9db837a12ce6"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtMy0xLTEtMA_da56f28e-d91a-4269-99ac-7f03012c87fc"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtNS0xLTEtMA_c2685689-420a-4bb1-bd80-3fc5acb44bb0"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i4c449fb5ca67473f98ac63f3ac55af83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzUtNy0xLTEtMA_39ceefa7-781e-42b0-8003-a3270c2bb7fa"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctMS0xLTEtMA_31c311a8-cd81-4713-9d31-110367224f90"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctMy0xLTEtMA_5764aaa3-1a49-41c4-8004-89ec4c1eb878"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctNS0xLTEtMA_15eb84ac-54a6-4b80-95ff-fe5267b9789b"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie3eec56c8d824574affec4d66d71660d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzctNy0xLTEtMA_8ec48b83-4492-4087-9847-3f502cc49570"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtMS0xLTEtMA_71851602-0f43-4df1-a552-5792167bedc6"
      unitRef="usd">271575000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtMy0xLTEtMA_bac1420c-45d2-4f7d-9edd-219236cd3803"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtNS0xLTEtMA_bbb25108-5317-4e46-a7dd-6b65c15e116f"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i9f0a69895e164f97977732e2bfd75452_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTpiNTBmOGNlZTI5YTM0NWU1OTc5YWYxMDhiODE5YzQzZS90YWJsZXJhbmdlOmI1MGY4Y2VlMjlhMzQ1ZTU5NzlhZjEwOGI4MTljNDNlXzgtNy0xLTEtMA_51673b25-ae4a-49e4-9275-b7a57c420881"
      unitRef="usd">271659000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtMS0xLTEtMA_ea75cf48-e2d2-4b25-9b72-d77e023b11d6"
      unitRef="usd">80386000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtMy0xLTEtMA_8eab78b2-b634-4e14-8a9c-11169024a6b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtNS0xLTEtMA_b6edfbeb-9885-484d-94ba-80bfcf80670e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i0fe9e860df2f49179681c5585ac22f36_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzMtNy0xLTEtMA_e0e1f457-de13-4eca-9668-3f501656adbe"
      unitRef="usd">80386000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtMS0xLTEtMA_73d52683-9a32-4458-9031-15bf28832ba6"
      unitRef="usd">73983000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtMy0xLTEtMA_b406a222-f7a8-4c36-bbda-6d65cb53bf7d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtNS0xLTEtMA_7db1f0d4-490e-4106-b0a0-4ea739b98c38"
      unitRef="usd">9000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i316f73cb06a346f38a3dc3eaf9d871b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzUtNy0xLTEtMA_256d713a-42e2-49c9-a399-ce8be702d4f6"
      unitRef="usd">73974000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtMS0xLTEtMA_60d49e5d-dbe2-4c26-8482-ee5db059e198"
      unitRef="usd">5695000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtMy0xLTEtMA_03ce8993-f8a0-4774-911f-4a76efabbf45"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtNS0xLTEtMA_f24e1da7-449f-4a4e-b79f-97003206e974"
      unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="if54c610d056a4769931c5fb35bdfbf57_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzYtNy0xLTEtMA_b4f5d8ca-1029-4338-9c1e-a47cf86fe395"
      unitRef="usd">5692000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctMS0xLTEtMA_eb7aca64-91e0-476b-98c7-a4e41aa21723"
      unitRef="usd">79678000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctMy0xLTEtMA_9a547088-a03c-44d4-932f-4419503e0c8d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctNS0xLTEtMA_617f813d-6ac2-4b35-a552-df3da4d44850"
      unitRef="usd">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i52761b423ed94c999cfcf4ff49cffcae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzctNy0xLTEtMA_452df47c-9b1f-410f-aeae-2d068695f752"
      unitRef="usd">79666000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtMS0xLTEtMA_df566745-05c6-4f18-a4d7-c8a41319df75"
      unitRef="usd">160064000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtMy0xLTEtMA_4fbb73a2-aa2e-4a52-ad08-29e1f72dfc24"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtNS0xLTEtMA_a783f020-c802-430c-883b-7223de8947d0"
      unitRef="usd">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="if42edf1b0c174407b6dc7acf67878cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90YWJsZTowNzFkY2RiZTM1Nzk0NmE4YTRjYWJiNmYxM2FkY2M2ZS90YWJsZXJhbmdlOjA3MWRjZGJlMzU3OTQ2YThhNGNhYmI2ZjEzYWRjYzZlXzgtNy0xLTEtMA_5bf3c6a2-71e5-4342-bdd7-bcb1b977c4dd"
      unitRef="usd">160052000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjYvZnJhZzo3Mzc1NjNmZTc0YzA0MmNmYmMzYjlmOTZjMWI5NGVjNi90ZXh0cmVnaW9uOjczNzU2M2ZlNzRjMDQyY2ZiYzNiOWY5NmMxYjk0ZWM2XzE2NA_d6384062-fb12-4494-adae-6afe6684fb5e"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90ZXh0cmVnaW9uOjgxYjVmMmMzOTNiMzQwOGJhZDQ0ZDEzZTBkMGQxZDM2XzI5MTk_4705b11f-94fa-46bf-a611-54e46b46495c">Fair Value Measurements&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; quoted prices in active markets for identical assets, which include U.S. treasury securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not have any Level 3 assets or liabilities at December&#160;31, 2019 or 2018. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010 and intangible assets associated with the acquisition of Symphony Icon in 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90ZXh0cmVnaW9uOjgxYjVmMmMzOTNiMzQwOGJhZDQ0ZDEzZTBkMGQxZDM2XzI5MTA_8cd77480-06e3-4e0f-98c0-bbc68f20bbec">&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtMS0xLTEtMA_837a609a-9358-446b-b4f7-03a97a38e57c"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtMy0xLTEtMA_228a6e1c-ed99-41b0-8765-ede31a3123b5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtNS0xLTEtMA_fb1481d6-9e4e-4707-80ee-631931b0d8b7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzUtNy0xLTEtMA_9c5b58fe-98f6-4648-b2e1-9ac854a2012b"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtMS0xLTEtMA_490eab61-b4d9-46eb-be85-bcb6d8fd6aef"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtMy0xLTEtMA_5277c868-ca47-4895-8ba1-85b95406a3a3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtNS0xLTEtMA_48b228b5-4be6-469a-8b95-1daad5f7cc47"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzYtNy0xLTEtMA_6c635b45-8559-416d-a367-efa3a782c304"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i163a07b670c94a9bbcce4a4f50d7bd26_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctMS0xLTEtMA_a61be7bc-3e71-4533-9c03-28ec77cf8ece"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iafa3a2a02ed444c58bd99b8c7d318975_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctMy0xLTEtMA_bc889476-8af5-4c9e-9b09-3b2cfbcd15e0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia2ec419047d94a2ba32418d003ec5498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctNS0xLTEtMA_a4bd03d1-e261-4c20-84c4-d638172b5872"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTpkNDgyMzdkZDcyYjY0Njk5YjY1N2JlY2FjMGQ2YWIzYy90YWJsZXJhbmdlOmQ0ODIzN2RkNzJiNjQ2OTliNjU3YmVjYWMwZDZhYjNjXzctNy0xLTEtMA_433c0568-0e4e-4ae4-b756-053bbe8260e1"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtMS0xLTEtMA_ea4748bd-d30a-4b55-a27b-70e7023cec32"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtMy0xLTEtMA_1d910fc5-5b04-4218-8054-c151c197be52"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91d5f1656d844951addb1fa04625751d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtNS0xLTEtMA_80bf5a6b-7b92-4740-92a7-5a8674133e8e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzUtNy0xLTEtMA_a4dfe099-8f4a-4167-b7eb-f9de5bd0f422"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtMS0xLTEtMA_534d8721-d568-4cfc-b20a-8fa24a615a5d"
      unitRef="usd">73974000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtMy0xLTEtMA_29e81a70-67de-4e20-b535-48b996cc4a67"
      unitRef="usd">5692000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i91d5f1656d844951addb1fa04625751d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtNS0xLTEtMA_cf39365b-3070-46d1-8af5-1c60d54960b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzYtNy0xLTEtMA_571f986c-01db-4992-bb4e-c922d6726a73"
      unitRef="usd">79666000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2edf8da90db84523a6fc9be2eb374ea8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctMS0xLTEtMA_7198b166-f935-4b2d-aaae-3802cc9af0b4"
      unitRef="usd">154360000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idd0883ce436140d4aedbccded39fec5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctMy0xLTEtMA_4d8d1208-a3e7-4808-b243-6c96d360c057"
      unitRef="usd">5692000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i91d5f1656d844951addb1fa04625751d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctNS0xLTEtMA_62b6c0e2-2abe-471a-88fc-e419e255d016"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNjkvZnJhZzo4MWI1ZjJjMzkzYjM0MDhiYWQ0NGQxM2UwZDBkMWQzNi90YWJsZTo4ZTgzNjhiNDA2Njc0MmYxYmMwMzZhYmYzMzFmYzkwNC90YWJsZXJhbmdlOjhlODM2OGI0MDY2NzQyZjFiYzAzNmFiZjMzMWZjOTA0XzctNy0xLTEtMA_314e81b6-6b75-4b50-bd4a-192be01f989b"
      unitRef="usd">160052000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90ZXh0cmVnaW9uOmZiMjYzYzk3ZWE5MDRlMjNiZDI5NDhjM2RjNDhlOGExXzEwMA_0f3801e3-1ad0-486e-b96e-55c1814f079a">Property and Equipment&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment at December&#160;31, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.331%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:3.278%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.372%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:3.278%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15-40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90ZXh0cmVnaW9uOmZiMjYzYzk3ZWE5MDRlMjNiZDI5NDhjM2RjNDhlOGExXzg4_61ba7044-e2a5-4d86-8d18-6d3680bf9acf">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.331%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:3.278%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.372%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:3.278%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3-7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15-40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(61,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(60,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i94d65b504af44fc3a8e21bcd23052cfd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzMtNS0xLTEtMA_5ceb1c7e-d5a5-4fd8-a6ae-99214008c45e"
      unitRef="usd">4587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i326024d73cea4d15aa9ac4c2c5c24f6a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzMtNy0xLTEtMA_12f7540c-ca87-47d9-b0ee-f7b961796286"
      unitRef="usd">4557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c3e10389e3543398ede188dc42287b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzQtNS0xLTEtMA_242803b3-e2b5-4039-9139-ac5fb5f0845a"
      unitRef="usd">5629000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1a3b8f069656465fb49124367dada928_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzQtNy0xLTEtMA_c9686df1-dfe2-44d8-bd23-7563197b3801"
      unitRef="usd">5644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i490ae890935942b1b6b3556c3099574e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzUtNS0xLTEtMA_ebb5ddbe-f6ac-4f81-b5ee-a23e1b5c5745"
      unitRef="usd">3279000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib4b49290934c41a6aad3724b4c80bbd6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzUtNy0xLTEtMA_1f139a74-13d2-4e32-9d16-20307d8e2d62"
      unitRef="usd">3378000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15b062ad588146aca58efd416bfc6a9b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzYtNS0xLTEtMA_c308ecca-d287-4ed3-bfae-3b67a4811366"
      unitRef="usd">417000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2bcb52391538408c8580e9d00fbeb629_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzYtNy0xLTEtMA_ef9706a1-5def-42ca-9319-f09ee456277d"
      unitRef="usd">416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1340081d4b804484b5d1dca5c73bf782_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzctNS0xLTEtMA_3a6b3182-eabc-43ed-b883-b34117acaabe"
      unitRef="usd">59212000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if9476eb367804eba9e26e39f94e0c1d3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzctNy0xLTEtMA_0f3b0c51-e596-4991-a925-ab62206a85ae"
      unitRef="usd">59212000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i428262586cfe46008e720b64332fe571_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzgtNS0xLTEtMA_05eab823-63e9-4f9b-ad2b-79466af185a4"
      unitRef="usd">2664000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1c95eef01a704b3a945e493cf9b53436_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzgtNy0xLTEtMA_f367eb09-763d-4e4a-a020-489f0581ba4b"
      unitRef="usd">2664000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzktNS0xLTEtMA_0f21a987-f567-446d-b267-190ed907356b"
      unitRef="usd">75788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzktNy0xLTEtMA_1f78d0de-5fe5-4d0d-80a7-bd1ac8a14e55"
      unitRef="usd">75871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzEwLTUtMS0xLTA_8714c9d9-f014-4d12-b222-3c28c217a7ae"
      unitRef="usd">61741000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzEwLTctMS0xLTA_a597925f-1887-40f7-8705-bbd7d5596844"
      unitRef="usd">60006000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzExLTUtMS0xLTA_00355a84-5c7b-41fc-a52d-18557a7c016e"
      unitRef="usd">14047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzIvZnJhZzpmYjI2M2M5N2VhOTA0ZTIzYmQyOTQ4YzNkYzQ4ZThhMS90YWJsZTpjOTI1MGU0NWJhMzk0NTVkYjU4MGZmN2FlN2VlN2UzYy90YWJsZXJhbmdlOmM5MjUwZTQ1YmEzOTQ1NWRiNTgwZmY3YWU3ZWU3ZTNjXzExLTctMS0xLTA_1fa2ff42-e8b3-4d2b-8339-4a3a0fce6385"
      unitRef="usd">15865000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4NzM_b8048332-9b24-4a5a-bed2-b0762f884a15">Income Taxes &lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of Lexicon&#x2019;s deferred tax assets (liabilities) at December&#160;31, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(329,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(364,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred tax assets associated with net operating losses (NOLs), deferred revenue and interest decreased in 2019 due to the Termination Agreement (as defined in Note 13) with Sanofi.  Refer to Note 13, Collaboration and License Agreements, for additional information.  The $4.1&#160;million deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.783%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.021%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.839%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:2.682%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.537%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:2.682%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.239%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected income tax expense (benefit) at 21%, 21% and 35%, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(978)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Symphony Icon fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Other &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Other is primarily comprised of expiring Research and Development credits for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At December&#160;31, 2019, Lexicon had both federal and state NOL carryforwards of approximately $879.7 million and $83.0 million, respectively.&#160;&#160;In 2019, federal NOLs decreased by $62.2&#160;million primarily due to utilization against taxable income.  The state NOL carryforwards decreased due to a legislative change from pre-apportionment to post-apportionment reporting in New Jersey.  The federal and state NOL carryforwards will begin to expire in 2022.&#160;&#160;The Company&#x2019;s R&amp;amp;D tax credit carryforwards of approximately $46.3&#160;million begin to expire in 2020.  The orphan drug credit relates to a credit that is calculated as a percentage of expenditures for development of XERMELO, which has received Orphan Drug designation from the FDA.&#160;&#160;Utilization of the NOL, R&amp;amp;D credit and orphan drug credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Although NOLs were utilized in 2019, based on the federal tax law limits and the Company's cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended December&#160;31, 2019, the valuation allowance decreased $35.3 million, primarily due to the Company&#x2019;s utilization of NOLs and decreases to deferred revenue and interest deferred tax assets.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Lexicon recorded an income tax benefit of $6.0&#160;million in the year ended December&#160;31, 2019 despite reporting pretax income for the year. The result reflects the impact of the impairment of intangible assets associated with Symphony Icon and the benefit from the utilization of federal NOLs for which a tax benefit had not previously been recognized, partially offset by nondeductible expenses.  There were no income tax benefits in the year ended December&#160;31, 2018.  Income tax benefits of $12.7&#160;million were recorded for the year ended December&#160;31, 2017.  Of the $12.7&#160;million tax benefits, $8.7&#160;million is the release of a valuation allowance as a result of the ability to estimate the reversal of the deferred tax liability related to the intangible associated with XERMELO and $4.0&#160;million was recorded to remeasure the deferred tax liability associated with the remaining indefinite-lived intangible asset associated with Symphony Icon at the newly enacted U.S. corporate income tax rate.  As of December&#160;31, 2019 and 2018, the Company did not have any unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax &lt;/span&gt;&lt;/div&gt;expense.&#160;&#160;As of December&#160;31, 2019 and 2018, the Company had no accruals for interest or penalties related to income tax matters.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4ODI_16b97296-1cd0-4749-9e29-d9a57eaef825">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;58,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;369,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(329,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(364,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzQtMS0xLTEtMA_a120e494-a4ff-453c-b706-ce19027d98ba"
      unitRef="usd">193270000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzQtMy0xLTEtMA_d571458d-82d6-4941-a355-b98ed1fcb00c"
      unitRef="usd">206789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzUtMS0xLTEtMA_9341e6d2-dc53-42e4-9cb3-f55e44b7dbc0"
      unitRef="usd">46306000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzUtMy0xLTEtMA_30c8a3c6-b761-41e4-bde2-007927ddb189"
      unitRef="usd">47087000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzYtMS0xLTEtMA_80b5c03e-4257-4228-bfec-8a59077fa986"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzYtMy0xLTEtMA_40e48420-6993-4f6c-b3e1-d5a5fb1bf568"
      unitRef="usd">24524000</lxrx:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzctMS0xLTEtMA_e45ba0e0-d9f1-42c0-b541-e09af6b1c8e1"
      unitRef="usd">58596000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzctMy0xLTEtMA_65d73c8d-75d4-491d-82a0-0fd86b72de6a"
      unitRef="usd">71047000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzgtMS0xLTEtMA_6346e0de-5ce1-44e1-a8be-44e10d27478c"
      unitRef="usd">5340000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzgtMy0xLTEtMA_cba5eafb-a728-4617-966d-a0434055b8c5"
      unitRef="usd">4641000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzktMS0xLTEtMA_2e150d50-0cbf-42e6-a0ff-cd307aa656d0"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzktMy0xLTEtMA_08357ad1-a67f-42ef-ba50-b657b1e7b5c7"
      unitRef="usd">5458000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <lxrx:DeferredTaxAssetsSection163j_LXRX
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEwLTMtMS0xLTA_20f30b96-8509-4193-8db1-8596ea72c9c6"
      unitRef="usd">3625000</lxrx:DeferredTaxAssetsSection163j_LXRX>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzExLTEtMS0xLTA_17686f2e-8db6-44ae-b339-b7d2111af358"
      unitRef="usd">5533000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzExLTMtMS0xLTA_e5cc619b-aed2-41ea-89bb-dc17c087fe8b"
      unitRef="usd">6044000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEyLTEtMS0xLTA_7299d423-595b-4cc1-97bb-a794d2eb371a"
      unitRef="usd">333569000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzEyLTMtMS0xLTA_7e49bdfb-2840-48aa-9a49-a28f95761fd9"
      unitRef="usd">369215000</us-gaap:DeferredTaxAssetsGross>
    <lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE0LTEtMS0xLTA_b4bd2e48-2219-416f-8d7d-ab531c418d3d"
      unitRef="usd">4140000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
    <lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE0LTMtMS0xLTA_796ee3b6-adeb-4a98-94c6-85d1ed865e8b"
      unitRef="usd">10525000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE1LTEtMS0xLTA_9c31baa1-0048-49e2-b27d-640e527fd988"
      unitRef="usd">3000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE1LTMtMS0xLTA_16b8122f-aee7-4777-acaf-72f54c53bf8c"
      unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE2LTEtMS0xLTA_9e5e4d71-7cf3-4648-9eb2-7cdfacadde5d"
      unitRef="usd">4143000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE2LTMtMS0xLTA_71d4f81f-f736-4b30-8a18-8778787940f8"
      unitRef="usd">10527000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE3LTEtMS0xLTA_33d4f072-9399-4bba-9064-ed3c3eccedbb"
      unitRef="usd">329426000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE3LTMtMS0xLTA_3763377c-e7de-47a8-8591-3f646e02161a"
      unitRef="usd">364702000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE4LTEtMS0xLTA_3a190b86-4c12-4cdf-92fb-3bff6e612fb1"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if05c5deaf74d41e7aa9d53b249dbcc42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTo4ZWM1MWQ3ZTJmNWY0Mzg3YThmMzQ4YjFhNzc4MjNhMy90YWJsZXJhbmdlOjhlYzUxZDdlMmY1ZjQzODdhOGYzNDhiMWE3NzgyM2EzXzE4LTMtMS0xLTA_da0d29a7-eed1-4d50-bea3-f7a0f96a5aa0"
      unitRef="usd">6014000</us-gaap:DeferredTaxLiabilities>
    <lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEyMDk0NjI3OTEwODkx_ee02e742-6481-4beb-a87c-b874842a05e5"
      unitRef="usd">4100000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEzNzQzODk1MzU4MjM5_cab194eb-d0e1-4498-bcd0-5781da47e792">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of the statutory tax rate to the effective tax rate for the years ended December&#160;31, 2019, 2018 and 2017 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.783%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.021%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.839%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:2.682%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.537%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:2.682%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.239%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected income tax expense (benefit) at 21%, 21% and 35%, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(978)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Orphan drug credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Symphony Icon fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Other &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjc4_bf4a7fd6-8cb4-4567-8a8a-c825344ac4db"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjgz_28e93f05-c1d4-4d56-b8b7-26d153af5f7a"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMC0xLTEtNzgzOC90ZXh0cmVnaW9uOmY1Y2YxZmNiZDQ1ZjRlYTc5YTFmZGQxNmY0NDVmMGExXzEzNzQzODk1MzQ3Mjg4_f408a711-e792-4bdc-b525-fedd217a6613"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMS0xLTEtNzc5OA_629e4a46-3a55-4a85-8542-5f48468be604"
      unitRef="usd">26065000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtMy0xLTEtNzgwMQ_49fb2373-27f8-42c0-80f0-60913c227499"
      unitRef="usd">-25315000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzMtNS0xLTEtNzgwNA_ae09b129-5ae7-4d75-a866-8c643316d619"
      unitRef="usd">-47479000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtMS0xLTEtNzc5OA_bbef9b31-58cb-454b-8aaa-080edaf05e69"
      unitRef="usd">445000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtMy0xLTEtNzgwMQ_d6194c75-325b-4b27-9cf2-895d7d5c92a2"
      unitRef="usd">-809000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzQtNS0xLTEtNzgwNA_b78c1a96-ab54-40b9-b24d-d1d388fc9795"
      unitRef="usd">-2324000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtMS0xLTEtNzc5OA_4bbf4088-ab79-4209-acb0-0e235cbf950e"
      unitRef="usd">1688000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtMy0xLTEtNzgwMQ_6204c559-e8a6-44a2-b2eb-1410472a1ec4"
      unitRef="usd">1059000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzUtNS0xLTEtNzgwNA_816ef7b3-7683-448b-a9da-2fec6df9e089"
      unitRef="usd">1447000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtMS0xLTEtNzc5OA_184b7bcf-5ba4-47bb-b982-fda83bb72a84"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtMy0xLTEtNzgwMQ_4716ac83-cfb1-48fe-bc6b-5746f9dd99e3"
      unitRef="usd">-978000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzYtNS0xLTEtNzgwNA_4ee1e218-52f4-46c3-a065-5e24d0ba4929"
      unitRef="usd">-1993000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctMS0xLTEtNzc5OA_cd25728b-2c5d-4071-9821-b8581f3c6cfa"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctMy0xLTEtNzgwMQ_00613283-8177-463a-a4eb-b02f92737887"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzctNS0xLTEtNzgwNA_819e092a-6004-4181-bbfb-c83ab6642e32"
      unitRef="usd">-189000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtMS0xLTEtNzc5OA_ed2ad472-cf21-4311-91ae-cbc025d8f624"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtMy0xLTEtNzgwMQ_933acafd-2387-47bc-967c-fabd72b52fb8"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzgtNS0xLTEtNzgwNA_6da0c8e6-64eb-44ad-9fbb-fc9c4c290d86"
      unitRef="usd">-5316000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktMS0xLTEtNzc5OA_99c78259-1acc-4e05-b3f8-f8a65a4b16c9"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktMy0xLTEtNzgwMQ_d5079e0d-1891-44a7-ac9c-63182879d42d"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzktNS0xLTEtNzgwNA_46c370d9-7a77-47c5-a744-4b01e0131eff"
      unitRef="usd">169464000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTEtMS0xLTc3OTg_05598669-6e04-487b-86f9-cc8d95c70ec5"
      unitRef="usd">0</lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment>
    <lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTMtMS0xLTc4MDE_23cc7fbe-8a68-4917-9115-052bd14c26da"
      unitRef="usd">0</lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment>
    <lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEwLTUtMS0xLTc4MDQ_a43f4ac2-622e-4da6-a298-43ee863a085f"
      unitRef="usd">735000</lxrx:EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTEtMS0xLTc3OTg_6904dcc4-a8fd-40f0-b5de-c424726e8cc1"
      unitRef="usd">-35276000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTMtMS0xLTc4MDE_72e6e3f2-7d2b-43b7-91d8-8bf34cfe45d7"
      unitRef="usd">25928000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzExLTUtMS0xLTc4MDQ_7886b73c-0e9b-490f-9369-268d6c74615d"
      unitRef="usd">-126634000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTEtMS0xLTc3OTg_25f9708a-d4dd-45c2-bcd7-e5837f26ca74"
      unitRef="usd">1064000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTMtMS0xLTc4MDE_4eaed4f1-b755-41e9-ab4c-a52d6ee097f0"
      unitRef="usd">115000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEyLTUtMS0xLTc4MDQ_05335f6f-0ad2-4309-8c10-b0f5398f7429"
      unitRef="usd">-372000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTEtMS0xLTc3OTg_67cf3318-35bd-4281-94f8-f0572445afdf"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTMtMS0xLTc4MDE_b656a60e-b7eb-41d7-b5d4-f5f5af84ab4f"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90YWJsZTpiYzZkZWJkYzgxMDE0YTk2ODM1MGFkNmY5MWMxOWI2OC90YWJsZXJhbmdlOmJjNmRlYmRjODEwMTRhOTY4MzUwYWQ2ZjkxYzE5YjY4XzEzLTUtMS0xLTc4MDQ_05cb5759-8c83-4918-ad40-841ef7256cb7"
      unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI2MzA_b1b4dd8b-ec46-4ee5-9171-6341c36d65bc"
      unitRef="usd">879700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI2Mzc_a7993fe7-413e-4e94-80ee-aadfa9255ae6"
      unitRef="usd">83000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lxrx:FederalNetOperatingLossChange
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzI3NDg3NzkwODAyMDg_a99697c8-50ec-4ea8-950c-fde91fd1714f"
      unitRef="usd">62200000</lxrx:FederalNetOperatingLossChange>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEyMDk0NjI3OTEwODk5_b348d296-137d-4a32-90d2-43a06f9c4c4f"
      unitRef="usd">46300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzM2NDc_47005b17-113f-469a-9a86-a22d9d425758"
      unitRef="usd">35300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2MzUyNTE_8e59543d-ccbe-45ff-9558-af3fa2360b54"
      unitRef="usd">-6000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQyNjE_2693de93-c51d-4a2f-87bf-305c46da42a5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzg0NjA_6f40cdfc-de26-4140-a8d1-4928e42de975"
      unitRef="usd">-12700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0MTA_6f40cdfc-de26-4140-a8d1-4928e42de975"
      unitRef="usd">-12700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset
      contextRef="i518a6981e36c42a6a7263b4a8fad852d_I20170227"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0Mjg_4a32e122-3298-4f18-8db6-4a63b7e2af5a"
      unitRef="usd">8700000</lxrx:DeferredTaxLiabilityfromReclassifiedIntangibleAsset>
    <lxrx:DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible
      contextRef="i2be9572e894e461092c842e6748a2b74_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzEwOTk1MTE2Mzc0NDU_4dade6a1-5b82-4b5f-a286-84a33cf7f182"
      unitRef="usd">4000000.0</lxrx:DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xNzgvZnJhZzpiM2NlNGMzZmUwNzA0ZjY1ODAwM2U3ZGFmODAzNTg5NS90ZXh0cmVnaW9uOmIzY2U0YzNmZTA3MDRmNjU4MDAzZTdkYWY4MDM1ODk1XzQ4MDA_78fe434d-6976-4962-89ba-d2483e3956d6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzEzMzI_3f326d0f-c540-4a70-a2f7-3b5fbf687792">Goodwill&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#x2019;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#x2019;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon, Inc.  Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#x2019;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <lxrx:CoelacanthGoodwill
      contextRef="i8c6df2280ae0495591132f2f5d361b8e_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzQ2NQ_1e216948-ddd5-4c80-accb-07f9002b7f4f"
      unitRef="usd">25800000</lxrx:CoelacanthGoodwill>
    <lxrx:CoelacanthPurchasePrice
      contextRef="i8c6df2280ae0495591132f2f5d361b8e_I20010712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzUwNA_c73df68c-b4b5-4f1d-a3f9-7cc51e013604"
      unitRef="usd">36000000.0</lxrx:CoelacanthPurchasePrice>
    <lxrx:SymphonyIconGoodwill
      contextRef="i9ef4d236906043df99288d5dec2fccfc_I20100730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODQvZnJhZzo1MGM0YTU3ZGRlNDQ0NjZlYTZhNDg2ZDNiYmVmZjEyOS90ZXh0cmVnaW9uOjUwYzRhNTdkZGU0NDQ2NmVhNmE0ODZkM2JiZWZmMTI5XzgxNg_ae46fc06-b818-44b0-98cb-8f483ab2250b"
      unitRef="usd">18700000</lxrx:SymphonyIconGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzcxMDU_987806be-4d80-4dae-b9be-2d83d68c1304">Debt Obligations&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Convertible Notes.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Convertible Notes are governed by an indenture (the &#x201c;Indenture&#x201d;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI1ODY_709f0024-f6ab-4884-930f-af1897447d75"&gt;seven&lt;/span&gt;-year term of the Convertible Notes.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $0.9&#160;million, which offsets long-term debt on the consolidated balance sheets. As of December&#160;31, 2019, the carrying value of the Convertible Notes was $86.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Convertible Notes was $64.8&#160;million as of December&#160;31, 2019 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Mortgage Loan. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#x201c;Property&#x201d;).  The Company recorded the refinancing as a debt extinguishment, with no recognition of gain or loss on the transaction.  The loan agreement provides for a $12.9 million mortgage on the Property and has a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0ODk_cd815874-61d3-4e93-b842-9068c8947236"&gt;two&lt;/span&gt;-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.  Lexicon incurred $0.4 million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the consolidated balance sheets and will be amortized as interest expense over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM5MTI_05762f89-6afe-4eba-b7d3-725a92223b9e"&gt;two&lt;/span&gt;-year term of the loan agreement.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $0.1 million.  The consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0&#160;million&#160;as of December&#160;31, 2019.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $59.2 million and $2.7 million, respectively, before accumulated depreciation, as of December&#160;31, 2019.  The fair value of Lexicon&#x2019;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#x2019;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, Lexicon&#x2019;s wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until April 9, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of six months with respect to a portion of the property concurrently with closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;BioPharma Term Loan.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $150 million was funded in December 2017 (the &#x201c;BioPharma Term Loan&#x201d;).  The BioPharma Term Loan matures in December 2022, bears interest at 9% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in our business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY1MzU_04b7db4d-7fa9-457a-afc5-ab80eee00947"&gt;five&lt;/span&gt;-year term of the BioPharma Term Loan.  As of December&#160;31, 2019, the balance of unamortized debt issuance costs was $2.4 million, which offsets long-term debt on the consolidated balance sheets.  As of December&#160;31, 2019, the carrying value of the BioPharma Term Loan was $147.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes the aggregate scheduled future principal payments of the Company&#x2019;s long-term debt as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:79.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ending&lt;br/&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;234,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzk3_19773d91-c9c0-4fc2-9c9c-48d1bb475293"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEzNw_7a759e72-55de-4a88-8108-db4190b84462"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY0Ng_7a759e72-55de-4a88-8108-db4190b84462"
      unitRef="number">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEzNzQ_7e03e478-a660-4d16-a2f8-812747c963b7"
      unitRef="number">118.4553</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzE0OTE_0b045b52-37a5-42b6-8b23-99f99150e24c"
      unitRef="usdPerShare">8.442</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lxrx:DebtInstrumentRepurchasePercentage
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzIxMDE_29336b3d-cc87-4095-8655-813c8cdfe25b"
      unitRef="number">1</lxrx:DebtInstrumentRepurchasePercentage>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i337cde26133a4419842ffadf1b382833_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzIzNDQ_6e214616-76e2-44b5-9f4d-e59c34e0d586"
      unitRef="usd">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI2ODc_70c3d47f-ba85-424f-9fc5-9e2d26cf6891"
      unitRef="usd">900000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzI4MDE_5753530f-b0de-48b6-9a3f-56829df04c31"
      unitRef="usd">64800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzMzNjU_065fea12-bcd1-42a8-a06b-edc7c2875b7f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="i505f2df038f048d09e005588782957fa_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM0NTE_77df5558-b7ac-4c6d-91cb-6f83c750f633"
      unitRef="usd">12900000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3c4a1bd15cb743fbb5bf07c38addb55f_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM1MDk_7875bfb6-ed46-423d-80c0-c0d20f1ca3a5">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i505f2df038f048d09e005588782957fa_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2NDA_9839f01a-8846-4264-8acd-31312770f838"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i505f2df038f048d09e005588782957fa_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2NTE_b4b01247-98f6-4266-a196-5c491ea72b0c"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i505f2df038f048d09e005588782957fa_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM2OTI_cbaa6182-aa4d-4413-b442-9f1117bd3216"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <lxrx:MortgageDebtIssueCosts_Revere_LXRX
      contextRef="i505f2df038f048d09e005588782957fa_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzM3MzM_54f28d98-9a01-4bd8-a53f-1011bf5717a6"
      unitRef="usd">400000</lxrx:MortgageDebtIssueCosts_Revere_LXRX>
    <lxrx:MortgageDebtIssueCosts_Revere_LXRX
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQwMTA_60b79463-1e53-43b8-ab2a-62974b3775fa"
      unitRef="usd">100000</lxrx:MortgageDebtIssueCosts_Revere_LXRX>
    <us-gaap:MortgageLoansOnRealEstate
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQwNzI_8572977e-6e8c-4c67-82c8-8da3b664535c"
      unitRef="usd">11000000.0</us-gaap:MortgageLoansOnRealEstate>
    <lxrx:BuildingsCollateral
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQxOTg_f379f034-7bd4-4071-8256-fbac1853d752"
      unitRef="usd">59200000</lxrx:BuildingsCollateral>
    <lxrx:LandCollateral
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQyMDU_62430f3e-5cad-489b-a598-0fc90442e9b2"
      unitRef="usd">2700000</lxrx:LandCollateral>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia8d9306784934680a1912cb049ecc58c_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzEwOTk1MTE2MzUwMTI_21e93269-579c-46a4-b462-738e1fab5fd8"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzQ4NDk_836110d5-6947-440a-9428-b3cb80c5c180"
      unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia8d9306784934680a1912cb049ecc58c_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzYyOTE_fc82acc7-b12e-476b-b84e-e35212387c5b"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzY2Mzg_cd9004e4-796b-4be8-8f89-4299ce6bdb2d"
      unitRef="usd">2400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90ZXh0cmVnaW9uOjU0NTIwZmIxN2VjZDQzZjA4ZmY5YjEwNzRiZGEyOTZjXzcwOTk_f27c0f27-111f-4be3-a6b6-a26e8b2157d9">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes the aggregate scheduled future principal payments of the Company&#x2019;s long-term debt as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:79.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ending&lt;br/&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;234,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzItMS0xLTEtMA_1e7cc976-0335-4870-9c78-ec10800931cd"
      unitRef="usd">11130000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzMtMS0xLTEtMA_d1a852ce-8140-4fab-8c02-f487e9432720"
      unitRef="usd">87500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzQtMS0xLTEtMA_1e95270a-4bb9-49c5-8aaf-cdfc888baf49"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzUtMS0xLTEtMA_003a3e36-2124-4db6-b68c-a386fc001463"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzYtMS0xLTEtMA_71dc0719-bfc6-4f11-9e25-76c70a50d757"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzctMS0xLTEtMA_17c6b095-08f8-4fd7-bcb7-fc0028de4a14"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzgtMS0xLTEtMA_026ed374-0a85-46ce-a830-eda9f09a0328"
      unitRef="usd">248630000</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzktMS0xLTEtMA_a5aaef03-f742-4c10-9507-ac8b96b6e5ac"
      unitRef="usd">3447000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzEwLTEtMS0xLTA_f088d668-edca-4213-a6a8-def493250fca"
      unitRef="usd">11012000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xODcvZnJhZzo1NDUyMGZiMTdlY2Q0M2YwOGZmOWIxMDc0YmRhMjk2Yy90YWJsZTplYTQ2MjljMWQxNzk0ZmJhOWRhNjRhMzI4ZjhmZTEwOS90YWJsZXJhbmdlOmVhNDYyOWMxZDE3OTRmYmE5ZGE2NGEzMjhmOGZlMTA5XzExLTEtMS0xLTA_f4ef8575-b5ff-4d41-b5c3-fd942f0fa98a"
      unitRef="usd">234171000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzI2ODE_fd8fd906-e1a5-44b7-8ddd-56693f82532e">Commitments and Contingencies&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Operating Lease Obligations&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;&#160;A Lexicon subsidiary leases office space in Basking Ridge, New Jersey under a lease agreement, the term of which began in June 2015 and terminates in December 2022.  As disclosed in Note 3, Lexicon adopted ASU 2016-02, "Leases", on January 1, 2019.  As of December&#160;31, 2019, the office space lease right-of-use (ROU) asset had a balance of $1.7 million, which is included in other assets in the consolidated balance sheet, and current and non-current liabilities relating to the ROU asset were $0.6&#160;million and $1.1&#160;million, respectively, which are included in accrued liabilities and other long-term liabilities in the consolidated balance sheet, respectively.  The discount rate used to record the office space lease was Lexicon's estimated borrowing rate of 9%.  Lexicon elected to apply the short-term lease exception to all leases one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:79.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Employment Arrangements:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. Some of the arrangements also provide for certain severance payments for either &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNjU_271664d5-aa24-4596-adff-6eaadc2549e8"&gt;six&lt;/span&gt; or 12 months and, in some cases, payment of a specified portion of the officer&#x2019;s bonus target for such year, in the event of a specified termination of the officer&#x2019;s employment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Legal Proceedings:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#x2019;s securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4NjA_aac13a2b-4d13-4325-9194-52c938f0eb7b"
      unitRef="usd">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4NzY_574407bc-9bbc-432b-9686-49ae1259b537"
      unitRef="usd">-600000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwOTk1MTE2MzE4Nzg_4b4d1022-f80f-4535-aa6d-b59c53247620"
      unitRef="usd">1100000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzI2OTI_dc378fb1-b0d6-4813-ac50-048265701696">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:79.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzItMS0xLTEtMA_5a8fb076-8f99-4361-b6a2-42541fd213c4"
      unitRef="usd">620000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzMtMS0xLTEtMA_465f72aa-e69b-4264-a2e2-8ca9595b72fc"
      unitRef="usd">632000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzQtMS0xLTEtMA_c3bb2526-9009-4101-b589-2391721746ec"
      unitRef="usd">645000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzUtMS0xLTEtMA_9088bc26-1659-4736-a47f-e8098a33ac3c"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzYtMS0xLTEtMA_2c3b014a-d7fe-46fe-a632-8ae88f90a0fa"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzctMS0xLTEtMA_32e5c7fd-bc57-4b22-a2d2-472e1b40a435"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzgtMS0xLTEtMA_474d1c7d-bf64-43f0-8efa-5395d6b56a16"
      unitRef="usd">1897000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <lxrx:InterestOnLeasePayments
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzktMS0xLTEtNDA2MQ_3e2e3540-be77-4079-b173-53eca1c2f091"
      unitRef="usd">-242000</lxrx:InterestOnLeasePayments>
    <lxrx:PresentValueOfFutureLeasePayments
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzEwLTEtMS0xLTQwNzI_2cc31a41-5389-4236-a67d-95f5dbcda914"
      unitRef="usd">1655000</lxrx:PresentValueOfFutureLeasePayments>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzExLTEtMS0xLTQwNzc_7126dedc-d0d9-4568-8f79-3944168788e8"
      unitRef="usd">-553000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90YWJsZTo0MDA3YmZhYzBjZjY0NWIzOTIyYjM0ZTQ4ODM4NTE3MS90YWJsZXJhbmdlOjQwMDdiZmFjMGNmNjQ1YjM5MjJiMzRlNDg4Mzg1MTcxXzEyLTEtMS0xLTQwODA_e0d1db1a-f238-43af-aa6e-63fcf524cf1a"
      unitRef="usd">1102000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod
      contextRef="i8041ad3e7cfe432bb3118f18b89c1202_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTMvZnJhZzphYzMyNjFiYmU2ZTM0YWM3YWFlZWUyMzQ5Mjc0ZjIwNi90ZXh0cmVnaW9uOmFjMzI2MWJiZTZlMzRhYzdhYWVlZTIzNDkyNzRmMjA2XzEwNzE_2b4193b3-93a6-4a06-ad6c-6190ba3ad675">P12M</lxrx:DeferredCompensationArrangementWithIndividualPaymentPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4ODQ_5bc8f307-aec8-4cb8-a291-68a329036248">Equity Incentive Awards&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2017 Equity Incentive Plan:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and renamed the 2017 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit awards, stock appreciation rights and performance stock awards. Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of the Company&#x2019;s common stock on the date of grant.&#160;&#160;Most stock options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Stock options granted under the Equity Incentive Plan have a term of ten years from the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate 20,000,000 shares at December&#160;31, 2019.&#160;&#160;In the first quarter of 2020, the Company amended the 2017 Equity Incentive Plan, subject to stockholder approval, to increase the aggregate number of shares that may be issued under the plan to 30,000,000 shares.  As of December&#160;31, 2019, options to purchase 7,456,905 shares and 2,801,928 restricted stock units were outstanding, 1,909,515 shares had been issued upon the exercise of stock options, 1,968,979 shares had been issued pursuant to restricted stock units and 113,940 shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2017 Non-Employee Directors&#x2019; Equity Incentive Plan:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#x2019; Stock Option Plan, which was subsequently amended and renamed the 2017 Non-Employee Directors&#x2019; Equity Incentive Plan (the &#x201c;Directors&#x2019; Plan&#x201d;).&#160;&#160;Under the Directors&#x2019; Plan, non-employee directors may be granted awards under the plan with an aggregate grant date fair value of no more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on Lexicon&#x2019;s board of directors during such calendar year.&#160;Stock options granted under the Directors&#x2019; Plan have an exercise price equal to the fair market value of the Company&#x2019;s common stock on the date of grant and a term of ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#x2019; Plan shall not exceed in the aggregate 600,000 shares.&#160;&#160;As of December&#160;31, 2019, stock options to purchase 237,850 shares were outstanding, none had been issued upon the exercise of stock options, 27,728 restricted stock units were outstanding and 103,208 shares had been issued pursuant to restricted stock awards granted under the Directors&#x2019; Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock Option Activity:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;The following is a summary of stock option activity under Lexicon&#x2019;s equity incentive plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.749%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.814%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted average estimated grant date fair value of stock options granted during the years ended December&#160;31, 2019, 2018 and 2017 were $3.18, $5.63 and&#160;$8.59, respectively.&#160;&#160;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2018 and 2017 were $0.2 million and $2.0 million, respectively.&#160; The weighted average remaining contractual term of stock options outstanding and exercisable was 6.8 and 5.3 years, respectively, as of December&#160;31, 2019.&#160;&#160;At December&#160;31, 2019, the aggregate intrinsic value of the outstanding stock options was $0.2 million.  At December&#160;31, 2019, there was no intrinsic value of exercisable stock options. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock Bonus and Restricted Stock Unit Activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the year ended December&#160;31, 2019, Lexicon granted its non-employee directors 27,728 restricted stock units and during the year ended December&#160;31, 2018 and 2017, granted its non-employee directors 20,512 and 10,248 shares, respectively, of restricted stock awards.  The restricted stock in 2019, 2018 and 2017 had weighted average grant date fair values of $5.67, $7.80 and $15.61 per share, respectively.  Vesting of restricted stock units occurs on the first anniversary of the grant date and vesting of restricted stock awards is immediate.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the years ended December&#160;31, 2019, 2018 and 2017, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxODc_3e3d37a1-a8e6-4c56-8f56-a53ef432e351"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQxOTM_6c3cd917-a52f-4bb3-8628-3b363616b2f4"&gt;four&lt;/span&gt; annual installments.  The total fair value of shares vested in 2019, 2018 and 2017 was $2.9&#160;million, $3.3&#160;million and $4.7&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the year ended December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.203%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Aggregate Shares Reserved for Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, an aggregate of 10,524,411 shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and 5,979,947 additional shares were available for future grants under Lexicon&#x2019;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzc0OQ_93a9ba8a-a0d1-410e-9d89-03d5d637ab8d"
      unitRef="number">1</lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzk0NA_dfe2a8bb-1afb-4fa4-bbad-e85f99cbd1f2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwODM_7cea93c0-df8b-4540-ae95-c85326929930">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEyNjc_d1424696-e8a8-474b-a9f2-6c65e092ade8"
      unitRef="shares">20000000</lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan>
    <lxrx:OptionsOutstandingEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEzODM_c56a9755-b149-49a7-abcb-810f86b4b2ce"
      unitRef="shares">7456905</lxrx:OptionsOutstandingEquityIncentivePlan>
    <lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEzOTc_09b6b755-e4e5-4ae8-8eda-0e043ea15a89"
      unitRef="shares">2801928</lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan>
    <lxrx:StockOptionsExercisedEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE0NDE_5fee111f-962e-491d-957a-2cf3aad50b8d"
      unitRef="shares">1909515</lxrx:StockOptionsExercisedEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE1MDM_74ed0c6d-5cf1-4ac1-8bb3-fd1c6b575fdd"
      unitRef="shares">1968979</lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzE1Njg_bf217bbb-4e35-4ccc-a69d-5a03151198a1"
      unitRef="shares">113940</lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan>
    <lxrx:Totalvalueofsharesbynonemployeeinayear
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzIxNjM_ca86333e-041e-436a-94b4-36c077f515f6"
      unitRef="usd">500000</lxrx:Totalvalueofsharesbynonemployeeinayear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI1MTU_01201b2c-a22b-4d44-9cdf-1eedc08feba4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI2OTE_a413458f-5ff9-4c4c-b82a-b32e9fea899e"
      unitRef="shares">600000</lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4MTM_43790527-cf18-4516-a00f-c7b345e19f7a"
      unitRef="shares">237850</lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4NDE_30bd3491-b587-419e-923f-ae8bc3fafa15"
      unitRef="shares">0</lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan>
    <lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzI4OTk_6d0c1712-cf11-4370-8321-8120fa9d6e1c"
      unitRef="shares">103208</lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4Nzg_d3a6c232-aff0-4643-b597-504ebd1fa0a6">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.749%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.814%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except exercise price data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMi0xLTEtMA_046a1ce5-1d0b-4d69-9846-fba8830c69a5"
      unitRef="shares">6152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItNC0xLTEtMA_9d9820f0-1be0-4f3c-8325-97dcf878b3cc"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItNi0xLTEtMA_c316bdad-5eb5-404f-b6e0-4bf34d4fecdb"
      unitRef="shares">4961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItOC0xLTEtMA_0896a1c6-974f-42e3-8466-81443d5e7522"
      unitRef="usdPerShare">11.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i676db318ef444ad296e217ae53030a14_I20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMTAtMS0xLTA_6d3a4dee-629e-461f-8f4c-9b62659c5805"
      unitRef="shares">4834000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i676db318ef444ad296e217ae53030a14_I20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzItMTItMS0xLTA_532ae5ba-a33f-4a0d-8cc3-b1c38b194972"
      unitRef="usdPerShare">11.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMi0xLTEtMA_6450b09d-8808-46f5-8000-3fe0062e3e36"
      unitRef="shares">2435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtNC0xLTEtMA_075dadc5-b8a2-462e-b161-84bf38cc597a"
      unitRef="usdPerShare">5.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtNi0xLTEtMA_664cd09a-a1f9-419b-8c68-52f0f4a3c8a4"
      unitRef="shares">1916000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtOC0xLTEtMA_64c66066-31ca-4b9e-8da5-7c2fd0d999b2"
      unitRef="usdPerShare">10.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMTAtMS0xLTA_5513a191-c8b6-4af6-94c2-1e421a22bec3"
      unitRef="shares">892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzMtMTItMS0xLTA_2d5b39ff-e53a-4668-b02f-751312d93d3f"
      unitRef="usdPerShare">14.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMi0xLTEtMA_17b5df2a-b1ed-4987-ab0b-747177382d3d"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtNC0xLTEtMA_0d33613c-7017-4909-9da9-b6eed42cac7d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtNi0xLTEtMA_bb3ed39f-10af-4a38-a82c-5663edd33e39"
      unitRef="shares">97000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtOC0xLTEtMA_258cc76f-9669-4356-993c-e835331f0200"
      unitRef="usdPerShare">7.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMTAtMS0xLTA_31a3a8b0-6e0e-4a79-8cca-a4991854b854"
      unitRef="shares">458000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzQtMTItMS0xLTA_0cbf09a0-f36a-46de-b4db-9d599dc43b15"
      unitRef="usdPerShare">11.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMi0xLTEtMA_b2d0f386-479c-4c03-a336-860c530e29bb"
      unitRef="shares">212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtNC0xLTEtMA_c4285959-9e8a-4203-9b0f-969755c983b1"
      unitRef="usdPerShare">9.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtNi0xLTEtMA_f7adb8c6-22cb-4cbf-96e2-02456a362b2a"
      unitRef="shares">239000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtOC0xLTEtMA_75251291-8eae-4f20-ab9f-c2833fa8a991"
      unitRef="usdPerShare">14.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMTAtMS0xLTA_a788b89c-4c44-4785-b573-b091b7a06559"
      unitRef="shares">157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzUtMTItMS0xLTA_f0506f54-e139-4125-8a94-44ed3c04e076"
      unitRef="usdPerShare">26.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMi0xLTEtMA_5c14819c-1a1c-4efa-9ca2-f9eda56f2acd"
      unitRef="shares">680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i058e0a0649d048bab8422dfc745256d8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtNC0xLTEtMA_2e024f84-97c2-4736-a9ed-6358fa29e1e8"
      unitRef="usdPerShare">10.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtNi0xLTEtMA_03329881-5059-4199-9366-8a101f458d56"
      unitRef="shares">389000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4e5b822ee52342f8b02cdf1953dcb9bd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtOC0xLTEtMA_f05dbcd5-9fe5-4cd8-87d1-e01d0e2a2191"
      unitRef="usdPerShare">12.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMTAtMS0xLTA_63e8639c-22ee-4086-a712-7d1462847ee5"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if8f6cc48daab4f78bb6adc746341b5db_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzYtMTItMS0xLTA_e2040ecd-aa26-4389-b674-c718bdf38352"
      unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i82e588be725e4af58a772fca835425ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMi0xLTEtMA_d232c3bc-dfb2-49f8-9cb7-45784d9861a8"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i82e588be725e4af58a772fca835425ca_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctNC0xLTEtMA_73801c5b-2c82-4f6d-a3b0-118509068065"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctNi0xLTEtMA_4ee88ae2-b23e-46ef-8a38-7f9f792d6298"
      unitRef="shares">6152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctOC0xLTEtMA_ec9e6129-66af-47bb-83ac-6b4fef940bc5"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMTAtMS0xLTA_6115fafa-871d-4ea6-b526-cb6c0b33a539"
      unitRef="shares">4961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzctMTItMS0xLTA_f6c16901-717d-45e8-8adb-72d249a53851"
      unitRef="usdPerShare">11.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i82e588be725e4af58a772fca835425ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMi0xLTEtMA_b67c5aac-a42a-4266-bfd8-e06bc4d6bcd6"
      unitRef="shares">4275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i82e588be725e4af58a772fca835425ca_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtNC0xLTEtMA_43e38dda-6b17-4ade-be47-d7ab582c685e"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtNi0xLTEtMA_1c61485f-81e9-4fac-9152-6c42272907f2"
      unitRef="shares">3620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibc703c71a5994ba2b8a490586719cf93_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtOC0xLTEtMA_660a87f4-0625-4eba-b3d6-b098caa44ed8"
      unitRef="usdPerShare">10.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMTAtMS0xLTA_e5a5d82c-c25c-40eb-a6e6-96524705db7b"
      unitRef="shares">3077000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i17260f0b7b8f41c4812252456551f9ea_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTo0YmNlNGUyOTU4NjM0MTQ1YmFmMzg3YzIzNmMwM2Y4Yi90YWJsZXJhbmdlOjRiY2U0ZTI5NTg2MzQxNDViYWYzODdjMjM2YzAzZjhiXzgtMTItMS0xLTA_bd07991a-2592-4ce6-bb9a-ad4ee05d1744"
      unitRef="usdPerShare">10.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyMzY_fe745eab-9f4e-4e72-a13d-3019fb108b19"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyNDA_34b71b6f-c7d9-4467-9476-fe2682f1de7a"
      unitRef="usdPerShare">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMyNDc_d56bb967-4a9a-45b8-b26f-d186f0db4b63"
      unitRef="usdPerShare">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMzNjU_4268b397-a4ff-4401-bb19-645427edce6e"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzMzNzI_bf6e190a-f949-41f7-a637-2ce2f36d61c5"
      unitRef="usd">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM0ODg_bca17b93-3e5a-45b0-999b-48f9929b4c21">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM0OTU_8ffaf2cf-297b-4412-affa-e05ed741032b">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM2Mzg_7e7f9858-a6a4-4124-ac6a-b96405ccc443"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM2NDU_dac6d08f-809c-45c6-9855-5249c2feca09"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzQyNTY_218488b1-c387-4079-a460-dd21c8f3998a"
      unitRef="shares">27728</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4MzU_630ca565-d09d-4505-9e37-0137e3808fba"
      unitRef="shares">20512</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4Mzg_7917c7b3-2abf-4dc5-b042-60e1b39417d9"
      unitRef="shares">10248</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzM5MzY_056c8550-8c7f-47b4-b9c2-37a284ce0165"
      unitRef="usdPerShare">5.67</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4NDE_4e4aed34-4be2-43ab-b0e6-17d0f5d473b9"
      unitRef="usdPerShare">7.80</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzI4NDQ_45ea6582-7d93-453f-bf30-77cc797bd43e"
      unitRef="usdPerShare">15.61</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyODY_14629ea9-8729-415a-a731-9569acbcbc75"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyOTA_4c3e461a-6be0-412c-b755-0cd0f91a1ccb"
      unitRef="usd">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzEwOTk1MTE2MzgyOTk_1feba533-0ad4-4e1a-911e-9851da00c242"
      unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ4ODI_99ae8d1f-e78d-41b5-b22b-0a2dc7030d3c">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.203%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.667%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzItMi0xLTEtMA_ab4cb4e9-04cb-4759-8693-71b3dda5a52d"
      unitRef="shares">1286000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6dc6ceba9c5d48b49f748eaf3453d078_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzItNC0xLTEtMA_8e274f17-430d-45f9-9473-1d66731cb997"
      unitRef="usdPerShare">10.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzMtMi0xLTEtMA_19822f4c-eb60-43f7-aeac-5c42004a1fcb"
      unitRef="shares">2446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzMtNC0xLTEtMA_25d2dd14-edf8-4bce-a947-3e2f42ea5035"
      unitRef="usdPerShare">5.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzQtMi0xLTEtMA_d67a2fba-4fb4-4408-8364-5540c1c83dfd"
      unitRef="shares">517000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzQtNC0xLTEtMA_7b89a566-f3a8-420b-912b-52f55938362f"
      unitRef="usdPerShare">9.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzUtMi0xLTEtMA_89562bb4-2a28-4aac-8e16-8f11030585fe"
      unitRef="shares">385000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue
      contextRef="i69aee3d2977a4b6f87ac0b167514fbc1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzUtNC0xLTEtMA_dc626dd1-b9ef-4e8e-845c-60ab1445a95e"
      unitRef="usdPerShare">6.50</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2cf18c961781453a902022b81e8fb9be_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzYtMi0xLTEtMA_2a748afb-25a7-4591-9199-94fc37a7b49d"
      unitRef="shares">2830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2cf18c961781453a902022b81e8fb9be_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90YWJsZTpiNzdhMmQ3NjU1MDE0Y2ViOTJmNTQ5OGQ2ZWE2ZjIwZC90YWJsZXJhbmdlOmI3N2EyZDc2NTUwMTRjZWI5MmY1NDk4ZDZlYTZmMjBkXzYtNC0xLTEtMA_f666793e-2c08-43f6-b21d-3057d790ebef"
      unitRef="usdPerShare">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ0MTk_1ecf2f6e-0d19-438e-b5f1-a0a91af6d2d6"
      unitRef="shares">10524411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8xOTkvZnJhZzo0MWZmZjVlMDZmMDk0NmJlOGU0MGYxYzM1MTE0NmViMy90ZXh0cmVnaW9uOjQxZmZmNWUwNmYwOTQ2YmU4ZTQwZjFjMzUxMTQ2ZWIzXzQ1Njk_c539f71b-84ea-4868-895e-5a97dff3434a"
      unitRef="shares">5979947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzY1MA_0e789609-c10e-4977-b6d3-b92a47de4145">Benefit Plan&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled $1.2 million, $1.0 million and $1.0 million in the years ended December&#160;31, 2019, 2018 and 2017, respectively.&#160;&#160;Company contributions are vested based on the employee&#x2019;s years of service, with full vesting after &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzYyOA_b159658f-ba94-40d2-bf42-41b82bcb07e0"&gt;four&lt;/span&gt; years of service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ2Ng_b4dfffd7-c687-4d11-9196-9cf6e6bae477"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ3MA_84069b5d-6eb3-4793-a9b9-32b750879d96"
      unitRef="usd">1000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDIvZnJhZzo0OGQ2YTVhNmM1OGU0MmE2YWFmMjZkNzliYTQ2MTE4Zi90ZXh0cmVnaW9uOjQ4ZDZhNWE2YzU4ZTQyYTZhYWYyNmQ3OWJhNDYxMThmXzQ3Nw_66906275-c9ad-44eb-9d5e-e6fa70346c59"
      unitRef="usd">1000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzIwMTUy_7df0a4cf-c75a-4ee5-b6a2-f78c0d9badfb">Collaboration and License Agreements&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sanofi.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#x201c;Sanofi Agreement&#x201d;), with Sanofi for the worldwide development and commercialization of Lexicon&#x2019;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective as of September 9, 2019 (the &#x201c;Settlement Date&#x201d;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the  &#x201c;Termination Agreement&#x201d;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and associated disputes between Lexicon and Sanofi were settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications.  Sanofi paid Lexicon $208&#160;million in September 2019, $26&#160;million in March 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement) and is obligated to pay an additional $26&#160;million within twelve months of the Settlement Date, and neither party will owe additional payments pursuant to the Sanofi Agreement.  The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  The following is a summary description of the Sanofi Agreement without giving effect to the Termination Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Sanofi Agreement, Lexicon had granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.  Subject to specified exceptions, neither party could (a) perform clinical development activities relating to any other compound which inhibits sodium-glucose cotransporters type 1 or type 2 or (b) commercialize any such compounds in the United States, countries of the European Union and certain other specified countries, in each case during the royalty terms applicable in such countries.  Among the specified exceptions was a right Lexicon retained to pursue the development of its development candidate LX2761, with respect to which Lexicon granted Sanofi certain rights of first negotiation specified in the Sanofi Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Sanofi Agreement, Sanofi paid Lexicon an upfront payment of $300 million.  In addition, Lexicon was eligible to receive from Sanofi (a) up to an aggregate of $110 million upon the achievement of four development milestones relating to the results of certain Phase 3 clinical trials of sotagliflozin in type 2 diabetes patients, (b) up to an aggregate of $220 million upon the achievement of four regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes, respectively, in each of the United States and Europe, of which two milestones representing the substantial majority of such aggregate amount relate to type 2 diabetes and the remaining two milestones relate to type 1 diabetes, (c) $100 million upon the achievement of a milestone based on the results of either of two outcomes studies in type 2 diabetes patients, the completion of which would likely occur after initial regulatory approval of sotagliflozin in type 2 diabetes, and (d) up to an aggregate of $990 million upon the achievement of six commercial milestones that will be achieved upon reaching specified levels of sales.  The Company believed that each of the development and regulatory milestones under the Sanofi Agreement was substantive.  Due to the uncertainty surrounding the achievement of the future development and regulatory milestones, these payments were deemed constrained and were not recognized as revenue.  Commercial milestones would have been accounted for as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria were met.  Lexicon was also entitled to tiered, escalating royalties ranging from low double digit percentages to forty percent of net sales of sotagliflozin, based on indication and territory, with royalties for the higher band of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;such range attributable to net sales for type 1 diabetes in the United States, and subject in each case to customary royalty reduction provisions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon continued to be responsible for all clinical development activities relating to type 1 diabetes and exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States. Under the terms of its co-promotion option, Lexicon would have funded forty percent of the commercialization costs relating to such co-promotion activities. Sanofi was responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and would have been solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States. Lexicon shared in the funding of a portion of the planned type 2 diabetes development costs over the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ0ODM_07c80404-0919-4d69-96df-eb1aa3ad8777"&gt;three&lt;/span&gt; years of the collaboration, up to an aggregate of $100 million, which was satisfied in 2018. Sanofi would have booked sales worldwide in all indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The parties were responsible for using commercially reasonable efforts to perform their development and commercialization obligations pursuant to mutually approved development and commercialization plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The parties&#x2019; activities under the Sanofi Agreement were governed by a joint steering committee and certain other governance committees which reflected equal or other appropriate representation from both parties. If the applicable governance committee was not able to make a decision by consensus and the parties were not able to resolve the issue through escalation to specified senior executive officers of the parties, then Sanofi would have final decision-making authority, subject to limitations specified in the Sanofi Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Sanofi Agreement would have expired upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country was the period commencing on the effective date of the Sanofi Agreement and ending on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity and 10 years following the first commercial sale in the applicable country. Either party could terminate the Sanofi Agreement in the event of an uncured material breach by the other party. Prior to completion of the core development activities for type 2 diabetes specified in the development plan, Sanofi could terminate the Sanofi Agreement on a country-by-country and licensed product-by-licensed product basis, in the event of (a) notification of a material safety issue relating to the licensed product or the class of sodium-glucose cotransporters type 1 or type 2 inhibitors resulting in a recommendation or requirement that Lexicon or Sanofi cease development, (b) failure to achieve positive results with respect to certain clinical trial results, (c) the occurrence of specified fundamental adverse events or (d) the exploitation of the licensed product infringing third party intellectual property rights in specified major markets and Sanofi is unable to obtain a license to such third party intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considered the following as its performance obligations with respect to the revenue recognition of the $300 million upfront payment: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The exclusive worldwide license granted to Sanofi to develop and commercialize sotagliflozin;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The development services Lexicon is performing for sotagliflozin relating to type 1 diabetes; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The funding Lexicon will provide for development relating to type 2 diabetes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the license had stand-alone value because it was an exclusive license that gave Sanofi the right to develop and commercialize sotagliflozin or to sublicense its rights.  In addition, sotagliflozin is currently in development and it was possible that Sanofi or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Sanofi Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company was recognizing as revenue the amount allocated to the development services for type 1 diabetes over the period of time Lexicon performed services, which was expected to be through 2027, and recognized as revenue the obligation to provide funding for development services for type 2 diabetes over the period of time Lexicon provided the funding, which was completed in 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the initial transaction price was the $300 million upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments or royalty payments.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: exercising the option to co-promote, estimated future &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services for type 1 diabetes by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the obligation to provide funding for type 2 diabetes by using internal estimates of the expected cash flows and timing for $100 million in funding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the allocation of the Sanofi Agreement, the Company recognized $126.8 million of the $300 million upfront payment for the license in 2015.  The Company was recognizing the $113.8 million allocated to the development services performance obligation and the $59.4 million allocated to the funding performance obligation over the estimated period of performance as the development and funding occurred.  The Termination Agreement was accounted for as a modification under ASC 606.  Upon execution of the Termination Agreement in September 2019, the Company recognized the remaining $23.5&#160;million allocated to Lexicon's performance obligations as revenue and reduced its remaining deferred revenue balance accordingly.  In addition, the Company recognized revenue of $260&#160;million, representing the full cash consideration from the Termination Agreement.  The Company has no remaining performance obligations to Sanofi.  Revenue recognized under the collaboration agreements with Sanofi was $286 million, $33.2 million and  $60.1 million for the years ended December&#160;31, 2019,  2018 and 2017, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Ipsen.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen&#160;for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $47.2 million through December&#160;31, 2019, consisting of $24.5 million in upfront payments, a $6.4 million milestone upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#x2019;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#x2019;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen's first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#x20ac;72&#160;million upon the achievement of specified sales milestones.  Milestone payments are deemed constrained. Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon supplies Ipsen&#x2019;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5 million upfront payment: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Territory;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The development services Lexicon is performing for XERMELO;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The obligation to participate in committees which govern the development of XERMELO&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;until commercialization; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the license had stand-alone value because it is an exclusive license that grants Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, which was completed in 2018.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen. As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the initial transaction price was the $24.5 million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. &lt;/span&gt;&lt;/div&gt;As a result of the allocation, the Company recognized $21.2 million of the $24.5 million upfront payment for the license in 2014, and an additional $1.4 million in 2015 upon entering into the amendment.  The Company recognized the $1.7 million allocated to the development services deliverable over the estimated period of performance as development occurs, and recognized the $0.1 million allocated to the committee participation deliverable ratably over the estimated period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  During 2019, the milestone earned when Ipsen made its first commercial sale in Canada was determined to be a distinct performance obligation relating to the development activities and accordingly, was recognized as revenue without further allocation to the remaining performance obligations.  Revenue recognized under the Agreement was $4.9 million, $4.6 million and $16.2 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $0.3&#160;million, $0.3 million and $0.1 million, respectively, of royalties from Ipsen.  Revenue for the years ended December&#160;31, 2019, 2018 and 2017 include $1.3 million,  $1.6 million and $0.8 million, respectively, from sales of bulk tablets of XERMELO to Ipsen.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:SettlementPaymentFromTermination
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NDg3OTU_383f8c22-5a0c-4e09-8f7c-35cc4f0880e6"
      unitRef="usd">208000000</lxrx:SettlementPaymentFromTermination>
    <lxrx:SettlementPaymentFromTermination
      contextRef="iea1681c8bfaf4cb7885ec38236a3a489_D20200301-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTUxNDg_4f1add72-31d3-4b85-8345-1fadb4b86d74"
      unitRef="usd">26000000</lxrx:SettlementPaymentFromTermination>
    <lxrx:SettlementPaymentObligation
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NDg4MDc_3557a631-85cc-4094-8300-3ff91a167dd0"
      unitRef="usd">26000000</lxrx:SettlementPaymentObligation>
    <lxrx:SanofiUpfrontPayment
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE2ODg_a38ea5c1-9fdb-407a-a11f-6848e794e1e2"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiDevelopmentMilestones
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3NzU_d4f2db62-6d85-4176-b9f3-26e05cf0f395"
      unitRef="usd">110000000</lxrx:SanofiDevelopmentMilestones>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MDI_29de12d8-457f-400a-9621-ab0cbb30cc7e"
      unitRef="milestone">4</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones>
    <lxrx:SanofiRegulatoryMilestones
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE5NTk_797c18ea-0b06-4d02-83e7-43bdb7bf2364"
      unitRef="usd">220000000</lxrx:SanofiRegulatoryMilestones>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE5ODY_f885f9c2-c180-4333-9bae-5fe1803e7596"
      unitRef="milestone">4</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones>
    <lxrx:SanofiOutcomesStudyMilestone
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzIzNjA_69552584-bcd6-4482-8b3d-858a3c602337"
      unitRef="usd">100000000</lxrx:SanofiOutcomesStudyMilestone>
    <lxrx:SanofiSalesMilestonePayments
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzI2Mjc_71916b43-7cdc-429a-a1a4-ced49614b98b"
      unitRef="usd">990000000</lxrx:SanofiSalesMilestonePayments>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzI2NTQ_8be1a32f-5be9-4fe1-a44b-22823b8fc480"
      unitRef="milestone">6</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzMzNjY_dfd29ab1-a699-4434-b892-2fc92f99c389"
      unitRef="number">0.40</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQwMTI_85b8328f-bb95-4499-933d-be77b02cddb8"
      unitRef="number">0.40</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage>
    <lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzQ1MzY_692d5424-e14b-4a5c-8cd3-130974d967c5"
      unitRef="usd">100000000</lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount>
    <lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzU3Mzc_176e4513-0f49-4c0c-8f4d-47ffd56dd119">P10Y</lxrx:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod>
    <lxrx:SanofiUpfrontPayment
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzY4Nzk_a38ea5c1-9fdb-407a-a11f-6848e794e1e2"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiUpfrontPayment
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzgyNTM_a38ea5c1-9fdb-407a-a11f-6848e794e1e2"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk1MzQ_692d5424-e14b-4a5c-8cd3-130974d967c5"
      unitRef="usd">100000000</lxrx:SanofiCommercializationCostsFundedbyLexiconMaximumAmount>
    <lxrx:SanofiRevenueAllocatedtoLicenseDeliverable
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2MDQ_cecff7a5-883e-437f-a7b2-045d4ae6ba74"
      unitRef="usd">126800000</lxrx:SanofiRevenueAllocatedtoLicenseDeliverable>
    <lxrx:SanofiUpfrontPayment
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2MTQ_a38ea5c1-9fdb-407a-a11f-6848e794e1e2"
      unitRef="usd">300000000</lxrx:SanofiUpfrontPayment>
    <lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk2OTA_d68fe752-8dcb-4d78-8f19-ae6831578ba8"
      unitRef="usd">113800000</lxrx:SanofiRevenueAllocatedtoDevelopmentDeliverable>
    <lxrx:SanofiRevenueAllocatedtoFundingDeliverable
      contextRef="i15195352c4e8468894a3f6db6b28643f_D20151101-20151130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0Xzk3NjI_1712e2e1-da00-4127-8b45-7618fbb31e5c"
      unitRef="usd">59400000</lxrx:SanofiRevenueAllocatedtoFundingDeliverable>
    <lxrx:SanofiDeferredRevenueFromTermination
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTM2OTY_5dfc89a6-15bc-46a4-8647-57956a79634a"
      unitRef="usd">23500000</lxrx:SanofiDeferredRevenueFromTermination>
    <lxrx:SanofiTerminationAgreement
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwOTk1MTE2NTM3MDk_cf455856-6b9e-45ff-8b0e-ccd24cc3a200"
      unitRef="usd">260000000</lxrx:SanofiTerminationAgreement>
    <lxrx:SanofiRevenueRecognized
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjIz_c165e424-c422-4fdd-b48a-ca6db58c76a9"
      unitRef="usd">286000000</lxrx:SanofiRevenueRecognized>
    <lxrx:SanofiRevenueRecognized
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjI3_671e604e-696e-4e22-a7db-213f6cd6fcfd"
      unitRef="usd">33200000</lxrx:SanofiRevenueRecognized>
    <lxrx:SanofiRevenueRecognized
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEwNjM1_2005b64d-dc4c-4114-866a-f00263404042"
      unitRef="usd">60100000</lxrx:SanofiRevenueRecognized>
    <lxrx:IpsenTotalPaymentsToDate
      contextRef="i1d6ed6d282844c3dbc84721dd2091ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMDg5_52e4be76-f85f-4463-9aad-9c9a7835c3fc"
      unitRef="usd">47200000</lxrx:IpsenTotalPaymentsToDate>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMTE4_78912b41-c168-427a-9ad4-5b1a9d70516f"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="iefd14d4f858f4035ae6b02237f016ab7_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMTQ0_ac9cd4a1-3514-43f0-8295-39163ef86ea9"
      unitRef="usd">6400000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyMzUz_734d873f-b086-4b63-85e5-04932c3d601c"
      unitRef="usd">5100000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="ib9b309ec36344fefbc30f63b0cbe55bb_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNTIz_ddfa5171-92bb-458e-b575-581f19ce5d59"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="iefb28917800949f293202b0888b3e175_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNTg1_c56c5964-0e35-47f5-a863-f048379f66a3"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i3b945f8014e44862a193e174495bd0fb_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyNjYx_a688a365-0dd3-44c7-b074-dda71f011330"
      unitRef="usd">1300000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMaximumRegulatoryAndCommercialMilestones
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyODIz_66e8e72f-4182-4938-9405-0fcbec7ee9a6"
      unitRef="usd">9600000</lxrx:IpsenMaximumRegulatoryAndCommercialMilestones>
    <lxrx:IpsenMaximumSalesMilestones
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEyOTM0_ed76e7be-e10f-4127-9a09-746ddc89704c"
      unitRef="eur">72000000</lxrx:IpsenMaximumSalesMilestones>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzEzNzE5_78912b41-c168-427a-9ad4-5b1a9d70516f"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE1ODAy_78912b41-c168-427a-9ad4-5b1a9d70516f"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MTc2_a3a6961d-6c4d-4bfc-a92b-4d10bb88e368"
      unitRef="usd">21200000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MTg2_78912b41-c168-427a-9ad4-5b1a9d70516f"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MjQ4_79872391-915e-40cb-ae56-bb8876a48699"
      unitRef="usd">1400000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3MzI1_09dc9e6c-e459-428c-a719-91476e3c212e"
      unitRef="usd">1700000</lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable>
    <lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable
      contextRef="iced88b66e20f4a21a01c5ebbac0e0e05_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE3NDY1_ea8b251c-8c0c-4c9c-b592-d37c26c107b0"
      unitRef="usd">100000</lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable>
    <lxrx:IpsenRevenueRecognized
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjQw_f6f035ae-cc13-44bd-800e-b442fc7b6a7f"
      unitRef="usd">4900000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjQ0_127b73ab-297d-44a1-aa50-97b0a980452f"
      unitRef="usd">4600000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MjUx_5cfafe5c-2a3a-4be4-9d38-67077abce144"
      unitRef="usd">16200000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRoyaltyIncome_LXRX
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MzUw_b2dce147-a231-4591-b205-10d1180451be"
      unitRef="usd">300000</lxrx:IpsenRoyaltyIncome_LXRX>
    <lxrx:IpsenRoyaltyIncome_LXRX
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4MzU3_2856e575-60ea-4ec0-b173-2c7e4eaf9aac"
      unitRef="usd">100000</lxrx:IpsenRoyaltyIncome_LXRX>
    <lxrx:Ipsenproductsales
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4NDQ3_56da7e28-8fae-4607-906b-e8e06f8032cf"
      unitRef="usd">1600000</lxrx:Ipsenproductsales>
    <lxrx:Ipsenproductsales
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDUvZnJhZzozYTJmYzNjNTJiZDY0MGMzOTM3NDlmOTFjOTlkMGQ3NC90ZXh0cmVnaW9uOjNhMmZjM2M1MmJkNjQwYzM5Mzc0OWY5MWM5OWQwZDc0XzE4NDU0_2e375cb5-d476-456e-a8ad-c6ad784658b4"
      unitRef="usd">800000</lxrx:Ipsenproductsales>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NzYx_e5c2f4d0-98cd-4e03-8fe7-2af6ad28c0fe">Earnings (Loss) Per Share&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of Lexicon's earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.042%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.420%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.052%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Add interest expense on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Add effect of potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Share based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 8,206,390, 7,438,134 and 5,907,643, respectively, for the years ended December&#160;31, 2019, 2018 and 2017.  For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NzYy_23b1e414-5dda-46bb-8eac-7456678dcc05">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of Lexicon's earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.042%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.420%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.052%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;130,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Add interest expense on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(122,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Add effect of potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Share based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTEtMS0xLTQxMzY_4ff83943-32cf-4955-a848-6b8b632421ab"
      unitRef="usd">130133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTMtMS0xLTQxMzY_db58e5a3-4e5a-4441-827b-bb314e0c8658"
      unitRef="usd">-120548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8zLTUtMS0xLTQxMzY_8fda6339-398e-4d45-900c-cb05707dd7d7"
      unitRef="usd">-122993000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTEtMS0xLTQxMzY_547112a6-538a-4975-8f38-94d3be061f03"
      unitRef="usd">5067000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTMtMS0xLTQxMzY_52e34885-0ba6-4ab7-8ada-77594d65c65a"
      unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV80LTUtMS0xLTQxMzY_146cca89-054b-45de-a3b9-3dfe740b70af"
      unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTEtMS0xLTQxMzY_eb4dbbac-e10a-43c3-8bf1-3c2d98878388"
      unitRef="usd">135200000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTMtMS0xLTQxMzY_4024d2ab-ccbf-467f-b7b0-15e28cd0a5dd"
      unitRef="usd">-120548000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV81LTUtMS0xLTQxMzY_fa5c1588-15a0-4146-a1a9-b2dee254062f"
      unitRef="usd">-122993000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTEtMS0xLTQxMzk_88937ab3-2dc8-43ab-8d0d-33bead17e6a5"
      unitRef="shares">106218000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTMtMS0xLTQxMzk_8f609501-bb4a-4193-b148-dfa71ba023b2"
      unitRef="shares">105830000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV84LTUtMS0xLTQxMzk_c71624ef-516f-4e2e-a359-253d40a721a4"
      unitRef="shares">105237000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC0xLTEtMS00MTM5_d8eca35f-09cb-4d57-9f5a-431ddb254050"
      unitRef="shares">164000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC0zLTEtMS00MTM5_f7758787-e120-4ef2-9f62-cefae778554c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMC01LTEtMS00MTM5_5bf5309c-0863-4ff5-8705-699e3bcb789d"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS0xLTEtMS00MTM5_3bb9840a-b77a-48eb-aa1f-da8fab9844bd"
      unitRef="shares">10365000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS0zLTEtMS00MTM5_37904723-682b-4745-af2d-c29056115f4a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMS01LTEtMS00MTM5_e5a06cf8-abdb-496c-9ce1-d4928f9fd3e0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi0xLTEtMS00MTM5_2932b4fe-95d0-429a-b85c-a5531195feec"
      unitRef="shares">116747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi0zLTEtMS00MTM5_940c989c-8570-43bb-92cd-6ebbb23a4453"
      unitRef="shares">105830000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xMi01LTEtMS00MTM5_da6cebc2-fbe0-4535-b5fd-beb1ee81d152"
      unitRef="shares">105237000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC0xLTEtMS00MTQy_cccccc7f-aece-476a-895b-3901aa86e8fe"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC0zLTEtMS00MTQy_9c60dd6a-db20-401d-a0e4-a5e674e40097"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNC01LTEtMS00MTQy_b2a1723d-43ef-45b0-b28e-0a582301f22e"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS0xLTEtMS00MTQy_6c5d2848-1f07-41fa-b488-fa5b28097165"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS0zLTEtMS00MTQy_4d3d733d-aa4e-4a23-aec2-60ef71fe455c"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGFibGU6ODg0Mzg5NjMxODQ5NGQ3ZWEyZTRjNTQzYWQ1ZjlmOWUvdGFibGVyYW5nZTo4ODQzODk2MzE4NDk0ZDdlYTJlNGM1NDNhZDVmOWY5ZV8xNS01LTEtMS00MTQy_42b5e653-a08f-447c-bad9-a64d5e7e9ccf"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4NjYx_76b6f6a3-4817-4a07-ba4e-9be28f5826ce"
      unitRef="shares">8206390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8180495170b24b8ebb36517b94125b49_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4Njc0_f0d7a508-f8ab-4962-a28f-ed651d0515c2"
      unitRef="shares">7438134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61a3cd3aae7248ecbca3253700db1f03_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDQ3L2ZyYWc6ZmM0ZGU1MTgxNjc5NDIyMWEzMzFiOGNkZjZmZGU0OWIvdGV4dHJlZ2lvbjpmYzRkZTUxODE2Nzk0MjIxYTMzMWI4Y2RmNmZkZTQ5Yl8xMDk5NTExNjI4Njk2_e6490612-15fe-4252-8f92-586abdc2b6a4"
      unitRef="shares">5907643</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzEwMDE_fc70560f-237f-4be0-87a3-6d73d8fe1209">Selected Quarterly Financial Data (Unaudited)&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;294,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(23,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;Shares used in computing net income (loss) per common share, basic &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1) Revenues for the three months ended September 30, 2019 include $260&#160;million from the Sanofi Termination Agreement, as defined in Note 13.&lt;/span&gt;&lt;/div&gt;For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzk5Nw_5860121a-ccf2-4542-b2a6-1c07c263e1d6">The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018:&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;294,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(47,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(23,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;226,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;Shares used in computing net income (loss) per common share, basic &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(41,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtMS0xLTEtMA_b084c9f4-ff02-4693-bbb4-d7eaf131940d"
      unitRef="usd">9216000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtMy0xLTEtMA_58f8b7d6-64c1-4212-af6d-be79a7dfbbba"
      unitRef="usd">9682000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtNS0xLTEtMA_a902e59c-dbf6-43ae-a815-2f8ebc4a63f3"
      unitRef="usd">294448000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzQtNy0xLTEtMA_be05d76c-187c-43e7-982f-5176f7e015a1"
      unitRef="usd">8727000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtMS0xLTEtMA_fbf6d39e-d0bc-45d1-a55f-705991bd2f0f"
      unitRef="usd">-17469000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtMy0xLTEtMA_361ce8d3-2a0b-4c9e-b2b0-8436fa6020c1"
      unitRef="usd">-18545000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtNS0xLTEtMA_937acdf8-f0e0-498f-b287-759fe53b91ce"
      unitRef="usd">224676000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzUtNy0xLTEtMA_f9a43d4f-7fb6-4187-89c9-62407504241e"
      unitRef="usd">-47217000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtMS0xLTEtMA_5522a1cb-2a4c-43a1-ae62-d6b9ea17f657"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtMy0xLTEtMA_cc1512f6-cb0a-47b7-aa97-f219bae02da4"
      unitRef="usd">-23018000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtNS0xLTEtMA_6ca956e6-e9a8-4b5e-8842-d8b7ff963787"
      unitRef="usd">226086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzYtNy0xLTEtMA_30048e70-3f3e-4172-abcf-2a9718e09d18"
      unitRef="usd">-51138000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctMS0xLTEtMA_9b9b9ea3-24b4-43e5-98e5-74b689ad73b7"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctMy0xLTEtMA_4739c7d2-d5d1-46da-bf49-cc2b76087dcf"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctNS0xLTEtMA_044627e8-dd52-41e0-b7f4-0ff5e7418d2a"
      unitRef="usdPerShare">2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzctNy0xLTEtMA_6220b8a0-b4c7-49d3-af03-9a402046efa9"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMS0xLTEtMTI0Ng_4159a958-8d28-4c5b-b4f0-3d43ad5bfe0d"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMy0xLTEtMTI0Ng_3a5b717c-8987-4b75-983b-caaca1664cfc"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNS0xLTEtMTI0Ng_57206c1c-29ec-4d67-bd64-055df558f3e2"
      unitRef="usdPerShare">1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNy0xLTEtNDE0OQ_0d08b9e7-1a85-4c48-8fb2-b060653d1ee1"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMS0xLTEtMA_9fe45697-36b0-4608-920d-3bb4f9e05032"
      unitRef="shares">106054000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtMy0xLTEtMA_4f3d8c76-d60d-49ce-b4c0-c547e987d790"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNS0xLTEtMA_19b51dab-950d-4308-923a-2bd1ecb68435"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzgtNy0xLTEtMA_fe58f428-5709-4186-b68f-b33dbc3fa8fe"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic7fe9be53f9a4b76b62e35c22c996880_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTEtMS0xLTEyNDM_2b002f4a-015b-4846-9fc8-06d02cbe9398"
      unitRef="shares">106054000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i745334f9a19e446ea6f364cc70d50aaa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTMtMS0xLTEyNDM_41ced991-5610-4336-8fa3-b13050589612"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i76d3757e3f234ad5bd5742b413ed742a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTUtMS0xLTEyNDA_d0939aec-fa64-4032-9786-10df2cb5603c"
      unitRef="shares">116640000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idb11f7948ad0456c9b1a6d7fe93d8d3a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTctMS0xLTQxNTI_788ad2ec-6879-4191-ae1b-e5512ea695d3"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:Revenues
      contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTEtMS0xLTA_b930916d-ba61-4969-8dfa-5a8bd4892847"
      unitRef="usd">25374000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTMtMS0xLTA_785d1dfe-e68e-4048-9dad-e24b646b7f99"
      unitRef="usd">13798000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTUtMS0xLTA_6a340f4e-c52e-4b13-9225-2afc78c1e22b"
      unitRef="usd">6966000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEwLTctMS0xLTA_06347f24-4aba-431a-8d8a-6605a62b41e7"
      unitRef="usd">17071000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTEtMS0xLTA_289a64a4-a4c6-44da-a114-9404f45c8283"
      unitRef="usd">-37713000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTMtMS0xLTA_1e5be2cc-2959-44e2-a1b7-71dce3a2d961"
      unitRef="usd">-30272000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTUtMS0xLTA_c228bc65-8d2d-4e58-bba9-3c85e6c98c12"
      unitRef="usd">-22927000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzExLTctMS0xLTA_3d2146f9-9cee-4d50-8eb8-63ec8c476bc6"
      unitRef="usd">-12367000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTEtMS0xLTA_d927e587-4528-41af-95a7-91fb5a0e6878"
      unitRef="usd">-41821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTMtMS0xLTA_78e95ea8-b596-431c-af52-a39eb477f51f"
      unitRef="usd">-34549000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTUtMS0xLTA_0c07e283-5c6b-4822-8d9b-d4df8e418e88"
      unitRef="usd">-27396000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEyLTctMS0xLTA_4583ebef-a49d-44c3-a0cf-5566f752d093"
      unitRef="usd">-16782000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTEtMS0xLTA_8dbb6f0b-390e-4780-9374-d754d2e85bfd"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTMtMS0xLTA_7836a4be-9ee2-4ed6-8fcf-9a7be9f0112a"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTUtMS0xLTA_171b9019-95b0-4453-9830-e5d823b20600"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzEzLTctMS0xLTA_3f0fce2c-dfee-4457-85e9-184065f3c361"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ied0c7299e00945369d3ea72496353df9_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTEtMS0xLTA_090fe152-dd7f-4146-aa15-8b049278d0ce"
      unitRef="shares">105668000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i39d23ccb739b4d998731e13dc1b96098_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTMtMS0xLTA_6559abe5-678c-4189-b3d6-c4e901eb1a9c"
      unitRef="shares">105848000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6e86892468984645956d23c25fe705dd_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTUtMS0xLTA_0ff7ecb5-eba7-4dbd-ac6a-54416d68fc95"
      unitRef="shares">105881000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i06fdca9bf7f54a40b672f2237dff63c8_D20181001-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90YWJsZTo3Zjc5MDY2YjU1NzY0YTdhYjVlNDYxZjhmNjI3MTZkNS90YWJsZXJhbmdlOjdmNzkwNjZiNTU3NjRhN2FiNWU0NjFmOGY2MjcxNmQ1XzE1LTctMS0xLTA_61207ec3-0efe-4a16-a1cb-e32e1440e73b"
      unitRef="shares">105920000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <lxrx:SanofiTerminationAgreement
      contextRef="i1dcec506d89f400abad09f47a9939a4f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OTEwZTVkOGJkYjQ2YmY4NGQ1ZWNjNTRkM2JhZmFiL3NlYzo1NDkxMGU1ZDhiZGI0NmJmODRkNWVjYzU0ZDNiYWZhYl8yMDgvZnJhZzo1YThjNjU2ZTkwYWE0OTBlYjZkNGFiMjYyNjQ3NDVhMy90ZXh0cmVnaW9uOjVhOGM2NTZlOTBhYTQ5MGViNmQ0YWIyNjI2NDc0NWEzXzE2NDkyNjc0NDMyMjc_cf455856-6b9e-45ff-8b0e-ccd24cc3a200"
      unitRef="usd">260000000</lxrx:SanofiTerminationAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806842928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent', window );">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure On Geographic Areas Revenue From External Customers Attributed to Germany</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from external customers attributed to France as a percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795725328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:34.749%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.814%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except exercise price data)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,834&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(458)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(212)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(239)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(157)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(680)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(389)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.04&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(150)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at end of year</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at end of year</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:65.203%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.667%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(517)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(385)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Incentive Awards [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
